{"ece8eca30b6c3349712fddb4e22fc04f5236e7f5": [["IntroductionVitamin D is obtained naturally from limited dietary components or from photochemical and thermal conversion of the cholesterol precursor 7-dehydrocholesterol in skin in the presence of adequate ultraviolet B radiation.", [["skin", "ANATOMY", 174, 178], ["IntroductionVitamin D", "CHEMICAL", 0, 21], ["cholesterol", "CHEMICAL", 128, 139], ["7-dehydrocholesterol", "CHEMICAL", 150, 170], ["ultraviolet B", "CHEMICAL", 207, 220], ["IntroductionVitamin D", "CHEMICAL", 0, 21], ["cholesterol", "CHEMICAL", 128, 139], ["7-dehydrocholesterol", "CHEMICAL", 150, 170], ["IntroductionVitamin D", "SIMPLE_CHEMICAL", 0, 21], ["cholesterol", "SIMPLE_CHEMICAL", 128, 139], ["7-dehydrocholesterol", "SIMPLE_CHEMICAL", 150, 170], ["skin", "ORGAN", 174, 178], ["the cholesterol precursor", "TEST", 124, 149], ["dehydrocholesterol in skin", "PROBLEM", 152, 178], ["adequate ultraviolet B radiation", "TREATMENT", 198, 230], ["skin", "ANATOMY", 174, 178], ["adequate", "OBSERVATION_MODIFIER", 198, 206], ["ultraviolet", "OBSERVATION", 207, 218]]], ["Cutaneous vitamin D synthesis occurs efficiently only when the angle of the sun is above 45 o .", [["Cutaneous", "ANATOMY", 0, 9], ["vitamin D", "CHEMICAL", 10, 19], ["vitamin D", "CHEMICAL", 10, 19], ["vitamin D", "SIMPLE_CHEMICAL", 10, 19], ["Cutaneous vitamin D synthesis", "TREATMENT", 0, 29]]], ["To become biologically active, dietary or cutaneous vitamin D undergoes sequential hydroxylations, predominantly hepatic 25-hydroxylation catalyzed by CYP2R1 and other enzymes (2) (3) (4) , followed by CYP27B1-catalyzed 1\u03b1-hydroxylation in peripheral tissues (5) .", [["cutaneous", "ANATOMY", 42, 51], ["hepatic", "ANATOMY", 113, 120], ["peripheral tissues", "ANATOMY", 240, 258], ["vitamin D", "CHEMICAL", 52, 61], ["25-hydroxylation", "CHEMICAL", 121, 137], ["1\u03b1-hydroxylation", "CHEMICAL", 220, 236], ["vitamin D", "CHEMICAL", 52, 61], ["vitamin D", "SIMPLE_CHEMICAL", 52, 61], ["hepatic 25-hydroxylation", "SIMPLE_CHEMICAL", 113, 137], ["CYP2R1", "SIMPLE_CHEMICAL", 151, 157], ["2) (3) (4)", "SIMPLE_CHEMICAL", 177, 187], ["CYP27B1", "GENE_OR_GENE_PRODUCT", 202, 209], ["1\u03b1-hydroxylation", "SIMPLE_CHEMICAL", 220, 236], ["peripheral tissues", "TISSUE", 240, 258], ["CYP2R1", "PROTEIN", 151, 157], ["CYP27B1", "PROTEIN", 202, 209], ["cutaneous vitamin D undergoes sequential hydroxylations", "TREATMENT", 42, 97], ["other enzymes", "TEST", 162, 175], ["CYP27B1", "TEST", 202, 209], ["hydroxylation in peripheral tissues", "TREATMENT", 223, 258], ["active", "OBSERVATION", 23, 29], ["hepatic", "ANATOMY", 113, 120], ["peripheral tissues", "ANATOMY", 240, 258]]], ["The family of ligand-regulated transcription factors, and exerts its physiological effects largely, but not exclusively, through regulation of gene transcription (6) .", [["ligand-regulated transcription factors", "PROTEIN", 14, 52]]], ["Notably, the most strongly induced 1,25D target gene encodes CYP24A1, the enzyme that initiates catabolism of both 25D and 1,25D and thus acts as a physiological negative feedback loop.IntroductionThe most well recognized functions of the vitamin D metabolic and signalling system relate to its classical effects on musculoskeletal health (7) .", [["musculoskeletal", "ANATOMY", 316, 331], ["1,25", "CHEMICAL", 35, 39], ["1,25D", "CHEMICAL", 123, 128], ["vitamin D", "CHEMICAL", 239, 248], ["1,25D", "CHEMICAL", 123, 128], ["vitamin D", "CHEMICAL", 239, 248], ["1,25D", "SIMPLE_CHEMICAL", 35, 40], ["CYP24A1", "GENE_OR_GENE_PRODUCT", 61, 68], ["25D", "SIMPLE_CHEMICAL", 115, 118], ["1,25D", "SIMPLE_CHEMICAL", 123, 128], ["vitamin D", "SIMPLE_CHEMICAL", 239, 248], ["1,25D target gene", "DNA", 35, 52], ["CYP24A1", "PROTEIN", 61, 68], ["1,25D target gene encodes CYP24A1", "PROBLEM", 35, 68], ["the enzyme", "TEST", 70, 80], ["catabolism", "TEST", 96, 106], ["the vitamin D metabolic and signalling system", "PROBLEM", 235, 280], ["feedback loop", "OBSERVATION", 171, 184]]], ["However, in recent years there has been an exponential increase in studies of non-classical, extra-skeletal actions of vitamin D (8) .", [["vitamin D", "CHEMICAL", 119, 128], ["vitamin D (8)", "CHEMICAL", 119, 132], ["vitamin D", "SIMPLE_CHEMICAL", 119, 128], ["vitamin D", "TREATMENT", 119, 128], ["exponential", "OBSERVATION_MODIFIER", 43, 54], ["increase", "OBSERVATION_MODIFIER", 55, 63]]], ["Prominent amongst these has been the growing body of evidence linking vitamin D with the immune system.", [["immune system", "ANATOMY", 89, 102], ["vitamin D", "CHEMICAL", 70, 79], ["vitamin D", "CHEMICAL", 70, 79], ["vitamin D", "SIMPLE_CHEMICAL", 70, 79], ["immune system", "ANATOMICAL_SYSTEM", 89, 102], ["vitamin D", "TREATMENT", 70, 79], ["growing", "OBSERVATION_MODIFIER", 37, 44]]], ["The potential role of vitamin D as an endogenous regulator of both innate and adaptive immunity has garnered considerable attention in the last few months because of the apparent prevalence of vitamin D-deficiency in peptides, which have direct antibacterial and antiviral actions, as well as the production of numerous cytokines that recruit other components of the immune system to site of infection.IntroductionThe paradigm shift in the perception of the physiological roles of vitamin D began with the finding that CYP27B1 is widely expressed in tissues that are unrelated to calcium homeostasis (5, 18) .IntroductionSimilarly, the vitamin D receptor (VDR) is widely expressed (19) ; its broad expression, along with that of CYP27B1, strongly implicate physiological roles of locally produced 1,25D acting in an intracrine or paracrine fashion.", [["immune system", "ANATOMY", 367, 380], ["tissues", "ANATOMY", 550, 557], ["intracrine", "ANATOMY", 816, 826], ["vitamin D", "CHEMICAL", 22, 31], ["vitamin D", "CHEMICAL", 193, 202], ["infection", "DISEASE", 392, 401], ["vitamin D", "CHEMICAL", 481, 490], ["calcium", "CHEMICAL", 580, 587], ["vitamin D", "CHEMICAL", 636, 645], ["1,25D", "CHEMICAL", 797, 802], ["vitamin D", "CHEMICAL", 22, 31], ["vitamin D", "CHEMICAL", 193, 202], ["vitamin D", "CHEMICAL", 481, 490], ["calcium", "CHEMICAL", 580, 587], ["vitamin D", "CHEMICAL", 636, 645], ["1,25D", "CHEMICAL", 797, 802], ["vitamin D", "SIMPLE_CHEMICAL", 22, 31], ["vitamin D", "SIMPLE_CHEMICAL", 193, 202], ["vitamin D", "SIMPLE_CHEMICAL", 481, 490], ["CYP27B1", "GENE_OR_GENE_PRODUCT", 519, 526], ["tissues", "TISSUE", 550, 557], ["calcium", "SIMPLE_CHEMICAL", 580, 587], ["vitamin D receptor", "GENE_OR_GENE_PRODUCT", 636, 654], ["VDR", "GENE_OR_GENE_PRODUCT", 656, 659], ["CYP27B1", "GENE_OR_GENE_PRODUCT", 729, 736], ["1,25D", "SIMPLE_CHEMICAL", 797, 802], ["cytokines", "PROTEIN", 320, 329], ["CYP27B1", "PROTEIN", 519, 526], ["vitamin D receptor", "PROTEIN", 636, 654], ["VDR", "PROTEIN", 656, 659], ["CYP27B1", "PROTEIN", 729, 736], ["vitamin D", "TREATMENT", 22, 31], ["an endogenous regulator", "TREATMENT", 35, 58], ["vitamin D-deficiency in peptides", "PROBLEM", 193, 225], ["direct antibacterial", "TREATMENT", 238, 258], ["antiviral actions", "TREATMENT", 263, 280], ["numerous cytokines", "PROBLEM", 311, 329], ["infection", "PROBLEM", 392, 401], ["The paradigm shift", "TREATMENT", 414, 432], ["vitamin D", "TREATMENT", 481, 490], ["calcium homeostasis", "TEST", 580, 599], ["IntroductionSimilarly", "TREATMENT", 609, 630], ["the vitamin D receptor (VDR)", "TREATMENT", 632, 660], ["an intracrine or paracrine fashion", "TREATMENT", 813, 847], ["numerous", "OBSERVATION_MODIFIER", 311, 319], ["cytokines", "OBSERVATION", 320, 329], ["infection", "OBSERVATION", 392, 401], ["paradigm shift", "OBSERVATION", 418, 432]]], ["Among the cells that express CYP27B1 are activated macrophages and dendritic cells of the innate immune system (20) (21) (22) .", [["cells", "ANATOMY", 10, 15], ["macrophages", "ANATOMY", 51, 62], ["dendritic cells", "ANATOMY", 67, 82], ["cells", "CELL", 10, 15], ["CYP27B1", "GENE_OR_GENE_PRODUCT", 29, 36], ["macrophages", "CELL", 51, 62], ["dendritic cells", "CELL", 67, 82], ["CYP27B1", "PROTEIN", 29, 36], ["activated macrophages", "CELL_TYPE", 41, 62], ["dendritic cells", "CELL_TYPE", 67, 82], ["activated macrophages", "PROBLEM", 41, 62], ["macrophages", "OBSERVATION_MODIFIER", 51, 62], ["dendritic cells", "OBSERVATION", 67, 82]]], ["Importantly, contrary to the renal 1\u03b1-hydroxylase, CYP27B1 activity in these cells is regulated by immune inputs such as interferon\u03b3 (IFN-\u03b3), a T cell cytokine secreted by pro-inflammatory Th1 cells as well as agonists of PRRs such as the Toll-like receptors (TLR).IntroductionThe most critical finding that provides evidence that 1,25D signaling contributes to innate immunity emerged from a study in which Modlin and collaborators stimulated human macrophages with the 19 kDa lipopeptide ligand of TLR 1/2 heterodimers, which led to induction of VDR and CYP27B1 expression, and enhanced endogenous production of 1,25D from circulating 25D (23) (Fig. 1) .", [["renal", "ANATOMY", 29, 34], ["cells", "ANATOMY", 77, 82], ["T cell", "ANATOMY", 144, 150], ["Th1 cells", "ANATOMY", 189, 198], ["macrophages", "ANATOMY", 450, 461], ["1,25D", "CHEMICAL", 331, 336], ["1,25D", "CHEMICAL", 614, 619], ["1,25D", "CHEMICAL", 331, 336], ["1,25D", "CHEMICAL", 614, 619], ["25D (23)", "CHEMICAL", 637, 645], ["renal 1\u03b1-hydroxylase", "GENE_OR_GENE_PRODUCT", 29, 49], ["CYP27B1", "GENE_OR_GENE_PRODUCT", 51, 58], ["cells", "CELL", 77, 82], ["interferon\u03b3", "GENE_OR_GENE_PRODUCT", 121, 132], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 134, 139], ["T cell", "CELL", 144, 150], ["Th1 cells", "CELL", 189, 198], ["PRRs", "GENE_OR_GENE_PRODUCT", 222, 226], ["Toll-like receptors", "GENE_OR_GENE_PRODUCT", 239, 258], ["TLR", "GENE_OR_GENE_PRODUCT", 260, 263], ["1,25D", "SIMPLE_CHEMICAL", 331, 336], ["Modlin", "GENE_OR_GENE_PRODUCT", 408, 414], ["human", "ORGANISM", 444, 449], ["macrophages", "CELL", 450, 461], ["TLR 1/2 heterodimers", "GENE_OR_GENE_PRODUCT", 500, 520], ["VDR", "GENE_OR_GENE_PRODUCT", 548, 551], ["CYP27B1", "GENE_OR_GENE_PRODUCT", 556, 563], ["1,25D", "SIMPLE_CHEMICAL", 614, 619], ["renal 1\u03b1-hydroxylase", "PROTEIN", 29, 49], ["CYP27B1", "PROTEIN", 51, 58], ["interferon\u03b3", "PROTEIN", 121, 132], ["IFN-\u03b3", "PROTEIN", 134, 139], ["T cell cytokine", "PROTEIN", 144, 159], ["pro-inflammatory Th1 cells", "CELL_TYPE", 172, 198], ["PRRs", "PROTEIN", 222, 226], ["Toll-like receptors", "PROTEIN", 239, 258], ["TLR", "PROTEIN", 260, 263], ["human macrophages", "CELL_TYPE", 444, 461], ["TLR 1/2 heterodimers", "PROTEIN", 500, 520], ["VDR", "PROTEIN", 548, 551], ["CYP27B1", "PROTEIN", 556, 563], ["human", "SPECIES", 444, 449], ["human", "SPECIES", 444, 449], ["CYP27B1 activity in these cells", "PROBLEM", 51, 82], ["immune inputs", "PROBLEM", 99, 112], ["interferon\u03b3", "TEST", 121, 132], ["IFN", "TEST", 134, 137], ["a T cell cytokine", "TEST", 142, 159], ["pro-inflammatory Th1 cells", "TREATMENT", 172, 198], ["PRRs", "PROBLEM", 222, 226], ["1,25D signaling", "PROBLEM", 331, 346], ["a study", "TEST", 391, 398], ["the 19 kDa lipopeptide ligand of TLR 1/2 heterodimers", "TREATMENT", 467, 520], ["VDR and CYP27B1 expression", "TEST", 548, 574], ["enhanced endogenous production", "PROBLEM", 580, 610], ["renal", "ANATOMY", 29, 34], ["pro-inflammatory Th1 cells", "OBSERVATION", 172, 198]]], ["Likewise, triggering TLR4 receptors through lipopolysaccharide (LPS) signaling also upregulated CYP27B1 expression (22) ( Fig. 1 ).", [["lipopolysaccharide", "CHEMICAL", 44, 62], ["LPS", "CHEMICAL", 64, 67], ["TLR4", "GENE_OR_GENE_PRODUCT", 21, 25], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 44, 62], ["LPS", "GENE_OR_GENE_PRODUCT", 64, 67], ["CYP27B1", "GENE_OR_GENE_PRODUCT", 96, 103], ["TLR4 receptors", "PROTEIN", 21, 35], ["CYP27B1", "PROTEIN", 96, 103], ["lipopolysaccharide (LPS", "TREATMENT", 44, 67], ["CYP27B1 expression", "TEST", 96, 114]]], ["1,25D synthesis by TLR4 is of interest given that we have known since the early 1990s that the gene encoding the TLR4 co-receptor, CD14, is a target gene of 1,25D (24) .", [["1,25D", "SIMPLE_CHEMICAL", 0, 5], ["TLR4", "GENE_OR_GENE_PRODUCT", 19, 23], ["TLR4", "GENE_OR_GENE_PRODUCT", 113, 117], ["CD14", "GENE_OR_GENE_PRODUCT", 131, 135], ["1,25D (24)", "GENE_OR_GENE_PRODUCT", 157, 167], ["1,25D", "PROTEIN", 0, 5], ["TLR4", "PROTEIN", 19, 23], ["TLR4 co-receptor", "PROTEIN", 113, 129], ["CD14", "PROTEIN", 131, 135], ["1,25D synthesis", "TREATMENT", 0, 15]]], ["In vitro studies of CYP27B1 induction in cells of the monocyte lineage are compatible with the clinical observation of excessive 1,25D production by macrophages in patients with the granulomatous disease sarcoidosis (25).", [["cells", "ANATOMY", 41, 46], ["monocyte lineage", "ANATOMY", 54, 70], ["macrophages", "ANATOMY", 149, 160], ["granulomatous disease", "DISEASE", 182, 203], ["sarcoidosis", "DISEASE", 204, 215], ["CYP27B1", "GENE_OR_GENE_PRODUCT", 20, 27], ["cells", "CELL", 41, 46], ["monocyte lineage", "CELL", 54, 70], ["1,25D", "SIMPLE_CHEMICAL", 129, 134], ["macrophages", "CELL", 149, 160], ["patients", "ORGANISM", 164, 172], ["CYP27B1", "PROTEIN", 20, 27], ["monocyte lineage", "CELL_TYPE", 54, 70], ["macrophages", "CELL_TYPE", 149, 160], ["patients", "SPECIES", 164, 172], ["CYP27B1 induction", "TREATMENT", 20, 37], ["excessive 1,25D production", "PROBLEM", 119, 145], ["the granulomatous disease sarcoidosis", "PROBLEM", 178, 215], ["monocyte", "ANATOMY", 54, 62], ["compatible with", "UNCERTAINTY", 75, 90], ["granulomatous", "OBSERVATION_MODIFIER", 182, 195], ["sarcoidosis", "OBSERVATION", 204, 215]]], ["An intermediate in the pathway from TLR1/2 stimulation to the synthesis of 1,25D was later identified as being IL-15; the cytokine likely induces CYP27B1 mRNA expression through the transcription factor C/EBP-\u03b2 (26).", [["1,25D", "CHEMICAL", 75, 80], ["1,25D", "CHEMICAL", 75, 80], ["TLR1/2", "GENE_OR_GENE_PRODUCT", 36, 42], ["1,25D", "SIMPLE_CHEMICAL", 75, 80], ["IL-15", "GENE_OR_GENE_PRODUCT", 111, 116], ["CYP27B1", "GENE_OR_GENE_PRODUCT", 146, 153], ["C/EBP-\u03b2", "GENE_OR_GENE_PRODUCT", 203, 210], ["TLR1", "PROTEIN", 36, 40], ["IL-15", "PROTEIN", 111, 116], ["cytokine", "PROTEIN", 122, 130], ["CYP27B1 mRNA", "RNA", 146, 158], ["transcription factor", "PROTEIN", 182, 202], ["EBP", "PROTEIN", 205, 208], ["\u03b2", "PROTEIN", 209, 210], ["TLR1/2 stimulation", "TREATMENT", 36, 54], ["the synthesis", "TEST", 58, 71], ["CYP27B1 mRNA expression", "PROBLEM", 146, 169], ["the transcription factor C", "TEST", 178, 204], ["EBP", "TEST", 205, 208], ["intermediate", "OBSERVATION_MODIFIER", 3, 15]]], ["Because IL-15 is an inducer of macrophage differentiation from monocytes, this finding also connects CYP27B1 expression to macrophage development.", [["macrophage", "ANATOMY", 31, 41], ["monocytes", "ANATOMY", 63, 72], ["macrophage", "ANATOMY", 123, 133], ["IL-15", "GENE_OR_GENE_PRODUCT", 8, 13], ["macrophage", "CELL", 31, 41], ["monocytes", "CELL", 63, 72], ["CYP27B1", "GENE_OR_GENE_PRODUCT", 101, 108], ["macrophage", "CELL", 123, 133], ["IL-15", "PROTEIN", 8, 13], ["monocytes", "CELL_TYPE", 63, 72], ["CYP27B1", "PROTEIN", 101, 108], ["IL", "TEST", 8, 10], ["monocytes", "PROBLEM", 63, 72], ["macrophage differentiation", "OBSERVATION", 31, 57], ["macrophage", "OBSERVATION_MODIFIER", 123, 133]]], ["In addition, TLR2/1 signaling induces VDR expression, and the degree of induction was contingent on serum 25D levels (23).", [["serum", "ANATOMY", 100, 105], ["TLR2", "GENE_OR_GENE_PRODUCT", 13, 17], ["1", "GENE_OR_GENE_PRODUCT", 18, 19], ["VDR", "GENE_OR_GENE_PRODUCT", 38, 41], ["serum", "ORGANISM_SUBSTANCE", 100, 105], ["25D", "SIMPLE_CHEMICAL", 106, 109], ["TLR2", "PROTEIN", 13, 17], ["VDR", "PROTEIN", 38, 41], ["VDR expression", "PROBLEM", 38, 52], ["serum 25D levels", "TEST", 100, 116]]], ["Responses were reduced or even absent in macrophages cultured from subjects deficient in vitamin D. In particular, 25D levels from African-Americans were roughly 50% less than those of Caucasian Americans, consistent with previous studies reporting vitamin D deficiency in the former population due to reduced cutaneous vitamin D synthesis in darker skin (27, 28) .", [["macrophages", "ANATOMY", 41, 52], ["cutaneous", "ANATOMY", 310, 319], ["skin", "ANATOMY", 350, 354], ["vitamin D.", "CHEMICAL", 89, 99], ["vitamin D", "CHEMICAL", 249, 258], ["vitamin D", "CHEMICAL", 320, 329], ["vitamin D", "CHEMICAL", 249, 258], ["vitamin D", "CHEMICAL", 320, 329], ["macrophages", "CELL", 41, 52], ["vitamin", "SIMPLE_CHEMICAL", 89, 96], ["vitamin D", "SIMPLE_CHEMICAL", 249, 258], ["vitamin D", "SIMPLE_CHEMICAL", 320, 329], ["skin", "ORGAN", 350, 354], ["macrophages", "CELL_TYPE", 41, 52], ["subjects deficient in vitamin D.", "PROBLEM", 67, 99], ["African-Americans", "TEST", 131, 148], ["previous studies", "TEST", 222, 238], ["vitamin D deficiency", "PROBLEM", 249, 269], ["reduced cutaneous vitamin D synthesis", "TREATMENT", 302, 339], ["consistent with", "UNCERTAINTY", 206, 221], ["reduced", "OBSERVATION_MODIFIER", 302, 309], ["cutaneous vitamin", "OBSERVATION", 310, 327], ["skin", "ANATOMY", 350, 354]]], ["Globally, these observations reveal the importance of vitamin D metabolism in macrophages, as well as the importance of vitamin D sufficiency in initiation of local 1,25D signaling.IntroductionFurther analyses showed that there are multiple transcription factors that regulate CYP27B1 expression.", [["macrophages", "ANATOMY", 78, 89], ["vitamin D", "CHEMICAL", 54, 63], ["vitamin D", "CHEMICAL", 120, 129], ["vitamin D", "CHEMICAL", 54, 63], ["vitamin D", "CHEMICAL", 120, 129], ["vitamin D", "SIMPLE_CHEMICAL", 54, 63], ["macrophages", "CELL", 78, 89], ["vitamin D", "SIMPLE_CHEMICAL", 120, 129], ["1,25D", "GENE_OR_GENE_PRODUCT", 165, 170], ["CYP27B1", "GENE_OR_GENE_PRODUCT", 277, 284], ["macrophages", "CELL_TYPE", 78, 89], ["1,25D", "PROTEIN", 165, 170], ["transcription factors", "PROTEIN", 241, 262], ["CYP27B1", "PROTEIN", 277, 284], ["these observations", "TEST", 10, 28], ["vitamin D metabolism in macrophages", "TREATMENT", 54, 89], ["vitamin D sufficiency", "TREATMENT", 120, 141], ["local 1,25D signaling", "TREATMENT", 159, 180], ["IntroductionFurther analyses", "TEST", 181, 209], ["multiple transcription factors", "PROBLEM", 232, 262], ["CYP27B1 expression", "OBSERVATION", 277, 295]]], ["In silico promoter analyses identified numerous NF-\u03baB sites in the proximal CYP27B1 promoter, which were confirmed by electrophoretic mobility shift assays (29).", [["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 48, 53], ["CYP27B1", "GENE_OR_GENE_PRODUCT", 76, 83], ["NF-\u03baB sites", "DNA", 48, 59], ["proximal CYP27B1 promoter", "DNA", 67, 92], ["\u03baB sites in the proximal CYP27B1 promoter", "TREATMENT", 51, 92], ["electrophoretic mobility shift assays", "TEST", 118, 155], ["numerous", "OBSERVATION_MODIFIER", 39, 47], ["proximal", "ANATOMY_MODIFIER", 67, 75], ["CYP27B1", "ANATOMY", 76, 83]]], ["Cotransfection of NF-\u03baB p50 and p65 subunits was found to substantially decrease activity of a CYP27B1 proximal promoter fragment, and treatment of human embryonic kidney 293 cells with an NF-\u03baB inhibitor yielded enhanced CYP27B1 mRNA expression (29).", [["embryonic kidney 293 cells", "ANATOMY", 154, 180], ["NF-\u03baB p50", "GENE_OR_GENE_PRODUCT", 18, 27], ["p65", "GENE_OR_GENE_PRODUCT", 32, 35], ["CYP27B1", "GENE_OR_GENE_PRODUCT", 95, 102], ["human", "ORGANISM", 148, 153], ["embryonic kidney 293 cells", "CELL", 154, 180], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 189, 194], ["CYP27B1", "GENE_OR_GENE_PRODUCT", 222, 229], ["NF-\u03baB p50 and p65 subunits", "PROTEIN", 18, 44], ["CYP27B1 proximal promoter fragment", "DNA", 95, 129], ["human embryonic kidney 293 cells", "CELL_LINE", 148, 180], ["NF-\u03baB", "PROTEIN", 189, 194], ["CYP27B1 mRNA", "RNA", 222, 234], ["human", "SPECIES", 148, 153], ["human", "SPECIES", 148, 153], ["Cotransfection of NF", "TEST", 0, 20], ["p65 subunits", "TEST", 32, 44], ["a CYP27B1 proximal promoter fragment", "TREATMENT", 93, 129], ["an NF", "TEST", 186, 191], ["B inhibitor", "TREATMENT", 193, 204], ["enhanced CYP27B1 mRNA expression", "PROBLEM", 213, 245], ["decrease", "OBSERVATION_MODIFIER", 72, 80], ["promoter fragment", "OBSERVATION", 112, 129], ["kidney", "ANATOMY", 164, 170], ["293 cells", "OBSERVATION", 171, 180]]], ["In addition to directly regulating CYP27B1 activity, NF-\u03baB can indirectly modulate the enzyme's transcription through mutual repression with nuclear receptors such as arylhydrocarbon receptor (AhR), the constitutive androstane receptor (CAR) and the glucocorticoid receptor (GR), as well as control its activity post-transcriptionally via induction of heme oxygenase or regulation of CYP protein stability (30).", [["nuclear", "ANATOMY", 141, 148], ["arylhydrocarbon", "CHEMICAL", 167, 182], ["androstane", "CHEMICAL", 216, 226], ["CYP27B1", "GENE_OR_GENE_PRODUCT", 35, 42], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 53, 58], ["arylhydrocarbon receptor", "GENE_OR_GENE_PRODUCT", 167, 191], ["AhR", "GENE_OR_GENE_PRODUCT", 193, 196], ["constitutive androstane receptor", "GENE_OR_GENE_PRODUCT", 203, 235], ["CAR", "GENE_OR_GENE_PRODUCT", 237, 240], ["glucocorticoid receptor", "GENE_OR_GENE_PRODUCT", 250, 273], ["GR", "GENE_OR_GENE_PRODUCT", 275, 277], ["heme oxygenase", "GENE_OR_GENE_PRODUCT", 352, 366], ["CYP", "GENE_OR_GENE_PRODUCT", 384, 387], ["CYP27B1", "PROTEIN", 35, 42], ["NF-\u03baB", "PROTEIN", 53, 58], ["nuclear receptors", "PROTEIN", 141, 158], ["arylhydrocarbon receptor", "PROTEIN", 167, 191], ["AhR", "PROTEIN", 193, 196], ["constitutive androstane receptor", "PROTEIN", 203, 235], ["CAR", "PROTEIN", 237, 240], ["glucocorticoid receptor", "PROTEIN", 250, 273], ["GR", "PROTEIN", 275, 277], ["heme oxygenase", "PROTEIN", 352, 366], ["CYP protein", "PROTEIN", 384, 395], ["nuclear receptors", "TREATMENT", 141, 158], ["the constitutive androstane receptor", "TREATMENT", 199, 235], ["the glucocorticoid receptor (GR)", "TREATMENT", 246, 278], ["heme oxygenase", "TREATMENT", 352, 366], ["CYP protein stability", "TEST", 384, 405]]], ["Another transcription factor that controls expression of the gene is C/EBP-\u03b2 (CCAAT/enhancer-binding protein \u03b2); TLR1/2 stimulation by mycobacterial lipoprotein was found to trigger CYP27B1 transcription by activating C/EBP-\u03b2, which was critical for lipoprotein-induced expression of the antimicrobial peptide cathelicidin and stimulation of autophagy (31).", [["C/EBP-\u03b2", "GENE_OR_GENE_PRODUCT", 69, 76], ["CCAAT/enhancer-binding protein \u03b2", "GENE_OR_GENE_PRODUCT", 78, 110], ["TLR1/2", "GENE_OR_GENE_PRODUCT", 113, 119], ["mycobacterial lipoprotein", "GENE_OR_GENE_PRODUCT", 135, 160], ["CYP27B1", "GENE_OR_GENE_PRODUCT", 182, 189], ["C/EBP-\u03b2", "GENE_OR_GENE_PRODUCT", 218, 225], ["lipoprotein", "SIMPLE_CHEMICAL", 250, 261], ["cathelicidin", "GENE_OR_GENE_PRODUCT", 310, 322], ["transcription factor", "PROTEIN", 8, 28], ["C/EBP-\u03b2", "PROTEIN", 69, 76], ["CCAAT/enhancer-binding protein \u03b2", "PROTEIN", 78, 110], ["TLR1", "PROTEIN", 113, 117], ["mycobacterial lipoprotein", "PROTEIN", 135, 160], ["CYP27B1", "PROTEIN", 182, 189], ["C/EBP-\u03b2", "PROTEIN", 218, 225], ["cathelicidin", "PROTEIN", 310, 322], ["C/EBP", "TEST", 69, 74], ["CCAAT/enhancer", "TEST", 78, 92], ["TLR1/2 stimulation", "TREATMENT", 113, 131], ["mycobacterial lipoprotein", "TEST", 135, 160], ["CYP27B1 transcription", "PROBLEM", 182, 203], ["activating C/EBP", "TEST", 207, 223], ["lipoprotein", "TEST", 250, 261], ["the antimicrobial peptide cathelicidin", "TREATMENT", 284, 322], ["stimulation of autophagy", "TREATMENT", 327, 351]]], ["Functional putative CCAAT boxes were also found in the promoter of the CYP27B1 gene (32).", [["CCAAT", "GENE_OR_GENE_PRODUCT", 20, 25], ["CYP27B1", "GENE_OR_GENE_PRODUCT", 71, 78], ["CCAAT boxes", "DNA", 20, 31], ["promoter", "DNA", 55, 63], ["CYP27B1 gene", "DNA", 71, 83], ["Functional putative CCAAT boxes", "TEST", 0, 31], ["CCAAT boxes", "OBSERVATION", 20, 31]]], ["Finally, two new putative transcription factors associated with CYP27B1 transcriptional regulation in LPS-challenged human mononuclear phagocytes were recently identified in silico: PLAGL2, a zinc finger protein that recognizes nucleic acids, and STAT4 (33).1,25D induces antimicrobial innate immunityFindings described above demonstrated that immune cells such as macrophages produce 1,25D upon pathogen intrusion.", [["mononuclear phagocytes", "ANATOMY", 123, 145], ["immune cells", "ANATOMY", 344, 356], ["macrophages", "ANATOMY", 365, 376], ["LPS", "CHEMICAL", 102, 105], ["1,25D", "CHEMICAL", 258, 263], ["zinc", "CHEMICAL", 192, 196], ["CYP27B1", "GENE_OR_GENE_PRODUCT", 64, 71], ["LPS", "SIMPLE_CHEMICAL", 102, 105], ["human", "ORGANISM", 117, 122], ["mononuclear phagocytes", "CELL", 123, 145], ["PLAGL2", "GENE_OR_GENE_PRODUCT", 182, 188], ["STAT4", "GENE_OR_GENE_PRODUCT", 247, 252], ["1,25D", "SIMPLE_CHEMICAL", 258, 263], ["immune cells", "CELL", 344, 356], ["macrophages", "CELL", 365, 376], ["1,25D", "GENE_OR_GENE_PRODUCT", 385, 390], ["transcription factors", "PROTEIN", 26, 47], ["CYP27B1", "PROTEIN", 64, 71], ["human mononuclear phagocytes", "CELL_TYPE", 117, 145], ["PLAGL2", "PROTEIN", 182, 188], ["zinc finger protein", "PROTEIN", 192, 211], ["STAT4", "PROTEIN", 247, 252], ["immune cells", "CELL_TYPE", 344, 356], ["macrophages", "CELL_TYPE", 365, 376], ["1,25D", "PROTEIN", 385, 390], ["human", "SPECIES", 117, 122], ["human", "SPECIES", 117, 122], ["two new putative transcription factors", "PROBLEM", 9, 47], ["CYP27B1 transcriptional regulation", "TREATMENT", 64, 98], ["LPS", "TEST", 102, 105], ["a zinc finger protein", "TEST", 190, 211], ["nucleic acids", "TEST", 228, 241], ["STAT4", "TEST", 247, 252], ["1,25D induces antimicrobial innate immunity", "TREATMENT", 258, 301], ["immune cells", "PROBLEM", 344, 356], ["macrophages", "PROBLEM", 365, 376], ["pathogen intrusion", "PROBLEM", 396, 414], ["mononuclear phagocytes", "OBSERVATION", 123, 145], ["nucleic acids", "OBSERVATION", 228, 241], ["immune cells", "OBSERVATION", 344, 356], ["pathogen intrusion", "OBSERVATION", 396, 414]]], ["1,25D through binding to the VDR, in turn can regulate innate immune responses upstream and downstream of PRR signaling by activating transcription of genes implicated in innate immunity.", [["1,25D", "GENE_OR_GENE_PRODUCT", 0, 5], ["VDR", "GENE_OR_GENE_PRODUCT", 29, 32], ["PRR", "GENE_OR_GENE_PRODUCT", 106, 109], ["1,25D", "PROTEIN", 0, 5], ["VDR", "PROTEIN", 29, 32], ["PRR", "PROTEIN", 106, 109]]], ["As mentioned previously, CD14, the co-receptor of TLR4 is robustly induced by 1,25D in human and murine cells (24, 34).", [["cells", "ANATOMY", 104, 109], ["1,25D", "CHEMICAL", 78, 83], ["1,25D", "CHEMICAL", 78, 83], ["CD14", "GENE_OR_GENE_PRODUCT", 25, 29], ["TLR4", "GENE_OR_GENE_PRODUCT", 50, 54], ["1,25D", "SIMPLE_CHEMICAL", 78, 83], ["human", "ORGANISM", 87, 92], ["murine", "ORGANISM", 97, 103], ["cells", "CELL", 104, 109], ["CD14", "PROTEIN", 25, 29], ["TLR4", "PROTEIN", 50, 54], ["human and murine cells", "CELL_TYPE", 87, 109], ["human", "SPECIES", 87, 92], ["murine", "SPECIES", 97, 103], ["human", "SPECIES", 87, 92], ["CD14", "TEST", 25, 29]]], ["Moreover, in human keratinocytes, vitamin D enhanced TLR2 expression, and considering that signaling through either TLR2 or TLR4 improves vitamin D signaling by boosting expression of the VDR and CYP27B1, the outcome of 1,25D signaling on TLR2 and CD14 expression in keratinocytes represents a positive feedback loop (34).", [["keratinocytes", "ANATOMY", 19, 32], ["keratinocytes", "ANATOMY", 267, 280], ["vitamin D", "CHEMICAL", 34, 43], ["vitamin D", "CHEMICAL", 138, 147], ["vitamin D", "CHEMICAL", 34, 43], ["vitamin D", "CHEMICAL", 138, 147], ["human", "ORGANISM", 13, 18], ["keratinocytes", "CELL", 19, 32], ["vitamin D", "SIMPLE_CHEMICAL", 34, 43], ["TLR2", "GENE_OR_GENE_PRODUCT", 53, 57], ["TLR2", "GENE_OR_GENE_PRODUCT", 116, 120], ["TLR4", "GENE_OR_GENE_PRODUCT", 124, 128], ["vitamin D", "SIMPLE_CHEMICAL", 138, 147], ["VDR", "GENE_OR_GENE_PRODUCT", 188, 191], ["CYP27B1", "GENE_OR_GENE_PRODUCT", 196, 203], ["1,25D", "GENE_OR_GENE_PRODUCT", 220, 225], ["TLR2", "GENE_OR_GENE_PRODUCT", 239, 243], ["CD14", "GENE_OR_GENE_PRODUCT", 248, 252], ["keratinocytes", "CELL", 267, 280], ["human keratinocytes", "CELL_TYPE", 13, 32], ["TLR2", "PROTEIN", 53, 57], ["TLR2", "PROTEIN", 116, 120], ["TLR4", "PROTEIN", 124, 128], ["VDR", "PROTEIN", 188, 191], ["CYP27B1", "PROTEIN", 196, 203], ["TLR2", "PROTEIN", 239, 243], ["CD14", "PROTEIN", 248, 252], ["keratinocytes", "CELL_TYPE", 267, 280], ["human", "SPECIES", 13, 18], ["human", "SPECIES", 13, 18], ["vitamin D enhanced TLR2 expression", "TREATMENT", 34, 68], ["vitamin D signaling", "TREATMENT", 138, 157], ["CYP27B1", "TEST", 196, 203], ["TLR2", "TEST", 239, 243], ["a positive feedback loop", "PROBLEM", 292, 316]]], ["Interestingly, this loop is not present in monocytes (35).", [["monocytes", "ANATOMY", 43, 52], ["monocytes", "CELL", 43, 52], ["monocytes", "CELL_TYPE", 43, 52], ["monocytes", "TEST", 43, 52], ["not present", "UNCERTAINTY", 28, 39]]], ["1,25D treatment of human monocytes inhibited both TLR2 and TLR4 mRNA and protein expression, and this regulation was found to be time-and dose-dependent.", [["monocytes", "ANATOMY", 25, 34], ["1,25D", "CHEMICAL", 0, 5], ["1,25D", "CHEMICAL", 0, 5], ["1,25D", "SIMPLE_CHEMICAL", 0, 5], ["human", "ORGANISM", 19, 24], ["monocytes", "CELL", 25, 34], ["TLR2", "GENE_OR_GENE_PRODUCT", 50, 54], ["TLR4", "GENE_OR_GENE_PRODUCT", 59, 63], ["human monocytes", "CELL_TYPE", 19, 34], ["human", "SPECIES", 19, 24], ["human", "SPECIES", 19, 24], ["human monocytes", "TEST", 19, 34], ["TLR4 mRNA", "TEST", 59, 68], ["protein expression", "TEST", 73, 91]]], ["However, CD14 expression was induced by 1,25D; it was hypothesized that downregulation of PRRs by vitamin D in antigen-presenting cells may serve to suppress extreme Th1-mediated inflammatory responses and downstream autoimmunity (35).", [["antigen-presenting cells", "ANATOMY", 111, 135], ["vitamin D", "CHEMICAL", 98, 107], ["autoimmunity", "DISEASE", 217, 229], ["vitamin D", "CHEMICAL", 98, 107], ["CD14", "GENE_OR_GENE_PRODUCT", 9, 13], ["1,25D", "GENE_OR_GENE_PRODUCT", 40, 45], ["PRRs", "GENE_OR_GENE_PRODUCT", 90, 94], ["vitamin D", "SIMPLE_CHEMICAL", 98, 107], ["cells", "CELL", 130, 135], ["Th1", "GENE_OR_GENE_PRODUCT", 166, 169], ["CD14", "PROTEIN", 9, 13], ["PRRs", "PROTEIN", 90, 94], ["antigen-presenting cells", "CELL_TYPE", 111, 135], ["downregulation of PRRs", "PROBLEM", 72, 94], ["vitamin D in antigen", "TREATMENT", 98, 118], ["extreme Th1-mediated inflammatory responses", "PROBLEM", 158, 201], ["downstream autoimmunity", "PROBLEM", 206, 229], ["inflammatory", "OBSERVATION", 179, 191]]], ["In addition, human macrophages, in the presence of 1,25D, were found to restrict dengue virus infection by suppressing expression of the mannose receptor, belonging to the C-type lectin family of PRRs (36).1,25D induces antimicrobial innate immunityStrong evidence implicating direct regulation of antimicrobial innate immune responses by 1,25D arose from the identification of vitamin D response elements (VDREs) adjacent to the transcription start sites of two genes that encode antimicrobial peptides (AMPs) \u03b2-defensin 2 (DEFB2/DEFB4/HBD2) and cathelicidin antimicrobial peptide (CAMP/LL37) (37) (Fig. 1) .", [["macrophages", "ANATOMY", 19, 30], ["dengue virus infection", "DISEASE", 81, 103], ["1,25D", "CHEMICAL", 206, 211], ["1,25D", "CHEMICAL", 339, 344], ["vitamin D", "CHEMICAL", 378, 387], ["mannose", "CHEMICAL", 137, 144], ["1,25D", "CHEMICAL", 339, 344], ["vitamin D", "CHEMICAL", 378, 387], ["human", "ORGANISM", 13, 18], ["macrophages", "CELL", 19, 30], ["1,25D", "GENE_OR_GENE_PRODUCT", 51, 56], ["dengue virus", "ORGANISM", 81, 93], ["mannose receptor", "GENE_OR_GENE_PRODUCT", 137, 153], ["C-type lectin", "GENE_OR_GENE_PRODUCT", 172, 185], ["PRRs", "GENE_OR_GENE_PRODUCT", 196, 200], ["1,25D", "SIMPLE_CHEMICAL", 206, 211], ["1,25D", "SIMPLE_CHEMICAL", 339, 344], ["vitamin D", "SIMPLE_CHEMICAL", 378, 387], ["antimicrobial peptides (AMPs) \u03b2-defensin 2", "GENE_OR_GENE_PRODUCT", 481, 523], ["DEFB2", "GENE_OR_GENE_PRODUCT", 525, 530], ["DEFB4", "GENE_OR_GENE_PRODUCT", 531, 536], ["HBD2", "GENE_OR_GENE_PRODUCT", 537, 541], ["cathelicidin antimicrobial peptide", "GENE_OR_GENE_PRODUCT", 547, 581], ["human macrophages", "CELL_TYPE", 13, 30], ["mannose receptor", "PROTEIN", 137, 153], ["C-type lectin family", "PROTEIN", 172, 192], ["PRRs", "PROTEIN", 196, 200], ["vitamin D response elements", "DNA", 378, 405], ["VDREs", "DNA", 407, 412], ["transcription start sites", "DNA", 430, 455], ["antimicrobial peptides (AMPs) \u03b2-defensin 2", "PROTEIN", 481, 523], ["DEFB2", "PROTEIN", 525, 530], ["DEFB4", "PROTEIN", 531, 536], ["HBD2", "PROTEIN", 537, 541], ["cathelicidin", "PROTEIN", 547, 559], ["human", "SPECIES", 13, 18], ["human", "SPECIES", 13, 18], ["dengue virus", "SPECIES", 81, 93], ["dengue virus infection", "PROBLEM", 81, 103], ["the mannose receptor", "TREATMENT", 133, 153], ["1,25D induces antimicrobial innate immunity", "TREATMENT", 206, 249], ["antimicrobial innate immune responses", "TREATMENT", 298, 335], ["vitamin D response elements", "TREATMENT", 378, 405], ["antimicrobial peptides", "TREATMENT", 481, 503], ["defensin 2 (DEFB2/DEFB4/HBD2)", "TREATMENT", 513, 542], ["cathelicidin antimicrobial peptide", "TREATMENT", 547, 581], ["CAMP/LL37", "TEST", 583, 592], ["human macrophages", "OBSERVATION", 13, 30]]], ["The study revealed a robust induction of CAMP by 1,25D in all tested cell types, which included multiple cell lines as well as human primary cell cultures; this initial finding was confirmed in subsequent in vitro and in vivo studies (23, 38, 39).", [["cell", "ANATOMY", 69, 73], ["cell lines", "ANATOMY", 105, 115], ["primary cell cultures", "ANATOMY", 133, 154], ["1,25D", "CHEMICAL", 49, 54], ["1,25D", "CHEMICAL", 49, 54], ["CAMP", "GENE_OR_GENE_PRODUCT", 41, 45], ["1,25D", "SIMPLE_CHEMICAL", 49, 54], ["cell", "CELL", 69, 73], ["cell lines", "CELL", 105, 115], ["human", "ORGANISM", 127, 132], ["cell cultures", "CELL", 141, 154], ["CAMP", "PROTEIN", 41, 45], ["1,25D", "PROTEIN", 49, 54], ["multiple cell lines", "CELL_LINE", 96, 115], ["human primary cell cultures", "CELL_LINE", 127, 154], ["human", "SPECIES", 127, 132], ["human", "SPECIES", 127, 132], ["The study", "TEST", 0, 9], ["CAMP", "TREATMENT", 41, 45], ["multiple cell lines", "TREATMENT", 96, 115], ["human primary cell cultures", "TEST", 127, 154], ["vivo studies", "TEST", 221, 233], ["multiple cell lines", "OBSERVATION", 96, 115]]], ["Consistent with this, treatment with 1,25D stimulated secretion of antibacterial activity against pathogens such as the lung pathogen, Pseudomonas aeruginosa into conditioned media (37).", [["lung", "ANATOMY", 120, 124], ["1,25D", "CHEMICAL", 37, 42], ["1,25D", "CHEMICAL", 37, 42], ["1,25D", "SIMPLE_CHEMICAL", 37, 42], ["lung", "ORGAN", 120, 124], ["Pseudomonas aeruginosa", "ORGANISM", 135, 157], ["Pseudomonas aeruginosa", "SPECIES", 135, 157], ["Pseudomonas aeruginosa", "SPECIES", 135, 157], ["treatment", "TREATMENT", 22, 31], ["1,25D stimulated secretion", "TREATMENT", 37, 63], ["antibacterial activity", "TREATMENT", 67, 89], ["pathogens", "PROBLEM", 98, 107], ["the lung pathogen", "PROBLEM", 116, 133], ["Pseudomonas aeruginosa", "PROBLEM", 135, 157], ["lung", "ANATOMY", 120, 124], ["pathogen", "OBSERVATION", 125, 133]]], ["As for HBD2, its expression by 1,25D alone was either modest or not detected (23).", [["1,25D", "CHEMICAL", 31, 36], ["1,25D", "CHEMICAL", 31, 36], ["HBD2", "GENE_OR_GENE_PRODUCT", 7, 11], ["1,25D", "SIMPLE_CHEMICAL", 31, 36], ["HBD2", "PROTEIN", 7, 11], ["HBD2", "PROBLEM", 7, 11]]], ["However, 1,25D was observed to enhance induction of HBD2 by IL-1\u03b2, a robust inducer of the antimicrobial peptide (37).1,25D induces antimicrobial innate immunitySignaling through TLR1/2 pattern recognition receptors in human monocytes was later shown to upregulate IL-1\u03b2 expression and signaling; moreover, the combination of IL-1\u03b2 and 1,25D is required to drive potent induction of HBD2 (40).", [["monocytes", "ANATOMY", 225, 234], ["1,25D", "CHEMICAL", 9, 14], ["1,25D", "CHEMICAL", 118, 123], ["1,25D", "CHEMICAL", 336, 341], ["1,25D", "CHEMICAL", 9, 14], ["1,25D", "CHEMICAL", 336, 341], ["1,25D", "SIMPLE_CHEMICAL", 9, 14], ["HBD2", "GENE_OR_GENE_PRODUCT", 52, 56], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 60, 65], ["1,25D", "SIMPLE_CHEMICAL", 118, 123], ["TLR1/2 pattern recognition receptors", "GENE_OR_GENE_PRODUCT", 179, 215], ["human", "ORGANISM", 219, 224], ["monocytes", "CELL", 225, 234], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 265, 270], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 326, 331], ["1,25D", "SIMPLE_CHEMICAL", 336, 341], ["HBD2", "GENE_OR_GENE_PRODUCT", 383, 387], ["HBD2", "PROTEIN", 52, 56], ["IL-1\u03b2", "PROTEIN", 60, 65], ["TLR1/2 pattern recognition receptors", "PROTEIN", 179, 215], ["human monocytes", "CELL_TYPE", 219, 234], ["IL-1\u03b2", "PROTEIN", 265, 270], ["IL", "PROTEIN", 326, 328], ["1,25D", "PROTEIN", 336, 341], ["human", "SPECIES", 219, 224], ["human", "SPECIES", 219, 224], ["HBD2", "TEST", 52, 56], ["the antimicrobial peptide", "TEST", 87, 112], ["1,25D induces antimicrobial innate immunity", "TREATMENT", 118, 161], ["human monocytes", "TEST", 219, 234], ["IL", "TEST", 265, 267], ["IL", "TREATMENT", 326, 328], ["HBD2", "TEST", 383, 387]]], ["It is likely that IL-1\u03b2 signaling stimulates binding of the NF-\u03baB transcription factor to tandem sites in the proximal HBD2 promoter (40).", [["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 18, 23], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 60, 65], ["HBD2", "GENE_OR_GENE_PRODUCT", 119, 123], ["IL-1\u03b2", "PROTEIN", 18, 23], ["NF-\u03baB transcription factor", "PROTEIN", 60, 86], ["tandem sites", "DNA", 90, 102], ["proximal HBD2 promoter", "DNA", 110, 132], ["IL", "TREATMENT", 18, 20], ["the NF", "TREATMENT", 56, 62], ["B transcription factor", "TREATMENT", 64, 86], ["the proximal HBD2 promoter", "TREATMENT", 106, 132], ["likely", "UNCERTAINTY", 6, 12], ["proximal", "ANATOMY_MODIFIER", 110, 118], ["HBD2", "ANATOMY", 119, 123]]], ["Hence, the above findings suggest a molecular basis for vitamin D sufficiency providing broad protection against bacteria and viruses.", [["vitamin D", "CHEMICAL", 56, 65], ["vitamin D", "CHEMICAL", 56, 65], ["vitamin D", "SIMPLE_CHEMICAL", 56, 65], ["vitamin D sufficiency", "TREATMENT", 56, 77], ["broad protection", "TREATMENT", 88, 104], ["bacteria", "PROBLEM", 113, 121], ["viruses", "PROBLEM", 126, 133]]], ["For instance, Helicobacter pylori and rhinovirus infections enhance the expression of defensins (41, 42) and human cathelicidin was demonstrated to inhibit HIV-1 replication (43), indicating that 1,25D-induced DEFB2 and CAMP expression may enhance protection against these pathogens (Fig. 1) .1,25D induces antimicrobial innate immunityInterestingly, many underlying mechanisms of vitamin D signaling on innate immunity appear species-specific.", [["Helicobacter pylori", "DISEASE", 14, 33], ["rhinovirus infections", "DISEASE", 38, 59], ["vitamin D", "CHEMICAL", 381, 390], ["vitamin D", "CHEMICAL", 381, 390], ["Helicobacter pylori", "ORGANISM", 14, 33], ["rhinovirus", "ORGANISM", 38, 48], ["defensins", "GENE_OR_GENE_PRODUCT", 86, 95], ["human", "ORGANISM", 109, 114], ["cathelicidin", "GENE_OR_GENE_PRODUCT", 115, 127], ["HIV-1", "ORGANISM", 156, 161], ["1,25D", "SIMPLE_CHEMICAL", 196, 201], ["DEFB2", "GENE_OR_GENE_PRODUCT", 210, 215], ["CAMP", "GENE_OR_GENE_PRODUCT", 220, 224], ["vitamin D", "SIMPLE_CHEMICAL", 381, 390], ["defensins", "PROTEIN", 86, 95], ["human cathelicidin", "PROTEIN", 109, 127], ["1,25D", "PROTEIN", 196, 201], ["DEFB2", "PROTEIN", 210, 215], ["CAMP", "PROTEIN", 220, 224], ["Helicobacter pylori", "SPECIES", 14, 33], ["human", "SPECIES", 109, 114], ["HIV-1", "SPECIES", 156, 161], ["Helicobacter pylori", "SPECIES", 14, 33], ["human", "SPECIES", 109, 114], ["HIV-1", "SPECIES", 156, 161], ["Helicobacter pylori", "PROBLEM", 14, 33], ["rhinovirus infections", "PROBLEM", 38, 59], ["defensins", "TEST", 86, 95], ["human cathelicidin", "TEST", 109, 127], ["HIV", "TEST", 156, 159], ["1,25D-induced DEFB2", "TREATMENT", 196, 215], ["CAMP expression", "TREATMENT", 220, 235], ["these pathogens", "PROBLEM", 267, 282], ["antimicrobial innate immunity", "TREATMENT", 307, 336], ["vitamin D signaling", "PROBLEM", 381, 400], ["Helicobacter pylori", "OBSERVATION", 14, 33]]], ["Although CD14 expression induced by 25D was abolished in mice that lack CYP27B1 (34) and macrophage Cyp27b1 expression can be induced by TLR signaling or interferon \u03b3 in rodents (21), there is substantial evidence suggesting that many mechanisms of vitamin D-regulated innate immunity are mechanistically conserved in primates only.", [["vitamin D", "CHEMICAL", 249, 258], ["vitamin D", "CHEMICAL", 249, 258], ["CD14", "GENE_OR_GENE_PRODUCT", 9, 13], ["25D", "GENE_OR_GENE_PRODUCT", 36, 39], ["mice", "ORGANISM", 57, 61], ["CYP27B1 (34)", "GENE_OR_GENE_PRODUCT", 72, 84], ["macrophage Cyp27b1", "GENE_OR_GENE_PRODUCT", 89, 107], ["TLR", "GENE_OR_GENE_PRODUCT", 137, 140], ["interferon \u03b3", "GENE_OR_GENE_PRODUCT", 154, 166], ["vitamin D", "SIMPLE_CHEMICAL", 249, 258], ["primates", "ORGANISM", 318, 326], ["CD14", "PROTEIN", 9, 13], ["Cyp27b1", "PROTEIN", 100, 107], ["TLR", "PROTEIN", 137, 140], ["interferon \u03b3", "PROTEIN", 154, 166], ["mice", "SPECIES", 57, 61], ["mice", "SPECIES", 57, 61], ["CYP27B1", "TEST", 72, 79], ["macrophage Cyp27b1 expression", "TREATMENT", 89, 118], ["vitamin D-regulated innate immunity", "TREATMENT", 249, 284], ["substantial evidence suggesting", "UNCERTAINTY", 193, 224]]], ["For instance, the VDRE in the CAMP gene was shown to be present within an Alu repeat found exclusively in primates (38).", [["VDRE", "GENE_OR_GENE_PRODUCT", 18, 22], ["CAMP", "GENE_OR_GENE_PRODUCT", 30, 34], ["VDRE", "DNA", 18, 22], ["CAMP gene", "DNA", 30, 39], ["Alu repeat", "DNA", 74, 84]]], ["The transposition event would appear to have occurred in a primate progenitor and as a result, is evolutionarily conserved in humans, apes, Old and New World monkeys (44).", [["progenitor", "ANATOMY", 67, 77], ["primate", "ORGANISM", 59, 66], ["progenitor", "CELL", 67, 77], ["humans", "ORGANISM", 126, 132], ["New World monkeys", "ORGANISM", 148, 165], ["primate progenitor", "CELL_TYPE", 59, 77], ["humans", "SPECIES", 126, 132], ["humans", "SPECIES", 126, 132], ["New World monkeys", "SPECIES", 148, 165], ["The transposition event", "PROBLEM", 0, 23]]], ["This species specificity is further highlighted by the conservation of VDREs in HBD2, CAMP, and NOD2 genes in primates, but not in rodents (45).1,25D induces antimicrobial innate immunityFurthermore, while the HBD2, CAMP, and NOD2 genes are induced by 1,25D in human cells of epithelial or myeloid origin, they are not similarly regulated in murine cells.", [["cells", "ANATOMY", 267, 272], ["epithelial", "ANATOMY", 276, 286], ["myeloid", "ANATOMY", 290, 297], ["cells", "ANATOMY", 349, 354], ["1,25D", "CHEMICAL", 144, 149], ["1,25D", "CHEMICAL", 252, 257], ["1,25D", "CHEMICAL", 252, 257], ["VDREs", "GENE_OR_GENE_PRODUCT", 71, 76], ["HBD2", "GENE_OR_GENE_PRODUCT", 80, 84], ["CAMP", "GENE_OR_GENE_PRODUCT", 86, 90], ["NOD2", "GENE_OR_GENE_PRODUCT", 96, 100], ["primates", "ORGANISM", 110, 118], ["1,25D", "SIMPLE_CHEMICAL", 144, 149], ["HBD2", "GENE_OR_GENE_PRODUCT", 210, 214], ["CAMP", "GENE_OR_GENE_PRODUCT", 216, 220], ["NOD2", "GENE_OR_GENE_PRODUCT", 226, 230], ["1,25D", "SIMPLE_CHEMICAL", 252, 257], ["human", "ORGANISM", 261, 266], ["cells", "CELL", 267, 272], ["epithelial", "CELL", 276, 286], ["myeloid", "CELL", 290, 297], ["murine", "ORGANISM", 342, 348], ["cells", "CELL", 349, 354], ["VDREs", "DNA", 71, 76], ["HBD2, CAMP, and NOD2 genes", "DNA", 80, 106], ["HBD2, CAMP, and NOD2 genes", "DNA", 210, 236], ["human cells", "CELL_TYPE", 261, 272], ["epithelial or myeloid origin", "CELL_TYPE", 276, 304], ["murine cells", "CELL_TYPE", 342, 354], ["human", "SPECIES", 261, 266], ["murine", "SPECIES", 342, 348], ["human", "SPECIES", 261, 266], ["This species specificity", "TEST", 0, 24], ["HBD2", "PROBLEM", 80, 84], ["1,25D induces antimicrobial innate immunity", "TREATMENT", 144, 187], ["the HBD2", "TEST", 206, 214], ["CAMP", "TEST", 216, 220], ["NOD2 genes", "PROBLEM", 226, 236], ["epithelial or myeloid origin", "PROBLEM", 276, 304], ["NOD2 genes", "OBSERVATION", 96, 106], ["epithelial", "ANATOMY_MODIFIER", 276, 286], ["myeloid origin", "OBSERVATION", 290, 304], ["murine cells", "OBSERVATION", 342, 354]]], ["Likewise, conditioned media from 1,25D-treated mouse epithelial cells did not generate antimicrobial activity against E. coli nor Pseudomonas aeruginosa, whereas the activity was produced against both bacterial types in human epithelial cells exposed to 1,25D (45).1,25D induces antimicrobial innate immunityDistinct mechanisms of regulation of AMP expression in humans and mice have been proposed to be due to mice being nocturnal whereas humans are active during daytime and can consequently acquire vitamin D from exposure to sunlight (23).", [["epithelial cells", "ANATOMY", 53, 69], ["epithelial cells", "ANATOMY", 226, 242], ["1,25D", "CHEMICAL", 33, 38], ["1,25D", "CHEMICAL", 265, 270], ["AMP", "CHEMICAL", 345, 348], ["vitamin D", "CHEMICAL", 502, 511], ["1,25D", "CHEMICAL", 33, 38], ["1,25D (45)", "CHEMICAL", 254, 264], ["AMP", "CHEMICAL", 345, 348], ["vitamin D", "CHEMICAL", 502, 511], ["1,25D", "SIMPLE_CHEMICAL", 33, 38], ["mouse", "ORGANISM", 47, 52], ["epithelial cells", "CELL", 53, 69], ["E. coli", "ORGANISM", 118, 125], ["Pseudomonas aeruginosa", "ORGANISM", 130, 152], ["human", "ORGANISM", 220, 225], ["epithelial cells", "CELL", 226, 242], ["1,25D", "SIMPLE_CHEMICAL", 265, 270], ["AMP", "GENE_OR_GENE_PRODUCT", 345, 348], ["humans", "ORGANISM", 363, 369], ["mice", "ORGANISM", 374, 378], ["mice", "ORGANISM", 411, 415], ["humans", "ORGANISM", 440, 446], ["vitamin D", "SIMPLE_CHEMICAL", 502, 511], ["1,25D-treated mouse epithelial cells", "CELL_LINE", 33, 69], ["human epithelial cells", "CELL_TYPE", 220, 242], ["mouse", "SPECIES", 47, 52], ["E. coli", "SPECIES", 118, 125], ["Pseudomonas aeruginosa", "SPECIES", 130, 152], ["human", "SPECIES", 220, 225], ["humans", "SPECIES", 363, 369], ["mice", "SPECIES", 374, 378], ["mice", "SPECIES", 411, 415], ["humans", "SPECIES", 440, 446], ["mouse", "SPECIES", 47, 52], ["E. coli", "SPECIES", 118, 125], ["Pseudomonas aeruginosa", "SPECIES", 130, 152], ["human", "SPECIES", 220, 225], ["humans", "SPECIES", 363, 369], ["mice", "SPECIES", 374, 378], ["mice", "SPECIES", 411, 415], ["humans", "SPECIES", 440, 446], ["1,25D-treated mouse epithelial cells", "TREATMENT", 33, 69], ["E. coli", "PROBLEM", 118, 125], ["Pseudomonas aeruginosa", "PROBLEM", 130, 152], ["both bacterial types in human epithelial cells", "PROBLEM", 196, 242], ["1,25D induces antimicrobial innate immunity", "TREATMENT", 265, 308], ["AMP expression", "TREATMENT", 345, 359], ["mice being nocturnal", "PROBLEM", 411, 431], ["vitamin D", "TREATMENT", 502, 511], ["epithelial cells", "OBSERVATION", 53, 69], ["Pseudomonas aeruginosa", "OBSERVATION", 130, 152], ["bacterial types", "OBSERVATION", 201, 216], ["human epithelial cells", "OBSERVATION", 220, 242], ["AMP expression", "OBSERVATION", 345, 359], ["active", "OBSERVATION", 451, 457]]], ["It is also possible that some differences in human versus murine immune function are due to different sites for synthesis of 1,25D, with some reports suggesting that CD8+ T cells rather than macrophages are the major immune cell source of CYP27B1 expression and activity in mice (46).", [["T cells", "ANATOMY", 171, 178], ["macrophages", "ANATOMY", 191, 202], ["immune cell", "ANATOMY", 217, 228], ["human", "ORGANISM", 45, 50], ["murine", "ORGANISM", 58, 64], ["1,25D", "SIMPLE_CHEMICAL", 125, 130], ["CD8", "GENE_OR_GENE_PRODUCT", 166, 169], ["T cells", "CELL", 171, 178], ["macrophages", "CELL", 191, 202], ["immune cell", "CELL", 217, 228], ["CYP27B1", "GENE_OR_GENE_PRODUCT", 239, 246], ["mice", "ORGANISM", 274, 278], ["CD8", "PROTEIN", 166, 169], ["T cells", "CELL_TYPE", 171, 178], ["macrophages", "CELL_TYPE", 191, 202], ["CYP27B1", "PROTEIN", 239, 246], ["human", "SPECIES", 45, 50], ["murine", "SPECIES", 58, 64], ["mice", "SPECIES", 274, 278], ["human", "SPECIES", 45, 50], ["mice", "SPECIES", 274, 278], ["some differences in human versus murine immune function", "PROBLEM", 25, 80], ["synthesis of 1,25D", "PROBLEM", 112, 130], ["macrophages", "PROBLEM", 191, 202], ["CYP27B1 expression", "PROBLEM", 239, 257], ["also possible", "UNCERTAINTY", 6, 19], ["CD8", "OBSERVATION", 166, 169], ["immune cell", "OBSERVATION", 217, 228], ["CYP27B1 expression", "OBSERVATION", 239, 257]]], ["Despite these key differences between humans and mice, it is important to recognise that there is also significant homology in immune responses to vitamin D. This is particularly evident in comparisons of human and mouse models of immune disease.", [["vitamin D.", "CHEMICAL", 147, 157], ["immune disease", "DISEASE", 231, 245], ["vitamin D.", "CHEMICAL", 147, 157], ["humans", "ORGANISM", 38, 44], ["mice", "ORGANISM", 49, 53], ["vitamin", "SIMPLE_CHEMICAL", 147, 154], ["human", "ORGANISM", 205, 210], ["mouse", "ORGANISM", 215, 220], ["humans", "SPECIES", 38, 44], ["mice", "SPECIES", 49, 53], ["human", "SPECIES", 205, 210], ["mouse", "SPECIES", 215, 220], ["humans", "SPECIES", 38, 44], ["mice", "SPECIES", 49, 53], ["human", "SPECIES", 205, 210], ["mouse", "SPECIES", 215, 220], ["significant homology in immune responses", "PROBLEM", 103, 143], ["vitamin D.", "TREATMENT", 147, 157], ["immune disease", "PROBLEM", 231, 245], ["immune disease", "OBSERVATION", 231, 245]]], ["Recent studies have shown similarities between human and murine models of infectious disorder such as sepsis (47), suggesting that there is some commonality in innate immune response to infection between species, including dysregulation of the murine CAMP homolog, cathelicidin-related antimicrobial protein (CRAMP) in vitamin D-deficient mice (47).", [["infectious disorder", "DISEASE", 74, 93], ["sepsis", "DISEASE", 102, 108], ["infection", "DISEASE", 186, 195], ["vitamin D", "CHEMICAL", 319, 328], ["vitamin D", "CHEMICAL", 319, 328], ["human", "ORGANISM", 47, 52], ["murine", "ORGANISM", 57, 63], ["murine", "ORGANISM", 244, 250], ["CAMP homolog", "GENE_OR_GENE_PRODUCT", 251, 263], ["cathelicidin-related antimicrobial protein", "GENE_OR_GENE_PRODUCT", 265, 307], ["CRAMP", "GENE_OR_GENE_PRODUCT", 309, 314], ["vitamin D", "SIMPLE_CHEMICAL", 319, 328], ["mice", "ORGANISM", 339, 343], ["murine CAMP homolog", "PROTEIN", 244, 263], ["cathelicidin", "PROTEIN", 265, 277], ["antimicrobial protein", "PROTEIN", 286, 307], ["CRAMP", "PROTEIN", 309, 314], ["human", "SPECIES", 47, 52], ["murine", "SPECIES", 57, 63], ["murine", "SPECIES", 244, 250], ["mice", "SPECIES", 339, 343], ["human", "SPECIES", 47, 52], ["Recent studies", "TEST", 0, 14], ["infectious disorder", "PROBLEM", 74, 93], ["sepsis", "PROBLEM", 102, 108], ["infection between species", "PROBLEM", 186, 211], ["the murine CAMP homolog", "TREATMENT", 240, 263], ["cathelicidin", "TREATMENT", 265, 277], ["antimicrobial protein (CRAMP", "TREATMENT", 286, 314], ["vitamin D-deficient mice", "TREATMENT", 319, 343], ["murine models", "OBSERVATION_MODIFIER", 57, 70], ["infectious", "OBSERVATION", 74, 84], ["sepsis", "OBSERVATION", 102, 108], ["immune response", "OBSERVATION", 167, 182], ["infection", "OBSERVATION", 186, 195]]], ["This study also highlighted another key facet of species homology in immune responses to vitamin D, namely the link between vitamin D-deficiency and dysregulated inflammation in humans and mice.", [["vitamin D", "CHEMICAL", 89, 98], ["vitamin D", "CHEMICAL", 124, 133], ["inflammation", "DISEASE", 162, 174], ["vitamin D", "CHEMICAL", 89, 98], ["vitamin D", "CHEMICAL", 124, 133], ["vitamin D", "SIMPLE_CHEMICAL", 89, 98], ["vitamin D", "SIMPLE_CHEMICAL", 124, 133], ["humans", "ORGANISM", 178, 184], ["mice", "ORGANISM", 189, 193], ["humans", "SPECIES", 178, 184], ["mice", "SPECIES", 189, 193], ["humans", "SPECIES", 178, 184], ["mice", "SPECIES", 189, 193], ["This study", "TEST", 0, 10], ["vitamin D", "TREATMENT", 89, 98], ["vitamin D-deficiency", "PROBLEM", 124, 144], ["dysregulated inflammation in humans", "PROBLEM", 149, 184], ["dysregulated", "OBSERVATION_MODIFIER", 149, 161], ["inflammation", "OBSERVATION", 162, 174]]], ["Indeed several mouse models of inflammation are known to replicate human diseases, notably autoimmune diseases such as multiple sclerosis and inflammatory bowel disease (IBD) (48) , where anti-inflammatory T cell responses to 1,25D show similarity to human T cell responses.1,25D induces antimicrobial innate immunity1,25D also regulates the expression of another antibacterial agent, hepcidin antibacterial protein (HAMP) (49) (Fig. 1) .", [["bowel", "ANATOMY", 155, 160], ["T cell", "ANATOMY", 206, 212], ["T cell", "ANATOMY", 257, 263], ["inflammation", "DISEASE", 31, 43], ["autoimmune diseases", "DISEASE", 91, 110], ["multiple sclerosis", "DISEASE", 119, 137], ["inflammatory bowel disease", "DISEASE", 142, 168], ["IBD", "DISEASE", 170, 173], ["1,25D", "CHEMICAL", 226, 231], ["1,25D", "CHEMICAL", 274, 279], ["1,25D", "CHEMICAL", 226, 231], ["mouse", "ORGANISM", 15, 20], ["human", "ORGANISM", 67, 72], ["bowel", "ORGAN", 155, 160], ["T cell", "CELL", 206, 212], ["1,25D", "SIMPLE_CHEMICAL", 226, 231], ["human", "ORGANISM", 251, 256], ["T cell", "CELL", 257, 263], ["1,25D", "SIMPLE_CHEMICAL", 274, 279], ["1,25D", "SIMPLE_CHEMICAL", 317, 322], ["hepcidin antibacterial protein", "GENE_OR_GENE_PRODUCT", 385, 415], ["HAMP", "GENE_OR_GENE_PRODUCT", 417, 421], ["1,25D", "PROTEIN", 274, 279], ["hepcidin antibacterial protein", "PROTEIN", 385, 415], ["HAMP", "PROTEIN", 417, 421], ["mouse", "SPECIES", 15, 20], ["human", "SPECIES", 67, 72], ["human", "SPECIES", 251, 256], ["mouse", "SPECIES", 15, 20], ["human", "SPECIES", 67, 72], ["human", "SPECIES", 251, 256], ["inflammation", "PROBLEM", 31, 43], ["human diseases", "PROBLEM", 67, 81], ["autoimmune diseases", "PROBLEM", 91, 110], ["multiple sclerosis", "PROBLEM", 119, 137], ["inflammatory bowel disease", "PROBLEM", 142, 168], ["IBD)", "PROBLEM", 170, 174], ["anti-inflammatory T cell responses", "TEST", 188, 222], ["1,25D induces antimicrobial innate immunity", "TREATMENT", 274, 317], ["another antibacterial agent", "TREATMENT", 356, 383], ["hepcidin antibacterial protein (HAMP)", "TEST", 385, 422], ["several", "OBSERVATION_MODIFIER", 7, 14], ["mouse models", "OBSERVATION_MODIFIER", 15, 27], ["inflammation", "OBSERVATION", 31, 43], ["autoimmune diseases", "OBSERVATION", 91, 110], ["multiple", "OBSERVATION_MODIFIER", 119, 127], ["sclerosis", "OBSERVATION", 128, 137], ["inflammatory", "OBSERVATION_MODIFIER", 142, 154], ["bowel", "ANATOMY", 155, 160], ["disease", "OBSERVATION", 161, 168]]], ["In contrast to CAMP and DEFB4, the direct microbiocidal properties of HAMP are not as apparent.", [["CAMP", "GENE_OR_GENE_PRODUCT", 15, 19], ["DEFB4", "GENE_OR_GENE_PRODUCT", 24, 29], ["HAMP", "GENE_OR_GENE_PRODUCT", 70, 74], ["CAMP", "PROTEIN", 15, 19], ["DEFB4", "PROTEIN", 24, 29], ["HAMP", "PROTEIN", 70, 74], ["CAMP", "TEST", 15, 19], ["not as apparent", "UNCERTAINTY", 79, 94]]], ["Rather, the major function of hepcidin is to suppress ferroportin-mediated export of iron, and it plays a role in the anemia of infection or inflammation.", [["iron", "CHEMICAL", 85, 89], ["anemia", "DISEASE", 118, 124], ["infection", "DISEASE", 128, 137], ["inflammation", "DISEASE", 141, 153], ["iron", "CHEMICAL", 85, 89], ["hepcidin", "GENE_OR_GENE_PRODUCT", 30, 38], ["ferroportin", "GENE_OR_GENE_PRODUCT", 54, 65], ["iron", "SIMPLE_CHEMICAL", 85, 89], ["hepcidin", "PROTEIN", 30, 38], ["ferroportin", "PROTEIN", 54, 65], ["iron", "TREATMENT", 85, 89], ["the anemia of infection", "PROBLEM", 114, 137], ["inflammation", "PROBLEM", 141, 153], ["anemia", "OBSERVATION", 118, 124], ["infection", "OBSERVATION", 128, 137], ["inflammation", "OBSERVATION", 141, 153]]], ["Almost all microorganisms use iron to sustain their growth, therefore restricting circulating levels of iron presents a significant host response to systemic infection (50) .", [["iron", "CHEMICAL", 30, 34], ["iron", "CHEMICAL", 104, 108], ["infection", "DISEASE", 158, 167], ["iron", "CHEMICAL", 30, 34], ["iron", "CHEMICAL", 104, 108], ["iron", "SIMPLE_CHEMICAL", 30, 34], ["iron", "SIMPLE_CHEMICAL", 104, 108], ["iron", "TREATMENT", 30, 34], ["restricting circulating levels of iron", "PROBLEM", 70, 108], ["systemic infection", "PROBLEM", 149, 167], ["significant", "OBSERVATION_MODIFIER", 120, 131], ["host response", "OBSERVATION", 132, 145], ["systemic", "OBSERVATION_MODIFIER", 149, 157], ["infection", "OBSERVATION", 158, 167]]], ["Moreover, bacterial and viral stimuli are known to enhance the expression of HAMP (51) .", [["HAMP", "GENE_OR_GENE_PRODUCT", 77, 81], ["HAMP", "PROTEIN", 77, 81], ["bacterial and viral stimuli", "PROBLEM", 10, 37], ["bacterial", "OBSERVATION_MODIFIER", 10, 19], ["viral stimuli", "OBSERVATION", 24, 37]]], ["Therefore, in this context, suppression, rather than induction, of HAMP by vitamin D may be of benefit since by abrogating HAMP-induced suppression of ferroportin, this facilitates iron export and lower intracellular concentrations of iron.", [["intracellular", "ANATOMY", 203, 216], ["vitamin D", "CHEMICAL", 75, 84], ["iron", "CHEMICAL", 181, 185], ["iron", "CHEMICAL", 235, 239], ["vitamin D", "CHEMICAL", 75, 84], ["iron", "CHEMICAL", 181, 185], ["iron", "CHEMICAL", 235, 239], ["HAMP", "GENE_OR_GENE_PRODUCT", 67, 71], ["vitamin D", "SIMPLE_CHEMICAL", 75, 84], ["HAMP", "GENE_OR_GENE_PRODUCT", 123, 127], ["ferroportin", "GENE_OR_GENE_PRODUCT", 151, 162], ["iron", "SIMPLE_CHEMICAL", 181, 185], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 203, 216], ["iron", "SIMPLE_CHEMICAL", 235, 239], ["HAMP", "PROTEIN", 67, 71], ["HAMP", "PROTEIN", 123, 127], ["ferroportin", "PROTEIN", 151, 162], ["HAMP by vitamin D", "TREATMENT", 67, 84], ["abrogating HAMP-induced suppression of ferroportin", "TREATMENT", 112, 162], ["iron export", "TREATMENT", 181, 192], ["lower intracellular concentrations of iron", "TREATMENT", 197, 239]]], ["Indeed, Hewison and colleagues have shown that once bound to the VDR, the active hormone transcriptionally supresses the HAMP gene in monocytes and hepatocytes (49) .", [["monocytes", "ANATOMY", 134, 143], ["hepatocytes", "ANATOMY", 148, 159], ["VDR", "GENE_OR_GENE_PRODUCT", 65, 68], ["HAMP", "GENE_OR_GENE_PRODUCT", 121, 125], ["monocytes", "CELL", 134, 143], ["hepatocytes", "CELL", 148, 159], ["VDR", "PROTEIN", 65, 68], ["HAMP gene", "DNA", 121, 130], ["monocytes", "CELL_TYPE", 134, 143], ["hepatocytes", "CELL_TYPE", 148, 159], ["hepatocytes", "TEST", 148, 159], ["hepatocytes", "ANATOMY", 148, 159]]], ["This led to a corresponding increase in the membrane expression of ferroportin and a decrease in ferritin expression, which serves as a biomarker for intracellular iron levels.", [["membrane", "ANATOMY", 44, 52], ["intracellular", "ANATOMY", 150, 163], ["iron", "CHEMICAL", 164, 168], ["iron", "CHEMICAL", 164, 168], ["membrane", "CELLULAR_COMPONENT", 44, 52], ["ferroportin", "GENE_OR_GENE_PRODUCT", 67, 78], ["ferritin", "GENE_OR_GENE_PRODUCT", 97, 105], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 150, 163], ["iron", "SIMPLE_CHEMICAL", 164, 168], ["ferroportin", "PROTEIN", 67, 78], ["ferritin", "PROTEIN", 97, 105], ["a corresponding increase", "PROBLEM", 12, 36], ["the membrane expression of ferroportin", "PROBLEM", 40, 78], ["a decrease in ferritin expression", "PROBLEM", 83, 116], ["a biomarker", "TEST", 134, 145], ["intracellular iron levels", "TEST", 150, 175], ["increase", "OBSERVATION_MODIFIER", 28, 36], ["membrane expression", "OBSERVATION", 44, 63], ["decrease", "OBSERVATION_MODIFIER", 85, 93], ["ferritin expression", "OBSERVATION", 97, 116]]], ["Furthermore, in contrast to CAMP and DEFB4, elevated serum 25D levels subsequent to vitamin D supplementation of human subjects were correlated with a decrease in the circulating concentrations of HAMP.", [["serum", "ANATOMY", 53, 58], ["vitamin D", "CHEMICAL", 84, 93], ["vitamin D", "CHEMICAL", 84, 93], ["CAMP", "GENE_OR_GENE_PRODUCT", 28, 32], ["DEFB4", "GENE_OR_GENE_PRODUCT", 37, 42], ["serum", "ORGANISM_SUBSTANCE", 53, 58], ["25D", "GENE_OR_GENE_PRODUCT", 59, 62], ["vitamin D", "SIMPLE_CHEMICAL", 84, 93], ["human", "ORGANISM", 113, 118], ["HAMP", "GENE_OR_GENE_PRODUCT", 197, 201], ["CAMP", "PROTEIN", 28, 32], ["DEFB4", "PROTEIN", 37, 42], ["HAMP", "PROTEIN", 197, 201], ["human", "SPECIES", 113, 118], ["human", "SPECIES", 113, 118], ["CAMP", "TEST", 28, 32], ["DEFB4", "TEST", 37, 42], ["elevated serum 25D levels", "PROBLEM", 44, 69], ["vitamin D supplementation of human subjects", "TREATMENT", 84, 127], ["the circulating concentrations of HAMP", "TREATMENT", 163, 201], ["decrease", "OBSERVATION_MODIFIER", 151, 159]]], ["However, similar to cathelicidin and defensin, 1,25D directly regulates hepcidin gene expression by binding to specific VDREs embedded in the HAMP promoter and its regulation is not observed in murine models, suggesting that control of the HAMP-ferroportin axis by vitamin D is part of the same evolutionary adaptations as those of the AMPs described earlier in this review (49) (Fig. 1 ).1,25D regulates pattern recognition receptor gene expressionAnother aspect of innate immune signaling regulated by vitamin D is PRR expression.", [["1,25", "CHEMICAL", 47, 51], ["vitamin D", "CHEMICAL", 265, 274], ["vitamin D", "CHEMICAL", 504, 513], ["1,25D", "CHEMICAL", 47, 52], ["vitamin D", "CHEMICAL", 265, 274], ["vitamin D", "CHEMICAL", 504, 513], ["cathelicidin", "GENE_OR_GENE_PRODUCT", 20, 32], ["defensin", "GENE_OR_GENE_PRODUCT", 37, 45], ["1,25D", "SIMPLE_CHEMICAL", 47, 52], ["hepcidin", "GENE_OR_GENE_PRODUCT", 72, 80], ["VDREs", "GENE_OR_GENE_PRODUCT", 120, 125], ["HAMP", "GENE_OR_GENE_PRODUCT", 142, 146], ["murine", "ORGANISM", 194, 200], ["HAMP", "GENE_OR_GENE_PRODUCT", 240, 244], ["ferroportin", "GENE_OR_GENE_PRODUCT", 245, 256], ["vitamin D", "SIMPLE_CHEMICAL", 265, 274], ["AMPs", "GENE_OR_GENE_PRODUCT", 336, 340], ["pattern recognition receptor", "GENE_OR_GENE_PRODUCT", 405, 433], ["vitamin D", "SIMPLE_CHEMICAL", 504, 513], ["PRR", "GENE_OR_GENE_PRODUCT", 517, 520], ["cathelicidin", "PROTEIN", 20, 32], ["defensin", "PROTEIN", 37, 45], ["1,25D", "PROTEIN", 47, 52], ["hepcidin", "PROTEIN", 72, 80], ["VDREs", "DNA", 120, 125], ["HAMP promoter", "DNA", 142, 155], ["HAMP", "PROTEIN", 240, 244], ["ferroportin", "PROTEIN", 245, 256], ["PRR", "PROTEIN", 517, 520], ["murine", "SPECIES", 194, 200], ["cathelicidin and defensin", "TREATMENT", 20, 45], ["hepcidin gene expression", "TREATMENT", 72, 96], ["the HAMP promoter", "TREATMENT", 138, 155], ["the HAMP", "TEST", 236, 244], ["vitamin D", "TREATMENT", 265, 274], ["the AMPs", "TREATMENT", 332, 340], ["innate immune signaling", "TREATMENT", 467, 490], ["vitamin D", "TREATMENT", 504, 513]]], ["In addition to CD14, expression of the intracellular pathogen sensing protein NOD2/CARD15/IBD1 is transcriptionally induced by 1,25D in cells of monocytic and epithelial origin (52) .", [["intracellular", "ANATOMY", 39, 52], ["cells", "ANATOMY", 136, 141], ["monocytic", "ANATOMY", 145, 154], ["epithelial", "ANATOMY", 159, 169], ["1,25D", "CHEMICAL", 127, 132], ["1,25D", "CHEMICAL", 127, 132], ["CD14", "GENE_OR_GENE_PRODUCT", 15, 19], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 39, 52], ["NOD2", "GENE_OR_GENE_PRODUCT", 78, 82], ["CARD15", "GENE_OR_GENE_PRODUCT", 83, 89], ["IBD1", "GENE_OR_GENE_PRODUCT", 90, 94], ["1,25D", "SIMPLE_CHEMICAL", 127, 132], ["cells", "CELL", 136, 141], ["monocytic", "CELL", 145, 154], ["epithelial", "TISSUE", 159, 169], ["CD14", "PROTEIN", 15, 19], ["intracellular pathogen sensing protein", "PROTEIN", 39, 77], ["NOD2", "PROTEIN", 78, 82], ["CARD15", "PROTEIN", 83, 89], ["IBD1", "PROTEIN", 90, 94], ["CD14", "TEST", 15, 19], ["the intracellular pathogen", "TEST", 35, 61], ["NOD2", "TEST", 78, 82], ["CARD15/IBD1", "TEST", 83, 94], ["monocytic", "OBSERVATION_MODIFIER", 145, 154], ["epithelial", "ANATOMY_MODIFIER", 159, 169], ["origin", "ANATOMY_MODIFIER", 170, 176]]], ["Two distal VDREs were located in the NOD2 gene, and the function of the putative VDREs were confirmed by chromatin conformation capture assay, which identifies loops between distant chromatin sites that can be viewed by the formation of ligation-dependent PCR products.", [["chromatin", "ANATOMY", 105, 114], ["chromatin sites", "ANATOMY", 182, 197], ["VDREs", "GENE_OR_GENE_PRODUCT", 11, 16], ["NOD2", "GENE_OR_GENE_PRODUCT", 37, 41], ["VDREs", "GENE_OR_GENE_PRODUCT", 81, 86], ["chromatin", "CELLULAR_COMPONENT", 105, 114], ["chromatin", "CELLULAR_COMPONENT", 182, 191], ["VDREs", "DNA", 11, 16], ["NOD2 gene", "DNA", 37, 46], ["VDREs", "DNA", 81, 86], ["distant chromatin sites", "DNA", 174, 197], ["ligation-dependent PCR products", "PROTEIN", 237, 268], ["chromatin conformation capture assay", "TEST", 105, 141], ["loops between distant chromatin sites", "PROBLEM", 160, 197], ["ligation-dependent PCR products", "TREATMENT", 237, 268], ["distal", "OBSERVATION_MODIFIER", 4, 10], ["VDREs", "OBSERVATION", 11, 16], ["NOD2 gene", "OBSERVATION", 37, 46], ["distant chromatin sites", "OBSERVATION", 174, 197], ["ligation", "OBSERVATION", 237, 245]]], ["NOD2/CARD15 recognizes muramyl dipeptide (MDP), a lysosomal breakdown product of bacterial peptidoglycan, and in cells expressing functional NOD2, co-treatment with 1,25D and MDP displayed synergistic NF-\u03baB-dependent induction of DEFB4 and CAMP (Fig. 1) .1,25D regulates pattern recognition receptor gene expressionHowever, the regulation was absent in cells from patients with Crohn's disease (CD) that were homozygous for a non-functional mutation of the NOD2 gene (52) .", [["lysosomal", "ANATOMY", 50, 59], ["cells", "ANATOMY", 113, 118], ["cells", "ANATOMY", 353, 358], ["muramyl dipeptide", "CHEMICAL", 23, 40], ["MDP", "CHEMICAL", 42, 45], ["MDP", "CHEMICAL", 175, 178], ["Crohn's disease", "DISEASE", 378, 393], ["CD", "DISEASE", 395, 397], ["muramyl dipeptide", "CHEMICAL", 23, 40], ["MDP", "CHEMICAL", 42, 45], ["MDP", "CHEMICAL", 175, 178], ["NOD2", "GENE_OR_GENE_PRODUCT", 0, 4], ["CARD15", "GENE_OR_GENE_PRODUCT", 5, 11], ["muramyl dipeptide", "SIMPLE_CHEMICAL", 23, 40], ["MDP", "SIMPLE_CHEMICAL", 42, 45], ["cells", "CELL", 113, 118], ["NOD2", "GENE_OR_GENE_PRODUCT", 141, 145], ["1,25D", "SIMPLE_CHEMICAL", 165, 170], ["MDP", "SIMPLE_CHEMICAL", 175, 178], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 201, 206], ["DEFB4", "GENE_OR_GENE_PRODUCT", 230, 235], ["CAMP (Fig. 1) .1,25D", "GENE_OR_GENE_PRODUCT", 240, 260], ["pattern recognition receptor", "GENE_OR_GENE_PRODUCT", 271, 299], ["cells", "CELL", 353, 358], ["patients", "ORGANISM", 364, 372], ["Crohn's disease", "CANCER", 378, 393], ["NOD2", "GENE_OR_GENE_PRODUCT", 457, 461], ["NOD2", "PROTEIN", 0, 4], ["CARD15", "PROTEIN", 5, 11], ["NOD2", "PROTEIN", 141, 145], ["NF-\u03baB", "PROTEIN", 201, 206], ["DEFB4", "PROTEIN", 230, 235], ["CAMP (Fig. 1) .1,25D", "PROTEIN", 240, 260], ["NOD2 gene", "DNA", 457, 466], ["patients", "SPECIES", 364, 372], ["a lysosomal breakdown product", "TREATMENT", 48, 77], ["bacterial peptidoglycan", "PROBLEM", 81, 104], ["co-treatment", "TEST", 147, 159], ["MDP", "TEST", 175, 178], ["synergistic NF", "TREATMENT", 189, 203], ["B-dependent induction of DEFB4", "TREATMENT", 205, 235], ["CAMP (Fig.", "TREATMENT", 240, 250], ["Crohn's disease", "PROBLEM", 378, 393], ["bacterial peptidoglycan", "OBSERVATION", 81, 104], ["functional NOD2", "OBSERVATION", 130, 145]]], ["Notably, these findings provide a strong association between 1,25D signaling and the pathogenesis of CD, a relapsing inflammatory bowel disease originating from insufficient management of intestinal bacterial load by innate immune cells (53) .", [["bowel", "ANATOMY", 130, 135], ["intestinal", "ANATOMY", 188, 198], ["immune cells", "ANATOMY", 224, 236], ["1,25D", "CHEMICAL", 61, 66], ["CD", "DISEASE", 101, 103], ["inflammatory bowel disease", "DISEASE", 117, 143], ["1,25D", "CHEMICAL", 61, 66], ["1,25D", "SIMPLE_CHEMICAL", 61, 66], ["bowel", "ORGAN", 130, 135], ["intestinal", "ORGAN", 188, 198], ["innate immune cells", "CELL", 217, 236], ["1,25D", "PROTEIN", 61, 66], ["innate immune cells", "CELL_TYPE", 217, 236], ["1,25D signaling", "PROBLEM", 61, 76], ["the pathogenesis of CD", "PROBLEM", 81, 103], ["a relapsing inflammatory bowel disease", "PROBLEM", 105, 143], ["intestinal bacterial load", "PROBLEM", 188, 213], ["relapsing", "OBSERVATION_MODIFIER", 107, 116], ["inflammatory", "OBSERVATION_MODIFIER", 117, 129], ["bowel", "ANATOMY", 130, 135], ["disease", "OBSERVATION", 136, 143], ["intestinal", "ANATOMY", 188, 198], ["bacterial load", "OBSERVATION", 199, 213]]], ["Susceptibility to CD has been linked with polymorphisms in both the NOD2 and HBD2 loci (54, 55) , and although vitamin D deficiency has been associated with CD, there is some disagreement as to whether the deficiency arises from intestinal malabsorption of the hormone or whether the insufficiency contributes to pathogenesis the disease.", [["intestinal", "ANATOMY", 229, 239], ["CD", "DISEASE", 18, 20], ["vitamin D", "CHEMICAL", 111, 120], ["CD", "DISEASE", 157, 159], ["intestinal malabsorption", "DISEASE", 229, 253], ["vitamin D", "CHEMICAL", 111, 120], ["NOD2", "GENE_OR_GENE_PRODUCT", 68, 72], ["HBD2", "GENE_OR_GENE_PRODUCT", 77, 81], ["vitamin D", "SIMPLE_CHEMICAL", 111, 120], ["intestinal", "ORGAN", 229, 239], ["NOD2 and HBD2 loci", "DNA", 68, 86], ["polymorphisms", "PROBLEM", 42, 55], ["HBD2 loci", "TEST", 77, 86], ["vitamin D deficiency", "PROBLEM", 111, 131], ["the deficiency", "PROBLEM", 202, 216], ["intestinal malabsorption of the hormone", "PROBLEM", 229, 268], ["the insufficiency", "PROBLEM", 280, 297], ["pathogenesis the disease", "PROBLEM", 313, 337], ["NOD2", "ANATOMY", 68, 72], ["HBD2 loci", "OBSERVATION", 77, 86], ["intestinal", "ANATOMY", 229, 239], ["insufficiency", "OBSERVATION", 284, 297], ["disease", "OBSERVATION", 330, 337]]], ["However, the direct induction of NOD2 expression as well as the direct and indirect regulation of HBD2 expression suggest a molecular link between 1,25D deficiency and CD.", [["CD", "DISEASE", 168, 170], ["NOD2", "GENE_OR_GENE_PRODUCT", 33, 37], ["HBD2", "GENE_OR_GENE_PRODUCT", 98, 102], ["1,25D", "GENE_OR_GENE_PRODUCT", 147, 152], ["NOD2", "PROTEIN", 33, 37], ["HBD2", "PROTEIN", 98, 102], ["1,25D", "PROTEIN", 147, 152], ["NOD2 expression", "PROBLEM", 33, 48], ["HBD2 expression", "PROBLEM", 98, 113], ["a molecular link between 1,25D deficiency", "PROBLEM", 122, 163]]], ["Furthermore, 1,25D-mediated regulation of NOD2 may be relevant to fighting intracellular infections by mycobacteria (e.g. M. tuberculosis), as these bacteria generate the N-glycoyl form of MDP, which binds to NOD2 with higher affinity than the N-acetyl form (56) (Fig. 1) .1,25D regulates pattern recognition receptor gene expressionThe identification of NOD2 as a 1,25D target gene also provides a connection between 1,25D and autophagy, a crucial defense mechanism involving the usage of autophagosomes to target intracellular pathogens for lysosomal degradation.", [["intracellular", "ANATOMY", 75, 88], ["autophagosomes", "ANATOMY", 490, 504], ["intracellular", "ANATOMY", 515, 528], ["lysosomal", "ANATOMY", 543, 552], ["infections", "DISEASE", 89, 99], ["N-glycoyl", "CHEMICAL", 171, 180], ["MDP", "CHEMICAL", 189, 192], ["N-acetyl", "CHEMICAL", 244, 252], ["1,25D", "CHEMICAL", 418, 423], ["N-glycoyl", "CHEMICAL", 171, 180], ["MDP", "CHEMICAL", 189, 192], ["N-acetyl", "CHEMICAL", 244, 252], ["1,25D", "CHEMICAL", 365, 370], ["1,25D", "CHEMICAL", 418, 423], ["1,25D", "SIMPLE_CHEMICAL", 13, 18], ["NOD2", "GENE_OR_GENE_PRODUCT", 42, 46], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 75, 88], ["M. tuberculosis", "ORGANISM", 122, 137], ["MDP", "SIMPLE_CHEMICAL", 189, 192], ["NOD2", "GENE_OR_GENE_PRODUCT", 209, 213], ["Fig. 1) .1,25D", "SIMPLE_CHEMICAL", 264, 278], ["pattern recognition receptor", "GENE_OR_GENE_PRODUCT", 289, 317], ["NOD2", "GENE_OR_GENE_PRODUCT", 355, 359], ["1,25D", "GENE_OR_GENE_PRODUCT", 365, 370], ["1,25D", "SIMPLE_CHEMICAL", 418, 423], ["autophagosomes", "CELLULAR_COMPONENT", 490, 504], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 515, 528], ["lysosomal", "CELLULAR_COMPONENT", 543, 552], ["1,25D", "PROTEIN", 13, 18], ["NOD2", "PROTEIN", 42, 46], ["NOD2", "PROTEIN", 209, 213], ["NOD2", "PROTEIN", 355, 359], ["1,25D target gene", "DNA", 365, 382], ["M. tuberculosis", "SPECIES", 122, 137], ["M. tuberculosis", "SPECIES", 122, 137], ["1,25D-mediated regulation of NOD2", "TREATMENT", 13, 46], ["fighting intracellular infections", "PROBLEM", 66, 99], ["mycobacteria (e.g. M. tuberculosis", "PROBLEM", 103, 137], ["these bacteria", "PROBLEM", 143, 157], ["MDP", "PROBLEM", 189, 192], ["higher affinity", "PROBLEM", 219, 234], ["the N-acetyl form", "TREATMENT", 240, 257], ["NOD2", "TREATMENT", 355, 359], ["a 1,25D target gene", "TREATMENT", 363, 382], ["autophagy", "TREATMENT", 428, 437], ["a crucial defense mechanism", "PROBLEM", 439, 466], ["lysosomal degradation", "PROBLEM", 543, 564], ["NOD2", "OBSERVATION", 42, 46], ["may be relevant", "UNCERTAINTY", 47, 62], ["infections", "OBSERVATION", 89, 99], ["mycobacteria", "OBSERVATION", 103, 115], ["NOD2", "OBSERVATION", 355, 359]]], ["In particular, MDP-bound NOD2 recruits the autophagy protein ATG16L1, the product of a CD susceptibility locus, to the plasma membrane at the entry site of bacteria and, upon stimulation, induces autophagy and clearance of pathogen.", [["plasma membrane", "ANATOMY", 119, 134], ["MDP", "CHEMICAL", 15, 18], ["MDP", "CHEMICAL", 15, 18], ["MDP", "SIMPLE_CHEMICAL", 15, 18], ["NOD2", "GENE_OR_GENE_PRODUCT", 25, 29], ["ATG16L1", "GENE_OR_GENE_PRODUCT", 61, 68], ["plasma membrane", "CELLULAR_COMPONENT", 119, 134], ["NOD2", "PROTEIN", 25, 29], ["autophagy protein", "PROTEIN", 43, 60], ["ATG16L1", "PROTEIN", 61, 68], ["CD susceptibility locus", "DNA", 87, 110], ["a CD susceptibility locus", "PROBLEM", 85, 110], ["bacteria", "PROBLEM", 156, 164], ["autophagy", "PROBLEM", 196, 205], ["pathogen", "PROBLEM", 223, 231], ["bacteria", "OBSERVATION", 156, 164]]], ["However, in cells homozygous for the CD-associated NOD2 and ATG16L1 mutations, this effect was abolished, indicating that impaired autophagy in cells with these mutations supports their contribution to the pathogenesis of CD (57) .", [["cells", "ANATOMY", 12, 17], ["cells", "ANATOMY", 144, 149], ["CD", "DISEASE", 222, 224], ["cells", "CELL", 12, 17], ["CD", "GENE_OR_GENE_PRODUCT", 37, 39], ["NOD2", "GENE_OR_GENE_PRODUCT", 51, 55], ["ATG16L1", "GENE_OR_GENE_PRODUCT", 60, 67], ["cells", "CELL", 144, 149], ["NOD2", "PROTEIN", 51, 55], ["ATG16L1", "PROTEIN", 60, 67], ["the CD", "TEST", 33, 39], ["NOD2", "PROBLEM", 51, 55], ["ATG16L1 mutations", "PROBLEM", 60, 77], ["impaired autophagy in cells", "PROBLEM", 122, 149], ["these mutations", "PROBLEM", 155, 170], ["NOD2", "OBSERVATION", 51, 55], ["ATG16L1 mutations", "OBSERVATION", 60, 77], ["impaired", "OBSERVATION_MODIFIER", 122, 130], ["autophagy", "OBSERVATION", 131, 140]]], ["In addition, there is evidence for 1,25D-induced expression of CAMP and enhanced autophagy in macrophages infected with mycobacteria (58) .", [["macrophages", "ANATOMY", 94, 105], ["1,25D", "SIMPLE_CHEMICAL", 35, 40], ["CAMP", "GENE_OR_GENE_PRODUCT", 63, 67], ["macrophages", "CELL", 94, 105], ["1,25D", "PROTEIN", 35, 40], ["CAMP", "PROTEIN", 63, 67], ["macrophages", "CELL_TYPE", 94, 105], ["CAMP", "PROBLEM", 63, 67], ["enhanced autophagy in macrophages", "PROBLEM", 72, 105], ["mycobacteria", "PROBLEM", 120, 132], ["evidence for", "UNCERTAINTY", 22, 34], ["enhanced", "OBSERVATION_MODIFIER", 72, 80], ["autophagy", "OBSERVATION_MODIFIER", 81, 90], ["macrophages", "OBSERVATION_MODIFIER", 94, 105], ["infected", "OBSERVATION_MODIFIER", 106, 114], ["mycobacteria", "OBSERVATION", 120, 132]]], ["Direct effects on autophagy by vitamin D have also been reported; for instance, synthetic 1,25D analogs were shown to inhibit the mammalian target of rapamycin (mTOR), which is known to result in autophagy (59) .", [["vitamin D", "CHEMICAL", 31, 40], ["rapamycin", "CHEMICAL", 150, 159], ["vitamin D", "CHEMICAL", 31, 40], ["1,25D", "CHEMICAL", 90, 95], ["rapamycin", "CHEMICAL", 150, 159], ["vitamin D", "SIMPLE_CHEMICAL", 31, 40], ["1,25D analogs", "SIMPLE_CHEMICAL", 90, 103], ["mammalian target of rapamycin", "GENE_OR_GENE_PRODUCT", 130, 159], ["mTOR", "GENE_OR_GENE_PRODUCT", 161, 165], ["mammalian target of rapamycin", "PROTEIN", 130, 159], ["mTOR", "PROTEIN", 161, 165], ["autophagy", "TREATMENT", 18, 27], ["vitamin D", "TREATMENT", 31, 40], ["synthetic 1,25D analogs", "TREATMENT", 80, 103], ["rapamycin (mTOR", "TREATMENT", 150, 165]]], ["Also, more recently, the VDR was documented as a master transcriptional regulator of autophagy in breast cancer cells (60).1,25D regulates expression of cytokines important in innate immunityThe induction of genes encoding cytokines and chemokines also represents a crucial part of 1,25Dmediated innate protection against pathogen threat; this was highlighted by transcriptome profiling of M. tuberculosis (Mtb) infected and non-infected macrophages in the presence or absence of 1,25D, which revealed numerous genes regulated by 1,25D being altered by infection (61) .", [["breast cancer cells", "ANATOMY", 98, 117], ["macrophages", "ANATOMY", 438, 449], ["breast cancer", "DISEASE", 98, 111], ["1,25", "CHEMICAL", 282, 286], ["1,25D", "CHEMICAL", 530, 535], ["infection", "DISEASE", 553, 562], ["1,25", "CHEMICAL", 282, 286], ["1,25D", "CHEMICAL", 530, 535], ["VDR", "GENE_OR_GENE_PRODUCT", 25, 28], ["breast cancer cells", "CELL", 98, 117], ["1,25D", "SIMPLE_CHEMICAL", 123, 128], ["1,25Dmediated", "SIMPLE_CHEMICAL", 282, 295], ["M. tuberculosis (Mtb)", "ORGANISM", 390, 411], ["macrophages", "CELL", 438, 449], ["1,25D", "GENE_OR_GENE_PRODUCT", 480, 485], ["1,25D", "SIMPLE_CHEMICAL", 530, 535], ["VDR", "PROTEIN", 25, 28], ["breast cancer cells", "CELL_TYPE", 98, 117], ["1,25D", "PROTEIN", 123, 128], ["cytokines", "PROTEIN", 153, 162], ["cytokines", "PROTEIN", 223, 232], ["chemokines", "PROTEIN", 237, 247], ["non-infected macrophages", "CELL_TYPE", 425, 449], ["1,25D", "PROTEIN", 480, 485], ["M. tuberculosis", "SPECIES", 390, 405], ["M. tuberculosis", "SPECIES", 390, 405], ["autophagy in breast cancer cells", "PROBLEM", 85, 117], ["cytokines", "TREATMENT", 153, 162], ["genes encoding cytokines", "TREATMENT", 208, 232], ["chemokines", "TREATMENT", 237, 247], ["pathogen threat", "PROBLEM", 322, 337], ["M. tuberculosis (Mtb) infected and non-infected macrophages", "PROBLEM", 390, 449], ["infection", "PROBLEM", 553, 562], ["breast", "ANATOMY", 98, 104], ["cancer", "OBSERVATION", 105, 111], ["tuberculosis", "OBSERVATION", 393, 405], ["non-infected macrophages", "OBSERVATION", 425, 449], ["numerous", "OBSERVATION_MODIFIER", 502, 510], ["genes", "OBSERVATION", 511, 516], ["infection", "OBSERVATION", 553, 562]]], ["Among those genes were several chemokines and cytokines, and 1,25D was found to broadly enhance the infectionstimulated chemokine/cytokine response.", [["1,25", "CHEMICAL", 61, 65], ["1,25D", "CHEMICAL", 61, 66], ["1,25D", "SIMPLE_CHEMICAL", 61, 66], ["chemokines", "PROTEIN", 31, 41], ["cytokines", "PROTEIN", 46, 55], ["1,25D", "PROTEIN", 61, 66], ["chemokine", "PROTEIN", 120, 129], ["cytokine", "PROTEIN", 130, 138], ["cytokines", "TEST", 46, 55], ["cytokine response", "OBSERVATION", 130, 147]]], ["Specifically, 1,25D directly augmented transcription of IL-1\u03b2, one of the first cytokines generated in response to infection and is released into the circulation from its pro-form by proteolytic cleavage catalyzed by caspase 1 coupled to PRR activated complex known as the inflammasome (Fig. 1) .", [["1,25D", "CHEMICAL", 14, 19], ["infection", "DISEASE", 115, 124], ["1,25D", "CHEMICAL", 14, 19], ["1,25D", "SIMPLE_CHEMICAL", 14, 19], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 56, 61], ["caspase 1", "GENE_OR_GENE_PRODUCT", 217, 226], ["PRR", "GENE_OR_GENE_PRODUCT", 238, 241], ["IL-1\u03b2", "PROTEIN", 56, 61], ["cytokines", "PROTEIN", 80, 89], ["caspase 1", "PROTEIN", 217, 226], ["PRR activated complex", "PROTEIN", 238, 259], ["IL", "TEST", 56, 58], ["infection", "PROBLEM", 115, 124], ["proteolytic cleavage catalyzed", "TREATMENT", 183, 213], ["infection", "OBSERVATION", 115, 124]]], ["The physiological significance of this was demonstrated by a co-culture of infected macrophages with primary human airway epithelial cells; from this, it was shown that the 1,25D1,25D regulates expression of cytokines important in innate immunityand Mtb induced IL-1\u03b2 secretion prolonged survival in infected macrophages and decreased Mtb burden in those cells by inducing DEFB4 production in the co-cultured lung epithelial cells.", [["macrophages", "ANATOMY", 84, 95], ["airway epithelial cells", "ANATOMY", 115, 138], ["macrophages", "ANATOMY", 309, 320], ["cells", "ANATOMY", 355, 360], ["lung epithelial cells", "ANATOMY", 409, 430], ["1,25", "CHEMICAL", 173, 177], ["macrophages", "CELL", 84, 95], ["human", "ORGANISM", 109, 114], ["airway epithelial cells", "CELL", 115, 138], ["1,25D1", "GENE_OR_GENE_PRODUCT", 173, 179], ["25D", "SIMPLE_CHEMICAL", 180, 183], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 262, 267], ["macrophages", "CELL", 309, 320], ["Mtb", "GENE_OR_GENE_PRODUCT", 335, 338], ["cells", "CELL", 355, 360], ["DEFB4", "GENE_OR_GENE_PRODUCT", 373, 378], ["lung epithelial cells", "CELL", 409, 430], ["infected macrophages", "CELL_TYPE", 75, 95], ["primary human airway epithelial cells", "CELL_TYPE", 101, 138], ["cytokines", "PROTEIN", 208, 217], ["IL-1\u03b2", "PROTEIN", 262, 267], ["infected macrophages", "CELL_TYPE", 300, 320], ["DEFB4", "PROTEIN", 373, 378], ["co-cultured lung epithelial cells", "CELL_LINE", 397, 430], ["human", "SPECIES", 109, 114], ["human", "SPECIES", 109, 114], ["infected macrophages", "PROBLEM", 75, 95], ["primary human airway epithelial cells", "PROBLEM", 101, 138], ["cytokines", "TREATMENT", 208, 217], ["IL", "TEST", 262, 264], ["secretion prolonged survival", "PROBLEM", 268, 296], ["infected macrophages", "PROBLEM", 300, 320], ["decreased Mtb burden in those cells", "PROBLEM", 325, 360], ["DEFB4 production", "PROBLEM", 373, 389], ["infected macrophages", "OBSERVATION", 75, 95], ["airway epithelial cells", "OBSERVATION", 115, 138], ["infected macrophages", "OBSERVATION", 300, 320], ["decreased", "OBSERVATION_MODIFIER", 325, 334], ["Mtb burden", "OBSERVATION", 335, 345], ["lung", "ANATOMY", 409, 413], ["epithelial cells", "OBSERVATION", 414, 430]]], ["IL-8, a neutrophil chemoattractant, is another cytokine robustly stimulated by 1,25D in uninfected and Mtb infected macrophages, and it would be of interest to investigate whether there is a corresponding effect on the expression of CXCR2, the IL-8 cell surface receptor, on 1,25D-treated pathogen-challenged human neutrophils (Fig. 1) .", [["neutrophil", "ANATOMY", 8, 18], ["macrophages", "ANATOMY", 116, 127], ["cell surface", "ANATOMY", 249, 261], ["neutrophils", "ANATOMY", 315, 326], ["1,25D", "CHEMICAL", 79, 84], ["1,25D", "CHEMICAL", 79, 84], ["IL-8", "GENE_OR_GENE_PRODUCT", 0, 4], ["neutrophil", "CELL", 8, 18], ["1,25D", "SIMPLE_CHEMICAL", 79, 84], ["Mtb", "CELL", 103, 106], ["macrophages", "CELL", 116, 127], ["CXCR2", "GENE_OR_GENE_PRODUCT", 233, 238], ["IL-8 cell surface receptor", "GENE_OR_GENE_PRODUCT", 244, 270], ["1,25D", "SIMPLE_CHEMICAL", 275, 280], ["human", "ORGANISM", 309, 314], ["neutrophils", "CELL", 315, 326], ["IL-8", "PROTEIN", 0, 4], ["neutrophil chemoattractant", "PROTEIN", 8, 34], ["cytokine", "PROTEIN", 47, 55], ["uninfected and Mtb infected macrophages", "CELL_TYPE", 88, 127], ["CXCR2", "PROTEIN", 233, 238], ["IL-8 cell surface receptor", "PROTEIN", 244, 270], ["1,25D-treated pathogen-challenged human neutrophils", "CELL_LINE", 275, 326], ["human", "SPECIES", 309, 314], ["human", "SPECIES", 309, 314], ["IL", "TEST", 0, 2], ["a neutrophil chemoattractant", "TREATMENT", 6, 34], ["CXCR2", "TEST", 233, 238], ["the IL-8 cell surface receptor", "TREATMENT", 240, 270], ["1,25D-treated pathogen", "TREATMENT", 275, 297], ["infected macrophages", "OBSERVATION", 107, 127]]], ["Other secreted agents generated by 1,25D-exposed infected macrophages include the chemokines CCL3, CCL4 and CCL8 (61).1,25D regulates expression of cytokines important in innate immunity1,25D has also been shown to dose-dependently attenuate the expression of pro-inflammatory cytokines IL-6, TNF\u03b1, and IFN-\u03b3 in Mtb infected human peripheral blood mononuclear cells (62) .", [["macrophages", "ANATOMY", 58, 69], ["peripheral blood mononuclear cells", "ANATOMY", 331, 365], ["1,25D", "CHEMICAL", 35, 40], ["1,25D", "CHEMICAL", 186, 191], ["1,25D", "CHEMICAL", 186, 191], ["1,25D", "SIMPLE_CHEMICAL", 35, 40], ["macrophages", "CELL", 58, 69], ["CCL3", "GENE_OR_GENE_PRODUCT", 93, 97], ["CCL4", "GENE_OR_GENE_PRODUCT", 99, 103], ["CCL8", "GENE_OR_GENE_PRODUCT", 108, 112], ["1,25D", "SIMPLE_CHEMICAL", 118, 123], ["1,25D", "SIMPLE_CHEMICAL", 186, 191], ["IL-6", "GENE_OR_GENE_PRODUCT", 287, 291], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 293, 297], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 303, 308], ["Mtb", "ORGANISM", 312, 315], ["human", "ORGANISM", 325, 330], ["peripheral blood mononuclear cells", "CELL", 331, 365], ["1,25D-exposed infected macrophages", "CELL_TYPE", 35, 69], ["chemokines", "PROTEIN", 82, 92], ["CCL3", "PROTEIN", 93, 97], ["CCL4", "PROTEIN", 99, 103], ["CCL8", "PROTEIN", 108, 112], ["61", "PROTEIN", 114, 116], ["1,25D", "PROTEIN", 118, 123], ["cytokines", "PROTEIN", 148, 157], ["pro-inflammatory cytokines", "PROTEIN", 260, 286], ["IL-6", "PROTEIN", 287, 291], ["TNF\u03b1", "PROTEIN", 293, 297], ["IFN-\u03b3", "PROTEIN", 303, 308], ["human peripheral blood mononuclear cells", "CELL_TYPE", 325, 365], ["human", "SPECIES", 325, 330], ["human", "SPECIES", 325, 330], ["Other secreted agents", "TREATMENT", 0, 21], ["the chemokines CCL3", "TEST", 78, 97], ["CCL8", "TEST", 108, 112], ["1,25D regulates expression of cytokines", "TREATMENT", 118, 157], ["pro-inflammatory cytokines IL", "TEST", 260, 289], ["TNF", "TEST", 293, 296], ["IFN", "TEST", 303, 306], ["peripheral blood mononuclear cells", "TEST", 331, 365], ["infected macrophages", "OBSERVATION", 49, 69], ["CCL4", "ANATOMY", 99, 103], ["peripheral", "ANATOMY_MODIFIER", 331, 341], ["blood", "ANATOMY", 342, 347], ["mononuclear cells", "OBSERVATION", 348, 365]]], ["On the other hand, the authors of this study also reported enhanced expression of IL-10, an anti-inflammatory cytokine, by 1,25D.", [["1,25D.", "CHEMICAL", 123, 129], ["1,25D.", "CHEMICAL", 123, 129], ["IL-10", "GENE_OR_GENE_PRODUCT", 82, 87], ["1,25D.", "SIMPLE_CHEMICAL", 123, 129], ["IL-10", "PROTEIN", 82, 87], ["anti-inflammatory cytokine", "PROTEIN", 92, 118], ["this study", "TEST", 34, 44]]], ["The proposed mechanism behind the inhibited proinflammatory cytokine response appears to involve a VDR-mediated repression at the mRNA and protein level of the PRRs TLR2, TLR4, Dectin-1 and mannose receptor (62) .", [["mannose", "CHEMICAL", 190, 197], ["VDR", "GENE_OR_GENE_PRODUCT", 99, 102], ["TLR2", "GENE_OR_GENE_PRODUCT", 165, 169], ["TLR4", "GENE_OR_GENE_PRODUCT", 171, 175], ["Dectin-1", "GENE_OR_GENE_PRODUCT", 177, 185], ["mannose receptor (62)", "GENE_OR_GENE_PRODUCT", 190, 211], ["proinflammatory cytokine", "PROTEIN", 44, 68], ["VDR", "PROTEIN", 99, 102], ["PRRs", "PROTEIN", 160, 164], ["TLR2", "PROTEIN", 165, 169], ["TLR4", "PROTEIN", 171, 175], ["Dectin-1", "PROTEIN", 177, 185], ["mannose receptor", "PROTEIN", 190, 206], ["the inhibited proinflammatory cytokine response", "PROBLEM", 30, 77], ["a VDR-mediated repression at the mRNA", "PROBLEM", 97, 134], ["Dectin", "TEST", 177, 183], ["PRRs TLR2", "ANATOMY", 160, 169]]], ["Furthermore, LPS-induced production of IL-6 and TNF\u03b1 was inhibited by 1,25D in human and murine monocytes and macrophages (63, 64) , and this regulation appeared to differ with the stage of monocyte/macrophage maturation and was dependent on MAPK phosphatase 1 (64) .", [["monocytes", "ANATOMY", 96, 105], ["macrophages", "ANATOMY", 110, 121], ["monocyte", "ANATOMY", 190, 198], ["macrophage", "ANATOMY", 199, 209], ["LPS", "CHEMICAL", 13, 16], ["1,25D", "CHEMICAL", 70, 75], ["1,25D", "CHEMICAL", 70, 75], ["LPS", "SIMPLE_CHEMICAL", 13, 16], ["IL-6", "GENE_OR_GENE_PRODUCT", 39, 43], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 48, 52], ["1,25D", "SIMPLE_CHEMICAL", 70, 75], ["human", "ORGANISM", 79, 84], ["murine", "ORGANISM", 89, 95], ["monocytes", "CELL", 96, 105], ["macrophages", "CELL", 110, 121], ["monocyte", "CELL", 190, 198], ["macrophage", "CELL", 199, 209], ["MAPK phosphatase 1", "GENE_OR_GENE_PRODUCT", 242, 260], ["IL-6", "PROTEIN", 39, 43], ["TNF\u03b1", "PROTEIN", 48, 52], ["human and murine monocytes", "CELL_TYPE", 79, 105], ["macrophages", "CELL_TYPE", 110, 121], ["MAPK phosphatase 1", "PROTEIN", 242, 260], ["human", "SPECIES", 79, 84], ["murine", "SPECIES", 89, 95], ["human", "SPECIES", 79, 84], ["LPS", "TEST", 13, 16], ["IL", "TEST", 39, 41], ["TNF\u03b1", "TEST", 48, 52], ["murine monocytes", "TEST", 89, 105], ["macrophages", "TEST", 110, 121], ["monocyte/macrophage maturation", "TREATMENT", 190, 220], ["MAPK phosphatase", "TEST", 242, 258], ["macrophages", "ANATOMY", 110, 121], ["macrophage maturation", "OBSERVATION", 199, 220]]], ["There is also evidence for 1,25D acting in synergy with other agents to regulate IL-6 expression.", [["1,25D", "CHEMICAL", 27, 32], ["1,25D", "CHEMICAL", 27, 32], ["1,25D", "SIMPLE_CHEMICAL", 27, 32], ["IL-6", "GENE_OR_GENE_PRODUCT", 81, 85], ["IL-6", "PROTEIN", 81, 85], ["1,25D acting in synergy", "PROBLEM", 27, 50], ["other agents", "TREATMENT", 56, 68]]], ["For example, 1,25D was found to enhance glucocorticoid-induced suppression of LPSstimulated IL-6 in human monocytes (65).Vitamin D and granulocyte biologyMost of the studies to date have investigated the innate immune regulation by vitamin D in monocytes and macrophages.", [["monocytes", "ANATOMY", 106, 115], ["monocytes", "ANATOMY", 245, 254], ["macrophages", "ANATOMY", 259, 270], ["1,25D", "CHEMICAL", 13, 18], ["Vitamin D", "CHEMICAL", 121, 130], ["vitamin D", "CHEMICAL", 232, 241], ["1,25D", "CHEMICAL", 13, 18], ["Vitamin D", "CHEMICAL", 121, 130], ["vitamin D", "CHEMICAL", 232, 241], ["1,25D", "SIMPLE_CHEMICAL", 13, 18], ["glucocorticoid", "SIMPLE_CHEMICAL", 40, 54], ["IL-6", "GENE_OR_GENE_PRODUCT", 92, 96], ["human", "ORGANISM", 100, 105], ["monocytes", "CELL", 106, 115], ["Vitamin D", "SIMPLE_CHEMICAL", 121, 130], ["granulocyte", "CELL", 135, 146], ["vitamin D", "SIMPLE_CHEMICAL", 232, 241], ["monocytes", "CELL", 245, 254], ["macrophages", "CELL", 259, 270], ["LPSstimulated IL-6", "PROTEIN", 78, 96], ["human monocytes", "CELL_TYPE", 100, 115], ["monocytes", "CELL_TYPE", 245, 254], ["macrophages", "CELL_TYPE", 259, 270], ["human", "SPECIES", 100, 105], ["human", "SPECIES", 100, 105], ["glucocorticoid", "TEST", 40, 54], ["LPSstimulated IL", "TREATMENT", 78, 94], ["Vitamin D", "TREATMENT", 121, 130], ["granulocyte biology", "TREATMENT", 135, 154], ["the studies", "TEST", 162, 173], ["vitamin D in monocytes", "TEST", 232, 254], ["macrophages", "ANATOMY", 259, 270]]], ["However, it is important to note that a variety of cell types express PRRs and acquire the necessary tools to generate innate immune responses to pathogen threat.", [["cell", "ANATOMY", 51, 55], ["cell", "CELL", 51, 55], ["PRRs", "GENE_OR_GENE_PRODUCT", 70, 74], ["PRRs", "PROTEIN", 70, 74]]], ["The most abundant among these are granulocytic cells such as neutrophils; these short-lived cells with a circulating half-life of 6-8 hours represent 70% of all leukocytes and, in response to inflammatory stimuli, are rapidly recruited to sites of infection where they efficiently bind, engulf, and inactivate bacteria (66) .Vitamin D and granulocyte biologyNeutrophils are known to express VDR mRNA at a level comparable to monocytes, and once treated with 1,25D, also induce expression of CD14 (67) .", [["granulocytic cells", "ANATOMY", 34, 52], ["neutrophils", "ANATOMY", 61, 72], ["cells", "ANATOMY", 92, 97], ["leukocytes", "ANATOMY", 161, 171], ["sites", "ANATOMY", 239, 244], ["Neutrophils", "ANATOMY", 358, 369], ["monocytes", "ANATOMY", 425, 434], ["infection", "DISEASE", 248, 257], ["Vitamin D", "CHEMICAL", 325, 334], ["Vitamin D", "CHEMICAL", 325, 334], ["granulocytic cells", "CELL", 34, 52], ["neutrophils", "CELL", 61, 72], ["cells", "CELL", 92, 97], ["leukocytes", "CELL", 161, 171], ["Vitamin D", "SIMPLE_CHEMICAL", 325, 334], ["granulocyte", "CELL", 339, 350], ["Neutrophils", "CELL", 358, 369], ["VDR", "GENE_OR_GENE_PRODUCT", 391, 394], ["monocytes", "CELL", 425, 434], ["CD14", "GENE_OR_GENE_PRODUCT", 491, 495], ["granulocytic cells", "CELL_TYPE", 34, 52], ["neutrophils", "CELL_TYPE", 61, 72], ["short-lived cells", "CELL_TYPE", 80, 97], ["leukocytes", "CELL_TYPE", 161, 171], ["Neutrophils", "CELL_TYPE", 358, 369], ["VDR mRNA", "RNA", 391, 399], ["monocytes", "CELL_TYPE", 425, 434], ["CD14", "PROTEIN", 491, 495], ["granulocytic cells", "PROBLEM", 34, 52], ["neutrophils", "TEST", 61, 72], ["all leukocytes", "TEST", 157, 171], ["inflammatory stimuli", "TEST", 192, 212], ["infection", "PROBLEM", 248, 257], ["inactivate bacteria", "PROBLEM", 299, 318], ["Vitamin D", "TREATMENT", 325, 334], ["granulocyte biology", "TREATMENT", 339, 358], ["Neutrophils", "TEST", 358, 369], ["VDR mRNA", "PROBLEM", 391, 399], ["monocytes", "TEST", 425, 434], ["CD14", "TEST", 491, 495], ["most abundant", "OBSERVATION_MODIFIER", 4, 17], ["granulocytic cells", "OBSERVATION", 34, 52], ["all leukocytes", "OBSERVATION_MODIFIER", 157, 171], ["inflammatory stimuli", "OBSERVATION", 192, 212], ["infection", "OBSERVATION", 248, 257]]], ["These granulocytic cells are among the cell types that exhibit 1,25D-driven expression of CAMP, although the physiological relevance of this has yet to be determined (37).", [["granulocytic cells", "ANATOMY", 6, 24], ["cell", "ANATOMY", 39, 43], ["granulocytic cells", "CELL", 6, 24], ["cell", "CELL", 39, 43], ["CAMP", "GENE_OR_GENE_PRODUCT", 90, 94], ["granulocytic cells", "CELL_TYPE", 6, 24], ["1,25D", "PROTEIN", 63, 68], ["CAMP", "PROTEIN", 90, 94], ["These granulocytic cells", "PROBLEM", 0, 24], ["CAMP", "PROBLEM", 90, 94], ["granulocytic cells", "OBSERVATION", 6, 24]]], ["Unlike monocytes, however, neutrophils do not appear to express CYP27B1, suggesting that they are more likely to be systemic responders to hormonal 1,25D.", [["monocytes", "ANATOMY", 7, 16], ["neutrophils", "ANATOMY", 27, 38], ["1,25D.", "CHEMICAL", 148, 154], ["monocytes", "CELL", 7, 16], ["neutrophils", "CELL", 27, 38], ["CYP27B1", "GENE_OR_GENE_PRODUCT", 64, 71], ["monocytes", "CELL_TYPE", 7, 16], ["neutrophils", "CELL_TYPE", 27, 38], ["CYP27B1", "PROTEIN", 64, 71], ["Unlike monocytes", "PROBLEM", 0, 16], ["neutrophils", "TEST", 27, 38], ["monocytes", "OBSERVATION", 7, 16]]], ["Despite this, they appear to be the major source of serum cathelicidin/LL37 due to their abundance and the presence of neutrophil granules that store the majority of LL37 released at infection sites (68, 69) .", [["serum", "ANATOMY", 52, 57], ["neutrophil granules", "ANATOMY", 119, 138], ["infection", "DISEASE", 183, 192], ["serum", "ORGANISM_SUBSTANCE", 52, 57], ["cathelicidin", "GENE_OR_GENE_PRODUCT", 58, 70], ["LL37", "GENE_OR_GENE_PRODUCT", 71, 75], ["neutrophil granules", "CELLULAR_COMPONENT", 119, 138], ["LL37", "GENE_OR_GENE_PRODUCT", 166, 170], ["serum cathelicidin", "PROTEIN", 52, 70], ["LL37", "PROTEIN", 71, 75], ["LL37", "PROTEIN", 166, 170], ["serum cathelicidin/LL37", "TREATMENT", 52, 75], ["neutrophil granules", "PROBLEM", 119, 138], ["neutrophil granules", "OBSERVATION", 119, 138], ["majority", "OBSERVATION_MODIFIER", 154, 162], ["infection", "OBSERVATION", 183, 192]]], ["A link between low serum LL37 and mortality in patients with chronic kidney disease has been reported; the levels of LL37 correlated with serum 1,25D rather than 25D, which may serve as an endocrine-regulated innate immune response that may involve CYP27B1-negative, VDR-positive neutrophils (70, 71) .", [["serum", "ANATOMY", 19, 24], ["kidney", "ANATOMY", 69, 75], ["serum", "ANATOMY", 138, 143], ["endocrine", "ANATOMY", 189, 198], ["neutrophils", "ANATOMY", 280, 291], ["chronic kidney disease", "DISEASE", 61, 83], ["serum", "ORGANISM_SUBSTANCE", 19, 24], ["LL37", "GENE_OR_GENE_PRODUCT", 25, 29], ["patients", "ORGANISM", 47, 55], ["kidney", "ORGAN", 69, 75], ["LL37", "GENE_OR_GENE_PRODUCT", 117, 121], ["serum", "ORGANISM_SUBSTANCE", 138, 143], ["1,25D", "GENE_OR_GENE_PRODUCT", 144, 149], ["25D", "GENE_OR_GENE_PRODUCT", 162, 165], ["CYP27B1", "GENE_OR_GENE_PRODUCT", 249, 256], ["VDR", "GENE_OR_GENE_PRODUCT", 267, 270], ["serum LL37", "PROTEIN", 19, 29], ["LL37", "PROTEIN", 117, 121], ["serum 1,25D", "PROTEIN", 138, 149], ["CYP27B1", "PROTEIN", 249, 256], ["VDR", "PROTEIN", 267, 270], ["positive neutrophils", "CELL_TYPE", 271, 291], ["patients", "SPECIES", 47, 55], ["A link between low serum LL37", "PROBLEM", 0, 29], ["chronic kidney disease", "PROBLEM", 61, 83], ["the levels", "TEST", 103, 113], ["serum 1,25D", "TEST", 138, 149], ["CYP27B1", "TEST", 249, 256], ["VDR", "TEST", 267, 270], ["neutrophils", "TEST", 280, 291], ["chronic", "OBSERVATION_MODIFIER", 61, 68], ["kidney", "ANATOMY", 69, 75], ["disease", "OBSERVATION", 76, 83], ["positive neutrophils", "OBSERVATION_MODIFIER", 271, 291]]], ["However, in patients with sepsis, a systemic inflammatory disease associated with maintained presence of neutrophils, circulating levels of LL37 are lower in more severe cases and this is correlated with low serum levels of 25D (72) .Vitamin D and granulocyte biologyIn the early 2000s, a physiological role for the VDR in neutrophils was investigated by using differential display analysis to identify expression of genes in 1,25D-treated, LPS-stimulated neutrophils (67) .", [["neutrophils", "ANATOMY", 105, 116], ["serum", "ANATOMY", 208, 213], ["neutrophils", "ANATOMY", 323, 334], ["neutrophils", "ANATOMY", 456, 467], ["sepsis", "DISEASE", 26, 32], ["inflammatory disease", "DISEASE", 45, 65], ["Vitamin D", "CHEMICAL", 234, 243], ["LPS", "CHEMICAL", 441, 444], ["Vitamin D", "CHEMICAL", 234, 243], ["patients", "ORGANISM", 12, 20], ["neutrophils", "CELL", 105, 116], ["LL37", "GENE_OR_GENE_PRODUCT", 140, 144], ["serum", "ORGANISM_SUBSTANCE", 208, 213], ["Vitamin D", "SIMPLE_CHEMICAL", 234, 243], ["granulocyte", "CELL", 248, 259], ["VDR", "GENE_OR_GENE_PRODUCT", 316, 319], ["neutrophils", "CELL", 323, 334], ["1,25D", "SIMPLE_CHEMICAL", 426, 431], ["LPS", "SIMPLE_CHEMICAL", 441, 444], ["neutrophils", "CELL", 456, 467], ["neutrophils", "CELL_TYPE", 105, 116], ["LL37", "PROTEIN", 140, 144], ["VDR", "PROTEIN", 316, 319], ["neutrophils", "CELL_TYPE", 323, 334], ["1,25D-treated, LPS-stimulated neutrophils", "CELL_LINE", 426, 467], ["patients", "SPECIES", 12, 20], ["sepsis", "PROBLEM", 26, 32], ["a systemic inflammatory disease", "PROBLEM", 34, 65], ["neutrophils", "TEST", 105, 116], ["circulating levels", "TEST", 118, 136], ["low serum levels", "PROBLEM", 204, 220], ["Vitamin D", "TREATMENT", 234, 243], ["granulocyte biology", "TREATMENT", 248, 267], ["the VDR in neutrophils", "TEST", 312, 334], ["differential display analysis", "TEST", 361, 390], ["expression of genes", "PROBLEM", 403, 422], ["LPS", "TEST", 441, 444], ["neutrophils", "TEST", 456, 467], ["sepsis", "OBSERVATION", 26, 32], ["systemic", "OBSERVATION_MODIFIER", 36, 44], ["inflammatory", "OBSERVATION", 45, 57], ["neutrophils", "OBSERVATION", 105, 116], ["lower", "OBSERVATION_MODIFIER", 149, 154], ["more severe", "OBSERVATION_MODIFIER", 158, 169]]], ["Of the genes identified, the neutrophil elastase inhibitor trappin-2/elafin/SKALP was potently induced in LPS-exposed neutrophils but was mildly suppressed by 1,25D.", [["neutrophil", "ANATOMY", 29, 39], ["neutrophils", "ANATOMY", 118, 129], ["trappin-2/elafin", "CHEMICAL", 59, 75], ["LPS", "CHEMICAL", 106, 109], ["1,25D.", "CHEMICAL", 159, 165], ["trappin-2", "CHEMICAL", 59, 68], ["1,25D.", "CHEMICAL", 159, 165], ["neutrophil elastase", "GENE_OR_GENE_PRODUCT", 29, 48], ["trappin-2", "GENE_OR_GENE_PRODUCT", 59, 68], ["elafin", "GENE_OR_GENE_PRODUCT", 69, 75], ["SKALP", "GENE_OR_GENE_PRODUCT", 76, 81], ["LPS", "SIMPLE_CHEMICAL", 106, 109], ["neutrophils", "CELL", 118, 129], ["neutrophil elastase inhibitor trappin-2/elafin/SKALP", "PROTEIN", 29, 81], ["LPS-exposed neutrophils", "CELL_LINE", 106, 129], ["the neutrophil elastase inhibitor trappin", "TEST", 25, 66], ["elafin/SKALP", "TREATMENT", 69, 81], ["mildly suppressed", "PROBLEM", 138, 155]]], ["Under the same conditions IL-1\u03b2 was slightly inhibited by the active hormone (67) .", [["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 26, 31], ["IL-1\u03b2", "PROTEIN", 26, 31]]], ["Since then, a few other studies have delved into the role of vitamin D in neutrophil innate immunity.", [["neutrophil", "ANATOMY", 74, 84], ["vitamin D", "CHEMICAL", 61, 70], ["vitamin D", "CHEMICAL", 61, 70], ["vitamin D", "SIMPLE_CHEMICAL", 61, 70], ["neutrophil", "CELL", 74, 84], ["a few other studies", "TEST", 12, 31], ["vitamin D in neutrophil innate immunity", "TREATMENT", 61, 100]]], ["Among those was one that found increased apoptosis in neutrophils from COPD patients treated with 1,25D (73) .", [["neutrophils", "ANATOMY", 54, 65], ["COPD", "DISEASE", 71, 75], ["1,25D (73)", "CHEMICAL", 98, 108], ["neutrophils", "CELL", 54, 65], ["patients", "ORGANISM", 76, 84], ["neutrophils", "CELL_TYPE", 54, 65], ["patients", "SPECIES", 76, 84], ["increased apoptosis in neutrophils", "PROBLEM", 31, 65], ["COPD", "PROBLEM", 71, 75], ["increased", "OBSERVATION_MODIFIER", 31, 40], ["apoptosis", "OBSERVATION", 41, 50], ["neutrophils", "OBSERVATION_MODIFIER", 54, 65], ["COPD", "OBSERVATION", 71, 75]]], ["This is noteworthy because COPD pathogenesis is characterized by a lower rate of neutrophil apoptosis, and vitamin D acquired the capacity to counter this via activation of p38 MAPK.", [["neutrophil", "ANATOMY", 81, 91], ["COPD", "DISEASE", 27, 31], ["vitamin D", "CHEMICAL", 107, 116], ["vitamin D", "CHEMICAL", 107, 116], ["neutrophil", "CELL", 81, 91], ["vitamin D", "SIMPLE_CHEMICAL", 107, 116], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 173, 181], ["neutrophil", "CELL_TYPE", 81, 91], ["p38 MAPK", "PROTEIN", 173, 181], ["COPD pathogenesis", "PROBLEM", 27, 44], ["a lower rate of neutrophil apoptosis", "PROBLEM", 65, 101], ["vitamin D", "TREATMENT", 107, 116], ["the capacity", "PROBLEM", 126, 138], ["this via activation of p38 MAPK", "TREATMENT", 150, 181], ["lower", "OBSERVATION_MODIFIER", 67, 72], ["neutrophil apoptosis", "OBSERVATION", 81, 101]]], ["Furthermore, 1,25D treatment enhanced the production of IL-8 in LPS-exposed neutrophils, however no effect was detected on the phagocytic capacity of the cells when challenged with E. Coli (74) .Vitamin D and granulocyte biologyRecently, the formation of neutrophil extracellular traps (NETs) by vitamin D was explored; the production of these networks of extracellular fibres composed of DNA, histones and enzymes that function to immobilize pathogens were enhanced by 1,25D (75) .", [["neutrophils", "ANATOMY", 76, 87], ["cells", "ANATOMY", 154, 159], ["neutrophil extracellular", "ANATOMY", 255, 279], ["extracellular fibres", "ANATOMY", 356, 376], ["1,25D", "CHEMICAL", 13, 18], ["LPS", "CHEMICAL", 64, 67], ["Vitamin D", "CHEMICAL", 195, 204], ["vitamin D", "CHEMICAL", 296, 305], ["1,25D", "CHEMICAL", 13, 18], ["Vitamin D", "CHEMICAL", 195, 204], ["vitamin D", "CHEMICAL", 296, 305], ["1,25D", "CHEMICAL", 470, 475], ["1,25D", "SIMPLE_CHEMICAL", 13, 18], ["IL-8", "GENE_OR_GENE_PRODUCT", 56, 60], ["LPS", "SIMPLE_CHEMICAL", 64, 67], ["neutrophils", "CELL", 76, 87], ["cells", "CELL", 154, 159], ["E. Coli", "ORGANISM", 181, 188], ["Vitamin D", "SIMPLE_CHEMICAL", 195, 204], ["granulocyte", "CELL", 209, 220], ["neutrophil", "CELL", 255, 265], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 266, 279], ["vitamin D", "SIMPLE_CHEMICAL", 296, 305], ["extracellular fibres", "CELLULAR_COMPONENT", 356, 376], ["DNA", "CELLULAR_COMPONENT", 389, 392], ["histones", "CELLULAR_COMPONENT", 394, 402], ["IL-8", "PROTEIN", 56, 60], ["neutrophils", "CELL_TYPE", 76, 87], ["histones", "PROTEIN", 394, 402], ["enzymes", "PROTEIN", 407, 414], ["E. Coli", "SPECIES", 181, 188], ["E. Coli", "SPECIES", 181, 188], ["1,25D treatment", "TREATMENT", 13, 28], ["IL", "TEST", 56, 58], ["exposed neutrophils", "PROBLEM", 68, 87], ["E. Coli", "TEST", 181, 188], ["Vitamin D", "TREATMENT", 195, 204], ["granulocyte biology", "TREATMENT", 209, 228], ["neutrophil extracellular traps", "TREATMENT", 255, 285], ["vitamin D", "TREATMENT", 296, 305], ["extracellular fibres", "PROBLEM", 356, 376], ["DNA, histones", "PROBLEM", 389, 402], ["enzymes", "TEST", 407, 414], ["no", "UNCERTAINTY", 97, 99]]], ["However, the NETs-like structures were not verified to be bona fide NETs.", [["NETs-like structures", "ANATOMY", 13, 33], ["NETs", "ANATOMY", 68, 72], ["NETs", "CANCER", 68, 72]]], ["Moreover, 1,25D was reported to augment neutrophil killing of Streptococcus pneumoniae and also to lower inflammatory cytokine production by inducing the expression of the anti-inflammatory cytokine IL-4 and suppressor of cytokine signaling (SOCS) proteins (76) .", [["neutrophil", "ANATOMY", 40, 50], ["1,25D", "CHEMICAL", 10, 15], ["1,25D", "CHEMICAL", 10, 15], ["1,25D", "SIMPLE_CHEMICAL", 10, 15], ["neutrophil", "CELL", 40, 50], ["Streptococcus pneumoniae", "ORGANISM", 62, 86], ["IL-4", "GENE_OR_GENE_PRODUCT", 199, 203], ["suppressor of cytokine signaling (SOCS) proteins", "GENE_OR_GENE_PRODUCT", 208, 256], ["inflammatory cytokine", "PROTEIN", 105, 126], ["anti-inflammatory cytokine IL-4", "PROTEIN", 172, 203], ["suppressor of cytokine signaling (SOCS) proteins", "PROTEIN", 208, 256], ["Streptococcus pneumoniae", "SPECIES", 62, 86], ["Streptococcus pneumoniae", "SPECIES", 62, 86], ["Streptococcus pneumoniae", "PROBLEM", 62, 86], ["lower inflammatory cytokine production", "PROBLEM", 99, 137], ["the anti-inflammatory cytokine IL", "TREATMENT", 168, 201], ["Streptococcus pneumoniae", "OBSERVATION", 62, 86], ["lower", "OBSERVATION_MODIFIER", 99, 104], ["inflammatory cytokine", "OBSERVATION", 105, 126]]], ["Overall, these findings suggest a role for vitamin D in dampening neutrophil-driven inflammatory responses while still boosting pathogen killing by the cells; however one study found that although 1,25D decreased LPS-induced expression of macrophage inflammatory protein-1\u03b2 and VEGF in adult neutrophils, this anti-inflammatory response was not observed in neonatal cells (77) .", [["neutrophil", "ANATOMY", 66, 76], ["cells", "ANATOMY", 152, 157], ["adult neutrophils", "ANATOMY", 286, 303], ["neonatal cells", "ANATOMY", 357, 371], ["vitamin D", "CHEMICAL", 43, 52], ["LPS", "CHEMICAL", 213, 216], ["vitamin D", "CHEMICAL", 43, 52], ["1,25D", "CHEMICAL", 197, 202], ["vitamin D", "SIMPLE_CHEMICAL", 43, 52], ["neutrophil", "CELL", 66, 76], ["cells", "CELL", 152, 157], ["1,25D", "SIMPLE_CHEMICAL", 197, 202], ["LPS", "SIMPLE_CHEMICAL", 213, 216], ["macrophage inflammatory protein-1\u03b2", "GENE_OR_GENE_PRODUCT", 239, 273], ["VEGF", "GENE_OR_GENE_PRODUCT", 278, 282], ["neutrophils", "CELL", 292, 303], ["cells", "CELL", 366, 371], ["neutrophil", "CELL_TYPE", 66, 76], ["macrophage inflammatory protein-1\u03b2", "PROTEIN", 239, 273], ["VEGF", "PROTEIN", 278, 282], ["adult neutrophils", "CELL_TYPE", 286, 303], ["neonatal cells", "CELL_TYPE", 357, 371], ["vitamin D in dampening neutrophil", "PROBLEM", 43, 76], ["inflammatory responses", "PROBLEM", 84, 106], ["one study", "TEST", 167, 176], ["1,25D decreased LPS", "PROBLEM", 197, 216], ["macrophage inflammatory protein", "TEST", 239, 270], ["VEGF in adult neutrophils", "PROBLEM", 278, 303], ["macrophage", "OBSERVATION_MODIFIER", 239, 249], ["inflammatory", "OBSERVATION_MODIFIER", 250, 262]]], ["The authors speculate that this may be due to decreased expression of VDR and CYP27B1 in neonates.Eosinophils, granulocytic effector cells involved in T helper type 2 cell (Th2)-mediated diseases,such as asthma and atopic dermatitis (78), are also subject to the effects of vitamin D. In a murine model of lung eosinophilic inflammation, treatment with vitamin D decreased airway eosinophilia, and this was attributed to the downregulatory effect of 1,25D on IL-15, the key cytokine implicated in recruitment of eosinophils to local inflammatory sites (79) .", [["Eosinophils", "ANATOMY", 98, 109], ["granulocytic effector cells", "ANATOMY", 111, 138], ["T helper type 2 cell", "ANATOMY", 151, 171], ["lung eosinophilic", "ANATOMY", 306, 323], ["airway", "ANATOMY", 373, 379], ["eosinophils", "ANATOMY", 512, 523], ["asthma", "DISEASE", 204, 210], ["atopic dermatitis", "DISEASE", 215, 232], ["vitamin D.", "CHEMICAL", 274, 284], ["lung eosinophilic inflammation", "DISEASE", 306, 336], ["vitamin D", "CHEMICAL", 353, 362], ["airway eosinophilia", "DISEASE", 373, 392], ["1,25D", "CHEMICAL", 450, 455], ["vitamin D.", "CHEMICAL", 274, 284], ["vitamin D", "CHEMICAL", 353, 362], ["1,25D", "CHEMICAL", 450, 455], ["VDR", "GENE_OR_GENE_PRODUCT", 70, 73], ["CYP27B1", "GENE_OR_GENE_PRODUCT", 78, 85], ["Eosinophils", "CELL", 98, 109], ["granulocytic effector cells", "CELL", 111, 138], ["T helper type 2 cell", "CELL", 151, 171], ["Th2", "GENE_OR_GENE_PRODUCT", 173, 176], ["vitamin D.", "SIMPLE_CHEMICAL", 274, 284], ["murine", "ORGANISM", 290, 296], ["lung eosinophilic", "PATHOLOGICAL_FORMATION", 306, 323], ["vitamin D", "SIMPLE_CHEMICAL", 353, 362], ["airway eosinophilia", "PATHOLOGICAL_FORMATION", 373, 392], ["1,25D", "SIMPLE_CHEMICAL", 450, 455], ["IL-15", "GENE_OR_GENE_PRODUCT", 459, 464], ["eosinophils", "CELL", 512, 523], ["VDR", "PROTEIN", 70, 73], ["CYP27B1", "PROTEIN", 78, 85], ["Eosinophils", "CELL_TYPE", 98, 109], ["granulocytic effector cells", "CELL_TYPE", 111, 138], ["T helper type 2 cell", "CELL_TYPE", 151, 171], ["IL-15", "PROTEIN", 459, 464], ["eosinophils", "CELL_TYPE", 512, 523], ["murine", "SPECIES", 290, 296], ["decreased expression of VDR and CYP27B1 in neonates", "PROBLEM", 46, 97], ["Eosinophils", "TEST", 98, 109], ["granulocytic effector cells", "PROBLEM", 111, 138], ["mediated diseases", "PROBLEM", 178, 195], ["asthma", "PROBLEM", 204, 210], ["atopic dermatitis", "PROBLEM", 215, 232], ["vitamin D.", "TREATMENT", 274, 284], ["lung eosinophilic inflammation", "PROBLEM", 306, 336], ["vitamin D", "TREATMENT", 353, 362], ["decreased airway eosinophilia", "PROBLEM", 363, 392], ["the downregulatory effect", "PROBLEM", 421, 446], ["IL", "TREATMENT", 459, 461], ["local inflammatory sites", "PROBLEM", 527, 551], ["granulocytic effector cells", "OBSERVATION", 111, 138], ["diseases", "OBSERVATION", 187, 195], ["asthma", "OBSERVATION", 204, 210], ["atopic dermatitis", "OBSERVATION", 215, 232], ["lung", "ANATOMY", 306, 310], ["eosinophilic inflammation", "OBSERVATION", 311, 336], ["airway", "ANATOMY", 373, 379], ["eosinophilia", "OBSERVATION", 380, 392], ["recruitment", "OBSERVATION_MODIFIER", 497, 508], ["inflammatory", "OBSERVATION_MODIFIER", 533, 545]]], ["Likewise, vitamin D supplementation was found to reduce eosinophilic airway inflammation in patients with nonatopic asthma and severe eosinophilic airway inflammation in a randomized controlled trial (80).", [["eosinophilic airway", "ANATOMY", 56, 75], ["airway", "ANATOMY", 147, 153], ["vitamin D", "CHEMICAL", 10, 19], ["airway inflammation", "DISEASE", 69, 88], ["nonatopic asthma", "DISEASE", 106, 122], ["airway inflammation", "DISEASE", 147, 166], ["vitamin D", "CHEMICAL", 10, 19], ["vitamin D", "SIMPLE_CHEMICAL", 10, 19], ["eosinophilic airway", "PATHOLOGICAL_FORMATION", 56, 75], ["patients", "ORGANISM", 92, 100], ["airway", "MULTI-TISSUE_STRUCTURE", 147, 153], ["patients", "SPECIES", 92, 100], ["vitamin D supplementation", "TREATMENT", 10, 35], ["eosinophilic airway inflammation", "PROBLEM", 56, 88], ["nonatopic asthma", "PROBLEM", 106, 122], ["severe eosinophilic airway inflammation", "PROBLEM", 127, 166], ["a randomized controlled trial", "TREATMENT", 170, 199], ["eosinophilic", "OBSERVATION_MODIFIER", 56, 68], ["airway", "ANATOMY", 69, 75], ["inflammation", "OBSERVATION", 76, 88], ["nonatopic asthma", "OBSERVATION", 106, 122], ["severe", "OBSERVATION_MODIFIER", 127, 133], ["eosinophilic airway inflammation", "OBSERVATION", 134, 166]]], ["Another cell type well known for its role in allergic responses is the mast cell, which expresses the VDR and, unlike neutrophils, also expresses CYP27B1 (81) .", [["cell", "ANATOMY", 8, 12], ["mast cell", "ANATOMY", 71, 80], ["neutrophils", "ANATOMY", 118, 129], ["allergic", "DISEASE", 45, 53], ["cell type", "CELL", 8, 17], ["mast cell", "CELL", 71, 80], ["VDR", "GENE_OR_GENE_PRODUCT", 102, 105], ["neutrophils", "CELL", 118, 129], ["CYP27B1", "GENE_OR_GENE_PRODUCT", 146, 153], ["mast cell", "CELL_TYPE", 71, 80], ["VDR", "PROTEIN", 102, 105], ["neutrophils", "CELL_TYPE", 118, 129], ["CYP27B1", "PROTEIN", 146, 153], ["allergic responses", "PROBLEM", 45, 63], ["the mast cell", "PROBLEM", 67, 80], ["CYP27B1", "TEST", 146, 153], ["allergic", "OBSERVATION", 45, 53], ["mast cell", "OBSERVATION", 71, 80]]], ["Both 25D and 1,25D were demonstrated to suppress IgE-mediated mast-cell derived proinflammatory and vasodilatory mediator production in human and murine mast cells.", [["mast-cell", "ANATOMY", 62, 71], ["mast cells", "ANATOMY", 153, 163], ["25D", "CHEMICAL", 5, 8], ["1,25D", "CHEMICAL", 13, 18], ["25D", "CHEMICAL", 5, 8], ["1,25D", "CHEMICAL", 13, 18], ["25D", "SIMPLE_CHEMICAL", 5, 8], ["1,25D", "SIMPLE_CHEMICAL", 13, 18], ["IgE", "GENE_OR_GENE_PRODUCT", 49, 52], ["mast-cell", "CELL", 62, 71], ["human", "ORGANISM", 136, 141], ["murine", "ORGANISM", 146, 152], ["mast cells", "CELL", 153, 163], ["IgE", "PROTEIN", 49, 52], ["human and murine mast cells", "CELL_TYPE", 136, 163], ["human", "SPECIES", 136, 141], ["murine", "SPECIES", 146, 152], ["human", "SPECIES", 136, 141], ["IgE", "TEST", 49, 52], ["vasodilatory mediator production in human and murine mast cells", "PROBLEM", 100, 163], ["mast", "ANATOMY", 62, 66], ["proinflammatory", "OBSERVATION_MODIFIER", 80, 95], ["mast cells", "OBSERVATION", 153, 163]]], ["In addition, in response to 1,25D, production of the immune regulatory IL-10 is significantly upregulated in mouse mast cells (82) , providing an explanation for why mice deficient in mast cells are resistant to the immune suppressive effects of UVB (83) .", [["mast cells", "ANATOMY", 115, 125], ["mast cells", "ANATOMY", 184, 194], ["UVB", "CHEMICAL", 246, 249], ["IL-10", "GENE_OR_GENE_PRODUCT", 71, 76], ["mouse", "ORGANISM", 109, 114], ["mast cells", "CELL", 115, 125], ["mice", "ORGANISM", 166, 170], ["mast cells", "CELL", 184, 194], ["UVB", "SIMPLE_CHEMICAL", 246, 249], ["immune regulatory IL-10", "PROTEIN", 53, 76], ["mouse mast cells", "CELL_TYPE", 109, 125], ["mast cells", "CELL_TYPE", 184, 194], ["mouse", "SPECIES", 109, 114], ["mice", "SPECIES", 166, 170], ["mouse", "SPECIES", 109, 114], ["mice", "SPECIES", 166, 170], ["the immune regulatory IL", "TEST", 49, 73], ["mice deficient in mast cells", "PROBLEM", 166, 194], ["the immune suppressive effects of UVB", "TREATMENT", 212, 249], ["mast cells", "OBSERVATION", 115, 125], ["mast cells", "OBSERVATION", 184, 194]]], ["UVB irradiation transmits the immune suppressive signal in the skin by triggering mast cells to migrate to lymph nodes (84) .", [["skin", "ANATOMY", 63, 67], ["mast cells", "ANATOMY", 82, 92], ["lymph nodes", "ANATOMY", 107, 118], ["UVB", "CHEMICAL", 0, 3], ["skin", "ORGAN", 63, 67], ["mast cells", "CELL", 82, 92], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 107, 118], ["mast cells", "CELL_TYPE", 82, 92], ["UVB irradiation", "TREATMENT", 0, 15], ["triggering mast cells", "PROBLEM", 71, 92], ["lymph nodes", "TEST", 107, 118], ["immune suppressive", "OBSERVATION", 30, 48], ["skin", "ANATOMY", 63, 67], ["mast cells", "OBSERVATION", 82, 92], ["lymph nodes", "OBSERVATION", 107, 118]]], ["There, the IL-10-producing mast cells contact B cells and inhibit antibody class-switch recombination and affinity maturation in germinal centers.Eosinophils, granulocytic effector cells involved in T helper type 2 cell (Th2)-mediated diseases,Because mast cells are known to induce activation of T regs and B cells, it is speculated that this is a mechanism by which UVB and vitamin D are working to repress some adaptive immune responses (84).Effects of vitamin D on NK, NKT, and \u03b3\u03b4 T cellsNatural killer (NK) cells acquire the capacity to efficiently kill infected cells and, because some NK subsets can modulate adaptive immune responses by the secretion of cytokines and chemokines, they are generally described to function at the interface between innate and adaptive immunity (85) .", [["mast cells", "ANATOMY", 27, 37], ["B cells", "ANATOMY", 46, 53], ["germinal centers", "ANATOMY", 129, 145], ["Eosinophils", "ANATOMY", 146, 157], ["granulocytic effector cells", "ANATOMY", 159, 186], ["T helper type 2 cell", "ANATOMY", 199, 219], ["mast cells", "ANATOMY", 252, 262], ["T regs", "ANATOMY", 297, 303], ["B cells", "ANATOMY", 308, 315], ["NK", "ANATOMY", 469, 471], ["NKT", "ANATOMY", 473, 476], ["\u03b3\u03b4 T cellsNatural killer (NK) cells", "ANATOMY", 482, 517], ["cells", "ANATOMY", 568, 573], ["NK", "ANATOMY", 592, 594], ["UVB", "CHEMICAL", 368, 371], ["vitamin D", "CHEMICAL", 376, 385], ["vitamin D", "CHEMICAL", 456, 465], ["vitamin D", "CHEMICAL", 376, 385], ["vitamin D", "CHEMICAL", 456, 465], ["IL-10", "GENE_OR_GENE_PRODUCT", 11, 16], ["mast cells", "CELL", 27, 37], ["B cells", "CELL", 46, 53], ["germinal centers", "MULTI-TISSUE_STRUCTURE", 129, 145], ["Eosinophils", "CELL", 146, 157], ["granulocytic effector cells", "CELL", 159, 186], ["T helper type 2 cell", "CELL", 199, 219], ["Th2", "GENE_OR_GENE_PRODUCT", 221, 224], ["mast cells", "CELL", 252, 262], ["T regs", "CELL", 297, 303], ["B cells", "CELL", 308, 315], ["UVB", "SIMPLE_CHEMICAL", 368, 371], ["vitamin D", "SIMPLE_CHEMICAL", 376, 385], ["vitamin D", "SIMPLE_CHEMICAL", 456, 465], ["NK", "CELL", 469, 471], ["NKT", "CELL", 473, 476], ["\u03b3\u03b4 T cellsNatural killer (NK) cells", "CELL", 482, 517], ["cells", "CELL", 568, 573], ["NK subsets", "CELL", 592, 602], ["IL-10", "PROTEIN", 11, 16], ["mast cells", "CELL_TYPE", 27, 37], ["B cells", "CELL_TYPE", 46, 53], ["Eosinophils", "CELL_TYPE", 146, 157], ["granulocytic effector cells", "CELL_TYPE", 159, 186], ["T helper type 2 cell", "CELL_TYPE", 199, 219], ["mast cells", "CELL_TYPE", 252, 262], ["T regs", "CELL_TYPE", 297, 303], ["B cells", "CELL_TYPE", 308, 315], ["NK, NKT, and \u03b3\u03b4 T cells", "CELL_TYPE", 469, 492], ["Natural killer (NK) cells", "CELL_TYPE", 492, 517], ["infected cells", "CELL_TYPE", 559, 573], ["NK subsets", "CELL_TYPE", 592, 602], ["cytokines", "PROTEIN", 662, 671], ["chemokines", "PROTEIN", 676, 686], ["the IL", "TEST", 7, 13], ["mast cells", "PROBLEM", 27, 37], ["inhibit antibody class", "PROBLEM", 58, 80], ["affinity maturation in germinal centers", "PROBLEM", 106, 145], ["Eosinophils", "TEST", 146, 157], ["granulocytic effector cells", "PROBLEM", 159, 186], ["mediated diseases", "PROBLEM", 226, 243], ["mast cells", "PROBLEM", 252, 262], ["UVB and vitamin D", "TREATMENT", 368, 385], ["vitamin D", "TREATMENT", 456, 465], ["NK", "TREATMENT", 469, 471], ["NKT", "PROBLEM", 473, 476], ["\u03b3\u03b4 T cellsNatural killer (NK) cells", "TREATMENT", 482, 517], ["the capacity", "PROBLEM", 526, 538], ["infected cells", "PROBLEM", 559, 573], ["some NK subsets", "PROBLEM", 587, 602], ["chemokines", "TREATMENT", 676, 686], ["mast cells", "OBSERVATION", 27, 37], ["germinal centers", "OBSERVATION", 129, 145], ["granulocytic effector cells", "OBSERVATION", 159, 186], ["diseases", "OBSERVATION", 235, 243], ["mast cells", "OBSERVATION", 252, 262]]], ["Despite some studies showing no effect of 1,25D on NK function (86) (87) (88) , others suggest an important role for 1,25D on NK cell biology (89) (90) (91) (92) (93) (94) .", [["NK", "ANATOMY", 51, 53], ["NK cell", "ANATOMY", 126, 133], ["1,25D", "CHEMICAL", 42, 47], ["1,25D", "CHEMICAL", 117, 122], ["1,25D", "CHEMICAL", 42, 47], ["1,25D", "CHEMICAL", 117, 122], ["1,25D", "SIMPLE_CHEMICAL", 42, 47], ["NK", "CELL", 51, 53], ["1,25D", "SIMPLE_CHEMICAL", 117, 122], ["NK cell", "CELL", 126, 133], ["some studies", "TEST", 8, 20], ["NK function", "TEST", 51, 62], ["NK cell biology", "TEST", 126, 141], ["no", "UNCERTAINTY", 29, 31]]], ["Patients with diseases that affect metabolism of vitamin D, such as chronic renal failure and vitamin D-resistant rickets, have impaired activity of NK cells (89, 90) .", [["renal", "ANATOMY", 76, 81], ["NK cells", "ANATOMY", 149, 157], ["vitamin D", "CHEMICAL", 49, 58], ["chronic renal failure", "DISEASE", 68, 89], ["vitamin D-", "CHEMICAL", 94, 104], ["rickets", "DISEASE", 114, 121], ["vitamin D", "CHEMICAL", 49, 58], ["vitamin D-", "CHEMICAL", 94, 104], ["Patients", "ORGANISM", 0, 8], ["vitamin D", "SIMPLE_CHEMICAL", 49, 58], ["renal", "ORGAN", 76, 81], ["vitamin D-", "SIMPLE_CHEMICAL", 94, 104], ["NK cells", "CELL", 149, 157], ["NK cells", "CELL_TYPE", 149, 157], ["Patients", "SPECIES", 0, 8], ["diseases", "PROBLEM", 14, 22], ["vitamin D", "TREATMENT", 49, 58], ["chronic renal failure", "PROBLEM", 68, 89], ["vitamin D-resistant rickets", "PROBLEM", 94, 121], ["impaired activity of NK cells", "PROBLEM", 128, 157], ["diseases", "OBSERVATION", 14, 22], ["renal", "ANATOMY", 76, 81], ["failure", "OBSERVATION", 82, 89], ["impaired", "OBSERVATION_MODIFIER", 128, 136], ["activity", "OBSERVATION_MODIFIER", 137, 145], ["NK cells", "OBSERVATION", 149, 157]]], ["In these patients, vitamin D supplementation can improve and even normalize NK cell activity.", [["NK cell", "ANATOMY", 76, 83], ["vitamin D", "CHEMICAL", 19, 28], ["vitamin D", "CHEMICAL", 19, 28], ["patients", "ORGANISM", 9, 17], ["vitamin D", "SIMPLE_CHEMICAL", 19, 28], ["NK cell", "CELL", 76, 83], ["patients", "SPECIES", 9, 17], ["vitamin D supplementation", "TREATMENT", 19, 44], ["NK cell activity", "OBSERVATION", 76, 92]]], ["In a healthy elderly population, it was shown that NK-cell cytolytic function is associated with serum 25D levels (93) .Effects of vitamin D on NK, NKT, and \u03b3\u03b4 T cellsThis was later confirmed in in vitro studies, where 1,25D treatment dose-dependently, enhanced the activity of NK cells without influencing cell proliferation by increasing cellular granule content and shortening the delay in the secretion of granzyme A (91, 94) .", [["NK-cell", "ANATOMY", 51, 58], ["serum", "ANATOMY", 97, 102], ["NK", "ANATOMY", 144, 146], ["NKT", "ANATOMY", 148, 151], ["\u03b3\u03b4 T cells", "ANATOMY", 157, 167], ["NK cells", "ANATOMY", 278, 286], ["cell", "ANATOMY", 307, 311], ["cellular granule", "ANATOMY", 340, 356], ["vitamin D", "CHEMICAL", 131, 140], ["1,25D", "CHEMICAL", 219, 224], ["vitamin D", "CHEMICAL", 131, 140], ["1,25D", "CHEMICAL", 219, 224], ["NK-cell", "CELL", 51, 58], ["serum", "ORGANISM_SUBSTANCE", 97, 102], ["25D", "SIMPLE_CHEMICAL", 103, 106], ["vitamin D", "SIMPLE_CHEMICAL", 131, 140], ["NK", "CELL", 144, 146], ["NKT", "CELL", 148, 151], ["\u03b3\u03b4 T cells", "CELL", 157, 167], ["1,25D", "SIMPLE_CHEMICAL", 219, 224], ["NK cells", "CELL", 278, 286], ["cell", "CELL", 307, 311], ["cellular granule", "CELLULAR_COMPONENT", 340, 356], ["granzyme A", "GENE_OR_GENE_PRODUCT", 410, 420], ["NK, NKT, and \u03b3\u03b4 T cells", "CELL_TYPE", 144, 167], ["NK cells", "CELL_TYPE", 278, 286], ["granzyme A", "PROTEIN", 410, 420], ["serum 25D levels", "TEST", 97, 113], ["vitamin D on NK", "TREATMENT", 131, 146], ["NKT", "PROBLEM", 148, 151], ["vitro studies", "TEST", 198, 211], ["1,25D treatment dose", "TREATMENT", 219, 239], ["NK cells", "PROBLEM", 278, 286], ["influencing cell proliferation", "PROBLEM", 295, 325], ["increasing cellular granule content", "PROBLEM", 329, 364], ["shortening the delay", "PROBLEM", 369, 389], ["NKT", "ANATOMY", 148, 151], ["NK cells", "OBSERVATION", 278, 286], ["cell proliferation", "OBSERVATION", 307, 325], ["increasing", "OBSERVATION_MODIFIER", 329, 339], ["cellular granule content", "OBSERVATION", 340, 364], ["shortening", "OBSERVATION_MODIFIER", 369, 379], ["delay", "OBSERVATION_MODIFIER", 384, 389]]], ["Furthermore, 1,25D in combination with the synthetic glucocorticoid dexamethasone induced IL-10 mRNA expression in NK cells, implying that vitamin D signaling can stimulate a regulatory phenotype, where antigen-specific T cell responses are suppressed, in NK cells (92) .", [["NK cells", "ANATOMY", 115, 123], ["T cell", "ANATOMY", 220, 226], ["NK cells", "ANATOMY", 256, 264], ["1,25D", "CHEMICAL", 13, 18], ["dexamethasone", "CHEMICAL", 68, 81], ["vitamin D", "CHEMICAL", 139, 148], ["1,25D", "CHEMICAL", 13, 18], ["dexamethasone", "CHEMICAL", 68, 81], ["vitamin D", "CHEMICAL", 139, 148], ["1,25D", "SIMPLE_CHEMICAL", 13, 18], ["dexamethasone", "SIMPLE_CHEMICAL", 68, 81], ["IL-10", "GENE_OR_GENE_PRODUCT", 90, 95], ["NK cells", "CELL", 115, 123], ["vitamin D", "SIMPLE_CHEMICAL", 139, 148], ["antigen", "GENE_OR_GENE_PRODUCT", 203, 210], ["T cell", "CELL", 220, 226], ["NK cells", "CELL", 256, 264], ["IL-10 mRNA", "RNA", 90, 100], ["NK cells", "CELL_TYPE", 115, 123], ["NK cells", "CELL_TYPE", 256, 264], ["the synthetic glucocorticoid dexamethasone induced IL", "TREATMENT", 39, 92], ["mRNA expression in NK cells", "TREATMENT", 96, 123], ["vitamin D signaling", "PROBLEM", 139, 158], ["a regulatory phenotype", "PROBLEM", 173, 195], ["antigen", "TEST", 203, 210], ["NK cells", "OBSERVATION", 115, 123]]], ["More recently, one study noted that 1,25D had regulated cytotoxicity, cytokine secretion and degranulation in NK cells isolated from women with idiopathic recurrent pregnancy losses, a condition associated with aberrant NK activity and vitamin D deficiency (95) .", [["NK cells", "ANATOMY", 110, 118], ["NK", "ANATOMY", 220, 222], ["1,25D", "CHEMICAL", 36, 41], ["pregnancy losses", "DISEASE", 165, 181], ["vitamin D", "CHEMICAL", 236, 245], ["1,25D", "CHEMICAL", 36, 41], ["vitamin D", "CHEMICAL", 236, 245], ["1,25D", "SIMPLE_CHEMICAL", 36, 41], ["NK cells", "CELL", 110, 118], ["women", "ORGANISM", 133, 138], ["NK", "CELL", 220, 222], ["vitamin D", "SIMPLE_CHEMICAL", 236, 245], ["cytokine", "PROTEIN", 70, 78], ["NK cells", "CELL_TYPE", 110, 118], ["women", "SPECIES", 133, 138], ["one study", "TEST", 15, 24], ["1,25D", "PROBLEM", 36, 41], ["regulated cytotoxicity", "PROBLEM", 46, 68], ["cytokine secretion", "PROBLEM", 70, 88], ["degranulation in NK cells", "PROBLEM", 93, 118], ["idiopathic recurrent pregnancy losses", "PROBLEM", 144, 181], ["a condition", "PROBLEM", 183, 194], ["aberrant NK activity", "PROBLEM", 211, 231], ["vitamin D deficiency", "PROBLEM", 236, 256], ["NK cells", "OBSERVATION", 110, 118], ["idiopathic", "OBSERVATION_MODIFIER", 144, 154], ["pregnancy losses", "OBSERVATION", 165, 181], ["aberrant NK activity", "OBSERVATION", 211, 231]]], ["Other current reports also corroborate a regulatory role for vitamin D in NK cell effector function (96, 97) .Effects of vitamin D on NK, NKT, and \u03b3\u03b4 T cellsCD1d-reactive natural killer T (NKT) cells, a subset of T cells that lack immunological memory (98) , are thought to be among the most immediate producers of cytokines in the innate immune response (99) .", [["NK cell", "ANATOMY", 74, 81], ["NK", "ANATOMY", 134, 136], ["NKT", "ANATOMY", 138, 141], ["\u03b3\u03b4 T cellsCD1d-reactive natural killer T (NKT) cells", "ANATOMY", 147, 199], ["T cells", "ANATOMY", 213, 220], ["vitamin D", "CHEMICAL", 61, 70], ["vitamin D", "CHEMICAL", 121, 130], ["vitamin D", "CHEMICAL", 61, 70], ["vitamin D", "CHEMICAL", 121, 130], ["vitamin D", "SIMPLE_CHEMICAL", 61, 70], ["NK cell", "CELL", 74, 81], ["vitamin D", "SIMPLE_CHEMICAL", 121, 130], ["NK", "CELL", 134, 136], ["NKT", "CELL", 138, 141], ["\u03b3\u03b4 T cellsCD1d", "GENE_OR_GENE_PRODUCT", 147, 161], ["T cells", "CELL", 213, 220], ["NK, NKT, and \u03b3\u03b4 T cellsCD1d-reactive natural killer T (NKT) cells", "CELL_TYPE", 134, 199], ["T cells", "CELL_TYPE", 213, 220], ["cytokines", "PROTEIN", 315, 324], ["vitamin D", "TREATMENT", 61, 70], ["vitamin D on NK", "TEST", 121, 136], ["NKT", "TEST", 138, 141], ["\u03b3\u03b4 T cellsCD1d", "TEST", 147, 161], ["NKT", "ANATOMY", 138, 141], ["reactive", "OBSERVATION_MODIFIER", 162, 170], ["natural killer", "OBSERVATION", 171, 185]]], ["As a result of early IL-4 production by activated NKT cells, NKT cell activation delays the onset and represses the symptoms of experimental autoimmune encephalomyelitis and experimentally induced colitis (100, 101) .", [["NKT cells", "ANATOMY", 50, 59], ["NKT cell", "ANATOMY", 61, 69], ["autoimmune encephalomyelitis", "DISEASE", 141, 169], ["colitis", "DISEASE", 197, 204], ["IL-4", "GENE_OR_GENE_PRODUCT", 21, 25], ["NKT cells", "CELL", 50, 59], ["NKT cell", "CELL", 61, 69], ["colitis", "PATHOLOGICAL_FORMATION", 197, 204], ["IL-4", "PROTEIN", 21, 25], ["activated NKT cells", "CELL_TYPE", 40, 59], ["early IL-4 production", "TREATMENT", 15, 36], ["activated NKT cells", "PROBLEM", 40, 59], ["NKT cell activation delays", "PROBLEM", 61, 87], ["the symptoms", "PROBLEM", 112, 124], ["experimental autoimmune encephalomyelitis", "PROBLEM", 128, 169], ["experimentally induced colitis", "PROBLEM", 174, 204], ["NKT cells", "OBSERVATION", 50, 59], ["NKT cell", "OBSERVATION", 61, 69], ["autoimmune encephalomyelitis", "OBSERVATION", 141, 169], ["colitis", "OBSERVATION", 197, 204]]], ["Furthermore, low numbers of NKT cells are correlated with increased susceptibility to autoimmunity (102) .", [["NKT cells", "ANATOMY", 28, 37], ["autoimmunity", "DISEASE", 86, 98], ["NKT cells", "CELL", 28, 37], ["NKT cells", "CELL_TYPE", 28, 37], ["low numbers of NKT cells", "PROBLEM", 13, 37], ["increased susceptibility to autoimmunity", "PROBLEM", 58, 98], ["low numbers", "OBSERVATION_MODIFIER", 13, 24], ["NKT cells", "OBSERVATION", 28, 37], ["increased", "OBSERVATION_MODIFIER", 58, 67]]], ["Although the role of vitamin D in NKT cell biology is not yet completely elucidated, animal studies on the topic have revealed differing roles for the VDR and 1,25DEffects of vitamin D on NK, NKT, and \u03b3\u03b4 T cellsin the regulation of invariant NKT cell (iNKT) numbers and function.", [["NKT cell", "ANATOMY", 34, 42], ["NK", "ANATOMY", 188, 190], ["NKT", "ANATOMY", 192, 195], ["\u03b3\u03b4 T cellsin", "ANATOMY", 201, 213], ["NKT cell", "ANATOMY", 242, 250], ["iNKT", "ANATOMY", 252, 256], ["vitamin D", "CHEMICAL", 21, 30], ["vitamin D", "CHEMICAL", 175, 184], ["vitamin D", "CHEMICAL", 21, 30], ["vitamin D", "CHEMICAL", 175, 184], ["vitamin D", "SIMPLE_CHEMICAL", 21, 30], ["NKT cell", "CELL", 34, 42], ["VDR", "GENE_OR_GENE_PRODUCT", 151, 154], ["1,25DEffects", "SIMPLE_CHEMICAL", 159, 171], ["vitamin D", "SIMPLE_CHEMICAL", 175, 184], ["NK", "CELL", 188, 190], ["NKT", "CELL", 192, 195], ["\u03b3\u03b4 T cellsin", "GENE_OR_GENE_PRODUCT", 201, 213], ["NKT cell", "CELL", 242, 250], ["iNKT", "CELL", 252, 256], ["VDR", "PROTEIN", 151, 154], ["NK, NKT, and \u03b3\u03b4 T cellsin", "CELL_TYPE", 188, 213], ["invariant NKT cell", "CELL_TYPE", 232, 250], ["iNKT", "CELL_TYPE", 252, 256], ["vitamin D in NKT cell biology", "TEST", 21, 50], ["animal studies", "TEST", 85, 99], ["the VDR", "TEST", 147, 154], ["vitamin D", "TREATMENT", 175, 184], ["NK", "TREATMENT", 188, 190], ["NKT", "TEST", 192, 195], ["invariant NKT cell", "OBSERVATION", 232, 250]]], ["VDR gene knock-out (KO) mice demonstrate a blockade in iNKT cell development, resulting in reduced numbers of NKT cells in the thymus, liver and spleen compared to their wild-type (WT) counterparts (103) .", [["iNKT cell", "ANATOMY", 55, 64], ["NKT cells", "ANATOMY", 110, 119], ["thymus", "ANATOMY", 127, 133], ["liver", "ANATOMY", 135, 140], ["spleen", "ANATOMY", 145, 151], ["VDR", "GENE_OR_GENE_PRODUCT", 0, 3], ["iNKT cell", "CELL", 55, 64], ["NKT cells", "CELL", 110, 119], ["thymus", "ORGAN", 127, 133], ["liver", "ORGAN", 135, 140], ["spleen", "ORGAN", 145, 151], ["wild-type (WT) counterparts", "ORGANISM", 170, 197], ["VDR gene", "DNA", 0, 8], ["NKT cells", "CELL_TYPE", 110, 119], ["mice", "SPECIES", 24, 28], ["mice", "SPECIES", 24, 28], ["VDR gene knock", "TEST", 0, 14], ["a blockade in iNKT cell development", "TREATMENT", 41, 76], ["reduced numbers of NKT cells in the thymus, liver and spleen", "PROBLEM", 91, 151], ["iNKT cell", "OBSERVATION", 55, 64], ["reduced", "OBSERVATION_MODIFIER", 91, 98], ["numbers", "OBSERVATION_MODIFIER", 99, 106], ["NKT cells", "OBSERVATION", 110, 119], ["thymus", "ANATOMY", 127, 133], ["liver", "ANATOMY", 135, 140], ["spleen", "ANATOMY", 145, 151]]], ["Furthermore, the residual iNKT cells from VDR KO mice are intrinsically defective and only a small fraction of the cells produce IL-4 and IFN-\u03b3.", [["iNKT cells", "ANATOMY", 26, 36], ["cells", "ANATOMY", 115, 120], ["iNKT cells", "CELL", 26, 36], ["VDR", "GENE_OR_GENE_PRODUCT", 42, 45], ["KO mice", "ORGANISM", 46, 53], ["cells", "CELL", 115, 120], ["IL-4", "GENE_OR_GENE_PRODUCT", 129, 133], ["IFN", "GENE_OR_GENE_PRODUCT", 138, 141], ["iNKT cells", "CELL_TYPE", 26, 36], ["VDR", "PROTEIN", 42, 45], ["IL-4", "PROTEIN", 129, 133], ["IFN", "PROTEIN", 138, 141], ["mice", "SPECIES", 49, 53], ["mice", "SPECIES", 49, 53], ["the residual iNKT cells", "TEST", 13, 36], ["VDR KO mice", "TEST", 42, 53], ["intrinsically defective", "PROBLEM", 58, 81], ["IL", "TEST", 129, 131], ["residual", "OBSERVATION_MODIFIER", 17, 25], ["iNKT cells", "OBSERVATION", 26, 36], ["small", "OBSERVATION_MODIFIER", 93, 98], ["fraction", "OBSERVATION_MODIFIER", 99, 107]]], ["In contrast, 1,25D sufficiency appears to only regulate the number of iNKT cells, as evidenced by decreased iNKT cell counts in vitamin D deficient mice in utero (104) .", [["iNKT cells", "ANATOMY", 70, 80], ["iNKT cell", "ANATOMY", 108, 117], ["1,25D", "CHEMICAL", 13, 18], ["vitamin D", "CHEMICAL", 128, 137], ["1,25D", "CHEMICAL", 13, 18], ["vitamin D", "CHEMICAL", 128, 137], ["1,25D", "SIMPLE_CHEMICAL", 13, 18], ["iNKT cells", "CELL", 70, 80], ["iNKT cell", "CELL", 108, 117], ["vitamin D", "SIMPLE_CHEMICAL", 128, 137], ["mice", "ORGANISM", 148, 152], ["iNKT cells", "CELL_TYPE", 70, 80], ["mice", "SPECIES", 148, 152], ["1,25D sufficiency", "PROBLEM", 13, 30], ["decreased iNKT cell counts", "PROBLEM", 98, 124], ["vitamin D deficient mice", "TREATMENT", 128, 152], ["number", "OBSERVATION_MODIFIER", 60, 66], ["iNKT cells", "OBSERVATION", 70, 80], ["decreased", "OBSERVATION_MODIFIER", 98, 107], ["iNKT cell counts", "OBSERVATION", 108, 124]]], ["Remarkably, this was found to not be corrected by subsequent intervention with 1,25D due to increased apoptosis of early thymic iNKT cell precursors.", [["thymic iNKT cell", "ANATOMY", 121, 137], ["1,25D", "CHEMICAL", 79, 84], ["1,25D", "CHEMICAL", 79, 84], ["1,25D", "SIMPLE_CHEMICAL", 79, 84], ["thymic iNKT cell", "CELL", 121, 137], ["early thymic iNKT cell precursors", "CELL_TYPE", 115, 148], ["subsequent intervention", "TREATMENT", 50, 73], ["increased apoptosis", "PROBLEM", 92, 111], ["early thymic iNKT cell precursors", "PROBLEM", 115, 148], ["increased", "OBSERVATION_MODIFIER", 92, 101], ["apoptosis", "OBSERVATION_MODIFIER", 102, 111], ["early", "OBSERVATION_MODIFIER", 115, 120], ["thymic iNKT cell precursors", "OBSERVATION", 121, 148]]], ["From these findings, it appears that the quantity of vitamin D available in the environment during prenatal development may influence the number of iNKT cells and the subsequent resulting risk of autoimmunity (104) .Effects of vitamin D on NK, NKT, and \u03b3\u03b4 T cellsArguably the most intricate and advanced cellular representative of the innate immune system are \u03b3\u03b4 T cells (105) .", [["iNKT cells", "ANATOMY", 148, 158], ["NK", "ANATOMY", 240, 242], ["NKT", "ANATOMY", 244, 247], ["\u03b3\u03b4 T cells", "ANATOMY", 253, 263], ["cellular", "ANATOMY", 304, 312], ["immune system", "ANATOMY", 342, 355], ["\u03b3\u03b4 T cells", "ANATOMY", 360, 370], ["vitamin D", "CHEMICAL", 53, 62], ["autoimmunity", "DISEASE", 196, 208], ["vitamin D", "CHEMICAL", 227, 236], ["vitamin D", "CHEMICAL", 53, 62], ["vitamin D", "CHEMICAL", 227, 236], ["vitamin D", "SIMPLE_CHEMICAL", 53, 62], ["iNKT cells", "CELL", 148, 158], ["vitamin D", "SIMPLE_CHEMICAL", 227, 236], ["NK", "CELL", 240, 242], ["NKT", "CELL", 244, 247], ["\u03b3\u03b4 T cells", "CELL", 253, 263], ["cellular", "CELL", 304, 312], ["\u03b3\u03b4 T cells", "CELL", 360, 370], ["iNKT cells", "CELL_TYPE", 148, 158], ["NK, NKT, and \u03b3\u03b4 T cells", "CELL_TYPE", 240, 263], ["\u03b3\u03b4 T cells", "CELL_TYPE", 360, 370], ["vitamin D", "TREATMENT", 53, 62], ["iNKT cells", "PROBLEM", 148, 158], ["autoimmunity", "PROBLEM", 196, 208], ["vitamin D on NK", "TREATMENT", 227, 242], ["NKT", "PROBLEM", 244, 247], ["iNKT cells", "OBSERVATION", 148, 158], ["NKT", "ANATOMY", 244, 247], ["most intricate", "OBSERVATION_MODIFIER", 276, 290]]], ["Representing a small number of T cells in the circulation of healthy individuals, an increase in the number and inflammatory phenotype of \u03b3\u03b4 T cells have been detected in patients with autoimmune hepatitis (106, 107) .", [["T cells", "ANATOMY", 31, 38], ["\u03b3\u03b4 T cells", "ANATOMY", 138, 148], ["autoimmune hepatitis", "DISEASE", 185, 205], ["T cells", "CELL", 31, 38], ["\u03b3\u03b4 T cells", "CELL", 138, 148], ["patients", "ORGANISM", 171, 179], ["T cells", "CELL_TYPE", 31, 38], ["\u03b3\u03b4 T cells", "CELL_TYPE", 138, 148], ["patients", "SPECIES", 171, 179], ["T cells", "PROBLEM", 31, 38], ["inflammatory phenotype of \u03b3\u03b4 T cells", "PROBLEM", 112, 148], ["autoimmune hepatitis", "PROBLEM", 185, 205], ["small", "OBSERVATION_MODIFIER", 15, 20], ["number", "OBSERVATION_MODIFIER", 21, 27], ["T cells", "OBSERVATION", 31, 38], ["circulation", "ANATOMY_MODIFIER", 46, 57], ["healthy individuals", "OBSERVATION_MODIFIER", 61, 80], ["increase", "OBSERVATION_MODIFIER", 85, 93], ["number", "OBSERVATION_MODIFIER", 101, 107], ["inflammatory", "OBSERVATION_MODIFIER", 112, 124], ["autoimmune", "OBSERVATION_MODIFIER", 185, 195], ["hepatitis", "OBSERVATION", 196, 205]]], ["Interestingly, transcriptional profiling of \u03b3\u03b4 T cells revealed an upregulation of VDR upon activation of these cells with phosphate-containing ligands (108) .", [["\u03b3\u03b4 T cells", "ANATOMY", 44, 54], ["cells", "ANATOMY", 112, 117], ["phosphate", "CHEMICAL", 123, 132], ["phosphate", "CHEMICAL", 123, 132], ["\u03b3\u03b4 T cells", "CELL", 44, 54], ["VDR", "GENE_OR_GENE_PRODUCT", 83, 86], ["cells", "CELL", 112, 117], ["phosphate", "SIMPLE_CHEMICAL", 123, 132], ["\u03b3\u03b4 T cells", "CELL_TYPE", 44, 54], ["VDR", "PROTEIN", 83, 86], ["phosphate", "TEST", 123, 132], ["upregulation", "OBSERVATION_MODIFIER", 67, 79], ["VDR", "OBSERVATION", 83, 86]]], ["Activity of the receptor was demonstrated by observing a 1,25D-mediated dose-dependent inhibition of phospholigand-induced \u03b3\u03b4 T cell expansion and IFN-\u03b3 production.", [["\u03b3\u03b4 T cell", "ANATOMY", 123, 132], ["1,25D", "SIMPLE_CHEMICAL", 57, 62], ["phospholigand", "SIMPLE_CHEMICAL", 101, 114], ["\u03b3\u03b4 T cell", "CELL", 123, 132], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 147, 152], ["IFN", "PROTEIN", 147, 150], ["\u03b3", "PROTEIN", 151, 152], ["a 1,25D-mediated dose", "TREATMENT", 55, 76], ["phospholigand", "TEST", 101, 114], ["\u03b3\u03b4 T cell expansion", "PROBLEM", 123, 142], ["IFN", "PROBLEM", 147, 150], ["\u03b3 production", "PROBLEM", 151, 163], ["cell expansion", "OBSERVATION", 128, 142]]], ["Similarly, in cattle, 1,25D production by macrophages within TB lesions inhibited proliferation of \u03b3\u03b4 T cells and decreased expression of the activation marker CD44 on the surfaces of remaining responding cells (109) .", [["macrophages", "ANATOMY", 42, 53], ["TB lesions", "ANATOMY", 61, 71], ["\u03b3\u03b4 T cells", "ANATOMY", 99, 109], ["cells", "ANATOMY", 205, 210], ["1,25D", "CHEMICAL", 22, 27], ["1,25D", "CHEMICAL", 22, 27], ["cattle", "ORGANISM", 14, 20], ["1,25D", "SIMPLE_CHEMICAL", 22, 27], ["macrophages", "CELL", 42, 53], ["TB lesions", "PATHOLOGICAL_FORMATION", 61, 71], ["\u03b3\u03b4 T cells", "CELL", 99, 109], ["CD44", "GENE_OR_GENE_PRODUCT", 160, 164], ["cells", "CELL", 205, 210], ["macrophages", "CELL_TYPE", 42, 53], ["\u03b3\u03b4 T cells", "CELL_TYPE", 99, 109], ["CD44", "PROTEIN", 160, 164], ["responding cells", "CELL_TYPE", 194, 210], ["cattle", "SPECIES", 14, 20], ["cattle", "SPECIES", 14, 20], ["TB lesions", "PROBLEM", 61, 71], ["proliferation of \u03b3\u03b4 T cells", "PROBLEM", 82, 109], ["macrophages", "ANATOMY", 42, 53], ["TB", "OBSERVATION_MODIFIER", 61, 63], ["lesions", "OBSERVATION", 64, 71], ["proliferation", "OBSERVATION_MODIFIER", 82, 95], ["decreased", "OBSERVATION_MODIFIER", 114, 123], ["expression", "OBSERVATION_MODIFIER", 124, 134], ["responding cells", "OBSERVATION", 194, 210]]], ["These studies globally propose an immune-suppressive role of vitamin D on this small subset of T cells as part of the more generalized anti-inflammatory response to 1,25D.Vitamin D and T cellsAlthough primarily an activator of the innate immune system to enhance immediate response to infection, vitamin D acts to regulate activity of the adaptive immune system.", [["T cells", "ANATOMY", 95, 102], ["T cells", "ANATOMY", 185, 192], ["vitamin D", "CHEMICAL", 61, 70], ["1,25D", "CHEMICAL", 165, 170], ["Vitamin D", "CHEMICAL", 171, 180], ["infection", "DISEASE", 285, 294], ["vitamin D", "CHEMICAL", 296, 305], ["vitamin D", "CHEMICAL", 61, 70], ["1,25D", "CHEMICAL", 165, 170], ["Vitamin D", "CHEMICAL", 171, 180], ["vitamin D", "CHEMICAL", 296, 305], ["vitamin D", "SIMPLE_CHEMICAL", 61, 70], ["T cells", "CELL", 95, 102], ["1,25D", "SIMPLE_CHEMICAL", 165, 170], ["Vitamin D", "SIMPLE_CHEMICAL", 171, 180], ["T cells", "CELL", 185, 192], ["vitamin D", "SIMPLE_CHEMICAL", 296, 305], ["immune system", "ANATOMICAL_SYSTEM", 348, 361], ["T cells", "CELL_TYPE", 95, 102], ["T cells", "CELL_TYPE", 185, 192], ["These studies", "TEST", 0, 13], ["vitamin D", "TREATMENT", 61, 70], ["this small subset of T cells", "TREATMENT", 74, 102], ["Vitamin D and T cells", "TREATMENT", 171, 192], ["infection", "PROBLEM", 285, 294], ["vitamin D acts", "TREATMENT", 296, 310], ["the adaptive immune system", "TREATMENT", 335, 361], ["anti-inflammatory response", "OBSERVATION", 135, 161], ["infection", "OBSERVATION", 285, 294]]], ["Consistently, low levels of circulating serum 25D have been correlated with increased risk of developing T cell-mediated autoimmune diseases such as MS (110, 111) , type 1 diabetes mellitus (T1D) (112) , inflammatory bowel disease (IBD) (113) , systemic lupus erythematous (SLE) (114) , and rheumatoid arthritis (RA) (115) .", [["serum", "ANATOMY", 40, 45], ["T cell", "ANATOMY", 105, 111], ["bowel", "ANATOMY", 217, 222], ["autoimmune diseases", "DISEASE", 121, 140], ["MS", "DISEASE", 149, 151], ["type 1 diabetes mellitus", "DISEASE", 165, 189], ["T1D", "DISEASE", 191, 194], ["inflammatory bowel disease", "DISEASE", 204, 230], ["IBD", "DISEASE", 232, 235], ["systemic lupus erythematous", "DISEASE", 245, 272], ["SLE", "DISEASE", 274, 277], ["rheumatoid arthritis", "DISEASE", 291, 311], ["RA", "DISEASE", 313, 315], ["serum", "ORGANISM_SUBSTANCE", 40, 45], ["25D", "GENE_OR_GENE_PRODUCT", 46, 49], ["T cell", "CELL", 105, 111], ["bowel", "ORGAN", 217, 222], ["type 1 diabetes mellitus (T1D)", "SPECIES", 165, 195], ["circulating serum", "TEST", 28, 45], ["developing T cell-mediated autoimmune diseases", "PROBLEM", 94, 140], ["MS", "TEST", 149, 151], ["type 1 diabetes mellitus (T1D)", "PROBLEM", 165, 195], ["inflammatory bowel disease (IBD)", "PROBLEM", 204, 236], ["systemic lupus erythematous (SLE)", "PROBLEM", 245, 278], ["rheumatoid arthritis", "PROBLEM", 291, 311], ["low levels", "OBSERVATION_MODIFIER", 14, 24], ["cell", "OBSERVATION", 107, 111], ["autoimmune diseases", "OBSERVATION", 121, 140], ["diabetes mellitus", "OBSERVATION", 172, 189], ["inflammatory", "OBSERVATION_MODIFIER", 204, 216], ["bowel", "ANATOMY", 217, 222], ["disease", "OBSERVATION", 223, 230], ["systemic lupus", "ANATOMY", 245, 259], ["erythematous", "OBSERVATION", 260, 272], ["rheumatoid arthritis", "OBSERVATION", 291, 311], ["RA", "ANATOMY", 313, 315]]], ["These associations may also correlate with exposure to ultraviolet (UV) light (112, 114) ; for example, SLE patients experience increased sensitivity to UV light which leads to avoidance (114) .", [["SLE", "DISEASE", 104, 107], ["patients", "ORGANISM", 108, 116], ["patients", "SPECIES", 108, 116], ["ultraviolet (UV)", "TREATMENT", 55, 71], ["increased sensitivity", "PROBLEM", 128, 149], ["UV light", "TREATMENT", 153, 161]]], ["However, despite these observations and the well described direct and indirect effects of 1,25D on T cells as detailed below, therapeutic use of vitamin D in supplementation trials has so far shown only modest effects.Vitamin D and T cellsThere remains a need to better understand the mechanisms of 1,25D-mediated immunomodulation to improve treatment of autoimmune inflammatory disease.VDR expression and T cell activationEarly studies showed that the intracellular VDR, as determined by specific 1,25D binding, was expressed in activated lymphocytes (116) .", [["T cells", "ANATOMY", 99, 106], ["T cells", "ANATOMY", 232, 239], ["T cell", "ANATOMY", 406, 412], ["intracellular", "ANATOMY", 453, 466], ["lymphocytes", "ANATOMY", 540, 551], ["1,25D", "CHEMICAL", 90, 95], ["vitamin D", "CHEMICAL", 145, 154], ["Vitamin D", "CHEMICAL", 218, 227], ["autoimmune inflammatory disease", "DISEASE", 355, 386], ["1,25D", "CHEMICAL", 90, 95], ["vitamin D", "CHEMICAL", 145, 154], ["Vitamin D", "CHEMICAL", 218, 227], ["1,25D", "CHEMICAL", 498, 503], ["1,25D", "SIMPLE_CHEMICAL", 90, 95], ["T cells", "CELL", 99, 106], ["vitamin D", "SIMPLE_CHEMICAL", 145, 154], ["Vitamin D", "SIMPLE_CHEMICAL", 218, 227], ["T cells", "CELL", 232, 239], ["1,25D", "SIMPLE_CHEMICAL", 299, 304], ["VDR", "GENE_OR_GENE_PRODUCT", 387, 390], ["T cell", "CELL", 406, 412], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 453, 466], ["VDR", "GENE_OR_GENE_PRODUCT", 467, 470], ["1,25D", "SIMPLE_CHEMICAL", 498, 503], ["lymphocytes", "CELL", 540, 551], ["T cells", "CELL_TYPE", 99, 106], ["T cells", "CELL_TYPE", 232, 239], ["VDR", "PROTEIN", 387, 390], ["intracellular VDR", "PROTEIN", 453, 470], ["activated lymphocytes", "CELL_TYPE", 530, 551], ["1,25D on T cells", "TREATMENT", 90, 106], ["vitamin D in supplementation trials", "TREATMENT", 145, 180], ["Vitamin D and T cells", "TREATMENT", 218, 239], ["1,25D-mediated immunomodulation", "TREATMENT", 299, 330], ["autoimmune inflammatory disease", "PROBLEM", 355, 386], ["VDR expression", "TEST", 387, 401], ["T cell activationEarly studies", "TEST", 406, 436], ["the intracellular VDR", "PROBLEM", 449, 470], ["autoimmune", "OBSERVATION_MODIFIER", 355, 365], ["inflammatory", "OBSERVATION", 366, 378], ["intracellular VDR", "OBSERVATION", 453, 470]]], ["Since then, levels of VDR expression on T cell subsets have been investigated further, occasionally with conflicting results.", [["T cell", "ANATOMY", 40, 46], ["VDR", "GENE_OR_GENE_PRODUCT", 22, 25], ["T cell", "CELL", 40, 46], ["VDR", "PROTEIN", 22, 25], ["T cell subsets", "CELL_TYPE", 40, 54], ["VDR expression", "PROBLEM", 22, 36], ["T cell subsets", "TREATMENT", 40, 54]]], ["As 1,25D acts primarily through binding to the VDR, it is important to consider VDR expression levels as a determinant of T cell function.", [["T cell", "ANATOMY", 122, 128], ["1,25D", "CHEMICAL", 3, 8], ["1,25D", "CHEMICAL", 3, 8], ["1,25D", "SIMPLE_CHEMICAL", 3, 8], ["VDR", "GENE_OR_GENE_PRODUCT", 47, 50], ["VDR", "GENE_OR_GENE_PRODUCT", 80, 83], ["T cell", "CELL", 122, 128], ["1,25D", "PROTEIN", 3, 8], ["VDR", "PROTEIN", 47, 50], ["VDR", "PROTEIN", 80, 83], ["VDR expression levels", "PROBLEM", 80, 101]]], ["Studies using VDR knockout (KO) mice have shown comparable levels of CD4 + and CD8\u03b1\u03b2 + T cells in the periphery, indicating that 1,25D is not required for T cell thymic development or subsequent egress from the thymus (117) .", [["CD4 +", "ANATOMY", 69, 74], ["CD8\u03b1\u03b2 + T cells", "ANATOMY", 79, 94], ["periphery", "ANATOMY", 102, 111], ["T cell thymic", "ANATOMY", 155, 168], ["thymus", "ANATOMY", 211, 217], ["1,25D", "CHEMICAL", 129, 134], ["1,25D", "CHEMICAL", 129, 134], ["VDR", "GENE_OR_GENE_PRODUCT", 14, 17], ["knockout (KO) mice", "ORGANISM", 18, 36], ["CD4", "GENE_OR_GENE_PRODUCT", 69, 72], ["CD8", "GENE_OR_GENE_PRODUCT", 79, 82], ["1,25D", "SIMPLE_CHEMICAL", 129, 134], ["T cell thymic", "CELL", 155, 168], ["thymus", "ORGAN", 211, 217], ["VDR", "PROTEIN", 14, 17], ["CD4", "PROTEIN", 69, 72], ["CD8\u03b1\u03b2 + T cells", "CELL_TYPE", 79, 94], ["mice", "SPECIES", 32, 36], ["mice", "SPECIES", 32, 36], ["Studies", "TEST", 0, 7], ["VDR knockout", "TEST", 14, 26], ["CD4", "TEST", 69, 72], ["CD8", "TEST", 79, 82], ["T cells in the periphery", "PROBLEM", 87, 111], ["T cell thymic development", "PROBLEM", 155, 180], ["T cells", "OBSERVATION", 87, 94], ["periphery", "ANATOMY_MODIFIER", 102, 111], ["thymus", "ANATOMY", 211, 217]]], ["This is with the exception of iNKT cells and CD8\u03b1\u03b1 + T cells, a protective subset found in the gut, which fail to develop from their thymic precursors in VDR KO mice (103, 118) .", [["iNKT cells", "ANATOMY", 30, 40], ["CD8\u03b1\u03b1 + T cells", "ANATOMY", 45, 60], ["gut", "ANATOMY", 95, 98], ["thymic precursors", "ANATOMY", 133, 150], ["iNKT cells", "CELL", 30, 40], ["CD8", "GENE_OR_GENE_PRODUCT", 45, 48], ["gut", "ORGANISM_SUBDIVISION", 95, 98], ["thymic precursors", "MULTI-TISSUE_STRUCTURE", 133, 150], ["VDR", "GENE_OR_GENE_PRODUCT", 154, 157], ["iNKT cells", "CELL_TYPE", 30, 40], ["CD8\u03b1\u03b1 + T cells", "CELL_TYPE", 45, 60], ["thymic precursors", "CELL_TYPE", 133, 150], ["VDR", "PROTEIN", 154, 157], ["mice", "SPECIES", 161, 165], ["iNKT cells", "PROBLEM", 30, 40], ["CD8", "TEST", 45, 48], ["T cells", "PROBLEM", 53, 60], ["a protective subset", "PROBLEM", 62, 81], ["iNKT cells", "OBSERVATION", 30, 40], ["gut", "ANATOMY", 95, 98], ["thymic", "ANATOMY", 133, 139]]], ["With no overall abnormalities in peripheral T cell numbers it appears that 1,25D acts more as a regulator of fully developed and differentiated cells, to dampen overactive responses, than a regulator of development.VDR expression and T cell activationVDR is expressed at very low (119) , and often undetectable (120, 121) , levels in na\u00efve T cells.VDR expression and T cell activationUpon activation, in response to T cell receptor (TCR) signalling via the p38 MAPK pathway, expression of the VDR is significantly increased in T cells (119, 120) .", [["peripheral T cell", "ANATOMY", 33, 50], ["cells", "ANATOMY", 144, 149], ["T cell", "ANATOMY", 234, 240], ["na\u00efve T cells", "ANATOMY", 334, 347], ["T cell", "ANATOMY", 367, 373], ["T cell", "ANATOMY", 416, 422], ["T cells", "ANATOMY", 527, 534], ["1,25D", "CHEMICAL", 75, 80], ["1,25D", "CHEMICAL", 75, 80], ["peripheral T cell", "CELL", 33, 50], ["1,25D", "SIMPLE_CHEMICAL", 75, 80], ["cells", "CELL", 144, 149], ["VDR", "GENE_OR_GENE_PRODUCT", 215, 218], ["T cell", "CELL", 234, 240], ["na\u00efve T cells", "CELL", 334, 347], ["VDR", "GENE_OR_GENE_PRODUCT", 348, 351], ["T cell", "CELL", 367, 373], ["T cell receptor", "GENE_OR_GENE_PRODUCT", 416, 431], ["TCR", "GENE_OR_GENE_PRODUCT", 433, 436], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 457, 465], ["VDR", "GENE_OR_GENE_PRODUCT", 493, 496], ["T cells", "CELL", 527, 534], ["peripheral T cell", "CELL_TYPE", 33, 50], ["1,25D", "PROTEIN", 75, 80], ["differentiated cells", "CELL_TYPE", 129, 149], ["VDR", "PROTEIN", 215, 218], ["T cell activationVDR", "PROTEIN", 234, 254], ["na\u00efve T cells", "CELL_TYPE", 334, 347], ["VDR", "PROTEIN", 348, 351], ["T cell receptor", "PROTEIN", 416, 431], ["TCR", "PROTEIN", 433, 436], ["p38 MAPK", "PROTEIN", 457, 465], ["VDR", "PROTEIN", 493, 496], ["T cells", "CELL_TYPE", 527, 534], ["overall abnormalities in peripheral T cell numbers", "PROBLEM", 8, 58], ["VDR expression", "TEST", 215, 229], ["T cell activationVDR", "TEST", 234, 254], ["levels in na\u00efve T cells", "PROBLEM", 324, 347], ["VDR expression", "PROBLEM", 348, 362], ["the p38 MAPK pathway", "TEST", 453, 473], ["the VDR", "TEST", 489, 496], ["no", "UNCERTAINTY", 5, 7], ["overall", "OBSERVATION_MODIFIER", 8, 15], ["abnormalities", "OBSERVATION", 16, 29], ["peripheral", "ANATOMY_MODIFIER", 33, 43], ["T cell numbers", "OBSERVATION", 44, 58], ["T cell", "OBSERVATION_MODIFIER", 367, 373], ["significantly", "OBSERVATION_MODIFIER", 500, 513], ["increased", "OBSERVATION_MODIFIER", 514, 523]]], ["One study suggested that this initial upregulation of the VDR then led to the upregulation of PLC\u03b3-1, a key enzyme in T cell activation, which was able to reciprocally further enhance TCR signalling (119) .", [["T cell", "ANATOMY", 118, 124], ["TCR", "CHEMICAL", 184, 187], ["VDR", "GENE_OR_GENE_PRODUCT", 58, 61], ["PLC\u03b3-1", "GENE_OR_GENE_PRODUCT", 94, 100], ["T cell", "CELL", 118, 124], ["TCR", "GENE_OR_GENE_PRODUCT", 184, 187], ["VDR", "PROTEIN", 58, 61], ["PLC\u03b3-1", "PROTEIN", 94, 100], ["TCR", "PROTEIN", 184, 187], ["One study", "TEST", 0, 9], ["PLC", "TEST", 94, 97], ["T cell activation", "OBSERVATION", 118, 135]]], ["It is also reported that 1,25D upregulates expression of the T cell markers CD38 and HLA-DR (122) .", [["T cell", "ANATOMY", 61, 67], ["1,25D", "SIMPLE_CHEMICAL", 25, 30], ["T cell", "CELL", 61, 67], ["CD38", "GENE_OR_GENE_PRODUCT", 76, 80], ["HLA-DR", "GENE_OR_GENE_PRODUCT", 85, 91], ["1,25D", "PROTEIN", 25, 30], ["T cell markers", "PROTEIN", 61, 75], ["CD38", "PROTEIN", 76, 80], ["HLA", "PROTEIN", 85, 88], ["the T cell markers", "TEST", 57, 75], ["CD38", "TEST", 76, 80], ["HLA", "TEST", 85, 88]]], ["However, these studies were carried out in vitro and require further investigation in vivo to fully define the relevance of this finding.", [["these studies", "TEST", 9, 22], ["further investigation", "TEST", 61, 82]]], ["In comparison, mice have sufficient levels of PLC\u03b3-1 prior to TCR activation and do not require upregulation of the enzyme (123) .VDR expression and T cell activationBinding of 1,25D to the VDR has been shown to prevent degradation of the receptor, forming a positive feedback loop for increased VDR levels in activated T cells (Fig. 2 ) (120).VDR expression in T cell subsetsAlthough it is known that all na\u00efve T cells upregulate VDR expression upon TCR activation, there are conflicting reports on the level of VDR expression in differentiated T cell subsets.", [["T cell", "ANATOMY", 149, 155], ["T cells", "ANATOMY", 320, 327], ["T cell", "ANATOMY", 362, 368], ["T cells", "ANATOMY", 412, 419], ["T cell", "ANATOMY", 546, 552], ["TCR", "CHEMICAL", 62, 65], ["1,25D", "CHEMICAL", 177, 182], ["1,25D", "CHEMICAL", 177, 182], ["mice", "ORGANISM", 15, 19], ["PLC\u03b3-1", "GENE_OR_GENE_PRODUCT", 46, 52], ["TCR", "GENE_OR_GENE_PRODUCT", 62, 65], ["VDR", "GENE_OR_GENE_PRODUCT", 130, 133], ["T cell", "CELL", 149, 155], ["1,25D", "SIMPLE_CHEMICAL", 177, 182], ["VDR", "GENE_OR_GENE_PRODUCT", 190, 193], ["VDR", "GENE_OR_GENE_PRODUCT", 296, 299], ["T cells", "CELL", 320, 327], ["VDR", "GENE_OR_GENE_PRODUCT", 344, 347], ["T cell", "CELL", 362, 368], ["na\u00efve T cells", "CELL", 406, 419], ["VDR", "GENE_OR_GENE_PRODUCT", 431, 434], ["TCR", "GENE_OR_GENE_PRODUCT", 451, 454], ["VDR", "GENE_OR_GENE_PRODUCT", 513, 516], ["T cell subsets", "CELL", 546, 560], ["PLC\u03b3-1", "PROTEIN", 46, 52], ["TCR", "PROTEIN", 62, 65], ["VDR", "PROTEIN", 130, 133], ["VDR", "PROTEIN", 190, 193], ["VDR", "PROTEIN", 296, 299], ["activated T cells", "CELL_TYPE", 310, 327], ["VDR", "PROTEIN", 344, 347], ["T cell subsets", "CELL_TYPE", 362, 376], ["na\u00efve T cells", "CELL_TYPE", 406, 419], ["VDR", "PROTEIN", 431, 434], ["TCR", "PROTEIN", 451, 454], ["VDR", "PROTEIN", 513, 516], ["differentiated T cell subsets", "CELL_TYPE", 531, 560], ["mice", "SPECIES", 15, 19], ["mice", "SPECIES", 15, 19], ["PLC", "TEST", 46, 49], ["the enzyme", "TEST", 112, 122], ["VDR expression", "PROBLEM", 130, 144], ["T cell activationBinding", "TEST", 149, 173], ["a positive feedback loop", "PROBLEM", 257, 281], ["increased VDR levels", "PROBLEM", 286, 306], ["activated T cells", "PROBLEM", 310, 327], ["VDR expression in T cell subsets", "PROBLEM", 344, 376], ["all na\u00efve T cells", "TREATMENT", 402, 419], ["TCR activation", "TEST", 451, 465], ["VDR expression", "PROBLEM", 513, 527], ["T cell subsets", "OBSERVATION", 362, 376], ["differentiated T cell subsets", "OBSERVATION", 531, 560]]], ["In one study, human na\u00efve CD4 + T cells differentiated for 3 days in the presence of polarising cytokines for Th1, Th17 and Th2 cells were shown to have equal expression of the VDR (120).", [["CD4 + T cells", "ANATOMY", 26, 39], ["Th2 cells", "ANATOMY", 124, 133], ["human", "ORGANISM", 14, 19], ["CD4", "GENE_OR_GENE_PRODUCT", 26, 29], ["Th1", "GENE_OR_GENE_PRODUCT", 110, 113], ["Th17", "CELL", 115, 119], ["Th2 cells", "CELL", 124, 133], ["VDR", "GENE_OR_GENE_PRODUCT", 177, 180], ["human na\u00efve CD4 + T cells", "CELL_TYPE", 14, 39], ["polarising cytokines", "PROTEIN", 85, 105], ["Th1, Th17 and Th2 cells", "CELL_TYPE", 110, 133], ["VDR", "PROTEIN", 177, 180], ["human", "SPECIES", 14, 19], ["human", "SPECIES", 14, 19], ["one study", "TEST", 3, 12], ["human na\u00efve CD4", "TEST", 14, 29], ["T cells", "PROBLEM", 32, 39], ["polarising cytokines", "PROBLEM", 85, 105], ["Th1", "TEST", 110, 113], ["Th2 cells", "TEST", 124, 133]]], ["However, it is likely that 3 days is not sufficient time for full polarisation of human CD4 + T cell subsets and may reflect the initial upregulation of the VDR after TCR engagement.", [["CD4 + T cell", "ANATOMY", 88, 100], ["TCR", "CHEMICAL", 167, 170], ["human", "ORGANISM", 82, 87], ["CD4", "GENE_OR_GENE_PRODUCT", 88, 91], ["VDR", "GENE_OR_GENE_PRODUCT", 157, 160], ["TCR", "GENE_OR_GENE_PRODUCT", 167, 170], ["human CD4 + T cell subsets", "CELL_TYPE", 82, 108], ["VDR", "PROTEIN", 157, 160], ["TCR", "PROTEIN", 167, 170], ["human", "SPECIES", 82, 87], ["human", "SPECIES", 82, 87], ["TCR engagement", "TREATMENT", 167, 181], ["cell subsets", "OBSERVATION", 96, 108]]], ["In mice, studies have reported that Th1 cells do not express the VDR to the same level as Th2 or Th17 cells (124, 125) , even suggesting levels to be comparable to na\u00efve T cells (124) .", [["Th1 cells", "ANATOMY", 36, 45], ["Th17 cells", "ANATOMY", 97, 107], ["na\u00efve T cells", "ANATOMY", 164, 177], ["mice", "ORGANISM", 3, 7], ["Th1 cells", "CELL", 36, 45], ["VDR", "GENE_OR_GENE_PRODUCT", 65, 68], ["Th2", "GENE_OR_GENE_PRODUCT", 90, 93], ["Th17 cells", "CELL", 97, 107], ["na\u00efve T cells", "CELL", 164, 177], ["Th1 cells", "CELL_TYPE", 36, 45], ["VDR", "PROTEIN", 65, 68], ["Th2 or Th17 cells", "CELL_TYPE", 90, 107], ["na\u00efve T cells", "CELL_TYPE", 164, 177], ["mice", "SPECIES", 3, 7], ["mice", "SPECIES", 3, 7], ["studies", "TEST", 9, 16], ["Th1 cells", "TEST", 36, 45], ["Th17 cells", "TEST", 97, 107], ["Th1 cells", "OBSERVATION", 36, 45]]], ["The latter of these studies saw no change in IFN-\u03b3 with 1,25D treatment (125) , an effect that is usually observed in vitro (126, 127) .", [["1,25D", "CHEMICAL", 56, 61], ["1,25D", "CHEMICAL", 56, 61], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 45, 50], ["1,25D", "SIMPLE_CHEMICAL", 56, 61], ["IFN", "PROTEIN", 45, 48], ["these studies", "TEST", 14, 27], ["IFN", "TEST", 45, 48], ["1,25D treatment", "TREATMENT", 56, 71], ["no", "UNCERTAINTY", 32, 34], ["change", "OBSERVATION_MODIFIER", 35, 41]]], ["There have been similar reports for inducible regulatory T cells (iTregs).", [["regulatory T cells", "ANATOMY", 46, 64], ["iTregs", "ANATOMY", 66, 72], ["T cells", "CELL", 57, 64], ["iTregs", "CELL", 66, 72], ["regulatory T cells", "CELL_TYPE", 46, 64], ["iTregs", "CELL_TYPE", 66, 72], ["inducible regulatory T cells", "PROBLEM", 36, 64]]], ["One study, sorting human Tregs as CD4 + CD25 hi cells, showed comparable expression of the VDR in Tregs and T conventional cells (128) .", [["Tregs", "ANATOMY", 25, 30], ["CD4 + CD25 hi cells", "ANATOMY", 34, 53], ["Tregs", "ANATOMY", 98, 103], ["T conventional cells", "ANATOMY", 108, 128], ["human", "ORGANISM", 19, 24], ["Tregs", "CELL", 25, 30], ["CD4", "GENE_OR_GENE_PRODUCT", 34, 37], ["CD25", "GENE_OR_GENE_PRODUCT", 40, 44], ["VDR", "GENE_OR_GENE_PRODUCT", 91, 94], ["Tregs", "CELL", 98, 103], ["T conventional cells", "CELL", 108, 128], ["sorting human Tregs", "CELL_TYPE", 11, 30], ["CD4", "PROTEIN", 34, 37], ["CD25 hi cells", "CELL_TYPE", 40, 53], ["VDR", "PROTEIN", 91, 94], ["Tregs", "CELL_TYPE", 98, 103], ["T conventional cells", "CELL_TYPE", 108, 128], ["human", "SPECIES", 19, 24], ["human", "SPECIES", 19, 24], ["One study", "TEST", 0, 9], ["sorting human Tregs", "TEST", 11, 30], ["CD4", "TEST", 34, 37], ["CD25 hi cells", "TEST", 40, 53], ["Tregs", "ANATOMY", 98, 103]]], ["However, since CD25 is upregulated during T cell activation, it is possible there was some contamination of the Treg population during sorting.", [["T cell", "ANATOMY", 42, 48], ["Treg", "ANATOMY", 112, 116], ["CD25", "GENE_OR_GENE_PRODUCT", 15, 19], ["T cell", "CELL", 42, 48], ["Treg", "CELL", 112, 116], ["CD25", "PROTEIN", 15, 19], ["Treg population", "CELL_TYPE", 112, 127], ["CD25", "TEST", 15, 19], ["cell activation", "OBSERVATION", 44, 59], ["some", "OBSERVATION_MODIFIER", 86, 90], ["contamination", "OBSERVATION", 91, 104], ["Treg population", "OBSERVATION", 112, 127]]], ["In mice, it was shown that Tregs have a much lower levels of VDR expression compared to Th2 and Th17 cells (124, 129) .", [["Tregs", "ANATOMY", 27, 32], ["Th17 cells", "ANATOMY", 96, 106], ["mice", "ORGANISM", 3, 7], ["Tregs", "CELL", 27, 32], ["VDR", "GENE_OR_GENE_PRODUCT", 61, 64], ["Th2", "CELL", 88, 91], ["Th17 cells", "CELL", 96, 106], ["Tregs", "CELL_TYPE", 27, 32], ["VDR", "PROTEIN", 61, 64], ["Th2 and Th17 cells", "CELL_LINE", 88, 106], ["mice", "SPECIES", 3, 7], ["mice", "SPECIES", 3, 7], ["VDR expression", "PROBLEM", 61, 75], ["Th17 cells", "TEST", 96, 106], ["VDR expression", "OBSERVATION", 61, 75]]], ["The potential functional impact of differences in VDR expression levels between T cell subsets, or between human and mouse, remains unclear.VDR polymorphisms and inflammatory diseaseIn addition to the relationship between circulating 25D status and risk of T cell-mediated inflammatory diseases described above, research has also implicated changes in VDR structure and function with susceptibility to autoimmune disease.", [["T cell", "ANATOMY", 80, 86], ["T cell", "ANATOMY", 257, 263], ["inflammatory diseases", "DISEASE", 273, 294], ["autoimmune disease", "DISEASE", 402, 420], ["VDR", "GENE_OR_GENE_PRODUCT", 50, 53], ["T cell", "CELL", 80, 86], ["human", "ORGANISM", 107, 112], ["mouse", "ORGANISM", 117, 122], ["VDR", "GENE_OR_GENE_PRODUCT", 140, 143], ["25D", "GENE_OR_GENE_PRODUCT", 234, 237], ["T cell", "CELL", 257, 263], ["VDR", "GENE_OR_GENE_PRODUCT", 352, 355], ["VDR", "PROTEIN", 50, 53], ["T cell subsets", "CELL_TYPE", 80, 94], ["VDR", "PROTEIN", 140, 143], ["VDR", "PROTEIN", 352, 355], ["human", "SPECIES", 107, 112], ["mouse", "SPECIES", 117, 122], ["human", "SPECIES", 107, 112], ["mouse", "SPECIES", 117, 122], ["VDR expression levels", "PROBLEM", 50, 71], ["T cell subsets", "TREATMENT", 80, 94], ["VDR polymorphisms", "PROBLEM", 140, 157], ["inflammatory diseaseIn", "PROBLEM", 162, 184], ["T cell-mediated inflammatory diseases", "PROBLEM", 257, 294], ["changes in VDR structure", "PROBLEM", 341, 365], ["autoimmune disease", "PROBLEM", 402, 420], ["inflammatory diseaseIn", "OBSERVATION", 162, 184], ["inflammatory", "OBSERVATION", 273, 285], ["VDR structure", "OBSERVATION", 352, 365], ["autoimmune disease", "OBSERVATION", 402, 420]]], ["Genome-wide association studies (GWAS) identify multiple single nucleotide polymorphisms (SNPs) that increase susceptibility to a disease.", [["multiple single nucleotide polymorphisms (SNPs", "PROBLEM", 48, 94], ["a disease", "PROBLEM", 128, 137], ["disease", "OBSERVATION", 130, 137]]], ["In such studies, 4 main polymorphisms in the Vdr gene: TaqI, BsmI, ApaI and FokI have been linked to increased susceptibility to multiple sclerosis (MS), type 1 diabetes (TID), inflammatory bowel disease (IBD), systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) (130) (131) (132) (133) (134) (135) .", [["bowel", "ANATOMY", 190, 195], ["multiple sclerosis", "DISEASE", 129, 147], ["MS", "DISEASE", 149, 151], ["type 1 diabetes", "DISEASE", 154, 169], ["TID", "DISEASE", 171, 174], ["inflammatory bowel disease", "DISEASE", 177, 203], ["IBD", "DISEASE", 205, 208], ["systemic lupus erythematosus", "DISEASE", 211, 239], ["SLE", "DISEASE", 241, 244], ["rheumatoid arthritis", "DISEASE", 250, 270], ["RA", "DISEASE", 272, 274], ["Vdr", "GENE_OR_GENE_PRODUCT", 45, 48], ["TaqI", "GENE_OR_GENE_PRODUCT", 55, 59], ["BsmI", "GENE_OR_GENE_PRODUCT", 61, 65], ["ApaI", "GENE_OR_GENE_PRODUCT", 67, 71], ["FokI", "GENE_OR_GENE_PRODUCT", 76, 80], ["bowel", "ORGAN", 190, 195], ["Vdr gene", "DNA", 45, 53], ["TaqI", "DNA", 55, 59], ["BsmI", "DNA", 61, 65], ["ApaI", "DNA", 67, 71], ["FokI", "DNA", 76, 80], ["such studies", "TEST", 3, 15], ["TaqI", "PROBLEM", 55, 59], ["BsmI", "PROBLEM", 61, 65], ["ApaI", "PROBLEM", 67, 71], ["FokI", "TREATMENT", 76, 80], ["increased susceptibility", "PROBLEM", 101, 125], ["multiple sclerosis (MS)", "PROBLEM", 129, 152], ["type 1 diabetes", "PROBLEM", 154, 169], ["inflammatory bowel disease", "PROBLEM", 177, 203], ["IBD)", "PROBLEM", 205, 209], ["systemic lupus erythematosus", "PROBLEM", 211, 239], ["SLE)", "PROBLEM", 241, 245], ["rheumatoid arthritis", "PROBLEM", 250, 270], ["multiple", "OBSERVATION_MODIFIER", 129, 137], ["sclerosis", "OBSERVATION", 138, 147], ["diabetes", "OBSERVATION", 161, 169], ["inflammatory", "OBSERVATION_MODIFIER", 177, 189], ["bowel", "ANATOMY", 190, 195], ["disease", "OBSERVATION", 196, 203], ["systemic", "OBSERVATION_MODIFIER", 211, 219], ["lupus erythematosus", "OBSERVATION", 220, 239], ["rheumatoid", "OBSERVATION_MODIFIER", 250, 260], ["arthritis", "OBSERVATION", 261, 270], ["RA", "ANATOMY", 272, 274]]], ["Association of the 4 VDR variants differs between population and disease, but the presence of SNPs in the VDR gene is common to GWAS studies of many T cell-mediated inflammatory diseases.VDR polymorphisms and inflammatory diseaseAlongside these genome-wide studies, others directly link VDR abnormalities in T cells to increased risk of autoimmune inflammatory disease.", [["T cell", "ANATOMY", 149, 155], ["T cells", "ANATOMY", 308, 315], ["inflammatory disease", "DISEASE", 209, 229], ["autoimmune inflammatory disease", "DISEASE", 337, 368], ["VDR", "GENE_OR_GENE_PRODUCT", 21, 24], ["VDR", "GENE_OR_GENE_PRODUCT", 106, 109], ["T cell", "CELL", 149, 155], ["VDR", "GENE_OR_GENE_PRODUCT", 187, 190], ["VDR", "GENE_OR_GENE_PRODUCT", 287, 290], ["T cells", "CELL", 308, 315], ["VDR", "PROTEIN", 21, 24], ["VDR gene", "DNA", 106, 114], ["VDR", "PROTEIN", 187, 190], ["VDR", "PROTEIN", 287, 290], ["T cells", "CELL_TYPE", 308, 315], ["the 4 VDR variants", "PROBLEM", 15, 33], ["disease", "PROBLEM", 65, 72], ["SNPs", "PROBLEM", 94, 98], ["GWAS studies", "TEST", 128, 140], ["many T cell-mediated inflammatory diseases", "PROBLEM", 144, 186], ["VDR polymorphisms", "PROBLEM", 187, 204], ["inflammatory disease", "PROBLEM", 209, 229], ["wide studies", "TEST", 252, 264], ["VDR abnormalities in T cells", "PROBLEM", 287, 315], ["autoimmune inflammatory disease", "PROBLEM", 337, 368], ["4 VDR", "OBSERVATION_MODIFIER", 19, 24], ["disease", "OBSERVATION", 65, 72], ["cell", "OBSERVATION", 151, 155], ["inflammatory", "OBSERVATION_MODIFIER", 165, 177], ["diseases", "OBSERVATION", 178, 186], ["inflammatory disease", "OBSERVATION", 209, 229], ["autoimmune", "OBSERVATION_MODIFIER", 337, 347], ["inflammatory disease", "OBSERVATION", 348, 368]]], ["For example, one study demonstrated that a promoter region of the VDR gene had increased levels of methylation in T cells from MS patients compared to healthy controls (136) .", [["T cells", "ANATOMY", 114, 121], ["MS", "DISEASE", 127, 129], ["VDR", "GENE_OR_GENE_PRODUCT", 66, 69], ["T cells", "CELL", 114, 121], ["patients", "ORGANISM", 130, 138], ["promoter region", "DNA", 43, 58], ["VDR gene", "DNA", 66, 74], ["T cells", "CELL_TYPE", 114, 121], ["patients", "SPECIES", 130, 138], ["one study", "TEST", 13, 22], ["methylation in T cells", "PROBLEM", 99, 121], ["increased", "OBSERVATION_MODIFIER", 79, 88]]], ["Additionally, in both cell lines and human T cells, when cells were cultured in the presence of low serum 25D, it was shown that there was decreased binding of the VDR to multiple gene variants commonly identified in GWAS studies to predispose to autoimmune disease (137) .", [["cell lines", "ANATOMY", 22, 32], ["T cells", "ANATOMY", 43, 50], ["cells", "ANATOMY", 57, 62], ["serum", "ANATOMY", 100, 105], ["autoimmune disease", "DISEASE", 247, 265], ["cell lines", "CELL", 22, 32], ["human", "ORGANISM", 37, 42], ["T cells", "CELL", 43, 50], ["cells", "CELL", 57, 62], ["serum", "ORGANISM_SUBSTANCE", 100, 105], ["25D", "SIMPLE_CHEMICAL", 106, 109], ["VDR", "GENE_OR_GENE_PRODUCT", 164, 167], ["cell lines", "CELL_LINE", 22, 32], ["human T cells", "CELL_TYPE", 37, 50], ["VDR", "PROTEIN", 164, 167], ["human", "SPECIES", 37, 42], ["human", "SPECIES", 37, 42], ["cells", "PROBLEM", 57, 62], ["low serum 25D", "PROBLEM", 96, 109], ["decreased binding of the VDR", "PROBLEM", 139, 167], ["multiple gene variants", "PROBLEM", 171, 193], ["GWAS studies", "TEST", 217, 229], ["autoimmune disease", "PROBLEM", 247, 265], ["cell lines", "OBSERVATION", 22, 32], ["decreased", "OBSERVATION", 139, 148], ["autoimmune", "OBSERVATION", 247, 257]]], ["The above studies highlight the complex nature of disease susceptibility, but strongly suggest a role for vitamin D in limiting the pathogenicity of T-cell mediated autoimmune diseases.", [["T-cell", "ANATOMY", 149, 155], ["vitamin D", "CHEMICAL", 106, 115], ["autoimmune diseases", "DISEASE", 165, 184], ["vitamin D", "CHEMICAL", 106, 115], ["vitamin D", "SIMPLE_CHEMICAL", 106, 115], ["T-cell", "CELL", 149, 155], ["The above studies", "TEST", 0, 17], ["disease susceptibility", "PROBLEM", 50, 72], ["vitamin D", "TREATMENT", 106, 115], ["T-cell mediated autoimmune diseases", "PROBLEM", 149, 184], ["complex", "OBSERVATION_MODIFIER", 32, 39], ["disease", "OBSERVATION", 50, 57], ["autoimmune diseases", "OBSERVATION", 165, 184]]], ["Direct effects of 1,25D on T cells 9.1.", [["T cells", "ANATOMY", 27, 34], ["1,25D", "CHEMICAL", 18, 23], ["1,25D", "CHEMICAL", 18, 23], ["1,25D", "SIMPLE_CHEMICAL", 18, 23], ["T cells", "CELL", 27, 34], ["T cells", "CELL_TYPE", 27, 34], ["T cells", "TEST", 27, 34]]], ["IL-2 production and proliferationVDR polymorphisms and inflammatory diseaseThe regulatory effects of 1,25D can be seen almost immediately after T cell activation with the inhibition of IL-2 production (Fig. 2) (138) .", [["T cell", "ANATOMY", 144, 150], ["inflammatory disease", "DISEASE", 55, 75], ["1,25D", "CHEMICAL", 101, 106], ["1,25D", "CHEMICAL", 101, 106], ["IL-2", "GENE_OR_GENE_PRODUCT", 0, 4], ["proliferationVDR", "GENE_OR_GENE_PRODUCT", 20, 36], ["1,25D", "SIMPLE_CHEMICAL", 101, 106], ["T cell", "CELL", 144, 150], ["IL-2", "GENE_OR_GENE_PRODUCT", 185, 189], ["IL", "PROTEIN", 0, 2], ["IL", "PROTEIN", 185, 187], ["IL", "TREATMENT", 0, 2], ["proliferationVDR polymorphisms", "PROBLEM", 20, 50], ["inflammatory disease", "PROBLEM", 55, 75], ["T cell activation", "TREATMENT", 144, 161], ["inflammatory disease", "OBSERVATION", 55, 75]]], ["The IL2 gene has two VDR response elements (139) , with another demonstrating that the VDR-RXR heterodimer prevents the formation of the NFAT/AP-1 complex which is required for activation of the IL2 promoter (140, 141) .", [["IL2", "GENE_OR_GENE_PRODUCT", 4, 7], ["VDR", "GENE_OR_GENE_PRODUCT", 21, 24], ["VDR-RXR", "GENE_OR_GENE_PRODUCT", 87, 94], ["NFAT", "GENE_OR_GENE_PRODUCT", 137, 141], ["AP-1", "GENE_OR_GENE_PRODUCT", 142, 146], ["IL2", "GENE_OR_GENE_PRODUCT", 195, 198], ["IL2 gene", "DNA", 4, 12], ["VDR response elements", "DNA", 21, 42], ["VDR", "PROTEIN", 87, 90], ["RXR heterodimer", "PROTEIN", 91, 106], ["NFAT", "PROTEIN", 137, 141], ["AP", "PROTEIN", 142, 144], ["IL2 promoter", "DNA", 195, 207], ["the VDR", "TEST", 83, 90], ["RXR heterodimer", "TREATMENT", 91, 106], ["activation of the IL2 promoter", "TREATMENT", 177, 207], ["IL2", "ANATOMY", 4, 7]]], ["Initial studies showed that 1,25D inhibited T cell proliferation (138, 142) .", [["T cell", "ANATOMY", 44, 50], ["1,25D", "CHEMICAL", 28, 33], ["1,25D", "SIMPLE_CHEMICAL", 28, 33], ["T cell", "CELL", 44, 50], ["1,25D", "PROTEIN", 28, 33], ["Initial studies", "TEST", 0, 15], ["1,25D inhibited T cell proliferation", "PROBLEM", 28, 64], ["cell proliferation", "OBSERVATION", 46, 64]]], ["This was observed in bulk peripheral blood mononuclear cells (PBMCs) and purified populations of CD4 + or CD8 + T cells (138, 142, 143) .", [["peripheral blood mononuclear cells", "ANATOMY", 26, 60], ["PBMCs", "ANATOMY", 62, 67], ["CD4 +", "ANATOMY", 97, 102], ["CD8 + T cells", "ANATOMY", 106, 119], ["peripheral blood mononuclear cells", "CELL", 26, 60], ["PBMCs", "CELL", 62, 67], ["CD4", "GENE_OR_GENE_PRODUCT", 97, 100], ["CD8", "GENE_OR_GENE_PRODUCT", 106, 109], ["bulk peripheral blood mononuclear cells", "CELL_TYPE", 21, 60], ["PBMCs", "CELL_TYPE", 62, 67], ["CD4", "PROTEIN", 97, 100], ["CD8", "PROTEIN", 106, 109], ["T cells", "CELL_TYPE", 112, 119], ["PBMCs", "TEST", 62, 67], ["CD4", "TEST", 97, 100], ["CD8 + T cells", "PROBLEM", 106, 119], ["bulk", "ANATOMY_MODIFIER", 21, 25], ["peripheral", "ANATOMY_MODIFIER", 26, 36], ["blood", "ANATOMY", 37, 42], ["mononuclear cells", "OBSERVATION", 43, 60]]], ["More recently, transcriptome analysis of CD4 + T cells from experimental autoimmune encephalomyelitis (EAE) mice, a model of MS, treated with vitamin D showed downregulation of multiple genes involved in proliferation (144) .", [["CD4 + T cells", "ANATOMY", 41, 54], ["autoimmune encephalomyelitis", "DISEASE", 73, 101], ["EAE", "DISEASE", 103, 106], ["MS", "DISEASE", 125, 127], ["vitamin D", "CHEMICAL", 142, 151], ["vitamin D", "CHEMICAL", 142, 151], ["CD4", "GENE_OR_GENE_PRODUCT", 41, 44], ["mice", "ORGANISM", 108, 112], ["vitamin D", "SIMPLE_CHEMICAL", 142, 151], ["CD4", "PROTEIN", 41, 44], ["T cells", "CELL_TYPE", 47, 54], ["mice", "SPECIES", 108, 112], ["mice", "SPECIES", 108, 112], ["transcriptome analysis", "TEST", 15, 37], ["CD4", "TEST", 41, 44], ["T cells", "PROBLEM", 47, 54], ["experimental autoimmune encephalomyelitis", "PROBLEM", 60, 101], ["MS", "PROBLEM", 125, 127], ["vitamin D", "TREATMENT", 142, 151], ["autoimmune encephalomyelitis", "OBSERVATION", 73, 101]]], ["The full anti-proliferative effects of 1,25D are not completely understood, however several potential mechanisms have been proposed.VDR polymorphisms and inflammatory diseaseIn cancer cells, it has been reported that 1,25D causes cells to arrest at the G1 phase of the cell cycle by preventing cyclin dependant kinase activity, inhibiting proliferation (145) .", [["cancer cells", "ANATOMY", 177, 189], ["cells", "ANATOMY", 230, 235], ["cell", "ANATOMY", 269, 273], ["1,25D", "CHEMICAL", 39, 44], ["inflammatory disease", "DISEASE", 154, 174], ["cancer", "DISEASE", 177, 183], ["1,25D", "CHEMICAL", 217, 222], ["1,25D", "CHEMICAL", 39, 44], ["1,25D", "CHEMICAL", 217, 222], ["1,25D", "SIMPLE_CHEMICAL", 39, 44], ["VDR", "GENE_OR_GENE_PRODUCT", 132, 135], ["cancer cells", "CELL", 177, 189], ["1,25D", "SIMPLE_CHEMICAL", 217, 222], ["cells", "CELL", 230, 235], ["cell", "CELL", 269, 273], ["cyclin", "GENE_OR_GENE_PRODUCT", 294, 300], ["VDR", "PROTEIN", 132, 135], ["cancer cells", "CELL_TYPE", 177, 189], ["cyclin", "PROTEIN", 294, 300], ["VDR polymorphisms", "PROBLEM", 132, 149], ["inflammatory disease", "PROBLEM", 154, 174], ["cancer cells", "PROBLEM", 177, 189], ["1,25D causes cells", "PROBLEM", 217, 235], ["arrest", "PROBLEM", 239, 245], ["cyclin dependant kinase activity", "PROBLEM", 294, 326], ["inflammatory disease", "OBSERVATION", 154, 174], ["cancer cells", "OBSERVATION", 177, 189], ["dependant kinase activity", "OBSERVATION", 301, 326]]], ["In EAE, 1,25D treatment decreased expression of cyclins in CD4 + T cells (144) .", [["CD4 + T cells", "ANATOMY", 59, 72], ["EAE", "DISEASE", 3, 6], ["1,25D", "CHEMICAL", 8, 13], ["1,25D", "CHEMICAL", 8, 13], ["1,25D", "SIMPLE_CHEMICAL", 8, 13], ["cyclins", "GENE_OR_GENE_PRODUCT", 48, 55], ["CD4", "GENE_OR_GENE_PRODUCT", 59, 62], ["cyclins", "PROTEIN", 48, 55], ["CD4", "PROTEIN", 59, 62], ["T cells", "CELL_TYPE", 65, 72], ["1,25D treatment", "TREATMENT", 8, 23], ["cyclins in CD4 + T cells", "PROBLEM", 48, 72]]], ["However, other evidence for cell cycle alteration by 1,25D in T cells is limited.", [["cell", "ANATOMY", 28, 32], ["T cells", "ANATOMY", 62, 69], ["1,25D", "CHEMICAL", 53, 58], ["1,25D", "CHEMICAL", 53, 58], ["cell", "CELL", 28, 32], ["1,25D", "SIMPLE_CHEMICAL", 53, 58], ["T cells", "CELL", 62, 69], ["T cells", "CELL_TYPE", 62, 69], ["cell cycle alteration", "PROBLEM", 28, 49], ["1,25D in T cells", "TEST", 53, 69], ["evidence for", "UNCERTAINTY", 15, 27], ["cell cycle", "OBSERVATION", 28, 38]]], ["Some studies have suggested that the anti-proliferative effects of 1,25D are attributable to the reduction in IL-2 production (138, 142) and others have linked it to the effects of 1,25D on antigen presenting cells, thereby indirectly suppressing T cell proliferation (126, 146) .VDR polymorphisms and inflammatory diseaseIn one study, cultured purified CD4 + CD25 -T cells in the presence of 1,25D demonstrated no changes in proliferative capacity, suggesting that the anti-proliferative effects seen previously were due to the actions of other cells in the environment (126) .", [["cells", "ANATOMY", 209, 214], ["T cell", "ANATOMY", 247, 253], ["CD4 + CD25 -T cells", "ANATOMY", 354, 373], ["cells", "ANATOMY", 546, 551], ["1,25D", "CHEMICAL", 67, 72], ["1,25D", "CHEMICAL", 181, 186], ["1,25D", "CHEMICAL", 393, 398], ["1,25D", "CHEMICAL", 67, 72], ["1,25D", "CHEMICAL", 181, 186], ["1,25D", "CHEMICAL", 393, 398], ["1,25D", "SIMPLE_CHEMICAL", 67, 72], ["IL-2", "GENE_OR_GENE_PRODUCT", 110, 114], ["1,25D", "SIMPLE_CHEMICAL", 181, 186], ["cells", "CELL", 209, 214], ["T cell", "CELL", 247, 253], ["VDR", "GENE_OR_GENE_PRODUCT", 280, 283], ["CD4", "GENE_OR_GENE_PRODUCT", 354, 357], ["CD25", "GENE_OR_GENE_PRODUCT", 360, 364], ["1,25D", "SIMPLE_CHEMICAL", 393, 398], ["cells", "CELL", 546, 551], ["antigen presenting cells", "CELL_TYPE", 190, 214], ["VDR", "PROTEIN", 280, 283], ["CD4", "PROTEIN", 354, 357], ["CD25", "PROTEIN", 360, 364], ["T cells", "CELL_TYPE", 366, 373], ["Some studies", "TEST", 0, 12], ["the anti-proliferative effects", "PROBLEM", 33, 63], ["the reduction in IL", "PROBLEM", 93, 112], ["VDR polymorphisms", "PROBLEM", 280, 297], ["inflammatory diseaseIn", "PROBLEM", 302, 324], ["one study", "TEST", 325, 334], ["CD4", "TEST", 354, 357], ["CD25", "TEST", 360, 364], ["T cells", "TEST", 366, 373], ["changes in proliferative capacity", "PROBLEM", 415, 448], ["the anti-proliferative effects", "PROBLEM", 466, 496], ["reduction", "OBSERVATION_MODIFIER", 97, 106], ["cell proliferation", "OBSERVATION", 249, 267], ["inflammatory", "OBSERVATION_MODIFIER", 302, 314], ["no", "UNCERTAINTY", 412, 414], ["proliferative capacity", "OBSERVATION", 426, 448]]], ["A few reports have suggested that 1,25D is able to sensitise T cells to undergo apoptosis in EAE (147) , and a T1D mouse model (148) , but the relevance of this effect for disease pathology has still to be determined.Th1 cellsIn both human and mouse studies, 1,25D has been shown to inhibit Th1 and reciprocally promote Th2 cell differentiation (79, 127, 149, 150) .", [["T cells", "ANATOMY", 61, 68], ["Th1 cells", "ANATOMY", 217, 226], ["Th2 cell", "ANATOMY", 320, 328], ["1,25D", "CHEMICAL", 34, 39], ["EAE", "DISEASE", 93, 96], ["T1D", "DISEASE", 111, 114], ["1,25D", "CHEMICAL", 259, 264], ["1,25D", "CHEMICAL", 34, 39], ["1,25D", "CHEMICAL", 259, 264], ["1,25D", "SIMPLE_CHEMICAL", 34, 39], ["T cells", "CELL", 61, 68], ["mouse", "ORGANISM", 115, 120], ["Th1 cells", "CELL", 217, 226], ["human", "ORGANISM", 234, 239], ["mouse", "ORGANISM", 244, 249], ["1,25D", "SIMPLE_CHEMICAL", 259, 264], ["Th1", "CELL", 291, 294], ["Th2 cell", "CELL", 320, 328], ["T cells", "CELL_TYPE", 61, 68], ["Th1 cells", "CELL_TYPE", 217, 226], ["mouse", "SPECIES", 115, 120], ["human", "SPECIES", 234, 239], ["mouse", "SPECIES", 244, 249], ["mouse", "SPECIES", 115, 120], ["human", "SPECIES", 234, 239], ["mouse", "SPECIES", 244, 249], ["apoptosis", "PROBLEM", 80, 89], ["EAE", "TEST", 93, 96], ["a T1D mouse model", "TEST", 109, 126], ["disease pathology", "PROBLEM", 172, 189], ["Th2 cell differentiation", "TEST", 320, 344], ["cells", "OBSERVATION", 221, 226], ["Th2 cell differentiation", "OBSERVATION", 320, 344]]], ["In these studies, the change in T cell subset is described as an alteration in cytokine profile.", [["T cell", "ANATOMY", 32, 38], ["T cell", "CELL", 32, 38], ["T cell subset", "CELL_TYPE", 32, 45], ["cytokine", "PROTEIN", 79, 87], ["these studies", "TEST", 3, 16], ["the change in T cell subset", "PROBLEM", 18, 45], ["an alteration in cytokine profile", "PROBLEM", 62, 95], ["change", "OBSERVATION_MODIFIER", 22, 28], ["T cell subset", "OBSERVATION", 32, 45], ["alteration", "OBSERVATION", 65, 75], ["cytokine profile", "OBSERVATION", 79, 95]]], ["This is often a decrease in the Th1 cell associated cytokine, IFN-\u03b3, and an increase in Th2 cell cytokines such as IL-4, but sometimes also IL-5 and IL-13.", [["Th1 cell", "ANATOMY", 32, 40], ["Th2 cell", "ANATOMY", 88, 96], ["Th1 cell", "CELL", 32, 40], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 62, 67], ["Th2 cell", "CELL", 88, 96], ["IL-4", "GENE_OR_GENE_PRODUCT", 115, 119], ["IL-5", "GENE_OR_GENE_PRODUCT", 140, 144], ["IL-13", "GENE_OR_GENE_PRODUCT", 149, 154], ["Th1 cell associated cytokine", "PROTEIN", 32, 60], ["IFN-\u03b3", "PROTEIN", 62, 67], ["Th2 cell cytokines", "PROTEIN", 88, 106], ["IL-4", "PROTEIN", 115, 119], ["IL-5 and IL-13", "PROTEIN", 140, 154], ["a decrease in the Th1 cell associated cytokine", "PROBLEM", 14, 60], ["IFN", "TEST", 62, 65], ["an increase in Th2 cell cytokines", "PROBLEM", 73, 106], ["IL", "TEST", 115, 117], ["IL", "TEST", 140, 142], ["IL", "TEST", 149, 151], ["decrease", "OBSERVATION_MODIFIER", 16, 24], ["Th1 cell", "OBSERVATION", 32, 40], ["increase", "OBSERVATION_MODIFIER", 76, 84], ["Th2 cell cytokines", "OBSERVATION", 88, 106]]], ["Transcription factors appear to be less consistently affected, although changes in T-bet (Tbx21) and Gata3 expression are reported (Fig. 2) (151) .", [["T-bet", "GENE_OR_GENE_PRODUCT", 83, 88], ["Tbx21", "GENE_OR_GENE_PRODUCT", 90, 95], ["Gata3", "GENE_OR_GENE_PRODUCT", 101, 106], ["Transcription factors", "PROTEIN", 0, 21], ["Tbx21", "PROTEIN", 90, 95], ["Gata3", "PROTEIN", 101, 106], ["Transcription factors", "PROBLEM", 0, 21], ["Gata3 expression", "PROBLEM", 101, 117], ["appear to be", "UNCERTAINTY", 22, 34], ["less consistently", "OBSERVATION_MODIFIER", 35, 52], ["affected", "OBSERVATION", 53, 61]]], ["Although described in multiple studies as a Th1 to Th2 skew, inhibition of Th1 cell differentiation is not always accompanied by an increase in Th2 cells (151, 152) .", [["Th1 cell", "ANATOMY", 75, 83], ["Th2 cells", "ANATOMY", 144, 153], ["Th1", "GENE_OR_GENE_PRODUCT", 44, 47], ["Th2", "GENE_OR_GENE_PRODUCT", 51, 54], ["Th1 cell", "CELL", 75, 83], ["Th2 cells", "CELL", 144, 153], ["Th2 cells", "CELL_TYPE", 144, 153], ["multiple studies", "TEST", 22, 38], ["inhibition of Th1 cell differentiation", "PROBLEM", 61, 99], ["an increase in Th2 cells", "PROBLEM", 129, 153], ["Th1 cell differentiation", "OBSERVATION", 75, 99], ["not always accompanied", "UNCERTAINTY", 103, 125], ["increase", "OBSERVATION_MODIFIER", 132, 140], ["Th2 cells", "OBSERVATION", 144, 153]]], ["In addition to these effects on Th differentiation, 1,25D is also reported to directly inhibit IFN-\u03b3 expression in existing Th1 effector cells (126, 153) .Th1 cellsMechanistically, it was demonstrated in one study that VDR-RXR binds to promoter regions of the Ifng gene to directly inhibit transcription (154) .", [["Th1 effector cells", "ANATOMY", 124, 142], ["Th1 cells", "ANATOMY", 155, 164], ["1,25D", "CHEMICAL", 52, 57], ["1,25D", "CHEMICAL", 52, 57], ["Th", "CELL", 32, 34], ["1,25D", "SIMPLE_CHEMICAL", 52, 57], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 95, 100], ["Th1 effector cells", "CELL", 124, 142], ["Th1 cells", "CELL", 155, 164], ["VDR-RXR", "GENE_OR_GENE_PRODUCT", 219, 226], ["Ifng", "GENE_OR_GENE_PRODUCT", 260, 264], ["IFN", "PROTEIN", 95, 98], ["\u03b3", "PROTEIN", 99, 100], ["Th1 effector cells", "CELL_TYPE", 124, 142], ["Th1 cells", "CELL_TYPE", 155, 164], ["VDR", "PROTEIN", 219, 222], ["RXR", "PROTEIN", 223, 226], ["promoter regions", "DNA", 236, 252], ["Ifng gene", "DNA", 260, 269], ["IFN", "TEST", 95, 98], ["one study", "TEST", 204, 213], ["VDR", "TEST", 219, 222], ["the Ifng gene", "TREATMENT", 256, 269], ["Th1 effector cells", "OBSERVATION", 124, 142]]], ["However, it is likely that there are other mechanisms of IFN-\u03b3 inhibition by 1,25D, as mRNA is not consistently downregulated in studies where downregulation of the protein is seen (150) .", [["1,25D", "CHEMICAL", 77, 82], ["1,25D", "CHEMICAL", 77, 82], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 57, 62], ["1,25D", "SIMPLE_CHEMICAL", 77, 82], ["IFN", "PROTEIN", 57, 60], ["mRNA", "RNA", 87, 91], ["IFN-\u03b3 inhibition", "TREATMENT", 57, 73], ["downregulation of the protein", "PROBLEM", 143, 172], ["is likely", "UNCERTAINTY", 12, 21]]], ["IL-12, an important cytokine for Th1 differentiation and expression of IFN-\u03b3, is also inhibited by 1,25D (152) .", [["1,25D (152)", "CHEMICAL", 99, 110], ["IL-12", "GENE_OR_GENE_PRODUCT", 0, 5], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 71, 76], ["IL-12", "PROTEIN", 0, 5], ["IFN", "PROTEIN", 71, 74], ["\u03b3", "PROTEIN", 75, 76], ["IL", "TEST", 0, 2], ["IFN", "TEST", 71, 74]]], ["It is likely that the decrease in IL-12 partially limits the induction of a Th1 phenotype.", [["IL-12", "GENE_OR_GENE_PRODUCT", 34, 39], ["IL-12", "PROTEIN", 34, 39], ["the decrease in IL", "PROBLEM", 18, 36], ["a Th1 phenotype", "PROBLEM", 74, 89], ["is likely", "UNCERTAINTY", 3, 12], ["decrease", "OBSERVATION_MODIFIER", 22, 30]]], ["This is demonstrated in two EAE studies, both highlighting the reduction in IL-12 as key in preventing Th1 cell development and ameliorating EAE (155, 156) .", [["Th1 cell", "ANATOMY", 103, 111], ["EAE", "DISEASE", 141, 144], ["IL-12", "GENE_OR_GENE_PRODUCT", 76, 81], ["Th1 cell", "CELL", 103, 111], ["IL-12", "PROTEIN", 76, 81], ["two EAE studies", "TEST", 24, 39], ["the reduction in IL", "TREATMENT", 59, 78], ["reduction", "OBSERVATION_MODIFIER", 63, 72], ["Th1 cell", "OBSERVATION", 103, 111]]], ["Moreover, some studies do not demonstrate a decrease in IFN-\u03b3 during Th1 cell polarisation in the presence of 1,25D, often these cultures contain supplemented IL-12 which may partially reduce the inhibitory effects of 1,25D.", [["Th1 cell", "ANATOMY", 69, 77], ["1,25D", "CHEMICAL", 110, 115], ["1,25D.", "CHEMICAL", 218, 224], ["1,25D", "CHEMICAL", 110, 115], ["1,25D.", "CHEMICAL", 218, 224], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 56, 61], ["Th1 cell", "CELL", 69, 77], ["1,25D", "SIMPLE_CHEMICAL", 110, 115], ["IL-12", "GENE_OR_GENE_PRODUCT", 159, 164], ["1,25D.", "SIMPLE_CHEMICAL", 218, 224], ["IFN", "PROTEIN", 56, 59], ["IL", "PROTEIN", 159, 161], ["some studies", "TEST", 10, 22], ["a decrease in IFN", "PROBLEM", 42, 59], ["Th1 cell polarisation", "TEST", 69, 90], ["these cultures", "TEST", 123, 137], ["supplemented IL", "TREATMENT", 146, 161], ["decrease", "OBSERVATION_MODIFIER", 44, 52], ["Th1 cell polarisation", "OBSERVATION", 69, 90]]], ["This is shown in one study, where the addition of IL-12 to 1,25D treated T cells increased IFN-\u03b3 production to a level between control and 1,25D alone (157).Th2 cellsIt is widely considered that Th2 cells are increased by 1,25D, as a consequence of the transcriptional increase of GATA3, seen in multiple mouse and human studies (127, 149, 158) .", [["T cells", "ANATOMY", 73, 80], ["Th2 cells", "ANATOMY", 157, 166], ["Th2 cells", "ANATOMY", 195, 204], ["1,25D", "CHEMICAL", 222, 227], ["1,25D", "CHEMICAL", 222, 227], ["IL-12", "GENE_OR_GENE_PRODUCT", 50, 55], ["1,25D", "SIMPLE_CHEMICAL", 59, 64], ["T cells", "CELL", 73, 80], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 91, 96], ["1,25D", "SIMPLE_CHEMICAL", 139, 144], ["Th2 cells", "CELL", 157, 166], ["Th2 cells", "CELL", 195, 204], ["1,25D", "SIMPLE_CHEMICAL", 222, 227], ["GATA3", "GENE_OR_GENE_PRODUCT", 281, 286], ["mouse", "ORGANISM", 305, 310], ["human", "ORGANISM", 315, 320], ["IL", "PROTEIN", 50, 52], ["1,25D treated T cells", "CELL_LINE", 59, 80], ["IFN", "PROTEIN", 91, 94], ["\u03b3", "PROTEIN", 95, 96], ["Th2 cells", "CELL_LINE", 157, 166], ["Th2 cells", "CELL_TYPE", 195, 204], ["GATA3", "PROTEIN", 281, 286], ["mouse", "SPECIES", 305, 310], ["human", "SPECIES", 315, 320], ["mouse", "SPECIES", 305, 310], ["human", "SPECIES", 315, 320], ["one study", "TEST", 17, 26], ["IL", "TREATMENT", 50, 52], ["T cells", "PROBLEM", 73, 80], ["IFN", "TEST", 91, 94], ["Th2 cells", "PROBLEM", 195, 204], ["the transcriptional increase of GATA3", "PROBLEM", 249, 286], ["human studies", "TEST", 315, 328], ["cells", "OBSERVATION", 161, 166], ["widely considered", "UNCERTAINTY", 172, 189], ["Th2 cells", "OBSERVATION", 195, 204], ["increased", "OBSERVATION_MODIFIER", 209, 218], ["increase", "OBSERVATION_MODIFIER", 269, 277]]], ["This is accompanied by an increase expression of the characteristic Th2 cytokine IL-4, with some studies also reported increased IL-5 and IL-13 (127, 150) .", [["IL-4", "GENE_OR_GENE_PRODUCT", 81, 85], ["IL-5", "GENE_OR_GENE_PRODUCT", 129, 133], ["IL-13", "GENE_OR_GENE_PRODUCT", 138, 143], ["Th2 cytokine IL-4", "PROTEIN", 68, 85], ["IL", "PROTEIN", 129, 131], ["some studies", "TEST", 92, 104], ["increased IL", "TEST", 119, 131], ["IL", "TEST", 138, 140], ["increase", "OBSERVATION_MODIFIER", 26, 34], ["increased", "OBSERVATION_MODIFIER", 119, 128]]], ["It has been suggested that the increase in GATA-3 is downstream of upregulated STAT-6 activity, mediated by 1,25D, although the mechanism for this is unclear (150) .", [["GATA-3", "GENE_OR_GENE_PRODUCT", 43, 49], ["STAT-6", "GENE_OR_GENE_PRODUCT", 79, 85], ["1,25D", "GENE_OR_GENE_PRODUCT", 108, 113], ["GATA-3", "PROTEIN", 43, 49], ["STAT-6", "PROTEIN", 79, 85], ["1,25D", "PROTEIN", 108, 113], ["the increase in GATA", "PROBLEM", 27, 47], ["upregulated STAT", "TEST", 67, 83], ["increase", "OBSERVATION_MODIFIER", 31, 39]]], ["Th2 cells are unique in that they are both induced by and producers of the same cytokine, IL-4.", [["Th2 cells", "ANATOMY", 0, 9], ["Th2 cells", "CELL", 0, 9], ["IL-4", "GENE_OR_GENE_PRODUCT", 90, 94], ["Th2 cells", "CELL_LINE", 0, 9], ["cytokine", "PROTEIN", 80, 88], ["IL-4", "PROTEIN", 90, 94]]], ["IL-4 is able to induce STAT-6 which then induces GATA-3 and production of IL-4 (150) (Fig. 2) .Th2 cellsLiterature on the effect of 1,25D on Th2 cells is however largely inconsistent, with differing effects between mouse, human, tissue and culture method.", [["Th2 cells", "ANATOMY", 141, 150], ["tissue", "ANATOMY", 229, 235], ["1,25D", "CHEMICAL", 132, 137], ["1,25D", "CHEMICAL", 132, 137], ["IL-4", "GENE_OR_GENE_PRODUCT", 0, 4], ["STAT-6", "GENE_OR_GENE_PRODUCT", 23, 29], ["GATA-3", "GENE_OR_GENE_PRODUCT", 49, 55], ["IL-4", "GENE_OR_GENE_PRODUCT", 74, 78], ["1,25D", "SIMPLE_CHEMICAL", 132, 137], ["Th2 cells", "CELL", 141, 150], ["mouse", "ORGANISM", 215, 220], ["human", "ORGANISM", 222, 227], ["tissue", "TISSUE", 229, 235], ["IL-4", "PROTEIN", 0, 4], ["STAT-6", "PROTEIN", 23, 29], ["GATA-3", "PROTEIN", 49, 55], ["Th2 cells", "CELL_LINE", 141, 150], ["mouse", "SPECIES", 215, 220], ["human", "SPECIES", 222, 227], ["mouse", "SPECIES", 215, 220], ["human", "SPECIES", 222, 227], ["STAT", "TEST", 23, 27], ["GATA", "TEST", 49, 53], ["IL", "TEST", 74, 76], ["Th2 cells", "TREATMENT", 141, 150], ["culture method", "TEST", 240, 254]]], ["One study showed that there was only an increase in IL-4 when T cells from human PBMCs were cultured in the presence of 1,25D and IL-4, suggesting a requirement for the presence of IL-4 in 1,25D-mediated effects on Th2 differentiation (157) .", [["T cells", "ANATOMY", 62, 69], ["PBMCs", "ANATOMY", 81, 86], ["IL-4", "GENE_OR_GENE_PRODUCT", 52, 56], ["T cells", "CELL", 62, 69], ["human", "ORGANISM", 75, 80], ["PBMCs", "CELL", 81, 86], ["IL-4", "GENE_OR_GENE_PRODUCT", 130, 134], ["IL-4", "GENE_OR_GENE_PRODUCT", 181, 185], ["1,25D", "SIMPLE_CHEMICAL", 189, 194], ["IL-4", "PROTEIN", 52, 56], ["T cells", "CELL_TYPE", 62, 69], ["PBMCs", "CELL_TYPE", 81, 86], ["1,25D and IL-4", "PROTEIN", 120, 134], ["IL-4", "PROTEIN", 181, 185], ["human", "SPECIES", 75, 80], ["human", "SPECIES", 75, 80], ["One study", "TEST", 0, 9], ["an increase in IL", "PROBLEM", 37, 54], ["T cells", "PROBLEM", 62, 69], ["human PBMCs", "TEST", 75, 86], ["IL", "TEST", 181, 183], ["increase", "OBSERVATION_MODIFIER", 40, 48]]], ["This is also highlighted by a polarisation study on murine CD4 + T cells from lymphoid tissue, where IL-4 was only increased in the cultures supplemented with IL-4 or no polarising conditions (153) .Th2 cellsHowever, in another study using Th2 polarising conditions on murine na\u00efve and memory CD4 + T cells from splenocytes, there was a decrease in IL-4 production in na\u00efve CD4 + T cells and no change in the memory CD4 + T cells (151) .", [["CD4 + T cells", "ANATOMY", 59, 72], ["lymphoid tissue", "ANATOMY", 78, 93], ["Th2 cells", "ANATOMY", 199, 208], ["memory CD4 + T cells", "ANATOMY", 286, 306], ["splenocytes", "ANATOMY", 312, 323], ["CD4 + T cells", "ANATOMY", 374, 387], ["memory CD4 + T cells", "ANATOMY", 409, 429], ["murine", "ORGANISM", 52, 58], ["CD4", "GENE_OR_GENE_PRODUCT", 59, 62], ["lymphoid tissue", "TISSUE", 78, 93], ["IL-4", "GENE_OR_GENE_PRODUCT", 101, 105], ["IL-4", "GENE_OR_GENE_PRODUCT", 159, 163], ["Th2 cells", "CELL", 199, 208], ["murine", "ORGANISM", 269, 275], ["na\u00efve", "CELL", 276, 281], ["CD4", "GENE_OR_GENE_PRODUCT", 293, 296], ["splenocytes", "CELL", 312, 323], ["IL-4", "GENE_OR_GENE_PRODUCT", 349, 353], ["CD4", "GENE_OR_GENE_PRODUCT", 374, 377], ["murine CD4 + T cells", "CELL_TYPE", 52, 72], ["IL-4", "PROTEIN", 101, 105], ["IL", "PROTEIN", 159, 161], ["Th2 cells", "CELL_LINE", 199, 208], ["murine na\u00efve and memory CD4 + T cells", "CELL_TYPE", 269, 306], ["splenocytes", "CELL_TYPE", 312, 323], ["IL-4", "PROTEIN", 349, 353], ["na\u00efve CD4 + T cells", "CELL_TYPE", 368, 387], ["memory CD4 + T cells", "CELL_TYPE", 409, 429], ["murine", "SPECIES", 52, 58], ["murine", "SPECIES", 269, 275], ["a polarisation study", "TEST", 28, 48], ["lymphoid tissue", "PROBLEM", 78, 93], ["IL-4", "TREATMENT", 101, 105], ["the cultures", "TEST", 128, 140], ["IL", "TEST", 159, 161], ["polarising conditions", "PROBLEM", 170, 191], ["another study", "TEST", 220, 233], ["murine na\u00efve", "TEST", 269, 281], ["T cells", "PROBLEM", 299, 306], ["splenocytes", "TEST", 312, 323], ["IL", "TEST", 349, 351], ["lymphoid tissue", "OBSERVATION", 78, 93], ["increased", "OBSERVATION_MODIFIER", 115, 124], ["splenocytes", "ANATOMY", 312, 323], ["decrease", "OBSERVATION_MODIFIER", 337, 345], ["no", "UNCERTAINTY", 392, 394], ["change", "OBSERVATION_MODIFIER", 395, 401]]], ["A further study that cultured human cord blood cells in the presence of 1,25D and IL-4, saw a decrease in IL-4 production when compared to the cells cultured with IL-4 alone (159) .", [["cord blood cells", "ANATOMY", 36, 52], ["cells", "ANATOMY", 143, 148], ["human", "ORGANISM", 30, 35], ["cord blood cells", "CELL", 36, 52], ["IL-4", "GENE_OR_GENE_PRODUCT", 82, 86], ["IL-4", "GENE_OR_GENE_PRODUCT", 106, 110], ["cells", "CELL", 143, 148], ["IL-4", "GENE_OR_GENE_PRODUCT", 163, 167], ["cultured human cord blood cells", "CELL_LINE", 21, 52], ["1,25D and IL-4", "PROTEIN", 72, 86], ["IL-4", "PROTEIN", 106, 110], ["IL", "PROTEIN", 163, 165], ["human", "SPECIES", 30, 35], ["human", "SPECIES", 30, 35], ["A further study", "TEST", 0, 15], ["human cord blood cells", "TEST", 30, 52], ["IL", "TEST", 82, 84], ["a decrease in IL", "PROBLEM", 92, 108], ["IL", "TEST", 163, 165], ["decrease", "OBSERVATION_MODIFIER", 94, 102]]], ["There is also often no change in IL-4 in 1,25D-treated mouse models of inflammation (160, 161) .Th2 cellsThese variable observations are well demonstrated in one study in which IL-4 was increased by 1,25D in murine T cell cultures, whereas in vivo, no change in IL-4 was seen (79).Th17 cellsTh17 cells are a unique subset of T cells characterised by their ability to produce IL-17, IL-22, and express the transcription factor ROR\u03b3t (58).", [["Th2 cells", "ANATOMY", 96, 105], ["T cell cultures", "ANATOMY", 215, 230], ["Th17 cellsTh17 cells", "ANATOMY", 281, 301], ["T cells", "ANATOMY", 325, 332], ["inflammation", "DISEASE", 71, 83], ["1,25D", "CHEMICAL", 199, 204], ["1,25D", "CHEMICAL", 199, 204], ["IL-4", "GENE_OR_GENE_PRODUCT", 33, 37], ["1,25D", "SIMPLE_CHEMICAL", 41, 46], ["mouse", "ORGANISM", 55, 60], ["Th2 cells", "CELL", 96, 105], ["IL-4", "GENE_OR_GENE_PRODUCT", 177, 181], ["1,25D", "SIMPLE_CHEMICAL", 199, 204], ["murine", "ORGANISM", 208, 214], ["T cell cultures", "CELL", 215, 230], ["IL-4", "GENE_OR_GENE_PRODUCT", 262, 266], ["Th17 cellsTh17 cells", "CELL", 281, 301], ["T cells", "CELL", 325, 332], ["IL-17", "GENE_OR_GENE_PRODUCT", 375, 380], ["IL-22", "GENE_OR_GENE_PRODUCT", 382, 387], ["ROR\u03b3t", "GENE_OR_GENE_PRODUCT", 426, 431], ["IL-4", "PROTEIN", 33, 37], ["Th2 cells", "CELL_LINE", 96, 105], ["IL-4", "PROTEIN", 177, 181], ["murine T cell cultures", "CELL_LINE", 208, 230], ["IL", "PROTEIN", 262, 264], ["Th17 cellsTh17 cells", "CELL_LINE", 281, 301], ["T cells", "CELL_TYPE", 325, 332], ["IL-17", "PROTEIN", 375, 380], ["IL-22", "PROTEIN", 382, 387], ["transcription factor", "PROTEIN", 405, 425], ["ROR\u03b3t", "PROTEIN", 426, 431], ["mouse", "SPECIES", 55, 60], ["murine", "SPECIES", 208, 214], ["mouse", "SPECIES", 55, 60], ["IL", "TEST", 33, 35], ["inflammation", "PROBLEM", 71, 83], ["one study", "TEST", 158, 167], ["murine T cell cultures", "TEST", 208, 230], ["Th17 cellsTh17 cells", "PROBLEM", 281, 301], ["T cells", "PROBLEM", 325, 332], ["IL", "TEST", 375, 377], ["no", "UNCERTAINTY", 20, 22], ["change", "OBSERVATION_MODIFIER", 23, 29], ["IL", "OBSERVATION_MODIFIER", 33, 35], ["treated mouse", "OBSERVATION_MODIFIER", 47, 60], ["inflammation", "OBSERVATION", 71, 83], ["cells", "OBSERVATION", 100, 105], ["no", "UNCERTAINTY", 249, 251], ["change", "OBSERVATION_MODIFIER", 252, 258]]], ["Vitamin D acts on Th17 cells to suppress expression of IL-17, IL-22, TNF-\u03b1, IFN-\u03b3, and the chemokine receptor CCR6, thereby preventing migration of Th17 cells to inflamed tissues (Fig. 2) (124, 126, 158, 162) .", [["Th17 cells", "ANATOMY", 18, 28], ["Th17 cells", "ANATOMY", 148, 158], ["inflamed tissues", "ANATOMY", 162, 178], ["Vitamin D", "CHEMICAL", 0, 9], ["Vitamin D", "CHEMICAL", 0, 9], ["Vitamin D", "SIMPLE_CHEMICAL", 0, 9], ["Th17 cells", "CELL", 18, 28], ["IL-17", "GENE_OR_GENE_PRODUCT", 55, 60], ["IL-22", "GENE_OR_GENE_PRODUCT", 62, 67], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 69, 74], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 76, 81], ["CCR6", "GENE_OR_GENE_PRODUCT", 110, 114], ["Th17 cells", "CELL", 148, 158], ["inflamed tissues", "TISSUE", 162, 178], ["Th17 cells", "CELL_TYPE", 18, 28], ["IL-17", "PROTEIN", 55, 60], ["IL-22", "PROTEIN", 62, 67], ["TNF", "PROTEIN", 69, 72], ["IFN", "PROTEIN", 76, 79], ["\u03b3", "PROTEIN", 80, 81], ["chemokine receptor", "PROTEIN", 91, 109], ["CCR6", "PROTEIN", 110, 114], ["Th17 cells", "CELL_TYPE", 148, 158], ["Vitamin D acts", "TREATMENT", 0, 14], ["Th17 cells", "TREATMENT", 18, 28], ["IL", "TEST", 55, 57], ["IL", "TEST", 62, 64], ["TNF", "TEST", 69, 72], ["IFN", "TEST", 76, 79], ["the chemokine receptor CCR6", "TEST", 87, 114], ["migration of Th17 cells", "PROBLEM", 135, 158], ["Th17 cells", "OBSERVATION", 148, 158]]], ["This inhibition of a Th17 phenotype has been reported following differentiation of na\u00efve CD4 + T cells and ex vivo human Th17 memory cells (158, 162) .", [["CD4 + T cells", "ANATOMY", 89, 102], ["Th17 memory cells", "ANATOMY", 121, 138], ["CD4", "GENE_OR_GENE_PRODUCT", 89, 92], ["human", "ORGANISM", 115, 120], ["Th17 memory cells", "CELL", 121, 138], ["na\u00efve CD4 + T cells", "CELL_TYPE", 83, 102], ["human Th17 memory cells", "CELL_TYPE", 115, 138], ["human", "SPECIES", 115, 120], ["human", "SPECIES", 115, 120], ["a Th17 phenotype", "TEST", 19, 35]]], ["Similar to Th1 cell suppression, data for effects of 1,25D on ROR\u03b3t expression are inconsistent.", [["Th1 cell", "ANATOMY", 11, 19], ["1,25D", "CHEMICAL", 53, 58], ["1,25D", "CHEMICAL", 53, 58], ["Th1 cell", "CELL", 11, 19], ["1,25D", "SIMPLE_CHEMICAL", 53, 58], ["ROR\u03b3t", "GENE_OR_GENE_PRODUCT", 62, 67], ["ROR\u03b3t", "PROTEIN", 62, 67], ["Th1 cell suppression", "OBSERVATION", 11, 31]]], ["Studies using isolated human CD4 + memory T cells, showed a reduction in cytokine transcription but no change in ROR\u03b3t (162), whereas others observed a reduction in ROR\u03b3t mRNA, suggesting that 1,25D has a greater influence on transcription factors before full polarisation, when T cells have a less stable phenotype (144, 153, 163) .Th17 cellsIt has been well described that a reduction in Th17 cells often occurs in parallel to an increase in regulatory T cells (Tregs), as part of a proposed Th17/Treg reciprocation axis.", [["CD4 + memory T cells", "ANATOMY", 29, 49], ["T cells", "ANATOMY", 279, 286], ["Th17 cells", "ANATOMY", 333, 343], ["Th17 cells", "ANATOMY", 390, 400], ["regulatory T cells", "ANATOMY", 444, 462], ["Tregs", "ANATOMY", 464, 469], ["1,25D", "CHEMICAL", 193, 198], ["1,25D", "CHEMICAL", 193, 198], ["human", "ORGANISM", 23, 28], ["CD4", "GENE_OR_GENE_PRODUCT", 29, 32], ["ROR\u03b3t (162)", "GENE_OR_GENE_PRODUCT", 113, 124], ["ROR\u03b3t", "GENE_OR_GENE_PRODUCT", 165, 170], ["1,25D", "SIMPLE_CHEMICAL", 193, 198], ["T cells", "CELL", 279, 286], ["Th17 cells", "CELL", 333, 343], ["Th17 cells", "CELL", 390, 400], ["T cells", "CELL", 455, 462], ["Tregs", "CELL", 464, 469], ["Th17", "GENE_OR_GENE_PRODUCT", 494, 498], ["Treg", "GENE_OR_GENE_PRODUCT", 499, 503], ["human CD4 + memory T cells", "CELL_TYPE", 23, 49], ["cytokine", "PROTEIN", 73, 81], ["ROR\u03b3t", "PROTEIN", 113, 118], ["ROR\u03b3t mRNA", "RNA", 165, 175], ["transcription factors", "PROTEIN", 226, 247], ["T cells", "CELL_TYPE", 279, 286], ["Th17 cells", "CELL_LINE", 333, 343], ["Th17 cells", "CELL_TYPE", 390, 400], ["regulatory T cells", "CELL_TYPE", 444, 462], ["Tregs", "CELL_TYPE", 464, 469], ["human", "SPECIES", 23, 28], ["human", "SPECIES", 23, 28], ["Studies", "TEST", 0, 7], ["isolated human CD4", "TEST", 14, 32], ["a reduction in cytokine transcription", "PROBLEM", 58, 95], ["change in ROR\u03b3t", "PROBLEM", 103, 118], ["a reduction in ROR\u03b3t mRNA", "PROBLEM", 150, 175], ["T cells", "PROBLEM", 279, 286], ["Th17 cells", "PROBLEM", 333, 343], ["a reduction in Th17 cells", "TREATMENT", 375, 400], ["a proposed Th17/Treg reciprocation axis", "TREATMENT", 483, 522], ["reduction", "OBSERVATION_MODIFIER", 60, 69], ["cytokine transcription", "OBSERVATION", 73, 95], ["no", "UNCERTAINTY", 100, 102], ["change", "OBSERVATION_MODIFIER", 103, 109], ["reduction", "OBSERVATION_MODIFIER", 152, 161], ["reduction", "OBSERVATION_MODIFIER", 377, 386], ["Th17 cells", "OBSERVATION", 390, 400], ["increase", "OBSERVATION_MODIFIER", 432, 440]]], ["An important focus of improving treatments for autoimmune diseases is to restore the Th17/Treg imbalance that occurs during chronic inflammation.", [["Th17/Treg", "ANATOMY", 85, 94], ["autoimmune diseases", "DISEASE", 47, 66], ["inflammation", "DISEASE", 132, 144], ["Th17", "CELL", 85, 89], ["Treg", "CELL", 90, 94], ["improving treatments", "TREATMENT", 22, 42], ["autoimmune diseases", "PROBLEM", 47, 66], ["the Th17/Treg imbalance", "PROBLEM", 81, 104], ["chronic inflammation", "PROBLEM", 124, 144], ["Treg imbalance", "OBSERVATION", 90, 104], ["chronic", "OBSERVATION_MODIFIER", 124, 131], ["inflammation", "OBSERVATION", 132, 144]]], ["Many studies analysing the effect of 1,25D on Th17 cells, have also reported an increase in Treg markers such as CTLA-4, CD25, FoxP3 and production of Treg cytokines such as IL-10 ( Fig. 2) (126, 162, 164) .", [["Th17 cells", "ANATOMY", 46, 56], ["Treg", "ANATOMY", 92, 96], ["Treg", "ANATOMY", 151, 155], ["1,25D", "CHEMICAL", 37, 42], ["1,25D", "CHEMICAL", 37, 42], ["1,25D", "SIMPLE_CHEMICAL", 37, 42], ["Th17 cells", "CELL", 46, 56], ["Treg", "CELL", 92, 96], ["CTLA-4", "GENE_OR_GENE_PRODUCT", 113, 119], ["CD25", "GENE_OR_GENE_PRODUCT", 121, 125], ["FoxP3", "GENE_OR_GENE_PRODUCT", 127, 132], ["Treg", "CELL", 151, 155], ["IL-10", "GENE_OR_GENE_PRODUCT", 174, 179], ["Th17 cells", "CELL_TYPE", 46, 56], ["Treg markers", "PROTEIN", 92, 104], ["CTLA-4", "PROTEIN", 113, 119], ["CD25", "PROTEIN", 121, 125], ["FoxP3", "PROTEIN", 127, 132], ["Treg cytokines", "PROTEIN", 151, 165], ["IL", "PROTEIN", 174, 176], ["Many studies", "TEST", 0, 12], ["Th17 cells", "TREATMENT", 46, 56], ["an increase in Treg markers", "PROBLEM", 77, 104], ["CTLA", "TEST", 113, 117], ["CD25", "TEST", 121, 125], ["Treg cytokines", "TREATMENT", 151, 165], ["IL", "TEST", 174, 176], ["increase", "OBSERVATION_MODIFIER", 80, 88], ["Treg markers", "OBSERVATION", 92, 104]]], ["The mechanism of action of 1,25D on Th17 cells is not completely understood but some pivotal pathways have been identified.", [["Th17 cells", "ANATOMY", 36, 46], ["1,25D", "CHEMICAL", 27, 32], ["1,25D", "CHEMICAL", 27, 32], ["1,25D", "SIMPLE_CHEMICAL", 27, 32], ["Th17 cells", "CELL", 36, 46], ["Th17 cells", "CELL_TYPE", 36, 46], ["Th17 cells", "TREATMENT", 36, 46]]], ["Expression of the Treg marker FoxP3 is directly upregulated by 1,25D, through binding of VDR to a VDRE in the FOXP3 gene (165, 166) .", [["Treg", "ANATOMY", 18, 22], ["Treg", "CELL", 18, 22], ["FoxP3", "GENE_OR_GENE_PRODUCT", 30, 35], ["1,25D", "GENE_OR_GENE_PRODUCT", 63, 68], ["VDR", "GENE_OR_GENE_PRODUCT", 89, 92], ["VDRE", "GENE_OR_GENE_PRODUCT", 98, 102], ["FOXP3", "GENE_OR_GENE_PRODUCT", 110, 115], ["Treg marker FoxP3", "PROTEIN", 18, 35], ["1,25D", "PROTEIN", 63, 68], ["VDR", "PROTEIN", 89, 92], ["VDRE", "DNA", 98, 102], ["FOXP3 gene", "DNA", 110, 120], ["Treg", "ANATOMY", 18, 22]]], ["FoxP3 is able to suppress the upregulation of ROR\u03b3t in CD4 + T cells (167) , suggesting that by inducing FoxP3 expression in a na\u00efve CD4 + or Th17 cells, 1,25D is able to suppress Th17 differentiation (166) .", [["CD4 + T cells", "ANATOMY", 55, 68], ["CD4 +", "ANATOMY", 133, 138], ["Th17 cells", "ANATOMY", 142, 152], ["Th17", "ANATOMY", 180, 184], ["1,25D", "CHEMICAL", 154, 159], ["1,25D", "CHEMICAL", 154, 159], ["FoxP3", "GENE_OR_GENE_PRODUCT", 0, 5], ["ROR\u03b3t", "GENE_OR_GENE_PRODUCT", 46, 51], ["CD4", "GENE_OR_GENE_PRODUCT", 55, 58], ["FoxP3", "GENE_OR_GENE_PRODUCT", 105, 110], ["CD4", "GENE_OR_GENE_PRODUCT", 133, 136], ["Th17 cells", "CELL", 142, 152], ["1,25D", "SIMPLE_CHEMICAL", 154, 159], ["Th17", "CELL", 180, 184], ["FoxP3", "PROTEIN", 0, 5], ["ROR\u03b3t", "PROTEIN", 46, 51], ["CD4", "PROTEIN", 55, 58], ["T cells", "CELL_TYPE", 61, 68], ["FoxP3", "PROTEIN", 105, 110], ["na\u00efve CD4 + or Th17 cells", "CELL_TYPE", 127, 152], ["FoxP3", "TREATMENT", 0, 5], ["a na\u00efve CD4", "TEST", 125, 136], ["Th17 cells", "PROBLEM", 142, 152], ["FoxP3 expression", "OBSERVATION", 105, 121], ["Th17 cells", "OBSERVATION", 142, 152]]], ["Additionally, 1,25D-mediated inhibition of the NFAT pathway blocks the production of IL-17 (166) , and upregulation of PLC\u03b3-1 by 1,25D induces the production of TGF-\u03b2, further promoting the differentiation of Tregs (168, 169).T regulatory cellsWhen reviewing the effects of 1,25D on Tregs it is important to distinguish effects on Treg differentiation and plasticity, from direct effects on Treg function.", [["Tregs", "ANATOMY", 209, 214], ["T regulatory cells", "ANATOMY", 226, 244], ["Tregs", "ANATOMY", 283, 288], ["Treg", "ANATOMY", 331, 335], ["Treg", "ANATOMY", 391, 395], ["1,25D", "CHEMICAL", 274, 279], ["1,25D", "CHEMICAL", 274, 279], ["1,25D", "SIMPLE_CHEMICAL", 14, 19], ["NFAT", "GENE_OR_GENE_PRODUCT", 47, 51], ["IL-17", "GENE_OR_GENE_PRODUCT", 85, 90], ["PLC\u03b3-1", "GENE_OR_GENE_PRODUCT", 119, 125], ["1,25D", "SIMPLE_CHEMICAL", 129, 134], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 161, 166], ["Tregs", "CELL", 209, 214], ["T regulatory cells", "CELL", 226, 244], ["1,25D", "SIMPLE_CHEMICAL", 274, 279], ["Tregs", "CELL", 283, 288], ["Treg", "CELL", 331, 335], ["Treg", "CELL", 391, 395], ["NFAT", "PROTEIN", 47, 51], ["PLC\u03b3", "PROTEIN", 119, 123], ["1,25D", "PROTEIN", 129, 134], ["TGF-\u03b2", "PROTEIN", 161, 166], ["Tregs", "CELL_TYPE", 209, 214], ["T regulatory cells", "CELL_TYPE", 226, 244], ["Tregs", "CELL_TYPE", 283, 288], ["IL", "TEST", 85, 87], ["PLC\u03b3", "TEST", 119, 123], ["TGF", "TEST", 161, 164], ["Tregs", "TREATMENT", 283, 288], ["Treg differentiation", "TREATMENT", 331, 351], ["Treg function", "TREATMENT", 391, 404], ["cells", "OBSERVATION", 239, 244]]], ["Evidence suggests that 1,25D is able to induce FoxP3 expression in na\u00efve CD4 + T cells and promote Treg differentiation, with resulting functional increases in expression of IL-10 and other regulatory markers such as CTLA-4 ( Fig. 2) (126, 165, 169) .", [["na\u00efve CD4 + T cells", "ANATOMY", 67, 86], ["Treg", "ANATOMY", 99, 103], ["1,25D", "CHEMICAL", 23, 28], ["1,25D", "CHEMICAL", 23, 28], ["1,25D", "SIMPLE_CHEMICAL", 23, 28], ["FoxP3", "GENE_OR_GENE_PRODUCT", 47, 52], ["CD4", "GENE_OR_GENE_PRODUCT", 73, 76], ["Treg", "CELL", 99, 103], ["IL-10", "GENE_OR_GENE_PRODUCT", 174, 179], ["CTLA-4", "GENE_OR_GENE_PRODUCT", 217, 223], ["FoxP3", "PROTEIN", 47, 52], ["na\u00efve CD4 + T cells", "CELL_TYPE", 67, 86], ["IL-10", "PROTEIN", 174, 179], ["regulatory markers", "PROTEIN", 190, 208], ["CTLA-4", "PROTEIN", 217, 223], ["FoxP3 expression", "TEST", 47, 63], ["other regulatory markers", "TEST", 184, 208], ["CTLA", "TEST", 217, 221], ["Treg differentiation", "OBSERVATION", 99, 119], ["functional", "OBSERVATION_MODIFIER", 136, 146], ["increases", "OBSERVATION_MODIFIER", 147, 156]]], ["Studies have also shown plasticity of Th17 and Th2 cells converted to a regulatory phenotype by 1,25D (162, 170) .", [["Th17", "ANATOMY", 38, 42], ["Th2 cells", "ANATOMY", 47, 56], ["1,25D", "CHEMICAL", 96, 101], ["Th17", "CELL", 38, 42], ["Th2 cells", "CELL", 47, 56], ["Th17 and Th2 cells", "CELL_TYPE", 38, 56], ["Th17", "OBSERVATION", 38, 42], ["Th2 cells", "OBSERVATION", 47, 56]]], ["As highlighted above, induction of a Treg phenotype by 1,25D is attributed to the direct upregulation of genes such as FOXP3 and CTLA4 and parallel downregulation of genes such as IFNG and IL17A (126, 165, 166, 168) .", [["Treg", "ANATOMY", 37, 41], ["1,25D", "CHEMICAL", 55, 60], ["1,25D", "CHEMICAL", 55, 60], ["Treg", "CELL", 37, 41], ["1,25D", "SIMPLE_CHEMICAL", 55, 60], ["FOXP3", "GENE_OR_GENE_PRODUCT", 119, 124], ["CTLA4", "GENE_OR_GENE_PRODUCT", 129, 134], ["IFNG", "GENE_OR_GENE_PRODUCT", 180, 184], ["IL17A", "GENE_OR_GENE_PRODUCT", 189, 194], ["Treg phenotype", "CELL_TYPE", 37, 51], ["FOXP3", "PROTEIN", 119, 124], ["CTLA4", "PROTEIN", 129, 134], ["IFNG", "DNA", 180, 184], ["IL17A", "DNA", 189, 194], ["a Treg phenotype", "PROBLEM", 35, 51], ["the direct upregulation of genes", "PROBLEM", 78, 110], ["FOXP3 and CTLA4", "TREATMENT", 119, 134], ["parallel downregulation of genes", "PROBLEM", 139, 171]]], ["There is little evidence for direct induction of IL-10 by 1,25D in T cells.", [["T cells", "ANATOMY", 67, 74], ["1,25D", "CHEMICAL", 58, 63], ["1,25D", "CHEMICAL", 58, 63], ["IL-10", "GENE_OR_GENE_PRODUCT", 49, 54], ["1,25D", "SIMPLE_CHEMICAL", 58, 63], ["T cells", "CELL", 67, 74], ["IL-10", "PROTEIN", 49, 54], ["T cells", "CELL_TYPE", 67, 74], ["direct induction of IL", "TREATMENT", 29, 51], ["little evidence for", "UNCERTAINTY", 9, 28]]], ["However, in monocytes VDR binding to a promoter region of the IL10 gene has been reported (139, 171) .", [["monocytes", "ANATOMY", 12, 21], ["monocytes", "CELL", 12, 21], ["VDR", "GENE_OR_GENE_PRODUCT", 22, 25], ["IL10", "GENE_OR_GENE_PRODUCT", 62, 66], ["monocytes", "CELL_TYPE", 12, 21], ["VDR", "PROTEIN", 22, 25], ["promoter region", "DNA", 39, 54], ["IL10 gene", "DNA", 62, 71], ["monocytes VDR binding", "PROBLEM", 12, 33], ["monocytes VDR", "OBSERVATION", 12, 25], ["IL10", "ANATOMY", 62, 66]]], ["Induction of IL-10 in 1,25D-treated T cell cultures was shown to be increased at lower doses than effects on FOXP3, and in distinct cell populations, suggesting that IL-10 upregulation is FoxP3 independent (172) .", [["T cell cultures", "ANATOMY", 36, 51], ["cell", "ANATOMY", 132, 136], ["IL-10", "GENE_OR_GENE_PRODUCT", 13, 18], ["1,25D", "SIMPLE_CHEMICAL", 22, 27], ["T cell cultures", "CELL", 36, 51], ["FOXP3", "GENE_OR_GENE_PRODUCT", 109, 114], ["cell populations", "CELL", 132, 148], ["IL-10", "GENE_OR_GENE_PRODUCT", 166, 171], ["FoxP3", "GENE_OR_GENE_PRODUCT", 188, 193], ["IL-10", "PROTEIN", 13, 18], ["1,25D-treated T cell cultures", "CELL_LINE", 22, 51], ["FOXP3", "PROTEIN", 109, 114], ["IL", "PROTEIN", 166, 168], ["FoxP3", "PROTEIN", 188, 193], ["Induction of IL", "TREATMENT", 0, 15], ["T cell cultures", "TEST", 36, 51], ["FOXP3", "TEST", 109, 114], ["IL", "TEST", 166, 168], ["increased", "OBSERVATION_MODIFIER", 68, 77], ["lower doses", "OBSERVATION_MODIFIER", 81, 92], ["distinct cell populations", "OBSERVATION", 123, 148]]], ["IL-10 induction by 1,25D in CD4 + T cells was shown to be partially dependent on a 1,25D-mediated increase in \u03b1-1-antitrypsin (173) , and \u03b1-1-antitrypsin has also been shown to induce IL-10 in DCs (174), suggesting a role for 1,25D-induced \u03b1-1-antitrypsin in immunomodulation.", [["CD4 + T cells", "ANATOMY", 28, 41], ["DCs", "ANATOMY", 193, 196], ["1,25D", "CHEMICAL", 19, 24], ["1,25D", "CHEMICAL", 19, 24], ["IL-10", "GENE_OR_GENE_PRODUCT", 0, 5], ["1,25D", "SIMPLE_CHEMICAL", 19, 24], ["CD4", "GENE_OR_GENE_PRODUCT", 28, 31], ["1,25D", "SIMPLE_CHEMICAL", 83, 88], ["\u03b1-1-antitrypsin", "GENE_OR_GENE_PRODUCT", 110, 125], ["\u03b1-1-antitrypsin", "GENE_OR_GENE_PRODUCT", 138, 153], ["IL-10", "GENE_OR_GENE_PRODUCT", 184, 189], ["DCs", "CELL", 193, 196], ["1,25D", "SIMPLE_CHEMICAL", 226, 231], ["\u03b1-1-antitrypsin", "GENE_OR_GENE_PRODUCT", 240, 255], ["IL-10", "PROTEIN", 0, 5], ["CD4", "PROTEIN", 28, 31], ["T cells", "CELL_TYPE", 34, 41], ["\u03b1-1", "PROTEIN", 110, 113], ["\u03b1-1", "PROTEIN", 138, 141], ["antitrypsin", "PROTEIN", 142, 153], ["IL-10", "PROTEIN", 184, 189], ["DCs", "CELL_TYPE", 193, 196], ["1,25D", "PROTEIN", 226, 231], ["\u03b1-1", "PROTEIN", 240, 243], ["antitrypsin", "PROTEIN", 244, 255], ["IL", "TEST", 0, 2], ["1,25D in CD4 + T cells", "TEST", 19, 41], ["partially dependent", "PROBLEM", 58, 77], ["antitrypsin", "TEST", 114, 125], ["IL", "TEST", 184, 186], ["1,25D", "TEST", 226, 231], ["antitrypsin in immunomodulation", "TREATMENT", 244, 275], ["antitrypsin", "OBSERVATION", 244, 255]]], ["The increase in IL-10 production is then able to indirectly mediate further anti-inflammatory effects of 1,25D (172) .Studies have shown the combination of 1,25D and TGF-\u03b2 on CD4 + T cells to increase the induction ofTregs above 1,25D used alone, which, mechanistically may relate to maintenance of the expression of IL-2 which is inhibited by 1,25D (139, 169) .", [["CD4 + T cells", "ANATOMY", 175, 188], ["Tregs", "ANATOMY", 217, 222], ["1,25D", "CHEMICAL", 105, 110], ["1,25D", "CHEMICAL", 229, 234], ["1,25D (172)", "CHEMICAL", 105, 116], ["1,25D", "CHEMICAL", 229, 234], ["1,25D", "CHEMICAL", 344, 349], ["IL-10", "GENE_OR_GENE_PRODUCT", 16, 21], ["1,25D (172)", "SIMPLE_CHEMICAL", 105, 116], ["1,25D", "SIMPLE_CHEMICAL", 156, 161], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 166, 171], ["CD4", "GENE_OR_GENE_PRODUCT", 175, 178], ["Tregs", "CELL", 217, 222], ["1,25D", "SIMPLE_CHEMICAL", 229, 234], ["IL-2", "GENE_OR_GENE_PRODUCT", 317, 321], ["IL", "PROTEIN", 16, 18], ["1,25D and TGF-\u03b2", "PROTEIN", 156, 171], ["CD4", "PROTEIN", 175, 178], ["T cells", "CELL_TYPE", 181, 188], ["Tregs", "CELL_TYPE", 217, 222], ["IL-2", "PROTEIN", 317, 321], ["The increase in IL", "TREATMENT", 0, 18], ["Studies", "TEST", 118, 125], ["1,25D", "TEST", 156, 161], ["TGF", "TEST", 166, 169], ["CD4 + T cells", "TREATMENT", 175, 188], ["the induction ofTregs", "TREATMENT", 201, 222], ["increase", "OBSERVATION_MODIFIER", 4, 12], ["may relate to", "UNCERTAINTY", 270, 283]]], ["Moreover, it has been shown in vitro that adding IL-2 to 1,25D-treated CD4 + T cells is able to increase the production of Tregs (169, 175) .Studies have shown the combination of 1,25D and TGF-\u03b2 on CD4 + T cells to increase the induction ofDirect effects of 1,25D on Treg function are less clear, especially considering the contradictory evidence supporting VDR expression in Tregs (124, 128, 129) .", [["CD4 + T cells", "ANATOMY", 71, 84], ["CD4 + T cells", "ANATOMY", 198, 211], ["Treg", "ANATOMY", 267, 271], ["Tregs", "ANATOMY", 376, 381], ["1,25D", "CHEMICAL", 258, 263], ["1,25D", "CHEMICAL", 57, 62], ["1,25D", "CHEMICAL", 258, 263], ["IL-2", "GENE_OR_GENE_PRODUCT", 49, 53], ["1,25D", "SIMPLE_CHEMICAL", 57, 62], ["CD4", "GENE_OR_GENE_PRODUCT", 71, 74], ["Tregs", "CELL", 123, 128], ["1,25D", "SIMPLE_CHEMICAL", 179, 184], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 189, 194], ["CD4", "GENE_OR_GENE_PRODUCT", 198, 201], ["1,25D", "SIMPLE_CHEMICAL", 258, 263], ["Treg", "CELL", 267, 271], ["VDR", "GENE_OR_GENE_PRODUCT", 358, 361], ["Tregs", "CELL", 376, 381], ["IL", "PROTEIN", 49, 51], ["1,25D-treated CD4 + T cells", "CELL_LINE", 57, 84], ["Tregs", "CELL_TYPE", 123, 128], ["1,25D and TGF-\u03b2", "PROTEIN", 179, 194], ["CD4 + T cells", "CELL_TYPE", 198, 211], ["VDR", "PROTEIN", 358, 361], ["Tregs", "CELL_TYPE", 376, 381], ["IL", "TEST", 49, 51], ["T cells", "PROBLEM", 77, 84], ["Studies", "TEST", 141, 148], ["1,25D", "TEST", 179, 184], ["TGF", "TEST", 189, 192], ["CD4 + T cells", "TREATMENT", 198, 211], ["the induction ofDirect effects", "TREATMENT", 224, 254], ["Treg function", "TEST", 267, 280], ["VDR expression in Tregs", "PROBLEM", 358, 381], ["less clear", "OBSERVATION_MODIFIER", 285, 295], ["VDR expression", "OBSERVATION", 358, 372]]], ["Consistent with the low VDR levels described in one study, they also observed no effect of 1,25D on Tregs (129) .", [["Tregs", "ANATOMY", 100, 105], ["1,25D", "CHEMICAL", 91, 96], ["1,25D", "CHEMICAL", 91, 96], ["VDR", "GENE_OR_GENE_PRODUCT", 24, 27], ["1,25D", "SIMPLE_CHEMICAL", 91, 96], ["Tregs", "CELL", 100, 105], ["VDR", "PROTEIN", 24, 27], ["Tregs", "CELL_TYPE", 100, 105], ["the low VDR levels", "PROBLEM", 16, 34], ["one study", "TEST", 48, 57], ["Tregs", "TEST", 100, 105], ["low VDR", "OBSERVATION_MODIFIER", 20, 27]]], ["However in another study, where equal levels of VDR in human T regulatory (CD4 + CD25 high ) and T conventional cells were described, a slight increase in IL-10 from the Treg population was also observed, alongside a decrease in proliferation, suggesting a level of response to 1,25D (128) .", [["T regulatory (CD4 + CD25 high )", "ANATOMY", 61, 92], ["T conventional cells", "ANATOMY", 97, 117], ["Treg", "ANATOMY", 170, 174], ["1,25D (128)", "CHEMICAL", 278, 289], ["VDR", "GENE_OR_GENE_PRODUCT", 48, 51], ["human", "ORGANISM", 55, 60], ["T", "CELL", 61, 62], ["CD4", "GENE_OR_GENE_PRODUCT", 75, 78], ["CD25", "GENE_OR_GENE_PRODUCT", 81, 85], ["IL-10", "GENE_OR_GENE_PRODUCT", 155, 160], ["Treg", "CELL", 170, 174], ["VDR", "PROTEIN", 48, 51], ["human T regulatory (CD4 + CD25 high ) and T conventional cells", "CELL_TYPE", 55, 117], ["IL-10", "PROTEIN", 155, 160], ["Treg population", "CELL_TYPE", 170, 185], ["human", "SPECIES", 55, 60], ["human", "SPECIES", 55, 60], ["another study", "TEST", 11, 24], ["VDR in human T regulatory", "TEST", 48, 73], ["CD4", "TEST", 75, 78], ["CD25", "TEST", 81, 85], ["T conventional cells", "PROBLEM", 97, 117], ["a slight increase in IL", "PROBLEM", 134, 157], ["a decrease in proliferation", "PROBLEM", 215, 242], ["slight", "OBSERVATION_MODIFIER", 136, 142], ["increase", "OBSERVATION_MODIFIER", 143, 151], ["Treg", "ANATOMY", 170, 174], ["decrease", "OBSERVATION_MODIFIER", 217, 225], ["proliferation", "OBSERVATION", 229, 242]]], ["However, as mentioned previously, it may be that CD4 + CD25 high is not a reliable identifier of human Tregs.", [["Tregs", "ANATOMY", 103, 108], ["CD4", "GENE_OR_GENE_PRODUCT", 49, 52], ["CD25", "GENE_OR_GENE_PRODUCT", 55, 59], ["human", "ORGANISM", 97, 102], ["Tregs", "CELL", 103, 108], ["CD4", "PROTEIN", 49, 52], ["CD25", "PROTEIN", 55, 59], ["human Tregs", "CELL_TYPE", 97, 108], ["human", "SPECIES", 97, 102], ["human", "SPECIES", 97, 102], ["CD4", "TEST", 49, 52]]], ["In disease, one study was able to correlate the levels of serum 25(OH)D 3 with Treg function in MS patients (176).Effects of 1,25D on T cell metabolismUpon activation, T cells require significant metabolic reprogramming to support their new energetic demands (177) .", [["serum", "ANATOMY", 58, 63], ["Treg", "ANATOMY", 79, 83], ["T cell", "ANATOMY", 134, 140], ["T cells", "ANATOMY", 168, 175], ["MS", "DISEASE", 96, 98], ["1,25D", "CHEMICAL", 125, 130], ["25(OH)D 3", "CHEMICAL", 64, 73], ["1,25D", "CHEMICAL", 125, 130], ["serum", "ORGANISM_SUBSTANCE", 58, 63], ["25(OH)D 3", "GENE_OR_GENE_PRODUCT", 64, 73], ["Treg", "CELL", 79, 83], ["patients", "ORGANISM", 99, 107], ["1,25D", "SIMPLE_CHEMICAL", 125, 130], ["T cell", "CELL", 134, 140], ["T cells", "CELL", 168, 175], ["T cells", "CELL_TYPE", 168, 175], ["patients", "SPECIES", 99, 107], ["one study", "TEST", 12, 21], ["the levels", "TEST", 44, 54], ["serum", "TEST", 58, 63], ["T cell metabolismUpon activation", "TREATMENT", 134, 166], ["T cells", "PROBLEM", 168, 175], ["significant metabolic reprogramming", "TREATMENT", 184, 219], ["disease", "OBSERVATION", 3, 10], ["metabolic reprogramming", "OBSERVATION", 196, 219]]], ["Na\u00efve and memory T cells maintain a catabolic metabolism, supported by oxidative phosphorylation (OXPHOS).", [["memory T cells", "ANATOMY", 10, 24], ["memory T cells", "CELL", 10, 24], ["Na\u00efve and memory T cells", "CELL_TYPE", 0, 24], ["OXPHOS", "PROTEIN", 98, 104], ["a catabolic metabolism", "PROBLEM", 34, 56]]], ["In contrast, effector T cells increase nutrient uptake from the environment and levels of glycolysis, to switch to an anabolic metabolism which favours biosynthesis of effector molecules and growth (177, 178) .", [["effector T cells", "ANATOMY", 13, 29], ["effector T cells", "CELL", 13, 29], ["effector T cells", "CELL_TYPE", 13, 29], ["effector molecules", "PROTEIN", 168, 186], ["effector T cells", "PROBLEM", 13, 29], ["glycolysis", "TREATMENT", 90, 100], ["an anabolic metabolism", "PROBLEM", 115, 137], ["biosynthesis of effector molecules", "PROBLEM", 152, 186]]], ["Changes in metabolism can also directly affect the function of T cells.Effects of 1,25D on T cell metabolismFor example, GAPDH is an enzyme used in glycolysis but also acts as a transcriptional repressor of IFNG.Effects of 1,25D on T cell metabolismWith increased glycolysis, GAPDH is released from binding to IFNG, resulting in increased IFN-\u03b3 expression (179) .", [["T cells", "ANATOMY", 63, 70], ["T cell", "ANATOMY", 91, 97], ["T cell", "ANATOMY", 232, 238], ["1,25D", "CHEMICAL", 82, 87], ["1,25D", "CHEMICAL", 223, 228], ["1,25D", "CHEMICAL", 82, 87], ["1,25D", "CHEMICAL", 223, 228], ["T cells", "CELL", 63, 70], ["1,25D", "SIMPLE_CHEMICAL", 82, 87], ["T cell", "CELL", 91, 97], ["GAPDH", "GENE_OR_GENE_PRODUCT", 121, 126], ["IFNG", "GENE_OR_GENE_PRODUCT", 207, 211], ["1,25D", "SIMPLE_CHEMICAL", 223, 228], ["T cell", "CELL", 232, 238], ["GAPDH", "GENE_OR_GENE_PRODUCT", 276, 281], ["IFNG", "GENE_OR_GENE_PRODUCT", 310, 314], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 339, 344], ["T cells", "CELL_TYPE", 63, 70], ["GAPDH", "PROTEIN", 121, 126], ["transcriptional repressor", "PROTEIN", 178, 203], ["IFNG", "PROTEIN", 207, 211], ["GAPDH", "PROTEIN", 276, 281], ["IFNG", "PROTEIN", 310, 314], ["IFN", "PROTEIN", 339, 342], ["\u03b3", "PROTEIN", 343, 344], ["Changes in metabolism", "PROBLEM", 0, 21], ["T cell metabolism", "TREATMENT", 91, 108], ["GAPDH", "PROBLEM", 121, 126], ["an enzyme", "TEST", 130, 139], ["increased glycolysis", "PROBLEM", 254, 274], ["GAPDH", "PROBLEM", 276, 281], ["increased IFN", "PROBLEM", 329, 342], ["increased", "OBSERVATION_MODIFIER", 329, 338], ["IFN", "OBSERVATION_MODIFIER", 339, 342]]], ["This tight link between cellular metabolism and function also means that each T cell subset has a unique metabolic profile, dependent on tissue environment and disease (180, 181) .", [["cellular", "ANATOMY", 24, 32], ["T cell", "ANATOMY", 78, 84], ["tissue", "ANATOMY", 137, 143], ["cellular", "CELL", 24, 32], ["T cell", "CELL", 78, 84], ["tissue", "TISSUE", 137, 143], ["T cell subset", "CELL_TYPE", 78, 91], ["disease", "PROBLEM", 160, 167], ["cellular metabolism", "OBSERVATION", 24, 43], ["metabolic profile", "OBSERVATION", 105, 122], ["dependent", "OBSERVATION_MODIFIER", 124, 133], ["on tissue", "OBSERVATION_MODIFIER", 134, 143]]], ["T cell metabolism can be altered by multiple stimuli, including cytokines, TCR signalling and cellular stress (178, (182) (183) (184) .", [["T cell", "ANATOMY", 0, 6], ["cellular", "ANATOMY", 94, 102], ["T cell", "CELL", 0, 6], ["TCR", "GENE_OR_GENE_PRODUCT", 75, 78], ["cellular", "CELL", 94, 102], ["cytokines", "PROTEIN", 64, 73], ["TCR", "PROTEIN", 75, 78], ["multiple stimuli", "TEST", 36, 52], ["cytokines", "TEST", 64, 73], ["cellular stress", "TEST", 94, 109], ["cell metabolism", "OBSERVATION", 2, 17]]], ["The impact of 1,25D on T cell metabolism has not been explored, but may warrant investigation given substantial effects on metabolism described in other cell types as detailed below.Cellular metabolismIn macrophages, 1,25D alters cholesterol metabolism to limit foam cell formation in type 2 diabetes mellitus (185, 186) .", [["T cell", "ANATOMY", 23, 29], ["cell", "ANATOMY", 153, 157], ["Cellular metabolismIn macrophages", "ANATOMY", 182, 215], ["foam cell", "ANATOMY", 262, 271], ["1,25D", "CHEMICAL", 14, 19], ["1,25D", "CHEMICAL", 217, 222], ["cholesterol", "CHEMICAL", 230, 241], ["type 2 diabetes mellitus", "DISEASE", 285, 309], ["1,25D", "CHEMICAL", 14, 19], ["1,25D", "CHEMICAL", 217, 222], ["cholesterol", "CHEMICAL", 230, 241], ["1,25D", "SIMPLE_CHEMICAL", 14, 19], ["T cell", "CELL", 23, 29], ["cell", "CELL", 153, 157], ["Cellular metabolismIn macrophages", "CELL", 182, 215], ["1,25D", "SIMPLE_CHEMICAL", 217, 222], ["cholesterol", "SIMPLE_CHEMICAL", 230, 241], ["foam cell", "CELL", 262, 271], ["metabolismIn macrophages", "CELL_TYPE", 191, 215], ["substantial effects on metabolism", "PROBLEM", 100, 133], ["Cellular metabolismIn macrophages", "PROBLEM", 182, 215], ["1,25D alters cholesterol metabolism", "PROBLEM", 217, 252], ["foam cell formation", "PROBLEM", 262, 281], ["type 2 diabetes mellitus", "PROBLEM", 285, 309], ["cell types", "OBSERVATION", 153, 163], ["metabolismIn macrophages", "OBSERVATION", 191, 215], ["limit foam", "OBSERVATION_MODIFIER", 256, 266], ["cell formation", "OBSERVATION", 267, 281], ["type 2", "OBSERVATION_MODIFIER", 285, 291], ["diabetes mellitus", "OBSERVATION", 292, 309]]], ["Dendritic cells differentiated in the presence of 1,25D form a tolerogenic phenotype (TolDC) with a unique metabolic profile, including induction of pathways of glycolysis and oxidative phosphorylation, forming a highly glycolytic TolDC dependent on the PI3K/Akt/mTOR pathway (187, 188) .", [["Dendritic cells", "ANATOMY", 0, 15], ["1,25D", "CHEMICAL", 50, 55], ["1,25D", "CHEMICAL", 50, 55], ["Dendritic cells", "CELL", 0, 15], ["1,25D", "SIMPLE_CHEMICAL", 50, 55], ["TolDC", "CANCER", 86, 91], ["TolDC", "GENE_OR_GENE_PRODUCT", 231, 236], ["PI3K", "GENE_OR_GENE_PRODUCT", 254, 258], ["Akt", "GENE_OR_GENE_PRODUCT", 259, 262], ["mTOR", "GENE_OR_GENE_PRODUCT", 263, 267], ["Dendritic cells", "CELL_TYPE", 0, 15], ["PI3K", "PROTEIN", 254, 258], ["Akt", "PROTEIN", 259, 262], ["mTOR", "PROTEIN", 263, 267], ["Dendritic cells", "PROBLEM", 0, 15], ["a tolerogenic phenotype", "PROBLEM", 61, 84], ["glycolysis", "TREATMENT", 161, 171], ["oxidative phosphorylation", "PROBLEM", 176, 201], ["mTOR pathway", "TEST", 263, 275], ["oxidative phosphorylation", "OBSERVATION", 176, 201]]], ["In contrast to upregulation of mTOR, 1,25D caused direct transcriptional upregulation of mTOR inhibitor DDIT4 in osteoblasts, leading to decreased proliferation (189) .", [["osteoblasts", "ANATOMY", 113, 124], ["mTOR", "GENE_OR_GENE_PRODUCT", 31, 35], ["1,25D", "GENE_OR_GENE_PRODUCT", 37, 42], ["mTOR", "GENE_OR_GENE_PRODUCT", 89, 93], ["DDIT4", "GENE_OR_GENE_PRODUCT", 104, 109], ["osteoblasts", "CELL", 113, 124], ["mTOR", "PROTEIN", 31, 35], ["1,25D", "PROTEIN", 37, 42], ["mTOR", "PROTEIN", 89, 93], ["DDIT4", "PROTEIN", 104, 109], ["osteoblasts", "CELL_TYPE", 113, 124], ["mTOR", "TREATMENT", 31, 35], ["mTOR inhibitor", "TREATMENT", 89, 103], ["osteoblasts", "PROBLEM", 113, 124], ["decreased proliferation", "PROBLEM", 137, 160], ["mTOR", "ANATOMY", 31, 35], ["mTOR inhibitor", "OBSERVATION", 89, 103], ["osteoblasts", "ANATOMY", 113, 124], ["decreased", "OBSERVATION_MODIFIER", 137, 146], ["proliferation", "OBSERVATION_MODIFIER", 147, 160]]], ["It is also well described that vitamin D increases OXPHOS and maintains mitochondrial function in skeletal muscle (190, 191) .", [["mitochondrial", "ANATOMY", 72, 85], ["skeletal muscle", "ANATOMY", 98, 113], ["vitamin D", "CHEMICAL", 31, 40], ["vitamin D", "CHEMICAL", 31, 40], ["vitamin D", "SIMPLE_CHEMICAL", 31, 40], ["OXPHOS", "GENE_OR_GENE_PRODUCT", 51, 57], ["mitochondrial", "CELLULAR_COMPONENT", 72, 85], ["skeletal muscle", "ORGAN", 98, 113], ["OXPHOS", "PROTEIN", 51, 57], ["vitamin D increases OXPHOS", "PROBLEM", 31, 57], ["mitochondrial function", "OBSERVATION", 72, 94], ["skeletal muscle", "ANATOMY", 98, 113]]], ["Most studies looking at the impact of 1,25D on cellular metabolism are in cancer models.", [["cellular", "ANATOMY", 47, 55], ["cancer", "ANATOMY", 74, 80], ["1,25D", "CHEMICAL", 38, 43], ["cancer", "DISEASE", 74, 80], ["1,25D", "CHEMICAL", 38, 43], ["1,25D", "SIMPLE_CHEMICAL", 38, 43], ["cellular", "CELL", 47, 55], ["cancer", "CANCER", 74, 80], ["Most studies", "TEST", 0, 12], ["cancer models", "PROBLEM", 74, 87], ["cellular metabolism", "OBSERVATION", 47, 66], ["cancer", "OBSERVATION", 74, 80]]], ["Vitamin D is suppressive of glycolysis in multiple cancers (192) (193) (194) (195) .", [["cancers", "ANATOMY", 51, 58], ["Vitamin D", "CHEMICAL", 0, 9], ["cancers", "DISEASE", 51, 58], ["Vitamin D", "CHEMICAL", 0, 9], ["Vitamin D", "SIMPLE_CHEMICAL", 0, 9], ["multiple cancers", "CANCER", 42, 58], ["Vitamin D", "TREATMENT", 0, 9], ["multiple cancers", "PROBLEM", 42, 58], ["multiple", "OBSERVATION_MODIFIER", 42, 50], ["cancers", "OBSERVATION", 51, 58]]], ["For highly glycolytic cancer cells, this inhibition of glucose metabolism is detrimental, resulting in loss of proliferation and increased apoptosis (193, 195, 196) .", [["glycolytic cancer cells", "ANATOMY", 11, 34], ["cancer", "DISEASE", 22, 28], ["glucose", "CHEMICAL", 55, 62], ["glucose", "CHEMICAL", 55, 62], ["glycolytic cancer cells", "CELL", 11, 34], ["glucose", "SIMPLE_CHEMICAL", 55, 62], ["highly glycolytic cancer cells", "CELL_TYPE", 4, 34], ["highly glycolytic cancer cells", "PROBLEM", 4, 34], ["this inhibition of glucose metabolism", "PROBLEM", 36, 73], ["loss of proliferation", "PROBLEM", 103, 124], ["increased apoptosis", "PROBLEM", 129, 148], ["glycolytic cancer cells", "OBSERVATION", 11, 34], ["glucose metabolism", "OBSERVATION", 55, 73], ["detrimental", "OBSERVATION_MODIFIER", 77, 88], ["loss", "OBSERVATION_MODIFIER", 103, 107], ["proliferation", "OBSERVATION_MODIFIER", 111, 124], ["increased", "OBSERVATION_MODIFIER", 129, 138], ["apoptosis", "OBSERVATION_MODIFIER", 139, 148]]], ["In several studies, this decrease in glycolysis is linked to inhibition of c-Myc, a regulator of glycolytic gene transcription, by 1,25D (192, 195, 196) .", [["1,25D", "CHEMICAL", 131, 136], ["c-Myc", "GENE_OR_GENE_PRODUCT", 75, 80], ["Myc", "PROTEIN", 77, 80], ["several studies", "TEST", 3, 18], ["this decrease in glycolysis", "PROBLEM", 20, 47], ["glycolytic gene transcription", "TREATMENT", 97, 126]]], ["It has also been reported that 1,25D is able to suppress glutamine metabolism in breast cancer cells, partially through inhibiting transcription of the glutamine transporter (197) .", [["breast cancer cells", "ANATOMY", 81, 100], ["1,25D", "CHEMICAL", 31, 36], ["glutamine", "CHEMICAL", 57, 66], ["breast cancer", "DISEASE", 81, 94], ["glutamine", "CHEMICAL", 152, 161], ["1,25D", "CHEMICAL", 31, 36], ["glutamine", "CHEMICAL", 57, 66], ["glutamine", "CHEMICAL", 152, 161], ["1,25D", "SIMPLE_CHEMICAL", 31, 36], ["glutamine", "AMINO_ACID", 57, 66], ["breast cancer cells", "CELL", 81, 100], ["glutamine transporter", "GENE_OR_GENE_PRODUCT", 152, 173], ["breast cancer cells", "CELL_TYPE", 81, 100], ["glutamine transporter", "PROTEIN", 152, 173], ["glutamine metabolism in breast cancer cells", "PROBLEM", 57, 100], ["the glutamine transporter", "TREATMENT", 148, 173], ["breast", "ANATOMY", 81, 87], ["cancer", "OBSERVATION", 88, 94]]], ["In skin, vitamin D can also protect against cancer by increasing glycolysis, autophagy and mitophagy after UV-mediated DNA damage to maintain DNA repair in keratinocytes (198) .T cell metabolismFew studies have investigated a role for 1,25D in modulating T cell metabolism.", [["skin", "ANATOMY", 3, 7], ["cancer", "ANATOMY", 44, 50], ["keratinocytes", "ANATOMY", 156, 169], ["T cell", "ANATOMY", 177, 183], ["T cell", "ANATOMY", 255, 261], ["vitamin D", "CHEMICAL", 9, 18], ["cancer", "DISEASE", 44, 50], ["1,25D", "CHEMICAL", 235, 240], ["vitamin D", "CHEMICAL", 9, 18], ["1,25D", "CHEMICAL", 235, 240], ["skin", "ORGAN", 3, 7], ["vitamin D", "SIMPLE_CHEMICAL", 9, 18], ["cancer", "CANCER", 44, 50], ["DNA", "CELLULAR_COMPONENT", 119, 122], ["DNA", "CELLULAR_COMPONENT", 142, 145], ["keratinocytes", "CELL", 156, 169], ["T cell", "CELL", 177, 183], ["1,25D", "SIMPLE_CHEMICAL", 235, 240], ["T cell", "CELL", 255, 261], ["keratinocytes", "CELL_TYPE", 156, 169], ["1,25D", "PROTEIN", 235, 240], ["vitamin D", "TREATMENT", 9, 18], ["cancer", "PROBLEM", 44, 50], ["increasing glycolysis", "PROBLEM", 54, 75], ["autophagy", "PROBLEM", 77, 86], ["mitophagy", "PROBLEM", 91, 100], ["UV", "TREATMENT", 107, 109], ["DNA damage", "PROBLEM", 119, 129], ["DNA repair", "TREATMENT", 142, 152], ["T cell metabolismFew studies", "TEST", 177, 205], ["skin", "ANATOMY", 3, 7], ["DNA repair", "OBSERVATION", 142, 152], ["keratinocytes", "ANATOMY", 156, 169], ["cell metabolism", "OBSERVATION", 257, 272]]], ["In bulk PBMCs isolated from adults with different serum levels of 25D, PMBCs from those in the low vitamin D group had consistently higher basal OXPHOS and basal glycolysis compared to those with higher serum 25D levels (199) .", [["PBMCs", "ANATOMY", 8, 13], ["serum", "ANATOMY", 50, 55], ["serum", "ANATOMY", 203, 208], ["vitamin D", "CHEMICAL", 99, 108], ["vitamin D", "CHEMICAL", 99, 108], ["PBMCs", "CELL", 8, 13], ["serum", "ORGANISM_SUBSTANCE", 50, 55], ["25D", "SIMPLE_CHEMICAL", 66, 69], ["PMBCs", "SIMPLE_CHEMICAL", 71, 76], ["vitamin D", "SIMPLE_CHEMICAL", 99, 108], ["OXPHOS", "GENE_OR_GENE_PRODUCT", 145, 151], ["serum", "ORGANISM_SUBSTANCE", 203, 208], ["25D", "SIMPLE_CHEMICAL", 209, 212], ["PBMCs", "CELL_TYPE", 8, 13], ["PMBCs", "CELL_TYPE", 71, 76], ["OXPHOS", "PROTEIN", 145, 151], ["different serum levels", "TEST", 40, 62], ["PMBCs", "TEST", 71, 76], ["higher basal OXPHOS", "PROBLEM", 132, 151], ["basal glycolysis", "PROBLEM", 156, 172], ["higher serum 25D levels", "TEST", 196, 219], ["bulk PBMCs", "OBSERVATION", 3, 13], ["basal glycolysis", "OBSERVATION", 156, 172]]], ["A similar study also correlated lower 25D levels in the winter with higher basal PBMC metabolism and increased inflammatory cytokines (200) .", [["PBMC", "ANATOMY", 81, 85], ["PBMC", "CELL", 81, 85], ["25D", "PROTEIN", 38, 41], ["PBMC", "CELL_TYPE", 81, 85], ["inflammatory cytokines", "PROTEIN", 111, 133], ["A similar study", "TEST", 0, 15], ["higher basal PBMC metabolism", "PROBLEM", 68, 96], ["increased inflammatory cytokines", "PROBLEM", 101, 133], ["basal", "ANATOMY_MODIFIER", 75, 80], ["PBMC metabolism", "OBSERVATION", 81, 96], ["increased", "OBSERVATION_MODIFIER", 101, 110], ["inflammatory cytokines", "OBSERVATION", 111, 133]]], ["Although only correlation, and confounded by multiple additional factors, these data warrant further study into the mechanisms of 1,25D-mediated metabolic regulation of immune cells.", [["immune cells", "ANATOMY", 169, 181], ["1,25D", "SIMPLE_CHEMICAL", 130, 135], ["immune cells", "CELL", 169, 181], ["1,25D", "PROTEIN", 130, 135], ["immune cells", "CELL_TYPE", 169, 181], ["multiple additional factors", "PROBLEM", 45, 72], ["further study", "TEST", 93, 106], ["immune cells", "PROBLEM", 169, 181], ["immune cells", "OBSERVATION", 169, 181]]], ["In a study on isolated CD4 + T cells, 1,25D treatment for 24 hours caused a reduction in c-Myc expression (201) .", [["CD4 + T cells", "ANATOMY", 23, 36], ["1,25D", "CHEMICAL", 38, 43], ["1,25D", "CHEMICAL", 38, 43], ["CD4", "GENE_OR_GENE_PRODUCT", 23, 26], ["c-Myc", "GENE_OR_GENE_PRODUCT", 89, 94], ["CD4", "PROTEIN", 23, 26], ["T cells", "CELL_TYPE", 29, 36], ["Myc", "PROTEIN", 91, 94], ["a study", "TEST", 3, 10], ["isolated CD4 + T cells", "TREATMENT", 14, 36], ["1,25D treatment", "TREATMENT", 38, 53], ["a reduction", "TREATMENT", 74, 85]]], ["This finding had been previously reported in study which saw 1,25D-mediated inhibition of c-Myc after 72 hours, but only in the presence of sufficient TCR stimulation to upregulate VDR expression (202) .", [["TCR", "CHEMICAL", 151, 154], ["1,25D", "SIMPLE_CHEMICAL", 61, 66], ["c-Myc", "GENE_OR_GENE_PRODUCT", 90, 95], ["TCR", "GENE_OR_GENE_PRODUCT", 151, 154], ["VDR", "GENE_OR_GENE_PRODUCT", 181, 184], ["1,25D", "PROTEIN", 61, 66], ["Myc", "PROTEIN", 92, 95], ["TCR", "PROTEIN", 151, 154], ["VDR", "PROTEIN", 181, 184], ["sufficient TCR stimulation", "TREATMENT", 140, 166], ["TCR stimulation", "OBSERVATION", 151, 166]]], ["Although not investigated by either study, this decrease in c-Myc may suppress glycolysis in CD4 + T cells.T cell metabolismTranscriptomic analysis of CD4 + T cells from EAE mice treated with vitamin D revealed the downregulation of multiple metabolic pathways, including multiple genes from the tricarboxylic acid (TCA) cycle and glycolysis, as well as the PI3K/Akt/mTOR pathway (144) .", [["CD4 + T cells", "ANATOMY", 93, 106], ["T cell", "ANATOMY", 107, 113], ["CD4 + T cells", "ANATOMY", 151, 164], ["vitamin D", "CHEMICAL", 192, 201], ["tricarboxylic acid", "CHEMICAL", 296, 314], ["TCA", "CHEMICAL", 316, 319], ["vitamin D", "CHEMICAL", 192, 201], ["tricarboxylic acid", "CHEMICAL", 296, 314], ["TCA", "CHEMICAL", 316, 319], ["c-Myc", "GENE_OR_GENE_PRODUCT", 60, 65], ["CD4", "GENE_OR_GENE_PRODUCT", 93, 96], ["T cell", "CELL", 107, 113], ["CD4", "GENE_OR_GENE_PRODUCT", 151, 154], ["mice", "ORGANISM", 174, 178], ["vitamin D", "SIMPLE_CHEMICAL", 192, 201], ["tricarboxylic acid", "SIMPLE_CHEMICAL", 296, 314], ["TCA", "SIMPLE_CHEMICAL", 316, 319], ["PI3K", "GENE_OR_GENE_PRODUCT", 358, 362], ["Akt", "GENE_OR_GENE_PRODUCT", 363, 366], ["mTOR", "GENE_OR_GENE_PRODUCT", 367, 371], ["Myc", "PROTEIN", 62, 65], ["CD4 + T cells", "CELL_TYPE", 93, 106], ["CD4", "PROTEIN", 151, 154], ["T cells", "CELL_TYPE", 157, 164], ["PI3K", "PROTEIN", 358, 362], ["Akt", "PROTEIN", 363, 366], ["mTOR", "PROTEIN", 367, 371], ["mice", "SPECIES", 174, 178], ["mice", "SPECIES", 174, 178], ["either study", "TEST", 29, 41], ["this decrease in c-Myc", "PROBLEM", 43, 65], ["glycolysis in CD4 + T cells", "PROBLEM", 79, 106], ["T cell metabolismTranscriptomic analysis", "TEST", 107, 147], ["CD4", "TEST", 151, 154], ["T cells", "PROBLEM", 157, 164], ["EAE mice", "TREATMENT", 170, 178], ["vitamin D", "TREATMENT", 192, 201], ["multiple metabolic pathways", "PROBLEM", 233, 260], ["the tricarboxylic acid", "TEST", 292, 314], ["glycolysis", "TEST", 331, 341], ["the PI3K", "TEST", 354, 362], ["mTOR pathway", "TEST", 367, 379], ["metabolic pathways", "OBSERVATION", 242, 260]]], ["In line with this, another study using CD4 + T cells from EAE mice, showed that those treated in vitro with 1,25D had reduced mTOR activity, however these data were only from a limited number of biological replicates (203) .", [["CD4 + T cells", "ANATOMY", 39, 52], ["1,25D", "CHEMICAL", 108, 113], ["1,25D", "CHEMICAL", 108, 113], ["CD4", "GENE_OR_GENE_PRODUCT", 39, 42], ["EAE mice", "ORGANISM", 58, 66], ["1,25D", "SIMPLE_CHEMICAL", 108, 113], ["mTOR", "GENE_OR_GENE_PRODUCT", 126, 130], ["CD4", "PROTEIN", 39, 42], ["T cells", "CELL_TYPE", 45, 52], ["mTOR", "PROTEIN", 126, 130], ["mice", "SPECIES", 62, 66], ["mice", "SPECIES", 62, 66], ["another study", "TEST", 19, 32], ["EAE mice", "TEST", 58, 66], ["reduced mTOR activity", "PROBLEM", 118, 139], ["these data", "TEST", 149, 159], ["mTOR activity", "OBSERVATION", 126, 139]]], ["The data also suggested that 1,25D was able to upregulate glucocorticoid-induced apoptosis and that in EAE mice with a specific mTOR defect in T cells, this effect was ablated (203) .", [["T cells", "ANATOMY", 143, 150], ["1,25D", "CHEMICAL", 29, 34], ["EAE", "DISEASE", 103, 106], ["1,25D", "CHEMICAL", 29, 34], ["1,25D", "SIMPLE_CHEMICAL", 29, 34], ["glucocorticoid", "SIMPLE_CHEMICAL", 58, 72], ["EAE mice", "ORGANISM", 103, 111], ["mTOR", "GENE_OR_GENE_PRODUCT", 128, 132], ["T cells", "CELL", 143, 150], ["mTOR", "PROTEIN", 128, 132], ["T cells", "CELL_TYPE", 143, 150], ["mice", "SPECIES", 107, 111], ["mice", "SPECIES", 107, 111], ["1,25D", "PROBLEM", 29, 34], ["glucocorticoid", "TREATMENT", 58, 72], ["apoptosis", "PROBLEM", 81, 90], ["a specific mTOR defect in T cells", "PROBLEM", 117, 150]]], ["Although a full mechanism was not explored and repeats are necessary, this study does highlight the need for further studies investigating the effect of 1,25D on T cell metabolism in autoimmune inflammatory diseases.", [["T cell", "ANATOMY", 162, 168], ["1,25D", "CHEMICAL", 153, 158], ["autoimmune inflammatory diseases", "DISEASE", 183, 215], ["1,25D", "CHEMICAL", 153, 158], ["1,25D", "SIMPLE_CHEMICAL", 153, 158], ["T cell", "CELL", 162, 168], ["this study", "TEST", 70, 80], ["further studies", "TEST", 109, 124], ["T cell metabolism", "TREATMENT", 162, 179], ["autoimmune inflammatory diseases", "PROBLEM", 183, 215], ["autoimmune", "OBSERVATION_MODIFIER", 183, 193], ["inflammatory diseases", "OBSERVATION", 194, 215]]], ["Another study in EAE, showed that 1,25D increased transcription of BHMT1, an enzyme involved in conversion of homocysteine to methionine.", [["EAE", "DISEASE", 17, 20], ["homocysteine", "CHEMICAL", 110, 122], ["methionine", "CHEMICAL", 126, 136], ["homocysteine", "CHEMICAL", 110, 122], ["methionine", "CHEMICAL", 126, 136], ["1,25D", "SIMPLE_CHEMICAL", 34, 39], ["BHMT1", "GENE_OR_GENE_PRODUCT", 67, 72], ["homocysteine", "SIMPLE_CHEMICAL", 110, 122], ["methionine", "SIMPLE_CHEMICAL", 126, 136], ["BHMT1", "PROTEIN", 67, 72], ["Another study in EAE", "TEST", 0, 20], ["1,25D increased transcription of BHMT1", "PROBLEM", 34, 72], ["an enzyme", "TEST", 74, 83], ["homocysteine to methionine", "TREATMENT", 110, 136]]], ["This upregulation of methionine increased the global DNA methylation status of antigen-specific CD4 + T cells and an increase in Treg numbers (204) .T cell metabolismCollectively, these studies show a potential role for 1,25D as a regulator of T cell metabolism.T cell metabolismThe data suggest that 1,25D suppresses T cell glycolysis.", [["CD4 + T cells", "ANATOMY", 96, 109], ["Treg", "ANATOMY", 129, 133], ["T cell", "ANATOMY", 149, 155], ["T cell", "ANATOMY", 244, 250], ["T cell", "ANATOMY", 262, 268], ["T cell", "ANATOMY", 318, 324], ["methionine", "CHEMICAL", 21, 31], ["1,25D", "CHEMICAL", 220, 225], ["methionine", "CHEMICAL", 21, 31], ["1,25D", "CHEMICAL", 220, 225], ["methionine", "SIMPLE_CHEMICAL", 21, 31], ["DNA", "CELLULAR_COMPONENT", 53, 56], ["antigen", "GENE_OR_GENE_PRODUCT", 79, 86], ["CD4", "GENE_OR_GENE_PRODUCT", 96, 99], ["Treg", "CELL", 129, 133], ["T cell", "CELL", 149, 155], ["1,25D", "SIMPLE_CHEMICAL", 220, 225], ["T cell", "CELL", 244, 250], ["T cell", "CELL", 262, 268], ["1,25D", "SIMPLE_CHEMICAL", 301, 306], ["T cell", "CELL", 318, 324], ["CD4", "PROTEIN", 96, 99], ["T cells", "CELL_TYPE", 102, 109], ["1,25D", "PROTEIN", 220, 225], ["1,25D", "PROTEIN", 301, 306], ["methionine", "TREATMENT", 21, 31], ["antigen", "TEST", 79, 86], ["T cells", "PROBLEM", 102, 109], ["Treg numbers", "TEST", 129, 141], ["these studies", "TEST", 180, 193], ["T cell metabolism", "PROBLEM", 244, 261], ["The data", "TEST", 279, 287], ["1,25D suppresses T cell glycolysis", "TREATMENT", 301, 335], ["increase", "OBSERVATION_MODIFIER", 117, 125], ["Treg numbers", "OBSERVATION", 129, 141], ["cell metabolism", "OBSERVATION", 246, 261], ["cell metabolism", "OBSERVATION", 264, 279]]], ["If confirmed, this reduction may link to the inhibition of IFN-\u03b3 by 1,25D, as glycolysis is known to regulate IFN-\u03b3 expression (179) .", [["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 59, 64], ["1,25D", "SIMPLE_CHEMICAL", 68, 73], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 110, 115], ["IFN", "PROTEIN", 59, 62], ["\u03b3", "PROTEIN", 63, 64], ["IFN", "PROTEIN", 110, 113], ["\u03b3", "PROTEIN", 114, 115], ["this reduction", "TREATMENT", 14, 28], ["IFN", "TREATMENT", 59, 62]]], ["Although shown to be transcriptionally regulated by vitamin D (154) , in some studies little change in IFNG mRNA is seen, despite a reduction in cytokine production (150) .", [["vitamin D", "CHEMICAL", 52, 61], ["vitamin D (154)", "CHEMICAL", 52, 67], ["vitamin D", "SIMPLE_CHEMICAL", 52, 61], ["IFNG", "GENE_OR_GENE_PRODUCT", 103, 107], ["IFNG mRNA", "RNA", 103, 112], ["cytokine", "PROTEIN", 145, 153], ["vitamin D", "TREATMENT", 52, 61], ["IFNG mRNA", "PROBLEM", 103, 112], ["a reduction in cytokine production", "PROBLEM", 130, 164], ["little", "OBSERVATION_MODIFIER", 86, 92], ["change", "OBSERVATION_MODIFIER", 93, 99], ["IFNG mRNA", "OBSERVATION", 103, 112], ["reduction", "OBSERVATION_MODIFIER", 132, 141], ["cytokine production", "OBSERVATION", 145, 164]]], ["This suggests additional post-translational control that may come into effect at different time points or doses.Indirect effects of vitamin D on T cellsFor T cells, the main source of 1,25D is locally synthesised by APCs expressing the enzyme CYP27B1, and conversion of 25D to 1,25D (146) .", [["T cells", "ANATOMY", 145, 152], ["T cells", "ANATOMY", 156, 163], ["APCs", "ANATOMY", 216, 220], ["vitamin D", "CHEMICAL", 132, 141], ["1,25D", "CHEMICAL", 184, 189], ["vitamin D", "CHEMICAL", 132, 141], ["1,25D", "CHEMICAL", 184, 189], ["1,25D", "CHEMICAL", 277, 282], ["vitamin D", "SIMPLE_CHEMICAL", 132, 141], ["T cells", "CELL", 145, 152], ["T cells", "CELL", 156, 163], ["1,25D", "SIMPLE_CHEMICAL", 184, 189], ["APCs", "CELL", 216, 220], ["CYP27B1", "GENE_OR_GENE_PRODUCT", 243, 250], ["T cells", "CELL_TYPE", 145, 152], ["T cells", "CELL_TYPE", 156, 163], ["APCs", "CELL_TYPE", 216, 220], ["enzyme CYP27B1", "PROTEIN", 236, 250], ["-translational control", "TREATMENT", 29, 51], ["vitamin D on T cells", "TREATMENT", 132, 152], ["T cells", "PROBLEM", 156, 163], ["the enzyme CYP27B1", "TEST", 232, 250]]], ["It has been reported that murine CD8 + T cells, but not CD4 + T cells, have functional CYP27B1 activity (205) .", [["CD8 + T cells", "ANATOMY", 33, 46], ["CD4 + T cells", "ANATOMY", 56, 69], ["murine", "ORGANISM", 26, 32], ["CD8", "GENE_OR_GENE_PRODUCT", 33, 36], ["CD4", "GENE_OR_GENE_PRODUCT", 56, 59], ["CYP27B1", "GENE_OR_GENE_PRODUCT", 87, 94], ["murine CD8 + T cells", "CELL_TYPE", 26, 46], ["CD4 + T cells", "CELL_TYPE", 56, 69], ["CYP27B1", "PROTEIN", 87, 94], ["murine", "SPECIES", 26, 32], ["murine CD8", "TEST", 26, 36], ["T cells", "PROBLEM", 39, 46], ["CD4 + T cells", "PROBLEM", 56, 69]]], ["Human CD4 + T cells do express functional CYP27B1, although at comparably low levels compared to dendritic cells (146, 206) .", [["CD4 + T cells", "ANATOMY", 6, 19], ["dendritic cells", "ANATOMY", 97, 112], ["Human", "ORGANISM", 0, 5], ["CD4", "GENE_OR_GENE_PRODUCT", 6, 9], ["CYP27B1", "GENE_OR_GENE_PRODUCT", 42, 49], ["dendritic cells", "CELL", 97, 112], ["Human CD4 + T cells", "CELL_TYPE", 0, 19], ["CYP27B1", "PROTEIN", 42, 49], ["dendritic cells", "CELL_TYPE", 97, 112], ["Human", "SPECIES", 0, 5], ["Human CD4", "TEST", 0, 9], ["T cells", "TEST", 12, 19], ["dendritic cells", "TEST", 97, 112], ["low levels", "OBSERVATION_MODIFIER", 74, 84], ["dendritic cells", "OBSERVATION", 97, 112]]], ["Vitamin D binding protein (DBP) present in serum also appears to blunt 25D conversion in T cells (146, 206) .", [["serum", "ANATOMY", 43, 48], ["T cells", "ANATOMY", 89, 96], ["Vitamin D", "CHEMICAL", 0, 9], ["Vitamin D", "CHEMICAL", 0, 9], ["Vitamin D binding protein", "GENE_OR_GENE_PRODUCT", 0, 25], ["DBP", "GENE_OR_GENE_PRODUCT", 27, 30], ["serum", "ORGANISM_SUBSTANCE", 43, 48], ["25D", "SIMPLE_CHEMICAL", 71, 74], ["T cells", "CELL", 89, 96], ["Vitamin D binding protein", "PROTEIN", 0, 25], ["DBP", "PROTEIN", 27, 30], ["25D", "PROTEIN", 71, 74], ["T cells", "CELL_TYPE", 89, 96], ["Vitamin D binding protein (DBP)", "TEST", 0, 31], ["blunt 25D conversion in T cells", "PROBLEM", 65, 96]]], ["The relevance of CYP27B1 expression by T cells in vivo is not clear.", [["T cells", "ANATOMY", 39, 46], ["CYP27B1", "GENE_OR_GENE_PRODUCT", 17, 24], ["T cells", "CELL", 39, 46], ["CYP27B1", "PROTEIN", 17, 24], ["T cells", "CELL_TYPE", 39, 46], ["CYP27B1 expression", "TREATMENT", 17, 35], ["not", "UNCERTAINTY", 58, 61], ["clear", "OBSERVATION", 62, 67]]], ["However, it is suggested that the activity level seen in vitro is too low to support any clear changes in cell phenotype (146) .", [["cell", "ANATOMY", 106, 110], ["cell", "CELL", 106, 110], ["the activity level", "PROBLEM", 30, 48], ["any clear changes in cell phenotype", "PROBLEM", 85, 120], ["clear", "OBSERVATION", 89, 94], ["cell phenotype", "OBSERVATION", 106, 120]]], ["Therefore, T cells rely heavily on the local production of 1,25D to reach a sufficient concentration for immunomodulatory effects (146, 207) .", [["T cells", "ANATOMY", 11, 18], ["1,25D", "CHEMICAL", 59, 64], ["1,25D", "CHEMICAL", 59, 64], ["T cells", "CELL", 11, 18], ["1,25D", "SIMPLE_CHEMICAL", 59, 64], ["T cells", "CELL_TYPE", 11, 18], ["T cells", "TREATMENT", 11, 18]]], ["As discussed above, vitamin D exerts a range of effects on innate immune cells.", [["immune cells", "ANATOMY", 66, 78], ["vitamin D", "CHEMICAL", 20, 29], ["vitamin D", "CHEMICAL", 20, 29], ["vitamin D", "SIMPLE_CHEMICAL", 20, 29], ["innate immune cells", "CELL", 59, 78], ["innate immune cells", "CELL_TYPE", 59, 78], ["vitamin D", "TREATMENT", 20, 29], ["innate immune cells", "TREATMENT", 59, 78]]], ["These can then indirectly impact T cell differentiation and function.Indirect effects of vitamin D on T cellsTreatment with 1,25D has been shown to decrease CD40L expression on macrophages which may limit T cell activation and induction of a pro-inflammatory phenotype (208) .", [["T cell", "ANATOMY", 33, 39], ["T cells", "ANATOMY", 102, 109], ["macrophages", "ANATOMY", 177, 188], ["T cell", "ANATOMY", 205, 211], ["vitamin D", "CHEMICAL", 89, 98], ["1,25D", "CHEMICAL", 124, 129], ["vitamin D", "CHEMICAL", 89, 98], ["1,25D", "CHEMICAL", 124, 129], ["T cell", "CELL", 33, 39], ["vitamin D", "SIMPLE_CHEMICAL", 89, 98], ["T cells", "CELL", 102, 109], ["1,25D", "SIMPLE_CHEMICAL", 124, 129], ["CD40L", "GENE_OR_GENE_PRODUCT", 157, 162], ["macrophages", "CELL", 177, 188], ["T cell", "CELL", 205, 211], ["T cells", "CELL_TYPE", 102, 109], ["CD40L", "PROTEIN", 157, 162], ["macrophages", "CELL_TYPE", 177, 188], ["vitamin D on T cells", "TREATMENT", 89, 109], ["Treatment", "TREATMENT", 109, 118], ["CD40L expression on macrophages", "PROBLEM", 157, 188], ["a pro-inflammatory phenotype", "TEST", 240, 268], ["cell differentiation", "OBSERVATION", 35, 55]]], ["Although macrophages are capable of antigen presentation to T cells, studies suggest that dendritic cells are much more influential in this role.", [["macrophages", "ANATOMY", 9, 20], ["T cells", "ANATOMY", 60, 67], ["dendritic cells", "ANATOMY", 90, 105], ["macrophages", "CELL", 9, 20], ["T cells", "CELL", 60, 67], ["dendritic cells", "CELL", 90, 105], ["macrophages", "CELL_TYPE", 9, 20], ["T cells", "CELL_TYPE", 60, 67], ["dendritic cells", "CELL_TYPE", 90, 105], ["macrophages", "PROBLEM", 9, 20], ["studies", "TEST", 69, 76], ["dendritic cells", "PROBLEM", 90, 105], ["macrophages", "OBSERVATION", 9, 20], ["dendritic cells", "OBSERVATION", 90, 105]]], ["During dendritic cell differentiation, treatment with 1,25D leads to development of a tolerogenic phenotype (188, 209) .", [["dendritic cell", "ANATOMY", 7, 21], ["1,25D", "CHEMICAL", 54, 59], ["dendritic cell", "CELL", 7, 21], ["1,25D", "SIMPLE_CHEMICAL", 54, 59], ["1,25D", "PROTEIN", 54, 59], ["treatment", "TREATMENT", 39, 48], ["a tolerogenic phenotype", "PROBLEM", 84, 107], ["dendritic cell differentiation", "OBSERVATION", 7, 37], ["tolerogenic phenotype", "OBSERVATION", 86, 107]]], ["TolDCs are less mature than mature dendritic cells and retain the monocyte marker CD14, as well as exhibiting lower expression of co-stimulatory molecules such as CD80/86 and MHCII/HLA-DR (188, 209) .", [["TolDCs", "ANATOMY", 0, 6], ["dendritic cells", "ANATOMY", 35, 50], ["monocyte", "ANATOMY", 66, 74], ["TolDCs", "CELL", 0, 6], ["dendritic cells", "CELL", 35, 50], ["monocyte", "CELL", 66, 74], ["CD14", "GENE_OR_GENE_PRODUCT", 82, 86], ["CD80/86", "GENE_OR_GENE_PRODUCT", 163, 170], ["MHCII", "GENE_OR_GENE_PRODUCT", 175, 180], ["HLA-DR", "GENE_OR_GENE_PRODUCT", 181, 187], ["TolDCs", "CELL_TYPE", 0, 6], ["mature dendritic cells", "CELL_TYPE", 28, 50], ["CD14", "PROTEIN", 82, 86], ["co-stimulatory molecules", "PROTEIN", 130, 154], ["CD80/86", "PROTEIN", 163, 170], ["MHCII", "PROTEIN", 175, 180], ["HLA", "PROTEIN", 181, 184], ["the monocyte marker CD14", "TEST", 62, 86], ["MHCII/HLA", "TEST", 175, 184], ["less mature", "OBSERVATION_MODIFIER", 11, 22], ["dendritic cells", "OBSERVATION", 35, 50], ["lower expression", "OBSERVATION_MODIFIER", 110, 126], ["co-stimulatory molecules", "OBSERVATION", 130, 154]]], ["TolDCs have the ability to suppress inflammatory T cell proliferation and favour Treg differentiation to restore Th17/Treg balance (207, 210, 211) .Indirect effects of vitamin D on T cellsTolDCs promote Treg generation through increased IL-10 production and a lower expression of co-stimulatory molecules, also preventing antigenic T cell activation (14, 209) .", [["TolDCs", "ANATOMY", 0, 6], ["inflammatory T cell", "ANATOMY", 36, 55], ["Treg", "ANATOMY", 81, 85], ["Th17/Treg", "ANATOMY", 113, 122], ["T cells", "ANATOMY", 181, 188], ["Treg", "ANATOMY", 203, 207], ["T cell", "ANATOMY", 332, 338], ["vitamin D", "CHEMICAL", 168, 177], ["vitamin D", "CHEMICAL", 168, 177], ["TolDCs", "SIMPLE_CHEMICAL", 0, 6], ["inflammatory T cell", "CELL", 36, 55], ["Treg", "CELL", 81, 85], ["Th17", "CELL", 113, 117], ["Treg", "CELL", 118, 122], ["vitamin D", "SIMPLE_CHEMICAL", 168, 177], ["T cells", "CELL", 181, 188], ["TolDCs", "CELL", 188, 194], ["Treg", "CELL", 203, 207], ["IL-10", "GENE_OR_GENE_PRODUCT", 237, 242], ["T cell", "CELL", 332, 338], ["TolDCs", "CELL_TYPE", 0, 6], ["T cells", "CELL_TYPE", 181, 188], ["TolDCs", "CELL_TYPE", 188, 194], ["co-stimulatory molecules", "PROTEIN", 280, 304], ["inflammatory T cell proliferation", "PROBLEM", 36, 69], ["Treg differentiation", "TREATMENT", 81, 101], ["vitamin D on T cellsTolDCs", "TREATMENT", 168, 194], ["Treg generation through increased IL", "TREATMENT", 203, 239], ["a lower expression of co-stimulatory molecules", "PROBLEM", 258, 304], ["antigenic T cell activation", "TREATMENT", 322, 349], ["inflammatory", "OBSERVATION_MODIFIER", 36, 48], ["cell proliferation", "OBSERVATION", 51, 69], ["co-stimulatory molecules", "OBSERVATION", 280, 304], ["cell activation", "OBSERVATION", 334, 349]]], ["One study has suggested that the ability of 1,25D to increase PFKFB4, an enzyme in glycolysis, is essential for the ability of dendritic cells to induce Tregs (207) .", [["dendritic cells", "ANATOMY", 127, 142], ["Tregs", "ANATOMY", 153, 158], ["1,25D", "CHEMICAL", 44, 49], ["1,25D", "CHEMICAL", 44, 49], ["1,25D", "SIMPLE_CHEMICAL", 44, 49], ["PFKFB4", "GENE_OR_GENE_PRODUCT", 62, 68], ["dendritic cells", "CELL", 127, 142], ["Tregs", "CELL", 153, 158], ["PFKFB4", "PROTEIN", 62, 68], ["dendritic cells", "CELL_TYPE", 127, 142], ["Tregs", "CELL_TYPE", 153, 158], ["One study", "TEST", 0, 9], ["PFKFB4", "TREATMENT", 62, 68], ["an enzyme in glycolysis", "TEST", 70, 93], ["dendritic cells", "PROBLEM", 127, 142], ["dendritic cells", "OBSERVATION", 127, 142]]], ["This highlights the relevance of 1,25D-mediated alterations in metabolism in modulating inflammatory cell function in disease.", [["inflammatory cell", "ANATOMY", 88, 105], ["1,25D", "SIMPLE_CHEMICAL", 33, 38], ["cell", "CELL", 101, 105], ["1,25D", "PROTEIN", 33, 38], ["1,25D-mediated alterations in metabolism", "PROBLEM", 33, 73], ["modulating inflammatory cell function in disease", "PROBLEM", 77, 125], ["metabolism", "OBSERVATION_MODIFIER", 63, 73], ["inflammatory cell function", "OBSERVATION", 88, 114]]], ["It was reported that 1,25D-induced TolDCs expressed higher levels of membrane-bound TNF (mTNF) which is essential for the generation of Tregs (212) .", [["TolDCs", "ANATOMY", 35, 41], ["membrane", "ANATOMY", 69, 77], ["Tregs", "ANATOMY", 136, 141], ["1,25D", "SIMPLE_CHEMICAL", 21, 26], ["TolDCs", "CELL", 35, 41], ["membrane", "CELLULAR_COMPONENT", 69, 77], ["TNF", "GENE_OR_GENE_PRODUCT", 84, 87], ["mTNF", "GENE_OR_GENE_PRODUCT", 89, 93], ["Tregs", "CELL", 136, 141], ["1,25D-induced TolDCs", "CELL_LINE", 21, 41], ["TNF", "PROTEIN", 84, 87], ["mTNF", "PROTEIN", 89, 93], ["Tregs", "CELL_TYPE", 136, 141]]], ["Another potential mechanism for 1,25D specific induction of TolDCs, is the upregulation of PD-L1, not seen in dexamethasone-treated TolDCs, but required for Treg production (210) .", [["TolDCs", "ANATOMY", 132, 138], ["Treg", "ANATOMY", 157, 161], ["1,25D", "CHEMICAL", 32, 37], ["dexamethasone", "CHEMICAL", 110, 123], ["1,25D", "CHEMICAL", 32, 37], ["dexamethasone", "CHEMICAL", 110, 123], ["1,25D", "SIMPLE_CHEMICAL", 32, 37], ["TolDCs", "GENE_OR_GENE_PRODUCT", 60, 66], ["PD-L1", "GENE_OR_GENE_PRODUCT", 91, 96], ["dexamethasone", "SIMPLE_CHEMICAL", 110, 123], ["TolDCs", "CELL", 132, 138], ["Treg", "CELL", 157, 161], ["TolDCs", "PROTEIN", 60, 66], ["PD-L1", "DNA", 91, 96], ["dexamethasone-treated TolDCs", "CELL_LINE", 110, 138], ["Treg", "CELL_TYPE", 157, 161], ["dexamethasone", "TREATMENT", 110, 123], ["TolDCs", "TREATMENT", 132, 138], ["L1", "ANATOMY", 94, 96]]], ["Overall, it is currently not fully understood how 1,25D-treated DCs are able to induce high levels of Tregs.", [["DCs", "ANATOMY", 64, 67], ["Tregs", "ANATOMY", 102, 107], ["1,25D", "CHEMICAL", 50, 55], ["1,25D", "SIMPLE_CHEMICAL", 50, 55], ["DCs", "CELL", 64, 67], ["Tregs", "CELL", 102, 107], ["1,25D-treated DCs", "CELL_LINE", 50, 67], ["Tregs", "CELL_TYPE", 102, 107]]], ["Of particular interest is the unique metabolic profile, directly induced by 1,25D (187, 188) , to TolDC function.", [["TolDC", "GENE_OR_GENE_PRODUCT", 98, 103]]], ["It has been reported in mouse models of autoimmune disease that TolDCs are immunosuppressive (14, 211, 213) .", [["TolDCs", "ANATOMY", 64, 70], ["autoimmune disease", "DISEASE", 40, 58], ["mouse", "ORGANISM", 24, 29], ["TolDCs", "CANCER", 64, 70], ["mouse", "SPECIES", 24, 29], ["mouse", "SPECIES", 24, 29], ["autoimmune disease", "PROBLEM", 40, 58], ["autoimmune disease", "OBSERVATION", 40, 58], ["immunosuppressive", "OBSERVATION_MODIFIER", 75, 92]]], ["Multiple clinical trials have also demonstrated the safety and therapeutic potential for patient administration of TolDC, although often these TolDCs are generated by dexamethasone (214) (215) (216) .", [["TolDC", "CHEMICAL", 115, 120], ["dexamethasone", "CHEMICAL", 167, 180], ["dexamethasone", "CHEMICAL", 167, 180], ["patient", "ORGANISM", 89, 96], ["TolDC", "SIMPLE_CHEMICAL", 115, 120], ["TolDCs", "SIMPLE_CHEMICAL", 143, 149], ["dexamethasone", "SIMPLE_CHEMICAL", 167, 180], ["patient", "SPECIES", 89, 96], ["TolDC", "TREATMENT", 115, 120], ["dexamethasone", "TREATMENT", 167, 180]]], ["Further understanding the mechanisms for 1,25D-TolDCs will be important to move to human trials and develop therapeutic options for 1,25D-TolDCs in inflammatory disease.Anti-inflammatory effects of vitamin D and autoimmune diseasePathogenesis in autoimmunity can be simplified as an increase in pro-inflammatory factors, often cytokines produced by inflammatory T cells, and a decrease in anti-inflammatory factors, such as Tregs and IL-10.", [["inflammatory T cells", "ANATOMY", 349, 369], ["Tregs", "ANATOMY", 424, 429], ["1,25D-TolDCs", "CHEMICAL", 132, 144], ["inflammatory disease", "DISEASE", 148, 168], ["vitamin D", "CHEMICAL", 198, 207], ["autoimmune disease", "DISEASE", 212, 230], ["autoimmunity", "DISEASE", 246, 258], ["vitamin D", "CHEMICAL", 198, 207], ["1,25D-TolDCs", "SIMPLE_CHEMICAL", 41, 53], ["human", "ORGANISM", 83, 88], ["1,25D-TolDCs", "SIMPLE_CHEMICAL", 132, 144], ["vitamin D", "SIMPLE_CHEMICAL", 198, 207], ["inflammatory T cells", "CELL", 349, 369], ["Tregs", "CELL", 424, 429], ["IL-10", "GENE_OR_GENE_PRODUCT", 434, 439], ["pro-inflammatory factors", "PROTEIN", 295, 319], ["cytokines", "PROTEIN", 327, 336], ["inflammatory T cells", "CELL_TYPE", 349, 369], ["anti-inflammatory factors", "PROTEIN", 389, 414], ["Tregs", "CELL_TYPE", 424, 429], ["IL", "PROTEIN", 434, 436], ["human", "SPECIES", 83, 88], ["human", "SPECIES", 83, 88], ["therapeutic options", "TREATMENT", 108, 127], ["inflammatory disease", "PROBLEM", 148, 168], ["vitamin D", "TREATMENT", 198, 207], ["autoimmune disease", "PROBLEM", 212, 230], ["Pathogenesis in autoimmunity", "PROBLEM", 230, 258], ["an increase in pro-inflammatory factors", "PROBLEM", 280, 319], ["inflammatory T cells", "PROBLEM", 349, 369], ["a decrease in anti-inflammatory factors", "PROBLEM", 375, 414], ["Tregs and IL", "TREATMENT", 424, 436], ["inflammatory", "OBSERVATION_MODIFIER", 148, 160], ["disease", "OBSERVATION", 161, 168], ["autoimmune disease", "OBSERVATION", 212, 230], ["increase", "OBSERVATION_MODIFIER", 283, 291], ["pro-inflammatory factors", "OBSERVATION", 295, 319], ["inflammatory", "OBSERVATION_MODIFIER", 349, 361], ["decrease", "OBSERVATION_MODIFIER", 377, 385], ["anti-inflammatory factors", "OBSERVATION", 389, 414]]], ["Using vitamin D as a therapeutic option for autoimmune inflammatory disease is therefore a promising avenue, due to the immunomodulatory actions described earlier in the review, although translating these potential therapies to human use has shown only limited success so far.Multiple sclerosisDue to the well-described correlation between sunlight exposure and incidence of MS (217, 218) , there have been a variety of studies on the effects of 1,25D in MS disease models such as Experimental Autoimmune Encephalomyelitis (EAE).", [["vitamin D", "CHEMICAL", 6, 15], ["autoimmune inflammatory disease", "DISEASE", 44, 75], ["MS", "DISEASE", 375, 377], ["1,25D", "CHEMICAL", 446, 451], ["MS disease", "DISEASE", 455, 465], ["Autoimmune Encephalomyelitis", "DISEASE", 494, 522], ["EAE", "DISEASE", 524, 527], ["vitamin D", "CHEMICAL", 6, 15], ["1,25D", "CHEMICAL", 446, 451], ["vitamin D", "SIMPLE_CHEMICAL", 6, 15], ["human", "ORGANISM", 228, 233], ["1,25D", "SIMPLE_CHEMICAL", 446, 451], ["human", "SPECIES", 228, 233], ["human", "SPECIES", 228, 233], ["vitamin D", "TREATMENT", 6, 15], ["a therapeutic option", "TREATMENT", 19, 39], ["autoimmune inflammatory disease", "PROBLEM", 44, 75], ["Multiple sclerosisDue", "PROBLEM", 276, 297], ["MS", "TEST", 375, 377], ["MS disease models", "PROBLEM", 455, 472], ["Experimental Autoimmune Encephalomyelitis", "PROBLEM", 481, 522], ["inflammatory", "OBSERVATION", 55, 67], ["sclerosisDue", "OBSERVATION", 285, 297], ["Autoimmune Encephalomyelitis", "OBSERVATION", 494, 522]]], ["Treatment with 1,25D has been shown to improve EAE symptoms, with increases in Th2 cells (150) , and decreases in Th1 and Th17 cells (144, 156, 175) .", [["Th2 cells", "ANATOMY", 79, 88], ["Th17 cells", "ANATOMY", 122, 132], ["1,25D", "CHEMICAL", 15, 20], ["EAE", "DISEASE", 47, 50], ["1,25D", "CHEMICAL", 15, 20], ["1,25D", "SIMPLE_CHEMICAL", 15, 20], ["Th2 cells", "CELL", 79, 88], ["Th1", "CELL", 114, 117], ["Th17 cells", "CELL", 122, 132], ["Th2 cells", "CELL_TYPE", 79, 88], ["Th1 and Th17 cells", "CELL_TYPE", 114, 132], ["Treatment", "TREATMENT", 0, 9], ["EAE symptoms", "PROBLEM", 47, 59], ["increases in Th2 cells", "PROBLEM", 66, 88], ["decreases in Th1 and Th17 cells", "PROBLEM", 101, 132], ["increases", "OBSERVATION_MODIFIER", 66, 75], ["Th2 cells", "OBSERVATION", 79, 88], ["decreases", "OBSERVATION_MODIFIER", 101, 110], ["Th1", "ANATOMY", 114, 117], ["Th17 cells", "OBSERVATION", 122, 132]]], ["Studies have also confirmed the essential role for VDR expression in CD4 + T cells, and the expression of IL-10, to mediate the protective effects of 1,25D in EAE (219, 220) .", [["CD4 + T cells", "ANATOMY", 69, 82], ["1,25D", "CHEMICAL", 150, 155], ["EAE", "DISEASE", 159, 162], ["1,25D", "CHEMICAL", 150, 155], ["VDR", "GENE_OR_GENE_PRODUCT", 51, 54], ["CD4", "GENE_OR_GENE_PRODUCT", 69, 72], ["IL-10", "GENE_OR_GENE_PRODUCT", 106, 111], ["1,25D", "SIMPLE_CHEMICAL", 150, 155], ["VDR", "PROTEIN", 51, 54], ["CD4", "PROTEIN", 69, 72], ["T cells", "CELL_TYPE", 75, 82], ["IL-10", "PROTEIN", 106, 111], ["VDR expression", "PROBLEM", 51, 65]]], ["A potential synergy of 1,25D and estrogen has been suggested by one EAE study, causing an increase in Tregs (221) .", [["Tregs", "ANATOMY", 102, 107], ["1,25D", "CHEMICAL", 23, 28], ["estrogen", "CHEMICAL", 33, 41], ["1,25D", "CHEMICAL", 23, 28], ["estrogen", "CHEMICAL", 33, 41], ["1,25D", "SIMPLE_CHEMICAL", 23, 28], ["estrogen", "SIMPLE_CHEMICAL", 33, 41], ["Tregs", "CELL", 102, 107], ["Tregs", "CELL_TYPE", 102, 107], ["1,25D and estrogen", "TREATMENT", 23, 41], ["EAE study", "TEST", 68, 77], ["an increase in Tregs", "PROBLEM", 87, 107], ["increase", "OBSERVATION_MODIFIER", 90, 98], ["Tregs", "OBSERVATION", 102, 107]]], ["This may be an important factor in the sex bias of MS incidence and for potential stratification of patient treatment (221) .", [["MS", "DISEASE", 51, 53], ["patient", "ORGANISM", 100, 107], ["patient", "SPECIES", 100, 107], ["MS incidence", "PROBLEM", 51, 63], ["patient treatment", "TREATMENT", 100, 117]]], ["In MS patients it has been reported that the ratio of serum 1,25D:25D but not 1,25D or 25D alone, correlates directly with peripheral Treg percentages (176, 222) .", [["serum", "ANATOMY", 54, 59], ["peripheral Treg", "ANATOMY", 123, 138], ["MS", "DISEASE", 3, 5], ["1,25D", "CHEMICAL", 78, 83], ["1,25D or 25D", "CHEMICAL", 78, 90], ["patients", "ORGANISM", 6, 14], ["serum", "ORGANISM_SUBSTANCE", 54, 59], ["1,25D:25D", "SIMPLE_CHEMICAL", 60, 69], ["1,25D", "SIMPLE_CHEMICAL", 78, 83], ["25D", "SIMPLE_CHEMICAL", 87, 90], ["peripheral Treg", "CELL", 123, 138], ["peripheral Treg", "CELL_TYPE", 123, 138], ["patients", "SPECIES", 6, 14], ["peripheral Treg percentages", "TEST", 123, 150], ["peripheral", "ANATOMY_MODIFIER", 123, 133], ["Treg", "ANATOMY", 134, 138]]], ["It was also demonstrated that vitamin D treatment increased Treg numbers in healthy adults (223) .", [["Treg", "ANATOMY", 60, 64], ["vitamin D", "CHEMICAL", 30, 39], ["vitamin D", "CHEMICAL", 30, 39], ["vitamin D", "SIMPLE_CHEMICAL", 30, 39], ["Treg", "CELL", 60, 64], ["Treg", "CELL_TYPE", 60, 64], ["vitamin D treatment", "TREATMENT", 30, 49]]], ["One study showed correlation of cytokine levels to disease progression, showing lower levels of inflammatory cytokines, such as IFN-\u03b3 and IL-17, associated with better disease scores (164) .", [["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 128, 133], ["IL-17", "GENE_OR_GENE_PRODUCT", 138, 143], ["cytokine", "PROTEIN", 32, 40], ["inflammatory cytokines", "PROTEIN", 96, 118], ["IFN", "PROTEIN", 128, 131], ["IL-17", "PROTEIN", 138, 143], ["One study", "TEST", 0, 9], ["cytokine levels", "TEST", 32, 47], ["disease progression", "PROBLEM", 51, 70], ["lower levels of inflammatory cytokines", "PROBLEM", 80, 118], ["IFN", "TEST", 128, 131], ["IL", "TEST", 138, 140], ["better disease scores", "PROBLEM", 161, 182], ["lower levels", "OBSERVATION_MODIFIER", 80, 92], ["inflammatory cytokines", "OBSERVATION", 96, 118]]], ["In this case 1,25D treatment of CD4 + T cells from MS patients in vitro, was able to reduce the production of inflammatory cytokines (164) .", [["CD4 + T cells", "ANATOMY", 32, 45], ["MS", "DISEASE", 51, 53], ["CD4", "GENE_OR_GENE_PRODUCT", 32, 35], ["patients", "ORGANISM", 54, 62], ["CD4", "PROTEIN", 32, 35], ["T cells", "CELL_TYPE", 38, 45], ["inflammatory cytokines", "PROTEIN", 110, 132], ["patients", "SPECIES", 54, 62], ["CD4 + T cells", "PROBLEM", 32, 45], ["inflammatory cytokines", "PROBLEM", 110, 132], ["inflammatory", "OBSERVATION_MODIFIER", 110, 122]]], ["In clinical trials, the effects ofRheumatoid arthritisIn a mouse model of RA, collagen-induced arthritis (CIA), 1,25D treatment showed significant effects, completely halting the progression of the disease (227) .", [["RA", "DISEASE", 74, 76], ["arthritis", "DISEASE", 95, 104], ["CIA", "DISEASE", 106, 109], ["1,25D", "CHEMICAL", 112, 117], ["1,25D", "CHEMICAL", 112, 117], ["mouse", "ORGANISM", 59, 64], ["collagen", "GENE_OR_GENE_PRODUCT", 78, 86], ["1,25D", "SIMPLE_CHEMICAL", 112, 117], ["collagen", "PROTEIN", 78, 86], ["mouse", "SPECIES", 59, 64], ["mouse", "SPECIES", 59, 64], ["Rheumatoid arthritisIn", "PROBLEM", 34, 56], ["collagen-induced arthritis", "PROBLEM", 78, 104], ["1,25D treatment", "TREATMENT", 112, 127], ["significant effects", "PROBLEM", 135, 154], ["the disease", "PROBLEM", 194, 205], ["Rheumatoid", "OBSERVATION", 34, 44], ["RA", "ANATOMY", 74, 76], ["arthritis", "OBSERVATION", 95, 104], ["progression", "OBSERVATION_MODIFIER", 179, 190], ["disease", "OBSERVATION", 198, 205]]], ["This improvement was linked to changes in multiple cell types, including synovial fibroblasts and monocytes, and likely involves a range of 1,25Dmediated immunomodulatory effects (228) (229) (230) .", [["cell", "ANATOMY", 51, 55], ["synovial fibroblasts", "ANATOMY", 73, 93], ["monocytes", "ANATOMY", 98, 107], ["1,25", "CHEMICAL", 140, 144], ["1,25", "CHEMICAL", 140, 144], ["cell", "CELL", 51, 55], ["synovial fibroblasts", "CELL", 73, 93], ["monocytes", "CELL", 98, 107], ["1,25Dmediated", "SIMPLE_CHEMICAL", 140, 153], ["synovial fibroblasts", "CELL_TYPE", 73, 93], ["monocytes", "CELL_TYPE", 98, 107], ["changes in multiple cell types", "PROBLEM", 31, 61], ["synovial fibroblasts", "PROBLEM", 73, 93], ["monocytes", "TEST", 98, 107], ["multiple cell types", "OBSERVATION", 42, 61], ["synovial fibroblasts", "OBSERVATION", 73, 93], ["monocytes", "OBSERVATION_MODIFIER", 98, 107]]], ["Another study using CIA mice showed 1,25D treatment to decrease the production of IL-17 and increase regulatory cells in the synovial fluid of diseased mice (231) .", [["regulatory cells", "ANATOMY", 101, 117], ["synovial fluid", "ANATOMY", 125, 139], ["1,25D", "CHEMICAL", 36, 41], ["1,25D", "CHEMICAL", 36, 41], ["CIA mice", "ORGANISM", 20, 28], ["1,25D", "SIMPLE_CHEMICAL", 36, 41], ["IL-17", "GENE_OR_GENE_PRODUCT", 82, 87], ["cells", "CELL", 112, 117], ["synovial fluid", "TISSUE", 125, 139], ["mice", "ORGANISM", 152, 156], ["IL-17", "PROTEIN", 82, 87], ["regulatory cells", "CELL_TYPE", 101, 117], ["mice", "SPECIES", 24, 28], ["mice", "SPECIES", 152, 156], ["mice", "SPECIES", 24, 28], ["mice", "SPECIES", 152, 156], ["Another study", "TEST", 0, 13], ["CIA mice", "TEST", 20, 28], ["1,25D treatment", "TREATMENT", 36, 51], ["the production of IL", "TEST", 64, 84], ["increase regulatory cells", "PROBLEM", 92, 117], ["increase", "OBSERVATION_MODIFIER", 92, 100], ["regulatory cells", "OBSERVATION", 101, 117], ["synovial", "ANATOMY", 125, 133], ["fluid", "OBSERVATION", 134, 139]]], ["This study suggested a novel mechanism of microRNA induction by 1,25D which then inhibited IL-6 signalling, a key inflammatory cytokine in RA (231) .Rheumatoid arthritisOther studies have focussed on in vitro treatment of human RA CD4 + T cells, where RA Th17 cells are able to differentiate into regulatory cells when cultured with 1,25D (158, 162) .", [["RA CD4 + T cells", "ANATOMY", 228, 244], ["RA Th17 cells", "ANATOMY", 252, 265], ["cells", "ANATOMY", 308, 313], ["Rheumatoid arthritis", "DISEASE", 149, 169], ["1,25D", "CHEMICAL", 333, 338], ["1,25D", "SIMPLE_CHEMICAL", 64, 69], ["IL-6", "GENE_OR_GENE_PRODUCT", 91, 95], ["human", "ORGANISM", 222, 227], ["RA CD4 + T cells", "CELL", 228, 244], ["RA Th17 cells", "CELL", 252, 265], ["cells", "CELL", 308, 313], ["IL-6", "PROTEIN", 91, 95], ["inflammatory cytokine", "PROTEIN", 114, 135], ["human RA CD4 + T cells", "CELL_TYPE", 222, 244], ["RA Th17 cells", "CELL_TYPE", 252, 265], ["regulatory cells", "CELL_TYPE", 297, 313], ["human", "SPECIES", 222, 227], ["human", "SPECIES", 222, 227], ["This study", "TEST", 0, 10], ["microRNA induction", "TREATMENT", 42, 60], ["IL", "TEST", 91, 93], ["a key inflammatory cytokine in RA", "PROBLEM", 108, 141], ["Rheumatoid arthritis", "PROBLEM", 149, 169], ["Other studies", "TEST", 169, 182], ["vitro treatment", "TREATMENT", 203, 218], ["human RA CD4", "TEST", 222, 234], ["T cells", "PROBLEM", 237, 244], ["RA Th17 cells", "TREATMENT", 252, 265], ["inflammatory", "OBSERVATION_MODIFIER", 114, 126], ["RA", "ANATOMY", 139, 141], ["arthritis", "OBSERVATION", 160, 169], ["RA", "ANATOMY", 228, 230], ["RA", "ANATOMY", 252, 254]]], ["These memory Th17 cells, although losing CCR6 expression, were still able to migrate to inflamed synovial fluid,Rheumatoid arthritisshowing promise for future therapeutic use (162) .", [["Th17 cells", "ANATOMY", 13, 23], ["synovial fluid", "ANATOMY", 97, 111], ["memory Th17 cells", "CELL", 6, 23], ["CCR6", "GENE_OR_GENE_PRODUCT", 41, 45], ["synovial fluid", "TISSUE", 97, 111], ["memory Th17 cells", "CELL_TYPE", 6, 23], ["CCR6", "PROTEIN", 41, 45], ["inflamed synovial fluid", "PROBLEM", 88, 111], ["Rheumatoid arthritisshowing promise", "TREATMENT", 112, 147], ["Th17 cells", "OBSERVATION", 13, 23], ["inflamed", "OBSERVATION_MODIFIER", 88, 96], ["synovial", "ANATOMY", 97, 105], ["fluid", "OBSERVATION", 106, 111], ["Rheumatoid", "OBSERVATION", 112, 122]]], ["Additionally, RA T cell-synovial fibroblast co-cultures have shown that, in combination with TNF-\u03b1 blockade, 1,25D-mediated decrease in IL-17 aids in dampening synovial inflammation (232) .", [["RA T cell", "ANATOMY", 14, 23], ["synovial fibroblast co-cultures", "ANATOMY", 24, 55], ["synovial", "ANATOMY", 160, 168], ["synovial inflammation", "DISEASE", 160, 181], ["RA T cell", "CELL", 14, 23], ["synovial fibroblast co-cultures", "CELL", 24, 55], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 93, 98], ["1,25D", "SIMPLE_CHEMICAL", 109, 114], ["IL-17", "GENE_OR_GENE_PRODUCT", 136, 141], ["synovial", "TISSUE", 160, 168], ["RA T cell-synovial fibroblast co-cultures", "CELL_LINE", 14, 55], ["TNF", "PROTEIN", 93, 96], ["IL-17", "PROTEIN", 136, 141], ["RA T cell", "TEST", 14, 23], ["synovial fibroblast co-cultures", "TEST", 24, 55], ["TNF-\u03b1 blockade", "TREATMENT", 93, 107], ["1,25D-mediated decrease in IL", "TREATMENT", 109, 138], ["dampening synovial inflammation", "PROBLEM", 150, 181], ["RA", "ANATOMY", 14, 16], ["synovial", "ANATOMY", 24, 32], ["fibroblast co-cultures", "OBSERVATION", 33, 55], ["decrease", "OBSERVATION_MODIFIER", 124, 132], ["dampening", "OBSERVATION_MODIFIER", 150, 159], ["synovial", "ANATOMY", 160, 168], ["inflammation", "OBSERVATION", 169, 181]]], ["Although multiple in vitro effects have been reported for 1,25D and RA, more trials and human studies evaluating a role for vitamin D supplementation in treating inflammatory RA are required.", [["vitamin D", "CHEMICAL", 124, 133], ["RA", "DISEASE", 175, 177], ["vitamin D", "CHEMICAL", 124, 133], ["1,25D", "SIMPLE_CHEMICAL", 58, 63], ["human", "ORGANISM", 88, 93], ["vitamin D", "SIMPLE_CHEMICAL", 124, 133], ["human", "SPECIES", 88, 93], ["human", "SPECIES", 88, 93], ["human studies", "TEST", 88, 101], ["vitamin D supplementation", "TREATMENT", 124, 149], ["inflammatory RA", "TREATMENT", 162, 177], ["multiple", "OBSERVATION_MODIFIER", 9, 17], ["inflammatory", "OBSERVATION", 162, 174]]], ["This is highlighted in a recent study which showed that CD4 + T cells from RA synovial fluid are less sensitive to suppression by 1,25D than those from peripheral blood (233) , an important factor to consider when developing vitamin D therapy.Systemic lupus erythematosus T cells are instrumental in SLE pathogenesis, aiding B cell responses and amplifying inflammation.", [["CD4 + T cells", "ANATOMY", 56, 69], ["RA synovial fluid", "ANATOMY", 75, 92], ["peripheral blood", "ANATOMY", 152, 168], ["Systemic lupus erythematosus T cells", "ANATOMY", 243, 279], ["B cell", "ANATOMY", 325, 331], ["1,25D", "CHEMICAL", 130, 135], ["vitamin D", "CHEMICAL", 225, 234], ["Systemic lupus erythematosus", "DISEASE", 243, 271], ["SLE", "DISEASE", 300, 303], ["inflammation", "DISEASE", 357, 369], ["1,25D", "CHEMICAL", 130, 135], ["vitamin D", "CHEMICAL", 225, 234], ["CD4", "GENE_OR_GENE_PRODUCT", 56, 59], ["synovial fluid", "ORGANISM_SUBSTANCE", 78, 92], ["1,25D", "SIMPLE_CHEMICAL", 130, 135], ["peripheral blood", "ORGANISM_SUBSTANCE", 152, 168], ["vitamin D", "SIMPLE_CHEMICAL", 225, 234], ["Systemic lupus erythematosus T cells", "CELL", 243, 279], ["SLE", "CANCER", 300, 303], ["B cell", "CELL", 325, 331], ["CD4", "PROTEIN", 56, 59], ["T cells", "CELL_TYPE", 62, 69], ["Systemic lupus erythematosus T cells", "CELL_TYPE", 243, 279], ["a recent study", "TEST", 23, 37], ["CD4", "TEST", 56, 59], ["T cells", "PROBLEM", 62, 69], ["RA synovial fluid", "TEST", 75, 92], ["peripheral blood", "TEST", 152, 168], ["vitamin D therapy", "TREATMENT", 225, 242], ["Systemic lupus erythematosus T cells", "PROBLEM", 243, 279], ["SLE pathogenesis", "PROBLEM", 300, 316], ["inflammation", "PROBLEM", 357, 369], ["synovial", "ANATOMY", 78, 86], ["fluid", "OBSERVATION", 87, 92], ["lupus", "ANATOMY", 252, 257], ["erythematosus", "OBSERVATION", 258, 271], ["B cell responses", "OBSERVATION", 325, 341], ["inflammation", "OBSERVATION", 357, 369]]], ["Due tothe systemic nature of SLE, in vitro and animal studies are more limited (234) (235) (236) .", [["SLE", "DISEASE", 29, 32], ["SLE", "PROBLEM", 29, 32], ["animal studies", "TEST", 47, 61], ["SLE", "OBSERVATION", 29, 32]]], ["However, vitamin D 3 therapy has shown considerable success in SLE patient trials.", [["vitamin D", "CHEMICAL", 9, 18], ["SLE", "DISEASE", 63, 66], ["vitamin D 3", "CHEMICAL", 9, 20], ["vitamin D 3", "SIMPLE_CHEMICAL", 9, 20], ["patient", "ORGANISM", 67, 74], ["patient", "SPECIES", 67, 74], ["vitamin D 3 therapy", "TREATMENT", 9, 28], ["SLE patient trials", "TREATMENT", 63, 81]]], ["Clinical studies focused on disease activity and fatigue in SLE have reported that vitamin D 3 supplementation has beneficial effects (237) .", [["fatigue", "DISEASE", 49, 56], ["SLE", "DISEASE", 60, 63], ["vitamin D", "CHEMICAL", 83, 92], ["vitamin D 3", "CHEMICAL", 83, 94], ["vitamin D 3", "SIMPLE_CHEMICAL", 83, 94], ["Clinical studies", "TEST", 0, 16], ["disease activity", "PROBLEM", 28, 44], ["fatigue in SLE", "PROBLEM", 49, 63], ["vitamin D 3 supplementation", "TREATMENT", 83, 110]]], ["Several of these trials have also reported alterations to T cells after vitamin D treatment.", [["T cells", "ANATOMY", 58, 65], ["vitamin D", "CHEMICAL", 72, 81], ["vitamin D", "CHEMICAL", 72, 81], ["T cells", "CELL", 58, 65], ["vitamin D", "SIMPLE_CHEMICAL", 72, 81], ["T cells", "CELL_TYPE", 58, 65], ["alterations to T cells", "PROBLEM", 43, 65], ["vitamin D treatment", "TREATMENT", 72, 91]]], ["One relatively large study of 267 patients showed a significant decrease in inflammatory cytokines, IL-18, IL-1, IL-6 and TNF-\u03b1, in the vitamin D treatment group (238) .", [["vitamin D", "CHEMICAL", 136, 145], ["vitamin D", "CHEMICAL", 136, 145], ["patients", "ORGANISM", 34, 42], ["IL-18", "GENE_OR_GENE_PRODUCT", 100, 105], ["IL-1", "GENE_OR_GENE_PRODUCT", 107, 111], ["IL-6", "GENE_OR_GENE_PRODUCT", 113, 117], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 122, 127], ["vitamin D", "SIMPLE_CHEMICAL", 136, 145], ["inflammatory cytokines", "PROTEIN", 76, 98], ["IL-18", "PROTEIN", 100, 105], ["IL-6", "PROTEIN", 113, 117], ["TNF-\u03b1", "PROTEIN", 122, 127], ["patients", "SPECIES", 34, 42], ["a significant decrease in inflammatory cytokines", "PROBLEM", 50, 98], ["IL", "TEST", 100, 102], ["IL", "TEST", 107, 109], ["IL", "TEST", 113, 115], ["TNF", "TEST", 122, 125], ["the vitamin D treatment", "TREATMENT", 132, 155], ["large", "OBSERVATION_MODIFIER", 15, 20], ["significant", "OBSERVATION_MODIFIER", 52, 63], ["decrease", "OBSERVATION_MODIFIER", 64, 72], ["inflammatory cytokines", "OBSERVATION", 76, 98]]], ["Multiple studies have also identified an increase in Tregs with vitamin D treatment, with less consistent decreases in Th17 cells, Th1 cells and increases in Th2 cells (239) (240) (241) .", [["Tregs", "ANATOMY", 53, 58], ["Th17 cells", "ANATOMY", 119, 129], ["Th1 cells", "ANATOMY", 131, 140], ["Th2 cells", "ANATOMY", 158, 167], ["vitamin D", "CHEMICAL", 64, 73], ["vitamin D", "CHEMICAL", 64, 73], ["Tregs", "CELL", 53, 58], ["vitamin D", "SIMPLE_CHEMICAL", 64, 73], ["Th17 cells", "CELL", 119, 129], ["Th1 cells", "CELL", 131, 140], ["Th2 cells", "CELL", 158, 167], ["Tregs", "CELL_TYPE", 53, 58], ["Th17 cells", "CELL_TYPE", 119, 129], ["Th1 cells", "CELL_TYPE", 131, 140], ["Th2 cells", "CELL_TYPE", 158, 167], ["Multiple studies", "TEST", 0, 16], ["vitamin D treatment", "TREATMENT", 64, 83], ["decreases in Th17 cells", "PROBLEM", 106, 129], ["Th1 cells", "TEST", 131, 140], ["Th2 cells", "TEST", 158, 167], ["increase", "OBSERVATION_MODIFIER", 41, 49], ["Tregs", "OBSERVATION", 53, 58], ["decreases", "OBSERVATION_MODIFIER", 106, 115], ["Th17 cells", "OBSERVATION", 119, 129], ["Th1 cells", "OBSERVATION", 131, 140], ["increases", "OBSERVATION_MODIFIER", 145, 154], ["Th2 cells", "OBSERVATION", 158, 167]]], ["In contrast, a study evaluating the effect of vitamin D on the IFN signature in patients, a key marker of SLE pathogenesis, showed no differences between vitamin D and placebo groups (242) .Systemic lupus erythematosus T cells are instrumental in SLE pathogenesis, aiding B cell responses and amplifying inflammation.", [["Systemic lupus erythematosus T cells", "ANATOMY", 190, 226], ["B cell", "ANATOMY", 272, 278], ["vitamin D", "CHEMICAL", 46, 55], ["SLE", "DISEASE", 106, 109], ["vitamin D", "CHEMICAL", 154, 163], ["Systemic lupus erythematosus", "DISEASE", 190, 218], ["SLE", "DISEASE", 247, 250], ["inflammation", "DISEASE", 304, 316], ["vitamin D", "CHEMICAL", 46, 55], ["vitamin D", "CHEMICAL", 154, 163], ["vitamin D", "SIMPLE_CHEMICAL", 46, 55], ["IFN", "GENE_OR_GENE_PRODUCT", 63, 66], ["patients", "ORGANISM", 80, 88], ["SLE", "CANCER", 106, 109], ["vitamin D", "SIMPLE_CHEMICAL", 154, 163], ["placebo", "SIMPLE_CHEMICAL", 168, 175], ["Systemic lupus erythematosus T cells", "CELL", 190, 226], ["SLE", "CANCER", 247, 250], ["B cell", "CELL", 272, 278], ["IFN", "PROTEIN", 63, 66], ["Systemic lupus erythematosus T cells", "CELL_TYPE", 190, 226], ["patients", "SPECIES", 80, 88], ["a study", "TEST", 13, 20], ["vitamin D", "TREATMENT", 46, 55], ["the IFN signature", "TEST", 59, 76], ["SLE pathogenesis", "PROBLEM", 106, 122], ["vitamin D and placebo groups", "TREATMENT", 154, 182], ["Systemic lupus erythematosus T cells", "PROBLEM", 190, 226], ["SLE pathogenesis", "PROBLEM", 247, 263], ["inflammation", "PROBLEM", 304, 316], ["lupus", "ANATOMY", 199, 204], ["erythematosus", "OBSERVATION", 205, 218], ["B cell responses", "OBSERVATION", 272, 288], ["inflammation", "OBSERVATION", 304, 316]]], ["Due toHowever, this was a relatively short-term study of 12 weeks and analysed the expression of only 3 signature genes (242).Inflammatory bowel diseaseMouse models of IBD have identified multiple anti-inflammatory effects of vitamin D in the gut (243) (244) (245) .", [["bowel", "ANATOMY", 139, 144], ["gut", "ANATOMY", 243, 246], ["Inflammatory bowel diseaseMouse", "DISEASE", 126, 157], ["IBD", "DISEASE", 168, 171], ["vitamin D", "CHEMICAL", 226, 235], ["vitamin D", "CHEMICAL", 226, 235], ["bowel", "ORGAN", 139, 144], ["vitamin D", "SIMPLE_CHEMICAL", 226, 235], ["gut", "ORGANISM_SUBDIVISION", 243, 246], ["signature genes", "DNA", 104, 119], ["Inflammatory bowel diseaseMouse models of IBD", "PROBLEM", 126, 171], ["vitamin D", "TREATMENT", 226, 235], ["bowel", "ANATOMY", 139, 144], ["diseaseMouse", "OBSERVATION", 145, 157], ["IBD", "OBSERVATION", 168, 171], ["multiple", "OBSERVATION_MODIFIER", 188, 196], ["anti-inflammatory", "OBSERVATION_MODIFIER", 197, 214], ["gut", "ANATOMY", 243, 246]]], ["A study using the trinitrobenzene sulfonic acid (TNBS) IBD model with vitamin D treatment, showed increases in IL-10, IL-4, TGF-\u03b2 and IL-4 along with a decrease in Th1 cells (149) .", [["Th1 cells", "ANATOMY", 164, 173], ["trinitrobenzene sulfonic acid", "CHEMICAL", 18, 47], ["TNBS", "CHEMICAL", 49, 53], ["vitamin D", "CHEMICAL", 70, 79], ["trinitrobenzene sulfonic acid", "CHEMICAL", 18, 47], ["TNBS", "CHEMICAL", 49, 53], ["vitamin D", "CHEMICAL", 70, 79], ["trinitrobenzene sulfonic acid", "SIMPLE_CHEMICAL", 18, 47], ["TNBS", "SIMPLE_CHEMICAL", 49, 53], ["vitamin D", "SIMPLE_CHEMICAL", 70, 79], ["IL-10", "GENE_OR_GENE_PRODUCT", 111, 116], ["IL-4", "GENE_OR_GENE_PRODUCT", 118, 122], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 124, 129], ["IL-4", "GENE_OR_GENE_PRODUCT", 134, 138], ["Th1 cells", "CELL", 164, 173], ["TGF-\u03b2", "PROTEIN", 124, 129], ["IL-4", "PROTEIN", 134, 138], ["Th1 cells", "CELL_TYPE", 164, 173], ["A study", "TEST", 0, 7], ["the trinitrobenzene sulfonic acid (TNBS)", "TREATMENT", 14, 54], ["IBD model", "TEST", 55, 64], ["vitamin D treatment", "TREATMENT", 70, 89], ["IL", "TEST", 111, 113], ["IL", "TEST", 118, 120], ["TGF", "TEST", 124, 127], ["IL", "TEST", 134, 136], ["a decrease in Th1 cells", "PROBLEM", 150, 173], ["increases", "OBSERVATION_MODIFIER", 98, 107], ["decrease", "OBSERVATION_MODIFIER", 152, 160], ["Th1 cells", "OBSERVATION", 164, 173]]], ["Another common model of IBD is the use of IL-10 KO mice.", [["IBD", "DISEASE", 24, 27], ["IL-10", "GENE_OR_GENE_PRODUCT", 42, 47], ["mice", "ORGANISM", 51, 55], ["IL", "PROTEIN", 42, 44], ["mice", "SPECIES", 51, 55], ["mice", "SPECIES", 51, 55], ["IL", "TREATMENT", 42, 44], ["IBD", "OBSERVATION", 24, 27]]], ["In these studies using these mice, although lacking the increase in IL-10 associated with 1,25D activity, vitamin D supplementation was nonetheless able to improve symptoms and decrease TNF-\u03b1 expression (244, 245) .", [["vitamin D", "CHEMICAL", 106, 115], ["vitamin D", "CHEMICAL", 106, 115], ["mice", "ORGANISM", 29, 33], ["IL-10", "GENE_OR_GENE_PRODUCT", 68, 73], ["1,25D", "SIMPLE_CHEMICAL", 90, 95], ["vitamin D", "SIMPLE_CHEMICAL", 106, 115], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 186, 191], ["IL-10", "PROTEIN", 68, 73], ["TNF", "PROTEIN", 186, 189], ["mice", "SPECIES", 29, 33], ["mice", "SPECIES", 29, 33], ["these studies", "TEST", 3, 16], ["these mice", "TREATMENT", 23, 33], ["1,25D activity", "TREATMENT", 90, 104], ["vitamin D supplementation", "TREATMENT", 106, 131], ["symptoms", "PROBLEM", 164, 172], ["increase", "OBSERVATION_MODIFIER", 56, 64]]], ["In human CD4 + T cells from Crohn's disease patients exhibited similar results to the mouse studies with increased IL-10 and decreased IFN-\u03b3 production upon 1,25D treatment (246).", [["CD4 + T cells", "ANATOMY", 9, 22], ["Crohn's disease", "DISEASE", 28, 43], ["1,25D", "CHEMICAL", 157, 162], ["1,25D", "CHEMICAL", 157, 162], ["human", "ORGANISM", 3, 8], ["CD4", "GENE_OR_GENE_PRODUCT", 9, 12], ["patients", "ORGANISM", 44, 52], ["mouse", "ORGANISM", 86, 91], ["IL-10", "GENE_OR_GENE_PRODUCT", 115, 120], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 135, 140], ["1,25D", "SIMPLE_CHEMICAL", 157, 162], ["human CD4 + T cells", "CELL_TYPE", 3, 22], ["IL-10", "PROTEIN", 115, 120], ["IFN", "PROTEIN", 135, 138], ["human", "SPECIES", 3, 8], ["patients", "SPECIES", 44, 52], ["mouse", "SPECIES", 86, 91], ["human", "SPECIES", 3, 8], ["mouse", "SPECIES", 86, 91], ["Crohn's disease", "PROBLEM", 28, 43], ["the mouse studies", "TEST", 82, 99], ["increased IL", "PROBLEM", 105, 117], ["decreased IFN", "PROBLEM", 125, 138], ["1,25D treatment", "TREATMENT", 157, 172]]], ["Vitamin D supplementation trials for IBD have shown some benefit in suppressing inflammatory disease score (247) (248) (249) (250) .", [["Vitamin D", "CHEMICAL", 0, 9], ["IBD", "DISEASE", 37, 40], ["Vitamin D", "CHEMICAL", 0, 9], ["Vitamin D", "SIMPLE_CHEMICAL", 0, 9], ["Vitamin D supplementation trials", "TREATMENT", 0, 32], ["IBD", "PROBLEM", 37, 40], ["suppressing inflammatory disease score", "PROBLEM", 68, 106], ["inflammatory", "OBSERVATION_MODIFIER", 80, 92]]], ["However, additional parameters such as cytokine levels have yet to be investigated.", [["cytokine", "PROTEIN", 39, 47], ["additional parameters", "TEST", 9, 30], ["cytokine levels", "TEST", 39, 54]]], ["Of particular interest, is the potential use of vitamin D as a supplement to anti-TNF-\u03b1 treatment to improve immunomodulation in IBD patients (251, 252) .Inflammatory bowel diseaseCurrently trials have focussed on and reported a reduction in IBD disease progression with the view to move to larger cohort studies (248, 249).Type 1 diabetes mellitusConsistent with the other mouse models of chronic autoimmunity, vitamin D treatment of non-obese diabetic (NOD) mice has been shown to alleviate diabetes in these mice by reducing the production of IFN-\u03b3, increasing Treg numbers and restoring defective T cell apoptosis (148, 211, 253) .", [["bowel", "ANATOMY", 167, 172], ["Treg", "ANATOMY", 564, 568], ["T cell", "ANATOMY", 601, 607], ["vitamin D", "CHEMICAL", 48, 57], ["IBD", "DISEASE", 129, 132], ["Type 1 diabetes mellitus", "DISEASE", 324, 348], ["chronic autoimmunity", "DISEASE", 390, 410], ["vitamin D", "CHEMICAL", 412, 421], ["non-obese diabetic", "DISEASE", 435, 453], ["diabetes", "DISEASE", 493, 501], ["vitamin D", "CHEMICAL", 48, 57], ["vitamin D", "CHEMICAL", 412, 421], ["vitamin D", "SIMPLE_CHEMICAL", 48, 57], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 82, 87], ["patients", "ORGANISM", 133, 141], ["bowel", "ORGAN", 167, 172], ["mouse", "ORGANISM", 374, 379], ["vitamin D", "SIMPLE_CHEMICAL", 412, 421], ["non-obese diabetic (NOD) mice", "ORGANISM", 435, 464], ["mice", "ORGANISM", 511, 515], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 546, 551], ["Treg", "CELL", 564, 568], ["T cell", "CELL", 601, 607], ["TNF", "PROTEIN", 82, 85], ["IFN-\u03b3", "PROTEIN", 546, 551], ["patients", "SPECIES", 133, 141], ["mouse", "SPECIES", 374, 379], ["mice", "SPECIES", 460, 464], ["mice", "SPECIES", 511, 515], ["mouse", "SPECIES", 374, 379], ["mice", "SPECIES", 460, 464], ["mice", "SPECIES", 511, 515], ["vitamin D", "TREATMENT", 48, 57], ["anti-TNF", "TREATMENT", 77, 85], ["\u03b1 treatment", "TREATMENT", 86, 97], ["immunomodulation", "TREATMENT", 109, 125], ["Inflammatory bowel diseaseCurrently trials", "PROBLEM", 154, 196], ["IBD disease progression", "PROBLEM", 242, 265], ["larger cohort studies", "TEST", 291, 312], ["Type 1 diabetes mellitus", "PROBLEM", 324, 348], ["chronic autoimmunity", "PROBLEM", 390, 410], ["vitamin D treatment", "TREATMENT", 412, 431], ["non-obese diabetic", "PROBLEM", 435, 453], ["diabetes", "PROBLEM", 493, 501], ["IFN", "TEST", 546, 549], ["increasing Treg numbers", "PROBLEM", 553, 576], ["restoring defective T cell apoptosis", "PROBLEM", 581, 617], ["bowel", "ANATOMY", 167, 172], ["diseaseCurrently", "OBSERVATION", 173, 189], ["reduction", "OBSERVATION_MODIFIER", 229, 238], ["IBD", "OBSERVATION", 242, 245], ["diabetes", "OBSERVATION", 331, 339], ["chronic", "OBSERVATION_MODIFIER", 390, 397], ["autoimmunity", "OBSERVATION", 398, 410], ["Treg", "ANATOMY", 564, 568], ["defective T cell apoptosis", "OBSERVATION", 591, 617]]], ["In contrast, a study using VDR -/-NOD mice showed that mice lacking the VDR were no worse off in diabetes presentation, suggesting that vitamin D has little effect in disease progression (254) .", [["diabetes", "DISEASE", 97, 105], ["vitamin D", "CHEMICAL", 136, 145], ["vitamin D", "CHEMICAL", 136, 145], ["VDR", "GENE_OR_GENE_PRODUCT", 27, 30], ["-/-NOD mice", "ORGANISM", 31, 42], ["mice", "ORGANISM", 55, 59], ["VDR", "GENE_OR_GENE_PRODUCT", 72, 75], ["vitamin D", "SIMPLE_CHEMICAL", 136, 145], ["VDR", "PROTEIN", 27, 30], ["VDR", "PROTEIN", 72, 75], ["mice", "SPECIES", 38, 42], ["mice", "SPECIES", 55, 59], ["mice", "SPECIES", 38, 42], ["mice", "SPECIES", 55, 59], ["a study", "TEST", 13, 20], ["diabetes presentation", "PROBLEM", 97, 118], ["vitamin D", "PROBLEM", 136, 145], ["disease progression", "PROBLEM", 167, 186], ["no", "UNCERTAINTY", 81, 83], ["worse", "OBSERVATION_MODIFIER", 84, 89]]], ["Human studies are similarly contradictory, two studies have reported no association with pregnancy/neonatal 25D levels and risk of developing T1D (255, 256) .", [["T1D", "DISEASE", 142, 145], ["Human", "ORGANISM", 0, 5], ["Human", "SPECIES", 0, 5], ["Human studies", "TEST", 0, 13], ["two studies", "TEST", 43, 54], ["pregnancy/neonatal 25D levels", "PROBLEM", 89, 118]]], ["Whereas, another larger study reported a reduced risk of developing T1D with neonatal vitamin D supplementation (257) .", [["T1D", "DISEASE", 68, 71], ["vitamin D", "CHEMICAL", 86, 95], ["vitamin D", "CHEMICAL", 86, 95], ["vitamin D", "SIMPLE_CHEMICAL", 86, 95], ["another larger study", "TEST", 9, 29], ["neonatal vitamin D supplementation", "TREATMENT", 77, 111], ["reduced", "OBSERVATION_MODIFIER", 41, 48]]], ["Several adult cohort studies have investigated a potential protective effect of vitamin D on beta-cell function.", [["beta-cell", "ANATOMY", 93, 102], ["vitamin D", "CHEMICAL", 80, 89], ["vitamin D", "CHEMICAL", 80, 89], ["vitamin D", "SIMPLE_CHEMICAL", 80, 89], ["beta-cell", "CELL", 93, 102], ["Several adult cohort studies", "TEST", 0, 28], ["vitamin D", "TREATMENT", 80, 89], ["beta-cell function", "TREATMENT", 93, 111]]], ["Two studies showed that 1,25D provided no protection to beta-cells (258, 259) but another suggested beta-cell function is preserved with a combination of insulin and 1\u03b1-hydroxyvitamin D 3 therapy (260) .", [["beta-cells", "ANATOMY", 56, 66], ["beta-cell", "ANATOMY", 100, 109], ["1,25D", "CHEMICAL", 24, 29], ["1\u03b1-hydroxyvitamin D", "CHEMICAL", 166, 185], ["1\u03b1-hydroxyvitamin D 3", "CHEMICAL", 166, 187], ["1,25D", "SIMPLE_CHEMICAL", 24, 29], ["beta-cells", "CELL", 56, 66], ["beta-cell", "MULTI-TISSUE_STRUCTURE", 100, 109], ["insulin", "GENE_OR_GENE_PRODUCT", 154, 161], ["1\u03b1-hydroxyvitamin D 3", "SIMPLE_CHEMICAL", 166, 187], ["beta-cells", "CELL_TYPE", 56, 66], ["Two studies", "TEST", 0, 11], ["beta-cells", "TEST", 56, 66], ["beta-cell function", "TEST", 100, 118], ["insulin", "TREATMENT", 154, 161], ["hydroxyvitamin D 3 therapy", "TREATMENT", 169, 195]]], ["In the only study to report changes in the T cell compartment, an increase in Tregs was reported in males treated with vitamin D 3 (261) .", [["T cell compartment", "ANATOMY", 43, 61], ["Tregs", "ANATOMY", 78, 83], ["vitamin D", "CHEMICAL", 119, 128], ["vitamin D 3", "CHEMICAL", 119, 130], ["T cell", "CELL", 43, 49], ["Tregs", "CELL", 78, 83], ["vitamin D 3", "SIMPLE_CHEMICAL", 119, 130], ["Tregs", "CELL_TYPE", 78, 83], ["changes in the T cell compartment", "PROBLEM", 28, 61], ["an increase in Tregs", "PROBLEM", 63, 83], ["vitamin D", "TREATMENT", 119, 128], ["increase", "OBSERVATION_MODIFIER", 66, 74], ["Tregs", "OBSERVATION", 78, 83]]], ["This provides a good rationale for further studies investigating vitamin D-mediated improvements in T cell function in diabetes and highlights a potential sex bias in some effects (261, 262).Airway diseaseIn several studies, lower circulating 25D levels have been reported in individuals with severe asthma (263) .", [["T cell", "ANATOMY", 100, 106], ["Airway", "ANATOMY", 191, 197], ["vitamin D", "CHEMICAL", 65, 74], ["diabetes", "DISEASE", 119, 127], ["asthma", "DISEASE", 300, 306], ["vitamin D", "CHEMICAL", 65, 74], ["vitamin D", "SIMPLE_CHEMICAL", 65, 74], ["T cell", "CELL", 100, 106], ["Airway", "MULTI-TISSUE_STRUCTURE", 191, 197], ["25D", "GENE_OR_GENE_PRODUCT", 243, 246], ["further studies", "TEST", 35, 50], ["vitamin D", "TREATMENT", 65, 74], ["diabetes", "PROBLEM", 119, 127], ["Airway diseaseIn", "PROBLEM", 191, 207], ["several studies", "TEST", 208, 223], ["lower circulating 25D levels", "PROBLEM", 225, 253], ["severe asthma", "PROBLEM", 293, 306], ["T cell", "OBSERVATION_MODIFIER", 100, 106], ["severe", "OBSERVATION_MODIFIER", 293, 299], ["asthma", "OBSERVATION", 300, 306]]], ["Moreover in one study, patients with the lowest baseline 25D levels were found to be at highest risk of severe asthma exacerbation requiring hospital admission over a 4 year period, which may indicate some degree of causality (264) .", [["asthma", "DISEASE", 111, 117], ["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31], ["one study", "TEST", 12, 21], ["severe asthma exacerbation", "PROBLEM", 104, 130], ["severe", "OBSERVATION_MODIFIER", 104, 110], ["asthma", "OBSERVATION", 111, 117], ["may indicate", "UNCERTAINTY", 188, 200], ["some degree", "OBSERVATION_MODIFIER", 201, 212]]], ["Studies aimed at identifying a mechanistic basis for this relationship have identified positive correlations between vitamin D status and both the frequency of This article is protected by copyright.", [["vitamin D", "CHEMICAL", 117, 126], ["vitamin D", "CHEMICAL", 117, 126], ["vitamin D", "SIMPLE_CHEMICAL", 117, 126], ["positive correlations between vitamin D status", "PROBLEM", 87, 133]]], ["All rights reserved.Airway diseaseFoxP3 + regulatory T cells and levels of the anti-inflammatory cytokine IL-10 in the airways of patients with asthma (172, 265) , consistent with the capacity of 1,25D to drive differentiation of CD4 + T cell populations in vitro (126, 172) .", [["Airway diseaseFoxP3 + regulatory T cells", "ANATOMY", 20, 60], ["airways", "ANATOMY", 119, 126], ["CD4 + T cell", "ANATOMY", 230, 242], ["asthma", "DISEASE", 144, 150], ["1,25D", "CHEMICAL", 196, 201], ["1,25D", "CHEMICAL", 196, 201], ["Airway diseaseFoxP3", "CELL", 20, 39], ["IL-10", "GENE_OR_GENE_PRODUCT", 106, 111], ["airways", "MULTI-TISSUE_STRUCTURE", 119, 126], ["patients", "ORGANISM", 130, 138], ["1,25D", "SIMPLE_CHEMICAL", 196, 201], ["CD4", "GENE_OR_GENE_PRODUCT", 230, 233], ["Airway diseaseFoxP3 + regulatory T cells", "CELL_TYPE", 20, 60], ["anti-inflammatory cytokine IL-10", "PROTEIN", 79, 111], ["CD4", "PROTEIN", 230, 233], ["patients", "SPECIES", 130, 138], ["Airway diseaseFoxP3", "TEST", 20, 39], ["regulatory T cells", "PROBLEM", 42, 60], ["the anti-inflammatory cytokine IL", "TEST", 75, 108], ["asthma", "PROBLEM", 144, 150], ["the capacity", "PROBLEM", 180, 192], ["CD4", "TEST", 230, 233], ["T cell populations", "PROBLEM", 236, 254], ["regulatory T cells", "OBSERVATION", 42, 60], ["anti-inflammatory", "OBSERVATION_MODIFIER", 79, 96], ["airways", "ANATOMY", 119, 126], ["asthma", "OBSERVATION", 144, 150], ["T cell populations", "OBSERVATION", 236, 254]]], ["Effects on other types of cells present in the airway may also partly explain these relationships, for example 1,25D suppresses production of IgE by B lymphocytes (266) ; and of inflammatory cytokines by neutrophils (76) but promotes epithelial cell secretion of antiinflammatory ST2, which blocks mast cell priming by IL-33 (267) .", [["cells", "ANATOMY", 26, 31], ["airway", "ANATOMY", 47, 53], ["B lymphocytes", "ANATOMY", 149, 162], ["neutrophils", "ANATOMY", 204, 215], ["epithelial cell", "ANATOMY", 234, 249], ["mast cell", "ANATOMY", 298, 307], ["cells", "CELL", 26, 31], ["airway", "MULTI-TISSUE_STRUCTURE", 47, 53], ["1,25D", "SIMPLE_CHEMICAL", 111, 116], ["IgE", "GENE_OR_GENE_PRODUCT", 142, 145], ["B lymphocytes", "CELL", 149, 162], ["neutrophils", "CELL", 204, 215], ["epithelial cell", "CELL", 234, 249], ["ST2", "GENE_OR_GENE_PRODUCT", 280, 283], ["mast cell", "CELL", 298, 307], ["IL-33", "GENE_OR_GENE_PRODUCT", 319, 324], ["1,25D", "PROTEIN", 111, 116], ["IgE", "PROTEIN", 142, 145], ["B lymphocytes", "CELL_TYPE", 149, 162], ["inflammatory cytokines", "PROTEIN", 178, 200], ["neutrophils", "CELL_TYPE", 204, 215], ["antiinflammatory ST2", "PROTEIN", 263, 283], ["IL", "PROTEIN", 319, 321], ["B lymphocytes", "TEST", 149, 162], ["inflammatory cytokines", "PROBLEM", 178, 200], ["neutrophils", "TEST", 204, 215], ["antiinflammatory ST2", "PROBLEM", 263, 283], ["IL", "TEST", 319, 321], ["cells", "OBSERVATION", 26, 31], ["airway", "ANATOMY", 47, 53], ["may also partly explain", "UNCERTAINTY", 54, 77], ["inflammatory", "OBSERVATION_MODIFIER", 178, 190], ["epithelial cell secretion", "OBSERVATION", 234, 259], ["antiinflammatory ST2", "OBSERVATION", 263, 283], ["mast cell", "OBSERVATION", 298, 307]]], ["Notably, 1,25D also augments the sensitivity of both T cells and monocytes to the anti-inflammatory activity of corticosteroids, which are a mainstay of treatment of this disease (268) (269) (270) .", [["T cells", "ANATOMY", 53, 60], ["monocytes", "ANATOMY", 65, 74], ["1,25D", "CHEMICAL", 9, 14], ["corticosteroids", "CHEMICAL", 112, 127], ["1,25D", "CHEMICAL", 9, 14], ["corticosteroids", "CHEMICAL", 112, 127], ["1,25D", "SIMPLE_CHEMICAL", 9, 14], ["T cells", "CELL", 53, 60], ["monocytes", "CELL", 65, 74], ["corticosteroids", "SIMPLE_CHEMICAL", 112, 127], ["T cells", "CELL_TYPE", 53, 60], ["monocytes", "CELL_TYPE", 65, 74], ["the sensitivity", "TEST", 29, 44], ["corticosteroids", "TREATMENT", 112, 127], ["this disease", "PROBLEM", 166, 178], ["anti-inflammatory activity", "OBSERVATION_MODIFIER", 82, 108]]], ["Despite these in vitro findings and the relationship between vitamin D status and asthma severity described above, interventional randomised controlled trials of vitamin D supplementation in respiratory disease have so far produced inconsistent results in adults, although more encouraging results have been described in children (263) .Airway diseaseAlthough studies of the effects of vitamin D on inflammatory disease using mouse models have providedVitamin D and antiviral innate immunityMechanisms of antiviral innate immunity parallel those that counter bacterial infections; viral pathogens are first detected through a series of pattern recognition receptors, which initiate signaling cascades that induce type 1 interferon and cytokine responses as well as antiviral effectors (274, 275) .", [["respiratory", "ANATOMY", 191, 202], ["Airway", "ANATOMY", 337, 343], ["vitamin D", "CHEMICAL", 61, 70], ["asthma", "DISEASE", 82, 88], ["vitamin D", "CHEMICAL", 162, 171], ["respiratory disease", "DISEASE", 191, 210], ["vitamin D", "CHEMICAL", 386, 395], ["inflammatory disease", "DISEASE", 399, 419], ["Vitamin D", "CHEMICAL", 452, 461], ["bacterial infections", "DISEASE", 559, 579], ["vitamin D", "CHEMICAL", 61, 70], ["vitamin D", "CHEMICAL", 162, 171], ["vitamin D", "CHEMICAL", 386, 395], ["Vitamin D", "CHEMICAL", 452, 461], ["vitamin D", "SIMPLE_CHEMICAL", 61, 70], ["vitamin D", "SIMPLE_CHEMICAL", 162, 171], ["children", "ORGANISM", 321, 329], ["Airway", "MULTI-TISSUE_STRUCTURE", 337, 343], ["vitamin D", "SIMPLE_CHEMICAL", 386, 395], ["mouse", "ORGANISM", 426, 431], ["Vitamin D", "SIMPLE_CHEMICAL", 452, 461], ["type 1 interferon", "GENE_OR_GENE_PRODUCT", 713, 730], ["pattern recognition receptors", "PROTEIN", 636, 665], ["type 1 interferon", "PROTEIN", 713, 730], ["cytokine", "PROTEIN", 735, 743], ["antiviral effectors", "PROTEIN", 765, 784], ["children", "SPECIES", 321, 329], ["mouse", "SPECIES", 426, 431], ["mouse", "SPECIES", 426, 431], ["vitamin D status", "PROBLEM", 61, 77], ["asthma severity", "PROBLEM", 82, 97], ["interventional randomised controlled trials", "TREATMENT", 115, 158], ["vitamin D supplementation", "TREATMENT", 162, 187], ["respiratory disease", "PROBLEM", 191, 210], ["Airway diseaseAlthough studies", "TEST", 337, 367], ["vitamin D", "TREATMENT", 386, 395], ["inflammatory disease", "PROBLEM", 399, 419], ["mouse models", "TREATMENT", 426, 438], ["Vitamin D", "TREATMENT", 452, 461], ["antiviral innate immunity", "TREATMENT", 466, 491], ["antiviral innate immunity parallel", "TREATMENT", 505, 539], ["bacterial infections", "PROBLEM", 559, 579], ["viral pathogens", "PROBLEM", 581, 596], ["signaling cascades", "PROBLEM", 682, 700], ["type 1 interferon and cytokine responses", "TREATMENT", 713, 753], ["respiratory disease", "OBSERVATION", 191, 210], ["antiviral innate", "OBSERVATION_MODIFIER", 466, 482], ["infections", "OBSERVATION", 569, 579]]], ["Several was accompanied by increased expression of CAMP and interferon-stimulated genes (282) .Vitamin D and antiviral innate immunityOther facets of the antibacterial mechanisms that are activated by vitamin D may also play a pivotal role in mediating its antiviral functions.", [["Vitamin D", "CHEMICAL", 95, 104], ["vitamin D", "CHEMICAL", 201, 210], ["Vitamin D", "CHEMICAL", 95, 104], ["vitamin D", "CHEMICAL", 201, 210], ["CAMP", "GENE_OR_GENE_PRODUCT", 51, 55], ["interferon-stimulated genes", "GENE_OR_GENE_PRODUCT", 60, 87], ["Vitamin D", "SIMPLE_CHEMICAL", 95, 104], ["vitamin D", "SIMPLE_CHEMICAL", 201, 210], ["CAMP", "PROTEIN", 51, 55], ["interferon-stimulated genes", "DNA", 60, 87], ["CAMP and interferon", "TREATMENT", 51, 70], ["Vitamin D", "TREATMENT", 95, 104], ["antiviral innate immunity", "TREATMENT", 109, 134], ["the antibacterial mechanisms", "PROBLEM", 150, 178], ["vitamin D", "TREATMENT", 201, 210], ["increased", "OBSERVATION_MODIFIER", 27, 36], ["facets", "OBSERVATION_MODIFIER", 140, 146], ["antibacterial mechanisms", "OBSERVATION", 154, 178], ["antiviral functions", "OBSERVATION", 257, 276]]], ["NOD2 is known to recognise single stranded (ss) RNA to trigger type I interferon antiviral responses (292) .", [["NOD2", "GENE_OR_GENE_PRODUCT", 0, 4], ["type I interferon", "GENE_OR_GENE_PRODUCT", 63, 80], ["NOD2", "PROTEIN", 0, 4], ["single stranded (ss) RNA", "RNA", 27, 51], ["type I interferon antiviral responses", "TREATMENT", 63, 100]]], ["Thus, the ability of 1,25D to strongly induce NOD2 expression (52) may indirectly enhance antiviral activity.", [["1,25D", "CHEMICAL", 21, 26], ["1,25D", "CHEMICAL", 21, 26], ["1,25D", "SIMPLE_CHEMICAL", 21, 26], ["NOD2", "GENE_OR_GENE_PRODUCT", 46, 50], ["NOD2", "PROTEIN", 46, 50], ["antiviral activity", "OBSERVATION", 90, 108]]], ["NOD2 is also known to trigger autophagy (57), and autophagy has been shown to be induced by herpes simplex virus and human cytomegalovirus herpes virus infection (293) .", [["herpes simplex virus", "DISEASE", 92, 112], ["cytomegalovirus herpes virus infection", "DISEASE", 123, 161], ["NOD2", "GENE_OR_GENE_PRODUCT", 0, 4], ["herpes simplex virus", "ORGANISM", 92, 112], ["human", "ORGANISM", 117, 122], ["cytomegalovirus herpes virus", "ORGANISM", 123, 151], ["NOD2", "PROTEIN", 0, 4], ["herpes simplex virus", "SPECIES", 92, 112], ["human", "SPECIES", 117, 122], ["cytomegalovirus herpes virus", "SPECIES", 123, 151], ["herpes simplex virus", "SPECIES", 92, 112], ["human cytomegalovirus herpes virus", "SPECIES", 117, 151], ["autophagy", "TEST", 30, 39], ["autophagy", "PROBLEM", 50, 59], ["herpes simplex virus", "PROBLEM", 92, 112], ["human cytomegalovirus herpes virus infection", "PROBLEM", 117, 161], ["cytomegalovirus", "OBSERVATION_MODIFIER", 123, 138]]], ["Thus, the potent effects of 1,25D in promoting autophagy to enhance the intracellular environment for bacterial killing, may also play a role in antiviral activity by facilitating viral clearance (294, 295) .", [["intracellular", "ANATOMY", 72, 85], ["1,25D", "CHEMICAL", 28, 33], ["1,25D", "CHEMICAL", 28, 33], ["1,25D", "SIMPLE_CHEMICAL", 28, 33], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 72, 85], ["bacterial killing", "PROBLEM", 102, 119], ["antiviral activity", "TREATMENT", 145, 163]]], ["By packaging viral particles for lysosomal degradation and antigen-presentation, autophagic encapsulation provides an initial step in development of adaptive antiviral immune responses (296) .", [["lysosomal", "ANATOMY", 33, 42], ["autophagic", "ANATOMY", 81, 91], ["lysosomal", "CELLULAR_COMPONENT", 33, 42], ["lysosomal degradation", "PROBLEM", 33, 54], ["antigen", "TEST", 59, 66], ["autophagic encapsulation", "TREATMENT", 81, 105], ["adaptive antiviral immune responses", "TREATMENT", 149, 184], ["viral particles", "OBSERVATION", 13, 28]]], ["However, it is important to recognise that some viruses are able to hijack components of autophagy to promote viral replication.", [["some viruses", "PROBLEM", 43, 55], ["viral replication", "TREATMENT", 110, 127], ["viruses", "OBSERVATION", 48, 55], ["viral replication", "OBSERVATION", 110, 127]]], ["For example, hepatitis C virus infection is known to promote autophagy (297) , but the resulting lipid-filled autophagosomes can act to enhance the assembly of hepatitis C virions (298) .Vitamin D and antiviral innate immunityThis article is protected by copyright.", [["autophagosomes", "ANATOMY", 110, 124], ["hepatitis C virus infection", "DISEASE", 13, 40], ["hepatitis C virions", "DISEASE", 160, 179], ["Vitamin D", "CHEMICAL", 187, 196], ["Vitamin D", "CHEMICAL", 187, 196], ["hepatitis C virus", "ORGANISM", 13, 30], ["lipid", "SIMPLE_CHEMICAL", 97, 102], ["autophagosomes", "CELLULAR_COMPONENT", 110, 124], ["hepatitis C virions", "ORGANISM", 160, 179], ["Vitamin D", "SIMPLE_CHEMICAL", 187, 196], ["hepatitis C virus", "SPECIES", 13, 30], ["hepatitis C virus", "SPECIES", 13, 30], ["hepatitis C virus infection", "PROBLEM", 13, 40], ["the resulting lipid-filled autophagosomes", "PROBLEM", 83, 124], ["hepatitis C virions", "PROBLEM", 160, 179], ["Vitamin D", "TREATMENT", 187, 196], ["antiviral innate immunity", "TREATMENT", 201, 226], ["hepatitis", "OBSERVATION", 13, 22], ["hepatitis", "OBSERVATION", 160, 169]]], ["All rights reserved.Vitamin D and antiviral innate immunityAutophagy is another key mechanism for viral infection and replication, and both 25D and 1,25D have been shown to enhance macrophage expression of the autophagy marker LC3 (31, 58).", [["macrophage", "ANATOMY", 181, 191], ["Vitamin D", "CHEMICAL", 20, 29], ["viral infection", "DISEASE", 98, 113], ["1,25D", "CHEMICAL", 148, 153], ["Vitamin D", "CHEMICAL", 20, 29], ["25D", "CHEMICAL", 140, 143], ["1,25D", "CHEMICAL", 148, 153], ["Vitamin D", "SIMPLE_CHEMICAL", 20, 29], ["25D", "SIMPLE_CHEMICAL", 140, 143], ["1,25D", "SIMPLE_CHEMICAL", 148, 153], ["macrophage", "CELL", 181, 191], ["LC3", "GENE_OR_GENE_PRODUCT", 227, 230], ["LC3", "PROTEIN", 227, 230], ["Vitamin D", "TREATMENT", 20, 29], ["antiviral innate immunity", "TREATMENT", 34, 59], ["viral infection", "PROBLEM", 98, 113], ["viral", "OBSERVATION_MODIFIER", 98, 103], ["infection", "OBSERVATION", 104, 113]]], ["Thus, autophagy is subject to the same localised innate immune intracrine vitamin D metabolic system observed for antibacterial proteins (299) .", [["vitamin D", "CHEMICAL", 74, 83], ["vitamin D", "CHEMICAL", 74, 83], ["vitamin D", "SIMPLE_CHEMICAL", 74, 83], ["antibacterial proteins", "PROTEIN", 114, 136], ["antibacterial proteins", "TEST", 114, 136]]], ["Vitamin D can promote autophagy firstly by direct induction of key enzyme drivers of autophagy such as promoting Beclin 1 and PI3KC3 (300) .", [["Vitamin D", "CHEMICAL", 0, 9], ["Vitamin D", "CHEMICAL", 0, 9], ["Vitamin D", "SIMPLE_CHEMICAL", 0, 9], ["Beclin 1", "GENE_OR_GENE_PRODUCT", 113, 121], ["PI3KC3", "GENE_OR_GENE_PRODUCT", 126, 132], ["Beclin 1", "PROTEIN", 113, 121], ["PI3KC3", "PROTEIN", 126, 132], ["Vitamin D", "TREATMENT", 0, 9]]], ["However, it can also enhance autophagy indirectly by suppressing inhibition of autophagy by the mTOR signaling pathway (301) , and by stimulating intracellular calcium and NO by 1,25D to enhance PI3KC3 activity (302) .Vitamin D and antiviral innate immunityAnother key indirect mechanism for 1,25D-mediated induction of autophagy is via the cathelicidin expression which, in turn, stimulates key autophagy factors such as Beclin 1 (58) .", [["intracellular", "ANATOMY", 146, 159], ["calcium", "CHEMICAL", 160, 167], ["NO", "CHEMICAL", 172, 174], ["1,25D", "CHEMICAL", 178, 183], ["Vitamin D", "CHEMICAL", 218, 227], ["calcium", "CHEMICAL", 160, 167], ["NO", "CHEMICAL", 172, 174], ["1,25D", "CHEMICAL", 178, 183], ["Vitamin D", "CHEMICAL", 218, 227], ["mTOR", "GENE_OR_GENE_PRODUCT", 96, 100], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 146, 159], ["calcium", "SIMPLE_CHEMICAL", 160, 167], ["NO", "SIMPLE_CHEMICAL", 172, 174], ["1,25D", "SIMPLE_CHEMICAL", 178, 183], ["PI3KC3", "GENE_OR_GENE_PRODUCT", 195, 201], ["Vitamin D", "SIMPLE_CHEMICAL", 218, 227], ["1,25D", "SIMPLE_CHEMICAL", 292, 297], ["cathelicidin", "GENE_OR_GENE_PRODUCT", 341, 353], ["Beclin 1", "GENE_OR_GENE_PRODUCT", 422, 430], ["mTOR", "PROTEIN", 96, 100], ["PI3KC3", "PROTEIN", 195, 201], ["1,25D", "PROTEIN", 292, 297], ["cathelicidin", "PROTEIN", 341, 353], ["autophagy factors", "PROTEIN", 396, 413], ["Beclin 1", "PROTEIN", 422, 430], ["stimulating intracellular calcium", "TEST", 134, 167], ["Vitamin D", "TREATMENT", 218, 227], ["antiviral innate immunity", "TREATMENT", 232, 257], ["1,25D-mediated induction of autophagy", "TREATMENT", 292, 329], ["the cathelicidin expression", "TREATMENT", 337, 364]]], ["The overall autophagy effect of vitamin D appears to be as a homeostatic regulator of the balance between autophagy and apoptosis to enable optimal antiviral responses to infection (303) .", [["vitamin D", "CHEMICAL", 32, 41], ["infection", "DISEASE", 171, 180], ["vitamin D", "CHEMICAL", 32, 41], ["vitamin D", "SIMPLE_CHEMICAL", 32, 41], ["vitamin D", "TREATMENT", 32, 41], ["apoptosis", "PROBLEM", 120, 129], ["infection", "PROBLEM", 171, 180], ["autophagy effect", "OBSERVATION", 12, 28]]], ["The potential benefit of vitamin Dinduced autophagy as an inhibitory mechanism to counter viral infection has been reviewed in detail elsewhere (303) , and notably includes beneficial effects on infection by hepatitis C (304), influenza A (305), rotavirus (306) , and HIV-1 (307, 308) .Vitamin D and antiviral innate immunityComorbidities such as chronic obstructive pulmonary disease (COPD) and asthma can aggravate respiratory infections, and available, albeit partially conflicting, results suggest that vitamin D metabolism is disrupted in these conditions.", [["pulmonary", "ANATOMY", 367, 376], ["respiratory", "ANATOMY", 417, 428], ["vitamin Dinduced", "CHEMICAL", 25, 41], ["viral infection", "DISEASE", 90, 105], ["infection by hepatitis C", "DISEASE", 195, 219], ["influenza A", "DISEASE", 227, 238], ["rotavirus", "DISEASE", 246, 255], ["Vitamin D", "CHEMICAL", 286, 295], ["chronic obstructive pulmonary disease", "DISEASE", 347, 384], ["COPD", "DISEASE", 386, 390], ["asthma", "DISEASE", 396, 402], ["respiratory infections", "DISEASE", 417, 439], ["vitamin D", "CHEMICAL", 507, 516], ["Vitamin D", "CHEMICAL", 286, 295], ["vitamin D", "CHEMICAL", 507, 516], ["vitamin Dinduced", "SIMPLE_CHEMICAL", 25, 41], ["hepatitis C", "ORGANISM", 208, 219], ["influenza A", "ORGANISM", 227, 238], ["rotavirus", "ORGANISM", 246, 255], ["HIV-1", "ORGANISM", 268, 273], ["Vitamin D", "SIMPLE_CHEMICAL", 286, 295], ["pulmonary", "ORGAN", 367, 376], ["vitamin D", "SIMPLE_CHEMICAL", 507, 516], ["HIV-1", "SPECIES", 268, 273], ["hepatitis C", "SPECIES", 208, 219], ["influenza A", "SPECIES", 227, 238], ["HIV-1", "SPECIES", 268, 273], ["vitamin Dinduced autophagy", "TREATMENT", 25, 51], ["an inhibitory mechanism", "PROBLEM", 55, 78], ["viral infection", "PROBLEM", 90, 105], ["infection", "PROBLEM", 195, 204], ["hepatitis C", "PROBLEM", 208, 219], ["influenza A", "TEST", 227, 238], ["rotavirus", "TEST", 246, 255], ["HIV", "TEST", 268, 271], ["Vitamin D", "TREATMENT", 286, 295], ["antiviral innate immunityComorbidities", "TREATMENT", 300, 338], ["chronic obstructive pulmonary disease", "PROBLEM", 347, 384], ["COPD)", "PROBLEM", 386, 391], ["asthma", "PROBLEM", 396, 402], ["aggravate respiratory infections", "PROBLEM", 407, 439], ["vitamin D metabolism", "PROBLEM", 507, 527], ["infection", "OBSERVATION", 195, 204], ["chronic", "OBSERVATION_MODIFIER", 347, 354], ["obstructive", "OBSERVATION_MODIFIER", 355, 366], ["pulmonary", "ANATOMY", 367, 376], ["disease", "OBSERVATION", 377, 384], ["COPD", "OBSERVATION", 386, 390], ["asthma", "OBSERVATION", 396, 402], ["infections", "OBSERVATION", 429, 439]]], ["TGF-\u03b21 levels are elevated in COPD and suppress expression of host defence mediators.", [["COPD", "DISEASE", 30, 34], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 0, 6], ["TGF-\u03b21", "PROTEIN", 0, 6], ["host defence mediators", "PROTEIN", 62, 84], ["TGF", "TEST", 0, 3], ["elevated", "PROBLEM", 18, 26], ["COPD", "PROBLEM", 30, 34], ["elevated", "OBSERVATION_MODIFIER", 18, 26], ["COPD", "OBSERVATION", 30, 34]]], ["Schrumpf et al investigated the combined effects of 1,25D and TGF-\u03b21 on airway epithelial cell host defences in vitro (309) .", [["airway epithelial cell", "ANATOMY", 72, 94], ["1,25D", "SIMPLE_CHEMICAL", 52, 57], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 62, 68], ["airway epithelial cell", "CELL", 72, 94], ["1,25D and TGF-\u03b21", "PROTEIN", 52, 68], ["1,25D and TGF", "TREATMENT", 52, 65], ["airway", "ANATOMY", 72, 78], ["epithelial cell host defences", "OBSERVATION", 79, 108]]], ["TGF-\u03b21 inhibited 1,25D-induced CAMP expression in part by augmentation of CYP24A1 production.", [["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 0, 6], ["1,25D", "SIMPLE_CHEMICAL", 17, 22], ["CAMP", "GENE_OR_GENE_PRODUCT", 31, 35], ["CYP24A1", "GENE_OR_GENE_PRODUCT", 74, 81], ["TGF-\u03b21", "PROTEIN", 0, 6], ["CAMP", "PROTEIN", 31, 35], ["CYP24A1", "PROTEIN", 74, 81], ["TGF", "TEST", 0, 3], ["1,25D-induced CAMP expression", "TREATMENT", 17, 46], ["CYP24A1 production", "PROBLEM", 74, 92], ["CAMP expression", "OBSERVATION", 31, 46], ["CYP24A1 production", "OBSERVATION", 74, 92]]], ["TGF-\u03b21 also attenuated the expression of vitamin D-independent defence mediators, consistent with an attenuation of vitamin D-dependent and -independent host defences (309) .", [["vitamin D", "CHEMICAL", 41, 50], ["vitamin D", "CHEMICAL", 116, 125], ["vitamin D", "CHEMICAL", 41, 50], ["vitamin D", "CHEMICAL", 116, 125], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 0, 6], ["vitamin D", "SIMPLE_CHEMICAL", 41, 50], ["vitamin D", "SIMPLE_CHEMICAL", 116, 125], ["TGF-\u03b21", "PROTEIN", 0, 6], ["vitamin D-independent defence mediators", "PROTEIN", 41, 80], ["TGF", "TEST", 0, 3], ["an attenuation of vitamin D-dependent", "PROBLEM", 98, 135], ["consistent with", "UNCERTAINTY", 82, 97], ["attenuation", "OBSERVATION_MODIFIER", 101, 112]]], ["However, these findings were not borne out by the results of a longitudinal study by Jolliffe et al (310) , who found vitamin D supplementation did not augment circulating 25D levels to the same degree in patients with COPD or asthma as in healthy controls.", [["vitamin D", "CHEMICAL", 118, 127], ["COPD", "DISEASE", 219, 223], ["asthma", "DISEASE", 227, 233], ["vitamin D", "CHEMICAL", 118, 127], ["vitamin D", "SIMPLE_CHEMICAL", 118, 127], ["25D", "SIMPLE_CHEMICAL", 172, 175], ["patients", "ORGANISM", 205, 213], ["patients", "SPECIES", 205, 213], ["a longitudinal study", "TEST", 61, 81], ["vitamin D supplementation", "TREATMENT", 118, 143], ["COPD", "PROBLEM", 219, 223], ["asthma", "PROBLEM", 227, 233], ["same degree", "OBSERVATION_MODIFIER", 190, 201], ["COPD", "OBSERVATION", 219, 223], ["asthma", "OBSERVATION", 227, 233]]], ["This may have been due to reduced 25-hydroxylation of vitamin D but could not be attributed to elevated 25D catabolism in COPD, as CYP24A1 levels were somewhat reduced in COPD patients.", [["vitamin D", "CHEMICAL", 54, 63], ["COPD", "DISEASE", 122, 126], ["COPD", "DISEASE", 171, 175], ["vitamin D", "CHEMICAL", 54, 63], ["25D", "CHEMICAL", 104, 107], ["vitamin D", "SIMPLE_CHEMICAL", 54, 63], ["25D", "SIMPLE_CHEMICAL", 104, 107], ["CYP24A1", "GENE_OR_GENE_PRODUCT", 131, 138], ["patients", "ORGANISM", 176, 184], ["CYP24A1", "PROTEIN", 131, 138], ["patients", "SPECIES", 176, 184], ["vitamin D", "TREATMENT", 54, 63], ["elevated 25D catabolism", "PROBLEM", 95, 118], ["COPD", "PROBLEM", 122, 126], ["CYP24A1 levels", "TEST", 131, 145], ["COPD patients", "PROBLEM", 171, 184], ["COPD", "OBSERVATION", 122, 126], ["reduced", "OBSERVATION_MODIFIER", 160, 167], ["COPD", "OBSERVATION", 171, 175]]], ["1,25Ddependent gene expression signatures were also modestly attenuated in COPD (310).Vitamin D and COVID-19Given the extensive number of reports establishing an antiviral role for vitamin D signaling, it is reasonable to speculate the vitamin D sufficiency may have a role in attenuating the current outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that is causing the widespread coronavirus disease .", [["1,25", "CHEMICAL", 0, 4], ["COPD", "DISEASE", 75, 79], ["Vitamin D", "CHEMICAL", 86, 95], ["COVID-19Given", "CHEMICAL", 100, 113], ["vitamin D", "CHEMICAL", 181, 190], ["vitamin D", "CHEMICAL", 236, 245], ["acute respiratory syndrome coronavirus", "DISEASE", 330, 368], ["coronavirus disease", "DISEASE", 415, 434], ["Vitamin D", "CHEMICAL", 86, 95], ["COVID-19Given", "CHEMICAL", 100, 113], ["vitamin D", "CHEMICAL", 181, 190], ["vitamin D", "CHEMICAL", 236, 245], ["Vitamin D", "SIMPLE_CHEMICAL", 86, 95], ["COVID-19Given", "GENE_OR_GENE_PRODUCT", 100, 113], ["vitamin D", "SIMPLE_CHEMICAL", 181, 190], ["vitamin D", "SIMPLE_CHEMICAL", 236, 245], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 323, 370], ["SARS-CoV-2", "ORGANISM", 372, 382], ["coronavirus", "ORGANISM", 415, 426], ["coronavirus", "SPECIES", 415, 426], ["severe acute respiratory syndrome coronavirus", "SPECIES", 323, 368], ["SARS-CoV-2", "SPECIES", 372, 382], ["COPD", "PROBLEM", 75, 79], ["Vitamin D", "TREATMENT", 86, 95], ["COVID", "TREATMENT", 100, 105], ["vitamin D signaling", "TREATMENT", 181, 200], ["the vitamin D sufficiency", "PROBLEM", 232, 257], ["the novel severe acute respiratory syndrome coronavirus", "PROBLEM", 313, 368], ["SARS-CoV", "TEST", 372, 380], ["the widespread coronavirus disease", "PROBLEM", 400, 434], ["COPD", "OBSERVATION", 75, 79], ["severe", "OBSERVATION_MODIFIER", 323, 329], ["acute", "OBSERVATION_MODIFIER", 330, 335], ["respiratory syndrome", "OBSERVATION", 336, 356], ["widespread", "OBSERVATION_MODIFIER", 404, 414], ["coronavirus disease", "OBSERVATION", 415, 434]]], ["Although randomized controlled trials and large population studies assessing vitamin D status and severity of COVID-19 have yet to be completed, there is existing evidence to suggest that vitamin D could exert a protective effect against the disease.", [["vitamin D", "CHEMICAL", 77, 86], ["vitamin D", "CHEMICAL", 188, 197], ["vitamin D", "CHEMICAL", 77, 86], ["COVID-19", "CHEMICAL", 110, 118], ["vitamin D", "CHEMICAL", 188, 197], ["vitamin D", "SIMPLE_CHEMICAL", 77, 86], ["vitamin D", "SIMPLE_CHEMICAL", 188, 197], ["randomized controlled trials", "TREATMENT", 9, 37], ["large population studies", "TEST", 42, 66], ["vitamin D status", "TEST", 77, 93], ["COVID", "TEST", 110, 115], ["vitamin D", "PROBLEM", 188, 197], ["the disease", "PROBLEM", 238, 249], ["large", "OBSERVATION_MODIFIER", 42, 47], ["disease", "OBSERVATION", 242, 249]]], ["SARS-CoV-2 initially uses immune evasion mechanisms, which in certain patients, is accompanied with elevated pro-inflammatory cytokine release, increased risk of pneumonia (311), sepsis, and subsequent acute respiratory distress syndrome (ARDS) that frequently results in mortality (312) .", [["respiratory", "ANATOMY", 208, 219], ["SARS", "DISEASE", 0, 4], ["pneumonia", "DISEASE", 162, 171], ["sepsis", "DISEASE", 179, 185], ["acute respiratory distress syndrome", "DISEASE", 202, 237], ["ARDS", "DISEASE", 239, 243], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["patients", "ORGANISM", 70, 78], ["pro-inflammatory cytokine", "PROTEIN", 109, 134], ["patients", "SPECIES", 70, 78], ["SARS-CoV", "SPECIES", 0, 8], ["SARS", "PROBLEM", 0, 4], ["immune evasion mechanisms", "TREATMENT", 26, 51], ["elevated pro-inflammatory cytokine release", "PROBLEM", 100, 142], ["pneumonia", "PROBLEM", 162, 171], ["sepsis", "PROBLEM", 179, 185], ["subsequent acute respiratory distress syndrome", "PROBLEM", 191, 237], ["ARDS", "PROBLEM", 239, 243], ["pneumonia", "OBSERVATION", 162, 171], ["sepsis", "OBSERVATION", 179, 185], ["acute", "OBSERVATION_MODIFIER", 202, 207], ["respiratory distress syndrome", "OBSERVATION", 208, 237]]], ["In this regard, there is evidence for a protective role of vitamin D in many conditions associated with pneumonia, cytokine hyperproduction and ARDS (313, 314) .", [["vitamin D", "CHEMICAL", 59, 68], ["pneumonia", "DISEASE", 104, 113], ["ARDS", "DISEASE", 144, 148], ["vitamin D", "CHEMICAL", 59, 68], ["vitamin D", "SIMPLE_CHEMICAL", 59, 68], ["cytokine", "PROTEIN", 115, 123], ["vitamin D", "TREATMENT", 59, 68], ["pneumonia", "PROBLEM", 104, 113], ["cytokine hyperproduction", "PROBLEM", 115, 139], ["ARDS", "PROBLEM", 144, 148], ["evidence for", "UNCERTAINTY", 25, 37], ["associated with", "UNCERTAINTY", 88, 103], ["pneumonia", "OBSERVATION", 104, 113], ["cytokine hyperproduction", "OBSERVATION", 115, 139], ["ARDS", "OBSERVATION", 144, 148]]], ["1,25D has also recently been proposed as a repurposed drug for influenza A H5N1 virus-induced lung injury, an infectious disease with characteristic features similar to COVID-19 (315) .Vitamin D and COVID-19The study found that vitamin D supplementation in H5N1 virus-infected mice decreased the lung injury score, improved mouse lung edema, and increased survival of H5N1-virus infected mice.", [["lung", "ANATOMY", 94, 98], ["lung", "ANATOMY", 296, 300], ["lung edema", "ANATOMY", 330, 340], ["1,25D", "CHEMICAL", 0, 5], ["influenza A H5N1 virus", "DISEASE", 63, 85], ["lung injury", "DISEASE", 94, 105], ["infectious disease", "DISEASE", 110, 128], ["Vitamin D", "CHEMICAL", 185, 194], ["COVID-19", "CHEMICAL", 199, 207], ["vitamin D", "CHEMICAL", 228, 237], ["lung injury", "DISEASE", 296, 307], ["lung edema", "DISEASE", 330, 340], ["H5N1-virus infected", "DISEASE", 368, 387], ["1,25D", "CHEMICAL", 0, 5], ["Vitamin D", "CHEMICAL", 185, 194], ["COVID-19", "CHEMICAL", 199, 207], ["vitamin D", "CHEMICAL", 228, 237], ["1,25D", "SIMPLE_CHEMICAL", 0, 5], ["influenza A H5N1 virus", "ORGANISM", 63, 85], ["lung", "ORGAN", 94, 98], ["Vitamin D", "SIMPLE_CHEMICAL", 185, 194], ["vitamin D", "SIMPLE_CHEMICAL", 228, 237], ["H5N1 virus", "ORGANISM", 257, 267], ["mice", "ORGANISM", 277, 281], ["lung", "ORGAN", 296, 300], ["mouse", "ORGANISM", 324, 329], ["lung", "ORGAN", 330, 334], ["edema", "PATHOLOGICAL_FORMATION", 335, 340], ["H5N1-virus", "ORGANISM", 368, 378], ["mice", "ORGANISM", 388, 392], ["influenza", "SPECIES", 63, 72], ["A H5N1 virus", "SPECIES", 73, 85], ["H5N1 virus-", "SPECIES", 257, 268], ["mice", "SPECIES", 277, 281], ["mouse", "SPECIES", 324, 329], ["H5N1-virus", "SPECIES", 368, 378], ["mice", "SPECIES", 388, 392], ["influenza A H5N1 virus", "SPECIES", 63, 85], ["H5N1 virus", "SPECIES", 257, 267], ["mice", "SPECIES", 277, 281], ["mouse", "SPECIES", 324, 329], ["H5N1-virus", "SPECIES", 368, 378], ["mice", "SPECIES", 388, 392], ["a repurposed drug", "TREATMENT", 41, 58], ["influenza", "PROBLEM", 63, 72], ["A H5N1 virus", "PROBLEM", 73, 85], ["lung injury", "PROBLEM", 94, 105], ["an infectious disease", "PROBLEM", 107, 128], ["characteristic features", "PROBLEM", 134, 157], ["COVID", "TEST", 169, 174], ["Vitamin D", "TREATMENT", 185, 194], ["COVID", "TEST", 199, 204], ["The study", "TEST", 207, 216], ["vitamin D supplementation", "TREATMENT", 228, 253], ["H5N1 virus", "PROBLEM", 257, 267], ["infected mice", "PROBLEM", 268, 281], ["the lung injury score", "PROBLEM", 292, 313], ["improved mouse lung edema", "PROBLEM", 315, 340], ["H5N1", "PROBLEM", 368, 372], ["lung", "ANATOMY", 94, 98], ["injury", "OBSERVATION", 99, 105], ["infectious", "OBSERVATION", 110, 120], ["lung", "ANATOMY", 296, 300], ["injury", "OBSERVATION", 301, 307], ["improved", "OBSERVATION_MODIFIER", 315, 323], ["mouse", "OBSERVATION_MODIFIER", 324, 329], ["lung", "ANATOMY", 330, 334], ["edema", "OBSERVATION", 335, 340], ["increased", "OBSERVATION_MODIFIER", 346, 355]]], ["Moreover, vitamin D treatment was beneficial in animal models of ARDS as 1,25D was shown to reduce LPSinduced-increased lung permeability by regulating activity of the renin-angiotensin system and expression of angiotensin converting enzyme 2 (ACE2), the host cell receptor responsible for mediating infection by SARS-CoV-2 (316) .", [["lung", "ANATOMY", 120, 124], ["cell", "ANATOMY", 260, 264], ["vitamin D", "CHEMICAL", 10, 19], ["ARDS", "DISEASE", 65, 69], ["1,25D", "CHEMICAL", 73, 78], ["angiotensin", "CHEMICAL", 174, 185], ["angiotensin", "CHEMICAL", 211, 222], ["infection", "DISEASE", 300, 309], ["vitamin D", "CHEMICAL", 10, 19], ["1,25D", "CHEMICAL", 73, 78], ["vitamin D", "SIMPLE_CHEMICAL", 10, 19], ["1,25D", "SIMPLE_CHEMICAL", 73, 78], ["LPSinduced", "SIMPLE_CHEMICAL", 99, 109], ["lung", "ORGAN", 120, 124], ["renin-angiotensin", "GENE_OR_GENE_PRODUCT", 168, 185], ["angiotensin converting enzyme 2", "GENE_OR_GENE_PRODUCT", 211, 242], ["ACE2", "GENE_OR_GENE_PRODUCT", 244, 248], ["host cell receptor", "GENE_OR_GENE_PRODUCT", 255, 273], ["SARS-CoV-2", "ORGANISM", 313, 323], ["renin", "PROTEIN", 168, 173], ["angiotensin converting enzyme 2", "PROTEIN", 211, 242], ["ACE2", "PROTEIN", 244, 248], ["host cell receptor", "PROTEIN", 255, 273], ["SARS-CoV", "SPECIES", 313, 321], ["vitamin D treatment", "TREATMENT", 10, 29], ["ARDS", "PROBLEM", 65, 69], ["increased lung permeability", "PROBLEM", 110, 137], ["the renin-angiotensin system", "TREATMENT", 164, 192], ["angiotensin converting enzyme", "PROBLEM", 211, 240], ["the host cell receptor", "TREATMENT", 251, 273], ["mediating infection", "PROBLEM", 290, 309], ["CoV", "TEST", 318, 321], ["increased", "OBSERVATION_MODIFIER", 110, 119], ["lung", "ANATOMY", 120, 124], ["permeability", "OBSERVATION", 125, 137], ["infection", "OBSERVATION", 300, 309]]], ["Consistent with this, gene set enrichment analysis of genomic datasets identified the VDR as being co-expressed with both ACE2 and FURIN genes, both of which have a key role in promoting high-affinity binding of viruses and their entry into human cells, in human tissues (317) .", [["cells", "ANATOMY", 247, 252], ["tissues", "ANATOMY", 263, 270], ["VDR", "GENE_OR_GENE_PRODUCT", 86, 89], ["ACE2", "GENE_OR_GENE_PRODUCT", 122, 126], ["FURIN", "GENE_OR_GENE_PRODUCT", 131, 136], ["human", "ORGANISM", 241, 246], ["cells", "CELL", 247, 252], ["human", "ORGANISM", 257, 262], ["tissues", "TISSUE", 263, 270], ["VDR", "PROTEIN", 86, 89], ["ACE2 and FURIN genes", "DNA", 122, 142], ["human cells", "CELL_TYPE", 241, 252], ["human", "SPECIES", 241, 246], ["human", "SPECIES", 257, 262], ["human", "SPECIES", 241, 246], ["human", "SPECIES", 257, 262], ["gene set enrichment analysis", "TEST", 22, 50], ["genomic datasets", "PROBLEM", 54, 70], ["the VDR", "PROBLEM", 82, 89], ["human tissues", "ANATOMY", 257, 270]]], ["The study also reported that 1,25D altered expression of genes encoding human proteins for 19 of 27 (70%) of SARS-CoV-2 proteins.", [["1,25", "CHEMICAL", 29, 33], ["SARS", "DISEASE", 109, 113], ["1,25D", "CHEMICAL", 29, 34], ["1,25D", "SIMPLE_CHEMICAL", 29, 34], ["human", "ORGANISM", 72, 77], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 109, 119], ["human proteins", "PROTEIN", 72, 86], ["SARS-CoV-2 proteins", "PROTEIN", 109, 128], ["human", "SPECIES", 72, 77], ["human", "SPECIES", 72, 77], ["SARS-CoV", "SPECIES", 109, 117], ["The study", "TEST", 0, 9], ["encoding human proteins", "TEST", 63, 86], ["SARS", "TEST", 109, 113], ["CoV", "TEST", 114, 117]]], ["Vitamin D deficiency in individuals self-isolating due to the COVID-19 pandemic may be aggravated by confinement indoors, a condition that could be reversed by short, daily exposures to the sun in the middle of day (318) .", [["Vitamin D", "CHEMICAL", 0, 9], ["Vitamin D", "CHEMICAL", 0, 9], ["Vitamin D", "SIMPLE_CHEMICAL", 0, 9], ["Vitamin D deficiency", "PROBLEM", 0, 20]]], ["Moderate exposure to sunlight would promote sufficient vitamin D production in the skin from March through to September in most countries in northern latitudes.Vitamin D and COVID-19Several epidemiological findings support a therapeutic role for vitamin D in COVID-19 pathogenesis.", [["skin", "ANATOMY", 83, 87], ["vitamin D", "CHEMICAL", 55, 64], ["Vitamin D", "CHEMICAL", 160, 169], ["vitamin D", "CHEMICAL", 246, 255], ["vitamin D", "CHEMICAL", 55, 64], ["Vitamin D", "CHEMICAL", 160, 169], ["COVID-19Several", "CHEMICAL", 174, 189], ["vitamin D", "CHEMICAL", 246, 255], ["vitamin D", "SIMPLE_CHEMICAL", 55, 64], ["skin", "ORGAN", 83, 87], ["Vitamin D", "SIMPLE_CHEMICAL", 160, 169], ["vitamin D", "SIMPLE_CHEMICAL", 246, 255], ["COVID-19", "CELL", 259, 267], ["Moderate exposure", "PROBLEM", 0, 17], ["sunlight", "TREATMENT", 21, 29], ["sufficient vitamin D production", "TREATMENT", 44, 75], ["Vitamin D", "TREATMENT", 160, 169], ["COVID", "TREATMENT", 174, 179], ["vitamin D in COVID", "TREATMENT", 246, 264], ["skin", "ANATOMY", 83, 87]]], ["As an example, Australia is one week behind the UK in the spread of the virus, however if one compares the mortality (68 per million) in the UK with the mortality (2 per million) in Australia at corresponding dates in the pandemic, there is a large discrepancy.", [["the virus", "PROBLEM", 68, 77], ["a large discrepancy", "PROBLEM", 241, 260], ["virus", "OBSERVATION", 72, 77], ["pandemic", "OBSERVATION", 222, 230], ["large", "OBSERVATION_MODIFIER", 243, 248], ["discrepancy", "OBSERVATION", 249, 260]]], ["It is important to note that there are outliers; for instance, mortality is low in Scandinavian countries that instituted confinement protocols such as Norway.", [["confinement protocols", "TREATMENT", 122, 143]]], ["However, the country is relatively thinly populated and vitamin D insufficiency is rare because of widespread consumption of cod liver oil supplements as well as fortification of milk and dairy products (320) .", [["liver oil", "ANATOMY", 129, 138], ["milk", "ANATOMY", 179, 183], ["vitamin D", "CHEMICAL", 56, 65], ["vitamin D", "CHEMICAL", 56, 65], ["vitamin D", "SIMPLE_CHEMICAL", 56, 65], ["liver", "ORGAN", 129, 134], ["milk", "ORGANISM_SUBSTANCE", 179, 183], ["cod", "SPECIES", 125, 128], ["vitamin D insufficiency", "PROBLEM", 56, 79], ["cod liver oil supplements", "TREATMENT", 125, 150], ["milk and dairy products", "TREATMENT", 179, 202], ["relatively", "OBSERVATION_MODIFIER", 24, 34], ["thinly", "OBSERVATION_MODIFIER", 35, 41], ["populated", "OBSERVATION", 42, 51], ["liver", "ANATOMY", 129, 134]]], ["Conversely, Italy and Spain have higher total death counts as well as a relatively high prevalence of vitamin D deficiency, possibly due to the population's strong preference to the shade under the strong sun (321) as well as darker skin pigmentation, which decreases vitamin D synthesis (322) .", [["skin", "ANATOMY", 233, 237], ["death", "DISEASE", 46, 51], ["vitamin D", "CHEMICAL", 102, 111], ["vitamin D", "CHEMICAL", 268, 277], ["vitamin D", "CHEMICAL", 102, 111], ["vitamin D", "CHEMICAL", 268, 277], ["vitamin D", "SIMPLE_CHEMICAL", 102, 111], ["skin", "ORGAN", 233, 237], ["vitamin D", "SIMPLE_CHEMICAL", 268, 277], ["higher total death counts", "PROBLEM", 33, 58], ["vitamin D deficiency", "PROBLEM", 102, 122], ["darker skin pigmentation", "PROBLEM", 226, 250], ["vitamin D synthesis", "TREATMENT", 268, 287], ["skin", "ANATOMY", 233, 237], ["pigmentation", "OBSERVATION", 238, 250]]], ["Another trend observed is the number of COVID-19 case-fatality rates that increase with age and chronic disease comorbidity, both of which are associated with lower serum 25D levels (323) (324) (325) (326) .Vitamin D and COVID-19One recent study suggested a crude negative correlation between mean vitamin D levels in European countries and the number of COVID-19 cases and deaths caused by the disease (327); in contrast, another group that explored COVID-19 transmission and UV radiation in 62 Chinese cities did not find evidence for such an association (328) .", [["serum", "ANATOMY", 165, 170], ["Vitamin D", "CHEMICAL", 207, 216], ["vitamin D", "CHEMICAL", 298, 307], ["deaths", "DISEASE", 374, 380], ["UV", "CHEMICAL", 477, 479], ["25D", "CHEMICAL", 171, 174], ["Vitamin D", "CHEMICAL", 207, 216], ["COVID-19One", "CHEMICAL", 221, 232], ["vitamin D", "CHEMICAL", 298, 307], ["serum", "ORGANISM_SUBSTANCE", 165, 170], ["25D", "SIMPLE_CHEMICAL", 171, 174], ["Vitamin D", "SIMPLE_CHEMICAL", 207, 216], ["vitamin D", "SIMPLE_CHEMICAL", 298, 307], ["COVID", "TEST", 40, 45], ["fatality rates", "TEST", 54, 68], ["chronic disease comorbidity", "PROBLEM", 96, 123], ["Vitamin D", "TREATMENT", 207, 216], ["COVID", "TREATMENT", 221, 226], ["mean vitamin D levels", "TEST", 293, 314], ["COVID", "TEST", 355, 360], ["the disease", "PROBLEM", 391, 402], ["COVID", "TEST", 451, 456], ["UV radiation", "TREATMENT", 477, 489], ["increase", "OBSERVATION_MODIFIER", 74, 82], ["chronic", "OBSERVATION_MODIFIER", 96, 103], ["disease", "OBSERVATION", 104, 111], ["lower", "ANATOMY_MODIFIER", 159, 164]]], ["However, as mentioned earlier, randomized controlled trials and large population studies are still required to evaluate whether vitamin D could be of benefit as well as whether it could be used as a preventive or a therapeutic measure.", [["vitamin D", "CHEMICAL", 128, 137], ["vitamin D", "CHEMICAL", 128, 137], ["vitamin D", "SIMPLE_CHEMICAL", 128, 137], ["randomized controlled trials", "TREATMENT", 31, 59], ["large population studies", "TEST", 64, 88], ["vitamin D", "TREATMENT", 128, 137]]], ["Given that ethnic minorities are disproportionately affected with COVID-19 in the UK, USA, and other countries in Europe, further research is warranted, especially since there is evidence for vitamin D deficiency in these ethnic groups (329, 330) .", [["vitamin D", "CHEMICAL", 192, 201], ["vitamin D", "CHEMICAL", 192, 201], ["vitamin D", "SIMPLE_CHEMICAL", 192, 201], ["COVID", "TEST", 66, 71], ["vitamin D deficiency", "PROBLEM", 192, 212]]], ["At this writing, there are 18 clinical trials registered (www.clinicaltrials.gov) investigating links between vitamin D and COVID-19, (331-344), a number that is growing rapidly.ConclusionsThere is strong evidence that vitamin D metabolic enzymes are expressed in virtually all cells in the innate and adaptive arms of the immune system.", [["cells", "ANATOMY", 278, 283], ["immune system", "ANATOMY", 323, 336], ["vitamin D", "CHEMICAL", 110, 119], ["vitamin D", "CHEMICAL", 219, 228], ["vitamin D", "CHEMICAL", 110, 119], ["COVID-19", "CHEMICAL", 124, 132], ["vitamin D", "CHEMICAL", 219, 228], ["vitamin D", "SIMPLE_CHEMICAL", 110, 119], ["COVID-19", "SIMPLE_CHEMICAL", 124, 132], ["vitamin D", "SIMPLE_CHEMICAL", 219, 228], ["cells", "CELL", 278, 283], ["immune system", "ANATOMICAL_SYSTEM", 323, 336], ["vitamin D metabolic enzymes", "PROTEIN", 219, 246], ["vitamin D", "TREATMENT", 110, 119], ["COVID", "TEST", 124, 129], ["vitamin D metabolic enzymes", "TEST", 219, 246], ["growing", "OBSERVATION_MODIFIER", 162, 169], ["rapidly", "OBSERVATION_MODIFIER", 170, 177], ["all cells", "OBSERVATION", 274, 283], ["immune system", "OBSERVATION", 323, 336]]], ["Considering the findings discussed above, vitamin D signaling appears to influence susceptibility to and severity of bacterial and viral infection via several mechanisms.", [["vitamin D", "CHEMICAL", 42, 51], ["bacterial and viral infection", "DISEASE", 117, 146], ["vitamin D", "CHEMICAL", 42, 51], ["vitamin D", "SIMPLE_CHEMICAL", 42, 51], ["vitamin D signaling", "PROBLEM", 42, 61], ["bacterial and viral infection", "PROBLEM", 117, 146], ["bacterial", "OBSERVATION", 117, 126], ["viral infection", "OBSERVATION", 131, 146]]], ["These include its direct effects on the production of antimicrobial peptides and cytokines as well as its regulation of the NF-\u03baB pathway during infection.", [["infection", "DISEASE", 145, 154], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 124, 129], ["cytokines", "PROTEIN", 81, 90], ["NF-\u03baB", "PROTEIN", 124, 129], ["antimicrobial peptides", "TREATMENT", 54, 76], ["cytokines", "TREATMENT", 81, 90], ["the NF", "TREATMENT", 120, 126], ["infection", "PROBLEM", 145, 154], ["infection", "OBSERVATION", 145, 154]]], ["Overall, preclinical and clinical data propose a strong link between vitamin D status and susceptibility to infectious and autoimmune diseases.", [["vitamin D", "CHEMICAL", 69, 78], ["infectious and autoimmune diseases", "DISEASE", 108, 142], ["vitamin D", "CHEMICAL", 69, 78], ["vitamin D", "SIMPLE_CHEMICAL", 69, 78], ["a strong link between vitamin D status", "PROBLEM", 47, 85], ["autoimmune diseases", "PROBLEM", 123, 142], ["infectious", "OBSERVATION_MODIFIER", 108, 118]]], ["There is evidence that vitamin D deficiency during early life may predispose the immune system to a greater risk of autoimmune disease or allergy (345) .", [["vitamin D", "CHEMICAL", 23, 32], ["autoimmune disease", "DISEASE", 116, 134], ["allergy", "DISEASE", 138, 145], ["vitamin D", "CHEMICAL", 23, 32], ["vitamin D", "SIMPLE_CHEMICAL", 23, 32], ["vitamin D deficiency", "PROBLEM", 23, 43], ["autoimmune disease", "PROBLEM", 116, 134], ["allergy", "PROBLEM", 138, 145], ["vitamin D deficiency", "OBSERVATION", 23, 43], ["autoimmune", "OBSERVATION", 116, 126]]], ["Several laboratory and clinical studies have provided support for a role of vitamin D in combating respiratory tract infections.", [["respiratory tract", "ANATOMY", 99, 116], ["vitamin D", "CHEMICAL", 76, 85], ["respiratory tract infections", "DISEASE", 99, 127], ["vitamin D", "CHEMICAL", 76, 85], ["vitamin D", "SIMPLE_CHEMICAL", 76, 85], ["respiratory tract", "ORGANISM_SUBDIVISION", 99, 116], ["clinical studies", "TEST", 23, 39], ["vitamin D", "TREATMENT", 76, 85], ["respiratory tract infections", "PROBLEM", 99, 127], ["respiratory tract", "ANATOMY", 99, 116], ["infections", "OBSERVATION", 117, 127]]], ["Evaluation of vitamin D supplementation as an adjuvant therapeutic intervention could be clinically and economically significant in the ongoing COVID-19 crisis, as well as in the treatment of other infectious diseases.", [["vitamin D", "CHEMICAL", 14, 23], ["infectious diseases", "DISEASE", 198, 217], ["vitamin D", "CHEMICAL", 14, 23], ["vitamin D", "SIMPLE_CHEMICAL", 14, 23], ["Evaluation", "TEST", 0, 10], ["vitamin D supplementation", "TREATMENT", 14, 39], ["an adjuvant therapeutic intervention", "TREATMENT", 43, 79], ["the ongoing COVID", "TEST", 132, 149], ["other infectious diseases", "PROBLEM", 192, 217], ["infectious", "OBSERVATION", 198, 208]]], ["Based on the immunoregulatory properties of vitamin D presented above, improving circulating 25D levels may slow progression of disease or even ameliorate patient survival.", [["vitamin D", "CHEMICAL", 44, 53], ["vitamin D", "CHEMICAL", 44, 53], ["vitamin D", "SIMPLE_CHEMICAL", 44, 53], ["25D", "SIMPLE_CHEMICAL", 93, 96], ["patient", "ORGANISM", 155, 162], ["patient", "SPECIES", 155, 162], ["vitamin D", "TREATMENT", 44, 53], ["slow progression of disease", "PROBLEM", 108, 135]]], ["Though the evidence for a mechanistic role for vitamin D signaling in immune system regulation is highly compelling, there is still a need for large-scale RCTs to confirm whether maintaining vitamin D sufficiency reduces the incidence and severity of infections and/or autoimmune diseases.Conflict of InterestThe authors have no conflict of interest to declare.Author contributionsELB was involved in the conceptualization, visualization, writing, reviewing and editing of the manuscript.", [["immune system", "ANATOMY", 70, 83], ["vitamin D", "CHEMICAL", 47, 56], ["vitamin D", "CHEMICAL", 191, 200], ["infections", "DISEASE", 251, 261], ["autoimmune diseases", "DISEASE", 269, 288], ["vitamin D", "CHEMICAL", 47, 56], ["vitamin D", "CHEMICAL", 191, 200], ["vitamin D", "SIMPLE_CHEMICAL", 47, 56], ["vitamin D", "SIMPLE_CHEMICAL", 191, 200], ["vitamin D signaling", "TREATMENT", 47, 66], ["large-scale RCTs", "TREATMENT", 143, 159], ["vitamin D sufficiency", "TREATMENT", 191, 212], ["infections", "PROBLEM", 251, 261], ["autoimmune diseases", "PROBLEM", 269, 288], ["infections", "OBSERVATION", 251, 261], ["autoimmune diseases", "OBSERVATION", 269, 288]]], ["MH was involved in conceptualization, investigation and administration of the project, as well as supervision, visualization, writing, review & editing of the manuscript.", [["MH", "DISEASE", 0, 2]]]], "7c1b76a985da7b0e69f00d79ae8da7eb3272fec5": [["IntroductionLet H be a complex Hilbert space with inner product \u27e8\u22c5, \u22c5\u27e9 and L(H) be the C * -algebra of all bounded linear operators on H. The numerical range of T \u2208 B(H) is defined asIntroductionThe numerical radius of T , denoted by w(T ), is defined as w(T ) = sup{ z \u2236 z \u2208 W (T )}.", [["H", "CHEMICAL", 77, 78], ["H", "CHEMICAL", 167, 168], ["a complex Hilbert space", "TREATMENT", 21, 44], ["inner product", "TREATMENT", 50, 63], ["z", "TEST", 268, 269]]], ["It is well-known that w(\u22c5) defines a norm on H, and is equivalent to the usual operator norm T = sup{ T x \u2236 x \u2208 H, x = 1}.", [["T x \u2236 x \u2208 H", "TEST", 102, 113]]], ["In fact, for every T \u2208 B(H), Here onward, we fix A and A for positive operators on H and H \u2295 H, respectively.", [["H", "CHEMICAL", 83, 84], ["H \u2295 H", "CHEMICAL", 89, 94], ["H \u2295 H", "SIMPLE_CHEMICAL", 89, 94]]], ["T A denotes the A-operator seminorm of T \u2208 L(H).", [["T \u2208 L", "GENE_OR_GENE_PRODUCT", 39, 44]]], ["Note that if T is A-positive, thenIntroductionAn operator X \u2208 B(H) is called an A-adjoint operator of T \u2208 B(H) if \u27e8T x, y\u27e9 A = \u27e8x, Xy\u27e9 A for every x, y \u2208 H, i.e., AX = T * A. By Douglas Theorem [9] , the existence of an A-adjoint operator is not guaranteed.", [["AX", "CHEMICAL", 163, 165], ["H", "CHEMICAL", 108, 109], ["H", "CHEMICAL", 154, 155], ["AX", "TEST", 163, 165], ["Douglas Theorem", "TEST", 178, 193]]], ["An operator T \u2208 B(H) may admit none, one or many A-adjoints. hold with equality if A is injective and has a closed range.", [["closed", "OBSERVATION", 108, 114]]], ["The Moore-Penrose inverse of A \u2208 B(H) [16] is the operator X \u2236 R(A) \u2295 R(A) \u22a5 \u2192 H which satisfies the following four equations:IntroductionHere N(A) and P L denote the null space of A and the orthogonal projection onto L, respectively.", [["H", "CHEMICAL", 35, 36], ["H", "CHEMICAL", 79, 80], ["P L", "PROTEIN", 152, 155], ["null space", "OBSERVATION", 167, 177]]], ["The Moore-Penrose inverse is unique, and is denoted by A \u2020 .", [["Penrose inverse", "OBSERVATION_MODIFIER", 10, 25]]], ["An operatorIntroductionBy applying Douglas theorem, one can easily see that the subspace of all operators admitting A 1 2 -adjoints, denoted by L A 1 2 (H), is equal the collection of all A-bounded operators, i.e.,IntroductionNotice that L A (H) and L A 1 2 (H) are two subalgebras of L(H) which are, in general, neither closed nor dense in L(H).", [["H", "CHEMICAL", 259, 260], ["H", "CHEMICAL", 287, 288], ["H", "CHEMICAL", 343, 344], ["Douglas theorem", "TREATMENT", 35, 50], ["equal", "OBSERVATION_MODIFIER", 160, 165], ["L", "ANATOMY_MODIFIER", 285, 286], ["closed", "OBSERVATION", 321, 327], ["dense", "OBSERVATION_MODIFIER", 332, 337], ["L", "ANATOMY_MODIFIER", 341, 342]]], ["Moreover, we have L A (H) \u2282 L A 1 2 (H) (see [2, 3] ).IntroductionIn 2012, Saddi [19] introduced A-numerical radius of T for T \u2208 B(H), which is denoted as w A (T ), and is defined as follows:IntroductionA fundamental inequality for the A-numerical radius is the power inequality (see [15] ) which says that for T \u2208 B(H),IntroductionNotice that the A-numerical radius of semi-Hilbertian space operators satisfies the weak A-unitary invariance property which asserts thatIntroduction(1.5) 3 for every T \u2208 L A (H) and every A-unitary operator U \u2208 L A (H) (see [7, Lemma 3.8] ).IntroductionAn interested reader may refer [1, 2] for further properties of operators on Semi-Hilbertian space.IntroductionLetIntroductionfor any arbitrary operator T \u2208 B A (H).", [["the A-numerical radius", "TREATMENT", 232, 254], ["the A-numerical radius of semi-Hilbertian space operators", "TREATMENT", 344, 401]]], ["Recently, in 2019 Zamani [24, Theorem 2.5] showed that if T \u2208 L A (H), thenIntroductionIn 2019, Zamani [24] showed that if T \u2208 L A (H), thenIntroduction(1.7)IntroductionThe author then extended the inequality (1.1) using A-numerical radius of T , and the same is produced below:IntroductionIn 2019, Moslehian et al. [15] again continued the study of A-numerical radius and established some inequalities for A-numerical radius.", [["H", "CHEMICAL", 132, 133], ["the study", "TEST", 337, 346], ["A-numerical radius", "TREATMENT", 350, 368], ["A-numerical radius", "PROBLEM", 407, 425]]], ["Further generalizations and refinements of A-numerical radius are discussed in [5, 6, 17] .", [["A-numerical radius", "TREATMENT", 43, 61]]], ["For the sequel, if A = I, then T , r(T ) and \u03c9(T ) denote respectively the classical operator norm, the spectral radius and the numerical radius of an operator T .", [["the spectral radius", "TREATMENT", 100, 119], ["spectral radius", "ANATOMY", 104, 119]]], ["In this aspect, the rest of the paper is broken down as follows.", [["broken", "OBSERVATION", 41, 47]]], ["In 4 section 2, we collect a few results about A-numerical radius inequalities which are required to state and prove the results in the subsequent section.", [["A-numerical radius inequalities", "PROBLEM", 47, 78]]], ["Section 3 contains our main results, and is of two parts.", [["main", "OBSERVATION_MODIFIER", 23, 27]]], ["[Theorem 7 and corollary 2, [11] ] If T \u2208 L A 1 2 (H).ThenPreliminariesThe following lemma is already proved by Bhunia et al. [8] for the case strictly positive operator A. Very recentely the same result proved by Rout et al. [18] without the condition A > 0 is stated next for our purpose.PreliminariesThe following Lemma is proved by Rout et al. [18] .PreliminariesLemma 2.6.", [["ThenPreliminaries", "CHEMICAL", 54, 71], ["corollary 2, [11]", "SIMPLE_CHEMICAL", 15, 32], ["Theorem", "TEST", 1, 8]]], ["[Lemma 2.4 and Lemma 3.1, [10, 7] ] Let T 1 , T 4 \u2208 L A 1 2 (H).", [["10, 7] ]", "SIMPLE_CHEMICAL", 27, 35], ["Let T 1", "GENE_OR_GENE_PRODUCT", 36, 43], ["Lemma", "TEST", 1, 6], ["Lemma", "TEST", 15, 20], ["T", "TEST", 46, 47]]], ["The first part deals with A-numerical radius of 2 \u00d7 2 operator matrices.", [["A-numerical radius of 2 \u00d7 2 operator matrices", "TREATMENT", 26, 71]]], ["The second part concerns some upper bound for A numerical radius inequalities.Certain A-numerical radius inequalities of operator matricesHere, we establish our main results dealing with different upper and lower bounds for Anumerical radius of 2 \u00d7 2 block operator matrices.", [["upper", "ORGANISM_SUBDIVISION", 197, 202], ["some upper bound", "PROBLEM", 25, 41], ["different upper and lower bounds", "PROBLEM", 187, 219], ["Anumerical radius", "TREATMENT", 224, 241], ["upper bound", "OBSERVATION_MODIFIER", 30, 41], ["upper", "ANATOMY_MODIFIER", 197, 202]]], ["The very first result is stated next.Certain A-numerical radius inequalities of operator matrices6This in turn impliesNow, using identity (2.3) and Lemma 2.4, we haveThis in turn impliesReplacing T 3 by \u2212T 3 in the inequality (3.1) and using Lemma 2.4, we getThis in turn impliesFrom the inequalities (3.1) and (3.2), we haveThis in turn impliesAgain, in the inequality (3.3), interchanging T 2 and T 3 and using Lemma 2.4(ii), we getThis in turn impliesFrom the inequalities (3.3) and (3.4), we getThis in turn impliesThis completes the proof.This in turn implies(3.6)This in turn impliesThis impliesThis in turn impliesWhich in turn implies thatThis in turn impliesThus, using inequality (2.3) and Lemma 2.4This in turn impliesReplacing T 3 by \u2212T 3 in the inequality (3.7) we haveThis in turn impliesNow from inequality (3.7) and (3.8) thatThis in turn impliesInterchanging T 2 and T 3 in the ininequality (3.9), we getThis in turn implies(3.10)This in turn impliesFrom inequalities (3.9) and (3.10), we haveThis in turn impliesWhich proves the first inequality.", [["T 3", "GENE_OR_GENE_PRODUCT", 196, 199], ["T 3", "GENE_OR_GENE_PRODUCT", 739, 742], ["T 3", "GENE_OR_GENE_PRODUCT", 884, 887], ["Lemma", "TEST", 242, 247], ["Lemma", "TEST", 413, 418]]], ["Again, by identity (3.5) and inequality (2.3) thatThis in turn impliesThus,This in turn impliesReplacing T 3 by \u2212T 3 in the inequality (3.12) and using Lemma 2.4, we getThis in turn impliesIt follows from inequalities (3.12) and (3.13) thatThis in turn implies(3.14)This in turn impliesInterchanging T 2 and T 3 in the inequality (3.14) and using Lemma 2.4, we get maxThis in turn impliesNow combining (3.14) and (3.15), we have maxThis in turn impliesThis completes the proof.Proof.", [["T 3", "GENE_OR_GENE_PRODUCT", 308, 311], ["Lemma", "TEST", 347, 352]]], ["Based on Lemma 2.5, Lemma 2.4 and Theorem 3.3 we haveProof.", [["Lemma", "TEST", 9, 14], ["Lemma", "TEST", 20, 25], ["Theorem", "TEST", 34, 41]]], ["Let us considerThe following lemma is already proved by Hirzallah et al. [13] for the case of Hilbert space operators.", [["Hilbert space operators", "TREATMENT", 94, 117]]], ["Using similar techinque we can prove this lemma for the case of semi-Hilbert space.", [["semi-Hilbert space", "PROBLEM", 64, 82]]], ["Let us considerand P \u2212 Q = ((T 1 + T 2 )(T 1 \u2212 T 2 )) n .", [["P", "DNA", 19, 20], ["Let us", "TEST", 0, 6], ["P", "TEST", 19, 20]]], ["Let us considerFrom inequality (2.1), combining inequality (3.23) and (3.24), we obtainSome A-numerical radius inequalities for operatorsIn this subsection we establish some upper bounds for A-numerical radius of operators.", [["A-numerical radius of operators", "TREATMENT", 191, 222], ["upper", "ANATOMY_MODIFIER", 174, 179]]], ["In the next result, we derive an upper bound for A-numerical radius of product of operators on semi-Hilbertian space.Some A-numerical radius inequalities for operatorsTheorem 3.7.", [["an upper bound", "PROBLEM", 30, 44], ["A-numerical radius of product of operators on semi-Hilbertian space", "TREATMENT", 49, 116], ["Theorem", "TEST", 167, 174], ["radius inequalities", "OBSERVATION", 134, 153]]], ["Let T 1 , T 2 \u2208 L A (H).", [["Let T 1", "GENE_OR_GENE_PRODUCT", 0, 7]]], ["So, by Lemma 2.2 we have R A (e i\u03b8 T 1 T 2 ) A = w A (R A (e i\u03b8 T 1 T 2 )).Some A-numerical radius inequalities for operatorsSo,Some A-numerical radius inequalities for operatorsSo by applying Lemma 2.2 we see thatSome A-numerical radius inequalities for operatorsSo, by using (1.10) we haveSome A-numerical radius inequalities for operatorsSo by taking supremum over \u03b8 \u2208 R, then using 1.6 we get our desired result.", [["Some A-numerical radius inequalities", "TREATMENT", 291, 327], ["radius inequalities", "OBSERVATION", 92, 111]]]], "PMC7164918": [["While the diversity of these paths is impressive, we now must merge efforts to meet a collective need.", [["impressive", "OBSERVATION_MODIFIER", 38, 48]]], ["Focused efforts of 3D printing enthusiasts and 3D printing laboratories can help address the critical shortage of personal protective equipment (PPE) during the global COVID-19 pandemic.", [["3D printing enthusiasts", "TREATMENT", 19, 42], ["3D printing laboratories", "TEST", 47, 71], ["the global COVID", "TEST", 157, 173], ["pandemic", "PROBLEM", 177, 185]]], ["The purpose of this letter is to discuss the role of 3D printing particularly in the production of face shields, examine its feasibility and adherence under new CDC and FDA pandemic guidelines, and recommend a focused effort by 3D printing hobbyists and industries alike.", [["3D printing", "TREATMENT", 53, 64], ["face shields", "TREATMENT", 99, 111]]]], "7d4411027e3eda774dd191249580f42ef6f396f4": [["IntroductionIt was recently described that COVID-19 pneumonia patients had an atypical form of the ARDS syndrome suggesting instead hyperperfusion of gasless alveolar tissue.", [["alveolar tissue", "ANATOMY", 158, 173], ["pneumonia", "DISEASE", 52, 61], ["ARDS syndrome", "DISEASE", 99, 112], ["hyperperfusion", "DISEASE", 132, 146], ["COVID-19", "ORGANISM", 43, 51], ["patients", "ORGANISM", 62, 70], ["alveolar tissue", "TISSUE", 158, 173], ["patients", "SPECIES", 62, 70], ["COVID", "TEST", 43, 48], ["pneumonia", "PROBLEM", 52, 61], ["the ARDS syndrome", "PROBLEM", 95, 112], ["hyperperfusion of gasless alveolar tissue", "PROBLEM", 132, 173], ["pneumonia", "OBSERVATION", 52, 61], ["atypical", "OBSERVATION_MODIFIER", 78, 86], ["ARDS syndrome", "OBSERVATION", 99, 112], ["hyperperfusion", "OBSERVATION_MODIFIER", 132, 146], ["gasless", "OBSERVATION_MODIFIER", 150, 157], ["alveolar tissue", "OBSERVATION", 158, 173]]], ["Increased oxygenation could be achieved through the redistribution of perfusion in response to an applied positive pressure and/or gravitational forces in these patients.", [["patients", "ORGANISM", 161, 169], ["patients", "SPECIES", 161, 169], ["Increased oxygenation", "PROBLEM", 0, 21], ["positive pressure", "TREATMENT", 106, 123], ["gravitational forces", "TREATMENT", 131, 151], ["oxygenation", "OBSERVATION", 10, 21], ["redistribution", "OBSERVATION_MODIFIER", 52, 66], ["pressure", "OBSERVATION_MODIFIER", 115, 123]]], ["Thus, the lowest possible PEEP and gentle ventilation were proposed in these patients [1] .", [["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85], ["PEEP", "TREATMENT", 26, 30], ["gentle ventilation", "TREATMENT", 35, 53]]], ["Gentle ventilation systems have often been used in the literature in the management of acute respiratory failure to improve oxygen delivery.", [["respiratory", "ANATOMY", 93, 104], ["respiratory failure", "DISEASE", 93, 112], ["oxygen", "CHEMICAL", 124, 130], ["oxygen", "CHEMICAL", 124, 130], ["oxygen", "SIMPLE_CHEMICAL", 124, 130], ["Gentle ventilation systems", "TREATMENT", 0, 26], ["the management", "TREATMENT", 69, 83], ["acute respiratory failure", "PROBLEM", 87, 112], ["oxygen delivery", "TREATMENT", 124, 139], ["acute", "OBSERVATION_MODIFIER", 87, 92], ["respiratory failure", "OBSERVATION", 93, 112]]], ["Some authors have demonstrated that the use of CPAP through a Helmet mask in the ARDS has prevented intubation in a significant number of patients [2] .", [["ARDS", "DISEASE", 81, 85], ["CPAP", "CHEMICAL", 47, 51], ["patients", "ORGANISM", 138, 146], ["patients", "SPECIES", 138, 146], ["CPAP", "TREATMENT", 47, 51], ["a Helmet mask", "TREATMENT", 60, 73], ["the ARDS", "PROBLEM", 77, 85], ["intubation", "TREATMENT", 100, 110], ["ARDS", "OBSERVATION", 81, 85]]], ["The Boussignac CPAP [3] , which is a disposable and inexpensive system, has also shown a reduction in the rate of intubation in acute respiratory failure related to cardiogenic edema [3] .", [["respiratory", "ANATOMY", 134, 145], ["acute respiratory failure", "DISEASE", 128, 153], ["cardiogenic edema", "DISEASE", 165, 182], ["CPAP", "CHEMICAL", 15, 19], ["The Boussignac CPAP", "TREATMENT", 0, 19], ["a reduction", "TREATMENT", 87, 98], ["intubation", "TREATMENT", 114, 124], ["acute respiratory failure", "PROBLEM", 128, 153], ["cardiogenic edema", "PROBLEM", 165, 182], ["reduction", "OBSERVATION_MODIFIER", 89, 98], ["acute", "OBSERVATION_MODIFIER", 128, 133], ["respiratory failure", "OBSERVATION", 134, 153], ["cardiogenic", "OBSERVATION_MODIFIER", 165, 176], ["edema", "OBSERVATION", 177, 182]]], ["In our center, the absence of necessary sterilization (disposable device) made it preferable to the conventional CPAP, which risked being \"condemned\" due to difficulties of guaranteed sterilization .IntroductionHowever, clinical illustrations in the case of management of acute respiratory failure of pneumonia COVID-19 are missing in the literature.", [["respiratory", "ANATOMY", 278, 289], ["respiratory failure", "DISEASE", 278, 297], ["pneumonia", "DISEASE", 301, 310], ["necessary sterilization (disposable device", "TREATMENT", 30, 72], ["the conventional CPAP", "TREATMENT", 96, 117], ["guaranteed sterilization", "TREATMENT", 173, 197], ["management", "TREATMENT", 258, 268], ["acute respiratory failure", "PROBLEM", 272, 297], ["pneumonia COVID", "PROBLEM", 301, 316], ["acute", "OBSERVATION_MODIFIER", 272, 277], ["respiratory failure", "OBSERVATION", 278, 297], ["pneumonia", "OBSERVATION", 301, 310]]], ["Clinicians should know the benefits and modalities of this type of treatment on the management of COVID-19 pneumonia.IntroductionWe wish to report here on the possible benefits of CPAP treatment in a patient with COVID-19 pneumonia.Patient InformationA 63-year-old patient of African origin presented to the emergency room following an influenza-like illness that had started 5 days earlier with persistent fever up to 39.2\u00b0C at home.", [["pneumonia", "DISEASE", 107, 116], ["pneumonia", "DISEASE", 222, 231], ["influenza-like illness", "DISEASE", 336, 358], ["fever", "DISEASE", 407, 412], ["CPAP", "CHEMICAL", 180, 184], ["patient", "ORGANISM", 200, 207], ["patient", "ORGANISM", 265, 272], ["patient", "SPECIES", 200, 207], ["Patient", "SPECIES", 232, 239], ["patient", "SPECIES", 265, 272], ["treatment", "TREATMENT", 67, 76], ["the management", "TREATMENT", 80, 94], ["COVID", "TEST", 98, 103], ["pneumonia", "PROBLEM", 107, 116], ["CPAP treatment", "TREATMENT", 180, 194], ["COVID", "TEST", 213, 218], ["pneumonia", "PROBLEM", 222, 231], ["an influenza-like illness", "PROBLEM", 333, 358], ["persistent fever", "PROBLEM", 396, 412], ["pneumonia", "OBSERVATION", 107, 116], ["pneumonia", "OBSERVATION", 222, 231], ["influenza", "OBSERVATION", 336, 345]]], ["The patient was working in an intensive care unit and had been in This article is part of the Topical Collection on Covid-19 contact with patients with COVID-19 pneumonia.", [["pneumonia", "DISEASE", 161, 170], ["patient", "ORGANISM", 4, 11], ["patients", "ORGANISM", 138, 146], ["patient", "SPECIES", 4, 11], ["patients", "SPECIES", 138, 146], ["COVID", "TREATMENT", 152, 157], ["pneumonia", "PROBLEM", 161, 170], ["pneumonia", "OBSERVATION", 161, 170]]], ["Other symptoms were dry cough, rhinorrhea, sore throat, agueusia, and unusually severe headache.", [["dry cough", "DISEASE", 20, 29], ["rhinorrhea", "DISEASE", 31, 41], ["sore throat", "DISEASE", 43, 54], ["agueusia", "DISEASE", 56, 64], ["headache", "DISEASE", 87, 95], ["Other symptoms", "PROBLEM", 0, 14], ["dry cough", "PROBLEM", 20, 29], ["rhinorrhea", "PROBLEM", 31, 41], ["sore throat", "PROBLEM", 43, 54], ["agueusia", "PROBLEM", 56, 64], ["unusually severe headache", "PROBLEM", 70, 95], ["cough", "OBSERVATION", 24, 29], ["rhinorrhea", "OBSERVATION", 31, 41], ["sore throat", "ANATOMY", 43, 54], ["severe", "OBSERVATION_MODIFIER", 80, 86], ["headache", "OBSERVATION", 87, 95]]], ["No NSAIDs, ACE inhibitors/ sartans, or corticosteroids.", [["NSAIDs", "CHEMICAL", 3, 9], ["ACE inhibitors/ sartans", "CHEMICAL", 11, 34], ["sartans", "CHEMICAL", 27, 34], ["corticosteroids", "CHEMICAL", 39, 54], ["NSAIDs", "SIMPLE_CHEMICAL", 3, 9], ["ACE inhibitors", "SIMPLE_CHEMICAL", 11, 25], ["sartans", "SIMPLE_CHEMICAL", 27, 34], ["corticosteroids", "SIMPLE_CHEMICAL", 39, 54], ["NSAIDs", "TREATMENT", 3, 9], ["ACE inhibitors", "TREATMENT", 11, 25], ["sartans", "TREATMENT", 27, 34], ["corticosteroids", "TREATMENT", 39, 54], ["NSAIDs", "OBSERVATION", 3, 9]]], ["Previous medical history included systemic hypertension controlled with Amlopdipine, type II diabetes treated with Metformin, well-controlled hypothyroidism, and grade 2 obesity.Patient InformationHigh-resolution chest CT scan revealed extensive ground glass opacities occupying more than 50% of the pulmonary parenchyma.", [["pulmonary parenchyma", "ANATOMY", 300, 320], ["hypertension", "DISEASE", 43, 55], ["Amlopdipine", "CHEMICAL", 72, 83], ["type II diabetes", "DISEASE", 85, 101], ["Metformin", "CHEMICAL", 115, 124], ["hypothyroidism", "DISEASE", 142, 156], ["obesity", "DISEASE", 170, 177], ["Amlopdipine", "CHEMICAL", 72, 83], ["Metformin", "CHEMICAL", 115, 124], ["Amlopdipine", "SIMPLE_CHEMICAL", 72, 83], ["Metformin", "SIMPLE_CHEMICAL", 115, 124], ["pulmonary parenchyma", "MULTI-TISSUE_STRUCTURE", 300, 320], ["Patient", "SPECIES", 178, 185], ["systemic hypertension", "PROBLEM", 34, 55], ["Amlopdipine", "TREATMENT", 72, 83], ["type II diabetes", "PROBLEM", 85, 101], ["Metformin", "TREATMENT", 115, 124], ["well-controlled hypothyroidism", "PROBLEM", 126, 156], ["grade 2 obesity", "PROBLEM", 162, 177], ["High-resolution chest CT scan", "TEST", 197, 226], ["extensive ground glass opacities", "PROBLEM", 236, 268], ["systemic", "OBSERVATION_MODIFIER", 34, 42], ["hypertension", "OBSERVATION", 43, 55], ["hypothyroidism", "OBSERVATION", 142, 156], ["grade 2", "OBSERVATION_MODIFIER", 162, 169], ["obesity", "OBSERVATION", 170, 177], ["chest", "ANATOMY", 213, 218], ["extensive", "OBSERVATION_MODIFIER", 236, 245], ["ground glass opacities", "OBSERVATION", 246, 268], ["pulmonary", "ANATOMY", 300, 309], ["parenchyma", "ANATOMY_MODIFIER", 310, 320]]], ["Biology revealed a mild inflammatory syndrome with a CRP of 43 mg/dl with no hematological abnormalities.", [["hematological", "ANATOMY", 77, 90], ["hematological abnormalities", "DISEASE", 77, 104], ["CRP", "GENE_OR_GENE_PRODUCT", 53, 56], ["CRP", "PROTEIN", 53, 56], ["a mild inflammatory syndrome", "PROBLEM", 17, 45], ["a CRP", "TEST", 51, 56], ["hematological abnormalities", "PROBLEM", 77, 104], ["mild", "OBSERVATION_MODIFIER", 19, 23], ["inflammatory syndrome", "OBSERVATION", 24, 45], ["no", "UNCERTAINTY", 74, 76], ["hematological", "ANATOMY", 77, 90], ["abnormalities", "OBSERVATION", 91, 104]]], ["A PCR performed on nasopharyngeal smear was positive for SARS-CoV-2.", [["nasopharyngeal smear", "ANATOMY", 19, 39], ["nasopharyngeal smear", "CANCER", 19, 39], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 57, 67], ["SARS-CoV", "SPECIES", 57, 65], ["A PCR", "TEST", 0, 5], ["nasopharyngeal smear", "TEST", 19, 39], ["SARS", "TEST", 57, 61], ["CoV", "TEST", 62, 65], ["nasopharyngeal", "ANATOMY", 19, 33]]], ["The patient had fever up to 2 days after admission (38.9\u00b0C) and then remained apyretic.", [["fever", "DISEASE", 16, 21], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["fever", "PROBLEM", 16, 21], ["apyretic", "PROBLEM", 78, 86]]], ["Oxygen saturation was 95% with 2 l oxygen(FIO2 = 28%) administered by nasal prongs.Treatments and OutcomesShe was started on hydrochloroquine for 5 days.Treatments and OutcomesOn day 3 after admission (i.e., D8 after onset of symptoms), tachypnea developed at 35 per minute and oxygen requirements increased with 4-6 l administered by oxygen mask (FIO2 = 50%) for an oxygen saturation of 93%.", [["nasal", "ANATOMY", 70, 75], ["oxygen", "CHEMICAL", 35, 41], ["hydrochloroquine", "CHEMICAL", 125, 141], ["tachypnea", "DISEASE", 237, 246], ["oxygen", "CHEMICAL", 278, 284], ["oxygen", "CHEMICAL", 335, 341], ["oxygen", "CHEMICAL", 367, 373], ["Oxygen", "CHEMICAL", 0, 6], ["oxygen", "CHEMICAL", 35, 41], ["FIO2", "CHEMICAL", 42, 46], ["hydrochloroquine", "CHEMICAL", 125, 141], ["oxygen", "CHEMICAL", 278, 284], ["oxygen", "CHEMICAL", 335, 341], ["oxygen", "CHEMICAL", 367, 373], ["Oxygen", "SIMPLE_CHEMICAL", 0, 6], ["2 l oxygen", "SIMPLE_CHEMICAL", 31, 41], ["hydrochloroquine", "SIMPLE_CHEMICAL", 125, 141], ["oxygen", "SIMPLE_CHEMICAL", 278, 284], ["oxygen", "SIMPLE_CHEMICAL", 335, 341], ["oxygen", "SIMPLE_CHEMICAL", 367, 373], ["Oxygen saturation", "TEST", 0, 17], ["2 l oxygen", "TREATMENT", 31, 41], ["FIO2", "TREATMENT", 42, 46], ["nasal prongs", "TREATMENT", 70, 82], ["Treatments", "TREATMENT", 83, 93], ["hydrochloroquine", "TREATMENT", 125, 141], ["symptoms", "PROBLEM", 226, 234], ["tachypnea", "PROBLEM", 237, 246], ["oxygen requirements", "PROBLEM", 278, 297], ["oxygen mask", "TREATMENT", 335, 346], ["FIO2", "TREATMENT", 348, 352], ["an oxygen saturation", "TEST", 364, 384], ["oxygen", "OBSERVATION_MODIFIER", 278, 284], ["requirements", "OBSERVATION_MODIFIER", 285, 297], ["increased", "OBSERVATION_MODIFIER", 298, 307]]], ["The evolution of the measured oxygen saturation, the respiratory rate, and the mechanical supports is summarized in Table 1 .Treatments and OutcomesOn day 4 faced with increasing dyspnea, 15 liters per minute oxygen was administered via a Boussignac valve and a facial mask in order to create a small positive pressure (a HEPA filter was placed in front of the expiratory leak in order to limit the aerosolization in the room) (see Fig. 1 ).", [["respiratory", "ANATOMY", 53, 64], ["facial", "ANATOMY", 262, 268], ["oxygen", "CHEMICAL", 30, 36], ["dyspnea", "DISEASE", 179, 186], ["oxygen", "CHEMICAL", 209, 215], ["oxygen", "CHEMICAL", 30, 36], ["oxygen", "CHEMICAL", 209, 215], ["oxygen", "SIMPLE_CHEMICAL", 30, 36], ["oxygen", "SIMPLE_CHEMICAL", 209, 215], ["the measured oxygen saturation", "TEST", 17, 47], ["the respiratory rate", "TEST", 49, 69], ["the mechanical supports", "TREATMENT", 75, 98], ["Treatments", "TREATMENT", 125, 135], ["increasing dyspnea", "PROBLEM", 168, 186], ["minute oxygen", "TREATMENT", 202, 215], ["a Boussignac valve", "TREATMENT", 237, 255], ["a facial mask", "TREATMENT", 260, 273], ["a small positive pressure", "TREATMENT", 293, 318], ["a HEPA filter", "TREATMENT", 320, 333], ["the expiratory leak", "PROBLEM", 357, 376], ["oxygen saturation", "OBSERVATION", 30, 47], ["respiratory rate", "OBSERVATION", 53, 69], ["increasing", "OBSERVATION_MODIFIER", 168, 178], ["dyspnea", "OBSERVATION", 179, 186], ["facial", "ANATOMY", 262, 268], ["small", "OBSERVATION_MODIFIER", 295, 300], ["positive", "OBSERVATION", 301, 309], ["pressure", "OBSERVATION_MODIFIER", 310, 318], ["expiratory leak", "OBSERVATION", 361, 376]]], ["However, our patient, although willing to accept the treatment, did not tolerate it, with a daily use of the Boussignac valve for only 2-3 h per day.Treatments and OutcomesOxygen saturation measured by pulse oximeter with the Boussignac valve was then 97%, and the respiratory rate decreased too.", [["respiratory", "ANATOMY", 265, 276], ["patient", "ORGANISM", 13, 20], ["OutcomesOxygen", "SIMPLE_CHEMICAL", 164, 178], ["Boussignac valve", "MULTI-TISSUE_STRUCTURE", 226, 242], ["patient", "SPECIES", 13, 20], ["the treatment", "TREATMENT", 49, 62], ["the Boussignac valve", "TREATMENT", 105, 125], ["Treatments", "TREATMENT", 149, 159], ["OutcomesOxygen saturation", "TEST", 164, 189], ["pulse oximeter", "TEST", 202, 216], ["the Boussignac valve", "TREATMENT", 222, 242], ["the respiratory rate", "TEST", 261, 281]]], ["Unfortunately, this saturation was not maintained when the patient removed her mask.", [["patient", "ORGANISM", 59, 66], ["patient", "SPECIES", 59, 66], ["this saturation", "TEST", 15, 30], ["her mask", "TREATMENT", 75, 83]]], ["There was a drop in oxygen saturation when measured under 6 l (FIO2, 50%\u00b0) of administered oxygen.Treatments and OutcomesOn day 6 a sudden deterioration was observed; an increase in oxygen requirements and a very significant increase in the inflammatory syndrome were observed with a CRP 175.2 mg/ dl (see Table 1 ).", [["oxygen", "CHEMICAL", 20, 26], ["oxygen", "CHEMICAL", 91, 97], ["oxygen", "CHEMICAL", 182, 188], ["oxygen", "CHEMICAL", 20, 26], ["oxygen", "CHEMICAL", 91, 97], ["oxygen", "CHEMICAL", 182, 188], ["oxygen", "SIMPLE_CHEMICAL", 20, 26], ["oxygen", "SIMPLE_CHEMICAL", 91, 97], ["oxygen", "SIMPLE_CHEMICAL", 182, 188], ["CRP", "PROTEIN", 284, 287], ["a drop in oxygen saturation", "PROBLEM", 10, 37], ["FIO2", "TREATMENT", 63, 67], ["oxygen", "TREATMENT", 91, 97], ["a sudden deterioration", "PROBLEM", 130, 152], ["an increase in oxygen requirements", "PROBLEM", 167, 201], ["the inflammatory syndrome", "PROBLEM", 237, 262], ["a CRP", "TEST", 282, 287], ["drop", "OBSERVATION_MODIFIER", 12, 16], ["oxygen saturation", "OBSERVATION", 20, 37], ["increase", "OBSERVATION_MODIFIER", 170, 178], ["oxygen requirements", "OBSERVATION", 182, 201], ["very", "OBSERVATION_MODIFIER", 208, 212], ["significant", "OBSERVATION_MODIFIER", 213, 224], ["increase", "OBSERVATION_MODIFIER", 225, 233], ["inflammatory syndrome", "OBSERVATION", 241, 262]]], ["There was no neutrophil hyperleukocytosis, and the patient was apyretic.", [["neutrophil", "ANATOMY", 13, 23], ["neutrophil", "CELL", 13, 23], ["patient", "ORGANISM", 51, 58], ["patient", "SPECIES", 51, 58], ["neutrophil hyperleukocytosis", "PROBLEM", 13, 41], ["apyretic", "PROBLEM", 63, 71], ["no", "UNCERTAINTY", 10, 12], ["neutrophil hyperleukocytosis", "OBSERVATION", 13, 41]]], ["Respiratory alkalosis (pCO 2 = 27 mmHg) and hypokalemia ensued.", [["Respiratory", "ANATOMY", 0, 11], ["Respiratory alkalosis", "DISEASE", 0, 21], ["hypokalemia", "DISEASE", 44, 55], ["Respiratory alkalosis", "PROBLEM", 0, 21], ["pCO", "TEST", 23, 26], ["hypokalemia", "PROBLEM", 44, 55], ["alkalosis", "OBSERVATION", 12, 21], ["hypokalemia", "OBSERVATION", 44, 55]]], ["Saturation measured on ambient air was 82%.", [["Saturation", "TEST", 0, 10], ["ambient air", "TEST", 23, 34]]], ["With 10 l of supplemental oxygen (FIO2 = 99%) the measured saturation was 93%.", [["oxygen", "CHEMICAL", 26, 32], ["oxygen", "CHEMICAL", 26, 32], ["oxygen", "SIMPLE_CHEMICAL", 26, 32], ["supplemental oxygen", "TREATMENT", 13, 32], ["FIO2", "TEST", 34, 38], ["the measured saturation", "TEST", 46, 69]]], ["The respiratory rate was 44 per minute without the Boussignac valve.", [["respiratory", "ANATOMY", 4, 15], ["valve", "PATHOLOGICAL_FORMATION", 62, 67], ["The respiratory rate", "TEST", 0, 20], ["the Boussignac valve", "TREATMENT", 47, 67], ["respiratory", "ANATOMY", 4, 15], ["Boussignac valve", "OBSERVATION", 51, 67]]], ["To try to increase the time on positive pressure, the Boussignac valve was replaced by a CPAP machine (Gooknight\u00ae device) started at a pressure of 8 cm H 2 O via the same nasal-oral mask, with a leak in the connection nozzle to the mask equipped with a HEPA filter and oxygen flow of 12 liters per minute.", [["nasal", "ANATOMY", 171, 176], ["oral", "ANATOMY", 177, 181], ["oxygen", "CHEMICAL", 269, 275], ["oxygen", "CHEMICAL", 269, 275], ["Boussignac valve", "MULTI-TISSUE_STRUCTURE", 54, 70], ["nasal", "ORGANISM_SUBDIVISION", 171, 176], ["oral", "ORGANISM_SUBDIVISION", 177, 181], ["oxygen", "SIMPLE_CHEMICAL", 269, 275], ["positive pressure", "TREATMENT", 31, 48], ["the Boussignac valve", "TREATMENT", 50, 70], ["a CPAP machine", "TREATMENT", 87, 101], ["Gooknight\u00ae device", "TREATMENT", 103, 120], ["the same nasal-oral mask", "TREATMENT", 162, 186], ["a leak", "PROBLEM", 193, 199], ["the mask", "TREATMENT", 228, 236], ["a HEPA filter", "TREATMENT", 251, 264], ["oxygen flow", "TREATMENT", 269, 280], ["Boussignac valve", "ANATOMY", 54, 70], ["oral mask", "ANATOMY", 177, 186], ["leak", "OBSERVATION", 195, 199], ["HEPA filter", "OBSERVATION", 253, 264]]], ["The patient's respiratory rate fell to 22 per minute.", [["respiratory", "ANATOMY", 14, 25], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["The patient's respiratory rate", "TEST", 0, 30]]], ["CPAP was maintained almost continuously except for drinking water.", [["CPAP", "CHEMICAL", 0, 4], ["CPAP", "TREATMENT", 0, 4]]], ["Oxygen saturation measured with CPAP was 98%.", [["Oxygen", "CHEMICAL", 0, 6], ["Oxygen", "SIMPLE_CHEMICAL", 0, 6], ["Oxygen saturation", "TEST", 0, 17], ["CPAP", "TEST", 32, 36]]], ["The treatment was well tolerated; the patient was placed in the prone position for as long as she tolerated it.", [["patient", "ORGANISM", 38, 45], ["patient", "SPECIES", 38, 45], ["The treatment", "TREATMENT", 0, 13]]], ["Azithromycin was started.", [["Azithromycin", "CHEMICAL", 0, 12], ["Azithromycin", "CHEMICAL", 0, 12], ["Azithromycin", "SIMPLE_CHEMICAL", 0, 12], ["Azithromycin", "TREATMENT", 0, 12]]], ["After 48 h, administration of corticosteroids (Solu-Medrol (0.5 mg/kg)) was followed by a decrease in the CRP to 19 mg/dl.", [["corticosteroids", "CHEMICAL", 30, 45], ["Solu-Medrol", "CHEMICAL", 47, 58], ["corticosteroids", "CHEMICAL", 30, 45], ["Solu-Medrol", "CHEMICAL", 47, 58], ["corticosteroids", "SIMPLE_CHEMICAL", 30, 45], ["Solu-Medrol", "SIMPLE_CHEMICAL", 47, 58], ["CRP", "GENE_OR_GENE_PRODUCT", 106, 109], ["CRP", "PROTEIN", 106, 109], ["corticosteroids", "TREATMENT", 30, 45], ["Solu-Medrol", "TREATMENT", 47, 58], ["the CRP", "TEST", 102, 109]]], ["After 5 days of treatment, the CPAP treatment could be completely weaned; the total duration of use of the machine during this period was 38 consecutive hours followed by another 20 h and then 2 nights of 8 h.Treatments and OutcomesThe patient showed no further deterioration and could be discharged home.DiscussionIn our patient, it seems that the positive pressure added to oxygen administration allowed for a safe oxygen saturation level, that oxygen alone could not grant.", [["oxygen", "CHEMICAL", 376, 382], ["oxygen", "CHEMICAL", 417, 423], ["oxygen", "CHEMICAL", 447, 453], ["CPAP", "CHEMICAL", 31, 35], ["oxygen", "CHEMICAL", 376, 382], ["oxygen", "CHEMICAL", 417, 423], ["oxygen", "CHEMICAL", 447, 453], ["patient", "ORGANISM", 236, 243], ["patient", "ORGANISM", 322, 329], ["oxygen", "SIMPLE_CHEMICAL", 376, 382], ["oxygen", "SIMPLE_CHEMICAL", 417, 423], ["oxygen", "SIMPLE_CHEMICAL", 447, 453], ["patient", "SPECIES", 236, 243], ["patient", "SPECIES", 322, 329], ["treatment", "TREATMENT", 16, 25], ["the CPAP treatment", "TREATMENT", 27, 45], ["the machine", "TREATMENT", 103, 114], ["further deterioration", "PROBLEM", 254, 275], ["the positive pressure", "TREATMENT", 345, 366], ["oxygen administration", "TREATMENT", 376, 397], ["a safe oxygen saturation level", "TEST", 410, 440], ["oxygen", "TREATMENT", 447, 453], ["no", "UNCERTAINTY", 251, 253], ["deterioration", "OBSERVATION", 262, 275]]], ["Indeed, our patient was receiving 99% oxygen with an oxygen saturation of 91% when her clinical condition deteriorated.", [["oxygen", "CHEMICAL", 38, 44], ["oxygen", "CHEMICAL", 53, 59], ["oxygen", "CHEMICAL", 38, 44], ["oxygen", "CHEMICAL", 53, 59], ["patient", "ORGANISM", 12, 19], ["oxygen", "SIMPLE_CHEMICAL", 38, 44], ["oxygen", "SIMPLE_CHEMICAL", 53, 59], ["patient", "SPECIES", 12, 19], ["99% oxygen", "TREATMENT", 34, 44], ["an oxygen saturation", "TEST", 50, 70]]], ["Six-day CPAP was instrumental in buying time while the patient recovered.", [["patient", "ORGANISM", 55, 62], ["patient", "SPECIES", 55, 62], ["CPAP", "TREATMENT", 8, 12]]], ["At the end of this period of CPAP use, she required only 24% oxygen.DiscussionA group of Italian physicians reported that a cohort of COVID-19 patients, suffering from acute respiratory distress syndrome, had a dissociation between their relatively well preserved lung mechanics and the severity of hypoxemia, which they called \"atypical\" for ARDS [1] .", [["respiratory", "ANATOMY", 174, 185], ["lung", "ANATOMY", 264, 268], ["oxygen", "CHEMICAL", 61, 67], ["acute respiratory distress syndrome", "DISEASE", 168, 203], ["hypoxemia", "DISEASE", 299, 308], ["ARDS", "DISEASE", 343, 347], ["CPAP", "CHEMICAL", 29, 33], ["oxygen", "CHEMICAL", 61, 67], ["oxygen", "SIMPLE_CHEMICAL", 61, 67], ["patients", "ORGANISM", 143, 151], ["lung", "ORGAN", 264, 268], ["patients", "SPECIES", 143, 151], ["CPAP", "TREATMENT", 29, 33], ["24% oxygen", "TREATMENT", 57, 67], ["acute respiratory distress syndrome", "PROBLEM", 168, 203], ["a dissociation", "PROBLEM", 209, 223], ["hypoxemia", "PROBLEM", 299, 308], ["ARDS", "PROBLEM", 343, 347], ["acute", "OBSERVATION_MODIFIER", 168, 173], ["respiratory distress syndrome", "OBSERVATION", 174, 203], ["lung", "ANATOMY", 264, 268], ["mechanics", "OBSERVATION", 269, 278], ["hypoxemia", "OBSERVATION", 299, 308]]], ["Taking into account this observation and that high PEEP in a poorly recruitable lung tends to result in severe hemodynamic impairment and fluid retention, the content of this manuscript and described patient management are consistent with data and supported by evidence.DiscussionThis clinical illustration about the benefits and modalities of a treatment with CPAP is helpful and sustains the possibility of gentle ventilation for the management of COVID-19 pneumonia.", [["lung", "ANATOMY", 80, 84], ["hemodynamic impairment", "DISEASE", 111, 133], ["COVID", "DISEASE", 450, 455], ["pneumonia", "DISEASE", 459, 468], ["lung", "ORGAN", 80, 84], ["patient", "ORGANISM", 200, 207], ["patient", "SPECIES", 200, 207], ["this observation", "TEST", 20, 36], ["high PEEP", "TREATMENT", 46, 55], ["a poorly recruitable lung", "PROBLEM", 59, 84], ["severe hemodynamic impairment", "PROBLEM", 104, 133], ["fluid retention", "PROBLEM", 138, 153], ["a treatment", "TREATMENT", 344, 355], ["CPAP", "TREATMENT", 361, 365], ["gentle ventilation", "TREATMENT", 409, 427], ["the management", "TREATMENT", 432, 446], ["COVID", "TEST", 450, 455], ["pneumonia", "PROBLEM", 459, 468], ["lung", "ANATOMY", 80, 84], ["severe", "OBSERVATION_MODIFIER", 104, 110], ["hemodynamic impairment", "OBSERVATION", 111, 133], ["fluid retention", "OBSERVATION", 138, 153], ["pneumonia", "OBSERVATION", 459, 468]]], ["Anyway, in patients who are treated with continuous positive airway pressure or noninvasive ventilation and who present with clinical signs of excessive inspiratory efforts, intubation should be prioritized to avoid excessive intrathoracic negative pressures and self-inflicted lung injury, beyond any patient preference or tolerance [4] .DiscussionConcerning tolerance, a substantial advantage was noted for CPAP machine compared to the Boussignac valve with in addition, a clear decrease in respiratory rate indeed studies using CPAP Boussignac have been performed in the management of acute respiratory failure related to cardiogenic edema.", [["airway", "ANATOMY", 61, 67], ["intrathoracic", "ANATOMY", 226, 239], ["lung", "ANATOMY", 278, 282], ["respiratory", "ANATOMY", 594, 605], ["lung injury", "DISEASE", 278, 289], ["Boussignac", "CHEMICAL", 536, 546], ["respiratory failure", "DISEASE", 594, 613], ["cardiogenic edema", "DISEASE", 625, 642], ["patients", "ORGANISM", 11, 19], ["airway", "MULTI-TISSUE_STRUCTURE", 61, 67], ["lung", "ORGAN", 278, 282], ["patient", "ORGANISM", 302, 309], ["edema", "PATHOLOGICAL_FORMATION", 637, 642], ["patients", "SPECIES", 11, 19], ["patient", "SPECIES", 302, 309], ["continuous positive airway pressure", "TREATMENT", 41, 76], ["noninvasive ventilation", "TREATMENT", 80, 103], ["excessive inspiratory efforts", "PROBLEM", 143, 172], ["intubation", "TREATMENT", 174, 184], ["excessive intrathoracic negative pressures", "PROBLEM", 216, 258], ["self-inflicted lung injury", "PROBLEM", 263, 289], ["CPAP machine", "TREATMENT", 409, 421], ["the Boussignac valve", "TREATMENT", 434, 454], ["a clear decrease in respiratory rate", "PROBLEM", 473, 509], ["CPAP Boussignac", "TREATMENT", 531, 546], ["acute respiratory failure", "PROBLEM", 588, 613], ["cardiogenic edema", "PROBLEM", 625, 642], ["pressures", "OBSERVATION_MODIFIER", 249, 258], ["lung", "ANATOMY", 278, 282], ["injury", "OBSERVATION", 283, 289], ["valve", "OBSERVATION", 449, 454], ["clear", "OBSERVATION_MODIFIER", 475, 480], ["decrease", "OBSERVATION_MODIFIER", 481, 489], ["respiratory rate", "OBSERVATION", 493, 509], ["acute", "OBSERVATION_MODIFIER", 588, 593], ["respiratory failure", "OBSERVATION", 594, 613], ["cardiogenic", "OBSERVATION_MODIFIER", 625, 636], ["edema", "OBSERVATION", 637, 642]]], ["Boussignac valve was used as a mechanical support in combination with the use of diuretics.", [["Boussignac valve", "TREATMENT", 0, 16], ["a mechanical support", "TREATMENT", 29, 49], ["diuretics", "TREATMENT", 81, 90], ["valve", "OBSERVATION", 11, 16], ["mechanical support", "OBSERVATION", 31, 49]]], ["The duration of use reported by the authors is often from 2 to 6 h, allowing the action of drug treatment.", [["drug treatment", "TREATMENT", 91, 105]]], ["As mentioned by the authors, the limitations of its use are related to mask tightening, noise, and discomfort.", [["mask tightening", "TREATMENT", 71, 86], ["discomfort", "PROBLEM", 99, 109]]], ["However, conventional CPAP is designed to be used all night long on a regular basis in patients treated for sleep apnea; moreover, the pressure generated is not related to oxygen flow.", [["sleep apnea", "DISEASE", 108, 119], ["oxygen", "CHEMICAL", 172, 178], ["oxygen", "CHEMICAL", 172, 178], ["patients", "ORGANISM", 87, 95], ["oxygen", "SIMPLE_CHEMICAL", 172, 178], ["patients", "SPECIES", 87, 95], ["conventional CPAP", "TREATMENT", 9, 26], ["sleep apnea", "PROBLEM", 108, 119], ["the pressure", "TEST", 131, 143], ["oxygen flow", "TEST", 172, 183], ["not related to", "UNCERTAINTY", 157, 171], ["oxygen flow", "OBSERVATION", 172, 183]]], ["Improvements have been made by manufacturers since its introduction to improve its tolerance.DiscussionTherefore, although the Boussignac valve in the management of acute respiratory failure has not demonstrated any inferiority compared to mechanical ventilation (BPAP) in studies [3] , we believe that the need for continuous ventilation of longer duration gives conventional CPAP an advantage.", [["respiratory", "ANATOMY", 171, 182], ["respiratory failure", "DISEASE", 171, 190], ["the Boussignac valve", "TREATMENT", 123, 143], ["acute respiratory failure", "PROBLEM", 165, 190], ["mechanical ventilation", "TREATMENT", 240, 262], ["continuous ventilation of longer duration", "TREATMENT", 316, 357], ["conventional CPAP", "TREATMENT", 364, 381], ["valve", "OBSERVATION", 138, 143], ["acute", "OBSERVATION_MODIFIER", 165, 170], ["respiratory failure", "OBSERVATION", 171, 190]]], ["It should be recommended as a first-line treatment.", [["a first-line treatment", "TREATMENT", 28, 50]]], ["It should be noted that tolerance comparison studies between conventional CPAP and Boussignac valve are missing in the literature and should be conducted.DiscussionHowever, it is important to emphasize that the administration of corticosteroids has perhaps been beneficial in the evolution of our patient, allowing the patient to pass the clinical milestone of the excessive inflammatory reaction responsible for the phenomena of acute respiratory distress [5] .", [["respiratory", "ANATOMY", 436, 447], ["corticosteroids", "CHEMICAL", 229, 244], ["respiratory distress", "DISEASE", 436, 456], ["corticosteroids", "CHEMICAL", 229, 244], ["valve", "MULTI-TISSUE_STRUCTURE", 94, 99], ["patient", "ORGANISM", 297, 304], ["patient", "ORGANISM", 319, 326], ["patient", "SPECIES", 297, 304], ["patient", "SPECIES", 319, 326], ["tolerance comparison studies", "TEST", 24, 52], ["conventional CPAP", "TREATMENT", 61, 78], ["Boussignac valve", "TREATMENT", 83, 99], ["corticosteroids", "TREATMENT", 229, 244], ["the excessive inflammatory reaction", "PROBLEM", 361, 396], ["acute respiratory distress", "PROBLEM", 430, 456], ["valve", "OBSERVATION", 94, 99], ["excessive", "OBSERVATION_MODIFIER", 365, 374], ["inflammatory", "OBSERVATION", 375, 387], ["acute", "OBSERVATION_MODIFIER", 430, 435], ["respiratory distress", "OBSERVATION", 436, 456]]], ["A retrospective study of 200 patients with ARDS due to COVID-19 apparently showed a lower mortality among those receiving [6] .", [["ARDS", "DISEASE", 43, 47], ["patients", "ORGANISM", 29, 37], ["patients", "SPECIES", 29, 37], ["A retrospective study", "TEST", 0, 21], ["ARDS", "PROBLEM", 43, 47], ["COVID", "TEST", 55, 60], ["a lower mortality", "PROBLEM", 82, 99]]], ["A recent expert opinion has proposed the administration of glucocorticoids in different stages of COVID-19 infection, due to the adrenal insufficiency and increased immune response characteristic of this virus [7] .DiscussionIn conclusion, this clinical case illustrates the use of CPAP to avoid intubation in a patient with respiratory failure.", [["adrenal", "ANATOMY", 129, 136], ["respiratory", "ANATOMY", 325, 336], ["glucocorticoids", "CHEMICAL", 59, 74], ["infection", "DISEASE", 107, 116], ["adrenal insufficiency", "DISEASE", 129, 150], ["respiratory failure", "DISEASE", 325, 344], ["COVID-19", "CELL", 98, 106], ["adrenal", "ORGAN", 129, 136], ["patient", "ORGANISM", 312, 319], ["patient", "SPECIES", 312, 319], ["glucocorticoids", "TREATMENT", 59, 74], ["COVID-19 infection", "PROBLEM", 98, 116], ["the adrenal insufficiency", "PROBLEM", 125, 150], ["increased immune response", "PROBLEM", 155, 180], ["this virus", "PROBLEM", 199, 209], ["CPAP", "TREATMENT", 282, 286], ["intubation", "TREATMENT", 296, 306], ["respiratory failure", "PROBLEM", 325, 344], ["infection", "OBSERVATION", 107, 116], ["adrenal", "ANATOMY", 129, 136], ["insufficiency", "OBSERVATION", 137, 150], ["increased", "OBSERVATION_MODIFIER", 155, 164], ["immune response", "OBSERVATION", 165, 180], ["respiratory", "ANATOMY", 325, 336], ["failure", "OBSERVATION", 337, 344]]], ["We would like to encourage the use of CPAP, better tolerated for extended hours with lower oxygen flows, in patients with COVID-19 pneumonia, where acute respiratory distress all too often leads to patient intubation and the genesis of deleterious lung lesions.Patient PerspectiveThe patient was very eager to share her experience; the use of CPAP allowed her to avoid intubation.", [["respiratory", "ANATOMY", 154, 165], ["lung lesions", "ANATOMY", 248, 260], ["oxygen", "CHEMICAL", 91, 97], ["pneumonia", "DISEASE", 131, 140], ["respiratory distress", "DISEASE", 154, 174], ["lung lesions", "DISEASE", 248, 260], ["CPAP", "CHEMICAL", 38, 42], ["oxygen", "CHEMICAL", 91, 97], ["oxygen", "SIMPLE_CHEMICAL", 91, 97], ["patients", "ORGANISM", 108, 116], ["patient", "ORGANISM", 198, 205], ["lung lesions", "PATHOLOGICAL_FORMATION", 248, 260], ["patient", "ORGANISM", 284, 291], ["patients", "SPECIES", 108, 116], ["patient", "SPECIES", 198, 205], ["Patient", "SPECIES", 261, 268], ["patient", "SPECIES", 284, 291], ["CPAP", "TREATMENT", 38, 42], ["lower oxygen flows", "TREATMENT", 85, 103], ["COVID", "TEST", 122, 127], ["pneumonia", "PROBLEM", 131, 140], ["acute respiratory distress", "PROBLEM", 148, 174], ["patient intubation", "TREATMENT", 198, 216], ["deleterious lung lesions", "PROBLEM", 236, 260], ["CPAP", "TREATMENT", 343, 347], ["intubation", "TREATMENT", 369, 379], ["oxygen flows", "OBSERVATION", 91, 103], ["pneumonia", "OBSERVATION", 131, 140], ["acute", "OBSERVATION_MODIFIER", 148, 153], ["respiratory distress", "OBSERVATION", 154, 174], ["deleterious", "OBSERVATION_MODIFIER", 236, 247], ["lung", "ANATOMY", 248, 252], ["lesions", "OBSERVATION", 253, 260]]], ["As a critical care worker, she had seen several patients who had had to be intubated and did not wish to be.", [["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 48, 56]]], ["She reports that the most important element is to have remained at all times conscious and master of her follow-up.Compliance with Ethical StandardsConflict of Interest The authors declare that they have no conflict of interest.Compliance with Ethical StandardsInformed consent The patient has given her consent for the publication of this article.", [["patient", "ORGANISM", 282, 289], ["patient", "SPECIES", 282, 289], ["Ethical Standards", "TREATMENT", 131, 148], ["Ethical Standards", "TREATMENT", 244, 261]]]], "2c36ea09786e80d9676de3075e7d597a16e47cfb": [["For example, the PERSEUS digital library aimed to make humanities documents accessible spatially, while e.g. the SEQUOIA and SPIRIT projects [8] , as well as the GeoCLEF shared task [1] aimed to study geographic information retrieval.", [["PERSEUS digital library", "DNA", 17, 40]]], ["More recently, the pervasiveness of mobile computing devices [11] and other developments associated to the Internet of Things (IoT) all necessitate reflection on the role of geographic space in making information collected and stored accessible, not just indexed using words and numbers but also spatially.", [["mobile computing devices", "TREATMENT", 36, 60]]], ["However, to date, not ECIR nor other IR conferences have offered a tutorial for interested researchers and practitioners, making the body of research that make up the state of the art accessible.IntroductionTo this end, we propose a half-day to address this gap.", [["this gap", "PROBLEM", 253, 261]]], ["We will introduce or recap the core concepts from geography and its intersection with IR, and survey existing techniques to (a) construct spatial representations from textual documents and queries (typically exploiting geographic knowledge from gazetteers [7] in doing so), and to (b) utilize geographic knowledge (prior and extracted from data) to better access document collections in which geographic space place a substantial roles.", [["collections", "PROBLEM", 372, 383], ["collections", "OBSERVATION", 372, 383], ["substantial", "OBSERVATION_MODIFIER", 418, 429]]], ["We will also cover example applications [5] , e.g. in fields such as the digital humanities [12] , and discuss possible avenues for future work in the area.Goals and ObjectivesIn this tutorial, we aim to give a survey of the concepts and methods used to make implicit spatial evidence contained in text collections accessible.", [["methods", "TREATMENT", 238, 245]]], ["Discuss what is geographic relevance, and how it varies with context and application domain; -Applications: Concrete examples for the application of the introduced methods, in fields ranging from Digital Humanities to Web search, together with a discussion on requirements and their implications on algorithmic and data choices; -Future challenges: Where are the most likely applications of GIR in the future, and what are key societal and methodologically driven challenges;Description and Structure of the TutorialThe first four sessions will each present fundamental challenges, a selection of examples from the state of the art, and include interactive exercises (computer and/or paper based) to illustrate basic concepts to participants.PrerequisitesIn terms of prerequisites, some knowledge of basic IR and ML concepts will be helpful.", [["participants", "SPECIES", 729, 741], ["the introduced methods", "TREATMENT", 149, 171], ["basic IR and ML concepts", "TREATMENT", 800, 824], ["most likely", "UNCERTAINTY", 363, 374]]], ["However, the tutorial is designed for a broad audience, introducing key high level concepts, and providing participants with material to deepen knowledge subsequently.Target AudienceThe target audience for this tutorial includes the following three groups:Target Audience-students of computer science, especially in information retrieval, who want to learn about mobility-relevant spatial computation around search/IR (e.g. [2] ); -practicing IR engineers who would like to expand their areas of expertise so as to include geographic search; -information retrieval researchers interested in and introduction and state-ofthe-art review [14] on GIR and Geo-NLP; -geographers or GIS experts who have not yet worked with text, and who would like to learn how the spatial knowledge implicit in text collections can be used to support geospatial analysis.Target AudienceBeyond these directly targeted groups, the tutorial could be of interest to anyone who would like to understand better how the world of geographic space relates to the world of unstructured textual documents.", [["participants", "SPECIES", 107, 119], ["geospatial analysis", "TEST", 829, 848]]], ["He has been involved in several research projects related to geospatial aspects in information access and retrieval, and he has accumulated a significant expertise in addressing challenges at the intersection of information retrieval, machine learning, and the geographical information sciences.Katherine McDonough is a Senior Research Associate at The Alan TuringInstitute with the Living with Machines project and a Research Fellow at Queen Mary, University of London.", [["significant", "OBSERVATION_MODIFIER", 142, 153]]], ["She has written on GIR challenges for humanities research and is a member of the G\u00e9oDisco project, which examines geographic discourse in historical French encyclopedias.", [["GIR challenges", "TREATMENT", 19, 33]]], ["His research focuses on the geographic analysis of text, exploring both methodological issues (e.g. gazetteer quality and representation of vernacular names) and analysis of text to better understand landscape.", [["both methodological issues", "PROBLEM", 67, 93]]], ["Together with Chris Jones, he organises the workshop on Geographic Information Retrieval which has been hosted by CIKM, SIGIR and ACM SIGSPATIAL, and which has been an important incubator of many ideas related to GIR.", [["GIR", "GENE_OR_GENE_PRODUCT", 213, 216]]], ["He recently co-authored a comprehensive review of GIR [14] .Previous EventsThis is a new tutorial, and therefore was never presented before.", [["new", "OBSERVATION_MODIFIER", 85, 88]]], ["All of the presenters are experienced teachers and have given seminars at a range of international conferences on related material.Summary and ConclusionWe have presented a tutorial proposal for geospatial content processing and retrieval.", [["geospatial content processing", "TREATMENT", 195, 224], ["retrieval", "TREATMENT", 229, 238]]], ["Geographic aspects in information access and retrieval have been increasing in relevance, given the interest in analysing huge volumes of unstructured data in fields such as the digital humanities or the computational social sciences, and given the pervasiveness of networked sensors, GPS-enabled mobile devices, and in-car navigation systems.", [["retrieval", "TREATMENT", 45, 54], ["GPS", "TEST", 285, 288], ["mobile devices", "TREATMENT", 297, 311], ["increasing", "OBSERVATION_MODIFIER", 65, 75]]]], "613de67ef668211d2ad990dd1aa788f4322da530": [["IntroductionIn the UK, the death toll from severe COVID-19 is among the highest worldwide.", [["death", "DISEASE", 27, 32], ["COVID", "DISEASE", 50, 55], ["severe COVID", "PROBLEM", 43, 55], ["severe", "OBSERVATION_MODIFIER", 43, 49]]], ["1 Severe COVID-19 is characterised by respiratory failure, with so-called cytokine storm occurring in some patient subsets.", [["respiratory", "ANATOMY", 38, 49], ["respiratory failure", "DISEASE", 38, 57], ["patient", "ORGANISM", 107, 114], ["cytokine", "PROTEIN", 74, 82], ["patient", "SPECIES", 107, 114], ["Severe COVID", "PROBLEM", 2, 14], ["respiratory failure", "PROBLEM", 38, 57], ["cytokine storm", "TREATMENT", 74, 88], ["Severe", "OBSERVATION_MODIFIER", 2, 8], ["respiratory failure", "OBSERVATION", 38, 57], ["cytokine storm", "OBSERVATION", 74, 88]]], ["2 Pathological correlates are required to understand the pathophysiology of COVID-19.", [["COVID-19", "CHEMICAL", 76, 84], ["COVID", "TEST", 76, 81]]], ["Autopsy-based histopathological analysis is crucial in this respect.", [["Autopsy", "TEST", 0, 7], ["histopathological analysis", "TEST", 14, 40]]], ["In anticipation of the COVID-19 pandemic, our group produced national guidelines for autopsy performance in suspected COVID-19 cases.", [["COVID", "DISEASE", 118, 123], ["autopsy performance", "TEST", 85, 104], ["suspected COVID", "TEST", 108, 123]]], ["3 COVID-19 is caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).", [["infection", "DISEASE", 24, 33], ["acute respiratory syndrome coronavirus", "DISEASE", 46, 84], ["severe acute respiratory syndrome coronavirus", "SPECIES", 39, 84], ["SARS-CoV-2", "SPECIES", 88, 98], ["infection", "PROBLEM", 24, 33], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 39, 84], ["CoV", "TEST", 93, 96], ["infection", "OBSERVATION", 24, 33], ["severe", "OBSERVATION_MODIFIER", 39, 45], ["acute", "OBSERVATION_MODIFIER", 46, 51], ["respiratory syndrome coronavirus", "OBSERVATION", 52, 84]]], ["4, 5 Although SARS-CoV-2 and its predecessor SARS-CoV (causing severe acute respiratory syndrome [SARS]) are similar on a molecular and clinical level, COVID-19 has a lower death rate (4% for COVID-19 vs 15% for SARS) and a substantially higher death toll (700 539 deaths worldwide from COVID-19 as of Aug 5, 2020 vs 774 from SARS) than SARS due to a higher basic reproduction number.", [["SARS-CoV", "DISEASE", 45, 53], ["acute respiratory syndrome", "DISEASE", 70, 96], ["SARS", "DISEASE", 98, 102], ["death", "DISEASE", 173, 178], ["SARS", "DISEASE", 212, 216], ["death", "DISEASE", 245, 250], ["deaths", "DISEASE", 265, 271], ["SARS", "DISEASE", 326, 330], ["SARS", "DISEASE", 337, 341], ["SARS-CoV-2", "ORGANISM", 14, 24], ["SARS-CoV", "ORGANISM", 45, 53], ["SARS-CoV", "SPECIES", 14, 22], ["SARS-CoV", "SPECIES", 45, 53], ["SARS", "TEST", 14, 18], ["CoV", "TEST", 19, 22], ["severe acute respiratory syndrome", "PROBLEM", 63, 96], ["COVID", "TEST", 152, 157], ["a lower death rate", "PROBLEM", 165, 183], ["COVID", "TEST", 192, 197], ["SARS", "PROBLEM", 212, 216], ["COVID", "TEST", 287, 292], ["SARS", "PROBLEM", 326, 330], ["SARS", "PROBLEM", 337, 341], ["severe", "OBSERVATION_MODIFIER", 63, 69], ["acute", "OBSERVATION_MODIFIER", 70, 75], ["respiratory syndrome", "OBSERVATION", 76, 96]]], ["1 The post-mortem findings in patients with SARS-CoV infection included diffuse alveolar damage (DAD), splenic and nodal lymphocyte depletion, haemophagocytosis, renal acute tubular injury, cerebral oedema, micro-thrombosis, and adrenalitis with necrosis, with intracellular SARS-CoV detected in the lungs, kidney, brain, and haematological organs.", [["alveolar", "ANATOMY", 80, 88], ["splenic", "ANATOMY", 103, 110], ["nodal lymphocyte", "ANATOMY", 115, 131], ["renal", "ANATOMY", 162, 167], ["tubular", "ANATOMY", 174, 181], ["cerebral", "ANATOMY", 190, 198], ["intracellular", "ANATOMY", 261, 274], ["lungs", "ANATOMY", 300, 305], ["kidney", "ANATOMY", 307, 313], ["brain", "ANATOMY", 315, 320], ["haematological organs", "ANATOMY", 326, 347], ["SARS-CoV infection", "DISEASE", 44, 62], ["alveolar damage", "DISEASE", 80, 95], ["DAD", "DISEASE", 97, 100], ["haemophagocytosis", "DISEASE", 143, 160], ["renal acute tubular injury", "DISEASE", 162, 188], ["cerebral oedema", "DISEASE", 190, 205], ["micro-thrombosis", "DISEASE", 207, 223], ["adrenalitis", "DISEASE", 229, 240], ["necrosis", "DISEASE", 246, 254], ["patients", "ORGANISM", 30, 38], ["SARS-CoV", "ORGANISM", 44, 52], ["alveolar", "TISSUE", 80, 88], ["nodal lymphocyte", "CELL", 115, 131], ["tubular", "MULTI-TISSUE_STRUCTURE", 174, 181], ["cerebral oedema", "PATHOLOGICAL_FORMATION", 190, 205], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 261, 274], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 275, 283], ["lungs", "ORGAN", 300, 305], ["kidney", "ORGAN", 307, 313], ["brain", "ORGAN", 315, 320], ["haematological organs", "MULTI-TISSUE_STRUCTURE", 326, 347], ["patients", "SPECIES", 30, 38], ["SARS-CoV", "SPECIES", 44, 52], ["SARS-CoV", "SPECIES", 275, 283], ["SARS", "PROBLEM", 44, 48], ["CoV infection", "PROBLEM", 49, 62], ["diffuse alveolar damage (DAD)", "PROBLEM", 72, 101], ["splenic and nodal lymphocyte depletion", "PROBLEM", 103, 141], ["haemophagocytosis", "PROBLEM", 143, 160], ["renal acute tubular injury", "PROBLEM", 162, 188], ["cerebral oedema", "PROBLEM", 190, 205], ["micro-thrombosis", "PROBLEM", 207, 223], ["adrenalitis", "PROBLEM", 229, 240], ["necrosis", "PROBLEM", 246, 254], ["intracellular SARS-CoV detected in the lungs, kidney, brain, and haematological organs", "PROBLEM", 261, 347], ["diffuse", "OBSERVATION_MODIFIER", 72, 79], ["alveolar damage", "OBSERVATION", 80, 95], ["splenic", "ANATOMY", 103, 110], ["nodal lymphocyte depletion", "OBSERVATION", 115, 141], ["renal", "ANATOMY", 162, 167], ["acute", "OBSERVATION_MODIFIER", 168, 173], ["tubular", "ANATOMY_MODIFIER", 174, 181], ["injury", "OBSERVATION", 182, 188], ["cerebral", "ANATOMY", 190, 198], ["oedema", "OBSERVATION", 199, 205], ["thrombosis", "OBSERVATION", 213, 223], ["necrosis", "OBSERVATION", 246, 254], ["intracellular", "OBSERVATION_MODIFIER", 261, 274], ["SARS", "OBSERVATION", 275, 279], ["lungs", "ANATOMY", 300, 305], ["kidney", "ANATOMY", 307, 313], ["brain", "ANATOMY", 315, 320], ["haematological organs", "ANATOMY", 326, 347]]], ["6 Various autopsy series on COVID-19 have begun to emerge in the literature.", [["Various autopsy series", "TEST", 2, 24], ["COVID", "TEST", 28, 33]]], ["[7] [8] [9] [10] [11] [12] [13] [14] [15] Here, we document the major pathological findings of ten post-mortem examinations done on patients with clinically confirmed COVID-19.Patient selectionFor this study, eligible patients were older than 18 years with premortem SARS-CoV-2 infection and COVID-19 listed clinically as the direct cause of death (under part 1 on the Medical Certificate of Cause of Death [MCCD]).", [["[7] [8] [9] [10] [11]", "CHEMICAL", 0, 21], ["SARS-CoV-2 infection", "DISEASE", 267, 287], ["death", "DISEASE", 342, 347], ["[7] [8] [9] [10] [11] [12] [13] [14] [15", "SIMPLE_CHEMICAL", 0, 40], ["patients", "ORGANISM", 132, 140], ["patients", "ORGANISM", 218, 226], ["patients", "SPECIES", 132, 140], ["Patient", "SPECIES", 176, 183], ["patients", "SPECIES", 218, 226], ["ten post-mortem examinations", "TEST", 95, 123], ["COVID", "TEST", 167, 172], ["this study", "TEST", 197, 207], ["premortem SARS", "PROBLEM", 257, 271], ["CoV-2 infection", "PROBLEM", 272, 287], ["COVID", "TEST", 292, 297], ["death", "PROBLEM", 342, 347], ["Death", "PROBLEM", 401, 406]]], ["Consent was obtained for all included patients according to the Human Tissue Authority 2009 codes of practice, by a member of the Trust Core Post-Mortem Consent Team.", [["patients", "ORGANISM", 38, 46], ["Human", "ORGANISM", 64, 69], ["Tissue", "TISSUE", 70, 76], ["patients", "SPECIES", 38, 46], ["Human", "SPECIES", 64, 69]]], ["Consent rate was 52\u00b76% (ten of 19 patients).", [["patients", "ORGANISM", 34, 42], ["patients", "SPECIES", 34, 42], ["Consent rate", "TEST", 0, 12]]], ["Exclusion criteria included extended post-mortem interval before autopsy (>10 days) and patients with COVID-19 contributing, but not directly leading to death (under part 2 of the MCCD).", [["death", "DISEASE", 153, 158], ["patients", "ORGANISM", 88, 96], ["patients", "SPECIES", 88, 96], ["autopsy", "TEST", 65, 72], ["COVID", "TEST", 102, 107]]], ["Patients were from Imperial College National Health Service (NHS) Trust (nine patients; London, UK) and Royal Brompton & Harefield Foundation NHS Trust (one patient; London, UK).", [["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 78, 86], ["patient", "ORGANISM", 157, 164], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 78, 86], ["patient", "SPECIES", 157, 164]]], ["Premortem SARS-CoV-2 infection was identified using the Coronavirus Typing multiplex-tandem PCR High-Plex 24 System (Aus Diagnostics, Chesham, UK).", [["infection", "DISEASE", 21, 30], ["CoV-2", "ORGANISM", 15, 20], ["SARS-CoV-2", "SPECIES", 10, 20], ["Premortem SARS", "PROBLEM", 0, 14], ["CoV-2 infection", "PROBLEM", 15, 30], ["the Coronavirus Typing multiplex", "TEST", 52, 84], ["tandem PCR", "TEST", 85, 95], ["SARS", "OBSERVATION", 10, 14], ["infection", "OBSERVATION", 21, 30]]], ["Ethical approval for this project was provided by the Imperial College Healthcare Tissue Bank (R20012).Autopsy proceduresFull autopsies were done on nine patients (PM1-9), and one patient underwent percutaneous biopsy sampling (heart, lungs, pancreas, kidneys, and liver) using percutaneous biopsy under ultrasound guidance (PM10).", [["percutaneous", "ANATOMY", 198, 210], ["heart", "ANATOMY", 228, 233], ["lungs", "ANATOMY", 235, 240], ["pancreas", "ANATOMY", 242, 250], ["kidneys", "ANATOMY", 252, 259], ["liver", "ANATOMY", 265, 270], ["percutaneous", "ANATOMY", 278, 290], ["PM1-9", "CHEMICAL", 164, 169], ["patients", "ORGANISM", 154, 162], ["patient", "ORGANISM", 180, 187], ["heart", "ORGAN", 228, 233], ["lungs", "ORGAN", 235, 240], ["pancreas", "ORGAN", 242, 250], ["kidneys", "ORGAN", 252, 259], ["liver", "ORGAN", 265, 270], ["patients", "SPECIES", 154, 162], ["patient", "SPECIES", 180, 187], ["Ethical approval", "TREATMENT", 0, 16], ["Autopsy procedures", "TEST", 103, 121], ["Full autopsies", "TEST", 121, 135], ["PM1", "TEST", 164, 167], ["percutaneous biopsy sampling", "TEST", 198, 226], ["percutaneous biopsy under ultrasound guidance", "TEST", 278, 323], ["heart", "ANATOMY", 228, 233], ["lungs", "ANATOMY", 235, 240], ["pancreas", "ANATOMY", 242, 250], ["kidneys", "ANATOMY", 252, 259], ["liver", "ANATOMY", 265, 270]]], ["Full post-mortem examinations included standard sampling and were done according to Royal College of Pathologists guidelines.", [["Full post-mortem examinations", "TEST", 0, 29], ["standard sampling", "TEST", 39, 56]]], ["3 Eight different regions of the brain were sampled for each full neuropathological examination.", [["brain", "ANATOMY", 33, 38], ["brain", "ORGAN", 33, 38], ["each full neuropathological examination", "TEST", 56, 95], ["brain", "ANATOMY", 33, 38]]], ["All tissue samples were fixed in formalin for a minimum of 72 h before embedding.", [["tissue samples", "ANATOMY", 4, 18], ["formalin", "CHEMICAL", 33, 41], ["formalin", "CHEMICAL", 33, 41], ["tissue samples", "CANCER", 4, 18], ["formalin", "SIMPLE_CHEMICAL", 33, 41], ["All tissue samples", "TREATMENT", 0, 18]]], ["Histochemical stains and immunohistochemistry were applied according to local protocols (appendix p 19).", [["Histochemical stains", "TEST", 0, 20], ["immunohistochemistry", "TEST", 25, 45], ["local protocols", "TEST", 72, 87]]], ["Organs were reviewed by subspecialist pathologists in lung (AGN and PV), haem ato pathology and immune pathology (KNN), liver (RG), gastrointestinal (MO), neuropathology (SA-S), and renal pathology (CR).", [["Organs", "ANATOMY", 0, 6], ["lung", "ANATOMY", 54, 58], ["liver", "ANATOMY", 120, 125], ["gastrointestinal", "ANATOMY", 132, 148], ["renal", "ANATOMY", 182, 187], ["liver (RG), gastrointestinal (MO), neuropathology", "DISEASE", 120, 169], ["Organs", "ORGAN", 0, 6], ["lung", "ORGAN", 54, 58], ["liver", "ORGAN", 120, 125], ["gastrointestinal", "ORGAN", 132, 148], ["renal", "ORGAN", 182, 187], ["PV", "SPECIES", 68, 70], ["haem ato pathology", "TEST", 73, 91], ["immune pathology", "TEST", 96, 112], ["neuropathology (SA-S", "TEST", 155, 175], ["renal pathology", "PROBLEM", 182, 197], ["CR", "TEST", 199, 201], ["lung", "ANATOMY", 54, 58], ["liver", "ANATOMY", 120, 125], ["gastrointestinal", "ANATOMY", 132, 148], ["renal", "ANATOMY", 182, 187], ["pathology", "OBSERVATION", 188, 197]]], ["All cases were reviewed independently by at least two pathologists.PCR proceduresFresh tissue for quantitative RT-PCR (qRT-PCR) analysis was processed within the biosafety level 3 facilities at St Mary's Hospital (London, UK), approved by the UK Health and Safety Executive and in accordance with local rules at Imperial College London.", [["Fresh tissue", "ANATOMY", 81, 93], ["Fresh tissue", "TISSUE", 81, 93], ["PCR procedures", "TEST", 67, 81], ["quantitative RT-PCR", "TEST", 98, 117], ["qRT", "TEST", 119, 122], ["PCR", "TEST", 123, 126]]], ["Total RNA was obtained from fresh tissue samples by use of TRIzolchloroform extraction, followed by precipitation and purification using the RNeasy kit (Qiagen, Hilden, Germany). qRT-PCR against E gene, RdRp, and subgenomic RNA was done as described elsewhere.", [["tissue samples", "ANATOMY", 34, 48], ["TRIzolchloroform", "CHEMICAL", 59, 75], ["tissue samples", "TISSUE", 34, 48], ["TRIzolchloroform", "SIMPLE_CHEMICAL", 59, 75], ["E", "GENE_OR_GENE_PRODUCT", 195, 196], ["RdRp", "GENE_OR_GENE_PRODUCT", 203, 207], ["E gene", "DNA", 195, 201], ["RdRp", "DNA", 203, 207], ["subgenomic RNA", "RNA", 213, 227], ["Total RNA", "TEST", 0, 9], ["TRIzolchloroform extraction", "TREATMENT", 59, 86], ["purification", "TREATMENT", 118, 130], ["the RNeasy kit", "TREATMENT", 137, 151], ["qRT", "TEST", 179, 182], ["PCR", "TEST", 183, 186], ["RdRp", "PROBLEM", 203, 207], ["subgenomic RNA", "PROBLEM", 213, 227], ["subgenomic RNA", "OBSERVATION", 213, 227]]], ["16, 17 In patient PM5, total fungal genomic DNA was extracted from four to five ribbon slices of a formalin-fixed, paraffinembedded lung tissue block.", [["lung tissue", "ANATOMY", 132, 143], ["formalin", "CHEMICAL", 99, 107], ["patient", "ORGANISM", 10, 17], ["DNA", "CELLULAR_COMPONENT", 44, 47], ["lung tissue", "TISSUE", 132, 143], ["PM5", "DNA", 18, 21], ["total fungal genomic DNA", "DNA", 23, 47], ["patient", "SPECIES", 10, 17], ["total fungal genomic DNA", "PROBLEM", 23, 47], ["a formalin-fixed, paraffinembedded lung tissue block", "TREATMENT", 97, 149], ["fungal genomic DNA", "OBSERVATION", 29, 47], ["lung", "ANATOMY", 132, 136], ["tissue block", "OBSERVATION", 137, 149]]], ["Purified DNA was amplified with PCR for panfungal and Mucorales-specific targets.Statistical analysisAll data was analysed using SPSS software, version 25, and expressed using median (IQR) and percentage.Role of the funding sourceThe funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the Article.", [["DNA", "CELLULAR_COMPONENT", 9, 12], ["Mucorales", "SIMPLE_CHEMICAL", 54, 63], ["panfungal and Mucorales-specific targets", "DNA", 40, 80], ["Purified DNA", "PROBLEM", 0, 12], ["PCR", "TEST", 32, 35], ["panfungal", "TEST", 40, 49], ["Mucorales", "TEST", 54, 63], ["Statistical analysis", "TEST", 81, 101], ["All data", "TEST", 101, 109], ["SPSS software", "TEST", 129, 142], ["the study", "TEST", 244, 253], ["data collection", "TEST", 283, 298], ["data analysis", "TEST", 300, 313], ["data interpretation", "TEST", 315, 334], ["DNA", "OBSERVATION", 9, 12]]], ["The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.ResultsBetween March 1 and April 30, 2020, ten patients were included in the study.", [["patients", "ORGANISM", 189, 197], ["patients", "SPECIES", 189, 197], ["the study", "TEST", 60, 69], ["the study", "TEST", 215, 224]]], ["The median age at death was 73 yearsResearch in contextEvidence before this study COVID-19 is a new disease and comprehensive descriptions of the histopathological findings at autopsy are scarce.", [["death", "DISEASE", 18, 23], ["this study COVID", "TEST", 71, 87], ["a new disease", "PROBLEM", 94, 107], ["new", "OBSERVATION_MODIFIER", 96, 99], ["disease", "OBSERVATION", 100, 107]]], ["For this, we searched PubMed and Google Scholar databases with no language restrictions using the search terms \"COVID-19\", \"SARS-CoV-2\", \"histology\", \"autopsy\", and \"post-mortem\".Added value of this studyOur series focused on providing a comprehensive description of the histopathological findings in patients with severe, fatal COVID-19 and correlating these findings with data on viral tropism.", [["SARS", "DISEASE", 124, 128], ["patients", "ORGANISM", 301, 309], ["patients", "SPECIES", 301, 309], ["this study", "TEST", 194, 204], ["fatal COVID", "TEST", 323, 334], ["viral tropism", "PROBLEM", 382, 395], ["severe", "OBSERVATION_MODIFIER", 315, 321], ["viral tropism", "OBSERVATION", 382, 395]]], ["The most prominent findings included diffuse alveolar damage, thrombosis, haemophagocytosis, and immune cell depletion.", [["alveolar", "ANATOMY", 45, 53], ["immune cell", "ANATOMY", 97, 108], ["alveolar damage", "DISEASE", 45, 60], ["thrombosis", "DISEASE", 62, 72], ["haemophagocytosis", "DISEASE", 74, 91], ["alveolar", "TISSUE", 45, 53], ["immune cell", "CELL", 97, 108], ["diffuse alveolar damage", "PROBLEM", 37, 60], ["thrombosis", "PROBLEM", 62, 72], ["haemophagocytosis", "PROBLEM", 74, 91], ["immune cell depletion", "PROBLEM", 97, 118], ["most prominent", "OBSERVATION_MODIFIER", 4, 18], ["diffuse", "OBSERVATION_MODIFIER", 37, 44], ["alveolar damage", "OBSERVATION", 45, 60], ["thrombosis", "OBSERVATION", 62, 72], ["immune cell depletion", "OBSERVATION", 97, 118]]], ["Several novel autopsy findings in patients with COVID-19 were also described, including pancreatitis, pericarditis, adrenal micro-infarction, secondary disseminated mucormycosis, and brain microglial activation.Implications of all the available evidenceOur study supports the existing clinical and autopsy literature that identified diffuse alveolar damage, thrombosis, immune cell depletion, and macrophage activation as the most prominent pathological features in COVID-19.", [["adrenal", "ANATOMY", 116, 123], ["brain", "ANATOMY", 183, 188], ["alveolar", "ANATOMY", 341, 349], ["immune cell", "ANATOMY", 370, 381], ["macrophage", "ANATOMY", 397, 407], ["pancreatitis", "DISEASE", 88, 100], ["pericarditis", "DISEASE", 102, 114], ["adrenal micro-infarction", "DISEASE", 116, 140], ["mucormycosis", "DISEASE", 165, 177], ["alveolar damage", "DISEASE", 341, 356], ["thrombosis", "DISEASE", 358, 368], ["patients", "ORGANISM", 34, 42], ["adrenal", "ORGAN", 116, 123], ["brain microglial", "CELL", 183, 199], ["alveolar", "TISSUE", 341, 349], ["immune cell", "CELL", 370, 381], ["macrophage", "CELL", 397, 407], ["patients", "SPECIES", 34, 42], ["COVID", "TEST", 48, 53], ["pancreatitis", "PROBLEM", 88, 100], ["pericarditis", "PROBLEM", 102, 114], ["adrenal micro-infarction", "PROBLEM", 116, 140], ["secondary disseminated mucormycosis", "PROBLEM", 142, 177], ["brain microglial activation", "PROBLEM", 183, 210], ["Our study", "TEST", 253, 262], ["diffuse alveolar damage", "PROBLEM", 333, 356], ["thrombosis", "PROBLEM", 358, 368], ["immune cell depletion", "PROBLEM", 370, 391], ["macrophage activation", "PROBLEM", 397, 418], ["COVID", "TEST", 466, 471], ["autopsy", "OBSERVATION", 14, 21], ["pancreatitis", "OBSERVATION", 88, 100], ["pericarditis", "OBSERVATION", 102, 114], ["adrenal", "ANATOMY", 116, 123], ["micro-infarction", "OBSERVATION", 124, 140], ["secondary", "OBSERVATION_MODIFIER", 142, 151], ["disseminated", "OBSERVATION_MODIFIER", 152, 164], ["mucormycosis", "OBSERVATION", 165, 177], ["brain", "ANATOMY", 183, 188], ["microglial activation", "OBSERVATION", 189, 210], ["diffuse", "OBSERVATION_MODIFIER", 333, 340], ["alveolar damage", "OBSERVATION", 341, 356], ["thrombosis", "OBSERVATION", 358, 368], ["immune cell depletion", "OBSERVATION", 370, 391], ["macrophage activation", "OBSERVATION", 397, 418], ["most prominent", "OBSERVATION_MODIFIER", 426, 440]]], ["Other factors, including acute kidney injury, pancreatitis, pericarditis, secondary fungal infections, and pre-existing liver disease, require further investigation.", [["kidney", "ANATOMY", 31, 37], ["liver", "ANATOMY", 120, 125], ["acute kidney injury", "DISEASE", 25, 44], ["pancreatitis", "DISEASE", 46, 58], ["pericarditis", "DISEASE", 60, 72], ["fungal infections", "DISEASE", 84, 101], ["liver disease", "DISEASE", 120, 133], ["kidney", "ORGAN", 31, 37], ["liver", "ORGAN", 120, 125], ["Other factors", "PROBLEM", 0, 13], ["acute kidney injury", "PROBLEM", 25, 44], ["pancreatitis", "PROBLEM", 46, 58], ["pericarditis", "PROBLEM", 60, 72], ["secondary fungal infections", "PROBLEM", 74, 101], ["pre-existing liver disease", "PROBLEM", 107, 133], ["further investigation", "TEST", 143, 164], ["acute", "OBSERVATION_MODIFIER", 25, 30], ["kidney", "ANATOMY", 31, 37], ["injury", "OBSERVATION", 38, 44], ["pancreatitis", "OBSERVATION", 46, 58], ["pericarditis", "OBSERVATION", 60, 72], ["secondary", "OBSERVATION_MODIFIER", 74, 83], ["fungal infections", "OBSERVATION", 84, 101], ["liver", "ANATOMY", 120, 125], ["disease", "OBSERVATION", 126, 133]]], ["The presence of ongoing viral replication in late stage COVID-19 supports the continued use of antiviral therapy, even at a point in illness when immunopathology is dominant.Implications of all the available evidenceSee Online for appendix (IQR 52-79).", [["immunopathology", "DISEASE", 146, 161], ["ongoing viral replication", "PROBLEM", 16, 41], ["antiviral therapy", "TREATMENT", 95, 112], ["ongoing", "OBSERVATION_MODIFIER", 16, 23], ["viral replication", "OBSERVATION", 24, 41], ["late stage", "OBSERVATION_MODIFIER", 45, 55], ["antiviral therapy", "OBSERVATION", 95, 112], ["dominant", "OBSERVATION", 165, 173], ["appendix", "ANATOMY", 231, 239]]], ["Seven (70%) of ten patients were men, three (30%) were women, and most patients were White or Asian (nine [90%]).", [["patients", "ORGANISM", 19, 27], ["men", "ORGANISM", 33, 36], ["women", "ORGANISM", 55, 60], ["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 19, 27], ["men", "SPECIES", 33, 36], ["women", "SPECIES", 55, 60], ["patients", "SPECIES", 71, 79]]], ["Hypertension (four [40%] patients) and chronic obstructive pulmonary disease (three [30%]) were the most common contributing factors to death according to MCCD.", [["pulmonary", "ANATOMY", 59, 68], ["Hypertension", "DISEASE", 0, 12], ["chronic obstructive pulmonary disease", "DISEASE", 39, 76], ["death", "DISEASE", 136, 141], ["MCCD", "DISEASE", 155, 159], ["patients", "ORGANISM", 25, 33], ["pulmonary", "ORGAN", 59, 68], ["patients", "SPECIES", 25, 33], ["Hypertension", "PROBLEM", 0, 12], ["chronic obstructive pulmonary disease", "PROBLEM", 39, 76], ["chronic", "OBSERVATION_MODIFIER", 39, 46], ["obstructive", "OBSERVATION_MODIFIER", 47, 58], ["pulmonary", "ANATOMY", 59, 68], ["disease", "OBSERVATION", 69, 76]]], ["All ten patients developed fever and had at least two respiratory symptoms or signs (cough, shortness of breath, reduced oxygen saturations, or pleuritic chest pain) during their early presentation.", [["respiratory", "ANATOMY", 54, 65], ["chest", "ANATOMY", 154, 159], ["fever", "DISEASE", 27, 32], ["cough", "DISEASE", 85, 90], ["shortness of breath", "DISEASE", 92, 111], ["oxygen", "CHEMICAL", 121, 127], ["chest pain", "DISEASE", 154, 164], ["oxygen", "CHEMICAL", 121, 127], ["patients", "ORGANISM", 8, 16], ["oxygen", "SIMPLE_CHEMICAL", 121, 127], ["chest", "ORGANISM_SUBDIVISION", 154, 159], ["patients", "SPECIES", 8, 16], ["fever", "PROBLEM", 27, 32], ["two respiratory symptoms", "PROBLEM", 50, 74], ["signs (cough", "PROBLEM", 78, 90], ["shortness of breath", "PROBLEM", 92, 111], ["reduced oxygen saturations", "PROBLEM", 113, 139], ["pleuritic chest pain", "PROBLEM", 144, 164], ["fever", "OBSERVATION", 27, 32], ["chest", "ANATOMY", 154, 159]]], ["Of eight patients assessed for inflammatory markers, all (100%) had elevated inflammatory markers.", [["patients", "ORGANISM", 9, 17], ["inflammatory markers", "PROTEIN", 31, 51], ["inflammatory markers", "PROTEIN", 77, 97], ["patients", "SPECIES", 9, 17], ["inflammatory markers", "PROBLEM", 31, 51], ["elevated inflammatory markers", "PROBLEM", 68, 97], ["inflammatory", "OBSERVATION_MODIFIER", 31, 43], ["elevated", "OBSERVATION_MODIFIER", 68, 76], ["inflammatory markers", "OBSERVATION", 77, 97]]], ["These features were either apparent upon presentation to hospital (eight [80%] of ten patients) or developed in an inpatient (two [20%] patients, PM8 and PM9).", [["patients", "ORGANISM", 86, 94], ["patients", "ORGANISM", 136, 144], ["patients", "SPECIES", 86, 94], ["patients", "SPECIES", 136, 144], ["PM8", "TEST", 146, 149]]], ["Most patients died within 3 weeks of symptom onset (seven [70%] patients) and were not intubated or ventilated (six [60%] patients).", [["patients", "ORGANISM", 5, 13], ["patients", "ORGANISM", 64, 72], ["patients", "ORGANISM", 122, 130], ["patients", "SPECIES", 5, 13], ["patients", "SPECIES", 64, 72], ["patients", "SPECIES", 122, 130], ["symptom onset", "PROBLEM", 37, 50]]], ["Four patients were intubated during their presentation (PM2 for 7 days, PM5 for 22 days, PM6 for less than 1 day, and PM7 for 13 days).", [["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["intubated", "TREATMENT", 19, 28]]], ["The median body-mass index (BMI) was in the obese range (31\u00b72, IQR 22\u00b73-40\u00b70) and more patients were obese according to BMI at post mortem (five [56%] of nine) than indicated on the MCCD (one [10%] of ten).", [["body", "ANATOMY", 11, 15], ["body", "ORGANISM_SUBDIVISION", 11, 15], ["patients", "ORGANISM", 87, 95], ["patients", "SPECIES", 87, 95], ["The median body-mass index", "TEST", 0, 26], ["BMI", "TEST", 28, 31], ["IQR", "TEST", 63, 66], ["obese", "PROBLEM", 101, 106], ["BMI", "TEST", 120, 123], ["median body", "ANATOMY", 4, 15], ["mass", "OBSERVATION", 16, 20], ["index", "OBSERVATION_MODIFIER", 21, 26], ["obese", "OBSERVATION", 44, 49], ["obese", "OBSERVATION", 101, 106]]], ["The median interval between death and post-mortem examination was 6 days (IQR 4\u00b78-7\u00b70), although the limited post mortem had a shorter interval (less than 20 h after death).", [["death", "DISEASE", 28, 33], ["death", "DISEASE", 166, 171], ["post-mortem examination", "TEST", 38, 61]]], ["Detailed clinical case vignettes are available in the appendix (p 3), and clinical data are summarised also in the appendix (p 20).Implications of all the available evidenceAll patients had DAD: six showed purely exudative phase DAD and four showed a mixture of exudative and organising DAD (appendix p 22, figure 1 ).", [["DAD", "DISEASE", 190, 193], ["DAD", "DISEASE", 229, 232], ["exudative", "DISEASE", 262, 271], ["DAD", "DISEASE", 287, 290], ["patients", "ORGANISM", 177, 185], ["patients", "SPECIES", 177, 185], ["clinical data", "TEST", 74, 87], ["purely exudative phase DAD", "PROBLEM", 206, 232], ["exudative", "PROBLEM", 262, 271], ["appendix", "ANATOMY", 54, 62], ["appendix", "ANATOMY", 115, 123], ["exudative", "OBSERVATION", 262, 271], ["appendix", "ANATOMY", 292, 300]]], ["Three of four patients with organising-phase DAD had spent a substantial period on a ventilator (6 days, 12 days, and >20 days).", [["DAD", "DISEASE", 45, 48], ["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["a ventilator", "TREATMENT", 83, 95]]], ["Florid acute bronchopneumonia and ventilator-associated pneumonia were not noted in this series, although mild interstitial neutrophilic inflammation (three [30%] of ten patients) and patchy acute bronchopneumonia (three [30%] patients) were observed.", [["interstitial neutrophilic", "ANATOMY", 111, 136], ["bronchopneumonia", "DISEASE", 13, 29], ["pneumonia", "DISEASE", 56, 65], ["interstitial neutrophilic inflammation", "DISEASE", 111, 149], ["bronchopneumonia", "DISEASE", 197, 213], ["patients", "ORGANISM", 170, 178], ["patients", "ORGANISM", 227, 235], ["patients", "SPECIES", 170, 178], ["patients", "SPECIES", 227, 235], ["Florid acute bronchopneumonia", "PROBLEM", 0, 29], ["ventilator-associated pneumonia", "PROBLEM", 34, 65], ["this series", "TEST", 84, 95], ["mild interstitial neutrophilic inflammation", "PROBLEM", 106, 149], ["patchy acute bronchopneumonia", "PROBLEM", 184, 213], ["acute", "OBSERVATION_MODIFIER", 7, 12], ["bronchopneumonia", "OBSERVATION", 13, 29], ["ventilator", "OBSERVATION", 34, 44], ["pneumonia", "OBSERVATION", 56, 65], ["mild", "OBSERVATION_MODIFIER", 106, 110], ["interstitial", "ANATOMY_MODIFIER", 111, 123], ["neutrophilic inflammation", "OBSERVATION", 124, 149], ["patchy", "OBSERVATION_MODIFIER", 184, 190], ["acute", "OBSERVATION_MODIFIER", 191, 196], ["bronchopneumonia", "OBSERVATION", 197, 213]]], ["Interstitial macrophages were prominent.Implications of all the available evidenceMacrophages were accompanied by scattered plasma cells.", [["Interstitial macrophages", "ANATOMY", 0, 24], ["Macrophages", "ANATOMY", 82, 93], ["plasma cells", "ANATOMY", 124, 136], ["Interstitial macrophages", "CELL", 0, 24], ["Macrophages", "CELL", 82, 93], ["plasma cells", "CELL", 124, 136], ["Interstitial macrophages", "CELL_TYPE", 0, 24], ["Macrophages", "CELL_TYPE", 82, 93], ["scattered plasma cells", "CELL_TYPE", 114, 136], ["Interstitial macrophages", "PROBLEM", 0, 24], ["scattered plasma cells", "PROBLEM", 114, 136], ["macrophages", "OBSERVATION", 13, 24], ["prominent", "OBSERVATION_MODIFIER", 30, 39], ["Macrophages", "OBSERVATION", 82, 93], ["scattered", "OBSERVATION_MODIFIER", 114, 123], ["plasma cells", "OBSERVATION", 124, 136]]], ["Mild or moderate lymphocyte inflammation was present in all ten patients, although focal lymphocyte cuffing of small vessels was noted in six patients (60%).", [["lymphocyte", "ANATOMY", 17, 27], ["focal lymphocyte", "ANATOMY", 83, 99], ["small vessels", "ANATOMY", 111, 124], ["inflammation", "DISEASE", 28, 40], ["lymphocyte", "CELL", 17, 27], ["patients", "ORGANISM", 64, 72], ["lymphocyte", "CELL", 89, 99], ["small vessels", "MULTI-TISSUE_STRUCTURE", 111, 124], ["patients", "ORGANISM", 142, 150], ["patients", "SPECIES", 64, 72], ["patients", "SPECIES", 142, 150], ["Mild or moderate lymphocyte inflammation", "PROBLEM", 0, 40], ["focal lymphocyte cuffing of small vessels", "PROBLEM", 83, 124], ["moderate", "OBSERVATION_MODIFIER", 8, 16], ["lymphocyte inflammation", "OBSERVATION", 17, 40], ["all ten", "OBSERVATION_MODIFIER", 56, 63], ["focal", "OBSERVATION_MODIFIER", 83, 88], ["lymphocyte cuffing", "OBSERVATION", 89, 107], ["small", "OBSERVATION_MODIFIER", 111, 116], ["vessels", "ANATOMY", 117, 124]]], ["We noted that lymphocytes in the lung were predominantly CD4-positive T cells.", [["lymphocytes", "ANATOMY", 14, 25], ["lung", "ANATOMY", 33, 37], ["CD4-positive T cells", "ANATOMY", 57, 77], ["lymphocytes", "CELL", 14, 25], ["lung", "ORGAN", 33, 37], ["CD4", "GENE_OR_GENE_PRODUCT", 57, 60], ["lymphocytes", "CELL_TYPE", 14, 25], ["CD4", "PROTEIN", 57, 60], ["T cells", "CELL_TYPE", 70, 77], ["lymphocytes in the lung", "PROBLEM", 14, 37], ["CD4", "TEST", 57, 60], ["positive T cells", "PROBLEM", 61, 77], ["lymphocytes", "OBSERVATION", 14, 25], ["lung", "ANATOMY", 33, 37], ["predominantly", "OBSERVATION_MODIFIER", 43, 56], ["CD4", "OBSERVATION", 57, 60], ["positive T cells", "OBSERVATION", 61, 77]]], ["CD56-positive natural killer cells were rarely found.", [["natural killer cells", "ANATOMY", 14, 34], ["CD56", "GENE_OR_GENE_PRODUCT", 0, 4], ["CD56", "PROTEIN", 0, 4], ["positive natural killer cells", "CELL_TYPE", 5, 34], ["CD56", "TEST", 0, 4], ["positive natural killer cells", "PROBLEM", 5, 34], ["positive", "OBSERVATION_MODIFIER", 5, 13], ["natural killer cells", "OBSERVATION", 14, 34]]], ["Occasionally, a patient had small aggregates of small B cells.", [["B cells", "ANATOMY", 54, 61], ["patient", "ORGANISM", 16, 23], ["B cells", "CELL", 54, 61], ["small B cells", "CELL_TYPE", 48, 61], ["patient", "SPECIES", 16, 23], ["small aggregates of small B cells", "PROBLEM", 28, 61], ["small", "OBSERVATION_MODIFIER", 28, 33], ["aggregates", "OBSERVATION", 34, 44], ["small B cells", "OBSERVATION", 48, 61]]], ["Chronic bronchiolitis was seen in most patients (nine [90%] of ten).", [["bronchiolitis", "DISEASE", 8, 21], ["patients", "ORGANISM", 39, 47], ["patients", "SPECIES", 39, 47], ["Chronic bronchiolitis", "PROBLEM", 0, 21], ["bronchiolitis", "OBSERVATION", 8, 21]]], ["No granulomas or viral inclusion were seen.", [["granulomas", "ANATOMY", 3, 13], ["granulomas", "DISEASE", 3, 13], ["granulomas", "PROBLEM", 3, 13], ["viral inclusion", "PROBLEM", 17, 32], ["granulomas", "OBSERVATION", 3, 13], ["viral", "OBSERVATION_MODIFIER", 17, 22], ["inclusion", "OBSERVATION", 23, 32]]], ["Invasive mucormycosis was noted in one patient (PM5, figure 1 ) and confirmed with Mucorales-specific PCR.", [["mucormycosis", "ANATOMY", 9, 21], ["mucormycosis", "DISEASE", 9, 21], ["mucormycosis", "CANCER", 9, 21], ["patient", "ORGANISM", 39, 46], ["patient", "SPECIES", 39, 46], ["Invasive mucormycosis", "PROBLEM", 0, 21], ["Mucorales", "TEST", 83, 92], ["specific PCR", "TEST", 93, 105], ["mucormycosis", "OBSERVATION", 9, 21]]], ["The mucormycosis was vasculocentric and disseminated, involving the hilar lymph nodes, heart, brain, and kidney in the same patient.Implications of all the available evidenceMacroscopic (two [23%] of nine patients) and microscopic (eight [89%] of nine) pulmonary thromboemboli were frequent observations (appendix p 22, figure 2 ).", [["mucormycosis", "ANATOMY", 4, 16], ["hilar lymph nodes", "ANATOMY", 68, 85], ["heart", "ANATOMY", 87, 92], ["brain", "ANATOMY", 94, 99], ["kidney", "ANATOMY", 105, 111], ["pulmonary", "ANATOMY", 253, 262], ["mucormycosis", "DISEASE", 4, 16], ["pulmonary thromboemboli", "DISEASE", 253, 276], ["mucormycosis", "CANCER", 4, 16], ["hilar lymph nodes", "MULTI-TISSUE_STRUCTURE", 68, 85], ["heart", "ORGAN", 87, 92], ["brain", "ORGAN", 94, 99], ["kidney", "ORGAN", 105, 111], ["patient", "ORGANISM", 124, 131], ["patients", "ORGANISM", 205, 213], ["pulmonary", "ORGAN", 253, 262], ["patient", "SPECIES", 124, 131], ["patients", "SPECIES", 205, 213], ["The mucormycosis", "PROBLEM", 0, 16], ["vasculocentric", "PROBLEM", 21, 35], ["the hilar lymph nodes, heart, brain, and kidney", "PROBLEM", 64, 111], ["microscopic", "TEST", 219, 230], ["pulmonary thromboemboli", "PROBLEM", 253, 276], ["appendix p", "TEST", 305, 315], ["mucormycosis", "OBSERVATION", 4, 16], ["disseminated", "OBSERVATION_MODIFIER", 40, 52], ["hilar", "ANATOMY", 68, 73], ["lymph nodes", "OBSERVATION", 74, 85], ["heart", "ANATOMY", 87, 92], ["brain", "ANATOMY", 94, 99], ["kidney", "ANATOMY", 105, 111], ["pulmonary", "ANATOMY", 253, 262], ["thromboemboli", "OBSERVATION", 263, 276]]], ["Both fibrin-rich and platelet-rich thrombi were identified in small-sized and medium-sized vessels and within the capillaries in alveolar septa (figure 2).", [["platelet-rich thrombi", "ANATOMY", 21, 42], ["vessels", "ANATOMY", 91, 98], ["capillaries", "ANATOMY", 114, 125], ["alveolar septa", "ANATOMY", 129, 143], ["fibrin", "GENE_OR_GENE_PRODUCT", 5, 11], ["platelet", "CELL", 21, 29], ["rich thrombi", "PATHOLOGICAL_FORMATION", 30, 42], ["vessels", "MULTI-TISSUE_STRUCTURE", 91, 98], ["capillaries", "TISSUE", 114, 125], ["alveolar septa", "MULTI-TISSUE_STRUCTURE", 129, 143], ["fibrin", "PROTEIN", 5, 11], ["platelet-rich thrombi", "PROBLEM", 21, 42], ["fibrin", "OBSERVATION", 5, 11], ["rich", "OBSERVATION_MODIFIER", 12, 16], ["platelet", "OBSERVATION_MODIFIER", 21, 29], ["rich", "OBSERVATION_MODIFIER", 30, 34], ["thrombi", "OBSERVATION", 35, 42], ["small", "OBSERVATION_MODIFIER", 62, 67], ["sized", "OBSERVATION_MODIFIER", 68, 73], ["medium-", "ANATOMY_MODIFIER", 78, 85], ["sized", "ANATOMY_MODIFIER", 85, 90], ["vessels", "ANATOMY", 91, 98], ["capillaries", "ANATOMY_MODIFIER", 114, 125], ["alveolar septa", "ANATOMY", 129, 143]]], ["External examination findings of deep venous thrombosis were not noted.", [["venous", "ANATOMY", 38, 44], ["venous thrombosis", "DISEASE", 38, 55], ["deep venous", "MULTI-TISSUE_STRUCTURE", 33, 44], ["External examination", "TEST", 0, 20], ["deep venous thrombosis", "PROBLEM", 33, 55], ["deep", "ANATOMY_MODIFIER", 33, 37], ["venous", "ANATOMY", 38, 44], ["thrombosis", "OBSERVATION", 45, 55]]], ["Very focal lymphocytic vasculitis was identified in one patient.Implications of all the available evidenceThrombotic features were universal in this cohort and all nine patients who underwent a full autopsy had at least one micro-thrombosis or macro-thrombosis in a major organ.", [["focal lymphocytic", "ANATOMY", 5, 22], ["organ", "ANATOMY", 272, 277], ["focal lymphocytic vasculitis", "DISEASE", 5, 33], ["micro-thrombosis", "DISEASE", 224, 240], ["macro-thrombosis", "DISEASE", 244, 260], ["lymphocytic vasculitis", "PATHOLOGICAL_FORMATION", 11, 33], ["patient", "ORGANISM", 56, 63], ["patients", "ORGANISM", 169, 177], ["organ", "ORGAN", 272, 277], ["patient", "SPECIES", 56, 63], ["patients", "SPECIES", 169, 177], ["Very focal lymphocytic vasculitis", "PROBLEM", 0, 33], ["Thrombotic features", "PROBLEM", 106, 125], ["a full autopsy", "TEST", 192, 206], ["one micro-thrombosis", "PROBLEM", 220, 240], ["macro-thrombosis", "PROBLEM", 244, 260], ["focal", "OBSERVATION_MODIFIER", 5, 10], ["lymphocytic vasculitis", "OBSERVATION", 11, 33], ["micro-thrombosis", "OBSERVATION", 224, 240], ["macro-thrombosis", "OBSERVATION", 244, 260], ["major organ", "ANATOMY", 266, 277]]], ["One (11%) of nine patients had a macroscopic acute coronary thrombosis in the right coronary artery, whereas five patients (56%) had thrombi in the microcirculation of the heart on histological analysis.", [["coronary", "ANATOMY", 51, 59], ["right coronary artery", "ANATOMY", 78, 99], ["thrombi", "ANATOMY", 133, 140], ["heart", "ANATOMY", 172, 177], ["thrombosis", "DISEASE", 60, 70], ["thrombi", "DISEASE", 133, 140], ["patients", "ORGANISM", 18, 26], ["coronary", "PATHOLOGICAL_FORMATION", 51, 59], ["right coronary artery", "MULTI-TISSUE_STRUCTURE", 78, 99], ["patients", "ORGANISM", 114, 122], ["thrombi", "PATHOLOGICAL_FORMATION", 133, 140], ["heart", "ORGAN", 172, 177], ["patients", "SPECIES", 18, 26], ["patients", "SPECIES", 114, 122], ["a macroscopic acute coronary thrombosis in the right coronary artery", "PROBLEM", 31, 99], ["thrombi in the microcirculation of the heart", "PROBLEM", 133, 177], ["histological analysis", "TEST", 181, 202], ["acute", "OBSERVATION_MODIFIER", 45, 50], ["coronary", "ANATOMY", 51, 59], ["thrombosis", "OBSERVATION", 60, 70], ["right coronary artery", "ANATOMY", 78, 99], ["thrombi", "OBSERVATION", 133, 140], ["microcirculation", "ANATOMY_MODIFIER", 148, 164], ["heart", "ANATOMY", 172, 177]]], ["Coronary artery disease was negligible or mild in most patients (seven [78%] of nine).", [["Coronary artery", "ANATOMY", 0, 15], ["Coronary artery disease", "DISEASE", 0, 23], ["Coronary artery", "MULTI-TISSUE_STRUCTURE", 0, 15], ["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["Coronary artery disease", "PROBLEM", 0, 23], ["artery", "ANATOMY", 9, 15], ["disease", "OBSERVATION", 16, 23], ["mild", "OBSERVATION_MODIFIER", 42, 46]]], ["Acute myocardial ischaemic damage (<24 h old) was noted in the patient with an acute coronary artery thrombus (figure 2A, PM1).", [["myocardial", "ANATOMY", 6, 16], ["coronary artery thrombus", "ANATOMY", 85, 109], ["myocardial ischaemic damage", "DISEASE", 6, 33], ["acute coronary artery thrombus", "DISEASE", 79, 109], ["myocardial", "MULTI-TISSUE_STRUCTURE", 6, 16], ["patient", "ORGANISM", 63, 70], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 85, 100], ["thrombus", "PATHOLOGICAL_FORMATION", 101, 109], ["patient", "SPECIES", 63, 70], ["Acute myocardial ischaemic damage", "PROBLEM", 0, 33], ["an acute coronary artery thrombus", "PROBLEM", 76, 109], ["myocardial", "ANATOMY", 6, 16], ["ischaemic", "OBSERVATION", 17, 26], ["acute", "OBSERVATION_MODIFIER", 79, 84], ["coronary artery", "ANATOMY", 85, 100], ["thrombus", "OBSERVATION", 101, 109]]], ["A mottled myocardium and subendocardial contraction band necrosis was noted in a second patient (PM2); whether the contraction band necrosis was related to ischaemia or inotropic medication received in the intensive care unit is uncertain (appendix p 28).", [["myocardium", "ANATOMY", 10, 20], ["subendocardial", "ANATOMY", 25, 39], ["necrosis", "DISEASE", 57, 65], ["necrosis", "DISEASE", 132, 140], ["ischaemia", "DISEASE", 156, 165], ["myocardium", "MULTI-TISSUE_STRUCTURE", 10, 20], ["patient", "ORGANISM", 88, 95], ["patient", "SPECIES", 88, 95], ["A mottled myocardium", "PROBLEM", 0, 20], ["subendocardial contraction band necrosis", "PROBLEM", 25, 65], ["the contraction band necrosis", "PROBLEM", 111, 140], ["ischaemia", "PROBLEM", 156, 165], ["inotropic medication", "TREATMENT", 169, 189], ["mottled", "OBSERVATION", 2, 9], ["myocardium", "ANATOMY", 10, 20], ["subendocardial", "ANATOMY_MODIFIER", 25, 39], ["contraction", "OBSERVATION_MODIFIER", 40, 51], ["band", "OBSERVATION_MODIFIER", 52, 56], ["necrosis", "OBSERVATION", 57, 65], ["contraction", "OBSERVATION", 115, 126], ["band necrosis", "OBSERVATION", 127, 140]]], ["PM1 and PM2 were the two patients with the highest active viral load detected in the heart.", [["heart", "ANATOMY", 85, 90], ["PM2", "GENE_OR_GENE_PRODUCT", 8, 11], ["patients", "ORGANISM", 25, 33], ["heart", "ORGAN", 85, 90], ["patients", "SPECIES", 25, 33], ["PM1", "TEST", 0, 3], ["PM2", "TEST", 8, 11], ["the highest active viral load", "PROBLEM", 39, 68], ["viral load", "OBSERVATION", 58, 68], ["heart", "ANATOMY", 85, 90]]], ["A single patient (11%) had a right atrial thrombus.", [["right atrial thrombus", "ANATOMY", 29, 50], ["atrial thrombus", "DISEASE", 35, 50], ["patient", "ORGANISM", 9, 16], ["atrial thrombus", "PATHOLOGICAL_FORMATION", 35, 50], ["patient", "SPECIES", 9, 16], ["a right atrial thrombus", "PROBLEM", 27, 50], ["right", "ANATOMY_MODIFIER", 29, 34], ["atrial", "ANATOMY", 35, 41], ["thrombus", "OBSERVATION", 42, 50]]], ["Pericarditis was identified in two patients (22%); one patient showed florid fibrinous pericarditis containing fungal hyphae (PM5), while the other showed only microscopic acute pericarditis (appendix p 22, figure 3 ).", [["hyphae", "ANATOMY", 118, 124], ["Pericarditis", "DISEASE", 0, 12], ["pericarditis", "DISEASE", 87, 99], ["pericarditis", "DISEASE", 178, 190], ["patients", "ORGANISM", 35, 43], ["patient", "ORGANISM", 55, 62], ["fungal hyphae", "PATHOLOGICAL_FORMATION", 111, 124], ["patients", "SPECIES", 35, 43], ["patient", "SPECIES", 55, 62], ["Pericarditis", "PROBLEM", 0, 12], ["florid fibrinous pericarditis", "PROBLEM", 70, 99], ["fungal hyphae", "PROBLEM", 111, 124], ["microscopic acute pericarditis", "PROBLEM", 160, 190], ["florid", "OBSERVATION_MODIFIER", 70, 76], ["fibrinous", "OBSERVATION_MODIFIER", 77, 86], ["pericarditis", "OBSERVATION", 87, 99], ["fungal hyphae", "OBSERVATION", 111, 124], ["microscopic", "OBSERVATION_MODIFIER", 160, 171], ["acute", "OBSERVATION_MODIFIER", 172, 177], ["pericarditis", "OBSERVATION", 178, 190], ["appendix", "ANATOMY", 192, 200]]], ["The median heart weight was high (450 g) and four (44%) of nine patients had left ventricular hypertrophy.", [["heart", "ANATOMY", 11, 16], ["left ventricular", "ANATOMY", 77, 93], ["left ventricular hypertrophy", "DISEASE", 77, 105], ["heart", "ORGAN", 11, 16], ["patients", "ORGANISM", 64, 72], ["ventricular", "MULTI-TISSUE_STRUCTURE", 82, 93], ["patients", "SPECIES", 64, 72], ["The median heart weight", "TEST", 0, 23], ["left ventricular hypertrophy", "PROBLEM", 77, 105], ["left ventricular", "ANATOMY", 77, 93], ["hypertrophy", "OBSERVATION", 94, 105]]], ["Non-bacterial thrombotic (marantic) endocarditis was noted in one patient (PM5) with no known history or autopsy findings consistent with malignancy or chronic disorder associated with non-bacterial thrombotic (marantic) endocarditis (appendix p 22, figure 2 ).", [["Non-bacterial", "ANATOMY", 0, 13], ["non-bacterial", "ANATOMY", 185, 198], ["thrombotic", "DISEASE", 14, 24], ["marantic) endocarditis", "DISEASE", 26, 48], ["malignancy", "DISEASE", 138, 148], ["chronic disorder", "DISEASE", 152, 168], ["non-bacterial thrombotic (marantic) endocarditis", "DISEASE", 185, 233], ["patient", "ORGANISM", 66, 73], ["patient", "SPECIES", 66, 73], ["Non-bacterial thrombotic (marantic) endocarditis", "PROBLEM", 0, 48], ["autopsy findings", "PROBLEM", 105, 121], ["malignancy", "PROBLEM", 138, 148], ["chronic disorder", "PROBLEM", 152, 168], ["non-bacterial thrombotic (marantic) endocarditis", "PROBLEM", 185, 233], ["thrombotic", "OBSERVATION", 14, 24], ["endocarditis", "OBSERVATION", 36, 48], ["consistent with", "UNCERTAINTY", 122, 137], ["malignancy", "OBSERVATION", 138, 148], ["chronic", "OBSERVATION_MODIFIER", 152, 159], ["non-bacterial", "OBSERVATION_MODIFIER", 185, 198], ["thrombotic", "OBSERVATION", 199, 209], ["endocarditis", "OBSERVATION", 221, 233], ["appendix", "ANATOMY", 235, 243]]], ["PM5 had disseminated mucormycosis and numerous other thrombotic features (appendix p 3).", [["PM5", "CHEMICAL", 0, 3], ["mucormycosis", "DISEASE", 21, 33], ["thrombotic", "DISEASE", 53, 63], ["mucormycosis", "CANCER", 21, 33], ["disseminated mucormycosis", "PROBLEM", 8, 33], ["numerous other thrombotic features", "PROBLEM", 38, 72], ["disseminated", "OBSERVATION_MODIFIER", 8, 20], ["mucormycosis", "OBSERVATION", 21, 33], ["numerous", "OBSERVATION_MODIFIER", 38, 46], ["thrombotic", "OBSERVATION", 53, 63], ["appendix", "ANATOMY", 74, 82]]], ["Cardiac amyloidosis and right atrial thrombosis were identified in one (10%) of ten patients (PM8; appendix p 28).", [["Cardiac", "ANATOMY", 0, 7], ["right atrial", "ANATOMY", 24, 36], ["Cardiac amyloidosis", "DISEASE", 0, 19], ["atrial thrombosis", "DISEASE", 30, 47], ["atrial", "ORGAN", 30, 36], ["patients", "ORGANISM", 84, 92], ["patients", "SPECIES", 84, 92], ["Cardiac amyloidosis", "PROBLEM", 0, 19], ["right atrial thrombosis", "PROBLEM", 24, 47], ["amyloidosis", "OBSERVATION", 8, 19], ["right", "ANATOMY_MODIFIER", 24, 29], ["atrial", "ANATOMY", 30, 36], ["thrombosis", "OBSERVATION", 37, 47], ["appendix", "ANATOMY", 99, 107]]], ["Lymphocyte depletion involving specific compartments and increased phagocytosis were prominent findings (appendix p 24, figure 4 ).", [["Lymphocyte", "ANATOMY", 0, 10], ["compartments", "ANATOMY", 40, 52], ["Lymphocyte", "CELL", 0, 10], ["Lymphocyte depletion", "PROBLEM", 0, 20], ["increased phagocytosis", "PROBLEM", 57, 79], ["depletion", "OBSERVATION", 11, 20], ["increased", "OBSERVATION_MODIFIER", 57, 66], ["phagocytosis", "OBSERVATION", 67, 79], ["prominent", "OBSERVATION_MODIFIER", 85, 94], ["appendix", "ANATOMY", 105, 113]]], ["Increased phagocytosis of other cells was identified in the sinusoidal macrophages of the red pulp of the spleen (in four [57%] of seven patients), sinus histiocytes of hilar lymph nodes (in three [50%] of six), and bone marrow (four [50%] of eight).", [["cells", "ANATOMY", 32, 37], ["sinusoidal macrophages", "ANATOMY", 60, 82], ["red pulp", "ANATOMY", 90, 98], ["spleen", "ANATOMY", 106, 112], ["sinus histiocytes", "ANATOMY", 148, 165], ["hilar lymph nodes", "ANATOMY", 169, 186], ["bone marrow", "ANATOMY", 216, 227], ["cells", "CELL", 32, 37], ["sinusoidal macrophages", "CELL", 60, 82], ["red pulp", "TISSUE", 90, 98], ["spleen", "ORGAN", 106, 112], ["patients", "ORGANISM", 137, 145], ["sinus histiocytes", "TISSUE", 148, 165], ["hilar lymph nodes", "MULTI-TISSUE_STRUCTURE", 169, 186], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 216, 227], ["sinusoidal macrophages", "CELL_TYPE", 60, 82], ["patients", "SPECIES", 137, 145], ["Increased phagocytosis of other cells", "PROBLEM", 0, 37], ["sinus histiocytes of hilar lymph nodes", "PROBLEM", 148, 186], ["bone marrow", "TEST", 216, 227], ["phagocytosis", "OBSERVATION", 10, 22], ["other cells", "OBSERVATION", 26, 37], ["sinusoidal macrophages", "OBSERVATION", 60, 82], ["red pulp", "ANATOMY_MODIFIER", 90, 98], ["spleen", "ANATOMY", 106, 112], ["sinus", "ANATOMY", 148, 153], ["histiocytes", "OBSERVATION", 154, 165], ["hilar", "ANATOMY", 169, 174], ["lymph nodes", "OBSERVATION", 175, 186], ["bone marrow", "ANATOMY", 216, 227]]], ["Phagocytosis was identified in at least one of these organs in six (67%) of nine patients.", [["organs", "ANATOMY", 53, 59], ["organs", "ORGAN", 53, 59], ["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89], ["Phagocytosis", "PROBLEM", 0, 12], ["at least", "OBSERVATION_MODIFIER", 31, 39], ["organs", "ANATOMY", 53, 59]]], ["Bone marrow haemophagocytosis was prominent in two patients (PM4 and PM8) and focal in two patients (PM7 and PM9).", [["Bone marrow", "ANATOMY", 0, 11], ["Bone marrow", "MULTI-TISSUE_STRUCTURE", 0, 11], ["patients", "ORGANISM", 51, 59], ["PM4", "CANCER", 61, 64], ["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 51, 59], ["patients", "SPECIES", 91, 99], ["Bone marrow haemophagocytosis", "TEST", 0, 29], ["PM4", "TEST", 61, 64], ["focal in two patients (PM7 and PM9)", "PROBLEM", 78, 113], ["marrow", "ANATOMY", 5, 11], ["haemophagocytosis", "OBSERVATION", 12, 29], ["prominent", "OBSERVATION_MODIFIER", 34, 43], ["focal", "OBSERVATION_MODIFIER", 78, 83]]], ["Depletion of periarteriolar T-cell sheaths within the white pulp was observed (figure 4).", [["periarteriolar T-cell sheaths", "ANATOMY", 13, 42], ["white pulp", "ANATOMY", 54, 64], ["T-cell sheaths", "TISSUE", 28, 42], ["pulp", "TISSUE", 60, 64], ["periarteriolar T-cell sheaths", "TREATMENT", 13, 42], ["the white pulp", "PROBLEM", 50, 64], ["periarteriolar T-cell sheaths", "OBSERVATION", 13, 42], ["white pulp", "ANATOMY", 54, 64]]], ["Red pulp was generally congested, showing reduced numbers of CD8-positive T cells.", [["Red pulp", "ANATOMY", 0, 8], ["CD8-positive T cells", "ANATOMY", 61, 81], ["Red pulp", "TISSUE", 0, 8], ["CD8", "GENE_OR_GENE_PRODUCT", 61, 64], ["CD8-positive T cells", "CELL_TYPE", 61, 81], ["Red pulp", "TEST", 0, 8], ["generally congested", "PROBLEM", 13, 32], ["CD8", "TEST", 61, 64], ["pulp", "ANATOMY", 4, 8], ["generally", "OBSERVATION_MODIFIER", 13, 22], ["congested", "OBSERVATION", 23, 32], ["reduced", "OBSERVATION_MODIFIER", 42, 49], ["numbers", "OBSERVATION_MODIFIER", 50, 57], ["positive T cells", "OBSERVATION", 65, 81]]], ["Plasma cells were variably prominent, and sinusoidal histiocytes showed phagocytosis of red blood cells and other cells to varying extents.", [["Plasma cells", "ANATOMY", 0, 12], ["sinusoidal histiocytes", "ANATOMY", 42, 64], ["red blood cells", "ANATOMY", 88, 103], ["cells", "ANATOMY", 114, 119], ["Plasma cells", "CELL", 0, 12], ["sinusoidal histiocytes", "CELL", 42, 64], ["red blood cells", "CELL", 88, 103], ["cells", "CELL", 114, 119], ["Plasma cells", "CELL_TYPE", 0, 12], ["sinusoidal histiocytes", "CELL_TYPE", 42, 64], ["red blood cells", "CELL_TYPE", 88, 103], ["Plasma cells", "TEST", 0, 12], ["sinusoidal histiocytes", "TEST", 42, 64], ["red blood cells", "TEST", 88, 103], ["prominent", "OBSERVATION_MODIFIER", 27, 36], ["sinusoidal histiocytes", "OBSERVATION", 42, 64], ["phagocytosis", "OBSERVATION_MODIFIER", 72, 84], ["blood cells", "OBSERVATION", 92, 103], ["varying", "OBSERVATION_MODIFIER", 123, 130], ["extents", "OBSERVATION_MODIFIER", 131, 138]]], ["Both IgM-positive and IgG-positive plasma cells were identified, and they were polytypic for light-chain expression (figure 4).", [["plasma cells", "ANATOMY", 35, 47], ["IgM", "GENE_OR_GENE_PRODUCT", 5, 8], ["IgG", "GENE_OR_GENE_PRODUCT", 22, 25], ["IgM", "PROTEIN", 5, 8], ["IgG", "PROTEIN", 22, 25], ["positive plasma cells", "CELL_TYPE", 26, 47], ["Both IgM", "TEST", 0, 8], ["IgG", "TEST", 22, 25], ["positive plasma cells", "PROBLEM", 26, 47], ["IgM", "OBSERVATION_MODIFIER", 5, 8], ["positive", "OBSERVATION_MODIFIER", 9, 17], ["positive plasma cells", "OBSERVATION", 26, 47]]], ["Lymph nodes showed preservation of follicles and relative depletion of paracortical areas.", [["Lymph nodes", "ANATOMY", 0, 11], ["follicles", "ANATOMY", 35, 44], ["paracortical areas", "ANATOMY", 71, 89], ["Lymph nodes", "MULTI-TISSUE_STRUCTURE", 0, 11], ["follicles", "MULTI-TISSUE_STRUCTURE", 35, 44], ["Lymph nodes", "TEST", 0, 11], ["preservation of follicles", "PROBLEM", 19, 44], ["relative depletion of paracortical areas", "PROBLEM", 49, 89], ["Lymph nodes", "OBSERVATION", 0, 11], ["preservation", "OBSERVATION_MODIFIER", 19, 31], ["follicles", "OBSERVATION_MODIFIER", 35, 44], ["relative", "OBSERVATION_MODIFIER", 49, 57], ["depletion", "OBSERVATION_MODIFIER", 58, 67], ["paracortical", "ANATOMY_MODIFIER", 71, 83]]], ["Medullary areas showed prominence of plasma cells, and histiocytes were prominent in the sinuses.", [["Medullary areas", "ANATOMY", 0, 15], ["plasma cells", "ANATOMY", 37, 49], ["histiocytes", "ANATOMY", 55, 66], ["sinuses", "ANATOMY", 89, 96], ["Medullary", "ORGAN", 0, 9], ["plasma cells", "CELL", 37, 49], ["histiocytes", "CELL", 55, 66], ["sinuses", "ORGAN", 89, 96], ["plasma cells", "CELL_TYPE", 37, 49], ["histiocytes", "CELL_TYPE", 55, 66], ["prominence of plasma cells", "PROBLEM", 23, 49], ["histiocytes", "PROBLEM", 55, 66], ["prominence", "OBSERVATION", 23, 33], ["plasma cells", "OBSERVATION", 37, 49], ["histiocytes", "OBSERVATION", 55, 66], ["prominent", "OBSERVATION_MODIFIER", 72, 81], ["sinuses", "ANATOMY", 89, 96]]], ["Bone marrow samples showed reactive changes with trilineage hyperplasia, and prominence of plasma cells and histiocytes were a common finding.", [["Bone marrow samples", "ANATOMY", 0, 19], ["trilineage hyperplasia", "ANATOMY", 49, 71], ["plasma cells", "ANATOMY", 91, 103], ["histiocytes", "ANATOMY", 108, 119], ["hyperplasia", "DISEASE", 60, 71], ["Bone marrow samples", "MULTI-TISSUE_STRUCTURE", 0, 19], ["plasma cells", "CELL", 91, 103], ["histiocytes", "CELL", 108, 119], ["plasma cells", "CELL_TYPE", 91, 103], ["Bone marrow samples", "TEST", 0, 19], ["reactive changes", "PROBLEM", 27, 43], ["trilineage hyperplasia", "PROBLEM", 49, 71], ["prominence of plasma cells", "PROBLEM", 77, 103], ["histiocytes", "PROBLEM", 108, 119], ["marrow", "ANATOMY", 5, 11], ["reactive", "OBSERVATION_MODIFIER", 27, 35], ["trilineage hyperplasia", "OBSERVATION", 49, 71], ["prominence", "OBSERVATION_MODIFIER", 77, 87], ["plasma cells", "OBSERVATION", 91, 103], ["histiocytes", "OBSERVATION", 108, 119]]], ["A necrotising granuloma was noted in a single hilar lymph node in one patient, and acid-fast bacilli were noted on Ziehl Neelson staining (appendix p 28).", [["granuloma", "ANATOMY", 14, 23], ["hilar lymph node", "ANATOMY", 46, 62], ["granuloma", "DISEASE", 14, 23], ["granuloma", "PATHOLOGICAL_FORMATION", 14, 23], ["hilar lymph node", "MULTI-TISSUE_STRUCTURE", 46, 62], ["patient", "ORGANISM", 70, 77], ["patient", "SPECIES", 70, 77], ["A necrotising granuloma", "PROBLEM", 0, 23], ["a single hilar lymph node", "PROBLEM", 37, 62], ["acid-fast bacilli", "TEST", 83, 100], ["necrotising", "OBSERVATION_MODIFIER", 2, 13], ["granuloma", "OBSERVATION", 14, 23], ["hilar", "ANATOMY", 46, 51], ["lymph node", "OBSERVATION", 52, 62], ["bacilli", "OBSERVATION", 93, 100], ["appendix", "ANATOMY", 139, 147]]], ["All spleen and lymphoid material examined with immuno histochemistry were negative for Epstein-Barr virus and cytomegalovirus.Implications of all the available evidencePancreatitis was noted in two (25%) of eight patients. adrenalitis was noted.", [["spleen", "ANATOMY", 4, 10], ["lymphoid material", "ANATOMY", 15, 32], ["Pancreatitis", "DISEASE", 168, 180], ["adrenalitis", "DISEASE", 223, 234], ["spleen", "ORGAN", 4, 10], ["lymphoid material", "TISSUE", 15, 32], ["Epstein-Barr virus", "ORGANISM", 87, 105], ["cytomegalovirus", "ORGANISM", 110, 125], ["patients", "ORGANISM", 213, 221], ["adrenalitis", "CANCER", 223, 234], ["patients", "SPECIES", 213, 221], ["Epstein-Barr virus", "SPECIES", 87, 105], ["immuno histochemistry", "TEST", 47, 68], ["Epstein-Barr virus", "PROBLEM", 87, 105], ["cytomegalovirus", "PROBLEM", 110, 125], ["Pancreatitis", "PROBLEM", 168, 180], ["adrenalitis", "PROBLEM", 223, 234], ["spleen", "ANATOMY", 4, 10], ["lymphoid material", "OBSERVATION", 15, 32], ["Barr virus", "OBSERVATION", 95, 105]]], ["Two (22%) of nine patients showed chronic inflammation in the thyroid with follicular epithelial cell disruption; however, the significance of this finding is uncertain.", [["thyroid", "ANATOMY", 62, 69], ["follicular epithelial cell", "ANATOMY", 75, 101], ["inflammation", "DISEASE", 42, 54], ["patients", "ORGANISM", 18, 26], ["thyroid", "ORGAN", 62, 69], ["follicular epithelial cell", "CELL", 75, 101], ["patients", "SPECIES", 18, 26], ["chronic inflammation in the thyroid", "PROBLEM", 34, 69], ["follicular epithelial cell disruption", "PROBLEM", 75, 112], ["chronic", "OBSERVATION_MODIFIER", 34, 41], ["inflammation", "OBSERVATION", 42, 54], ["thyroid", "ANATOMY", 62, 69], ["follicular epithelial cell disruption", "OBSERVATION", 75, 112]]], ["Median combined kidney weight was within normal range, at 264 g (IQR 187-356).", [["kidney", "ANATOMY", 16, 22], ["kidney", "ORGAN", 16, 22], ["Median combined kidney weight", "TEST", 0, 29], ["kidney", "ANATOMY", 16, 22]]], ["Salient renal pathology findings were acute tubular injury in all nine patients, underlying moderate cortical scarring of uncertain cause in one patient (11%), glomerular microaneurysm and thrombi in one patient (11%; figure 2) , and rare thrombi in interlobular arteries in four patients (44%).", [["renal", "ANATOMY", 8, 13], ["tubular", "ANATOMY", 44, 51], ["cortical", "ANATOMY", 101, 109], ["glomerular microaneurysm", "ANATOMY", 160, 184], ["thrombi", "ANATOMY", 189, 196], ["thrombi", "ANATOMY", 239, 246], ["interlobular arteries", "ANATOMY", 250, 271], ["acute tubular injury", "DISEASE", 38, 58], ["glomerular microaneurysm", "DISEASE", 160, 184], ["thrombi", "DISEASE", 189, 196], ["thrombi", "DISEASE", 239, 246], ["renal", "ORGAN", 8, 13], ["tubular", "TISSUE", 44, 51], ["patients", "ORGANISM", 71, 79], ["cortical", "MULTI-TISSUE_STRUCTURE", 101, 109], ["patient", "ORGANISM", 145, 152], ["glomerular microaneurysm", "CANCER", 160, 184], ["thrombi", "PATHOLOGICAL_FORMATION", 189, 196], ["patient", "ORGANISM", 204, 211], ["thrombi", "PATHOLOGICAL_FORMATION", 239, 246], ["interlobular arteries", "MULTI-TISSUE_STRUCTURE", 250, 271], ["patients", "ORGANISM", 280, 288], ["patients", "SPECIES", 71, 79], ["patient", "SPECIES", 145, 152], ["patient", "SPECIES", 204, 211], ["patients", "SPECIES", 280, 288], ["Salient renal pathology", "PROBLEM", 0, 23], ["acute tubular injury in all nine patients", "PROBLEM", 38, 79], ["underlying moderate cortical scarring", "PROBLEM", 81, 118], ["glomerular microaneurysm", "PROBLEM", 160, 184], ["thrombi", "PROBLEM", 189, 196], ["rare thrombi in interlobular arteries", "PROBLEM", 234, 271], ["renal", "ANATOMY", 8, 13], ["pathology", "OBSERVATION", 14, 23], ["acute", "OBSERVATION_MODIFIER", 38, 43], ["tubular", "OBSERVATION_MODIFIER", 44, 51], ["injury", "OBSERVATION", 52, 58], ["all nine", "OBSERVATION_MODIFIER", 62, 70], ["moderate", "OBSERVATION_MODIFIER", 92, 100], ["cortical", "OBSERVATION_MODIFIER", 101, 109], ["scarring", "OBSERVATION", 110, 118], ["uncertain", "UNCERTAINTY", 122, 131], ["glomerular", "ANATOMY", 160, 170], ["microaneurysm", "OBSERVATION", 171, 184], ["thrombi", "OBSERVATION", 189, 196], ["one", "OBSERVATION_MODIFIER", 200, 203], ["rare", "OBSERVATION_MODIFIER", 234, 238], ["thrombi", "OBSERVATION", 239, 246], ["interlobular arteries", "ANATOMY", 250, 271]]], ["PM6 (24-year-old man) had a higher degree of arterial intimal thickening than expected for that age (appendix p 28).", [["arterial intimal", "ANATOMY", 45, 61], ["PM6", "CHEMICAL", 0, 3], ["man", "ORGANISM", 17, 20], ["arterial intimal", "PATHOLOGICAL_FORMATION", 45, 61], ["man", "SPECIES", 17, 20], ["PM6", "TEST", 0, 3], ["arterial intimal thickening", "PROBLEM", 45, 72], ["higher degree", "OBSERVATION_MODIFIER", 28, 41], ["arterial", "ANATOMY_MODIFIER", 45, 53], ["intimal", "ANATOMY", 54, 61], ["thickening", "OBSERVATION", 62, 72]]], ["We observed no evidence of focal and segmental glomerulosclerosis, diabetic glomerulopathy, or glomerulonephritis.Implications of all the available evidenceLarge droplet fatty change was seen in most patients (seven [88%] of eight).", [["glomerulosclerosis", "DISEASE", 47, 65], ["diabetic glomerulopathy", "DISEASE", 67, 90], ["glomerulonephritis", "DISEASE", 95, 113], ["patients", "ORGANISM", 200, 208], ["patients", "SPECIES", 200, 208], ["focal and segmental glomerulosclerosis", "PROBLEM", 27, 65], ["diabetic glomerulopathy", "PROBLEM", 67, 90], ["glomerulonephritis", "PROBLEM", 95, 113], ["all the available evidenceLarge droplet fatty change", "PROBLEM", 130, 182], ["no evidence of", "UNCERTAINTY", 12, 26], ["focal", "OBSERVATION_MODIFIER", 27, 32], ["segmental", "OBSERVATION_MODIFIER", 37, 46], ["glomerulosclerosis", "OBSERVATION", 47, 65], ["diabetic", "OBSERVATION_MODIFIER", 67, 75], ["glomerulopathy", "OBSERVATION", 76, 90], ["glomerulonephritis", "OBSERVATION", 95, 113]]], ["Cirrhosis or bridging hepatic fibrosis were noted in three patients (38%).", [["hepatic", "ANATOMY", 22, 29], ["Cirrhosis", "DISEASE", 0, 9], ["hepatic fibrosis", "DISEASE", 22, 38], ["hepatic", "ORGAN", 22, 29], ["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67], ["Cirrhosis", "PROBLEM", 0, 9], ["bridging hepatic fibrosis", "PROBLEM", 13, 38], ["bridging", "OBSERVATION_MODIFIER", 13, 21], ["hepatic", "ANATOMY", 22, 29], ["fibrosis", "OBSERVATION", 30, 38]]], ["No liver thrombosis was identified histologically, but one patient showed macroscopic liver infarction (figure 2).", [["liver", "ANATOMY", 3, 8], ["liver", "ANATOMY", 86, 91], ["liver thrombosis", "DISEASE", 3, 19], ["liver infarction", "DISEASE", 86, 102], ["liver", "ORGAN", 3, 8], ["patient", "ORGANISM", 59, 66], ["liver", "ORGAN", 86, 91], ["patient", "SPECIES", 59, 66], ["liver thrombosis", "PROBLEM", 3, 19], ["macroscopic liver infarction", "PROBLEM", 74, 102], ["liver", "ANATOMY", 3, 8], ["thrombosis", "OBSERVATION", 9, 19], ["liver", "ANATOMY", 86, 91], ["infarction", "OBSERVATION", 92, 102]]], ["The median liver weight was 1432 g (IQR 1012-2466) and three (33%) of nine patients showed hepatomegaly (liver weighing >2000 g).", [["liver", "ANATOMY", 11, 16], ["liver", "ANATOMY", 105, 110], ["hepatomegaly", "DISEASE", 91, 103], ["liver", "ORGAN", 11, 16], ["patients", "ORGANISM", 75, 83], ["liver", "ORGAN", 105, 110], ["patients", "SPECIES", 75, 83], ["The median liver weight", "TEST", 0, 23], ["IQR", "TEST", 36, 39], ["hepatomegaly", "PROBLEM", 91, 103], ["liver weighing", "TEST", 105, 119], ["median", "ANATOMY_MODIFIER", 4, 10], ["liver", "ANATOMY", 11, 16], ["hepatomegaly", "OBSERVATION", 91, 103], ["liver", "ANATOMY", 105, 110]]], ["Two patients (PM4 and PM7) showed marked autolysis and were not included in analysis.Implications of all the available evidenceModerate to intense microglial activation was the most prominent pathological feature in the CNS (five [100%] of five patients).", [["microglial", "ANATOMY", 147, 157], ["CNS", "ANATOMY", 220, 223], ["patients", "ORGANISM", 4, 12], ["microglial", "CELL", 147, 157], ["CNS", "ANATOMICAL_SYSTEM", 220, 223], ["patients", "ORGANISM", 245, 253], ["patients", "SPECIES", 4, 12], ["patients", "SPECIES", 245, 253], ["Two patients (PM4 and PM7", "TEST", 0, 25], ["marked autolysis", "PROBLEM", 34, 50], ["marked", "OBSERVATION_MODIFIER", 34, 40], ["autolysis", "OBSERVATION", 41, 50], ["most prominent", "OBSERVATION_MODIFIER", 177, 191], ["CNS", "ANATOMY", 220, 223]]], ["Mild T-cell infiltration was noted around blood vessels and capillaries in all five patients, but B cells were absent.", [["T-cell", "ANATOMY", 5, 11], ["blood vessels", "ANATOMY", 42, 55], ["capillaries", "ANATOMY", 60, 71], ["B cells", "ANATOMY", 98, 105], ["T-cell", "CELL", 5, 11], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 42, 55], ["capillaries", "TISSUE", 60, 71], ["patients", "ORGANISM", 84, 92], ["B cells", "CELL", 98, 105], ["B cells", "CELL_TYPE", 98, 105], ["patients", "SPECIES", 84, 92], ["Mild T-cell infiltration", "PROBLEM", 0, 24], ["B cells", "TEST", 98, 105], ["-cell infiltration", "OBSERVATION", 6, 24], ["blood vessels", "ANATOMY", 42, 55], ["capillaries", "ANATOMY_MODIFIER", 60, 71]]], ["We found ischaemic changes of variable extent in the neurons of the cortex and in the white matter detected by BAPP (\u03b2 amyloid precursor protein) stain.", [["neurons", "ANATOMY", 53, 60], ["cortex", "ANATOMY", 68, 74], ["white matter", "ANATOMY", 86, 98], ["neurons", "CELL", 53, 60], ["cortex", "CANCER", 68, 74], ["BAPP", "GENE_OR_GENE_PRODUCT", 111, 115], ["\u03b2 amyloid precursor protein", "GENE_OR_GENE_PRODUCT", 117, 144], ["BAPP", "PROTEIN", 111, 115], ["\u03b2 amyloid precursor protein", "PROTEIN", 117, 144], ["ischaemic changes", "PROBLEM", 9, 26], ["the white matter", "PROBLEM", 82, 98], ["BAPP", "TEST", 111, 115], ["ischaemic", "OBSERVATION_MODIFIER", 9, 18], ["variable", "OBSERVATION_MODIFIER", 30, 38], ["extent", "OBSERVATION_MODIFIER", 39, 45], ["neurons", "ANATOMY_MODIFIER", 53, 60], ["cortex", "ANATOMY_MODIFIER", 68, 74], ["white matter", "ANATOMY", 86, 98]]], ["However, no necrosis of brain tissue or extensive infiltration of inflammatory cells in brain parenchyma or meninges was observed on histological examination, although one (11%) of nine patients showed macroscopic haemorrhagic transformation in a large recent cerebral infarction in the distribution of the middle cerebral artery.Implications of all the available evidenceTissues from five patients were analysed for presence of viral genomes against E gene and indications of viral replication against subgenomic RNA transcripts by qRT-PCR.", [["brain tissue", "ANATOMY", 24, 36], ["inflammatory cells", "ANATOMY", 66, 84], ["brain parenchyma", "ANATOMY", 88, 104], ["meninges", "ANATOMY", 108, 116], ["cerebral", "ANATOMY", 260, 268], ["middle cerebral artery", "ANATOMY", 307, 329], ["Tissues", "ANATOMY", 372, 379], ["necrosis", "DISEASE", 12, 20], ["haemorrhagic transformation", "DISEASE", 214, 241], ["cerebral infarction", "DISEASE", 260, 279], ["brain tissue", "TISSUE", 24, 36], ["inflammatory cells", "CELL", 66, 84], ["brain parenchyma", "MULTI-TISSUE_STRUCTURE", 88, 104], ["meninges", "ORGAN", 108, 116], ["patients", "ORGANISM", 186, 194], ["cerebral", "ORGAN", 260, 268], ["middle cerebral artery", "MULTI-TISSUE_STRUCTURE", 307, 329], ["Tissues", "CANCER", 372, 379], ["patients", "ORGANISM", 390, 398], ["E", "GENE_OR_GENE_PRODUCT", 451, 452], ["inflammatory cells", "CELL_TYPE", 66, 84], ["viral genomes", "DNA", 429, 442], ["E gene", "DNA", 451, 457], ["subgenomic RNA transcripts", "RNA", 503, 529], ["patients", "SPECIES", 186, 194], ["patients", "SPECIES", 390, 398], ["necrosis of brain tissue", "PROBLEM", 12, 36], ["extensive infiltration of inflammatory cells in brain parenchyma", "PROBLEM", 40, 104], ["meninges", "PROBLEM", 108, 116], ["histological examination", "TEST", 133, 157], ["macroscopic haemorrhagic transformation", "PROBLEM", 202, 241], ["a large recent cerebral infarction", "PROBLEM", 245, 279], ["viral genomes", "PROBLEM", 429, 442], ["viral replication", "TREATMENT", 477, 494], ["subgenomic RNA transcripts", "TREATMENT", 503, 529], ["no", "UNCERTAINTY", 9, 11], ["necrosis", "OBSERVATION", 12, 20], ["brain", "ANATOMY", 24, 29], ["tissue", "OBSERVATION", 30, 36], ["extensive", "OBSERVATION_MODIFIER", 40, 49], ["infiltration", "OBSERVATION", 50, 62], ["inflammatory cells", "OBSERVATION", 66, 84], ["brain", "ANATOMY", 88, 93], ["parenchyma", "ANATOMY_MODIFIER", 94, 104], ["meninges", "OBSERVATION", 108, 116], ["macroscopic", "OBSERVATION_MODIFIER", 202, 213], ["haemorrhagic transformation", "OBSERVATION", 214, 241], ["large", "OBSERVATION_MODIFIER", 247, 252], ["cerebral", "ANATOMY", 260, 268], ["infarction", "OBSERVATION", 269, 279], ["distribution", "ANATOMY_MODIFIER", 287, 299], ["middle cerebral artery", "ANATOMY", 307, 329]]], ["Viral RNA was present in respiratory tract samples, including lung, of all five cases analysed.", [["respiratory tract samples", "ANATOMY", 25, 50], ["lung", "ANATOMY", 62, 66], ["Viral", "ORGANISM", 0, 5], ["respiratory tract samples", "CANCER", 25, 50], ["lung", "ORGAN", 62, 66], ["Viral RNA", "RNA", 0, 9], ["Viral RNA", "PROBLEM", 0, 9], ["respiratory tract samples", "TEST", 25, 50], ["RNA", "OBSERVATION", 6, 9], ["respiratory tract", "ANATOMY", 25, 42], ["lung", "ANATOMY", 62, 66]]], ["In addition, two of three patients had detectable viral RNA in the nasal epithelium and four of five patients in the trachea.", [["nasal epithelium", "ANATOMY", 67, 83], ["trachea", "ANATOMY", 117, 124], ["patients", "ORGANISM", 26, 34], ["nasal epithelium", "TISSUE", 67, 83], ["patients", "ORGANISM", 101, 109], ["trachea", "ORGAN", 117, 124], ["viral RNA", "RNA", 50, 59], ["patients", "SPECIES", 26, 34], ["patients", "SPECIES", 101, 109], ["detectable viral RNA in the nasal epithelium", "PROBLEM", 39, 83], ["viral RNA", "OBSERVATION", 50, 59], ["nasal epithelium", "ANATOMY", 67, 83], ["four", "OBSERVATION_MODIFIER", 88, 92], ["trachea", "ANATOMY", 117, 124]]], ["Evidence of viral genomes outside the respiratory tract was found for all five patients, but the distribution and viral loads varied case by case ( figure 5A ).", [["respiratory tract", "ANATOMY", 38, 55], ["respiratory tract", "ORGANISM_SUBDIVISION", 38, 55], ["patients", "ORGANISM", 79, 87], ["viral genomes", "DNA", 12, 25], ["patients", "SPECIES", 79, 87], ["viral genomes outside the respiratory tract", "PROBLEM", 12, 55], ["viral genomes", "OBSERVATION", 12, 25], ["respiratory tract", "ANATOMY", 38, 55], ["viral loads", "OBSERVATION", 114, 125]]], ["Viral genomes were also detected using a different qRT-PCR targeted at RdRp gene, and patterns were consistent between the two sets of primers (data not shown).", [["Viral", "ORGANISM", 0, 5], ["Viral genomes", "DNA", 0, 13], ["qRT", "DNA", 51, 54], ["RdRp gene", "DNA", 71, 80], ["Viral genomes", "PROBLEM", 0, 13], ["a different qRT", "TEST", 39, 54], ["PCR", "TEST", 55, 58], ["genomes", "OBSERVATION", 6, 13]]], ["A third primer set that detected subgenomic RNA indicated virus replication in all tissues examined, with variation between patients in levels and distribution ( figure 5B ).DiscussionIn this series, we have described the major pathological findings identified at autopsy in ten patients who died of severe COVID-19.", [["tissues", "ANATOMY", 83, 90], ["COVID", "DISEASE", 307, 312], ["COVID-19", "CHEMICAL", 307, 315], ["tissues", "TISSUE", 83, 90], ["patients", "ORGANISM", 124, 132], ["patients", "ORGANISM", 279, 287], ["subgenomic RNA", "RNA", 33, 47], ["patients", "SPECIES", 124, 132], ["patients", "SPECIES", 279, 287], ["A third primer", "PROBLEM", 0, 14], ["subgenomic RNA", "PROBLEM", 33, 47], ["virus replication in all tissues", "PROBLEM", 58, 90], ["severe COVID", "PROBLEM", 300, 312], ["subgenomic RNA", "OBSERVATION", 33, 47], ["virus replication", "OBSERVATION", 58, 75], ["all tissues", "OBSERVATION_MODIFIER", 79, 90], ["variation", "OBSERVATION_MODIFIER", 106, 115]]], ["The most consistent findings were DAD, thrombosis, haemophagocytosis, and immune cell depletion, although unexpected pathologies that are probably related to SARS-CoV-2 infection were also identified.DiscussionDAD was the most consistent and prominent feature in our series and others.", [["immune cell", "ANATOMY", 74, 85], ["DAD", "DISEASE", 34, 37], ["thrombosis", "DISEASE", 39, 49], ["haemophagocytosis", "DISEASE", 51, 68], ["SARS", "DISEASE", 158, 162], ["infection", "DISEASE", 169, 178], ["immune cell", "CELL", 74, 85], ["SARS-CoV-2", "ORGANISM", 158, 168], ["SARS-CoV", "SPECIES", 158, 166], ["DAD", "PROBLEM", 34, 37], ["thrombosis", "PROBLEM", 39, 49], ["haemophagocytosis", "PROBLEM", 51, 68], ["immune cell depletion", "PROBLEM", 74, 95], ["unexpected pathologies", "PROBLEM", 106, 128], ["SARS", "PROBLEM", 158, 162], ["CoV-2 infection", "PROBLEM", 163, 178], ["thrombosis", "OBSERVATION", 39, 49], ["immune cell depletion", "OBSERVATION", 74, 95], ["probably related to", "UNCERTAINTY", 138, 157], ["SARS", "OBSERVATION", 158, 162], ["CoV", "OBSERVATION_MODIFIER", 163, 166], ["infection", "OBSERVATION", 169, 178], ["prominent", "OBSERVATION_MODIFIER", 242, 251]]], ["7, 8 The specific phase of DAD probably represents the degree and chronicity of the offending insult (SARS-CoV-2 infection) in relation to the time of death.", [["DAD", "DISEASE", 27, 30], ["offending insult", "DISEASE", 84, 100], ["SARS-CoV-2 infection", "DISEASE", 102, 122], ["death", "DISEASE", 151, 156], ["the offending insult", "PROBLEM", 80, 100], ["SARS-CoV-2 infection", "PROBLEM", 102, 122], ["death", "PROBLEM", 151, 156], ["probably represents", "UNCERTAINTY", 31, 50]]], ["This is similar to previous coronavirus epidemics.", [["coronavirus", "DISEASE", 28, 39], ["coronavirus", "ORGANISM", 28, 39], ["previous coronavirus epidemics", "PROBLEM", 19, 49], ["coronavirus epidemics", "OBSERVATION", 28, 49]]], ["6 The conclusion by Copin and colleagues 7 that COVID-19-related lung injury \"is not diffuse alveolar damage\" might relate to their sampling strategy and chronicity (five patients had spent approximately 3 weeks on a ventilator).", [["lung", "ANATOMY", 65, 69], ["alveolar", "ANATOMY", 93, 101], ["COVID-19", "CHEMICAL", 48, 56], ["lung injury", "DISEASE", 65, 76], ["alveolar damage", "DISEASE", 93, 108], ["lung", "ORGAN", 65, 69], ["alveolar", "TISSUE", 93, 101], ["patients", "ORGANISM", 171, 179], ["patients", "SPECIES", 171, 179], ["COVID", "TEST", 48, 53], ["lung injury", "PROBLEM", 65, 76], ["diffuse alveolar damage", "PROBLEM", 85, 108], ["a ventilator", "TREATMENT", 215, 227], ["lung", "ANATOMY", 65, 69], ["injury", "OBSERVATION", 70, 76], ["not", "UNCERTAINTY", 81, 84], ["diffuse", "OBSERVATION_MODIFIER", 85, 92], ["alveolar damage", "OBSERVATION", 93, 108]]], ["Barton and colleagues 8 described prominent acute bronchopneumonia as the major finding in one of two patients, although the authors acknowledge that this was probably affected by aspiration in their patient with muscular dystrophy.", [["muscular", "ANATOMY", 213, 221], ["bronchopneumonia", "DISEASE", 50, 66], ["muscular dystrophy", "DISEASE", 213, 231], ["patients", "ORGANISM", 102, 110], ["patient", "ORGANISM", 200, 207], ["muscular", "ORGAN", 213, 221], ["patients", "SPECIES", 102, 110], ["patient", "SPECIES", 200, 207], ["prominent acute bronchopneumonia", "PROBLEM", 34, 66], ["aspiration", "PROBLEM", 180, 190], ["muscular dystrophy", "PROBLEM", 213, 231], ["prominent", "OBSERVATION_MODIFIER", 34, 43], ["acute", "OBSERVATION_MODIFIER", 44, 49], ["bronchopneumonia", "OBSERVATION", 50, 66], ["major", "OBSERVATION_MODIFIER", 74, 79], ["aspiration", "OBSERVATION", 180, 190], ["muscular", "ANATOMY", 213, 221], ["dystrophy", "OBSERVATION", 222, 231]]], ["Reports of lung histology in early COVID-19 also suggest a degree of lymphocytic pneumonia, although DAD is probably superimposed on this over time in the majority of fatal cases.", [["lung", "ANATOMY", 11, 15], ["lymphocytic", "ANATOMY", 69, 80], ["pneumonia", "DISEASE", 81, 90], ["DAD", "DISEASE", 101, 104], ["lung", "ORGAN", 11, 15], ["lung histology", "TEST", 11, 25], ["early COVID", "TEST", 29, 40], ["lymphocytic pneumonia", "PROBLEM", 69, 90], ["lung", "ANATOMY", 11, 15], ["histology", "OBSERVATION", 16, 25], ["degree", "OBSERVATION_MODIFIER", 59, 65], ["lymphocytic", "OBSERVATION_MODIFIER", 69, 80], ["pneumonia", "OBSERVATION", 81, 90], ["probably superimposed", "UNCERTAINTY", 108, 129]]], ["7 Pulmonary macrophage infiltration and multinucleated giant cell reactions are prominent, similar to other series.", [["Pulmonary macrophage", "ANATOMY", 2, 22], ["multinucleated giant cell", "ANATOMY", 40, 65], ["Pulmonary macrophage", "CELL", 2, 22], ["multinucleated giant cell", "CELL", 40, 65], ["Pulmonary macrophage infiltration", "PROBLEM", 2, 35], ["multinucleated giant cell reactions", "PROBLEM", 40, 75], ["Pulmonary", "ANATOMY", 2, 11], ["macrophage infiltration", "OBSERVATION", 12, 35], ["multinucleated", "OBSERVATION_MODIFIER", 40, 54], ["giant cell reactions", "OBSERVATION", 55, 75], ["prominent", "OBSERVATION_MODIFIER", 80, 89]]], ["[8] [9] [10] [11] [12] Definite evidence of tissue-related lymphocyte depletion in COVID-19 will require quantitative analysis comparing tissues from COVID-19 patients with DAD associated with other conditions and unaffected tissues.", [["tissue", "ANATOMY", 44, 50], ["lymphocyte", "ANATOMY", 59, 69], ["tissues", "ANATOMY", 137, 144], ["tissues", "ANATOMY", 225, 232], ["DAD", "DISEASE", 173, 176], ["[8] [9] [10] [11] [12]", "SIMPLE_CHEMICAL", 0, 22], ["tissue", "TISSUE", 44, 50], ["lymphocyte", "CELL", 59, 69], ["tissues", "TISSUE", 137, 144], ["patients", "ORGANISM", 159, 167], ["tissues", "TISSUE", 225, 232], ["patients", "SPECIES", 159, 167], ["tissue-related lymphocyte depletion", "PROBLEM", 44, 79], ["COVID", "TEST", 83, 88], ["quantitative analysis", "TEST", 105, 126], ["COVID", "TEST", 150, 155], ["DAD", "PROBLEM", 173, 176], ["other conditions and unaffected tissues", "PROBLEM", 193, 232], ["Definite evidence of", "UNCERTAINTY", 23, 43], ["tissue", "ANATOMY", 44, 50], ["lymphocyte depletion", "OBSERVATION", 59, 79]]], ["Several cases of invasive pulmonary aspergillosis have been reported in patients with severe COVID-19 pneumonia.", [["invasive pulmonary aspergillosis", "ANATOMY", 17, 49], ["invasive pulmonary aspergillosis", "DISEASE", 17, 49], ["pneumonia", "DISEASE", 102, 111], ["pulmonary", "ORGAN", 26, 35], ["aspergillosis", "PATHOLOGICAL_FORMATION", 36, 49], ["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80], ["invasive pulmonary aspergillosis", "PROBLEM", 17, 49], ["severe COVID-19 pneumonia", "PROBLEM", 86, 111], ["invasive", "OBSERVATION_MODIFIER", 17, 25], ["pulmonary", "ANATOMY", 26, 35], ["aspergillosis", "OBSERVATION", 36, 49], ["severe", "OBSERVATION_MODIFIER", 86, 92], ["pneumonia", "OBSERVATION", 102, 111]]], ["18 To our knowledge, this is the first description of histologically proven mucormycosis in patients with COVID-19 and suggests that other human fungal pathogens, including members of Mucoromycotina, can complicate COVID-19-associated infections.DiscussionNumerous clinical features, including raised serum D-dimer concentrations, raised pro-calcitonin concentrations, and imaging findings, suggest thrombosis is prominent in patients with COVID-19.", [["mucormycosis", "ANATOMY", 76, 88], ["serum", "ANATOMY", 301, 306], ["mucormycosis", "DISEASE", 76, 88], ["COVID-19", "CHEMICAL", 106, 114], ["fungal pathogens", "DISEASE", 145, 161], ["COVID-19", "CHEMICAL", 215, 223], ["infections", "DISEASE", 235, 245], ["thrombosis", "DISEASE", 399, 409], ["pro-calcitonin", "CHEMICAL", 338, 352], ["COVID-19", "CHEMICAL", 440, 448], ["mucormycosis", "CANCER", 76, 88], ["patients", "ORGANISM", 92, 100], ["human", "ORGANISM", 139, 144], ["Mucoromycotina", "GENE_OR_GENE_PRODUCT", 184, 198], ["serum", "ORGANISM_SUBSTANCE", 301, 306], ["D-dimer", "SIMPLE_CHEMICAL", 307, 314], ["pro-calcitonin", "SIMPLE_CHEMICAL", 338, 352], ["patients", "ORGANISM", 426, 434], ["patients", "SPECIES", 92, 100], ["human", "SPECIES", 139, 144], ["patients", "SPECIES", 426, 434], ["human", "SPECIES", 139, 144], ["mucormycosis", "PROBLEM", 76, 88], ["COVID", "TEST", 106, 111], ["other human fungal pathogens", "PROBLEM", 133, 161], ["Mucoromycotina", "PROBLEM", 184, 198], ["COVID", "TEST", 215, 220], ["associated infections", "PROBLEM", 224, 245], ["raised serum D-dimer concentrations", "PROBLEM", 294, 329], ["raised pro-calcitonin concentrations", "PROBLEM", 331, 367], ["imaging findings", "TEST", 373, 389], ["thrombosis", "PROBLEM", 399, 409], ["COVID", "TEST", 440, 445], ["mucormycosis", "OBSERVATION", 76, 88], ["fungal pathogens", "OBSERVATION", 145, 161], ["infections", "OBSERVATION", 235, 245], ["suggest", "UNCERTAINTY", 391, 398], ["thrombosis", "OBSERVATION", 399, 409], ["prominent", "OBSERVATION_MODIFIER", 413, 422]]], ["2 Thrombotic features were universal among patients who underwent full autopsies (all nine patients had thrombi in at least one major organ) and have been noted to be prominent in other COVID-19 autopsy series.", [["thrombi", "ANATOMY", 104, 111], ["organ", "ANATOMY", 134, 139], ["thrombi", "DISEASE", 104, 111], ["patients", "ORGANISM", 43, 51], ["patients", "ORGANISM", 91, 99], ["organ", "ORGAN", 134, 139], ["patients", "SPECIES", 43, 51], ["patients", "SPECIES", 91, 99], ["Thrombotic features", "PROBLEM", 2, 21], ["full autopsies", "TEST", 66, 80], ["thrombi", "PROBLEM", 104, 111], ["Thrombotic", "OBSERVATION", 2, 12], ["thrombi", "OBSERVATION", 104, 111], ["prominent", "OBSERVATION", 167, 176]]], ["15 In a retrospective study of 159 autopsies in patients with acute respiratory distress syndrome and DAD of various causes, only 24% showed thrombi within the small vessels of the lung despite sampling of every lobe of the lung.", [["respiratory", "ANATOMY", 68, 79], ["thrombi", "ANATOMY", 141, 148], ["small vessels", "ANATOMY", 160, 173], ["lung", "ANATOMY", 181, 185], ["lobe", "ANATOMY", 212, 216], ["lung", "ANATOMY", 224, 228], ["acute respiratory distress syndrome", "DISEASE", 62, 97], ["DAD", "DISEASE", 102, 105], ["thrombi", "DISEASE", 141, 148], ["patients", "ORGANISM", 48, 56], ["thrombi", "PATHOLOGICAL_FORMATION", 141, 148], ["small vessels", "MULTI-TISSUE_STRUCTURE", 160, 173], ["lung", "ORGAN", 181, 185], ["lobe", "ORGAN", 212, 216], ["lung", "ORGAN", 224, 228], ["patients", "SPECIES", 48, 56], ["a retrospective study", "TEST", 6, 27], ["acute respiratory distress syndrome", "PROBLEM", 62, 97], ["thrombi", "PROBLEM", 141, 148], ["acute", "OBSERVATION_MODIFIER", 62, 67], ["respiratory distress", "OBSERVATION", 68, 88], ["thrombi", "OBSERVATION", 141, 148], ["small", "ANATOMY_MODIFIER", 160, 165], ["vessels", "ANATOMY", 166, 173], ["lung", "ANATOMY", 181, 185], ["lobe", "ANATOMY_MODIFIER", 212, 216], ["lung", "ANATOMY", 224, 228]]], ["19 Another study used post-mortem angiography and identified thrombi in nearly all cases of acute respiratory distress syndrome from various causes.", [["thrombi", "ANATOMY", 61, 68], ["respiratory", "ANATOMY", 98, 109], ["thrombi", "DISEASE", 61, 68], ["respiratory distress syndrome", "DISEASE", 98, 127], ["Another study", "TEST", 3, 16], ["post-mortem angiography", "TEST", 22, 45], ["thrombi", "PROBLEM", 61, 68], ["acute respiratory distress syndrome", "PROBLEM", 92, 127], ["various causes", "PROBLEM", 133, 147], ["thrombi", "OBSERVATION", 61, 68], ["acute", "OBSERVATION_MODIFIER", 92, 97], ["respiratory distress syndrome", "OBSERVATION", 98, 127]]], ["20 Whether thrombosis in COVID-19 is more common than in other causes of DAD remains uncertain; however, our data support thrombosis as being a striking feature in these patients.", [["thrombosis", "DISEASE", 11, 21], ["COVID-19", "CHEMICAL", 25, 33], ["DAD", "DISEASE", 73, 76], ["thrombosis", "DISEASE", 122, 132], ["patients", "ORGANISM", 170, 178], ["patients", "SPECIES", 170, 178], ["thrombosis", "PROBLEM", 11, 21], ["COVID", "TEST", 25, 30], ["thrombosis", "PROBLEM", 122, 132], ["thrombosis", "OBSERVATION", 11, 21], ["more common", "OBSERVATION_MODIFIER", 37, 48], ["thrombosis", "OBSERVATION", 122, 132]]], ["A study suggested endotheliitis as a prominent feature in patients with severe COVID-19, 10 but this was not a prominent feature in our patients.", [["endotheliitis", "DISEASE", 18, 31], ["COVID", "DISEASE", 79, 84], ["patients", "ORGANISM", 58, 66], ["patients", "ORGANISM", 136, 144], ["patients", "SPECIES", 58, 66], ["patients", "SPECIES", 136, 144], ["A study", "TEST", 0, 7], ["endotheliitis", "PROBLEM", 18, 31], ["severe COVID", "PROBLEM", 72, 84], ["prominent", "OBSERVATION_MODIFIER", 37, 46], ["severe", "OBSERVATION_MODIFIER", 72, 78], ["prominent", "OBSERVATION_MODIFIER", 111, 120]]], ["Importantly, limited post mortem or postmortem cross-sectional imaging are likely to underrepresent the true extent of thrombosis (particularly micro-thrombosis) and its impact on patient death.", [["thrombosis", "DISEASE", 119, 129], ["micro-thrombosis", "DISEASE", 144, 160], ["death", "DISEASE", 188, 193], ["patient", "ORGANISM", 180, 187], ["patient", "SPECIES", 180, 187], ["postmortem cross-sectional imaging", "TEST", 36, 70], ["thrombosis", "PROBLEM", 119, 129], ["micro-thrombosis", "PROBLEM", 144, 160], ["patient death", "PROBLEM", 180, 193], ["thrombosis", "OBSERVATION", 119, 129], ["thrombosis", "OBSERVATION", 150, 160]]], ["The extent of cardiomegaly, fibro-intimal thickening of renal blood vessels, and obesity in our series supports a contribution of hypertension beyond that noted clinically (only four patients had hypertension documented on the MCCD).DiscussionA raised cytokine profile has been documented in a subset of patients with severe COVID-19.", [["intimal", "ANATOMY", 34, 41], ["renal blood vessels", "ANATOMY", 56, 75], ["cardiomegaly", "DISEASE", 14, 26], ["obesity", "DISEASE", 81, 88], ["hypertension", "DISEASE", 130, 142], ["hypertension", "DISEASE", 196, 208], ["intimal", "TISSUE", 34, 41], ["renal blood vessels", "MULTI-TISSUE_STRUCTURE", 56, 75], ["patients", "ORGANISM", 183, 191], ["patients", "ORGANISM", 304, 312], ["cytokine", "PROTEIN", 252, 260], ["patients", "SPECIES", 183, 191], ["patients", "SPECIES", 304, 312], ["cardiomegaly", "PROBLEM", 14, 26], ["fibro-intimal thickening of renal blood vessels", "PROBLEM", 28, 75], ["obesity", "PROBLEM", 81, 88], ["hypertension", "PROBLEM", 130, 142], ["hypertension", "PROBLEM", 196, 208], ["severe COVID", "PROBLEM", 318, 330], ["extent", "OBSERVATION_MODIFIER", 4, 10], ["cardiomegaly", "OBSERVATION", 14, 26], ["fibro", "OBSERVATION_MODIFIER", 28, 33], ["intimal", "ANATOMY_MODIFIER", 34, 41], ["thickening", "OBSERVATION", 42, 52], ["renal", "ANATOMY_MODIFIER", 56, 61], ["blood vessels", "ANATOMY", 62, 75], ["obesity", "OBSERVATION", 81, 88], ["hypertension", "OBSERVATION", 130, 142], ["hypertension", "OBSERVATION", 196, 208]]], ["2 Consistent with this, haematological organs in our series showed prominent phagocytosis in several patients, which has not been documented in previous series.", [["haematological organs", "ANATOMY", 24, 45], ["organs", "ORGAN", 39, 45], ["patients", "ORGANISM", 101, 109], ["patients", "SPECIES", 101, 109], ["our series", "TEST", 49, 59], ["prominent phagocytosis", "PROBLEM", 67, 89], ["Consistent with", "UNCERTAINTY", 2, 17], ["prominent", "OBSERVATION_MODIFIER", 67, 76], ["phagocytosis", "OBSERVATION", 77, 89], ["several patients", "OBSERVATION_MODIFIER", 93, 109]]], ["21 Of the four patients with bone marrow haemophagocytosis, one patient (PM7) showed mild transaminitis, hyperbilirubinaemia, elevated serum ferritin concentrations, and fever of 39\u00b71\u00b0C; however, most clinical data were insufficient to assess the presence of haemophagocytic lympho histiocytosis.", [["bone marrow", "ANATOMY", 29, 40], ["serum", "ANATOMY", 135, 140], ["bone marrow haemophagocytosis", "DISEASE", 29, 58], ["transaminitis", "DISEASE", 90, 103], ["hyperbilirubinaemia", "DISEASE", 105, 124], ["fever", "DISEASE", 170, 175], ["haemophagocytic lympho histiocytosis", "DISEASE", 259, 295], ["patients", "ORGANISM", 15, 23], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 29, 40], ["patient", "ORGANISM", 64, 71], ["serum", "ORGANISM_SUBSTANCE", 135, 140], ["ferritin", "GENE_OR_GENE_PRODUCT", 141, 149], ["haemophagocytic lympho histiocytosis", "CANCER", 259, 295], ["ferritin", "PROTEIN", 141, 149], ["patients", "SPECIES", 15, 23], ["patient", "SPECIES", 64, 71], ["bone marrow haemophagocytosis", "PROBLEM", 29, 58], ["mild transaminitis", "PROBLEM", 85, 103], ["hyperbilirubinaemia", "PROBLEM", 105, 124], ["elevated serum ferritin concentrations", "PROBLEM", 126, 164], ["fever", "PROBLEM", 170, 175], ["haemophagocytic lympho histiocytosis", "PROBLEM", 259, 295], ["bone", "ANATOMY", 29, 33], ["marrow haemophagocytosis", "OBSERVATION", 34, 58], ["mild", "OBSERVATION_MODIFIER", 85, 89], ["transaminitis", "OBSERVATION", 90, 103], ["hyperbilirubinaemia", "OBSERVATION", 105, 124], ["elevated", "OBSERVATION_MODIFIER", 126, 134], ["serum ferritin", "OBSERVATION_MODIFIER", 135, 149], ["concentrations", "OBSERVATION_MODIFIER", 150, 164], ["fever", "OBSERVATION_MODIFIER", 170, 175], ["haemophagocytic lympho histiocytosis", "OBSERVATION", 259, 295]]], ["A substantial feature in COVID-19 is lymphocyte depletion, and this is supported in our series by the spleen and lymph node findings.", [["lymphocyte", "ANATOMY", 37, 47], ["spleen", "ANATOMY", 102, 108], ["lymph node", "ANATOMY", 113, 123], ["COVID-19", "CELL", 25, 33], ["lymphocyte", "CELL", 37, 47], ["spleen", "ORGAN", 102, 108], ["lymph node", "MULTI-TISSUE_STRUCTURE", 113, 123], ["COVID-19", "DNA", 25, 33], ["COVID", "TEST", 25, 30], ["lymphocyte depletion", "PROBLEM", 37, 57], ["lymph node findings", "TEST", 113, 132], ["substantial", "OBSERVATION_MODIFIER", 2, 13], ["lymphocyte depletion", "OBSERVATION", 37, 57], ["spleen", "ANATOMY", 102, 108], ["lymph node", "OBSERVATION", 113, 123]]], ["When compared with those with mild disease, patients with severe COVID-19 tend to have a higher neutrophil to lymphocyte ratio and higher CD4-positive to CD8-positive T-cell ratio.", [["neutrophil", "ANATOMY", 96, 106], ["lymphocyte", "ANATOMY", 110, 120], ["CD8-positive T-cell", "ANATOMY", 154, 173], ["patients", "ORGANISM", 44, 52], ["neutrophil", "CELL", 96, 106], ["lymphocyte", "CELL", 110, 120], ["CD4", "GENE_OR_GENE_PRODUCT", 138, 141], ["CD8", "GENE_OR_GENE_PRODUCT", 154, 157], ["CD4", "PROTEIN", 138, 141], ["CD8", "PROTEIN", 154, 157], ["patients", "SPECIES", 44, 52], ["mild disease", "PROBLEM", 30, 42], ["severe COVID", "PROBLEM", 58, 70], ["a higher neutrophil", "PROBLEM", 87, 106], ["lymphocyte ratio", "TEST", 110, 126], ["CD4", "TEST", 138, 141], ["CD8", "TEST", 154, 157], ["mild", "OBSERVATION_MODIFIER", 30, 34], ["disease", "OBSERVATION", 35, 42]]], ["22 Additionally, a negative correlation exists between peripheral blood lymphocyte count and viral copy number.", [["peripheral blood lymphocyte", "ANATOMY", 55, 82], ["peripheral blood lymphocyte", "CELL", 55, 82], ["peripheral blood lymphocyte count", "TEST", 55, 88]]], ["22 We have corroborated this evidence by documenting a low number of T cells (especially CD8-positive T cells and FOXP3-positive regulatory T cells) in the spleen and lymph nodes in severe fatal COVID-19.", [["T cells", "ANATOMY", 69, 76], ["CD8-positive T cells", "ANATOMY", 89, 109], ["FOXP3-positive regulatory T cells", "ANATOMY", 114, 147], ["spleen", "ANATOMY", 156, 162], ["lymph nodes", "ANATOMY", 167, 178], ["T cells", "CELL", 69, 76], ["CD8", "GENE_OR_GENE_PRODUCT", 89, 92], ["FOXP3", "GENE_OR_GENE_PRODUCT", 114, 119], ["spleen", "ORGAN", 156, 162], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 167, 178], ["T cells", "CELL_TYPE", 69, 76], ["CD8-positive T cells", "CELL_TYPE", 89, 109], ["FOXP3", "PROTEIN", 114, 119], ["positive regulatory T cells", "CELL_TYPE", 120, 147], ["a low number of T cells", "PROBLEM", 53, 76], ["CD8", "TEST", 89, 92], ["positive T cells", "PROBLEM", 93, 109], ["FOXP3", "TEST", 114, 119], ["positive regulatory T cells", "PROBLEM", 120, 147], ["lymph nodes", "TEST", 167, 178], ["severe fatal COVID", "PROBLEM", 182, 200], ["low number", "OBSERVATION_MODIFIER", 55, 65], ["spleen", "ANATOMY", 156, 162], ["lymph nodes", "OBSERVATION", 167, 178], ["severe", "OBSERVATION_MODIFIER", 182, 188], ["fatal", "OBSERVATION_MODIFIER", 189, 194]]], ["Notably, normal plasma cell (both IgM and IgG positive) response was present in haematological organs in most patients.DiscussionThe extent to which organ-specific pathologies relate to direct viral replication or consequent immunological and cardiovascular complications is of clinical relevance.", [["plasma cell", "ANATOMY", 16, 27], ["haematological organs", "ANATOMY", 80, 101], ["organ", "ANATOMY", 149, 154], ["cardiovascular", "ANATOMY", 243, 257], ["plasma cell", "CELL", 16, 27], ["IgM", "GENE_OR_GENE_PRODUCT", 34, 37], ["IgG", "GENE_OR_GENE_PRODUCT", 42, 45], ["haematological organs", "MULTI-TISSUE_STRUCTURE", 80, 101], ["patients", "ORGANISM", 110, 118], ["organ", "ORGAN", 149, 154], ["cardiovascular", "ANATOMICAL_SYSTEM", 243, 257], ["IgM", "PROTEIN", 34, 37], ["IgG", "PROTEIN", 42, 45], ["patients", "SPECIES", 110, 118], ["IgM", "TEST", 34, 37], ["IgG", "TEST", 42, 45], ["specific pathologies", "PROBLEM", 155, 175], ["direct viral replication", "TREATMENT", 186, 210], ["consequent immunological and cardiovascular complications", "PROBLEM", 214, 271], ["normal", "OBSERVATION", 9, 15], ["plasma cell", "OBSERVATION", 16, 27], ["haematological organs", "ANATOMY", 80, 101]]], ["We report here evidence of viral genomic RNA outside the respiratory tract.", [["respiratory tract", "ANATOMY", 57, 74], ["respiratory tract", "ORGANISM_SUBDIVISION", 57, 74], ["viral genomic RNA", "RNA", 27, 44], ["viral genomic RNA", "PROBLEM", 27, 44], ["viral genomic RNA", "OBSERVATION", 27, 44], ["respiratory tract", "ANATOMY", 57, 74]]], ["This finding is in agreement with several previous studies that have identified viral genomes by qRT-PCR in post-mortem tissues including the colon, 14 spleen, 14 liver, 14,23 skin, 24 heart, 23 and brain.", [["post-mortem tissues", "ANATOMY", 108, 127], ["colon", "ANATOMY", 142, 147], ["spleen", "ANATOMY", 152, 158], ["liver", "ANATOMY", 163, 168], ["skin", "ANATOMY", 176, 180], ["heart", "ANATOMY", 185, 190], ["brain", "ANATOMY", 199, 204], ["post-mortem tissues", "TISSUE", 108, 127], ["colon", "ORGAN", 142, 147], ["spleen", "ORGAN", 152, 158], ["liver", "ORGAN", 163, 168], ["skin", "ORGAN", 176, 180], ["heart", "ORGAN", 185, 190], ["brain", "ORGAN", 199, 204], ["viral genomes", "DNA", 80, 93], ["several previous studies", "TEST", 34, 58], ["viral genomes", "PROBLEM", 80, 93], ["qRT", "TEST", 97, 100], ["viral genomes", "OBSERVATION", 80, 93], ["colon", "ANATOMY", 142, 147], ["spleen", "ANATOMY", 152, 158], ["liver", "ANATOMY", 163, 168], ["skin", "ANATOMY", 176, 180], ["heart", "ANATOMY", 185, 190], ["brain", "ANATOMY", 199, 204]]], ["25 We also report detection of subgenomic RNA, a product that is only produced in actively infected cells.", [["cells", "ANATOMY", 100, 105], ["cells", "CELL", 100, 105], ["subgenomic RNA", "RNA", 31, 45], ["actively infected cells", "CELL_TYPE", 82, 105], ["subgenomic RNA", "PROBLEM", 31, 45], ["actively infected cells", "PROBLEM", 82, 105], ["subgenomic RNA", "OBSERVATION", 31, 45], ["infected cells", "OBSERVATION", 91, 105]]], ["A report identified low viral load in the brain of three of 18 patients with COVID-19, but could not detect the virus in subsequent immunohistochemistry and concluded that the viral genomes might have been present in the blood.", [["brain", "ANATOMY", 42, 47], ["blood", "ANATOMY", 221, 226], ["brain", "ORGAN", 42, 47], ["patients", "ORGANISM", 63, 71], ["blood", "ORGANISM_SUBSTANCE", 221, 226], ["viral genomes", "DNA", 176, 189], ["patients", "SPECIES", 63, 71], ["low viral load in the brain", "PROBLEM", 20, 47], ["COVID", "TEST", 77, 82], ["the virus", "PROBLEM", 108, 117], ["subsequent immunohistochemistry", "TEST", 121, 152], ["the viral genomes", "PROBLEM", 172, 189], ["low viral load", "OBSERVATION", 20, 34], ["brain", "ANATOMY", 42, 47], ["viral genomes", "OBSERVATION", 176, 189]]], ["25 Although we cannot exclude that the RNAs detected in our series were similarly carried to the site of sampling in blood, the distribution of RNA in different tissues varied widely between post-mortem cases.DiscussionPM3 and PM4 appear to have died earlier in the disease course (<12 days after symptom onset) and had higher viral loads in the respiratory tract than other patients, whereas PM3 and PM4 died after long stays in intensive care units and had either lower overall viral RNA (PM5) or higher viral RNA outside the respiratory tract (PM2).", [["blood", "ANATOMY", 117, 122], ["tissues", "ANATOMY", 161, 168], ["respiratory tract", "ANATOMY", 346, 363], ["respiratory tract", "ANATOMY", 528, 545], ["blood", "ORGANISM_SUBSTANCE", 117, 122], ["tissues", "TISSUE", 161, 168], ["PM4", "GENE_OR_GENE_PRODUCT", 227, 230], ["respiratory tract", "ORGANISM_SUBDIVISION", 346, 363], ["patients", "ORGANISM", 375, 383], ["respiratory tract", "ORGANISM_SUBDIVISION", 528, 545], ["viral RNA", "RNA", 480, 489], ["viral RNA", "RNA", 506, 515], ["patients", "SPECIES", 375, 383], ["the RNAs", "PROBLEM", 35, 43], ["sampling in blood", "PROBLEM", 105, 122], ["RNA in different tissues", "PROBLEM", 144, 168], ["higher viral loads in the respiratory tract", "PROBLEM", 320, 363], ["lower overall viral RNA (PM5)", "PROBLEM", 466, 495], ["higher viral RNA", "PROBLEM", 499, 515], ["cannot exclude", "UNCERTAINTY", 15, 29], ["distribution", "OBSERVATION_MODIFIER", 128, 140], ["RNA", "OBSERVATION", 144, 147], ["different tissues", "OBSERVATION", 151, 168], ["viral loads", "OBSERVATION", 327, 338], ["respiratory tract", "ANATOMY", 346, 363], ["lower", "ANATOMY_MODIFIER", 466, 471], ["viral RNA", "OBSERVATION", 480, 489], ["viral RNA", "OBSERVATION", 506, 515], ["respiratory tract", "ANATOMY", 528, 545]]], ["PM1 and PM2 were the only patients in whom we detected viral RNA and subgenomic RNA in the heart and are the only two patients with evidence of acute myocardial injury.", [["heart", "ANATOMY", 91, 96], ["myocardial", "ANATOMY", 150, 160], ["acute myocardial injury", "DISEASE", 144, 167], ["PM2", "GENE_OR_GENE_PRODUCT", 8, 11], ["patients", "ORGANISM", 26, 34], ["heart", "ORGAN", 91, 96], ["patients", "ORGANISM", 118, 126], ["myocardial", "MULTI-TISSUE_STRUCTURE", 150, 160], ["PM1", "CELL_LINE", 0, 3], ["viral RNA", "RNA", 55, 64], ["subgenomic RNA", "RNA", 69, 83], ["patients", "SPECIES", 26, 34], ["patients", "SPECIES", 118, 126], ["viral RNA", "PROBLEM", 55, 64], ["subgenomic RNA in the heart", "PROBLEM", 69, 96], ["acute myocardial injury", "PROBLEM", 144, 167], ["viral RNA", "OBSERVATION", 55, 64], ["subgenomic RNA", "OBSERVATION", 69, 83], ["heart", "ANATOMY", 91, 96], ["evidence of", "UNCERTAINTY", 132, 143], ["acute", "OBSERVATION_MODIFIER", 144, 149], ["myocardial", "ANATOMY", 150, 160], ["injury", "OBSERVATION", 161, 167]]], ["Moreover, unlike the previously mentioned study, where virus detected in the brain was 100 000 times less than that detected in the lung, the number of viral genomes detected in external tissues in our series was frequently of similar or even higher levels than that found in the respiratory tree.", [["brain", "ANATOMY", 77, 82], ["lung", "ANATOMY", 132, 136], ["external tissues", "ANATOMY", 178, 194], ["respiratory tree", "ANATOMY", 280, 296], ["brain", "ORGAN", 77, 82], ["lung", "ORGAN", 132, 136], ["external tissues", "TISSUE", 178, 194], ["viral genomes", "DNA", 152, 165], ["the previously mentioned study", "TEST", 17, 47], ["virus", "PROBLEM", 55, 60], ["viral genomes", "PROBLEM", 152, 165], ["brain", "ANATOMY", 77, 82], ["lung", "ANATOMY", 132, 136], ["number", "OBSERVATION_MODIFIER", 142, 148], ["viral genomes", "OBSERVATION", 152, 165], ["external tissues", "ANATOMY", 178, 194], ["respiratory", "ANATOMY", 280, 291], ["tree", "ANATOMY_MODIFIER", 292, 296]]], ["One study has detected SARS-CoV-2 infection of the endothelium in the vasculature of the skin and lung by immunofluorescent staining for viral antigens.", [["endothelium", "ANATOMY", 51, 62], ["vasculature", "ANATOMY", 70, 81], ["skin", "ANATOMY", 89, 93], ["lung", "ANATOMY", 98, 102], ["infection", "DISEASE", 34, 43], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 23, 33], ["endothelium", "TISSUE", 51, 62], ["vasculature", "MULTI-TISSUE_STRUCTURE", 70, 81], ["skin", "ORGAN", 89, 93], ["lung", "ORGAN", 98, 102], ["viral antigens", "PROTEIN", 137, 151], ["SARS-CoV", "SPECIES", 23, 31], ["One study", "TEST", 0, 9], ["SARS", "PROBLEM", 23, 27], ["2 infection", "PROBLEM", 32, 43], ["immunofluorescent staining", "TEST", 106, 132], ["viral antigens", "PROBLEM", 137, 151], ["SARS", "OBSERVATION", 23, 27], ["CoV", "OBSERVATION_MODIFIER", 28, 31], ["infection", "OBSERVATION", 34, 43], ["endothelium", "ANATOMY_MODIFIER", 51, 62], ["vasculature", "ANATOMY", 70, 81], ["skin", "ANATOMY", 89, 93], ["lung", "ANATOMY", 98, 102], ["viral antigens", "OBSERVATION", 137, 151]]], ["24 It is not obvious what determines spread and tropism of SARS-CoV-2 outside the respiratory tract.", [["respiratory tract", "ANATOMY", 82, 99], ["SARS", "DISEASE", 59, 63], ["SARS-CoV-2", "ORGANISM", 59, 69], ["respiratory tract", "ORGANISM_SUBDIVISION", 82, 99], ["SARS-CoV", "SPECIES", 59, 67], ["SARS", "TEST", 59, 63], ["CoV", "TEST", 64, 67], ["not obvious", "UNCERTAINTY", 9, 20], ["tropism", "OBSERVATION_MODIFIER", 48, 55], ["respiratory tract", "ANATOMY", 82, 99]]], ["Several studies have reported ACE2 expression levels that were higher in some organs than in others.", [["organs", "ANATOMY", 78, 84], ["ACE2", "GENE_OR_GENE_PRODUCT", 30, 34], ["organs", "ORGAN", 78, 84], ["ACE2", "PROTEIN", 30, 34], ["Several studies", "TEST", 0, 15], ["ACE2 expression levels", "TEST", 30, 52], ["higher", "OBSERVATION_MODIFIER", 63, 69]]], ["26 The sites of highest expression did not correlate with areas of most severe pathological involvement in our series.", [["most severe pathological involvement", "PROBLEM", 67, 103], ["highest expression", "OBSERVATION", 16, 34], ["most", "OBSERVATION_MODIFIER", 67, 71], ["severe", "OBSERVATION_MODIFIER", 72, 78], ["pathological", "OBSERVATION", 79, 91]]], ["We should note that cellular receptor status is one of many things that determines the degree of pathological involvement.", [["cellular", "ANATOMY", 20, 28], ["cellular", "CELL", 20, 28], ["pathological involvement", "PROBLEM", 97, 121], ["pathological", "OBSERVATION", 97, 109]]], ["Other aspects are likely to play a role, such as route of transmission, acid lability in the stomach, coreceptors, expression of proteases required to activate entry of virus into the cell (eg, TMPRSS2), possibly other yet unidentified host factors, and in-vivo routes of dissemination.", [["stomach", "ANATOMY", 93, 100], ["cell", "ANATOMY", 184, 188], ["stomach", "ORGAN", 93, 100], ["cell", "CELL", 184, 188], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 194, 201], ["proteases", "PROTEIN", 129, 138], ["TMPRSS2", "PROTEIN", 194, 201], ["host factors", "PROTEIN", 236, 248], ["acid lability in the stomach", "PROBLEM", 72, 100], ["proteases", "PROBLEM", 129, 138], ["dissemination", "PROBLEM", 272, 285], ["stomach", "ANATOMY", 93, 100], ["dissemination", "OBSERVATION", 272, 285]]], ["The evidence of ongoing replication late in disease supports the use of antiviral therapy even at a point in illness when immunopathology is dominant.DiscussionPancreatic pathology was a major unexpected pathology in this series, which had not been previously reported in COVID-19 autopsies or large clinical COVID-19 series.", [["Pancreatic", "ANATOMY", 160, 170], ["immunopathology", "DISEASE", 122, 137], ["Pancreatic", "ORGAN", 160, 170], ["ongoing replication late in disease", "PROBLEM", 16, 51], ["antiviral therapy", "TREATMENT", 72, 89], ["Pancreatic pathology", "TEST", 160, 180], ["a major unexpected pathology", "PROBLEM", 185, 213], ["large clinical COVID", "TEST", 294, 314], ["evidence of", "UNCERTAINTY", 4, 15], ["ongoing", "OBSERVATION_MODIFIER", 16, 23], ["replication", "OBSERVATION_MODIFIER", 24, 35], ["late", "OBSERVATION_MODIFIER", 36, 40], ["dominant", "OBSERVATION", 141, 149], ["Pancreatic", "ANATOMY", 160, 170], ["pathology", "OBSERVATION", 204, 213], ["large", "OBSERVATION_MODIFIER", 294, 299]]], ["2 A 22-year-old man had haemorrhagic, necrotic pancreatitis (PM5).", [["haemorrhagic", "DISEASE", 24, 36], ["necrotic pancreatitis", "DISEASE", 38, 59], ["man", "ORGANISM", 16, 19], ["necrotic pancreatitis", "PATHOLOGICAL_FORMATION", 38, 59], ["man", "SPECIES", 16, 19], ["haemorrhagic, necrotic pancreatitis", "PROBLEM", 24, 59], ["haemorrhagic", "OBSERVATION_MODIFIER", 24, 36], ["necrotic", "OBSERVATION_MODIFIER", 38, 46], ["pancreatitis", "OBSERVATION", 47, 59]]], ["Although this patient also had disseminated mucormycosis, he had evidence of viral persistence in the lung and no fungal hyphae were identified in the pancreas on histological sections.", [["lung", "ANATOMY", 102, 106], ["hyphae", "ANATOMY", 121, 127], ["pancreas", "ANATOMY", 151, 159], ["sections", "ANATOMY", 176, 184], ["mucormycosis", "DISEASE", 44, 56], ["patient", "ORGANISM", 14, 21], ["mucormycosis", "CANCER", 44, 56], ["lung", "ORGAN", 102, 106], ["pancreas", "ORGAN", 151, 159], ["patient", "SPECIES", 14, 21], ["disseminated mucormycosis", "PROBLEM", 31, 56], ["viral persistence in the lung", "PROBLEM", 77, 106], ["fungal hyphae", "PROBLEM", 114, 127], ["disseminated", "OBSERVATION_MODIFIER", 31, 43], ["mucormycosis", "OBSERVATION", 44, 56], ["viral", "OBSERVATION_MODIFIER", 77, 82], ["persistence", "OBSERVATION", 83, 94], ["lung", "ANATOMY", 102, 106], ["no", "UNCERTAINTY", 111, 113], ["fungal hyphae", "OBSERVATION", 114, 127], ["pancreas", "ANATOMY", 151, 159]]], ["The other patient with pancreatic pathology had microscopic evidence of pancreatitis that could be missed at autopsy without adequate sampling.", [["pancreatic", "ANATOMY", 23, 33], ["pancreatitis", "DISEASE", 72, 84], ["patient", "ORGANISM", 10, 17], ["pancreatic", "ORGAN", 23, 33], ["patient", "SPECIES", 10, 17], ["pancreatic pathology", "PROBLEM", 23, 43], ["pancreatitis", "PROBLEM", 72, 84], ["pancreatic", "ANATOMY", 23, 33], ["pathology", "OBSERVATION", 34, 43], ["evidence of", "UNCERTAINTY", 60, 71], ["pancreatitis", "OBSERVATION", 72, 84]]], ["The pancreas is a classic site of unexpected pathology identified at autopsy.", [["pancreas", "ANATOMY", 4, 12], ["pancreas", "ORGAN", 4, 12], ["unexpected pathology", "PROBLEM", 34, 54], ["pancreas", "ANATOMY", 4, 12], ["pathology", "OBSERVATION", 45, 54]]], ["27 Serum amylase is not part of the routine care bundle for COVID-19 in our Trust.", [["Serum", "ANATOMY", 3, 8], ["Serum", "ORGANISM_SUBSTANCE", 3, 8], ["amylase", "GENE_OR_GENE_PRODUCT", 9, 16], ["Serum amylase", "PROTEIN", 3, 16], ["Serum amylase", "TEST", 3, 16], ["COVID", "TEST", 60, 65]]], ["Whether the pancreatitis was related to SARS-CoV-2 infection or other causes (iatrogenic, comorbidities, or secondary infection) is not clear in our study.", [["pancreatitis", "DISEASE", 12, 24], ["SARS", "DISEASE", 40, 44], ["infection", "DISEASE", 51, 60], ["infection", "DISEASE", 118, 127], ["SARS-CoV-2", "ORGANISM", 40, 50], ["SARS-CoV", "SPECIES", 40, 48], ["the pancreatitis", "PROBLEM", 8, 24], ["SARS", "PROBLEM", 40, 44], ["CoV-2 infection", "PROBLEM", 45, 60], ["iatrogenic", "PROBLEM", 78, 88], ["comorbidities", "PROBLEM", 90, 103], ["secondary infection", "PROBLEM", 108, 127], ["our study", "TEST", 145, 154], ["pancreatitis", "OBSERVATION", 12, 24], ["infection", "OBSERVATION", 51, 60], ["iatrogenic", "OBSERVATION_MODIFIER", 78, 88], ["secondary", "OBSERVATION_MODIFIER", 108, 117], ["infection", "OBSERVATION", 118, 127]]], ["Most cases had evidence of hepatic steatosis, which is consistent with clinical findings that obesity is a risk factor for poor outcome in COVID-19, and liver cirrhosis or bridging fibrosis was prominent in this cohort.", [["hepatic", "ANATOMY", 27, 34], ["liver", "ANATOMY", 153, 158], ["hepatic steatosis", "DISEASE", 27, 44], ["obesity", "DISEASE", 94, 101], ["liver cirrhosis", "DISEASE", 153, 168], ["fibrosis", "DISEASE", 181, 189], ["hepatic steatosis", "PATHOLOGICAL_FORMATION", 27, 44], ["liver", "ORGAN", 153, 158], ["hepatic steatosis", "PROBLEM", 27, 44], ["obesity", "PROBLEM", 94, 101], ["a risk factor", "PROBLEM", 105, 118], ["COVID", "TEST", 139, 144], ["liver cirrhosis", "PROBLEM", 153, 168], ["bridging fibrosis", "PROBLEM", 172, 189], ["hepatic", "ANATOMY", 27, 34], ["steatosis", "OBSERVATION", 35, 44], ["consistent with", "UNCERTAINTY", 55, 70], ["obesity", "OBSERVATION", 94, 101], ["liver", "ANATOMY", 153, 158], ["cirrhosis", "OBSERVATION", 159, 168], ["bridging", "OBSERVATION_MODIFIER", 172, 180], ["fibrosis", "OBSERVATION", 181, 189], ["prominent", "OBSERVATION_MODIFIER", 194, 203]]], ["28 From these data, nothing suggests direct viral inflammation of the liver.", [["liver", "ANATOMY", 70, 75], ["inflammation of the liver", "DISEASE", 50, 75], ["liver", "ORGAN", 70, 75], ["these data", "TEST", 8, 18], ["direct viral inflammation of the liver", "PROBLEM", 37, 75], ["viral", "OBSERVATION_MODIFIER", 44, 49], ["inflammation", "OBSERVATION", 50, 62], ["liver", "ANATOMY", 70, 75]]], ["The interval between time of death and autopsy impaired histological interpretation in many organs and affected antigen preservation.", [["organs", "ANATOMY", 92, 98], ["death", "DISEASE", 29, 34], ["organs", "ORGAN", 92, 98], ["antigen", "GENE_OR_GENE_PRODUCT", 112, 119], ["death", "PROBLEM", 29, 34], ["autopsy", "TEST", 39, 46], ["affected antigen preservation", "TREATMENT", 103, 132]]], ["Post-mortem endothelial stripping did affect the endothelial interpretation in our study; however, a substantial number of intact vessels did not show endothelialitis or vasculitis.", [["endothelial", "ANATOMY", 12, 23], ["endothelial", "ANATOMY", 49, 60], ["vessels", "ANATOMY", 130, 137], ["endothelialitis", "DISEASE", 151, 166], ["vasculitis", "DISEASE", 170, 180], ["endothelial", "CELL", 12, 23], ["endothelial", "CELL", 49, 60], ["vessels", "MULTI-TISSUE_STRUCTURE", 130, 137], ["Post-mortem endothelial stripping", "TREATMENT", 0, 33], ["our study", "TEST", 79, 88], ["endothelialitis", "PROBLEM", 151, 166], ["vasculitis", "PROBLEM", 170, 180], ["endothelial stripping", "OBSERVATION", 12, 33], ["intact", "OBSERVATION", 123, 129], ["vessels", "ANATOMY", 130, 137], ["not show", "UNCERTAINTY", 142, 150], ["endothelialitis", "OBSERVATION", 151, 166], ["vasculitis", "OBSERVATION", 170, 180]]], ["Additionally, there might be a bias in the cohort, because some religious groups (particularly Jewish and Muslim faiths) will often not give consent for hospital post-mortem examinations.", [["hospital post-mortem examinations", "TEST", 153, 186], ["bias", "OBSERVATION", 31, 35]]], ["Of note, five of ten patients were of Asian ethnicity in this study, which might be relevant when considering future studies, especially because some ethnicities are reported to have a worse outcome.", [["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29], ["this study", "TEST", 57, 67], ["future studies", "TEST", 110, 124], ["some ethnicities", "PROBLEM", 145, 161]]], ["29 Possible solutions for these limitations include rapid autopsy examination, limited autopsies, post-mortem cross-sectional imaging, and improved information dissemination in these groups.DiscussionOur findings support the role of autopsy in drawing clinicopathological correlations in COVID-19.", [["rapid autopsy examination", "TEST", 52, 77], ["limited autopsies", "TEST", 79, 96], ["post-mortem cross-sectional imaging", "TEST", 98, 133], ["autopsy", "TEST", 233, 240], ["clinicopathological correlations", "TEST", 252, 284], ["COVID", "TEST", 288, 293]]], ["We have shown pathological evidence of DAD, thrombosis, immune cell depletion, and macrophage activation.", [["immune cell", "ANATOMY", 56, 67], ["macrophage", "ANATOMY", 83, 93], ["DAD", "DISEASE", 39, 42], ["thrombosis", "DISEASE", 44, 54], ["immune cell", "CELL", 56, 67], ["macrophage", "CELL", 83, 93], ["DAD", "PROBLEM", 39, 42], ["thrombosis", "PROBLEM", 44, 54], ["immune cell depletion", "PROBLEM", 56, 77], ["macrophage activation", "PROBLEM", 83, 104], ["evidence of", "UNCERTAINTY", 27, 38], ["DAD", "OBSERVATION", 39, 42], ["thrombosis", "OBSERVATION", 44, 54], ["immune cell depletion", "OBSERVATION", 56, 77], ["macrophage activation", "OBSERVATION", 83, 104]]], ["Other factors including acute kidney injury, pancreatitis, pericarditis, secondary fungal infections, and pre-existing liver disease require additional investigation.", [["kidney", "ANATOMY", 30, 36], ["liver", "ANATOMY", 119, 124], ["acute kidney injury", "DISEASE", 24, 43], ["pancreatitis", "DISEASE", 45, 57], ["pericarditis", "DISEASE", 59, 71], ["fungal infections", "DISEASE", 83, 100], ["liver disease", "DISEASE", 119, 132], ["kidney", "ORGAN", 30, 36], ["liver", "ORGAN", 119, 124], ["Other factors", "PROBLEM", 0, 13], ["acute kidney injury", "PROBLEM", 24, 43], ["pancreatitis", "PROBLEM", 45, 57], ["pericarditis", "PROBLEM", 59, 71], ["secondary fungal infections", "PROBLEM", 73, 100], ["pre-existing liver disease", "PROBLEM", 106, 132], ["additional investigation", "TEST", 141, 165], ["acute", "OBSERVATION_MODIFIER", 24, 29], ["kidney", "ANATOMY", 30, 36], ["injury", "OBSERVATION", 37, 43], ["pancreatitis", "OBSERVATION", 45, 57], ["pericarditis", "OBSERVATION", 59, 71], ["secondary", "OBSERVATION_MODIFIER", 73, 82], ["fungal infections", "OBSERVATION", 83, 100], ["liver", "ANATOMY", 119, 124], ["disease", "OBSERVATION", 125, 132]]], ["The evidence of ongoing replication late in disease supports the use of antiviral therapy, even at a point in illness when immunopathology is dominant.ContributorsBH and MO did the autopsies.", [["immunopathology", "DISEASE", 123, 138], ["ongoing replication late in disease", "PROBLEM", 16, 51], ["antiviral therapy", "TREATMENT", 72, 89], ["evidence of", "UNCERTAINTY", 4, 15], ["ongoing", "OBSERVATION_MODIFIER", 16, 23], ["replication", "OBSERVATION_MODIFIER", 24, 35], ["late", "OBSERVATION_MODIFIER", 36, 40], ["antiviral therapy", "OBSERVATION", 72, 89], ["dominant", "OBSERVATION", 142, 150]]], ["BH, MO, and GSC designed the study.", [["the study", "TEST", 25, 34]]], ["Subspecialist histopathology interpretation and microphotography was done by AGN and PV (lung pathology), KNN (haematopathology), RG (liver pathology), JW (head and neck pathology), CR (renal pathology), and SA-S (neuropathology).", [["lung", "ANATOMY", 89, 93], ["liver", "ANATOMY", 134, 139], ["head", "ANATOMY", 156, 160], ["neck", "ANATOMY", 165, 169], ["renal", "ANATOMY", 186, 191], ["neuropathology", "DISEASE", 214, 228], ["lung", "ORGAN", 89, 93], ["liver", "ORGAN", 134, 139], ["head", "ORGANISM_SUBDIVISION", 156, 160], ["and neck pathology", "CANCER", 161, 179], ["renal", "ORGAN", 186, 191], ["PV", "SPECIES", 85, 87], ["Subspecialist histopathology interpretation", "TEST", 0, 43], ["microphotography", "TEST", 48, 64], ["PV (lung pathology", "TEST", 85, 103], ["KNN", "TEST", 106, 109], ["haematopathology", "TEST", 111, 127], ["RG (liver pathology", "TEST", 130, 149], ["JW (head and neck pathology", "TEST", 152, 179], ["CR", "TEST", 182, 184], ["renal pathology", "TEST", 186, 201], ["PV", "ANATOMY", 85, 87], ["lung", "ANATOMY", 89, 93], ["liver", "ANATOMY", 134, 139], ["head", "ANATOMY", 156, 160], ["neck", "ANATOMY", 165, 169], ["renal", "ANATOMY", 186, 191]]], ["OCS, LB, RP, and WSB did the viral studies.", [["OCS", "CHEMICAL", 0, 3], ["the viral studies", "TEST", 25, 42], ["RP", "OBSERVATION", 9, 11]]], ["OCS prepared sections of the manuscript related to viral tropism.", [["sections", "ANATOMY", 13, 21], ["viral tropism", "PROBLEM", 51, 64], ["viral tropism", "OBSERVATION", 51, 64]]], ["BH collected clinical data, and GSC, PM, MT, and RC assisted in ultrasound-guided biopsy sampling in the limited post mortem.", [["ultrasound", "TEST", 64, 74], ["biopsy sampling", "TEST", 82, 97]]], ["BH, CR, KNN, RG, GSC, MT, RC, AGN, OCS, WSB, PV, and MO reviewed the manuscript.Declaration of interestsWe declare no competing interests.", [["PV", "SPECIES", 45, 47], ["CR", "TEST", 4, 6], ["KNN", "TEST", 8, 11], ["GSC", "TEST", 17, 20], ["OCS", "TEST", 35, 38], ["GSC", "ANATOMY", 17, 20], ["RC", "ANATOMY", 26, 28], ["AGN", "OBSERVATION", 30, 33], ["PV", "ANATOMY", 45, 47]]]], "PMC7217113": [], "7f4558c4cb1d6fb9bbe9a522ca25924740e76b0a": [["IntroductionA newly emerged betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causes a worldwide pandemic of the coronavirus disease 2019 (COVID- 19) , presenting a devastating threat to human public health attributed to its high infectivity and fatality (1) (2) (3) (4) .", [["betacoronavirus", "CHEMICAL", 28, 43], ["acute respiratory syndrome coronavirus", "DISEASE", 52, 90], ["coronavirus disease", "DISEASE", 142, 161], ["COVID- 19", "CHEMICAL", 168, 177], ["fatality", "DISEASE", 275, 283], ["betacoronavirus", "ORGANISM", 28, 43], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 45, 92], ["SARS-CoV-2", "ORGANISM", 94, 104], ["human", "ORGANISM", 216, 221], ["human", "SPECIES", 216, 221], ["severe acute respiratory syndrome coronavirus", "SPECIES", 45, 90], ["SARS-CoV-2", "SPECIES", 94, 104], ["human", "SPECIES", 216, 221], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 45, 90], ["SARS-CoV", "TEST", 94, 102], ["the coronavirus disease", "PROBLEM", 138, 161], ["COVID", "TEST", 168, 173], ["its high infectivity", "PROBLEM", 250, 270], ["severe", "OBSERVATION_MODIFIER", 45, 51], ["acute", "OBSERVATION_MODIFIER", 52, 57], ["respiratory syndrome", "OBSERVATION", 58, 78], ["coronavirus disease", "OBSERVATION", 142, 161], ["high infectivity", "OBSERVATION_MODIFIER", 254, 270]]], ["As of 18 July 2020, COVID-19 has resulted in 14 RNA viruses usually have high mutation rates and tend to evolve rapidly (5) .", [["COVID-19", "CHEMICAL", 20, 28], ["COVID-19", "DNA", 20, 28], ["COVID", "TEST", 20, 25], ["14 RNA viruses", "PROBLEM", 45, 59], ["high mutation rates", "PROBLEM", 73, 92], ["high mutation", "OBSERVATION", 73, 86]]], ["For a new RNA virus affecting humans, such as SARS-CoV-2, a recent host shift likely decreases its fitness and impels the virus to adapt to the new host environments and public health interventions (6, 7) .", [["humans", "ORGANISM", 30, 36], ["SARS-CoV-2", "ORGANISM", 46, 56], ["humans", "SPECIES", 30, 36], ["humans", "SPECIES", 30, 36], ["SARS-CoV", "SPECIES", 46, 54], ["a new RNA virus affecting humans", "PROBLEM", 4, 36], ["the virus", "PROBLEM", 118, 127], ["public health interventions", "TREATMENT", 170, 197], ["new", "OBSERVATION_MODIFIER", 6, 9], ["RNA virus", "OBSERVATION", 10, 19]]], ["Natural selection may act on the transmissibility and virulence of SARS-CoV-2 through adaptive dynamics of specific genomic mutations, which has been observed in Ebola, Zika and other viruses (6, 7) .", [["SARS", "DISEASE", 67, 71], ["Ebola, Zika and other viruses", "DISEASE", 162, 191], ["SARS-CoV-2", "ORGANISM", 67, 77], ["Ebola", "ORGANISM", 162, 167], ["SARS-CoV", "SPECIES", 67, 75], ["Natural selection", "TREATMENT", 0, 17], ["the transmissibility", "TEST", 29, 49], ["SARS", "PROBLEM", 67, 71], ["CoV", "TEST", 72, 75], ["specific genomic mutations", "PROBLEM", 107, 133], ["Ebola", "PROBLEM", 162, 167], ["Zika and other viruses", "PROBLEM", 169, 191], ["genomic mutations", "OBSERVATION", 116, 133], ["Ebola", "OBSERVATION", 162, 167]]], ["SARS-CoV-2 has circulated globally since its first outbreak in late December, 2019, and accumulated plenty of genetic polymorphisms within the short period.", [["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "ORGANISM", 0, 10], ["SARS-CoV", "SPECIES", 0, 8], ["genetic polymorphisms", "OBSERVATION", 110, 131]]], ["There are currently more than 90,000 complete SARS-CoV-2 genome sequences publicly available, of which 16,183 nucleotide substitutions have been identified (data retrieved from https://bigd.big.ac.cn/ncov/), compiling the largest population genomic data of nonhumans so far.", [["nucleotide", "CHEMICAL", 110, 120], ["nucleotide", "CHEMICAL", 110, 120], ["SARS-CoV-2 genome sequences", "DNA", 46, 73], ["complete SARS", "TEST", 37, 50], ["nucleotide substitutions", "PROBLEM", 110, 134], ["largest", "OBSERVATION_MODIFIER", 222, 229]]], ["These SARS-CoV-2 lineages have exhibited considerable variation of transmission and clinical characteristics in different countries or regions.", [["SARS", "DISEASE", 6, 10], ["SARS-CoV-2", "ORGANISM", 6, 16], ["SARS-CoV", "SPECIES", 6, 14], ["These SARS", "TEST", 0, 10], ["considerable", "OBSERVATION_MODIFIER", 41, 53], ["variation", "OBSERVATION_MODIFIER", 54, 63]]], ["For example, the basic reproduction number (R0) ranges between 2.2 and 5.9 (8, 9) , and the mortality rate from 0.8% to 14.5% (10) .IntroductionIt is critical for epidemic trend prediciton and disease control to understand whether natural selection is actively driving the adaptive evolution of transmissibility and virulence of SARS-CoV-2 during the pandemic.", [["SARS", "DISEASE", 329, 333], ["SARS-CoV-2", "ORGANISM", 329, 339], ["SARS-CoV", "SPECIES", 329, 337], ["the mortality rate", "TEST", 88, 106], ["epidemic trend prediciton", "TREATMENT", 163, 188], ["disease control", "TREATMENT", 193, 208], ["SARS", "PROBLEM", 329, 333], ["CoV", "TEST", 334, 337], ["the pandemic", "PROBLEM", 347, 359], ["basic", "OBSERVATION_MODIFIER", 17, 22], ["reproduction", "OBSERVATION_MODIFIER", 23, 35], ["number", "OBSERVATION_MODIFIER", 36, 42]]], ["If it is under selection, further research is warranted to identify the functional mutants contributing to the evolving epidemiological and pathogenic characteristics.", [["the functional mutants", "PROBLEM", 68, 90], ["the evolving epidemiological and pathogenic characteristics", "PROBLEM", 107, 166], ["pathogenic", "OBSERVATION", 140, 150]]], ["Multiple studies have been carried out to explore the problem.", [["Multiple studies", "TEST", 0, 16]]], ["Tang et al (2020) noticed that at the early stage of the COVID-19 outbreak, two major virus lineages (the S and L lineages) showed dramatic allele frequency difference before and after the lockdown of .", [["S and L lineages", "CELL_TYPE", 106, 122], ["the COVID", "TEST", 53, 62], ["dramatic allele frequency difference", "PROBLEM", 131, 167], ["virus lineages", "OBSERVATION", 86, 100], ["dramatic", "OBSERVATION_MODIFIER", 131, 139], ["allele frequency", "OBSERVATION", 140, 156]]], ["CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.Introductionis the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintIntroductionThe copyright holder for this this version posted September 9, 2020. . https://doi.org/10.1101/2020.09.07.20189860 doi: medRxiv preprint Wuhan city, and proposed that it may be due to natural selection favoring the spread of less severe lineages (11) .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["natural selection", "PROBLEM", 418, 435], ["less severe lineages", "PROBLEM", 459, 479], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 128, 131], ["may be due to", "UNCERTAINTY", 404, 417], ["natural selection", "OBSERVATION", 418, 435], ["spread", "OBSERVATION_MODIFIER", 449, 455], ["less", "OBSERVATION_MODIFIER", 459, 463], ["severe", "OBSERVATION_MODIFIER", 464, 470]]], ["However the argument is not conclusive for that allele frequency change is more likely caused by other confounding factors, e.g., stochastic fluctuation, founder effect or sampling bias (7, 12) .", [["allele", "DNA", 48, 54], ["allele frequency change", "PROBLEM", 48, 71], ["stochastic fluctuation", "PROBLEM", 130, 152], ["sampling bias", "TEST", 172, 185], ["not conclusive for", "UNCERTAINTY", 24, 42], ["more likely", "UNCERTAINTY", 75, 86]]], ["Another study found the D614G replacement on one receptor binding domain of the Spike protein is predominant in multiple regions or countries and associated with higher upper respiratory tract viral loads, indicating a possible fitness advantage (10) .IntroductionNevertheless, all these studies are based on allele frequency increase or differentiation that is not necessarily due to natural selection.", [["Spike", "GENE_OR_GENE_PRODUCT", 80, 85], ["upper", "ORGANISM_SUBDIVISION", 169, 174], ["respiratory tract", "ORGANISM_SUBDIVISION", 175, 192], ["D614G", "DNA", 24, 29], ["receptor binding domain", "PROTEIN", 49, 72], ["Spike protein", "PROTEIN", 80, 93], ["Another study", "TEST", 0, 13], ["the D614G replacement", "TREATMENT", 20, 41], ["the Spike protein", "TEST", 76, 93], ["higher upper respiratory tract viral loads", "PROBLEM", 162, 204], ["all these studies", "TEST", 278, 295], ["predominant", "OBSERVATION_MODIFIER", 97, 108], ["multiple", "OBSERVATION_MODIFIER", 112, 120], ["upper", "ANATOMY_MODIFIER", 169, 174], ["respiratory tract", "ANATOMY", 175, 192], ["viral loads", "OBSERVATION", 193, 204], ["not necessarily due to", "UNCERTAINTY", 362, 384], ["natural selection", "OBSERVATION", 385, 402]]], ["It is only useful for screening for the putative mutant loci instead of serving as a persuasive proof of the hypothesis.", [["putative mutant loci", "DNA", 40, 60], ["screening", "TEST", 22, 31], ["the putative mutant loci", "PROBLEM", 36, 60], ["the hypothesis", "PROBLEM", 105, 119]]], ["Despite the individual functional mutants identified in aforementioned studies, \"there is a lack of compelling evidence\" of mutations that \"impact the progression, severity or transmission of COVID-19 in an adaptive manner\" (7) .", [["the individual functional mutants", "PROBLEM", 8, 41], ["aforementioned studies", "TEST", 56, 78], ["mutations", "PROBLEM", 124, 133], ["COVID", "TEST", 192, 197]]], ["Indeed, the evolutionary driving forces underlying the epidemiological dynamics and pathogenic changes of SARS-CoV-2 remain elusive and uncertain.", [["SARS", "DISEASE", 106, 110], ["SARS-CoV-2", "ORGANISM", 106, 116], ["SARS-CoV", "SPECIES", 106, 114], ["pathogenic changes of SARS", "PROBLEM", 84, 110], ["CoV", "TEST", 111, 114]]], ["Furthermore, a genomewide survey of functional mutations and their implication of the epidemiological perspective were not fully accomplished either.IntroductionHerein, we analyze SARS-CoV-2 genome sequences currently collected from different geographies and time points of the outbreaks.", [["SARS-CoV-2 genome sequences", "DNA", 180, 207], ["SARS-CoV", "SPECIES", 180, 188], ["functional mutations", "PROBLEM", 36, 56], ["CoV", "TEST", 185, 188]]], ["We utilize patterns of genomic polymorphism based on the ratio of nonsynonymous mutations (N) vs synonymous mutations (S) in different groups, which are exclusively caused by natural selection and robust to clustering infections, founder effects and sampling bias commonly existing in viral genomic data.", [["infections", "DISEASE", 218, 228], ["genomic polymorphism", "PROBLEM", 23, 43], ["nonsynonymous mutations", "PROBLEM", 66, 89], ["synonymous mutations", "PROBLEM", 97, 117], ["clustering infections", "PROBLEM", 207, 228], ["sampling bias", "TEST", 250, 263], ["natural selection", "OBSERVATION", 175, 192], ["infections", "OBSERVATION", 218, 228], ["viral genomic", "OBSERVATION", 285, 298]]], ["The analysis validates the hypothesis that ongoing natural selection is actively acting on the SARS-CoV-2 genomes, shaping the epidemic dynamics of COVID-19.", [["SARS", "DISEASE", 95, 99], ["SARS-CoV-2", "ORGANISM", 95, 105], ["SARS-CoV-2 genomes", "DNA", 95, 113], ["COVID-19", "DNA", 148, 156], ["SARS-CoV", "SPECIES", 95, 103], ["The analysis", "TEST", 0, 12], ["the SARS", "TEST", 91, 99], ["CoV", "TEST", 100, 103], ["COVID", "TEST", 148, 153]]], ["We then partition the viral lineages of world samples into clusters according to their genomic similarity as a result of global transmission and clustering outbreaks.", [["samples", "ANATOMY", 46, 53], ["clustering outbreaks", "PROBLEM", 145, 165], ["viral lineages", "OBSERVATION", 22, 36]]], ["A spatial and temporal landscape of mutants is constructed based on the clusters, and critical mutants potentially conferring pathogenic and clinical characteristics of SARS-CoV-2 are highlighted.", [["SARS", "DISEASE", 169, 173], ["SARS-CoV-2", "ORGANISM", 169, 179], ["SARS-CoV", "SPECIES", 169, 177], ["A spatial and temporal landscape of mutants", "PROBLEM", 0, 43], ["SARS", "PROBLEM", 169, 173], ["CoV", "TEST", 174, 177], ["temporal", "OBSERVATION_MODIFIER", 14, 22]]], ["Our results provide a reference of genomic mutations for epidemic prediction, surveillance and clinical treatments of COVID-19.", [["epidemic prediction", "TEST", 57, 76], ["surveillance", "TEST", 78, 90], ["COVID", "TEST", 118, 123]]], ["CoV-2 genome sequences publicly available from 84 countries as of June 2 , 2020, across Asia, Europe, America, Africa, and Oceania were downloaded and aligned using MUSCLE (13) .", [["CoV-2 genome sequences", "DNA", 0, 22], ["CoV", "TEST", 0, 3], ["MUSCLE", "ANATOMY", 165, 171]]], ["The 5'-and 3'untranslated regions (UTRs) and regions with a high missing rate were trimmed out, with a final length of 29,410 nucleotides remained.", [["nucleotides", "CHEMICAL", 126, 137], ["5'-and 3'untranslated regions", "DNA", 4, 33], ["UTRs", "DNA", 35, 39], ["a high missing rate", "PROBLEM", 58, 77], ["a final length", "TEST", 101, 115], ["regions", "ANATOMY_MODIFIER", 45, 52], ["high", "OBSERVATION_MODIFIER", 60, 64], ["length", "OBSERVATION_MODIFIER", 109, 115]]], ["A total number of 8,999 mutations were identified.22,078 SARS-Since the virus populations are undergoing multiple clustering infections and founder effects, it is hard to use allele frequencies to draw reliable conclusions on virus evolution (12) .22,078 SARS-On the premise of neutral evolution, the relative numbers (ratio) of non-synonymous mutants (N) vs synonymous mutants (S) should be a constant unaffected by changes of population sizes, sine both S and N sites should demonstrate identical population behavior under the common demographic history and neutrality.", [["SARS", "DISEASE", 57, 61], ["infections", "DISEASE", 125, 135], ["SARS", "DISEASE", 255, 259], ["SARS", "PROBLEM", 57, 61], ["the virus populations", "PROBLEM", 68, 89], ["multiple clustering infections", "PROBLEM", 105, 135], ["non-synonymous mutants", "PROBLEM", 329, 351], ["synonymous mutants (S", "PROBLEM", 359, 380], ["total", "OBSERVATION_MODIFIER", 2, 7], ["multiple", "OBSERVATION_MODIFIER", 105, 113], ["clustering", "OBSERVATION_MODIFIER", 114, 124], ["infections", "OBSERVATION", 125, 135], ["sizes", "OBSERVATION_MODIFIER", 439, 444]]], ["Accordingly in the following sections, our analysis is mainly based on the analysis of N and S numbers for different sets of mutations.Purifying selection dominates the viral genomic evolutionWe first calculate the ratio of N/S using only mutation sites in very low frequencies.", [["sections", "ANATOMY", 29, 37], ["viral genomic evolutionWe", "DNA", 169, 194], ["our analysis", "TEST", 39, 51], ["the analysis", "TEST", 71, 83], ["mutations", "PROBLEM", 125, 134], ["N/S", "TREATMENT", 224, 227], ["mutation sites", "PROBLEM", 239, 253], ["viral genomic", "OBSERVATION", 169, 182], ["very", "OBSERVATION_MODIFIER", 257, 261], ["low frequencies", "OBSERVATION_MODIFIER", 262, 277]]], ["4,573 non-synonymous mutations and 2,202 synonymous mutations with the minor frequencies (f) <0.01% are identified.", [["non-synonymous mutations", "TEST", 6, 30], ["synonymous mutations", "PROBLEM", 41, 61]]], ["The N/S ratio is calculated to be 2.0768.", [["The N/S ratio", "TEST", 0, 13]]], ["From population genetics theory we know that when in very low frequencies, the population behavior of deleterious or beneficial mutants is essentially the same as that of selectively neutral mutants (14) .", [["beneficial mutants", "PROBLEM", 117, 135]]], ["Therefore, the N/S ratio 2.0768 represents the relative abundance of N and S mutations when the genome evolves under neutrality, and is determined only by sequence composition and nucleotide substitution rates of viral genomes.", [["nucleotide", "CHEMICAL", 180, 190], ["nucleotide", "CHEMICAL", 180, 190], ["viral genomes", "DNA", 213, 226], ["the N/S ratio", "TEST", 11, 24], ["N and S mutations", "PROBLEM", 69, 86], ["nucleotide substitution rates of viral genomes", "PROBLEM", 180, 226], ["viral genomes", "OBSERVATION", 213, 226]]], ["In the following analysis, we use the N/S ratio of mutations with f <0.01% as the reference under neutral conditions.", [["the N/S ratio of mutations", "TREATMENT", 34, 60]]], ["We then check the relative occurrences of N and S mutations with higher frequencies.", [["N and S mutations", "PROBLEM", 42, 59]]], ["As we can see in Table 1 , the ratio of N/S for mutations with the frequency f>0.001 decreases to1.52 and is significantly lower than N/S for f<0.01% (P =0.0034, Chi-squared test), indicating .", [["N/S", "TREATMENT", 40, 43], ["mutations", "PROBLEM", 48, 57], ["the frequency f", "TEST", 63, 78], ["N/S", "TEST", 134, 137], ["P", "TEST", 151, 152], ["Chi-squared test", "TEST", 162, 178]]], ["CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.Purifying selection dominates the viral genomic evolutionis the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintPurifying selection dominates the viral genomic evolutionThe copyright holder for this this version posted September 9, 2020. . a negative selection against non-synonymous mutations with f>0.001 during the viral evolution.Purifying selection dominates the viral genomic evolutionWe further carry out the same analysis for subsets of mutations with different allele frequency ranges (e.g., (0.0001, 0.001], (0.001, 0.01], (0.01, 0.05]).", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["Purifying selection", "TREATMENT", 267, 286], ["the viral genomic evolution", "PROBLEM", 297, 324], ["non-synonymous mutations", "PROBLEM", 424, 448], ["the viral evolution", "PROBLEM", 469, 488], ["subsets of mutations", "PROBLEM", 589, 609], ["NC", "ANATOMY", 6, 8], ["viral genomic", "OBSERVATION", 112, 125], ["med", "ANATOMY", 173, 176], ["viral genomic evolution", "OBSERVATION", 301, 324], ["negative", "OBSERVATION", 397, 405], ["viral evolution", "OBSERVATION", 473, 488], ["viral genomic", "OBSERVATION", 523, 536]]], ["The pattern of reduced N/S ratio is consistently observed, and the N/S ratio value keeps decreasing with the increase of f.", [["f.", "SPECIES", 121, 123], ["reduced N/S ratio", "PROBLEM", 15, 32], ["the N/S ratio value", "TEST", 63, 82], ["reduced", "OBSERVATION_MODIFIER", 15, 22]]], ["The N/S ratio is 1.557 for SNPs with 0.0001 < f <= 0.001, is 1.50 for 0.001 60 days) is 1.498 (409/273).", [["The N/S ratio", "TEST", 0, 13], ["SNPs", "TEST", 27, 31]]], ["The lower N/S ratio indicates more selective constrains on these long-spanning-time mutations, again, confirming the effect of purifying selection (P = 0.0137, Chi-squared test; Table 1 ).Purifying selection dominates the viral genomic evolutionIn summary, the aforementioned three analyses reveal that despite of spreading for more than eight months and the accumulation of sufficient mutations, the SAR-CoV-2 genomes are overall under purifying selection and relatively conserved.", [["SAR-CoV-2 genomes", "DNA", 401, 418], ["The lower N/S ratio", "TEST", 0, 19], ["purifying selection", "TREATMENT", 127, 146], ["P", "TEST", 148, 149], ["Chi-squared test", "TEST", 160, 176], ["Purifying selection", "TREATMENT", 188, 207], ["the viral genomic evolution", "PROBLEM", 218, 245], ["sufficient mutations", "PROBLEM", 375, 395], ["the SAR", "TEST", 397, 404], ["selective", "OBSERVATION_MODIFIER", 35, 44], ["viral genomic evolution", "OBSERVATION", 222, 245], ["sufficient mutations", "OBSERVATION", 375, 395]]], ["The conclusion also accords with the low genome-wide mutation rate inferred recently (0.000869 per site per year (12)).Purifying selection dominates the viral genomic evolutionPositive selection drives the adaptive evolution of genes conferring pathogenicity and infectivity .", [["the low genome-wide mutation rate", "PROBLEM", 33, 66], ["Purifying selection", "TREATMENT", 119, 138], ["the viral genomic evolutionPositive selection", "PROBLEM", 149, 194], ["viral genomic", "OBSERVATION", 153, 166], ["evolutionPositive selection", "OBSERVATION", 167, 194], ["infectivity", "OBSERVATION_MODIFIER", 263, 274]]], ["CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.Purifying selection dominates the viral genomic evolutionis the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintPurifying selection dominates the viral genomic evolutionThe copyright holder for this this version posted September 9, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["Purifying selection", "TREATMENT", 267, 286], ["the viral genomic evolution", "PROBLEM", 297, 324], ["NC", "ANATOMY", 6, 8], ["viral genomic", "OBSERVATION", 112, 125], ["med", "ANATOMY", 173, 176], ["viral genomic evolution", "OBSERVATION", 301, 324]]], ["Table 2 ), presenting evidence of positive selection.", [["positive selection", "PROBLEM", 34, 52], ["positive selection", "OBSERVATION", 34, 52]]], ["Another gene encoding the nucleocapsid (N) protein also shows an elevated N/S ratio (2.422) with the P-value close to 0.05 (P = 0.065).", [["nucleocapsid (N)", "GENE_OR_GENE_PRODUCT", 26, 42], ["nucleocapsid (N) protein", "PROTEIN", 26, 50], ["the nucleocapsid (N) protein", "TEST", 22, 50], ["an elevated N/S ratio", "PROBLEM", 62, 83], ["the P", "TEST", 97, 102], ["elevated", "OBSERVATION", 65, 73]]], ["Interestingly, except for the ORF10 gene that has been under very limited studies, the rest three positively-selected genes encode viral accessory proteins that play critical roles in virus-host interactions and host immune response modulation, contributing to different pathogenic outcomes (15, 16) .", [["ORF10", "GENE_OR_GENE_PRODUCT", 30, 35], ["ORF10 gene", "DNA", 30, 40], ["viral accessory proteins", "PROTEIN", 131, 155], ["viral accessory proteins", "TREATMENT", 131, 155], ["host immune response modulation", "TREATMENT", 212, 243]]], ["ORF3a has been demonstrated to induce cellular apoptosis that is recognized to antagonize host antiviral immune defense system and facilitate viral pathogenicity (16) ; ORF8 was reported to disrupt antigen presentation and mediate immune evasion that warrants further investigation (17, 18); N protein, directly binding to viral RNA, is essential for viral encapsidation, and was also reported participating in immune-evasion mechanism and promoting viral infections (19) (20) (21) (22) .", [["cellular", "ANATOMY", 38, 46], ["ORF3a", "CHEMICAL", 0, 5], ["viral infections", "DISEASE", 450, 466], ["ORF3a", "GENE_OR_GENE_PRODUCT", 0, 5], ["cellular", "CELL", 38, 46], ["ORF8", "GENE_OR_GENE_PRODUCT", 169, 173], ["ORF3a", "PROTEIN", 0, 5], ["ORF8", "PROTEIN", 169, 173], ["N protein", "PROTEIN", 292, 301], ["viral RNA", "RNA", 323, 332], ["ORF3a", "TREATMENT", 0, 5], ["cellular apoptosis", "PROBLEM", 38, 56], ["viral pathogenicity", "PROBLEM", 142, 161], ["immune evasion", "TREATMENT", 231, 245], ["further investigation", "TEST", 260, 281], ["viral RNA", "PROBLEM", 323, 332], ["viral encapsidation", "PROBLEM", 351, 370], ["promoting viral infections", "PROBLEM", 440, 466], ["cellular apoptosis", "OBSERVATION", 38, 56], ["viral", "OBSERVATION_MODIFIER", 142, 147], ["viral RNA", "OBSERVATION", 323, 332], ["essential for", "UNCERTAINTY", 337, 350], ["viral encapsidation", "OBSERVATION", 351, 370]]], ["These findings highlight that during COVID-19 global pandemic, positive selection is very likely an essential driving force and is acting on the interplay between coronavirus infection and host immune system defense.Purifying selection dominates the viral genomic evolutionIn contrast, the majority of the viral genes demonstrates a N/S ratio < 2.0 ( Fig. 1 , Table 2 ), being consistent with last section that purifying selection is dominant.", [["immune system", "ANATOMY", 194, 207], ["coronavirus infection", "DISEASE", 163, 184], ["coronavirus", "ORGANISM", 163, 174], ["viral genes", "DNA", 306, 317], ["COVID", "TEST", 37, 42], ["global pandemic", "PROBLEM", 46, 61], ["coronavirus infection", "PROBLEM", 163, 184], ["Purifying selection", "TREATMENT", 216, 235], ["the viral genomic evolution", "PROBLEM", 246, 273], ["a N/S ratio", "TEST", 331, 342], ["very likely", "UNCERTAINTY", 85, 96], ["essential", "OBSERVATION_MODIFIER", 100, 109], ["driving force", "OBSERVATION", 110, 123], ["infection", "OBSERVATION", 175, 184], ["viral genomic evolution", "OBSERVATION", 250, 273], ["viral genes", "OBSERVATION", 306, 317], ["consistent with", "UNCERTAINTY", 377, 392], ["dominant", "OBSERVATION_MODIFIER", 434, 442]]], ["Nine genes show statistically significantly reduced proportion of nonsynonymous substitutions (P < 0.05; Table 2 ).", [["nonsynonymous substitutions", "PROBLEM", 66, 93], ["nonsynonymous substitutions", "OBSERVATION", 66, 93]]], ["Eight of the negatively selected genes (NSP12, NSP4, NSP13, NSP3, NSP1, NSP10, NSP7Purifying selection dominates the viral genomic evolutionand NSP5) encode non-structure proteins of SARS-CoV-2, including the main protease, papainlike protease, RNA helicase, RNA-dependent RNA polymerase, and so on, which are essential is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintPurifying selection dominates the viral genomic evolutionThe copyright holder for this this version posted September 9, 2020. . https://doi.org/10.1101/2020.09.07.20189860 doi: medRxiv preprint in viral RNA replication, transcription, and translation (23) .", [["NSP12", "GENE_OR_GENE_PRODUCT", 40, 45], ["NSP4", "GENE_OR_GENE_PRODUCT", 47, 51], ["NSP13", "GENE_OR_GENE_PRODUCT", 53, 58], ["NSP3", "GENE_OR_GENE_PRODUCT", 60, 64], ["NSP1", "GENE_OR_GENE_PRODUCT", 66, 70], ["NSP10", "GENE_OR_GENE_PRODUCT", 72, 77], ["NSP5", "GENE_OR_GENE_PRODUCT", 144, 148], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 183, 193], ["papainlike protease", "GENE_OR_GENE_PRODUCT", 224, 243], ["NSP12", "DNA", 40, 45], ["NSP4", "DNA", 47, 51], ["NSP13", "DNA", 53, 58], ["NSP3", "DNA", 60, 64], ["NSP1", "DNA", 66, 70], ["NSP10", "DNA", 72, 77], ["NSP7Purifying selection", "DNA", 79, 102], ["viral genomic evolutionand NSP5", "DNA", 117, 148], ["non-structure proteins", "PROTEIN", 157, 179], ["SARS-CoV-2", "DNA", 183, 193], ["protease", "PROTEIN", 214, 222], ["papainlike protease", "PROTEIN", 224, 243], ["RNA helicase", "PROTEIN", 245, 257], ["RNA-dependent RNA polymerase", "PROTEIN", 259, 287], ["NSP4", "TEST", 47, 51], ["NSP13", "TEST", 53, 58], ["NSP3", "TREATMENT", 60, 64], ["NSP1", "TEST", 66, 70], ["NSP10", "TREATMENT", 72, 77], ["NSP7Purifying selection", "TREATMENT", 79, 102], ["SARS", "PROBLEM", 183, 187], ["the main protease", "TREATMENT", 205, 222], ["papainlike protease", "TREATMENT", 224, 243], ["RNA helicase", "TREATMENT", 245, 257], ["dependent RNA polymerase", "PROBLEM", 263, 287], ["Purifying selection", "TREATMENT", 452, 471], ["the viral genomic evolution", "PROBLEM", 482, 509], ["medRxiv", "TREATMENT", 629, 636], ["med", "ANATOMY", 358, 361], ["viral genomic evolution", "OBSERVATION", 486, 509]]], ["In addition, the most significant gene under negative selection encodes the SARS-CoV-2 membrane (M) protein that plays a central role in viral assembly and viral particle formation (23) .", [["SARS-CoV-2 membrane (M)", "GENE_OR_GENE_PRODUCT", 76, 99], ["SARS-CoV-2 membrane (M) protein", "PROTEIN", 76, 107], ["the SARS", "TEST", 72, 80], ["a central role in viral assembly and viral particle formation", "PROBLEM", 119, 180], ["negative selection", "OBSERVATION", 45, 63], ["viral", "OBSERVATION", 137, 142], ["viral particle", "OBSERVATION", 156, 170]]], ["The results indicate that proteins conferring fundamental molecular functions, such as viral replication, translation etc., are under significant purifying selection.Clustering pattern of viral lineagesAs we have demonstrated, although the viral genomes are under purifying selection, positive selection has been driving the evolution of genes related to coronavirus infection and is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintClustering pattern of viral lineagesThe copyright holder for this this version posted September 9, 2020.", [["coronavirus infection", "DISEASE", 355, 376], ["coronavirus", "ORGANISM", 355, 366], ["viral lineages", "CELL_TYPE", 188, 202], ["viral genomes", "DNA", 240, 253], ["viral lineages", "CELL_TYPE", 535, 549], ["viral replication", "TREATMENT", 87, 104], ["viral lineages", "PROBLEM", 188, 202], ["the viral genomes", "PROBLEM", 236, 253], ["coronavirus infection", "PROBLEM", 355, 376], ["viral lineages", "PROBLEM", 535, 549], ["viral lineages", "OBSERVATION", 188, 202], ["viral genomes", "OBSERVATION", 240, 253], ["coronavirus", "OBSERVATION_MODIFIER", 355, 366], ["infection", "OBSERVATION", 367, 376], ["med", "ANATOMY", 419, 422], ["viral lineages", "OBSERVATION", 535, 549]]], ["We map the occurrence of these mutations to branches connecting the clusters on the haplotype network (see Fig. 2A ).", [["these mutations", "PROBLEM", 25, 40], ["branches", "OBSERVATION_MODIFIER", 44, 52]]], ["The numbers of inter-cluster mutants per branch vary from 1 to 6.", [["inter-cluster mutants", "PROTEIN", 15, 36], ["branch", "ANATOMY_MODIFIER", 41, 47]]], ["C01, the cluster preponderates in East and Southeast Asia is likely the earliest cluster if using sample-collection dates as a criterion (also with the inferred TMRCA, results not shown).Clustering pattern of viral lineagesA nonsynonymous mutation L84S in the ORF8 protein, together with a tightly linked synonymous variant (S76S) in the NSP4 protein, emerged on the branch leading to the other primary cluster C07 in Asia ( Fig. 2A) .", [["ORF8", "GENE_OR_GENE_PRODUCT", 260, 264], ["NSP4", "GENE_OR_GENE_PRODUCT", 338, 342], ["ORF8 protein", "PROTEIN", 260, 272], ["S76S", "DNA", 325, 329], ["NSP4 protein", "PROTEIN", 338, 350], ["C01", "TEST", 0, 3], ["viral lineagesA nonsynonymous mutation L84S", "PROBLEM", 209, 252], ["the ORF8 protein", "TEST", 256, 272], ["a tightly linked synonymous variant", "PROBLEM", 288, 323], ["the NSP4 protein", "TEST", 334, 350], ["cluster", "OBSERVATION_MODIFIER", 9, 16], ["viral lineages", "OBSERVATION", 209, 223], ["nonsynonymous mutation", "OBSERVATION", 225, 247], ["synonymous variant", "OBSERVATION", 305, 323], ["branch", "ANATOMY_MODIFIER", 367, 373]]], ["The L84S replacement together with S76S were used in .", [["S76S", "CHEMICAL", 35, 39], ["L84S", "SIMPLE_CHEMICAL", 4, 8], ["S76S", "SIMPLE_CHEMICAL", 35, 39], ["L84S", "DNA", 4, 8], ["S76S", "DNA", 35, 39], ["The L84S replacement", "TREATMENT", 0, 20], ["S76S", "TREATMENT", 35, 39]]], ["CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.Clustering pattern of viral lineagesis the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintClustering pattern of viral lineagesThe copyright holder for this this version posted September 9, 2020. . https://doi.org/10.1101/2020.09.07.20189860 doi: medRxiv preprint former studies to define two major haplotype groups in the early epidemic stage: the L and S lineages.", [["CC", "CHEMICAL", 0, 2], ["viral lineages", "CELL_TYPE", 268, 282], ["L and S lineages", "CELL_TYPE", 504, 520], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["viral lineages", "PROBLEM", 268, 282], ["NC", "ANATOMY", 6, 8], ["viral lineagesis", "OBSERVATION", 100, 116], ["med", "ANATOMY", 152, 155], ["viral lineages", "OBSERVATION", 268, 282]]], ["The proportion of L lineage in samples collected before and after Wuhan lockdown showed distinct differentiation (99% vs 70%), and it was hypothesized that the frequency change of L lineage may due to different pressures of negative selection from containment measures (11) .", [["L lineage", "ANATOMY", 18, 27], ["samples", "ANATOMY", 31, 38], ["L lineage", "CELL", 18, 27], ["samples", "CANCER", 31, 38], ["L lineage", "CELL", 180, 189], ["L lineage", "CELL_TYPE", 18, 27], ["L lineage", "CELL_TYPE", 180, 189], ["L lineage", "TREATMENT", 180, 189], ["L", "OBSERVATION_MODIFIER", 18, 19], ["lineage", "OBSERVATION_MODIFIER", 20, 27], ["distinct", "OBSERVATION_MODIFIER", 88, 96], ["differentiation", "OBSERVATION_MODIFIER", 97, 112], ["L lineage", "OBSERVATION", 180, 189], ["pressures", "OBSERVATION_MODIFIER", 211, 220], ["negative selection", "OBSERVATION", 224, 242], ["containment", "OBSERVATION_MODIFIER", 248, 259]]], ["It is disputable for that the allele frequency change can be caused by sampling bias and clustering infection as well (12) .", [["infection", "DISEASE", 100, 109], ["allele", "DNA", 30, 36], ["the allele frequency change", "PROBLEM", 26, 53], ["clustering infection", "PROBLEM", 89, 109], ["infection", "OBSERVATION", 100, 109]]], ["In the map of haplotype network, L84S is pinpointed to the branch connecting C01 and C07 (Fig. 2) , with a very low frequency of 0.1294% in C01 and increased to 100% in C07, demonstrating an obvious cluster expanding pattern in the fine scale.", [["L84S", "DNA", 33, 37], ["C01", "DNA", 77, 80], ["C07", "DNA", 85, 88], ["C01", "CELL_LINE", 140, 143], ["branch", "ANATOMY_MODIFIER", 59, 65], ["very", "OBSERVATION_MODIFIER", 107, 111], ["low", "OBSERVATION_MODIFIER", 112, 115], ["increased", "OBSERVATION_MODIFIER", 148, 157], ["obvious", "OBSERVATION_MODIFIER", 191, 198], ["cluster", "OBSERVATION_MODIFIER", 199, 206], ["expanding", "OBSERVATION_MODIFIER", 207, 216], ["pattern", "OBSERVATION_MODIFIER", 217, 224]]], ["Furthermore, we identified the signature of positive selection acting on ORF8 as mentioned previously.", [["ORF8", "GENE_OR_GENE_PRODUCT", 73, 77], ["ORF8", "DNA", 73, 77], ["positive selection", "OBSERVATION", 44, 62]]], ["Based on the two facts, this mutation is possibly a candidate site under positive selection for further evaluation.", [["this mutation", "PROBLEM", 24, 37], ["further evaluation", "TEST", 96, 114]]], ["According to COVID-3D database, the L84S amino acid alteration was predicted to eliminate 4 hydrophobic bonds and lead to destabilization of ORF8 protein.", [["amino acid", "CHEMICAL", 41, 51], ["amino acid", "CHEMICAL", 41, 51], ["amino acid", "AMINO_ACID", 41, 51], ["ORF8", "GENE_OR_GENE_PRODUCT", 141, 145], ["COVID-3D database", "DNA", 13, 30], ["ORF8 protein", "PROTEIN", 141, 153], ["3D database", "TEST", 19, 30], ["the L84S amino acid alteration", "PROBLEM", 32, 62], ["4 hydrophobic bonds", "PROBLEM", 90, 109], ["destabilization of ORF8 protein", "TREATMENT", 122, 153]]], ["Another study with computational protein modeling proposed that L84S can mitigate the binding of ORF8 to human complement C3b, which is negatively regulated by the C-terminus serine-protease catalytic domain of the human complement factor 1 (F1), and activates the host complement system (24) .", [["L84S", "CHEMICAL", 64, 68], ["C", "CHEMICAL", 164, 165], ["serine", "CHEMICAL", 175, 181], ["L84S", "SIMPLE_CHEMICAL", 64, 68], ["ORF8", "GENE_OR_GENE_PRODUCT", 97, 101], ["human", "ORGANISM", 105, 110], ["complement C3b", "GENE_OR_GENE_PRODUCT", 111, 125], ["human", "ORGANISM", 215, 220], ["complement factor 1", "GENE_OR_GENE_PRODUCT", 221, 240], ["F1", "GENE_OR_GENE_PRODUCT", 242, 244], ["L84S", "PROTEIN", 64, 68], ["ORF8", "PROTEIN", 97, 101], ["human complement C3b", "PROTEIN", 105, 125], ["C-terminus serine-protease catalytic domain", "PROTEIN", 164, 207], ["human complement factor 1", "PROTEIN", 215, 240], ["F1", "PROTEIN", 242, 244], ["human", "SPECIES", 105, 110], ["human", "SPECIES", 215, 220], ["human", "SPECIES", 105, 110], ["human", "SPECIES", 215, 220], ["Another study", "TEST", 0, 13], ["computational protein modeling", "TREATMENT", 19, 49], ["the human complement factor", "TEST", 211, 238]]], ["Therefore, the L84S mutation possibly impacts the normal function of ORF8, and plays an important role in the host immune responses and infection outcome.Clustering pattern of viral lineagesA recurrent nonsynonymous mutation D614G in the epitope region (the receptor-binding domain) of Spike glycoprotein protein (S) occurred in the common ancestor of the C11-C14 clusters ( Fig. 2A) .", [["infection", "DISEASE", 136, 145], ["C11-C14", "CHEMICAL", 356, 363], ["L84S", "GENE_OR_GENE_PRODUCT", 15, 19], ["ORF8", "GENE_OR_GENE_PRODUCT", 69, 73], ["Spike glycoprotein", "GENE_OR_GENE_PRODUCT", 286, 304], ["L84S", "DNA", 15, 19], ["ORF8", "PROTEIN", 69, 73], ["epitope region", "PROTEIN", 238, 252], ["receptor-binding domain", "PROTEIN", 258, 281], ["Spike glycoprotein protein", "PROTEIN", 286, 312], ["S", "PROTEIN", 314, 315], ["the L84S mutation", "PROBLEM", 11, 28], ["infection outcome", "PROBLEM", 136, 153], ["viral lineages", "PROBLEM", 176, 190], ["A recurrent nonsynonymous mutation", "PROBLEM", 190, 224], ["Spike glycoprotein protein (S", "PROBLEM", 286, 315], ["normal", "OBSERVATION", 50, 56], ["viral lineages", "OBSERVATION", 176, 190], ["recurrent", "OBSERVATION_MODIFIER", 192, 201], ["nonsynonymous mutation", "OBSERVATION", 202, 224], ["common", "ANATOMY_MODIFIER", 333, 339], ["ancestor", "ANATOMY_MODIFIER", 340, 348], ["C11", "ANATOMY_MODIFIER", 356, 359], ["C14", "ANATOMY", 360, 363]]], ["C11-C14 clusters were widely preponderated across Europe, America, Asia, and Africa.", [["C11-C14", "CHEMICAL", 0, 7], ["C11-C14", "CHEMICAL", 0, 7], ["C14", "ANATOMY", 4, 7]]], ["Spike glycoprotein is essential for the host cell infection of SARS-CoV-2.", [["cell", "ANATOMY", 45, 49], ["infection", "DISEASE", 50, 59], ["SARS", "DISEASE", 63, 67], ["Spike glycoprotein", "GENE_OR_GENE_PRODUCT", 0, 18], ["host cell", "CELL", 40, 49], ["SARS-CoV-2", "ORGANISM", 63, 73], ["Spike glycoprotein", "PROTEIN", 0, 18], ["SARS-CoV", "SPECIES", 63, 71], ["Spike glycoprotein", "PROBLEM", 0, 18], ["the host cell infection of SARS", "PROBLEM", 36, 67], ["CoV", "TEST", 68, 71], ["host cell infection", "OBSERVATION", 40, 59]]], ["D614G was reported to be relevant to a high viral load in COVID-19 patients and higher infectious titers of spike-pseudotyped viruses, indicating a possible fitness advantage (10) .", [["D614G", "GENE_OR_GENE_PRODUCT", 0, 5], ["patients", "ORGANISM", 67, 75], ["pseudotyped", "ORGANISM", 114, 125], ["patients", "SPECIES", 67, 75], ["a high viral load", "PROBLEM", 37, 54], ["COVID", "TEST", 58, 63], ["higher infectious titers", "PROBLEM", 80, 104], ["spike", "PROBLEM", 108, 113], ["pseudotyped viruses", "PROBLEM", 114, 133], ["infectious", "OBSERVATION_MODIFIER", 87, 97], ["pseudotyped viruses", "OBSERVATION", 114, 133]]], ["Another nonsynonymous mutation P323L in NSP12 (RNA-dependent RNA polymerase, RdRP) also occurred in the common ancestor of C11-C14, coupling the evolution with D614G.", [["C11-C14", "CHEMICAL", 123, 130], ["C11-C14", "CHEMICAL", 123, 130], ["NSP12", "GENE_OR_GENE_PRODUCT", 40, 45], ["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 47, 75], ["RdRP", "GENE_OR_GENE_PRODUCT", 77, 81], ["C11-C14", "SIMPLE_CHEMICAL", 123, 130], ["NSP12", "DNA", 40, 45], ["RNA-dependent RNA polymerase", "PROTEIN", 47, 75], ["RdRP", "PROTEIN", 77, 81], ["D614G", "PROTEIN", 160, 165], ["Another nonsynonymous mutation", "TEST", 0, 30], ["NSP12", "TEST", 40, 45], ["RNA", "TEST", 47, 50], ["dependent RNA polymerase", "PROBLEM", 51, 75], ["RdRP", "PROBLEM", 77, 81], ["D614G", "TREATMENT", 160, 165], ["nonsynonymous mutation", "OBSERVATION", 8, 30], ["C14", "ANATOMY", 127, 130]]], ["This mutation might regulate the activity of RdRp, and is related to viral replication and fidelity (25) . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintClustering pattern of viral lineagesThe copyright holder for this this version posted September 9, 2020.", [["RdRp", "GENE_OR_GENE_PRODUCT", 45, 49], ["RdRp", "PROTEIN", 45, 49], ["viral lineages", "CELL_TYPE", 261, 275], ["This mutation", "PROBLEM", 0, 13], ["viral lineages", "PROBLEM", 261, 275], ["related to", "UNCERTAINTY", 58, 68], ["viral replication", "OBSERVATION", 69, 86], ["med", "ANATOMY", 145, 148], ["viral lineages", "OBSERVATION", 261, 275]]], ["According to structural prediction provided by the COVID-3D database, R203K and G204R both destabilize the N protein, and the predicted actual free energy value (\u0394\u0394G) using the mutation Cutoff Scanning Matrix (\u0394\u0394G stability mCSM, henceforth) are -1.71 and -1.07 kcal.mol -1 respectively, resulting the alteration of their molecular interactions with other amino acids, such as carbonyl, polar bonds, and hydrogen bonds (Fig. 3A-D) .", [["amino acids", "CHEMICAL", 356, 367], ["carbonyl", "CHEMICAL", 377, 385], ["amino acids", "CHEMICAL", 356, 367], ["carbonyl", "CHEMICAL", 377, 385], ["hydrogen", "CHEMICAL", 404, 412], ["amino acids", "AMINO_ACID", 356, 367], ["carbonyl", "SIMPLE_CHEMICAL", 377, 385], ["polar bonds", "SIMPLE_CHEMICAL", 387, 398], ["hydrogen bonds", "SIMPLE_CHEMICAL", 404, 418], ["Fig. 3A-D", "SIMPLE_CHEMICAL", 420, 429], ["COVID-3D database", "DNA", 51, 68], ["N protein", "PROTEIN", 107, 116], ["the mutation Cutoff Scanning Matrix (\u0394\u0394G stability mCSM", "TREATMENT", 173, 228], ["other amino acids", "TREATMENT", 350, 367], ["carbonyl, polar bonds", "TEST", 377, 398], ["hydrogen bonds", "OBSERVATION", 404, 418]]], ["Mutations on N protein that was under positive selection may be functional relevant to viral replication, assembly and participating in immune-evasion and viral infections (19) (20) (21) (22) .", [["viral infections", "DISEASE", 155, 171], ["N protein", "PROTEIN", 13, 22], ["Mutations on N protein", "PROBLEM", 0, 22], ["viral replication", "PROBLEM", 87, 104], ["viral infections", "PROBLEM", 155, 171]]], ["We further infer the mortality rates of viruses belonging to the two clusters (see Methods).", [["viruses", "PROBLEM", 40, 47]]], ["The mortality rates of C11 and C12 are dramatically different (16.03% and 3.98%), and may be explained by the functional alternation of N protein caused by the two nonsynonymous mutations.Clustering pattern of viral lineagesDiverged from C11, the Q57H mutation in ORF3a, another positively selected gene, arose and fixed in the C13 cluster that dominates in Saudi Arabia and broadly distributed in Europe (Fig.2) .", [["Q57H", "GENE_OR_GENE_PRODUCT", 247, 251], ["ORF3a", "GENE_OR_GENE_PRODUCT", 264, 269], ["N protein", "PROTEIN", 136, 145], ["viral lineages", "CELL_TYPE", 210, 224], ["ORF3a", "DNA", 264, 269], ["C13 cluster", "DNA", 328, 339], ["The mortality rates", "TEST", 0, 19], ["N protein", "PROBLEM", 136, 145], ["the two nonsynonymous mutations", "PROBLEM", 156, 187], ["viral lineages", "PROBLEM", 210, 224], ["C11", "ANATOMY_MODIFIER", 23, 26], ["C12", "ANATOMY", 31, 34], ["dramatically", "OBSERVATION_MODIFIER", 39, 51], ["different", "OBSERVATION_MODIFIER", 52, 61], ["may be explained", "UNCERTAINTY", 86, 102], ["nonsynonymous mutations", "OBSERVATION", 164, 187], ["viral lineages", "OBSERVATION", 210, 224], ["C13", "ANATOMY", 328, 331], ["broadly", "OBSERVATION_MODIFIER", 375, 382], ["distributed", "OBSERVATION_MODIFIER", 383, 394]]], ["This variant was predicted to exert structural destabilization (\u0394\u0394G stability mCSM = -1.55 kcal.mol -1 ) (Fig. 3E -F) and deleterious effects on protein function (Issa et al., 2020).", [["structural destabilization", "PROBLEM", 36, 62], ["mCSM", "TEST", 78, 82], ["kcal.mol", "TEST", 91, 99], ["deleterious effects on protein function", "PROBLEM", 122, 161], ["destabilization", "OBSERVATION", 47, 62]]], ["Another mutation T85I in NSP2 further diverges C14 from C13 that preponderates (>50%) in USA and European countries and with a lower mortality rate (2.83%).", [["NSP2", "GENE_OR_GENE_PRODUCT", 25, 29], ["NSP2", "DNA", 25, 29], ["Another mutation T85I", "PROBLEM", 0, 21], ["a lower mortality rate", "TEST", 125, 147]]], ["This mutation also fall within the region of NSP2 homologous to the protein (PDB 3ld1), and may be functional in viral pathogenicity (28) .Clustering pattern of viral lineagesA full list of the 37 mutations and their functional significance can be found in Table 3 .Mutations with rapid increase of frequency within clusters as potential targetsOther than the mutations demonstrating nearly-fixed divergence among clusters, mutations presenting prominent frequency increasing trend over sampling times within a cluster are potential sites with evolutionary or functional significance in COVID-19 epidemic.", [["NSP2", "GENE_OR_GENE_PRODUCT", 45, 49], ["PDB 3ld1", "GENE_OR_GENE_PRODUCT", 77, 85], ["NSP2", "PROTEIN", 45, 49], ["PDB 3ld1", "PROTEIN", 77, 85], ["This mutation", "PROBLEM", 0, 13], ["functional in viral pathogenicity", "PROBLEM", 99, 132], ["Mutations", "PROBLEM", 266, 275], ["rapid increase of frequency within clusters", "PROBLEM", 281, 324], ["the mutations", "PROBLEM", 356, 369], ["fixed divergence among clusters", "PROBLEM", 391, 422], ["mutations", "PROBLEM", 424, 433], ["COVID", "TEST", 587, 592], ["epidemic", "PROBLEM", 596, 604], ["may be", "UNCERTAINTY", 92, 98], ["functional", "OBSERVATION_MODIFIER", 99, 109], ["viral pathogenicity", "OBSERVATION", 113, 132], ["viral lineages", "OBSERVATION", 161, 175], ["rapid", "OBSERVATION_MODIFIER", 281, 286], ["increase", "OBSERVATION_MODIFIER", 287, 295], ["prominent", "OBSERVATION_MODIFIER", 445, 454], ["frequency", "OBSERVATION_MODIFIER", 455, 464], ["increasing", "OBSERVATION_MODIFIER", 465, 475], ["trend", "OBSERVATION_MODIFIER", 476, 481]]], ["We is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintMutations with rapid increase of frequency within clusters as potential targetsThe copyright holder for this this version posted September 9, 2020. . https://doi.org/10.1101/2020.09.07.20189860 doi: medRxiv preprint profile those within-cluster mutations according to their frequency dynamics during a period of 5 sequential sampling times.", [["medRxiv preprint profile", "TREATMENT", 334, 358], ["cluster mutations", "PROBLEM", 372, 389], ["med", "ANATOMY", 41, 44]]], ["17 mutations demonstrating a trend of frequency increase over sampling times were identified (Table 4) .Mutations with rapid increase of frequency within clusters as potential targetsWithin the C1 cluster, 3 consecutive nucleotide deletions causing a frameshift and two amino acid changes in NSP2 (from 267N & 268D to N) rise in frequency especially in United Kingdom during the period of 5 sequential sampling times (Table 4) .", [["nucleotide", "CHEMICAL", 220, 230], ["frameshift", "DISEASE", 251, 261], ["amino acid", "CHEMICAL", 270, 280], ["nucleotide", "CHEMICAL", 220, 230], ["amino acid", "CHEMICAL", 270, 280], ["amino acid", "AMINO_ACID", 270, 280], ["C1 cluster", "DNA", 194, 204], ["NSP2", "PROTEIN", 292, 296], ["Mutations", "PROBLEM", 104, 113], ["rapid increase of frequency within clusters", "PROBLEM", 119, 162], ["3 consecutive nucleotide deletions", "PROBLEM", 206, 240], ["a frameshift", "PROBLEM", 249, 261], ["two amino acid changes in NSP2", "PROBLEM", 266, 296], ["rapid", "OBSERVATION_MODIFIER", 119, 124], ["increase", "OBSERVATION_MODIFIER", 125, 133], ["C1", "ANATOMY", 194, 196], ["frameshift", "OBSERVATION", 251, 261], ["amino acid", "OBSERVATION", 270, 280]]], ["This mutation appears in Australia in March 14, 2020 and its frequency arises subsequently.", [["This mutation", "PROBLEM", 0, 13]]], ["The variations locate in the region homologous to the endosome-associated protein in avian infectious bronchitis virus that plays a key role in the viral pathogenicity (28) .Mutations with rapid increase of frequency within clusters as potential targetsThree variations in complete linkage disequilibria uniquely occurred within C3, especially in Kazakhstan after April, 2020 ( Table 4 ).", [["endosome", "ANATOMY", 54, 62], ["infectious bronchitis", "DISEASE", 91, 112], ["endosome", "CELLULAR_COMPONENT", 54, 62], ["avian infectious bronchitis virus", "ORGANISM", 85, 118], ["endosome-associated protein", "PROTEIN", 54, 81], ["C3", "PROTEIN", 329, 331], ["avian infectious bronchitis virus", "SPECIES", 85, 118], ["infectious bronchitis virus", "SPECIES", 91, 118], ["avian infectious bronchitis virus", "PROBLEM", 85, 118], ["the viral pathogenicity", "PROBLEM", 144, 167], ["Mutations", "PROBLEM", 174, 183], ["rapid increase of frequency within clusters", "PROBLEM", 189, 232], ["Three variations in complete linkage disequilibria", "PROBLEM", 253, 303], ["infectious", "OBSERVATION_MODIFIER", 91, 101], ["bronchitis", "OBSERVATION", 102, 112], ["viral pathogenicity", "OBSERVATION", 148, 167], ["rapid", "OBSERVATION_MODIFIER", 189, 194], ["increase", "OBSERVATION_MODIFIER", 195, 203], ["complete", "OBSERVATION_MODIFIER", 273, 281], ["linkage disequilibria", "OBSERVATION", 282, 303], ["C3", "OBSERVATION_MODIFIER", 329, 331]]], ["The variations include 2 linked nonsynonymous mutations (NSP2 R27C and NSP4 M33I), and a 3-nucleotide deletion in NSP3 (3333T, 3334T, and 3335G) that results in a replacement of 205I & 206E with Lysine, as well as A302D substitution in the helicase domain of NSP13 that potently suppresses primary interferon production and signaling thereby immune suppression (29) .Mutations with rapid increase of frequency within clusters as potential targetsA nonsynonymous mutations G199E of NSP2 raises the frequency gradually from 0 to 0.5 within the C10 cluster across sampling dates ( Table 4 ).", [["Lysine", "CHEMICAL", 195, 201], ["3-nucleotide", "CHEMICAL", 89, 101], ["Lysine", "CHEMICAL", 195, 201], ["NSP2 R27C", "GENE_OR_GENE_PRODUCT", 57, 66], ["NSP4 M33I", "GENE_OR_GENE_PRODUCT", 71, 80], ["NSP3", "GENE_OR_GENE_PRODUCT", 114, 118], ["Lysine", "AMINO_ACID", 195, 201], ["A302D", "GENE_OR_GENE_PRODUCT", 214, 219], ["NSP13", "GENE_OR_GENE_PRODUCT", 259, 264], ["NSP2 R27C", "DNA", 57, 66], ["NSP4 M33I", "DNA", 71, 80], ["3-nucleotide deletion", "DNA", 89, 110], ["NSP3", "DNA", 114, 118], ["helicase domain", "PROTEIN", 240, 255], ["NSP13", "PROTEIN", 259, 264], ["interferon", "PROTEIN", 298, 308], ["NSP2", "DNA", 481, 485], ["2 linked nonsynonymous mutations", "PROBLEM", 23, 55], ["NSP2", "TEST", 57, 61], ["a 3-nucleotide deletion in NSP3", "PROBLEM", 87, 118], ["a replacement", "TREATMENT", 161, 174], ["Lysine", "TREATMENT", 195, 201], ["A302D substitution", "TREATMENT", 214, 232], ["the helicase domain of NSP13", "TREATMENT", 236, 264], ["primary interferon production", "PROBLEM", 290, 319], ["signaling thereby immune suppression", "PROBLEM", 324, 360], ["Mutations", "PROBLEM", 367, 376], ["rapid increase of frequency within clusters", "PROBLEM", 382, 425], ["A nonsynonymous mutations", "TEST", 446, 471], ["NSP2", "PROBLEM", 481, 485], ["nonsynonymous mutations", "OBSERVATION", 32, 55], ["rapid", "OBSERVATION_MODIFIER", 382, 387], ["increase", "OBSERVATION_MODIFIER", 388, 396]]], ["G199E locates in the homologous region (PDB 3ld1) of NSP2, and may be functionally important in viral pathogenicity according sequence homologous analysis (28).DiscussionIt is well known that viruses mutate and adapt rapidly to environments and hosts (30, 31) . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintSARS-CoVThe copyright holder for this this version posted September 9, 2020. . the viral pathogenicity, predicting the epidemic trend, and providing guidance for disease control and treatments.The dynamics of virus populations demonstrates a series of founder events caused byinfection clustering or bursts of epidemic in local regions.", [["NSP2", "GENE_OR_GENE_PRODUCT", 53, 57], ["G199E", "DNA", 0, 5], ["homologous region", "DNA", 21, 38], ["PDB 3ld1", "DNA", 40, 48], ["NSP2", "DNA", 53, 57], ["NSP2", "PROBLEM", 53, 57], ["viral pathogenicity", "PROBLEM", 96, 115], ["sequence homologous analysis", "TEST", 126, 154], ["the viral pathogenicity", "PROBLEM", 473, 496], ["disease control", "TREATMENT", 556, 571], ["treatments", "TREATMENT", 576, 586], ["virus populations", "PROBLEM", 603, 620], ["founder events", "PROBLEM", 646, 660], ["byinfection clustering", "PROBLEM", 668, 690], ["epidemic in local regions", "PROBLEM", 704, 729], ["homologous", "ANATOMY_MODIFIER", 21, 31], ["region", "ANATOMY_MODIFIER", 32, 38], ["may be", "UNCERTAINTY", 63, 69], ["med", "ANATOMY", 300, 303], ["viral pathogenicity", "OBSERVATION", 477, 496], ["bursts", "OBSERVATION_MODIFIER", 694, 700], ["epidemic", "OBSERVATION_MODIFIER", 704, 712]]], ["Besides, the genomic samples are usually collected from different times and locations disproportionally (sampling bias).", [["samples", "ANATOMY", 21, 28], ["the genomic samples", "TEST", 9, 28]]], ["Both significantly impact the allele frequencies and bring challenges in analyzing the virus genomic data with most population gendetic methods (12) .", [["the allele frequencies", "TREATMENT", 26, 48]]], ["Comparing the relative excess of synonymous and nonsynonymous substitutions is robust to population size changes, representing an efficient approach for evaluating the effects of natural selection on SARS-CoV-2.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 200, 210], ["SARS-CoV", "SPECIES", 200, 208], ["synonymous and nonsynonymous substitutions", "PROBLEM", 33, 75], ["natural selection", "TREATMENT", 179, 196], ["SARS", "TEST", 200, 204], ["CoV", "TEST", 205, 208], ["excess", "OBSERVATION_MODIFIER", 23, 29], ["synonymous", "OBSERVATION", 33, 43], ["nonsynonymous substitutions", "OBSERVATION", 48, 75], ["robust", "OBSERVATION_MODIFIER", 79, 85], ["population", "OBSERVATION_MODIFIER", 89, 99], ["size", "OBSERVATION_MODIFIER", 100, 104], ["efficient", "OBSERVATION_MODIFIER", 130, 139]]], ["The approach we used in this study is similar to the known McDonald-Kreitman test (MK test) in molecular evolution, which compares the ratios of non-synonymous site number over synonymous site number of between between-species divergence to that of within-species polymorphisms, and uses the latter as an internal control under neutrality.", [["this study", "TEST", 24, 34], ["MK test", "TEST", 83, 90], ["non-synonymous site", "PROBLEM", 145, 164], ["non-synonymous site", "OBSERVATION", 145, 164]]], ["The method is novel in using the N/S ratio of rare mutants with very low frequencies as the internal control under neutral evolution, which is valid according to population genetic theory (14) .", [["the N/S ratio", "TEST", 29, 42], ["rare mutants", "PROBLEM", 46, 58], ["very low frequencies", "PROBLEM", 64, 84]]], ["The method is only applicable for large-sample genomic sequencing data. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe dynamics of virus populations demonstrates a series of founder events caused byThe copyright holder for this this version posted September 9, 2020. . explain distinct pathogenicity and infectivity.", [["distinct pathogenicity and infectivity", "PROBLEM", 366, 404], ["med", "ANATOMY", 110, 113], ["distinct", "OBSERVATION_MODIFIER", 366, 374], ["pathogenicity", "OBSERVATION", 375, 388], ["infectivity", "OBSERVATION_MODIFIER", 393, 404]]], ["Thus the list of mutations provides a basis for further functional study and clinical treatment.Nucleotide mutation identificationAll the sequences were aligned using MUSCLE (13)Partition haplotypes into clustersThe haplotype network of the viral samples demonstrates a multi-cluster pattern.", [["samples", "ANATOMY", 247, 254], ["further functional study", "TEST", 48, 72], ["clinical treatment", "TREATMENT", 77, 95], ["Nucleotide mutation identification", "TEST", 96, 130], ["MUSCLE (13)Partition haplotypes", "TREATMENT", 167, 198], ["the viral samples", "TEST", 237, 254], ["MUSCLE", "ANATOMY", 167, 173]]], ["Each of the haplotypes are assigned to different clusters according to their alleles with the largest MAF (minor allele frequency) on the 14 SNP loci following the order of the features (Fig. S1 ).", [["SNP", "CHEMICAL", 141, 144], ["MAF", "DNA", 102, 105], ["14 SNP loci", "DNA", 138, 149], ["the haplotypes", "PROBLEM", 8, 22], ["the largest MAF", "PROBLEM", 90, 105], ["the 14 SNP loci", "TREATMENT", 134, 149], ["largest", "OBSERVATION_MODIFIER", 94, 101]]], ["This process continued until no alleles with MAF > 0.1 or the subtree sample number < 500 (see classification rule in Fig. S1 ).", [["S1", "GENE_OR_GENE_PRODUCT", 123, 125], ["MAF", "DNA", 45, 48], ["S1", "PROTEIN", 123, 125], ["MAF", "TEST", 45, 48]]], ["165 samples with missing data on the feature SNP locus are is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintPartition haplotypes into clustersThe copyright holder for this this version posted September 9, 2020. . excluded from further analysis.", [["samples", "ANATOMY", 4, 11], ["SNP", "CHEMICAL", 45, 48], ["samples", "CANCER", 4, 11], ["feature SNP locus", "DNA", 37, 54], ["missing data", "PROBLEM", 17, 29], ["further analysis", "TEST", 310, 326], ["med", "ANATOMY", 97, 100]]], ["After all samples are assigned to the clusters, we further implement an additional checking step by calculating the distance of all haplotypes to the MRCA sequences of the 14 clusters.", [["samples", "ANATOMY", 10, 17], ["MRCA sequences", "DNA", 150, 164], ["the MRCA sequences", "TEST", 146, 164]]], ["We found that 185 samples (0.84% out of 22,078 sequences) are with a closer distance to a cluster other than their assigned clusters.", [["samples", "ANATOMY", 18, 25], ["samples", "TEST", 18, 25]]], ["These 185 samples were then re-assigned to the closest clusters.Prediction of the effects of mutations on protein functionWe use COVID-3D (http://biosig.unimelb.edu.au/covid3d/), an online resource exploring the structural distribution of genetic variations of SARS-CoV-2, to predict the functional effects of mutations (24) .", [["samples", "ANATOMY", 10, 17], ["SARS", "DISEASE", 261, 265], ["samples", "CANCER", 10, 17], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 261, 271], ["SARS-CoV", "SPECIES", 261, 269], ["mutations", "PROBLEM", 93, 102], ["SARS", "PROBLEM", 261, 265], ["CoV", "TEST", 266, 269]]], ["It presents the change of energy of molecular structure and the difference in molecular interactions between wild-type and mutant-type alleles.Estimation of the lineage-specific mortality ratesWe estimate the mortality rates of three prevalent clusters C11, C12 and C14 in European countries (C11, C12 and C14 account for 78.3 % of the samples from European countries).", [["C11, C12 and C14", "CHEMICAL", 253, 269], ["wild-type and mutant-type alleles", "DNA", 109, 142], ["the mortality rates", "TEST", 205, 224], ["change", "OBSERVATION_MODIFIER", 16, 22], ["energy", "OBSERVATION_MODIFIER", 26, 32], ["molecular structure", "OBSERVATION", 36, 55], ["difference", "OBSERVATION_MODIFIER", 64, 74], ["molecular interactions", "OBSERVATION", 78, 100], ["lineage", "OBSERVATION_MODIFIER", 161, 168], ["C14", "ANATOMY_MODIFIER", 266, 269]]], ["We filter data of different countries with two criteria: 1) sample size of the three clusters > 100; 2) number of cumulative infected > 10,000.", [["sample size", "TEST", 60, 71], ["cumulative infected", "PROBLEM", 114, 133]]], ["The data of 12 remaining countries after filtering are used to estimate the mortality rate of the three clusters.Estimation of the lineage-specific mortality ratesLet the mortality rates of C11, C12 and C14 lineages be .", [["C11, C12 and C14 lineages", "CELL_LINE", 190, 215], ["The data", "TEST", 0, 8], ["the mortality rates", "TEST", 167, 186], ["lineage", "OBSERVATION_MODIFIER", 131, 138]]], ["12 ,..., 2 , 1 ,Estimation of the lineage-specific mortality ratesWe solved the above sets of linear equations using the least square method implemented by the MATLAB built-in function lsqlin.Acknowledgements.", [["linear equations", "TREATMENT", 94, 110]]], ["CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.Acknowledgementsis the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintAcknowledgementsThe copyright holder for this this version posted September 9, 2020. . https://doi.org/10.1101/2020.09.07.20189860 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintAcknowledgementsThe copyright holder for this this version posted September 9, 2020. . https://doi.org/10.1101/2020.09.07.20189860 doi: medRxiv preprint Figure S1 .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 132, 135], ["med", "ANATOMY", 417, 420]]], ["The classification tree and feature SNPs for assigning viral haplotypes to one of the 14 haplotype clusters.Acknowledgements.", [["feature SNPs", "PROBLEM", 28, 40], ["viral haplotypes", "PROBLEM", 55, 71], ["tree", "OBSERVATION_MODIFIER", 19, 23]]], ["CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.Acknowledgementsis the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintAcknowledgementsThe copyright holder for this this version posted September 9, 2020. . https://doi.org/10.1101/2020.09.07.20189860 doi: medRxiv preprint", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["medRxiv", "TREATMENT", 362, 369], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 132, 135]]]], "879ec664914d9676e0f7f511e142b6792f26ff73": [["IntroductionAn outbreak of coronavirus disease caused by the newly discovered severe acute respiratory syndrome coronavirus (SARS-CoV-2), started in December 2019, in the city of Wuhan, Hubei province, China.", [["coronavirus disease", "DISEASE", 27, 46], ["acute respiratory syndrome coronavirus", "DISEASE", 85, 123], ["SARS", "DISEASE", 125, 129], ["coronavirus", "ORGANISM", 27, 38], ["coronavirus", "SPECIES", 27, 38], ["severe acute respiratory syndrome coronavirus", "SPECIES", 78, 123], ["SARS-CoV-2", "SPECIES", 125, 135], ["coronavirus disease", "PROBLEM", 27, 46], ["the newly discovered severe acute respiratory syndrome coronavirus", "PROBLEM", 57, 123], ["coronavirus disease", "OBSERVATION", 27, 46], ["severe", "OBSERVATION_MODIFIER", 78, 84], ["acute", "OBSERVATION_MODIFIER", 85, 90], ["respiratory syndrome coronavirus", "OBSERVATION", 91, 123]]], ["As of July 6, 2020, COVID-19 has expanded globally with more than 11.6 million confirmed cases with over 538,000 deaths worldwide, imposing an unprecedented threat to public health (https://www.worldometers.info/coronavirus/).", [["deaths", "DISEASE", 113, 119], ["COVID", "TEST", 20, 25]]], ["In the past two decades, coronavirus outbreak has resulted in viral epidemics including severe acute respiratory syndrome (SARS-CoV) in 2002 with fatality of 10% and middle east respiratory syndrome (MERS-CoV) in 2012 with fatality of 36% [1] [2] [3] [4] .", [["coronavirus", "DISEASE", 25, 36], ["acute respiratory syndrome", "DISEASE", 95, 121], ["SARS-CoV)", "DISEASE", 123, 132], ["middle east respiratory syndrome", "DISEASE", 166, 198], ["coronavirus", "ORGANISM", 25, 36], ["SARS-CoV", "SPECIES", 123, 131], ["middle east respiratory syndrome (MERS-CoV", "SPECIES", 166, 208], ["coronavirus outbreak", "PROBLEM", 25, 45], ["viral epidemics", "PROBLEM", 62, 77], ["severe acute respiratory syndrome", "PROBLEM", 88, 121], ["middle east respiratory syndrome", "PROBLEM", 166, 198], ["fatality", "TEST", 223, 231], ["coronavirus", "OBSERVATION", 25, 36], ["viral epidemics", "OBSERVATION", 62, 77], ["severe", "OBSERVATION_MODIFIER", 88, 94], ["acute", "OBSERVATION_MODIFIER", 95, 100], ["respiratory syndrome", "OBSERVATION", 101, 121], ["middle", "ANATOMY_MODIFIER", 166, 172], ["respiratory syndrome", "OBSERVATION", 178, 198]]], ["Both SARS-CoV and MERS-CoV were zoonotic viruses originating in bat and camels respectively [5, 6] .", [["SARS-CoV", "ORGANISM", 5, 13], ["MERS-CoV", "ORGANISM", 18, 26], ["bat", "ORGANISM", 64, 67], ["camels", "ORGANISM_SUBDIVISION", 72, 78], ["SARS-CoV", "SPECIES", 5, 13], ["MERS-CoV", "SPECIES", 18, 26], ["Both SARS", "PROBLEM", 0, 9], ["zoonotic viruses", "PROBLEM", 32, 48], ["SARS", "OBSERVATION", 5, 9], ["CoV", "ANATOMY", 10, 13]]], ["However, the recurring emergence of highly pathogenic SARS-CoV, MERS-CoV and now SARS-CoV2 have indicated the potential for crossspecies transmission of these viruses thus raising a serious public health concern [7, 8] .", [["SARS", "DISEASE", 54, 58], ["SARS-CoV", "ORGANISM", 54, 62], ["MERS-CoV", "ORGANISM", 64, 72], ["SARS-CoV2", "ORGANISM", 81, 90], ["SARS-CoV", "SPECIES", 54, 62], ["MERS-CoV", "SPECIES", 64, 72], ["highly pathogenic SARS", "PROBLEM", 36, 58], ["CoV", "PROBLEM", 69, 72], ["these viruses", "PROBLEM", 153, 166], ["viruses", "OBSERVATION", 159, 166]]], ["SARS CoV-2 shares a sequence similarity of 80% and 50% with previously identified SARS-CoV and MERS-CoV respectively [9] [10] [11] [12] .", [["SARS", "DISEASE", 0, 4], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 82, 90], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 95, 103], ["[9] [10] [11] [12]", "SIMPLE_CHEMICAL", 117, 135], ["SARS CoV", "SPECIES", 0, 8], ["SARS-CoV", "SPECIES", 82, 90], ["MERS-CoV", "SPECIES", 95, 103], ["a sequence similarity", "TEST", 18, 39], ["previously identified SARS", "PROBLEM", 60, 86]]], ["Since its emergence, rapid efforts have illustrated the molecular features of SARS-CoV-2 that enables it to hijack the host cellular machinery and facilitates its genomic replication and assembly into new virions during the infection process [13] [14] [15] [16] .IntroductionCoronaviruses carry the largest genome among all RNA viruses, ranging from 26 to 32 kilobases in length [12] .", [["cellular", "ANATOMY", 124, 132], ["SARS", "DISEASE", 78, 82], ["infection", "DISEASE", 224, 233], ["SARS-CoV-2", "ORGANISM", 78, 88], ["cellular", "CELL", 124, 132], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 275, 288], ["SARS-CoV", "SPECIES", 78, 86], ["SARS", "PROBLEM", 78, 82], ["its genomic replication", "TREATMENT", 159, 182], ["new virions", "PROBLEM", 201, 212], ["the infection process", "PROBLEM", 220, 241], ["all RNA viruses", "PROBLEM", 320, 335], ["largest", "OBSERVATION_MODIFIER", 299, 306], ["RNA viruses", "OBSERVATION", 324, 335]]], ["These viruses have a characteristic \"crown\" like appearance under two-dimensional transmission electron microscopy.", [["a characteristic \"crown\" like appearance", "PROBLEM", 19, 59], ["viruses", "OBSERVATION", 6, 13], ["crown", "OBSERVATION_MODIFIER", 37, 42]]], ["SARS-CoV-2 is an enveloped positive -sense, single-stranded ribonucleic acid (RNA) viruses that belongs to the genus beta-coronavirus.", [["SARS", "DISEASE", 0, 4], ["ribonucleic acid", "CHEMICAL", 60, 76], ["SARS-CoV-2", "ORGANISM", 0, 10], ["beta-coronavirus", "GENE_OR_GENE_PRODUCT", 117, 133], ["SARS-CoV", "SPECIES", 0, 8], ["SARS-CoV", "TEST", 0, 8], ["single-stranded ribonucleic acid (RNA) viruses", "PROBLEM", 44, 90], ["positive", "OBSERVATION", 27, 35], ["genus beta-coronavirus", "OBSERVATION", 111, 133]]], ["Upon entry in the cell, SARS-CoV-2 RNA is translated into non-structural proteins (nsps) from two open reading frames (ORFs), ORF1a, and ORF1b [17, 18] .", [["cell", "ANATOMY", 18, 22], ["cell", "CELL", 18, 22], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 24, 34], ["nsps", "GENE_OR_GENE_PRODUCT", 83, 87], ["ORF1a", "GENE_OR_GENE_PRODUCT", 126, 131], ["ORF1b", "GENE_OR_GENE_PRODUCT", 137, 142], ["SARS-CoV-2 RNA", "RNA", 24, 38], ["non-structural proteins", "PROTEIN", 58, 81], ["nsps", "PROTEIN", 83, 87], ["open reading frames", "DNA", 98, 117], ["ORFs", "DNA", 119, 123], ["ORF1a", "DNA", 126, 131], ["ORF1b", "DNA", 137, 142], ["ORF1a", "TEST", 126, 131]]], ["The ORF1a produces polypeptide 1a that is cleaved further into 11 nsps, while ORF1b, yields polypeptide 1ab, that is cleaved into 16 nsps [17, 18] .", [["ORF1a", "GENE_OR_GENE_PRODUCT", 4, 9], ["polypeptide 1a", "GENE_OR_GENE_PRODUCT", 19, 33], ["nsps", "GENE_OR_GENE_PRODUCT", 66, 70], ["ORF1b", "GENE_OR_GENE_PRODUCT", 78, 83], ["ORF1a", "PROTEIN", 4, 9], ["polypeptide 1a", "PROTEIN", 19, 33], ["nsps", "PROTEIN", 66, 70], ["ORF1b", "PROTEIN", 78, 83], ["polypeptide 1a", "TREATMENT", 19, 33], ["11 nsps", "OBSERVATION_MODIFIER", 63, 70]]], ["Since, SARS-CoV-2 utilizes human machinery to translate its RNA after the entry into the cell, it could possibly impact several RNA-binding proteins from the host to bind the viral genome resulting in altered post-transcriptional regulation.", [["cell", "ANATOMY", 89, 93], ["SARS", "DISEASE", 7, 11], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 7, 17], ["human", "ORGANISM", 27, 32], ["cell", "CELL", 89, 93], ["RNA-binding proteins", "PROTEIN", 128, 148], ["viral genome", "DNA", 175, 187], ["human", "SPECIES", 27, 32], ["SARS-CoV", "SPECIES", 7, 15], ["human", "SPECIES", 27, 32], ["SARS", "PROBLEM", 7, 11], ["human machinery", "TREATMENT", 27, 42], ["several RNA-binding proteins", "PROBLEM", 120, 148], ["the viral genome", "PROBLEM", 171, 187], ["altered post-transcriptional regulation", "PROBLEM", 201, 240], ["viral genome", "OBSERVATION", 175, 187], ["altered", "OBSERVATION_MODIFIER", 201, 208], ["post-transcriptional regulation", "OBSERVATION", 209, 240]]], ["Next, the viral genome is used as the template for replication and transcription, mediated by non-structural protein, RNA-dependent RNA polymerase (RdRP) [18, 19] .", [["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 118, 146], ["viral genome", "DNA", 10, 22], ["non-structural protein", "PROTEIN", 94, 116], ["RNA-dependent RNA polymerase", "PROTEIN", 118, 146], ["RdRP", "PROTEIN", 148, 152], ["the viral genome", "TREATMENT", 6, 22], ["replication and transcription", "TREATMENT", 51, 80], ["non-structural protein", "TEST", 94, 116], ["RNA", "TEST", 118, 121], ["viral genome", "OBSERVATION", 10, 22]]], ["SARS-CoV-2 encodes four main structural proteins: spike (S), envelope (E), membrane (M), and nucleocapsid (N) that are conserved and several other accessory proteins (3a, 6, 7a, 7b, 8, and 10) according to the current annotation (GenBank: NC_045512.2) [17, 20] .", [["membrane", "ANATOMY", 75, 83], ["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["spike (S), envelope (E)", "GENE_OR_GENE_PRODUCT", 50, 73], ["membrane", "CELLULAR_COMPONENT", 75, 83], ["nucleocapsid (N)", "GENE_OR_GENE_PRODUCT", 93, 109], ["3a", "GENE_OR_GENE_PRODUCT", 167, 169], ["6", "GENE_OR_GENE_PRODUCT", 171, 172], ["7a", "GENE_OR_GENE_PRODUCT", 174, 176], ["7b", "GENE_OR_GENE_PRODUCT", 178, 180], ["8", "GENE_OR_GENE_PRODUCT", 182, 183], ["10", "GENE_OR_GENE_PRODUCT", 189, 191], ["SARS-CoV-2", "DNA", 0, 10], ["structural proteins", "PROTEIN", 29, 48], ["spike (S), envelope (E), membrane (M)", "PROTEIN", 50, 87], ["nucleocapsid (N)", "PROTEIN", 93, 109], ["accessory proteins", "PROTEIN", 147, 165], ["3a, 6, 7a, 7b, 8, and 10", "PROTEIN", 167, 191], ["SARS-CoV", "SPECIES", 0, 8], ["SARS", "TEST", 0, 4], ["spike (S), envelope (E), membrane (M), and nucleocapsid (N)", "PROBLEM", 50, 109]]], ["The spike protein, that has evolved the most during the COVID-19 outbreak, enables the virus to bind to angiotensin-converting enzyme 2 (ACE2) on the host cell membrane, following which it undergoes structural changes and subsequently allows the viral genome to make its way inside the host cell [21] .", [["cell membrane", "ANATOMY", 155, 168], ["cell", "ANATOMY", 291, 295], ["angiotensin", "CHEMICAL", 104, 115], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 104, 135], ["ACE2", "GENE_OR_GENE_PRODUCT", 137, 141], ["cell membrane", "CELLULAR_COMPONENT", 155, 168], ["cell", "CELL", 291, 295], ["spike protein", "PROTEIN", 4, 17], ["angiotensin-converting enzyme 2", "PROTEIN", 104, 135], ["ACE2", "PROTEIN", 137, 141], ["viral genome", "DNA", 246, 258], ["The spike protein", "TEST", 0, 17], ["the COVID", "TEST", 52, 61], ["the virus", "PROBLEM", 83, 92], ["angiotensin", "TEST", 104, 115], ["the host cell membrane", "TREATMENT", 146, 168], ["the viral genome", "TREATMENT", 242, 258], ["host cell membrane", "OBSERVATION", 150, 168], ["host cell", "OBSERVATION", 286, 295]]], ["Infections caused by these viruses result in severe pneumonia, fever and breathing difficulty [22] .IntroductionProtein-protein interaction map between SARS-CoV-2 and human proteins published recently has revealed several important targets for drug repurposing [23] .", [["Infections", "DISEASE", 0, 10], ["pneumonia", "DISEASE", 52, 61], ["fever", "DISEASE", 63, 68], ["breathing difficulty", "DISEASE", 73, 93], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 152, 162], ["human", "ORGANISM", 167, 172], ["SARS-CoV-2 and human proteins", "PROTEIN", 152, 181], ["human", "SPECIES", 167, 172], ["human", "SPECIES", 167, 172], ["Infections", "PROBLEM", 0, 10], ["these viruses", "PROBLEM", 21, 34], ["severe pneumonia", "PROBLEM", 45, 61], ["fever", "PROBLEM", 63, 68], ["breathing difficulty", "PROBLEM", 73, 93], ["IntroductionProtein", "TEST", 100, 119], ["map", "TEST", 140, 143], ["SARS", "TEST", 152, 156], ["CoV", "TEST", 157, 160], ["human proteins", "TEST", 167, 181], ["viruses", "OBSERVATION", 27, 34], ["severe", "OBSERVATION_MODIFIER", 45, 51], ["pneumonia", "OBSERVATION", 52, 61]]], ["Given the evolving nature of coronaviruses that results in frequent genetic diversity in their genome, it is crucial to identify the regulators in humans that interacts with the viral genome and their cross talk that results in altered regulatory mechanisms in the host during the infection process.", [["infection", "DISEASE", 281, 290], ["coronaviruses", "ORGANISM", 29, 42], ["humans", "ORGANISM", 147, 153], ["viral genome", "DNA", 178, 190], ["humans", "SPECIES", 147, 153], ["humans", "SPECIES", 147, 153], ["coronaviruses", "PROBLEM", 29, 42], ["the viral genome", "TREATMENT", 174, 190], ["altered regulatory mechanisms", "PROBLEM", 228, 257], ["the infection process", "PROBLEM", 277, 298], ["coronaviruses", "OBSERVATION", 29, 42], ["infection", "OBSERVATION", 281, 290]]], ["Therefore, it is imperative to investigate the interacting post-transcriptional regulators that asset these viral proteins in different tissues.IntroductionRNA-binding proteins (RBPs) and miRNAs (micro-RNAs) have been widely recognized in regulating the post-transcriptional gene regulatory network in humans [24] [25] [26] .", [["tissues", "ANATOMY", 136, 143], ["tissues", "TISSUE", 136, 143], ["IntroductionRNA-binding proteins", "GENE_OR_GENE_PRODUCT", 144, 176], ["RBPs", "GENE_OR_GENE_PRODUCT", 178, 182], ["micro-RNAs", "GENE_OR_GENE_PRODUCT", 196, 206], ["humans", "ORGANISM", 302, 308], ["post-transcriptional regulators", "PROTEIN", 59, 90], ["viral proteins", "PROTEIN", 108, 122], ["IntroductionRNA-binding proteins", "PROTEIN", 144, 176], ["RBPs", "PROTEIN", 178, 182], ["miRNAs (micro-RNAs", "RNA", 188, 206], ["humans", "SPECIES", 302, 308], ["humans", "SPECIES", 302, 308], ["these viral proteins in different tissues", "PROBLEM", 102, 143], ["IntroductionRNA", "TEST", 144, 159], ["binding proteins", "TEST", 160, 176], ["RBPs", "TEST", 178, 182], ["miRNAs (micro-RNAs", "TEST", 188, 206], ["viral proteins", "OBSERVATION", 108, 122], ["different tissues", "OBSERVATION", 126, 143]]], ["Dysregulated RBPs and miRNAs have been shown to contribute significantly to altered regulatory network in a plethora of diseases such as cancer, genetic diseases and viral infections [27] [28] [29] [30] [31] [32] [33] .", [["cancer", "ANATOMY", 137, 143], ["cancer", "DISEASE", 137, 143], ["genetic diseases", "DISEASE", 145, 161], ["viral infections", "DISEASE", 166, 182], ["cancer", "CANCER", 137, 143], ["[27] [28] [29] [30] [31] [32] [33]", "SIMPLE_CHEMICAL", 183, 217], ["RBPs", "PROTEIN", 13, 17], ["miRNAs", "PROTEIN", 22, 28], ["Dysregulated RBPs", "PROBLEM", 0, 17], ["miRNAs", "PROBLEM", 22, 28], ["altered regulatory network", "PROBLEM", 76, 102], ["diseases", "PROBLEM", 120, 128], ["cancer", "PROBLEM", 137, 143], ["genetic diseases", "PROBLEM", 145, 161], ["viral infections", "PROBLEM", 166, 182], ["diseases", "OBSERVATION", 120, 128], ["cancer", "OBSERVATION", 137, 143]]], ["Till date, the potential RBPs and miRNAs that either interact directly with the virus or cross talk with each other to facilitate SARS-CoV-2 infection has not been investigated and hence require a systematic investigation of their role in SARS-SoV-2 infection.IntroductionCurrently, there are no proven vaccines or anti-viral therapies that are effective against the novel coronavirus.", [["infection", "DISEASE", 141, 150], ["infection", "DISEASE", 250, 259], ["coronavirus", "DISEASE", 373, 384], ["SARS-CoV-2", "ORGANISM", 130, 140], ["SARS-SoV-2", "ORGANISM", 239, 249], ["coronavirus", "ORGANISM", 373, 384], ["RBPs", "PROTEIN", 25, 29], ["coronavirus", "SPECIES", 373, 384], ["SARS-SoV-2", "SPECIES", 239, 249], ["the virus", "PROBLEM", 76, 85], ["SARS", "PROBLEM", 130, 134], ["CoV-2 infection", "PROBLEM", 135, 150], ["a systematic investigation", "TEST", 195, 221], ["SARS", "PROBLEM", 239, 243], ["SoV", "PROBLEM", 244, 247], ["2 infection", "PROBLEM", 248, 259], ["vaccines", "TREATMENT", 303, 311], ["anti-viral therapies", "TREATMENT", 315, 335], ["the novel coronavirus", "PROBLEM", 363, 384], ["infection", "OBSERVATION", 250, 259], ["no proven", "UNCERTAINTY", 293, 302]]], ["Although, analysis of therapeutic targets for SARS-CoV-2 has been conducted to identify potential drugs by computational methods [34] , the targets have not clinically approved for vaccine development.", [["SARS", "DISEASE", 46, 50], ["SARS-CoV-2", "ORGANISM", 46, 56], ["SARS", "PROBLEM", 46, 50]]], ["Alternative therapeutics like angiotensin receptor blockers have been identified as tentative vaccine candidates but have shown concerns associated with disrupted angiotensin functions crucial for cell [35] .", [["cell", "ANATOMY", 197, 201], ["angiotensin", "CHEMICAL", 30, 41], ["angiotensin", "CHEMICAL", 163, 174], ["angiotensin receptor blockers", "GENE_OR_GENE_PRODUCT", 30, 59], ["angiotensin", "GENE_OR_GENE_PRODUCT", 163, 174], ["cell", "CELL", 197, 201], ["Alternative therapeutics", "TREATMENT", 0, 24], ["angiotensin receptor blockers", "TREATMENT", 30, 59], ["tentative vaccine", "TREATMENT", 84, 101], ["disrupted angiotensin functions", "PROBLEM", 153, 184]]], ["Therefore, to devise effective therapeutics, there is a need to determine the cellular targets in humans that interact with the virus and result in altered functional outcomes.", [["cellular", "ANATOMY", 78, 86], ["cellular", "CELL", 78, 86], ["humans", "ORGANISM", 98, 104], ["humans", "SPECIES", 98, 104], ["humans", "SPECIES", 98, 104], ["the virus", "PROBLEM", 124, 133], ["altered functional outcomes", "PROBLEM", 148, 175]]], ["In this study, we uncovered that several human RBPs and miRNAs harbor abundant binding sites across the SARS-CoV-2 genome, illustrating the titration of posttranscriptional regulators.", [["human", "ORGANISM", 41, 46], ["human RBPs", "PROTEIN", 41, 51], ["miRNAs", "DNA", 56, 62], ["binding sites", "DNA", 79, 92], ["SARS-CoV-2 genome", "DNA", 104, 121], ["posttranscriptional regulators", "PROTEIN", 153, 183], ["human", "SPECIES", 41, 46], ["human", "SPECIES", 41, 46], ["SARS-CoV", "SPECIES", 104, 112], ["this study", "TEST", 3, 13], ["several human RBPs", "PROBLEM", 33, 51], ["miRNAs harbor abundant binding sites", "PROBLEM", 56, 92], ["the SARS", "TEST", 100, 108], ["CoV", "TEST", 109, 112], ["posttranscriptional regulators", "TREATMENT", 153, 183]]], ["Interestingly, we show that most of these regulators were predominantly expressed in gonadal tissues, adrenal, pancreas, and blood cells.", [["gonadal tissues", "ANATOMY", 85, 100], ["adrenal", "ANATOMY", 102, 109], ["pancreas", "ANATOMY", 111, 119], ["blood cells", "ANATOMY", 125, 136], ["gonadal tissues", "TISSUE", 85, 100], ["adrenal", "ORGAN", 102, 109], ["pancreas", "ORGAN", 111, 119], ["blood cells", "CELL", 125, 136], ["blood cells", "CELL_TYPE", 125, 136], ["gonadal tissues", "ANATOMY", 85, 100], ["adrenal", "ANATOMY", 102, 109], ["pancreas", "ANATOMY", 111, 119], ["blood cells", "ANATOMY", 125, 136]]], ["Overall, this study will bridge the gap in our understanding of the impact of SARS-CoV-2 infection on post-transcriptional regulatory networks.Protein-protein interaction network analysis suggest an immediate interaction of functionally important human RBPs with SARS-CoV-2 viral proteinsWe obtained the affinity purification-mass spectrometry (AP-MS) based SARS-CoV-2 and human proteins interaction network established in HEK293 cells [23] and investigated the human RBPs that directly interact with viral proteins.", [["HEK293 cells", "ANATOMY", 423, 435], ["SARS", "DISEASE", 78, 82], ["infection", "DISEASE", 89, 98], ["SARS-CoV-2", "ORGANISM", 78, 88], ["human", "ORGANISM", 247, 252], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 263, 273], ["human", "ORGANISM", 373, 378], ["HEK293 cells", "CELL", 423, 435], ["human", "ORGANISM", 462, 467], ["RBPs", "GENE_OR_GENE_PRODUCT", 468, 472], ["human RBPs", "PROTEIN", 247, 257], ["SARS-CoV-2 viral proteins", "PROTEIN", 263, 288], ["HEK293 cells", "CELL_LINE", 423, 435], ["human RBPs", "PROTEIN", 462, 472], ["viral proteins", "PROTEIN", 501, 515], ["human", "SPECIES", 247, 252], ["human", "SPECIES", 373, 378], ["human", "SPECIES", 462, 467], ["human", "SPECIES", 247, 252], ["human", "SPECIES", 373, 378], ["human", "SPECIES", 462, 467], ["this study", "TEST", 9, 19], ["SARS", "PROBLEM", 78, 82], ["CoV-2 infection", "PROBLEM", 83, 98], ["post-transcriptional regulatory networks", "TREATMENT", 102, 142], ["Protein-protein interaction network analysis", "TEST", 143, 187], ["SARS", "TEST", 263, 267], ["CoV", "TEST", 268, 271], ["viral proteins", "PROBLEM", 274, 288], ["the affinity purification", "TEST", 300, 325], ["mass spectrometry", "PROBLEM", 326, 343], ["AP-MS)", "TEST", 345, 351], ["SARS", "TEST", 358, 362], ["CoV", "TEST", 363, 366], ["the human RBPs", "PROBLEM", 458, 472], ["viral proteins", "PROBLEM", 501, 515], ["infection", "OBSERVATION", 89, 98], ["viral proteins", "OBSERVATION", 501, 515]]], ["Our analysis revealed that SARS-CoV-2 encoded proteins interact directly with 51 human RBPs (Fig.1A) .", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 27, 37], ["human", "ORGANISM", 81, 86], ["SARS-CoV-2 encoded proteins", "PROTEIN", 27, 54], ["51 human RBPs", "PROTEIN", 78, 91], [".1A", "PROTEIN", 96, 99], ["human", "SPECIES", 81, 86], ["SARS-CoV", "SPECIES", 27, 35], ["human", "SPECIES", 81, 86], ["Our analysis", "TEST", 0, 12], ["SARS", "PROBLEM", 27, 31], ["CoV", "TEST", 32, 35], ["human RBPs", "TEST", 81, 91]]], ["We observed that these primary interacting RBPs were proven to serve several vital functions in the cells including RNA processing enzymes such as polyadenylate binding protein 4 (PABP4) and Dead-box helicases (DDX21 and DDX10), enzymes involved in translation machinery such as eukaryotic translation initiation factor 4H (EIF4H) and ribosomal protein L36 (RPL36) (Fig. 1A ).", [["cells", "ANATOMY", 100, 105], ["cells", "CELL", 100, 105], ["polyadenylate binding protein 4", "GENE_OR_GENE_PRODUCT", 147, 178], ["PABP4", "GENE_OR_GENE_PRODUCT", 180, 185], ["DDX21", "GENE_OR_GENE_PRODUCT", 211, 216], ["DDX10", "GENE_OR_GENE_PRODUCT", 221, 226], ["eukaryotic translation initiation factor 4H", "GENE_OR_GENE_PRODUCT", 279, 322], ["EIF4H", "GENE_OR_GENE_PRODUCT", 324, 329], ["ribosomal protein L36", "GENE_OR_GENE_PRODUCT", 335, 356], ["RPL36", "GENE_OR_GENE_PRODUCT", 358, 363], ["Fig. 1A", "GENE_OR_GENE_PRODUCT", 366, 373], ["RBPs", "PROTEIN", 43, 47], ["RNA processing enzymes", "PROTEIN", 116, 138], ["polyadenylate binding protein 4", "PROTEIN", 147, 178], ["PABP4", "PROTEIN", 180, 185], ["Dead-box helicases", "PROTEIN", 191, 209], ["DDX21", "PROTEIN", 211, 216], ["DDX10", "PROTEIN", 221, 226], ["enzymes", "PROTEIN", 229, 236], ["eukaryotic translation initiation factor 4H", "PROTEIN", 279, 322], ["EIF4H", "PROTEIN", 324, 329], ["ribosomal protein L36", "PROTEIN", 335, 356], ["RPL36", "PROTEIN", 358, 363], ["Fig. 1A", "PROTEIN", 366, 373], ["these primary interacting RBPs", "PROBLEM", 17, 47], ["RNA processing enzymes", "TEST", 116, 138], ["polyadenylate binding protein", "TEST", 147, 176], ["PABP4", "TEST", 180, 185], ["Dead-box helicases", "TREATMENT", 191, 209], ["DDX21", "TEST", 211, 216], ["enzymes", "TEST", 229, 236], ["translation machinery", "TREATMENT", 249, 270], ["ribosomal protein", "TEST", 335, 352]]], ["Among these immediate interactions, we also found human RBPs such as signal recognition particle 19 (SRP19 and SRP54) and Golgin subfamily B member 1 (GOLGB1) that have been well recognized for co-translational protein targeting to membrane and ER to Golgi vesicle-mediated transport [36, 37] (Fig. 1A) .", [["membrane", "ANATOMY", 232, 240], ["ER", "ANATOMY", 245, 247], ["Golgi vesicle", "ANATOMY", 251, 264], ["human", "ORGANISM", 50, 55], ["signal recognition particle 19", "GENE_OR_GENE_PRODUCT", 69, 99], ["SRP19", "GENE_OR_GENE_PRODUCT", 101, 106], ["SRP54", "GENE_OR_GENE_PRODUCT", 111, 116], ["Golgin subfamily B member 1", "GENE_OR_GENE_PRODUCT", 122, 149], ["GOLGB1", "GENE_OR_GENE_PRODUCT", 151, 157], ["membrane", "CELLULAR_COMPONENT", 232, 240], ["ER", "GENE_OR_GENE_PRODUCT", 245, 247], ["Golgi vesicle", "CELLULAR_COMPONENT", 251, 264], ["human RBPs", "PROTEIN", 50, 60], ["signal recognition particle 19", "PROTEIN", 69, 99], ["SRP19", "PROTEIN", 101, 106], ["SRP54", "PROTEIN", 111, 116], ["Golgin subfamily B member 1", "PROTEIN", 122, 149], ["GOLGB1", "PROTEIN", 151, 157], ["ER", "PROTEIN", 245, 247], ["human", "SPECIES", 50, 55], ["human", "SPECIES", 50, 55], ["human RBPs", "PROBLEM", 50, 60], ["signal recognition particle", "TEST", 69, 96]]], ["These results suggest that several human RBPs that come in direct contact with SARS-CoV-2 proteins could contribute to virus assembly and export.", [["human", "ORGANISM", 35, 40], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 79, 89], ["human RBPs", "PROTEIN", 35, 45], ["SARS-CoV-2 proteins", "PROTEIN", 79, 98], ["human", "SPECIES", 35, 40], ["human", "SPECIES", 35, 40], ["several human RBPs", "PROBLEM", 27, 45], ["SARS", "PROBLEM", 79, 83], ["CoV-2 proteins", "PROBLEM", 84, 98], ["virus", "PROBLEM", 119, 124]]], ["However, such findings require in-depth experimental validation to support the functional involvement of the identified RBPs in response to SARS-CoV-2 infection.Protein-protein interaction network analysis suggest an immediate interaction of functionally important human RBPs with SARS-CoV-2 viral proteinsFurther, we observed that among the SARS-CoV-2 encoded proteins, majority of direct interactions occurred with a range of non-structural proteins (nsp 2, 5, 8, 9, 11, 13 ) that contribute to viral replication and transcription along with structural proteins (E,N and M) (Fig. 1A) .", [["SARS", "DISEASE", 140, 144], ["infection", "DISEASE", 151, 160], ["SARS-CoV-2", "ORGANISM", 140, 150], ["human", "ORGANISM", 265, 270], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 281, 291], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 342, 352], ["nsp 2", "GENE_OR_GENE_PRODUCT", 453, 458], ["5", "GENE_OR_GENE_PRODUCT", 460, 461], ["8", "GENE_OR_GENE_PRODUCT", 463, 464], ["13", "GENE_OR_GENE_PRODUCT", 473, 475], ["RBPs", "PROTEIN", 120, 124], ["human RBPs", "PROTEIN", 265, 275], ["SARS-CoV-2 viral proteins", "PROTEIN", 281, 306], ["SARS-CoV-2 encoded proteins", "PROTEIN", 342, 369], ["non-structural proteins", "PROTEIN", 428, 451], ["nsp 2, 5, 8, 9, 11, 13", "PROTEIN", 453, 475], ["structural proteins", "PROTEIN", 544, 563], ["E,N and M", "PROTEIN", 565, 574], ["Fig. 1A", "PROTEIN", 577, 584], ["human", "SPECIES", 265, 270], ["SARS-CoV", "SPECIES", 140, 148], ["human", "SPECIES", 265, 270], ["SARS-CoV", "SPECIES", 342, 350], ["the identified RBPs", "PROBLEM", 105, 124], ["SARS", "PROBLEM", 140, 144], ["CoV-2 infection", "PROBLEM", 145, 160], ["Protein-protein interaction network analysis", "TEST", 161, 205], ["SARS", "TEST", 281, 285], ["CoV", "TEST", 286, 289], ["the SARS", "TEST", 338, 346], ["CoV", "TEST", 347, 350], ["direct interactions", "PROBLEM", 383, 402], ["non-structural proteins", "TEST", 428, 451], ["nsp", "TEST", 453, 456], ["viral replication", "PROBLEM", 497, 514], ["structural proteins", "TEST", 544, 563], ["infection", "OBSERVATION", 151, 160], ["viral replication", "OBSERVATION", 497, 514]]], ["It is likely that these identified RBPs assist in the viral transcription in the host cell.", [["cell", "ANATOMY", 86, 90], ["host cell", "CELL", 81, 90], ["RBPs", "PROTEIN", 35, 39], ["host cell", "CELL_TYPE", 81, 90], ["is likely", "UNCERTAINTY", 3, 12], ["viral transcription", "OBSERVATION", 54, 73], ["host cell", "OBSERVATION", 81, 90]]], ["Furthermore, we also observed ~65% of annotated human RBPs [38] were in immediate neighborhood (obtained from BioGRID, shown at the center in Fig. 1A ) of virus-protein interacting RBPs and could indirectly regulate the SARS-CoV-2 proteins, representing a comprehensive network of human RBPs and SARS-CoV-2 proteins likely to rewire the post-transcriptional gene regulatory mechanisms in human cells.Protein-protein interaction network analysis suggest an immediate interaction of functionally important human RBPs with SARS-CoV-2 viral proteinsNext, we examined the abundance of SARS-CoV-2 interacting RBPs across human tissues using the protein expression data from human proteome map [39] .", [["cells", "ANATOMY", 394, 399], ["tissues", "ANATOMY", 621, 628], ["human", "ORGANISM", 48, 53], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 220, 230], ["human", "ORGANISM", 281, 286], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 296, 306], ["human", "ORGANISM", 388, 393], ["cells", "CELL", 394, 399], ["human", "ORGANISM", 504, 509], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 520, 530], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 580, 590], ["human", "ORGANISM", 615, 620], ["tissues", "TISSUE", 621, 628], ["human", "ORGANISM", 668, 673], ["human RBPs", "PROTEIN", 48, 58], ["virus-protein interacting RBPs", "PROTEIN", 155, 185], ["SARS-CoV-2 proteins", "PROTEIN", 220, 239], ["human RBPs", "PROTEIN", 281, 291], ["SARS-CoV-2 proteins", "PROTEIN", 296, 315], ["human cells", "CELL_TYPE", 388, 399], ["human RBPs", "PROTEIN", 504, 514], ["SARS-CoV-2 viral proteins", "PROTEIN", 520, 545], ["SARS-CoV-2 interacting RBPs", "PROTEIN", 580, 607], ["human", "SPECIES", 48, 53], ["human", "SPECIES", 281, 286], ["human", "SPECIES", 388, 393], ["human", "SPECIES", 504, 509], ["human", "SPECIES", 615, 620], ["human", "SPECIES", 668, 673], ["human", "SPECIES", 48, 53], ["human", "SPECIES", 281, 286], ["human", "SPECIES", 388, 393], ["human", "SPECIES", 504, 509], ["SARS-CoV", "SPECIES", 580, 588], ["human", "SPECIES", 615, 620], ["human", "SPECIES", 668, 673], ["annotated human RBPs", "TEST", 38, 58], ["virus", "PROBLEM", 155, 160], ["protein interacting RBPs", "PROBLEM", 161, 185], ["the SARS", "TEST", 216, 224], ["CoV", "TEST", 225, 228], ["human RBPs", "TEST", 281, 291], ["SARS", "PROBLEM", 296, 300], ["CoV", "TEST", 301, 304], ["2 proteins", "PROBLEM", 305, 315], ["the post-transcriptional gene regulatory mechanisms in human cells", "PROBLEM", 333, 399], ["Protein-protein interaction network analysis", "TEST", 400, 444], ["SARS", "TEST", 520, 524], ["CoV", "TEST", 525, 528], ["SARS", "PROBLEM", 580, 584], ["CoV", "TEST", 585, 588], ["the protein expression data", "TEST", 635, 662], ["human proteome map", "TEST", 668, 686], ["virus", "OBSERVATION", 155, 160], ["human cells", "OBSERVATION", 388, 399]]], ["Our results suggest that majority of the human RBPs that have direct interaction with SARS-CoV-2 proteins were predominantly expressed in gonadal tissues (testis and ovary) (Fig. 1B) .", [["gonadal tissues", "ANATOMY", 138, 153], ["testis", "ANATOMY", 155, 161], ["ovary", "ANATOMY", 166, 171], ["human", "ORGANISM", 41, 46], ["RBPs", "GENE_OR_GENE_PRODUCT", 47, 51], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 86, 96], ["gonadal tissues", "TISSUE", 138, 153], ["testis", "ORGAN", 155, 161], ["ovary", "ORGAN", 166, 171], ["human RBPs", "PROTEIN", 41, 51], ["SARS-CoV-2 proteins", "PROTEIN", 86, 105], ["human", "SPECIES", 41, 46], ["human", "SPECIES", 41, 46], ["the human RBPs", "PROBLEM", 37, 51], ["SARS", "PROBLEM", 86, 90], ["CoV-2 proteins", "TEST", 91, 105], ["gonadal tissues", "ANATOMY", 138, 153], ["testis", "ANATOMY", 155, 161], ["ovary", "ANATOMY", 166, 171]]], ["These findings agreed with a recent study showing that male reproductive systems are vulnerable to SARS-CoV-2 infection, that was evident by dramatic changes in sex hormones of the infected patients suggesting gonadal function impairment [40, 41] .", [["gonadal", "ANATOMY", 210, 217], ["SARS", "DISEASE", 99, 103], ["infection", "DISEASE", 110, 119], ["gonadal function impairment", "DISEASE", 210, 237], ["SARS-CoV-2", "ORGANISM", 99, 109], ["patients", "ORGANISM", 190, 198], ["gonadal", "ORGAN", 210, 217], ["patients", "SPECIES", 190, 198], ["SARS-CoV", "SPECIES", 99, 107], ["a recent study", "TEST", 27, 41], ["male reproductive systems", "PROBLEM", 55, 80], ["SARS", "PROBLEM", 99, 103], ["CoV-2 infection", "PROBLEM", 104, 119], ["dramatic changes in sex hormones", "PROBLEM", 141, 173], ["gonadal function impairment", "PROBLEM", 210, 237], ["infection", "OBSERVATION", 110, 119], ["dramatic", "OBSERVATION_MODIFIER", 141, 149], ["infected", "OBSERVATION", 181, 189], ["gonadal", "ANATOMY", 210, 217]]], ["Additionally, we also found that, these SARS-CoV-2 interacting human RBPs were showing relatively higher expression in immune cell types such as T cells (CD4+ and CD8+) and NK cells that are a part of innate anti-viral immune response (Fig. 1B) .", [["immune cell", "ANATOMY", 119, 130], ["T cells", "ANATOMY", 145, 152], ["CD4+", "ANATOMY", 154, 158], ["CD8+)", "ANATOMY", 163, 168], ["NK cells", "ANATOMY", 173, 181], ["SARS", "DISEASE", 40, 44], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 40, 50], ["human", "ORGANISM", 63, 68], ["immune cell", "CELL", 119, 130], ["T cells", "CELL", 145, 152], ["CD4", "GENE_OR_GENE_PRODUCT", 154, 157], ["CD8", "GENE_OR_GENE_PRODUCT", 163, 166], ["NK cells", "CELL", 173, 181], ["SARS-CoV-2 interacting human RBPs", "PROTEIN", 40, 73], ["T cells", "CELL_TYPE", 145, 152], ["CD4", "PROTEIN", 154, 157], ["CD8", "PROTEIN", 163, 166], ["NK cells", "CELL_TYPE", 173, 181], ["human", "SPECIES", 63, 68], ["human", "SPECIES", 63, 68], ["these SARS", "TEST", 34, 44], ["CoV", "TEST", 45, 48], ["human RBPs", "TEST", 63, 73], ["relatively higher expression in immune cell types", "PROBLEM", 87, 136], ["T cells", "PROBLEM", 145, 152], ["CD4", "TEST", 154, 157], ["CD8", "TEST", 163, 166], ["NK cells", "PROBLEM", 173, 181], ["relatively", "OBSERVATION_MODIFIER", 87, 97], ["higher expression", "OBSERVATION_MODIFIER", 98, 115], ["immune cell types", "OBSERVATION", 119, 136], ["NK cells", "OBSERVATION", 173, 181]]], ["Our observations are supported by recently published studies suggesting that T cells, CD4+ T cells, and CD8+ T cells play a significant antiviral role during SARS-CoV-2 infection [20, [42] [43] [44] [45] .", [["T cells", "ANATOMY", 77, 84], ["CD4+ T cells", "ANATOMY", 86, 98], ["CD8+ T cells", "ANATOMY", 104, 116], ["infection", "DISEASE", 169, 178], ["T cells", "CELL", 77, 84], ["CD4", "GENE_OR_GENE_PRODUCT", 86, 89], ["CD8", "GENE_OR_GENE_PRODUCT", 104, 107], ["SARS-CoV-2", "ORGANISM", 158, 168], ["[42] [43] [44", "SIMPLE_CHEMICAL", 184, 197], ["T cells", "CELL_TYPE", 77, 84], ["CD4+ T cells", "CELL_TYPE", 86, 98], ["CD8+ T cells", "CELL_TYPE", 104, 116], ["SARS-CoV-2", "SPECIES", 158, 168], ["T cells", "PROBLEM", 77, 84], ["CD4", "TEST", 86, 89], ["T cells", "TEST", 91, 98], ["CD8", "TEST", 104, 107], ["T cells", "PROBLEM", 109, 116], ["SARS", "TEST", 158, 162], ["CoV", "TEST", 163, 166], ["infection", "PROBLEM", 169, 178]]], ["Overall, the results from this analysis provide a systematic dissection of potential RBPs in humans interacting with SARS-CoV-2 proteins across tissues.SARS-CoV-2 infected lung epithelial cells reveal the enrichment of several immunological and metabolic pathways.Due to rapidly evolving nature of SARS-CoV-2, the transcriptomic alterations contributed by the virus in humans remains unclear.", [["tissues", "ANATOMY", 144, 151], ["lung epithelial cells", "ANATOMY", 172, 193], ["SARS", "DISEASE", 152, 156], ["SARS", "DISEASE", 298, 302], ["humans", "ORGANISM", 93, 99], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 117, 127], ["tissues", "TISSUE", 144, 151], ["SARS-CoV-2", "CELL", 152, 162], ["lung epithelial cells", "CELL", 172, 193], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 298, 308], ["humans", "ORGANISM", 369, 375], ["RBPs", "PROTEIN", 85, 89], ["SARS-CoV-2 proteins", "PROTEIN", 117, 136], ["lung epithelial cells", "CELL_TYPE", 172, 193], ["humans", "SPECIES", 93, 99], ["humans", "SPECIES", 369, 375], ["humans", "SPECIES", 93, 99], ["SARS-CoV", "SPECIES", 298, 306], ["humans", "SPECIES", 369, 375], ["this analysis", "TEST", 26, 39], ["a systematic dissection", "TREATMENT", 48, 71], ["potential RBPs in humans", "PROBLEM", 75, 99], ["SARS", "TEST", 117, 121], ["CoV", "TEST", 122, 125], ["SARS", "TEST", 152, 156], ["CoV", "TEST", 157, 160], ["infected lung epithelial cells", "PROBLEM", 163, 193], ["SARS", "PROBLEM", 298, 302], ["CoV", "TEST", 303, 306], ["the transcriptomic alterations", "PROBLEM", 310, 340], ["the virus in humans", "PROBLEM", 356, 375], ["dissection", "OBSERVATION", 61, 71], ["lung", "ANATOMY", 172, 176], ["epithelial cells", "OBSERVATION", 177, 193], ["enrichment", "OBSERVATION_MODIFIER", 205, 215], ["metabolic pathways", "OBSERVATION", 245, 263], ["rapidly", "OBSERVATION_MODIFIER", 271, 278], ["SARS", "OBSERVATION", 298, 302], ["virus", "OBSERVATION", 360, 365]]], ["To gain insight into the effect of SARS-CoV-2 infection on host gene expression, we obtained the raw RNA sequencing data in normal versus SARS-CoV-2 infected human bronchial epithelial (NHBE) cells [46] deposited in Gene Expression Omnibus (GEO) [47] .", [["bronchial epithelial (NHBE) cells", "ANATOMY", 164, 197], ["SARS", "DISEASE", 35, 39], ["infection", "DISEASE", 46, 55], ["SARS-CoV-2", "ORGANISM", 35, 45], ["CoV-2", "CELL", 143, 148], ["human", "ORGANISM", 158, 163], ["bronchial epithelial (NHBE) cells", "CELL", 164, 197], ["SARS-CoV-2 infected human bronchial epithelial (NHBE) cells", "CELL_LINE", 138, 197], ["human", "SPECIES", 158, 163], ["SARS-CoV", "SPECIES", 138, 146], ["human", "SPECIES", 158, 163], ["SARS", "PROBLEM", 35, 39], ["CoV-2 infection", "PROBLEM", 40, 55], ["the raw RNA sequencing data", "TEST", 93, 120], ["SARS", "TEST", 138, 142], ["CoV", "TEST", 143, 146], ["infected human bronchial epithelial (NHBE) cells", "PROBLEM", 149, 197], ["bronchial epithelial", "ANATOMY", 164, 184]]], ["We investigated the differentially expressed genes between the mock treated versus SARS-CoV-2 infected cells and assessed the functional pathways associated with these genes ( Fig. 2A, Fig. S1 ).", [["cells", "ANATOMY", 103, 108], ["SARS", "DISEASE", 83, 87], ["SARS-CoV-2", "CELL", 83, 93], ["cells", "CELL", 103, 108], ["S1", "GENE_OR_GENE_PRODUCT", 190, 192], ["S1", "PROTEIN", 190, 192], ["SARS-CoV", "SPECIES", 83, 91], ["SARS", "PROBLEM", 83, 87], ["2 infected cells", "PROBLEM", 92, 108]]], ["Functional analysis of differentially expressed genes (at 5% fdr) using ClueGo [48] revealed an enrichment for immune response, cytokine mediated signaling, inflammatory response and metabolism associated genes ( Fig. 2A , Table S1 ).SARS-CoV-2 infected lung epithelial cells reveal the enrichment of several immunological and metabolic pathways.We observed a significant enrichment for the IL-17 pathway associated genes during SARS-CoV-2 infection ( Fig. 2A ).", [["lung epithelial cells", "ANATOMY", 254, 275], ["SARS", "DISEASE", 234, 238], ["infection", "DISEASE", 440, 449], ["SARS-CoV-2", "CELL", 234, 244], ["lung epithelial cells", "CELL", 254, 275], ["IL-17", "GENE_OR_GENE_PRODUCT", 391, 396], ["SARS-CoV-2", "ORGANISM", 429, 439], ["differentially expressed genes", "DNA", 23, 53], ["cytokine", "PROTEIN", 128, 136], ["lung epithelial cells", "CELL_TYPE", 254, 275], ["IL-17 pathway associated genes", "DNA", 391, 421], ["SARS-CoV-2", "SPECIES", 429, 439], ["immune response", "PROBLEM", 111, 126], ["cytokine mediated signaling", "PROBLEM", 128, 155], ["inflammatory response", "PROBLEM", 157, 178], ["metabolism associated genes", "PROBLEM", 183, 210], ["SARS", "TEST", 234, 238], ["CoV", "TEST", 239, 242], ["infected lung epithelial cells", "PROBLEM", 245, 275], ["the IL", "TREATMENT", 387, 393], ["SARS", "PROBLEM", 429, 433], ["CoV-2 infection", "PROBLEM", 434, 449], ["inflammatory", "OBSERVATION_MODIFIER", 157, 169], ["lung", "ANATOMY", 254, 258], ["epithelial cells", "OBSERVATION", 259, 275], ["enrichment", "OBSERVATION_MODIFIER", 287, 297], ["metabolic pathways", "OBSERVATION", 327, 345], ["significant", "OBSERVATION_MODIFIER", 360, 371], ["enrichment", "OBSERVATION", 372, 382], ["infection", "OBSERVATION", 440, 449]]], ["Our observation of overrepresented IL-17 pathway was in accordance with recent studies that show overactivation of IL-17 producing Th17 cells during severe immune injury in SARS-CoV-2 patients [49] [50] [51] .", [["Th17 cells", "ANATOMY", 131, 141], ["immune injury", "DISEASE", 156, 169], ["SARS", "DISEASE", 173, 177], ["IL-17", "GENE_OR_GENE_PRODUCT", 35, 40], ["IL-17", "GENE_OR_GENE_PRODUCT", 115, 120], ["Th17 cells", "CELL", 131, 141], ["SARS-CoV", "ORGANISM", 173, 181], ["patients", "ORGANISM", 184, 192], ["IL", "PROTEIN", 35, 37], ["IL-17", "PROTEIN", 115, 120], ["Th17 cells", "CELL_TYPE", 131, 141], ["patients", "SPECIES", 184, 192], ["SARS-CoV", "SPECIES", 173, 181], ["recent studies", "TEST", 72, 86], ["IL", "TEST", 115, 117], ["Th17 cells", "PROBLEM", 131, 141], ["severe immune injury", "PROBLEM", 149, 169], ["CoV", "TEST", 178, 181]]], ["In addition to this, a recent review has summarized that targeting IL-17 is immunologically plausible as a therapeutic strategy to prevent acute respiratory distress syndrome (ARDS) during SARS-CoV-2 infection, based on previous evidence that mice lacking functional IL-17 receptor (Il17ra\u2212/\u2212) signaling were shown to be more susceptible than wild-type mice to secondary pneumonia following infection with influenza A [52, 53] .", [["respiratory", "ANATOMY", 145, 156], ["acute respiratory distress syndrome", "DISEASE", 139, 174], ["ARDS", "DISEASE", 176, 180], ["infection", "DISEASE", 200, 209], ["pneumonia", "DISEASE", 371, 380], ["infection", "DISEASE", 391, 400], ["influenza", "DISEASE", 406, 415], ["IL-17", "GENE_OR_GENE_PRODUCT", 67, 72], ["CoV-2", "ORGANISM", 194, 199], ["mice", "ORGANISM", 243, 247], ["IL-17 receptor", "GENE_OR_GENE_PRODUCT", 267, 281], ["Il17ra\u2212", "GENE_OR_GENE_PRODUCT", 283, 290], ["\u2212", "GENE_OR_GENE_PRODUCT", 291, 292], ["mice", "ORGANISM", 353, 357], ["IL-17", "PROTEIN", 67, 72], ["IL-17 receptor", "PROTEIN", 267, 281], ["Il17ra\u2212", "PROTEIN", 283, 290], ["mice", "SPECIES", 243, 247], ["mice", "SPECIES", 353, 357], ["mice", "SPECIES", 243, 247], ["mice", "SPECIES", 353, 357], ["a therapeutic strategy", "TREATMENT", 105, 127], ["acute respiratory distress syndrome", "PROBLEM", 139, 174], ["ARDS", "PROBLEM", 176, 180], ["SARS", "PROBLEM", 189, 193], ["CoV-2 infection", "PROBLEM", 194, 209], ["functional IL", "TEST", 256, 269], ["secondary pneumonia", "PROBLEM", 361, 380], ["infection", "PROBLEM", 391, 400], ["influenza A", "PROBLEM", 406, 417], ["acute", "OBSERVATION_MODIFIER", 139, 144], ["respiratory", "ANATOMY", 145, 156], ["distress syndrome", "OBSERVATION", 157, 174], ["infection", "OBSERVATION", 200, 209], ["pneumonia", "OBSERVATION", 371, 380]]], ["Thus, our analysis shows several enriched pathways including IL-17 cytokine response in SARS-CoV-2 infected cells.SARS-CoV-2 infected lung epithelial cells reveal the enrichment of several immunological and metabolic pathways.We also provide parallel support for the dysregulation of multiple RNA binding proteins (FLNB, HDGF, ASS1, ZC3H12A, HK2, BST2, PPARGC1A) involved in immune response, cytokine mediated signaling, and metabolism by employing mock treated versus SARS-CoV2 infected lung cells (Fig. 2B ).", [["cells", "ANATOMY", 108, 113], ["lung epithelial cells", "ANATOMY", 134, 155], ["lung cells", "ANATOMY", 488, 498], ["SARS", "DISEASE", 114, 118], ["IL-17", "GENE_OR_GENE_PRODUCT", 61, 66], ["SARS-CoV-2", "ORGANISM", 88, 98], ["cells", "CELL", 108, 113], ["SARS-CoV-2", "CELL", 114, 124], ["lung epithelial cells", "CELL", 134, 155], ["FLNB", "GENE_OR_GENE_PRODUCT", 315, 319], ["HDGF", "GENE_OR_GENE_PRODUCT", 321, 325], ["ASS1", "GENE_OR_GENE_PRODUCT", 327, 331], ["ZC3H12A", "GENE_OR_GENE_PRODUCT", 333, 340], ["HK2", "GENE_OR_GENE_PRODUCT", 342, 345], ["BST2", "GENE_OR_GENE_PRODUCT", 347, 351], ["PPARGC1A", "GENE_OR_GENE_PRODUCT", 353, 361], ["SARS-CoV2", "CELL", 469, 478], ["lung cells", "CELL", 488, 498], ["Fig. 2B", "CELL", 500, 507], ["cytokine", "PROTEIN", 67, 75], ["SARS-CoV-2 infected cells", "CELL_LINE", 88, 113], ["lung epithelial cells", "CELL_TYPE", 134, 155], ["RNA binding proteins", "PROTEIN", 293, 313], ["FLNB", "PROTEIN", 315, 319], ["HDGF", "PROTEIN", 321, 325], ["ASS1", "PROTEIN", 327, 331], ["ZC3H12A", "PROTEIN", 333, 340], ["HK2", "PROTEIN", 342, 345], ["BST2", "PROTEIN", 347, 351], ["PPARGC1A", "PROTEIN", 353, 361], ["cytokine", "PROTEIN", 392, 400], ["SARS-CoV2 infected lung cells", "CELL_LINE", 469, 498], ["SARS-CoV", "SPECIES", 88, 96], ["our analysis", "TEST", 6, 18], ["IL", "TEST", 61, 63], ["cytokine response", "TEST", 67, 84], ["SARS", "TEST", 88, 92], ["CoV", "TEST", 93, 96], ["2 infected cells", "PROBLEM", 97, 113], ["SARS", "TEST", 114, 118], ["CoV", "TEST", 119, 122], ["infected lung epithelial cells", "PROBLEM", 125, 155], ["parallel support", "TREATMENT", 242, 258], ["the dysregulation", "PROBLEM", 263, 280], ["multiple RNA binding proteins", "PROBLEM", 284, 313], ["HDGF", "TEST", 321, 325], ["ASS1", "TEST", 327, 331], ["ZC3H12A", "TEST", 333, 340], ["HK2", "TEST", 342, 345], ["cytokine mediated signaling", "PROBLEM", 392, 419], ["SARS", "PROBLEM", 469, 473], ["CoV2 infected lung cells", "PROBLEM", 474, 498], ["infected cells", "OBSERVATION", 99, 113], ["lung", "ANATOMY", 134, 138], ["epithelial cells", "OBSERVATION", 139, 155], ["enrichment", "OBSERVATION_MODIFIER", 167, 177], ["metabolic pathways", "OBSERVATION", 207, 225], ["lung", "ANATOMY", 488, 492]]], ["We also observed that six of these differentially expressed genes that encode for RBPs were involved in at least 30% of the overrepresented pathways.", [["RBPs", "GENE_OR_GENE_PRODUCT", 82, 86], ["RBPs", "PROTEIN", 82, 86]]], ["Overall, our results imply that differentially expressed genes in SARS-CoV-2 infected cells may contribute to alterations in the post-transcriptional regulatory networks governed by the RBPs encoded by them.Alternative splicing analysis revealed the abundance of skipped and mutually exclusive exons during SARS-CoV-2 infection in lung epithelial cells.Alternative splicing is a principal mechanism that contributes to protein diversity in eukaryotes, while regulating physiologically important immune responses during bacterial and viral infections [54] .", [["cells", "ANATOMY", 86, 91], ["lung epithelial cells", "ANATOMY", 331, 352], ["SARS", "DISEASE", 66, 70], ["infection", "DISEASE", 318, 327], ["bacterial and viral infections", "DISEASE", 519, 549], ["SARS-CoV-2", "ORGANISM", 66, 76], ["cells", "CELL", 86, 91], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 307, 317], ["lung epithelial cells", "CELL", 331, 352], ["RBPs", "DNA", 186, 190], ["exons", "DNA", 294, 299], ["lung epithelial cells", "CELL_TYPE", 331, 352], ["SARS-CoV", "SPECIES", 66, 74], ["SARS-CoV-2", "SPECIES", 307, 317], ["SARS", "PROBLEM", 66, 70], ["CoV", "TEST", 71, 74], ["2 infected cells", "PROBLEM", 75, 91], ["Alternative splicing analysis", "TEST", 207, 236], ["SARS", "PROBLEM", 307, 311], ["CoV-2 infection in lung epithelial cells", "PROBLEM", 312, 352], ["protein diversity in eukaryotes", "PROBLEM", 419, 450], ["bacterial and viral infections", "PROBLEM", 519, 549], ["infection", "OBSERVATION", 318, 327], ["lung", "ANATOMY", 331, 335], ["epithelial cells", "OBSERVATION", 336, 352], ["protein diversity", "OBSERVATION", 419, 436]]], ["Viral infections have been shown to cause global changes in the alternative splicing signatures in the infected cells that may arise due to intrinsic factors like polymorphism at the splice sites or due to direct intervention by virulence factors [55] [56] [57] .", [["cells", "ANATOMY", 112, 117], ["Viral infections", "DISEASE", 0, 16], ["Viral", "ORGANISM", 0, 5], ["cells", "CELL", 112, 117], ["infected cells", "CELL_TYPE", 103, 117], ["splice sites", "DNA", 183, 195], ["virulence factors", "PROTEIN", 229, 246], ["Viral infections", "PROBLEM", 0, 16], ["global changes", "PROBLEM", 42, 56], ["the alternative splicing signatures", "PROBLEM", 60, 95], ["the infected cells", "PROBLEM", 99, 117], ["intrinsic factors", "PROBLEM", 140, 157], ["polymorphism at the splice sites", "PROBLEM", 163, 195], ["infections", "OBSERVATION", 6, 16], ["infected cells", "OBSERVATION", 103, 117]]], ["A previous study on virushost interactions has demonstrated that human coronavirus targets various signaling pathways of ER stress resulting in differential splicing outcomes [58] .", [["virushost", "GENE_OR_GENE_PRODUCT", 20, 29], ["human", "ORGANISM", 65, 70], ["coronavirus", "ORGANISM", 71, 82], ["ER", "GENE_OR_GENE_PRODUCT", 121, 123], ["ER", "PROTEIN", 121, 123], ["human", "SPECIES", 65, 70], ["human coronavirus", "SPECIES", 65, 82], ["A previous study", "TEST", 0, 16], ["human coronavirus", "PROBLEM", 65, 82], ["ER stress", "PROBLEM", 121, 130]]], ["Another study has shown that deletion of E protein in recombinant SARS-CoV resulted in significant XBP1 gene splicing and higher rate of apoptosis, suggesting that coronavirus infected cells are susceptible to differential splicing events [59] .", [["cells", "ANATOMY", 185, 190], ["SARS", "DISEASE", 66, 70], ["coronavirus infected", "DISEASE", 164, 184], ["E", "GENE_OR_GENE_PRODUCT", 41, 42], ["recombinant SARS-CoV", "ORGANISM", 54, 74], ["XBP1", "GENE_OR_GENE_PRODUCT", 99, 103], ["coronavirus", "ORGANISM", 164, 175], ["cells", "CELL", 185, 190], ["E protein", "PROTEIN", 41, 50], ["XBP1 gene", "DNA", 99, 108], ["coronavirus infected cells", "CELL_TYPE", 164, 190], ["SARS-CoV", "SPECIES", 66, 74], ["Another study", "TEST", 0, 13], ["deletion of E protein in recombinant SARS", "PROBLEM", 29, 70], ["CoV", "PROBLEM", 71, 74], ["significant XBP1 gene splicing", "PROBLEM", 87, 117], ["apoptosis", "PROBLEM", 137, 146], ["coronavirus infected cells", "PROBLEM", 164, 190], ["significant", "OBSERVATION_MODIFIER", 87, 98], ["XBP1 gene splicing", "OBSERVATION", 99, 117], ["coronavirus", "OBSERVATION_MODIFIER", 164, 175], ["infected cells", "OBSERVATION", 176, 190]]], ["Therefore, we next investigated the alternative splicing events in mock vs SARS-CoV-2 treated NHBE cells using rMATS (replicate Multivariate Analysis of Transcript Splicing) [60] .Alternative splicing analysis revealed the abundance of skipped and mutually exclusive exons during SARS-CoV-2 infection in lung epithelial cells.Our analysis revealed an abundance for skipped and mutually exclusive exonic events in the genes exhibiting alternative splicing events during SARS-CoV-2 infection at 5% fdr (Fig. 3A) .", [["NHBE cells", "ANATOMY", 94, 104], ["lung epithelial cells", "ANATOMY", 304, 325], ["infection", "DISEASE", 291, 300], ["infection", "DISEASE", 480, 489], ["NHBE cells", "CELL", 94, 104], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 280, 290], ["lung epithelial cells", "CELL", 304, 325], ["SARS-CoV-2", "ORGANISM", 469, 479], ["SARS-CoV-2 treated NHBE cells", "CELL_LINE", 75, 104], ["exons", "DNA", 267, 272], ["lung epithelial cells", "CELL_TYPE", 304, 325], ["SARS-CoV", "SPECIES", 75, 83], ["SARS-CoV-2", "SPECIES", 280, 290], ["SARS-CoV-2", "SPECIES", 469, 479], ["SARS", "PROBLEM", 75, 79], ["CoV", "TEST", 80, 83], ["NHBE cells", "TREATMENT", 94, 104], ["Transcript Splicing", "TREATMENT", 153, 172], ["Alternative splicing analysis", "TEST", 180, 209], ["SARS", "PROBLEM", 280, 284], ["CoV-2 infection in lung epithelial cells", "PROBLEM", 285, 325], ["Our analysis", "TEST", 326, 338], ["alternative splicing events", "PROBLEM", 434, 461], ["SARS", "PROBLEM", 469, 473], ["CoV-2 infection", "PROBLEM", 474, 489], ["infection", "OBSERVATION", 291, 300], ["lung", "ANATOMY", 304, 308], ["epithelial cells", "OBSERVATION", 309, 325]]], ["We also observed that 81 of the alternatively spliced genes encoded for RBPs (indicated in blue, Fig. 3A ) and hence could result in altering the downstream post-transcriptional regulatory networks in SARS-CoV-2 infected cells (Fig. 3A) .", [["cells", "ANATOMY", 221, 226], ["RBPs", "GENE_OR_GENE_PRODUCT", 72, 76], ["blue, Fig. 3A", "GENE_OR_GENE_PRODUCT", 91, 104], ["SARS-CoV-2", "ORGANISM", 201, 211], ["cells", "CELL", 221, 226], ["Fig. 3A", "CELL", 228, 235], ["RBPs", "PROTEIN", 72, 76], ["SARS-CoV-2 infected cells", "CELL_LINE", 201, 226], ["SARS-CoV", "SPECIES", 201, 209], ["RBPs", "PROBLEM", 72, 76], ["SARS", "TEST", 201, 205], ["CoV", "TEST", 206, 209], ["2 infected cells", "PROBLEM", 210, 226], ["infected cells", "OBSERVATION", 212, 226]]], ["These findings enhance our mechanistic understanding of the SARS-CoV-2 induced alternative splicing dyregulation in human cells and could be critical for developing novel therapeutic strategies.", [["cells", "ANATOMY", 122, 127], ["SARS", "DISEASE", 60, 64], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 60, 70], ["human", "ORGANISM", 116, 121], ["cells", "CELL", 122, 127], ["human cells", "CELL_TYPE", 116, 127], ["human", "SPECIES", 116, 121], ["SARS-CoV", "SPECIES", 60, 68], ["human", "SPECIES", 116, 121], ["the SARS", "PROBLEM", 56, 64], ["alternative splicing dyregulation in human cells", "PROBLEM", 79, 127], ["novel therapeutic strategies", "TREATMENT", 165, 193], ["human cells", "OBSERVATION", 116, 127]]], ["Our data revealed that majority of these genes were enriched for vital biological processes including cellular protein localization, protein metabolism, organelle organization, cellular biosynthetic process, cellular component assembly and cytochrome c-mediated apoptotic response (Fig. 3B) .", [["cellular", "ANATOMY", 102, 110], ["organelle", "ANATOMY", 153, 162], ["cellular", "ANATOMY", 177, 185], ["cellular", "ANATOMY", 208, 216], ["cellular", "CELL", 102, 110], ["organelle", "CELLULAR_COMPONENT", 153, 162], ["cellular", "CELL", 177, 185], ["cellular", "CELL", 208, 216], ["cytochrome c-mediated", "GENE_OR_GENE_PRODUCT", 240, 261], ["Our data", "TEST", 0, 8], ["vital biological processes", "PROBLEM", 65, 91], ["cellular protein localization", "TEST", 102, 131], ["protein metabolism", "TEST", 133, 151], ["cellular biosynthetic process", "PROBLEM", 177, 206], ["cellular component", "PROBLEM", 208, 226], ["cytochrome c-mediated apoptotic response", "PROBLEM", 240, 280], ["cellular biosynthetic process", "OBSERVATION", 177, 206], ["cellular component", "OBSERVATION", 208, 226]]], ["These findings suggest that SARS-CoV-2 infection could dysregulate the functionally important biological catalogue via alternatively spliced genes predominantly through skipped exons and mutually exclusive exons.", [["SARS", "DISEASE", 28, 32], ["infection", "DISEASE", 39, 48], ["SARS-CoV-2", "ORGANISM", 28, 38], ["exons", "DNA", 177, 182], ["exons", "DNA", 206, 211], ["SARS-CoV", "SPECIES", 28, 36], ["SARS", "PROBLEM", 28, 32], ["CoV-2 infection", "PROBLEM", 33, 48]]], ["In summary, this analysis provides a clustered network of enriched biological functions that could be significantly dysregulated in SARS-CoV-2 infected cells.Motif enrichment analysis reveals potential human RBPs titrated by SARS-CoV-2 viral genome.SARS-CoV-2 genome is the largest among the coronavirus family (~30kb) and has been attributed to enhanced virus pathogenicity in the newly evolved strains of COVID-19 pandemic [18, 61] .", [["cells", "ANATOMY", 152, 157], ["SARS", "DISEASE", 132, 136], ["SARS", "DISEASE", 249, 253], ["SARS-CoV-2", "CELL", 132, 142], ["cells", "CELL", 152, 157], ["human", "ORGANISM", 202, 207], ["SARS-CoV-2", "ORGANISM", 225, 235], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 249, 259], ["COVID-19", "ORGANISM", 407, 415], ["SARS-CoV-2 infected cells", "CELL_LINE", 132, 157], ["human RBPs", "PROTEIN", 202, 212], ["SARS-CoV-2 viral genome", "DNA", 225, 248], ["SARS-CoV-2 genome", "DNA", 249, 266], ["coronavirus family", "DNA", 292, 310], ["human", "SPECIES", 202, 207], ["SARS-CoV", "SPECIES", 132, 140], ["human", "SPECIES", 202, 207], ["SARS-CoV", "SPECIES", 225, 233], ["SARS-CoV", "SPECIES", 249, 257], ["this analysis", "TEST", 12, 25], ["significantly dysregulated", "PROBLEM", 102, 128], ["SARS", "PROBLEM", 132, 136], ["CoV", "TEST", 137, 140], ["2 infected cells", "PROBLEM", 141, 157], ["Motif enrichment analysis", "TEST", 158, 183], ["potential human RBPs", "PROBLEM", 192, 212], ["SARS", "PROBLEM", 225, 229], ["CoV", "TEST", 230, 233], ["enhanced virus pathogenicity", "PROBLEM", 346, 374], ["COVID", "TEST", 407, 412], ["infected cells", "OBSERVATION", 143, 157], ["viral genome", "OBSERVATION", 236, 248], ["largest", "OBSERVATION_MODIFIER", 274, 281], ["virus", "OBSERVATION", 355, 360]]], ["Among the host derived cellular factors, RBPs have been recognized as active participants in all steps of viral infection [29, 62, 63] .", [["cellular", "ANATOMY", 23, 31], ["viral infection", "DISEASE", 106, 121], ["cellular", "CELL", 23, 31], ["RBPs", "GENE_OR_GENE_PRODUCT", 41, 45], ["cellular factors", "PROTEIN", 23, 39], ["RBPs", "PROTEIN", 41, 45], ["participants", "SPECIES", 77, 89], ["RBPs", "TEST", 41, 45], ["viral infection", "PROBLEM", 106, 121], ["active", "OBSERVATION_MODIFIER", 70, 76], ["viral infection", "OBSERVATION", 106, 121]]], ["A recent review has shown linkage of 472 human proteins with viruses through unconventional RNA binding domains [63] .", [["human", "ORGANISM", 41, 46], ["472 human proteins", "PROTEIN", 37, 55], ["unconventional RNA binding domains", "PROTEIN", 77, 111], ["human", "SPECIES", 41, 46], ["human", "SPECIES", 41, 46], ["A recent review", "TEST", 0, 15], ["linkage of 472 human proteins", "PROBLEM", 26, 55], ["viruses", "PROBLEM", 61, 68]]], ["In the present research, we conducted a systematic and comprehensive bioinformatic study to investigate the RBPs that could potentially bind on RNA genome of SARS-CoV-2 by motif enrichment analysis of human RBPs using FIMO [64] .", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 158, 168], ["human", "ORGANISM", 201, 206], ["RBPs", "PROTEIN", 108, 112], ["RNA genome", "DNA", 144, 154], ["SARS-CoV-2", "DNA", 158, 168], ["human RBPs", "PROTEIN", 201, 211], ["human", "SPECIES", 201, 206], ["SARS-CoV", "SPECIES", 158, 166], ["human", "SPECIES", 201, 206], ["comprehensive bioinformatic study", "TEST", 55, 88], ["the RBPs", "PROBLEM", 104, 112], ["SARS", "PROBLEM", 158, 162], ["CoV", "TEST", 163, 166]]], ["Motif analysis for RBPs with established position specific weight matrices (PWMs) revealed significant number of binding sites spread across the SARS-CoV-2 genome illustrating the possible titration of post-transcriptional regulators by viral genome (Fig. 4A, Fig. S2 ).", [["RBPs", "PROTEIN", 19, 23], ["PWMs", "DNA", 76, 80], ["SARS-CoV-2 genome", "DNA", 145, 162], ["post-transcriptional regulators", "PROTEIN", 202, 233], ["viral genome", "DNA", 237, 249], ["S2", "PROTEIN", 265, 267], ["SARS-CoV", "SPECIES", 145, 153], ["Motif analysis", "TEST", 0, 14], ["RBPs", "PROBLEM", 19, 23], ["significant number of binding sites", "PROBLEM", 91, 126], ["the SARS", "PROBLEM", 141, 149], ["CoV", "TEST", 150, 153], ["post-transcriptional regulators", "TREATMENT", 202, 233], ["significant", "OBSERVATION_MODIFIER", 91, 102], ["number", "OBSERVATION_MODIFIER", 103, 109], ["binding sites", "OBSERVATION", 113, 126], ["viral genome", "OBSERVATION", 237, 249]]], ["Importantly, the binding pattern of the RBP motifs across the entire normalized length of the virus suggesting that, several of human RBPs could be titrated randomly across the viral genome (Fig. 4A) .", [["RBP", "GENE_OR_GENE_PRODUCT", 40, 43], ["human", "ORGANISM", 128, 133], ["RBPs", "GENE_OR_GENE_PRODUCT", 134, 138], ["RBP motifs", "DNA", 40, 50], ["human RBPs", "PROTEIN", 128, 138], ["viral genome", "DNA", 177, 189], ["human", "SPECIES", 128, 133], ["human", "SPECIES", 128, 133], ["the RBP motifs", "TEST", 36, 50], ["the virus", "PROBLEM", 90, 99], ["human RBPs", "TREATMENT", 128, 138], ["length", "OBSERVATION_MODIFIER", 80, 86], ["virus", "OBSERVATION", 94, 99], ["viral genome", "OBSERVATION", 177, 189]]], ["Our results showed an enrichment for RBPs such as SRSFs, PCBPs, ELAVs and HNRNPs being most likely to get sponged on the viral genome (Fig. 4B) .", [["SRSFs", "GENE_OR_GENE_PRODUCT", 50, 55], ["PCBPs", "GENE_OR_GENE_PRODUCT", 57, 62], ["ELAVs", "GENE_OR_GENE_PRODUCT", 64, 69], ["HNRNPs", "GENE_OR_GENE_PRODUCT", 74, 80], ["RBPs", "PROTEIN", 37, 41], ["SRSFs", "PROTEIN", 50, 55], ["PCBPs", "PROTEIN", 57, 62], ["ELAVs", "PROTEIN", 64, 69], ["HNRNPs", "PROTEIN", 74, 80], ["viral genome", "DNA", 121, 133], ["RBPs", "PROBLEM", 37, 41], ["SRSFs", "PROBLEM", 50, 55], ["PCBPs", "TREATMENT", 57, 62], ["ELAVs", "TREATMENT", 64, 69], ["HNRNPs", "TREATMENT", 74, 80], ["the viral genome", "PROBLEM", 117, 133], ["enrichment", "OBSERVATION", 22, 32], ["viral genome", "OBSERVATION", 121, 133]]], ["Specifically, our observation of RBPs well known for their role in splicing such as SRSF7, HNRNPA1 and TRA2A was in accordance with a recently published study that predicted binding sites of these RBPs on SARS-CoV-2 RNA [65] .", [["SRSF7", "GENE_OR_GENE_PRODUCT", 84, 89], ["HNRNPA1", "GENE_OR_GENE_PRODUCT", 91, 98], ["TRA2A", "GENE_OR_GENE_PRODUCT", 103, 108], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 205, 215], ["RBPs", "PROTEIN", 33, 37], ["SRSF7", "PROTEIN", 84, 89], ["HNRNPA1", "PROTEIN", 91, 98], ["TRA2A", "PROTEIN", 103, 108], ["binding sites", "DNA", 174, 187], ["RBPs", "PROTEIN", 197, 201], ["HNRNPA1", "TREATMENT", 91, 98], ["TRA2A", "TREATMENT", 103, 108], ["a recently published study", "TEST", 132, 158], ["these RBPs", "TEST", 191, 201], ["SARS", "TEST", 205, 209], ["CoV", "TEST", 210, 213]]], ["In summary, these findings suggest that SARS-CoV-2 could sponge human RBPs on its genome resulting in altered post-transcriptional gene regulatory network in the host cells.", [["cells", "ANATOMY", 167, 172], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 40, 50], ["human", "ORGANISM", 64, 69], ["host cells", "CELL", 162, 172], ["SARS-CoV-2", "DNA", 40, 50], ["human RBPs", "PROTEIN", 64, 74], ["host cells", "CELL_TYPE", 162, 172], ["human", "SPECIES", 64, 69], ["human", "SPECIES", 64, 69], ["SARS", "PROBLEM", 40, 44], ["CoV", "TEST", 45, 48], ["sponge human RBPs", "PROBLEM", 57, 74], ["altered post-transcriptional gene regulatory network", "PROBLEM", 102, 154], ["post-transcriptional gene regulatory network", "OBSERVATION", 110, 154], ["host cells", "OBSERVATION", 162, 172]]], ["Targeting host proteins has been appreciated as an effective strategy to combat a wide .", [["Targeting host proteins", "PROBLEM", 0, 23], ["host proteins", "OBSERVATION", 10, 23], ["wide", "OBSERVATION_MODIFIER", 82, 86]]], ["CC-BY-ND 4.0 International license was not certified by peer review) is the author/funder.", [["CC", "CHEMICAL", 0, 2]]], ["It is made available under a The copyright holder for this preprint (which this version posted July 6, 2020. . range of viral infections and therefore an understanding of the potential RBPs that are likely sponged on the viral genome is crucial to develop novel therapeutics [30] .SARS-CoV-2 genome titrates the abundance of functionally important miRs in human tissueMicro RNAs (miRs) are small non-coding RNA molecules that function as central regulators of post-transcriptional gene regulation.", [["viral infections", "DISEASE", 120, 136], ["SARS-CoV-2", "ORGANISM", 281, 291], ["human", "ORGANISM", 356, 361], ["tissueMicro RNAs", "GENE_OR_GENE_PRODUCT", 362, 378], ["miRs", "GENE_OR_GENE_PRODUCT", 380, 384], ["RBPs", "PROTEIN", 185, 189], ["viral genome", "DNA", 221, 233], ["SARS-CoV-2 genome", "DNA", 281, 298], ["miRs", "DNA", 348, 352], ["human tissueMicro RNAs", "RNA", 356, 378], ["miRs", "DNA", 380, 384], ["human", "SPECIES", 356, 361], ["SARS-CoV", "SPECIES", 281, 289], ["human", "SPECIES", 356, 361], ["viral infections", "PROBLEM", 120, 136], ["the potential RBPs", "PROBLEM", 171, 189], ["the viral genome", "PROBLEM", 217, 233], ["SARS", "PROBLEM", 281, 285], ["small non-coding RNA molecules", "PROBLEM", 390, 420], ["post-transcriptional gene regulation", "PROBLEM", 460, 496], ["viral infections", "OBSERVATION", 120, 136], ["post-transcriptional gene", "OBSERVATION", 460, 485]]], ["Human miRs have been associated with a variety of pathophysiological pathways and demonstrate differential expression during viral infections [66, 67] .", [["viral infections", "DISEASE", 125, 141], ["Human", "ORGANISM", 0, 5], ["miRs", "GENE_OR_GENE_PRODUCT", 6, 10], ["Human miRs", "PROTEIN", 0, 10], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["differential expression during viral infections", "PROBLEM", 94, 141]]], ["Recently, a machine learning based study predicted that miRs could impact SARS-CoV-2 infection through several mechanisms such as interfering with replication, translation and even modulating the host gene expression [68] .", [["infection", "DISEASE", 85, 94], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 74, 84], ["miRs", "DNA", 56, 60], ["SARS-CoV", "SPECIES", 74, 82], ["based study", "TEST", 29, 40], ["SARS", "PROBLEM", 74, 78], ["CoV-2 infection", "PROBLEM", 79, 94]]], ["In this study, we used computational approach to investigate the potential binding sites of human miRs in SARS-CoV-2 genome using FIMO [64] .", [["human", "ORGANISM", 92, 97], ["human miRs", "DNA", 92, 102], ["SARS-CoV-2 genome", "DNA", 106, 123], ["human", "SPECIES", 92, 97], ["human", "SPECIES", 92, 97], ["SARS-CoV-2", "SPECIES", 106, 116], ["this study", "TEST", 3, 13], ["computational approach", "TREATMENT", 23, 45]]], ["We identified 22 miRNAs that could potentially bind throughout the length of the SARS-CoV2 viral genome (Fig.5A, Table S5 ).", [["SARS-CoV2 viral genome", "DNA", 81, 103], ["22 miRNAs", "PROBLEM", 14, 23], ["the SARS", "PROBLEM", 77, 85], ["CoV2 viral genome", "TREATMENT", 86, 103], ["22 miRNAs", "OBSERVATION_MODIFIER", 14, 23], ["viral genome", "OBSERVATION", 91, 103]]], ["These results suggest that several important miRs are likely being titrated by SARS-CoV-2 genome that could result in dysregulation of post-transcriptional networks in the infected cells.SARS-CoV-2 genome titrates the abundance of functionally important miRs in human tissueMajority of the identified miRs were highly expressed in immune cells including CD8+T cells, CD4+T, NK cells, CD14 cells and mast cells, suggesting that these miRs might contribute to altered post-transcriptional regulation in specialized immune cells and could contribute to the progression of the viral infection and host immune response across other human tissues (Fig.5B) .", [["cells", "ANATOMY", 181, 186], ["immune cells", "ANATOMY", 331, 343], ["CD8+T cells", "ANATOMY", 354, 365], ["CD4+T", "ANATOMY", 367, 372], ["NK cells", "ANATOMY", 374, 382], ["CD14 cells", "ANATOMY", 384, 394], ["mast cells", "ANATOMY", 399, 409], ["immune cells", "ANATOMY", 513, 525], ["tissues", "ANATOMY", 633, 640], ["viral infection", "DISEASE", 573, 588], ["miRs", "GENE_OR_GENE_PRODUCT", 45, 49], ["SARS-CoV-2", "ORGANISM", 79, 89], ["cells", "CELL", 181, 186], ["SARS-CoV-2", "ORGANISM", 187, 197], ["miRs", "GENE_OR_GENE_PRODUCT", 254, 258], ["human", "ORGANISM", 262, 267], ["miRs", "GENE_OR_GENE_PRODUCT", 301, 305], ["immune cells", "CELL", 331, 343], ["CD8", "GENE_OR_GENE_PRODUCT", 354, 357], ["CD4", "GENE_OR_GENE_PRODUCT", 367, 370], ["CD14", "GENE_OR_GENE_PRODUCT", 384, 388], ["mast cells", "CELL", 399, 409], ["immune cells", "CELL", 513, 525], ["human", "ORGANISM", 627, 632], ["tissues", "TISSUE", 633, 640], ["miRs", "DNA", 45, 49], ["SARS-CoV-2 genome", "DNA", 79, 96], ["infected cells", "CELL_TYPE", 172, 186], ["SARS-CoV-2 genome", "DNA", 187, 204], ["miRs", "DNA", 254, 258], ["miRs", "DNA", 301, 305], ["immune cells", "CELL_TYPE", 331, 343], ["CD8+T cells", "CELL_TYPE", 354, 365], ["CD4+T, NK cells", "CELL_TYPE", 367, 382], ["CD14 cells", "CELL_TYPE", 384, 394], ["mast cells", "CELL_TYPE", 399, 409], ["miRs", "DNA", 433, 437], ["immune cells", "CELL_TYPE", 513, 525], ["human", "SPECIES", 262, 267], ["human", "SPECIES", 627, 632], ["SARS-CoV", "SPECIES", 79, 87], ["human", "SPECIES", 262, 267], ["human", "SPECIES", 627, 632], ["SARS", "PROBLEM", 79, 83], ["CoV-2 genome", "TREATMENT", 84, 96], ["dysregulation of post-transcriptional networks in the infected cells", "PROBLEM", 118, 186], ["SARS", "TEST", 187, 191], ["CoV", "TEST", 192, 195], ["CD8", "TEST", 354, 357], ["CD4", "TEST", 367, 370], ["CD14 cells", "PROBLEM", 384, 394], ["mast cells", "PROBLEM", 399, 409], ["these miRs", "PROBLEM", 427, 437], ["altered post-transcriptional regulation", "PROBLEM", 458, 497], ["the viral infection", "PROBLEM", 569, 588], ["post-transcriptional networks", "OBSERVATION", 135, 164], ["infected cells", "OBSERVATION", 172, 186], ["NK cells", "OBSERVATION", 374, 382], ["CD14 cells", "OBSERVATION", 384, 394], ["mast cells", "OBSERVATION", 399, 409], ["immune cells", "OBSERVATION", 513, 525], ["viral", "OBSERVATION_MODIFIER", 573, 578], ["infection", "OBSERVATION", 579, 588], ["human tissues", "ANATOMY", 627, 640]]], ["Our results also indicate that the high confident genes targeted by these sponged miRs were enriched for functional themes including 'regulation of metabolic processes', 'post transcriptional gene regulation' and 'cell to cell communication' suggestive of a large-scale dysregulation across tissues (Fig.5C) .", [["cell", "ANATOMY", 214, 218], ["cell", "ANATOMY", 222, 226], ["tissues", "ANATOMY", 291, 298], ["miRs", "GENE_OR_GENE_PRODUCT", 82, 86], ["cell", "CELL", 214, 218], ["cell", "CELL", 222, 226], ["tissues", "TISSUE", 291, 298], ["sponged miRs", "DNA", 74, 86], ["metabolic processes'", "PROBLEM", 148, 168], ["transcriptional gene regulation'", "TREATMENT", 176, 208], ["a large-scale dysregulation across tissues", "PROBLEM", 256, 298], ["metabolic processes", "OBSERVATION", 148, 167], ["large", "OBSERVATION_MODIFIER", 258, 263], ["-scale", "OBSERVATION_MODIFIER", 263, 269], ["dysregulation", "OBSERVATION", 270, 283]]], ["Overall, our results present a comprehensive analysis of the miRs being potentially titrated on the viral genome resulting in altered post-transcriptional gene regulation.", [["miRs", "GENE_OR_GENE_PRODUCT", 61, 65], ["miRs", "DNA", 61, 65], ["viral genome", "DNA", 100, 112], ["a comprehensive analysis", "TEST", 29, 53], ["the viral genome", "PROBLEM", 96, 112], ["altered post-transcriptional gene regulation", "PROBLEM", 126, 170], ["viral genome", "OBSERVATION", 100, 112], ["post-transcriptional gene", "OBSERVATION", 134, 159]]], ["These findings provide important clues that enhances our understanding of miR associated mechanism in viral pathogenesis.CONCLUSIONOur analysis integrates a comprehensive interaction network to map the immediate interactions between SARS-CoV-2 genome and proteome with human post-transcriptional regulators such as RBPs and miRNAs along with their tissue specific expression and functional annotations.", [["tissue", "ANATOMY", 348, 354], ["miR", "GENE_OR_GENE_PRODUCT", 74, 77], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 233, 243], ["human", "ORGANISM", 269, 274], ["RBPs", "GENE_OR_GENE_PRODUCT", 315, 319], ["tissue", "TISSUE", 348, 354], ["miR", "DNA", 74, 77], ["SARS-CoV-2 genome", "DNA", 233, 250], ["human post-transcriptional regulators", "PROTEIN", 269, 306], ["RBPs", "PROTEIN", 315, 319], ["human", "SPECIES", 269, 274], ["human", "SPECIES", 269, 274], ["SARS", "TEST", 233, 237], ["human post-transcriptional regulators", "TREATMENT", 269, 306], ["RBPs and miRNAs", "TREATMENT", 315, 330]]], ["Given the importance of developing effective therapeutic strategies in the current pandemic, understanding the effect of SARS-CoV-2 infection on human transcriptional and posttranscriptional regulatory networks is crucial for identifying effective drug targets.", [["SARS", "DISEASE", 121, 125], ["infection", "DISEASE", 132, 141], ["SARS-CoV-2", "ORGANISM", 121, 131], ["human", "ORGANISM", 145, 150], ["human", "SPECIES", 145, 150], ["human", "SPECIES", 145, 150], ["effective therapeutic strategies", "TREATMENT", 35, 67], ["SARS", "PROBLEM", 121, 125], ["CoV-2 infection", "PROBLEM", 126, 141], ["human transcriptional", "TREATMENT", 145, 166], ["posttranscriptional regulatory networks", "TREATMENT", 171, 210]]], ["To delineate the impact of SARS-CoV-2 on host cells post-transcriptional gene regulatory network, we integrated the immediate interactions between SARS-CoV-2 encoded proteins with human RNA binding proteins.", [["cells", "ANATOMY", 46, 51], ["SARS", "DISEASE", 27, 31], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 27, 37], ["host cells", "CELL", 41, 51], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 147, 157], ["human", "ORGANISM", 180, 185], ["RNA binding proteins", "GENE_OR_GENE_PRODUCT", 186, 206], ["SARS-CoV-2", "DNA", 27, 37], ["SARS-CoV-2 encoded proteins", "PROTEIN", 147, 174], ["human RNA binding proteins", "PROTEIN", 180, 206], ["human", "SPECIES", 180, 185], ["human", "SPECIES", 180, 185], ["SARS", "PROBLEM", 27, 31], ["CoV", "TEST", 32, 35], ["host cells", "TREATMENT", 41, 51], ["transcriptional gene regulatory network", "TREATMENT", 57, 96], ["human RNA binding proteins", "TREATMENT", 180, 206]]], ["Our findings indicate 51 human RBPs interact directly with the viral structural and non-structural proteins, that in turn interact indirectly with ~65% other secondary neighbor RBPs.", [["human", "ORGANISM", 25, 30], ["51 human RBPs", "PROTEIN", 22, 35], ["viral structural and non-structural proteins", "PROTEIN", 63, 107], ["secondary neighbor RBPs", "PROTEIN", 158, 181], ["human", "SPECIES", 25, 30], ["human", "SPECIES", 25, 30], ["51 human RBPs", "PROBLEM", 22, 35], ["the viral structural and non-structural proteins", "PROBLEM", 59, 107], ["secondary neighbor RBPs", "PROBLEM", 158, 181], ["51 human", "OBSERVATION_MODIFIER", 22, 30], ["non-structural proteins", "OBSERVATION", 84, 107]]], ["We show that the expression profiles of majority of the directly interacting RBPs were associated with gonadal tissues and immune cell types.", [["gonadal tissues", "ANATOMY", 103, 118], ["immune cell", "ANATOMY", 123, 134], ["gonadal tissues", "TISSUE", 103, 118], ["immune cell", "CELL", 123, 134], ["RBPs", "PROTEIN", 77, 81], ["immune cell types", "CELL_TYPE", 123, 140], ["the directly interacting RBPs", "PROBLEM", 52, 81], ["gonadal tissues", "PROBLEM", 103, 118], ["immune cell types", "PROBLEM", 123, 140], ["gonadal tissues", "ANATOMY", 103, 118], ["immune cell types", "OBSERVATION", 123, 140]]], ["Our study highlights that several of the differentially expressed genes in SARS-CoV-2 infected cells were enriched for biological .", [["cells", "ANATOMY", 95, 100], ["SARS", "DISEASE", 75, 79], ["SARS-CoV-2", "ORGANISM", 75, 85], ["cells", "CELL", 95, 100], ["SARS-CoV", "SPECIES", 75, 83], ["Our study", "TEST", 0, 9], ["SARS", "PROBLEM", 75, 79], ["CoV", "TEST", 80, 83], ["2 infected cells", "PROBLEM", 84, 100], ["infected cells", "OBSERVATION", 86, 100]]], ["CC-BY-ND 4.0 International license was not certified by peer review) is the author/funder.", [["CC", "CHEMICAL", 0, 2]]], ["It is made available under a The copyright holder for this preprint (which this version posted July 6, 2020. . pathways such as immune response, cytokine mediated signaling, inflammatory response and metabolism associated genes that are indispensable for cell survival.", [["cell", "ANATOMY", 255, 259], ["cell", "CELL", 255, 259], ["cytokine", "PROTEIN", 145, 153], ["immune response", "PROBLEM", 128, 143], ["cytokine mediated signaling", "PROBLEM", 145, 172], ["inflammatory response", "PROBLEM", 174, 195], ["metabolism associated genes", "PROBLEM", 200, 227], ["cell survival", "TREATMENT", 255, 268], ["inflammatory", "OBSERVATION_MODIFIER", 174, 186]]], ["Importantly, we found that among the differentially expressed genes, six genes encoded for RBPs implying a potential impact of SARS-CoV-2 infection on post-transcriptional regulation.", [["infection", "DISEASE", 138, 147], ["RBPs", "GENE_OR_GENE_PRODUCT", 91, 95], ["SARS-CoV-2", "ORGANISM", 127, 137], ["differentially expressed genes", "DNA", 37, 67], ["RBPs", "PROTEIN", 91, 95], ["RBPs", "PROBLEM", 91, 95], ["SARS", "PROBLEM", 127, 131], ["CoV", "PROBLEM", 132, 135], ["2 infection", "PROBLEM", 136, 147], ["post-transcriptional regulation", "TREATMENT", 151, 182], ["SARS", "OBSERVATION", 127, 131], ["infection", "OBSERVATION", 138, 147]]], ["Further, our analysis demonstrates the abundance of skipped exonic and mutually exclusive exonic events in the SARS-CoV-2 infected cells, suggesting these alternative splicing events as a plausible cause for altered posttranscriptional regulation in human cells.", [["cells", "ANATOMY", 131, 136], ["cells", "ANATOMY", 256, 261], ["SARS", "DISEASE", 111, 115], ["SARS-CoV-2", "ORGANISM", 111, 121], ["cells", "CELL", 131, 136], ["human", "ORGANISM", 250, 255], ["cells", "CELL", 256, 261], ["SARS-CoV-2 infected cells", "CELL_LINE", 111, 136], ["human cells", "CELL_TYPE", 250, 261], ["human", "SPECIES", 250, 255], ["SARS-CoV", "SPECIES", 111, 119], ["human", "SPECIES", 250, 255], ["our analysis", "TEST", 9, 21], ["skipped exonic", "PROBLEM", 52, 66], ["exclusive exonic events", "PROBLEM", 80, 103], ["the SARS", "TEST", 107, 115], ["2 infected cells", "PROBLEM", 120, 136], ["these alternative splicing events", "PROBLEM", 149, 182], ["altered posttranscriptional regulation in human cells", "PROBLEM", 208, 261], ["infected cells", "OBSERVATION", 122, 136], ["posttranscriptional regulation", "OBSERVATION", 216, 246], ["human cells", "OBSERVATION", 250, 261]]], ["Using motif enrichment analysis, we show that two key post-transcriptional regulators, RBPs and miRs are likely to be titrated by SARS-CoV-2 genome that could result in dysregulated transcriptional regulation in the infected cells.", [["cells", "ANATOMY", 225, 230], ["RBPs", "GENE_OR_GENE_PRODUCT", 87, 91], ["miRs", "GENE_OR_GENE_PRODUCT", 96, 100], ["SARS-CoV-2", "ORGANISM", 130, 140], ["cells", "CELL", 225, 230], ["post-transcriptional regulators", "PROTEIN", 54, 85], ["RBPs", "PROTEIN", 87, 91], ["miRs", "DNA", 96, 100], ["SARS-CoV-2 genome", "DNA", 130, 147], ["infected cells", "CELL_TYPE", 216, 230], ["SARS-CoV", "SPECIES", 130, 138], ["motif enrichment analysis", "TEST", 6, 31], ["SARS", "PROBLEM", 130, 134], ["dysregulated transcriptional regulation in the infected cells", "PROBLEM", 169, 230], ["dysregulated transcriptional regulation", "OBSERVATION", 169, 208], ["infected cells", "OBSERVATION", 216, 230]]], ["Currently, there are no anti-viral therapies or vaccines available for COVID-19.", [["anti-viral therapies", "TREATMENT", 24, 44], ["vaccines", "TREATMENT", 48, 56], ["COVID", "TEST", 71, 76], ["no", "UNCERTAINTY", 21, 23], ["anti-viral therapies", "OBSERVATION", 24, 44]]], ["Therefore, our analyses provide a roadmap to enhance our understanding of the interactions of SARS-CoV-2 with key postranscriptional regulators in the human genome.Dissection of SARS-CoV-2 proteins interacting with human RBPsWe obtained the high confidence mass spectrometry based SARS-CoV-2 viral protein to human protein interaction network established by Gordan et al, 2020 [23] in HEK293 cells.", [["HEK293 cells", "ANATOMY", 385, 397], ["SARS", "DISEASE", 94, 98], ["SARS", "DISEASE", 178, 182], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 94, 104], ["human", "ORGANISM", 151, 156], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 178, 188], ["human", "ORGANISM", 215, 220], ["RBPsWe", "GENE_OR_GENE_PRODUCT", 221, 227], ["human", "ORGANISM", 309, 314], ["HEK293 cells", "CELL", 385, 397], ["postranscriptional regulators", "PROTEIN", 114, 143], ["human genome", "DNA", 151, 163], ["SARS-CoV-2 proteins", "PROTEIN", 178, 197], ["human RBPsWe", "PROTEIN", 215, 227], ["SARS-CoV-2 viral protein", "PROTEIN", 281, 305], ["HEK293 cells", "CELL_LINE", 385, 397], ["human", "SPECIES", 151, 156], ["human", "SPECIES", 215, 220], ["human", "SPECIES", 309, 314], ["human", "SPECIES", 151, 156], ["human", "SPECIES", 215, 220], ["human", "SPECIES", 309, 314], ["Dissection of SARS", "PROBLEM", 164, 182], ["human RBPsWe", "TEST", 215, 227], ["the high confidence mass spectrometry", "PROBLEM", 237, 274], ["based SARS", "TEST", 275, 285], ["CoV", "TEST", 286, 289], ["viral protein", "TEST", 292, 305], ["human protein interaction network", "TEST", 309, 342], ["SARS", "OBSERVATION", 178, 182]]], ["We dissected the human RBPs directly interacting with viral proteins and integrated with 1 st neighbor interacting RBPs (obtained from BioGRID).", [["human", "ORGANISM", 17, 22], ["human RBPs", "PROTEIN", 17, 27], ["viral proteins", "PROTEIN", 54, 68], ["1 st neighbor interacting RBPs", "PROTEIN", 89, 119], ["BioGRID", "PROTEIN", 135, 142], ["human", "SPECIES", 17, 22], ["human", "SPECIES", 17, 22], ["viral proteins", "PROBLEM", 54, 68]]], ["We also extracted the protein abundance of these SARS-CoV2 interacting RBPs across human tissues from Human Proteome Map [39] .", [["tissues", "ANATOMY", 89, 96], ["SARS", "DISEASE", 49, 53], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 49, 58], ["human", "ORGANISM", 83, 88], ["tissues", "TISSUE", 89, 96], ["Human", "ORGANISM", 102, 107], ["SARS-CoV2 interacting RBPs", "PROTEIN", 49, 75], ["human", "SPECIES", 83, 88], ["Human", "SPECIES", 102, 107], ["human", "SPECIES", 83, 88], ["these SARS", "PROBLEM", 43, 53], ["Human Proteome Map", "TEST", 102, 120]]], ["The abundance of these proteins were hierarchically clustered and row normalized and represented as heatmap generated from Morpheus (https://software.broadinstitute.org/morpheus/).Differential expression analysis of mock treated versus SARS-CoV-2 infected primary human lung epithelial cells.We downloaded the raw RNA sequencing data deposited in Gene Expression Omnibus (GEO) [47] .", [["lung epithelial cells", "ANATOMY", 270, 291], ["SARS-CoV-2", "ORGANISM", 236, 246], ["human", "ORGANISM", 264, 269], ["lung epithelial cells", "CELL", 270, 291], ["primary human lung epithelial cells", "CELL_TYPE", 256, 291], ["human", "SPECIES", 264, 269], ["SARS-CoV", "SPECIES", 236, 244], ["human", "SPECIES", 264, 269], ["these proteins", "PROBLEM", 17, 31], ["mock", "TEST", 216, 220], ["SARS", "PROBLEM", 236, 240], ["CoV", "TEST", 241, 244], ["2 infected primary human lung epithelial cells", "PROBLEM", 245, 291], ["infected", "OBSERVATION_MODIFIER", 247, 255], ["primary human", "OBSERVATION", 256, 269], ["lung", "ANATOMY", 270, 274], ["epithelial cells", "OBSERVATION", 275, 291]]], ["Specifically, we downloaded the paired end raw sequencing (FASTQ) files of mock treated and SARS-CoV-2 (USA-WA1/2020) infected primary human lung epithelial cells (in biological triplicates) using the Sequence Read Archive (SRA) Toolkit (fastq-dump command), from the GEO cohort GSE147507 [46] .", [["lung epithelial cells", "ANATOMY", 141, 162], ["SARS-CoV-2", "ORGANISM", 92, 102], ["USA-WA1/2020", "CELL", 104, 116], ["human", "ORGANISM", 135, 140], ["lung epithelial cells", "CELL", 141, 162], ["primary human lung epithelial cells", "CELL_TYPE", 127, 162], ["human", "SPECIES", 135, 140], ["SARS-CoV-2", "SPECIES", 92, 102], ["human", "SPECIES", 135, 140], ["mock", "TEST", 75, 79], ["SARS", "TEST", 92, 96], ["CoV", "TEST", 97, 100], ["USA", "TEST", 104, 107], ["infected primary human lung epithelial cells", "PROBLEM", 118, 162], ["the Sequence", "TEST", 197, 209], ["Toolkit (fastq-dump command", "TEST", 229, 256], ["lung", "ANATOMY", 141, 145], ["epithelial cells", "OBSERVATION", 146, 162]]], ["Briefly, we used Hierarchical Indexing for Spliced Alignment of Transcripts (HISAT) [71] for aligning the short reads from RNA-seq experiments onto human reference genome (hg38).", [["human", "ORGANISM", 148, 153], ["human reference genome", "DNA", 148, 170], ["hg38", "DNA", 172, 176], ["human", "SPECIES", 148, 153], ["human", "SPECIES", 148, 153]]], ["SAM (Sequence Alignment/Map) files obtained from HISAT were post-processed using SAMtools (version 0.", [["SAM (Sequence Alignment/Map) files", "TEST", 0, 34]]], ["1.19) [72, 73] for converting SAM to BAM (Binary Alignment/Map) followed by sorting and indexing the output BAMs.", [["BAMs", "PROTEIN", 108, 112], ["the output BAMs", "TEST", 97, 112]]], ["The sorted BAM files were parsed using the python script provided by StringTie (version 1.2.1) [74] to obtain the count matrix of for gene levels across the samples.", [["samples", "ANATOMY", 157, 164], ["the count matrix", "TEST", 110, 126], ["gene levels", "TEST", 134, 145]]], ["This count matrix was used to perform differential expression analysis between mock vs SARS-CoV-2 infected NHBE cells using DE-seq2 [75] .", [["NHBE cells", "ANATOMY", 107, 117], ["matrix", "CELLULAR_COMPONENT", 11, 17], ["CoV-2", "ORGANISM", 92, 97], ["NHBE cells", "CELL", 107, 117], ["SARS-CoV-2 infected NHBE cells", "CELL_LINE", 87, 117], ["SARS-CoV", "SPECIES", 87, 95], ["This count matrix", "TEST", 0, 17], ["differential expression analysis", "TEST", 38, 70], ["mock", "TEST", 79, 83], ["SARS", "TEST", 87, 91], ["CoV", "TEST", 92, 95], ["infected NHBE cells", "PROBLEM", 98, 117]]], ["Statistically significant (at 5% fdr) differentially expressed genes were collected for .", [["significant", "OBSERVATION_MODIFIER", 14, 25]]], ["CC-BY-ND 4.0 International license was not certified by peer review) is the author/funder.", [["CC", "CHEMICAL", 0, 2]]], ["It is made available under a The copyright holder for this preprint (which this version posted July 6, 2020. . downstream data analysis.", [["downstream data analysis", "TEST", 111, 135]]], ["Functional enrichment analysis of these genes waere performed with pvalue threshold < 10 -10 using ClueGO [48] (a Cytoscape [76] plugin) and were represented as barplot illustrating the significant pathways obtained from GO-term based functional grouping of differentially expressed genes.Identification of alternative splicing events during SARS-CoV2 infection.We used rMATS (replicate Multivariate Analysis of Transcript Splicing) [60] to identify differential alternative splicing (AS) events between the mock vs SARS-CoV-2 treated NHBE cells. rMATS used sorted BAM (Binary Alignment/Map) files, obtained from aligning the fastq files against hg38 reference genome using HISAT (as discussed above).", [["NHBE cells", "ANATOMY", 535, 545], ["SARS-CoV2 infection", "DISEASE", 342, 361], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 342, 351], ["NHBE cells", "CELL", 535, 545], ["differentially expressed genes", "DNA", 258, 288], ["rMATS", "DNA", 370, 375], ["SARS-CoV-2 treated NHBE cells", "CELL_LINE", 516, 545], ["rMATS", "DNA", 547, 552], ["fastq files", "DNA", 626, 637], ["hg38 reference genome", "DNA", 646, 667], ["HISAT", "DNA", 674, 679], ["SARS-CoV", "SPECIES", 516, 524], ["these genes", "TEST", 34, 45], ["pvalue threshold", "TEST", 67, 83], ["a Cytoscape", "TEST", 112, 123], ["alternative splicing events", "PROBLEM", 307, 334], ["SARS", "PROBLEM", 342, 346], ["CoV2 infection", "PROBLEM", 347, 361], ["Transcript Splicing)", "TREATMENT", 412, 432], ["the mock", "TEST", 504, 512], ["SARS", "PROBLEM", 516, 520], ["CoV", "TEST", 521, 524], ["NHBE cells", "TREATMENT", 535, 545], ["infection", "OBSERVATION", 352, 361]]], ["It also uses a GTF file (gene transfer file format), downloaded from Ensembl (version 97) [77] for existing annotation of exons.", [["GTF file", "DNA", 15, 23], ["exons", "DNA", 122, 127], ["a GTF file", "TREATMENT", 13, 23]]], ["Briefly, rMATS enabled the analysis of the inclusion/exclusion of target exons/introns contributing to different types of alternative splicing events, namely skipped exon (SE), alternative 5' splice site (A5SS), alternative 3' splice site (A3SS), mutually exclusive exons (MXE) and retained intron (RI), between pair of conditions and provides the difference in level of inclusion of an exon denoted by Percentage Splicing Index ( ) (as described previously [69] ).", [["rMATS", "DNA", 9, 14], ["exons", "DNA", 73, 78], ["introns", "DNA", 79, 86], ["exon", "DNA", 166, 170], ["5' splice site", "DNA", 189, 203], ["A5SS", "DNA", 205, 209], ["alternative 3' splice site", "DNA", 212, 238], ["A3SS", "DNA", 240, 244], ["exons", "DNA", 266, 271], ["MXE", "DNA", 273, 276], ["intron", "DNA", 291, 297], ["RI", "DNA", 299, 301], ["exon", "DNA", 387, 391], ["target exons/introns", "TREATMENT", 66, 86], ["alternative splicing events", "PROBLEM", 122, 149], ["skipped exon (SE)", "PROBLEM", 158, 175], ["alternative 5' splice site", "TREATMENT", 177, 203], ["alternative 3' splice site", "TREATMENT", 212, 238], ["retained intron (RI)", "PROBLEM", 282, 302], ["an exon", "PROBLEM", 384, 391], ["Index", "OBSERVATION_MODIFIER", 423, 428]]], ["Genes exhibiting alternatively spliced events detected below 5% FDR threshold were documented in Table S3 .", [["Genes exhibiting alternatively spliced events", "PROBLEM", 0, 45], ["FDR threshold", "TEST", 64, 77]]], ["Functional enrichment analysis of these genes was performed using ClueGO [48] .Identification of potential binding blocks of RBPs in SARS-CoV-2 viral genome using motif enrichment analysis.We obtained the RBP-motifs from Attract [78] and scanned across the SARS-CoV-2 viral genome using FIMO [64, 79] with default parameters.", [["SARS", "DISEASE", 133, 137], ["SARS-CoV-2", "ORGANISM", 133, 143], ["RBP", "GENE_OR_GENE_PRODUCT", 205, 208], ["RBPs", "PROTEIN", 125, 129], ["SARS-CoV-2 viral genome", "DNA", 133, 156], ["RBP-motifs", "DNA", 205, 215], ["SARS-CoV-2 viral genome", "DNA", 257, 280], ["SARS-CoV", "SPECIES", 133, 141], ["SARS-CoV", "SPECIES", 257, 265], ["Functional enrichment analysis", "TEST", 0, 30], ["potential binding blocks of RBPs", "PROBLEM", 97, 129], ["SARS", "PROBLEM", 133, 137], ["CoV", "TEST", 138, 141], ["motif enrichment analysis", "TEST", 163, 188], ["the RBP", "TEST", 201, 208], ["the SARS", "TEST", 253, 261], ["CoV", "TEST", 262, 265], ["default parameters", "TEST", 306, 324], ["binding blocks", "OBSERVATION", 107, 121]]], ["Resulting genomic locations for each RBP motif were documented in Table S4 .", [["RBP", "GENE_OR_GENE_PRODUCT", 37, 40], ["RBP motif", "DNA", 37, 46], ["each RBP motif", "TEST", 32, 46]]], ["For each binding motif, the scanned genomic location was normalized by considering the mid-point of genomic coordinate divided with the SARS-CoV-2 genome length.", [["binding motif", "DNA", 9, 22], ["SARS-CoV-2 genome length", "DNA", 136, 160], ["each binding motif", "PROBLEM", 4, 22]]], ["Also, the occurrence of each RBP motif binding across the viral genome was computed.", [["RBP", "GENE_OR_GENE_PRODUCT", 29, 32], ["RBP motif", "DNA", 29, 38], ["viral genome", "DNA", 58, 70], ["each RBP motif binding", "PROBLEM", 24, 46], ["viral genome", "OBSERVATION", 58, 70]]], ["Statistically significant (p-value < e-05) preferential binding profile of RBP motifs (sorted by frequency of binding and greater than 10 sites) across the SARS-CoV-2 viral genome (length normalized) identified using FIMO was visualized in violin plot.", [["SARS", "DISEASE", 156, 160], ["RBP", "GENE_OR_GENE_PRODUCT", 75, 78], ["RBP motifs", "PROTEIN", 75, 85], ["SARS-CoV-2 viral genome", "DNA", 156, 179], ["FIMO", "DNA", 217, 221], ["SARS-CoV", "SPECIES", 156, 164], ["p-value", "TEST", 27, 34], ["RBP motifs", "TEST", 75, 85], ["the SARS", "TEST", 152, 160], ["CoV", "TEST", 161, 164], ["FIMO", "TREATMENT", 217, 221], ["significant", "OBSERVATION_MODIFIER", 14, 25], ["viral genome", "OBSERVATION", 167, 179]]], ["Also, the protein abundance of corresponding RBPs were extracted from human proteome map [39] and represented as hierarchically clustered heatmap across the tissues.Identification of potential binding blocks of microRNAs in SARS-CoV-2 viral genome using motif enrichment analysis.We obtained the miR-motifs from MEME [79] and scanned across the SARS-CoV-2 viral genome using FIMO [64, 79] with default parameters.", [["tissues", "ANATOMY", 157, 164], ["RBPs", "GENE_OR_GENE_PRODUCT", 45, 49], ["human", "ORGANISM", 70, 75], ["tissues", "TISSUE", 157, 164], ["SARS-CoV-2", "ORGANISM", 224, 234], ["miR", "GENE_OR_GENE_PRODUCT", 296, 299], ["RBPs", "PROTEIN", 45, 49], ["microRNAs", "DNA", 211, 220], ["SARS-CoV-2 viral genome", "DNA", 224, 247], ["miR-motifs", "DNA", 296, 306], ["SARS-CoV-2 viral genome", "DNA", 345, 368], ["human", "SPECIES", 70, 75], ["human", "SPECIES", 70, 75], ["SARS-CoV", "SPECIES", 224, 232], ["SARS-CoV", "SPECIES", 345, 353], ["corresponding RBPs", "PROBLEM", 31, 49], ["human proteome map", "TEST", 70, 88], ["hierarchically clustered heatmap across the tissues", "PROBLEM", 113, 164], ["potential binding blocks of microRNAs in SARS", "PROBLEM", 183, 228], ["CoV", "TEST", 229, 232], ["motif enrichment analysis", "TEST", 254, 279], ["the SARS", "TEST", 341, 349], ["CoV", "TEST", 350, 353], ["default parameters", "TEST", 394, 412], ["hierarchically", "OBSERVATION_MODIFIER", 113, 127], ["clustered", "OBSERVATION_MODIFIER", 128, 137], ["heatmap", "OBSERVATION", 138, 145], ["tissues", "ANATOMY", 157, 164], ["binding blocks", "OBSERVATION", 193, 207]]], ["Resulting genomic locations for each miR-motif were documented in Table S6 .", [["miR", "GENE_OR_GENE_PRODUCT", 37, 40], ["miR-motif", "DNA", 37, 46], ["S6", "PROTEIN", 72, 74], ["each miR-motif", "TREATMENT", 32, 46]]], ["For each miR motif, the scanned genomic location was normalized by considering the mid-point of genomic coordinate divided with the SARS-CoV-2 genome length.", [["miR", "GENE_OR_GENE_PRODUCT", 9, 12], ["miR motif", "DNA", 9, 18], ["SARS-CoV-2 genome length", "DNA", 132, 156], ["each miR motif", "TREATMENT", 4, 18], ["the SARS", "TEST", 128, 136]]], ["Also, the occurrence of each miR-motif binding across the viral genome was computed.", [["miR", "GENE_OR_GENE_PRODUCT", 29, 32], ["miR-motif", "DNA", 29, 38], ["viral genome", "DNA", 58, 70], ["each miR-motif binding", "PROBLEM", 24, 46], ["viral genome", "OBSERVATION", 58, 70]]], ["Statistically significant (p-value < e-05) preferential binding profile of miR-motifs (sorted by frequency of binding and greater than 15 sites) across the SARS-CoV-2 viral genome (length normalized) identified using FIMO was visualized in violin plot.", [["miR-motifs", "GENE_OR_GENE_PRODUCT", 75, 85], ["SARS-CoV-2", "ORGANISM", 156, 166], ["miR-motifs", "DNA", 75, 85], ["SARS-CoV-2 viral genome", "DNA", 156, 179], ["FIMO", "DNA", 217, 221], ["SARS-CoV", "SPECIES", 156, 164], ["p-value", "TEST", 27, 34], ["miR-motifs", "TREATMENT", 75, 85], ["the SARS", "TEST", 152, 160], ["CoV", "TEST", 161, 164], ["FIMO", "TREATMENT", 217, 221], ["significant", "OBSERVATION_MODIFIER", 14, 25], ["viral genome", "OBSERVATION", 167, 179]]], ["Also, the expression profile of corresponding miRs were extracted from FANTOM5 project [80] and represented as hierarchically clustered heatmap across the tissues.", [["tissues", "ANATOMY", 155, 162], ["miRs", "GENE_OR_GENE_PRODUCT", 46, 50], ["tissues", "TISSUE", 155, 162], ["miRs", "DNA", 46, 50], ["hierarchically", "OBSERVATION_MODIFIER", 111, 125], ["clustered", "OBSERVATION_MODIFIER", 126, 135], ["heatmap", "OBSERVATION", 136, 143], ["tissues", "ANATOMY", 155, 162]]], ["To understand the generic biological function of these miRs, that could be altered by being titrated by SARS-CoV-2 genome in host cells, we downloaded the high confidence miR target genes (obtained from miRNet [81, 82] ) and performed function annotation analysis.", [["cells", "ANATOMY", 130, 135], ["miRs", "GENE_OR_GENE_PRODUCT", 55, 59], ["CoV-2", "ORGANISM", 109, 114], ["host cells", "CELL", 125, 135], ["miR", "GENE_OR_GENE_PRODUCT", 171, 174], ["miRs", "DNA", 55, 59], ["SARS-CoV-2 genome", "DNA", 104, 121], ["host cells", "CELL_TYPE", 125, 135], ["miR target genes", "DNA", 171, 187], ["SARS-CoV", "SPECIES", 104, 112], ["function annotation analysis", "TEST", 235, 263]]], ["Resulting significant biological processes, obtained from gene ontology enrichment based functional grouping of these miR target genes were illustrated in barplot.", [["miR", "GENE_OR_GENE_PRODUCT", 118, 121], ["miR target genes", "DNA", 118, 134], ["significant biological processes", "PROBLEM", 10, 42], ["significant", "OBSERVATION_MODIFIER", 10, 21]]], ["Significant clustering (adj. p < 1e-10) of genes enriched in GO-biological processes were generated by ClueGO [48] analysis (a cytoscape [76] plugin). .", [["Significant clustering", "PROBLEM", 0, 22], ["a cytoscape", "TEST", 125, 136]]], ["CC-BY-ND 4.0 International license was not certified by peer review) is the author/funder.", [["CC", "CHEMICAL", 0, 2]]], ["CC-BY-ND 4.0 International license was not certified by peer review) is the author/funder.", [["CC", "CHEMICAL", 0, 2]]], ["SARS-CoV-2 genome titrates the abundance of functionally important miRs in human tissue (A) Violin plot shows the statistically significant (p-value < e-05) preferential binding profile of miRmotifs (sorted by frequency of binding >15 sites) across the SARS-CoV-2 viral genome (length normalized) identified using FIMO.", [["tissue", "ANATOMY", 81, 87], ["SARS", "DISEASE", 0, 4], ["human", "ORGANISM", 75, 80], ["tissue", "TISSUE", 81, 87], ["miRmotifs", "GENE_OR_GENE_PRODUCT", 189, 198], ["SARS-CoV-2 genome", "DNA", 0, 17], ["miRs", "DNA", 67, 71], ["miRmotifs", "PROTEIN", 189, 198], ["SARS-CoV-2 viral genome", "DNA", 253, 276], ["FIMO", "PROTEIN", 314, 318], ["human", "SPECIES", 75, 80], ["human", "SPECIES", 75, 80], ["SARS-CoV", "SPECIES", 253, 261], ["SARS", "PROBLEM", 0, 4], ["A) Violin plot", "TEST", 89, 103], ["preferential binding profile of miRmotifs", "PROBLEM", 157, 198], ["the SARS", "TEST", 249, 257], ["CoV", "TEST", 258, 261], ["viral genome", "OBSERVATION", 264, 276]]], ["(B) Hierarchically clustered heatmap showing the log10 expression (CPM, row normalized) of miRs across tissues.", [["tissues", "ANATOMY", 103, 110], ["tissues", "TISSUE", 103, 110], ["miRs", "DNA", 91, 95], ["Hierarchically clustered heatmap", "PROBLEM", 4, 36], ["miRs across tissues", "PROBLEM", 91, 110]]], ["(C) Bar-plot illustrating the significant biological processes, obtained from gene ontology enrichment based functional grouping of miR target genes (obtained from miRNet).", [["miR", "GENE_OR_GENE_PRODUCT", 132, 135], ["miR target genes", "DNA", 132, 148], ["miRNet", "DNA", 164, 170], ["the significant biological processes", "PROBLEM", 26, 62], ["significant", "OBSERVATION_MODIFIER", 30, 41]]], ["Significant clustering (adj. p < 1e-10) of genes enriched in GObiological processes generated by ClueGO analysis (Cytoscape plugin).Identification of potential binding blocks of microRNAs in SARS-CoV-2 viral genome using motif enrichment analysis..", [["SARS-CoV-2", "ORGANISM", 191, 201], ["microRNAs", "DNA", 178, 187], ["SARS-CoV-2 viral genome", "DNA", 191, 214], ["SARS-CoV", "SPECIES", 191, 199], ["Significant clustering", "PROBLEM", 0, 22], ["ClueGO analysis", "TEST", 97, 112], ["potential binding blocks of microRNAs in SARS", "PROBLEM", 150, 195], ["CoV", "TEST", 196, 199], ["motif enrichment analysis", "TEST", 221, 246], ["binding blocks", "OBSERVATION", 160, 174]]], ["CC-BY-ND 4.0 International license was not certified by peer review) is the author/funder.", [["CC", "CHEMICAL", 0, 2]]], ["Protein-protein interaction network of differentially expressed genes in mock treated versus SARS-CoV-2 infected primary human lung epithelium (NHBE cells) where node size and color show the absolute and relative log2 fold changes, respectively.Identification of potential binding blocks of microRNAs in SARS-CoV-2 viral genome using motif enrichment analysis..", [["lung epithelium", "ANATOMY", 127, 142], ["NHBE cells", "ANATOMY", 144, 154], ["node", "ANATOMY", 162, 166], ["SARS-CoV-2", "ORGANISM", 93, 103], ["human", "ORGANISM", 121, 126], ["lung epithelium", "CELL", 127, 142], ["NHBE cells", "CELL", 144, 154], ["node", "MULTI-TISSUE_STRUCTURE", 162, 166], ["SARS-CoV-2", "ORGANISM", 304, 314], ["differentially expressed genes", "DNA", 39, 69], ["NHBE cells", "CELL_TYPE", 144, 154], ["microRNAs", "DNA", 291, 300], ["SARS-CoV-2 viral genome", "DNA", 304, 327], ["human", "SPECIES", 121, 126], ["SARS-CoV", "SPECIES", 93, 101], ["human", "SPECIES", 121, 126], ["SARS-CoV", "SPECIES", 304, 312], ["Protein", "TEST", 0, 7], ["SARS", "PROBLEM", 93, 97], ["CoV", "TEST", 98, 101], ["2 infected primary human lung epithelium (NHBE cells", "PROBLEM", 102, 154], ["node size", "TEST", 162, 171], ["color", "TEST", 176, 181], ["the absolute", "TEST", 187, 199], ["relative log2 fold changes", "PROBLEM", 204, 230], ["potential binding blocks of microRNAs in SARS", "PROBLEM", 263, 308], ["CoV", "TEST", 309, 312], ["motif enrichment analysis", "TEST", 334, 359], ["infected", "OBSERVATION_MODIFIER", 104, 112], ["primary", "OBSERVATION_MODIFIER", 113, 120], ["human", "ANATOMY_MODIFIER", 121, 126], ["lung", "ANATOMY", 127, 131], ["epithelium", "ANATOMY_MODIFIER", 132, 142], ["NHBE cells", "OBSERVATION", 144, 154], ["node", "ANATOMY", 162, 166], ["size", "OBSERVATION_MODIFIER", 167, 171], ["absolute", "OBSERVATION_MODIFIER", 191, 199], ["log2 fold", "OBSERVATION", 213, 222], ["binding blocks", "OBSERVATION", 273, 287]]], ["CC-BY-ND 4.0 International license was not certified by peer review) is the author/funder.", [["CC", "CHEMICAL", 0, 2]]], ["(A) Violin plot shows the statistically significant (p-value < e-05) preferential binding profile of RBP motifs (sorted by frequency of binding) across the SARS-CoV2 viral genome (length normalized), identified using FIMO (B) Hierarchical clustered heatmap showing the protein abundance (row normalized) of RBPs across tissues.Identification of potential binding blocks of microRNAs in SARS-CoV-2 viral genome using motif enrichment analysis..", [["tissues", "ANATOMY", 319, 326], ["RBP", "GENE_OR_GENE_PRODUCT", 101, 104], ["tissues", "TISSUE", 319, 326], ["SARS-CoV-2", "ORGANISM", 386, 396], ["RBP motifs", "PROTEIN", 101, 111], ["SARS-CoV2 viral genome", "DNA", 156, 178], ["RBPs", "PROTEIN", 307, 311], ["microRNAs", "DNA", 373, 382], ["SARS-CoV-2 viral genome", "DNA", 386, 409], ["SARS-CoV", "SPECIES", 386, 394], ["A) Violin plot", "TEST", 1, 15], ["p-value", "TEST", 53, 60], ["RBP motifs", "TEST", 101, 111], ["the SARS", "PROBLEM", 152, 160], ["CoV2 viral genome", "PROBLEM", 161, 178], ["the protein abundance", "PROBLEM", 265, 286], ["RBPs across tissues", "PROBLEM", 307, 326], ["potential binding blocks of microRNAs in SARS", "PROBLEM", 345, 390], ["CoV", "TEST", 391, 394], ["motif enrichment analysis", "TEST", 416, 441], ["viral genome", "OBSERVATION", 166, 178], ["binding blocks", "OBSERVATION", 355, 369]]], ["CC-BY-ND 4.0 International license was not certified by peer review) is the author/funder.", [["CC", "CHEMICAL", 0, 2]]], ["It is made available under a The copyright holder for this preprint (which this version posted July 6, 2020. . https://doi.org/10.1101/2020.07.06.190348 doi: bioRxiv preprint Supplementary Table Legends: Table S1 .", [["S1", "ANATOMY", 210, 212]]], ["Significant biological pathways obtained from functional annotation analysis of differentially expressed genes (at 5% fdr) in mock treated versus SARS-CoV-2 infected primary human lung epithelium (NHBE cells) using ClueGO (a cytoscape plugin).", [["lung epithelium", "ANATOMY", 180, 195], ["NHBE cells", "ANATOMY", 197, 207], ["SARS-CoV-2", "ORGANISM", 146, 156], ["human", "ORGANISM", 174, 179], ["lung epithelium", "CELL", 180, 195], ["NHBE cells", "CELL", 197, 207], ["ClueGO", "SIMPLE_CHEMICAL", 215, 221], ["differentially expressed genes", "DNA", 80, 110], ["NHBE cells", "CELL_LINE", 197, 207], ["ClueGO", "PROTEIN", 215, 221], ["human", "SPECIES", 174, 179], ["SARS-CoV", "SPECIES", 146, 154], ["human", "SPECIES", 174, 179], ["Significant biological pathways", "PROBLEM", 0, 31], ["functional annotation analysis", "TEST", 46, 76], ["SARS", "PROBLEM", 146, 150], ["CoV", "TEST", 151, 154], ["2 infected primary human lung epithelium", "PROBLEM", 155, 195], ["lung", "ANATOMY", 180, 184], ["epithelium", "ANATOMY_MODIFIER", 185, 195]]], ["Table S2 .", [["S2", "ANATOMY", 6, 8]]], ["Identification of alternative splicing events using rMATS (replicate Multivariate Analysis of Transcript Splicing) in mock treated versus SARS-CoV-2 infected primary human lung epithelium (NHBE cells).", [["lung epithelium", "ANATOMY", 172, 187], ["NHBE cells", "ANATOMY", 189, 199], ["SARS-CoV-2", "ORGANISM", 138, 148], ["human", "ORGANISM", 166, 171], ["lung epithelium", "CELL", 172, 187], ["NHBE cells", "CELL", 189, 199], ["rMATS", "DNA", 52, 57], ["primary human lung epithelium (NHBE cells", "CELL_TYPE", 158, 199], ["human", "SPECIES", 166, 171], ["SARS-CoV", "SPECIES", 138, 146], ["human", "SPECIES", 166, 171], ["alternative splicing events", "PROBLEM", 18, 45], ["rMATS", "TREATMENT", 52, 57], ["Transcript Splicing", "TREATMENT", 94, 113], ["SARS", "PROBLEM", 138, 142], ["CoV", "TEST", 143, 146], ["2 infected primary human lung epithelium (NHBE cells", "PROBLEM", 147, 199], ["infected", "OBSERVATION_MODIFIER", 149, 157], ["primary human", "OBSERVATION", 158, 171], ["lung", "ANATOMY", 172, 176], ["epithelium", "ANATOMY_MODIFIER", 177, 187], ["NHBE cells", "OBSERVATION", 189, 199]]], ["Table S2 .", [["S2", "ANATOMY", 6, 8]]], ["Significant biological pathways obtained from functional annotation analysis of alternatively spliced genes (at 5% fdr) in mock treated versus SARS-CoV-2 infected primary human lung epithelium (NHBE cells) using ClueGO (a cytoscape plugin).", [["lung epithelium", "ANATOMY", 177, 192], ["NHBE cells", "ANATOMY", 194, 204], ["SARS-CoV-2", "ORGANISM", 143, 153], ["human", "ORGANISM", 171, 176], ["lung epithelium", "CELL", 177, 192], ["NHBE cells", "CELL", 194, 204], ["ClueGO", "SIMPLE_CHEMICAL", 212, 218], ["alternatively spliced genes", "DNA", 80, 107], ["NHBE cells", "CELL_LINE", 194, 204], ["ClueGO", "PROTEIN", 212, 218], ["human", "SPECIES", 171, 176], ["SARS-CoV", "SPECIES", 143, 151], ["human", "SPECIES", 171, 176], ["Significant biological pathways", "PROBLEM", 0, 31], ["functional annotation analysis", "TEST", 46, 76], ["spliced genes", "PROBLEM", 94, 107], ["SARS", "PROBLEM", 143, 147], ["CoV", "TEST", 148, 151], ["2 infected primary human lung epithelium (NHBE cells", "PROBLEM", 152, 204], ["lung", "ANATOMY", 177, 181], ["epithelium", "ANATOMY_MODIFIER", 182, 192]]], ["Preferential binding location of RBP motifs identified by FIMO across the SARS-CoV2 viral genome.", [["RBP", "GENE_OR_GENE_PRODUCT", 33, 36], ["FIMO", "GENE_OR_GENE_PRODUCT", 58, 62], ["RBP motifs", "DNA", 33, 43], ["FIMO", "PROTEIN", 58, 62], ["SARS-CoV2 viral genome", "DNA", 74, 96], ["RBP motifs", "TEST", 33, 43], ["the SARS", "PROBLEM", 70, 78], ["CoV2 viral genome", "PROBLEM", 79, 96], ["viral genome", "OBSERVATION", 84, 96]]], ["Preferential binding location of miR-motifs identified by FIMO across the SARS-CoV2 viral genome.", [["miR-motifs", "GENE_OR_GENE_PRODUCT", 33, 43], ["FIMO", "GENE_OR_GENE_PRODUCT", 58, 62], ["miR-motifs", "DNA", 33, 43], ["FIMO", "DNA", 58, 62], ["SARS-CoV2 viral genome", "DNA", 74, 96], ["the SARS", "PROBLEM", 70, 78], ["CoV2 viral genome", "PROBLEM", 79, 96], ["viral genome", "OBSERVATION", 84, 96]]], ["Table S6 .", [["S6", "PROTEIN", 6, 8]]], ["Significant biological pathways obtained from functional annotation analysis of mir-targeted genes (from mirNet) using ClueGO (a cytoscape plugin).Identification of potential binding blocks of microRNAs in SARS-CoV-2 viral genome using motif enrichment analysis..", [["ClueGO", "GENE_OR_GENE_PRODUCT", 119, 125], ["SARS-CoV-2", "ORGANISM", 206, 216], ["mir-targeted genes", "DNA", 80, 98], ["mirNet", "DNA", 105, 111], ["ClueGO", "PROTEIN", 119, 125], ["microRNAs", "DNA", 193, 202], ["SARS-CoV-2 viral genome", "DNA", 206, 229], ["SARS-CoV", "SPECIES", 206, 214], ["Significant biological pathways", "PROBLEM", 0, 31], ["functional annotation analysis", "TEST", 46, 76], ["potential binding blocks of microRNAs in SARS", "PROBLEM", 165, 210], ["CoV", "TEST", 211, 214], ["motif enrichment analysis", "TEST", 236, 261], ["binding blocks", "OBSERVATION", 175, 189]]], ["CC-BY-ND 4.0 International license was not certified by peer review) is the author/funder.", [["CC", "CHEMICAL", 0, 2]]], ["It is made available under a The copyright holder for this preprint (which this version posted July 6, 2020. . https://doi.org/10.1101/2020.07.06.190348 doi: bioRxiv preprint", [["bioRxiv", "TREATMENT", 158, 165]]]], "cfcc3c2e1ffe559ada6e0bc0445b12c46953852a": [["We read with interest your recent article by Fogarty et al., 1 in particular their conclusion that differences in thrombotic risk may contribute to ethnic disparities in mortality from coronavirus disease 2019 .", [["thrombotic", "DISEASE", 114, 124], ["coronavirus disease", "DISEASE", 185, 204], ["thrombotic risk", "PROBLEM", 114, 129], ["ethnic disparities", "PROBLEM", 148, 166], ["coronavirus disease", "PROBLEM", 185, 204], ["thrombotic", "OBSERVATION", 114, 124], ["coronavirus disease", "OBSERVATION", 185, 204]]], ["This is especially important in the UK, where age-sex adjusted hospital death rates for COVID-19 are 2\u00c117-times higher for people with ethnicity recorded as Black compared to those recorded as White, and 1\u00c195 higher for those recorded as Asian.", [["death", "DISEASE", 72, 77], ["people", "ORGANISM", 123, 129], ["people", "SPECIES", 123, 129], ["COVID", "TEST", 88, 93]]], ["2 This excess mortality persists after adjustment for deprivation, body mass index (BMI), smoking and comorbidities, 2 and despite correction for region, rural or urban living, deprivation, household composition, socioeconomic status and health.", [["body", "ANATOMY", 67, 71], ["body", "ORGANISM_SUBDIVISION", 67, 71], ["This excess mortality", "PROBLEM", 2, 23], ["deprivation", "TREATMENT", 54, 65], ["body mass index", "PROBLEM", 67, 82], ["comorbidities", "PROBLEM", 102, 115]]], ["3 Similar data from the USA show that in 14 States, African-Americans represent 33% of hospitalisations for COVID-19, despite only making up 14% of the catchment population.", [["COVID", "TEST", 108, 113]]], ["4 Black ethnicity is a construct incorporating diverse populations of African descent.", [["Black", "OBSERVATION_MODIFIER", 2, 7], ["ethnicity", "OBSERVATION", 8, 17], ["diverse", "OBSERVATION_MODIFIER", 47, 54], ["populations", "OBSERVATION_MODIFIER", 55, 66]]], ["Studies from several communities labelled as 'Black', in particular African-Americans, imply a common increase in thrombotic risk, which may contribute to unexplained ethnic disparities in the UK and USA in COVID-19.", [["thrombotic", "DISEASE", 114, 124], ["Studies", "TEST", 0, 7], ["a common increase in thrombotic risk", "PROBLEM", 93, 129], ["unexplained ethnic disparities", "PROBLEM", 155, 185], ["USA in COVID", "TEST", 200, 212], ["thrombotic", "OBSERVATION", 114, 124]]]]}